<SEC-DOCUMENT>0001493152-25-005072.txt : 20250709
<SEC-HEADER>0001493152-25-005072.hdr.sgml : 20250709
<ACCEPTANCE-DATETIME>20250205213032
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001493152-25-005072
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		25
FILED AS OF DATE:		20250206
<PUBLIC-REL-DATE>20250709
DATE AS OF CHANGE:		20250205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nasus Pharma Ltd
		CENTRAL INDEX KEY:			0002029039
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				516022712
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-07416
		FILM NUMBER:		25595173

	BUSINESS ADDRESS:	
		STREET 1:		29 HARAKEVET ST
		CITY:			TEL AVIV - YAFO
		STATE:			L3
		ZIP:			6618003
		BUSINESS PHONE:		972 54-255-3956

	MAIL ADDRESS:	
		STREET 1:		29 HARAKEVET ST
		CITY:			TEL AVIV - YAFO
		STATE:			L3
		ZIP:			6618003
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
submitted on February 5, 2025 to the Securities and Exchange Commission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
confidential review pursuant to the Jumpstart our Business Startups Act of 2012</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
DC 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Form
F-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Nasus
Pharma Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Exact
name of registrant as specified in its charter)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>State
    of Israel</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
    Applicable</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State
    or other jurisdiction of</I><BR>
    <I>incorporation or organization)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Primary
    Standard Industrial</I><BR>
    <I>Classification Code Number)</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S.
    Employer</I><BR>
    <I>Identification Number)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 49%">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Udi Gilboa</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Executive Chairman</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Yigal</B><B> Alon
    65</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Tel Aviv, Israel 6744317</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Tel: +972.3.573.6632</B></P></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center; font: 12pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center; width: 49%">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Puglisi &amp; Associates</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>850 Library Ave., Suite 204</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Newark, DE 19711</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B>Tel: (302) 738-6680</B></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><B></B></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><I>(Address, including zip code, and telephone number,</I></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><I>including area code, of registrant&rsquo;s principal executive offices)</I></P></TD>
    <TD STYLE="text-align: center">
    <P STYLE="text-align: center; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>
    <P STYLE="text-align: center; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P></TD>
    <TD STYLE="text-align: center">
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><I>(Name, address, including zip code, and telephone</I></P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><I>number, including area code, of agent for service)</I></P></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Copies
to:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Oded
    Har-Even, Esq. </B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ron
    Ben-Bassat, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Eric
    Victorson, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sullivan
    &amp; Worcester LLP</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1251
    Avenue of the Americas, 19th Floor</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
    York, NY 10020</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
    +1.212.660.3000</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 34%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reut
    Alfiah, Adv.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gal
    Cohen, Adv.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sullivan
    &amp; Worcester Tel-Aviv<BR>
    (Har-Even &amp; Co.)<BR>
    28 HaArba&rsquo;a St. HaArba&rsquo;a</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Towers,<BR>
    North Tower, 35th Floor<BR>
    Tel-Aviv, Israel 6473925<BR>
    Tel: +972.74.758.0480<BR>
    </B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leslie
    Marlow, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patrick
    Egan, Esq</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hank
    Gracin, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Blank
    Rome LLP<BR>
    1271 Avenue of the Americas</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
    York, New York 10020<BR>
    (212) 885-5000</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approximate
date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act, check the following box. &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards &dagger; provided
pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;The
term &ldquo;new or revised financial accounting standard&rdquo; refers to any update issued by the Financial Accounting Standards Board
to its Accounting Standards Codification after April 5, 2012.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act or until the Registration Statement shall become effective on such date as the
Commission, acting pursuant to said Section 8(a), may determine. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any state where the offer or sale is not permitted. </B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 34%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>SUBJECT
    TO COMPLETION </B></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; width: 33%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: red"><B>DATED
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025 </B></FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt">Ordinary
Shares</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Nasus
Pharma Ltd.</B></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
is a firm commitment initial public offering of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares, par value NIS 0.01 per
share, or Ordinary Shares, of Nasus Pharma Ltd., an Israeli company. Prior to this offering, there has been no public market for
our Ordinary Shares. We anticipate that the initial public offering price of our shares will be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to list our Ordinary Shares on the NYSE American LLC, or NYSE American, under the symbol &ldquo; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&rdquo; This offering is contingent
upon the Ordinary Shares being listed on the NYSE American, and no assurance can be given that our application will be approved or that
a trading market will develop.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are both an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and a &ldquo;foreign
private issuer&rdquo; as defined under the U.S. federal securities laws and have elected to comply with certain reduced public company
reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our Ordinary Shares involves a high degree of risk. See &ldquo;<I>Risk Factors</I>&rdquo; beginning on page 9. Neither the U.S.
Securities and Exchange Commission, or the SEC, nor any state securities commission has approved or disapproved these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Per Share</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Total</B></TD><TD STYLE="padding-bottom: 1pt; text-align: center"><B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%; text-align: left">Initial public offering price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discounts and commissions <SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds to us (before expenses)</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">discounts and commissions do not include
    a non-accountable expense allowance equal to 1.0% of the initial public offering price payable to the underwriters. We refer you
    to &ldquo;<I>Underwriting</I>&rdquo; beginning on page 163 for additional information regarding underwriters&rsquo; compensation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted a 45-day option to the representative of the underwriters to purchase up&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to additional Ordinary Shares solely to cover over-allotments,
if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters expect to deliver the Ordinary Shares on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
, 2025. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ThinkEquity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
date of this prospectus is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2025 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B> <FONT STYLE="background-color: yellow"></FONT></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Da_001">Prospectus Summary</A></FONT></TD>
    <TD STYLE="text-align: center">1</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Da_002">Risk Factors</A></FONT></TD>
    <TD STYLE="text-align: center">9</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#am_001">Cautionary Note Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="text-align: center">60</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#am_002">Listing Details</A></FONT></TD>
    <TD STYLE="text-align: center">62</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#am_003">Use of Proceeds</A></FONT></TD>
    <TD STYLE="text-align: center">63</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#am_004">Dividend Policy</A></FONT></TD>
    <TD STYLE="text-align: center">64</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#am_005">Capitalization</A></FONT></TD>
    <TD STYLE="text-align: center">65</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#am_006">Dilution</A></FONT></TD>
    <TD STYLE="text-align: center">67</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#am_007">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></TD>
    <TD STYLE="text-align: center">69</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#am_008">Business</A></FONT></TD>
    <TD STYLE="text-align: center">79</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#p_013">Management</A></FONT></TD>
    <TD STYLE="text-align: center">124</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Z_001">Beneficial Ownership of Principal Shareholders and Management</A></FONT></TD>
    <TD STYLE="text-align: center">147</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Z_002">Related Party Transactions</A></FONT></TD>
    <TD STYLE="text-align: center">148</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Z_003">Description of Share Capital and Governing Documents</A></FONT></TD>
    <TD STYLE="text-align: center">150</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Z_004">Shares Eligible for Future Sale</A></FONT></TD>
    <TD STYLE="text-align: center">154</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Z_005">Taxation</A></FONT></TD>
    <TD STYLE="text-align: center">156</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Z_006">Underwriting</A></FONT></TD>
    <TD STYLE="text-align: center">163</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Z_007">Expenses</A></FONT></TD>
    <TD STYLE="text-align: center">172</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Z_008">Legal Matters</A></FONT></TD>
    <TD STYLE="text-align: center">173</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Z_009">Experts</A></FONT></TD>
    <TD STYLE="text-align: center">174</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Z_010">Enforceability of Civil Liabilities</A></FONT></TD>
    <TD STYLE="text-align: center">174</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#Z_011">Where You Can Find Additional Information</A></FONT></TD>
    <TD STYLE="text-align: center">175</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ch_001">Index of Financial Statements</A></FONT></TD>
    <TD STYLE="text-align: center">F-1</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
should rely only on the information contained in this prospectus and any free writing prospectus prepared by or on behalf of us or to
which we have referred you. We have not authorized anyone to provide you with information that is different. We are offering to sell
the Ordinary Shares, and seeking offers to buy the Ordinary Shares, only in jurisdictions where offers and sales are permitted. The information
in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale
of the Ordinary Shares.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or
possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United
States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of
this prospectus.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this prospectus, &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company&rdquo; and &ldquo;Nasus&rdquo; refer to Nasus
Pharma Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated in the State of Israel, and a majority of our outstanding securities are owned by non-U.S. residents. Under the rules
of the SEC, we are currently eligible for treatment as a &ldquo;foreign private issuer.&rdquo; As a foreign private issuer, we will not
be required to file periodic reports and financial statements with the SEC as frequently or as promptly as domestic registrants whose
securities are registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRADEMARKS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks
and trade names in this prospectus are referred to without the &reg; and &trade; symbols, but such references should not be construed
as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do
not intend the use or display of other companies&rsquo; trademarks and trade names to imply a relationship with, or endorsement or sponsorship
of us by, any other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MARKET,
INDUSTRY AND OTHER DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Unless
otherwise indicated, this prospectus includes statistical, market and industry data and forecasts which we obtained from publicly available
information and independent industry publications and reports that we believe to be reliable sources, concerning our industry and the
markets in which we operate, including our general expectations and market position, market opportunity and market size estimates, is
based on information from independent industry analysts, third-party sources and management estimates. These publicly available industry
publications and reports generally state that they obtain their information from sources that they believe to be reliable, but they do
not guarantee the accuracy or completeness of the information. Although we believe that these sources are reliable, we have not independently
verified the information contained in such publications. Management estimates are derived from publicly available information released
by independent industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions made
by us based on such data and our knowledge of such industry and market, which we believe to be reasonable. In addition, while we believe
the market opportunity information included in this prospectus is generally reliable and is based on reasonable assumptions, such data
involves risks and uncertainties and is subject to change based on various factors, including those discussed under the heading &ldquo;<I>Risk
Factors</I>&rdquo; and &ldquo;<I>Cautionary Note Regarding Forward-Looking Statements.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRESENTATION
OF FINANCIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
reporting currency and functional currency is the U.S. dollar. Unless otherwise expressly stated or the context otherwise requires,
references in this prospectus to &ldquo;NIS&rdquo; are to New Israeli Shekels, references to &ldquo;Euro&rdquo; or
&ldquo;&euro;&rdquo; mean the currency of the European Union and references to &ldquo;dollars&rdquo; or &ldquo;$&rdquo; mean
U.S. dollars. Unless otherwise noted, all translations from NIS to U.S. dollars in this prospectus were made at a rate of NIS
3.759 for $1.00, the exchange rate as of June 28, 2024, published by the Bank of Israel. All translations from Euro to U.S. dollars
in this prospectus were made at a rate of &euro;1.00 for $1.0711, the exchange rate as of June 28, 2024, published by the H.10
statistical release of the Federal Reserve Board. The aforementioned exchange rate is provided solely for your convenience and may
differ from the actual rates used in the preparation of the consolidated financial statements included in this prospectus and other
financial data appearing in this prospectus. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
report our financial statements in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Da_001"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully,
including the &ldquo;Risk Factors&rdquo; section and the financial statements and related notes appearing elsewhere in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Company </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency
medical conditions. Intranasal administration is especially suitable for medical emergencies when prompt drug administration is critical,
since the nose is lined up with a very rich vascular bed enabling quick drug absorption. We are developing a unique powder-based intranasal
technology, or PBI, with a specialized product portfolio to address acute medical conditions and public health threats. We believe that
PBI may be superior over liquid-based solutions due to potentially significantly higher dispersion of powder throughout
the nasal cavity, thus creating a larger absorption area and enabling more rapid and higher drug absorption. In addition, the uniform
spherical powder particles of our proprietary formulation may enhance the consistency and reliability of the delivered dose. The
initial clinical trials of our PBI products involving different molecules performed thus far have demonstrated quicker
and higher drug absorption over similar solution-based nasal products. However, to date we have only tested our product candidates on a relatively small patient population
and none of our products have been approved by the Food and Drug Administration, or the FDA. Prior to obtaining FDA approval of any of
our product candidates, we will need to perform additional clinical testing of our product candidates to confirm any benefits and advantages
our products may have over similar nasal products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly
and immediately active PBI specialized products. To help achieve this we are developing NS002, an intranasal powder epinephrine nasal
spray for the treatment of type 1 severe allergies and anaphylaxis, and NS001, an intranasal Naloxone powder nasal spray for the treatment
of opioid overdose. We will need to obtain regulatory approval for our products in order for
us to grow our business. We currently have
no FDA approved products. Our products have been tested on relatively small patient populations thus far.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining regulatory approvals
and developing NS001 and NS002 will require the incurrence of significant costs and our success will depend, in part, on gaining market
acceptance. In order to gain market acceptance in the United States, we will require specific approval from the FDA for our product candidates.
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We intend to seek approval of NS002 as an approved molecule
and a new delivery route (with EpiPen autoinjector as the reference device) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic
Act, or FFDCA, which allows the applicant to rely in part on previous studies conducted by unrelated parties, such as another drug manufacturer,
and existing sources including published literature, for marketing approval by the FDA in the United States, and will seek approval under
the comparable hybrid application pathway in the European Union. The FDA may not agree that our product candidates satisfy the requirements
for the Section 505(b)(2) regulatory approval. Such abbreviated approval pathways may not lead to a faster development or review
process compared to traditional approval pathways and do not increase the likelihood that NS001 and NS002 will receive regulatory approval
in the United States or the European Union. <FONT STYLE="background-color: white">See &ldquo;<I>Business &ndash; Government Regulation</I>&rdquo;
and &ldquo;<I>Risk Factors &ndash; Risks Related to Product Development, Regulatory Approval and Commercialization</I>&rdquo; for additional
information).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have conducted a twelve-patient pilot study of NS002, which included the testing of bioavailability of epinephrine under
&ldquo;allergenic challenge&rdquo; - the creation of severe acute allergic reaction in the nose by inserting ascending doses of
allergens to the nose of the healthy volunteers with known allergic rhinitis included in the study. The results showed that
epinephrine intranasal delivery of our NS002 followed the established characteristics of our platform technology&mdash;namely, there
were higher levels of the drug in the plasma in situations where immediate administration could be lifesaving. The Phase 2 study,
which is meant to optimize the dose that will be used in the Phase 3 study for registration, is conducted in limited patient
populations to identify possible adverse effects and safety risks, to preliminarily evaluate the dosage tolerance of the product for
specific targeted diseases or conditions and to determine dosage tolerance, optimal dosage and dosing schedule. Our Phase 2 study is
aimed at defining the final clinical dose to be used in our powder epinephrine product candidate, compared to the bioavailability of
epinephrine following a various dosing of NS002 Microspheres Epinephrine powder. The pharmacokinetic results of our Phase 2 study
are in line with the known attributes of our nasal powder technology&mdash;namely: immediate absorption of epinephrine and reaching
higher peak plasma epinephrine levels quicker compared to intramuscular, or IM, Epinephrine injections. We intend to perform two
additional Phase 2 studies of NS002. The first will be aimed at determining whether, if necessary, during a real-life
anaphylaxis a second dose of NS002 should be administered in the same nostril as the one used for the first administration of
NS002 or whether it should be in the other nostril. The second Phase 2 study will test the &ldquo;carry-over effect,&rdquo; or
whether the first dose of epinephrine changes the absorption of epinephrine of a following dose. Each study is currently planned to
include at least 12 healthy volunteers with allergic rhinitis. Prior to submission to the FDA for marketing approval, we
also intend to perform a pivotal clinical, or Phase 3, study that will include a subsection of self-administration. We also
intend to separately perform: (1) stability testing which involves testing the product candidate under various temperature
and humidity points; (2) a reliability study, which is a subset of the stability study that tests the NS002&rsquo;s administration
device in several potential conditions; (3) a usability study, which tests how user friendly the device is; (4) preclinical studies
or short animal safety studies in two animal species; and (5) a pediatric study, the details of which will be agreed upon
with the FDA as we progress with the program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to NS001 Intranasal Naloxone, we have performed a pilot study, which is a first in human study aimed at safety and bioequivalence,
and pivotal clinical study, which is the Phase 3 registration study, in 14 and 42 healthy volunteers, respectively, with the
objective of evaluating the comparative bioavailability of naloxone between NS001 and certain competitor products. The pilot study results
were submitted to the FDA in support of the progression to the pivotal study. The results of the pilot study showed our technology having
a faster absorption rate in the immediate critical period after administration. The pivotal clinical, or Phase 3 study, is administered
to an expanded patient population to further evaluate dosage and clinical efficacy. Our pivotal clinical study consistently showed
an advantage in the first 30 minutes after administration. We intend to perform the following additional studies of NS001: (1) a stability study with reliability study; (2)
a usability study; and (3) short term preclinical studies in animals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
platform technology can also be incorporated into other products as it has been tested with several additional preclinical and invitro
molecules based on our proprietary nasal powder formulation and technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT>Competition
in the pharmaceutical industry is intense. Some of our competitors hold significant market share, have long histories and strong reputations
within the industry, greater brand recognition, and more financial and human resources than we do. They also have more experience and
capabilities in researching and developing testing devices, obtaining and maintaining regulatory clearances and other requirements, manufacturing
and marketing those products than we do. Their dominant market position and significant control over the market could significantly limit
our ability to introduce or effectively market and generate sales of NS001 and NS002.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To date, we have incurred significant operating losses, generated no revenues from existing products, and as
of June 30, 2024, our accumulated deficit was $12.0 million. We expect that we will need to raise substantial additional funding in the
future. See &ldquo;<I>Risk Factors &ndash; Risks Related to Our Financial Condition and Capital Requirements.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an Israeli corporation and were incorporated in Israel in May 2019 under the name Nasus Pharma Ltd. Our principal executive offices
are located at Yigal Alon 65, Tel Aviv, Israel <FONT STYLE="background-color: white">6744317</FONT>. Our telephone number is +972.3.573.6632.
Our website address is <I>www.nasus-pharma.com</I>. The information contained on, or that can be accessed through, our website is not
part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
SEC also maintains an Internet website that contains reports, proxy and information statements and other information regarding issuers
that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC&rsquo;s website at <I>http://www.sec.gov</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Implications
of Being an Emerging Growth Company </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are an &ldquo;emerging growth company,&rdquo; as defined in Section 2(a) of the Securities Act of 1933, as amended, or the Securities
Act, as modified by the JOBS Act. As such, we are eligible to, and intend to, take advantage of certain exemptions from various reporting
requirements applicable to other public companies that are not &ldquo;emerging growth companies&rdquo; such as not being required to
comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and not
being required to comply with any new or revised financial accounting standards until such date that a private company is otherwise required
to comply with such new or revised accounting standards. We could remain an &ldquo;emerging growth company&rdquo; until the end of the
fifth year following this offering, or until the earliest of (a) the last day of the first fiscal year in which our annual gross revenue
exceeds $1.235 billion, (b) the date that we become a &ldquo;large accelerated filer&rdquo; as defined in Rule 12b-2 under the U.S. Securities
Exchange Act of 1934, as amended, or the Exchange Act, which would occur if the market value of our Ordinary Shares that is held by non-affiliates
exceeds $700 million as of the last business day of our most recently completed second fiscal quarter, or (c) the date on which we have
issued more than $1 billion in nonconvertible debt during the preceding three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Implications
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of being a Foreign Private Issuer</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information reporting requirements of the Exchange Act that are applicable to &ldquo;foreign private issuers,&rdquo;
and under those requirements we file reports with the SEC. As a foreign private issuer, we are not <FONT STYLE="background-color: white">subject
</FONT>to the same requirements that are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting
obligations that, in certain respects, are less detailed and less frequent than those of U.S. domestic reporting companies. For example,
we are not required to issue quarterly reports, proxy statements that comply with the requirements applicable to U.S. domestic reporting
companies, or individual executive compensation information that is as detailed as that required of U.S. domestic reporting companies.
We also have four months after the end of each fiscal year to file our annual report with the SEC and are not required to file current
reports as frequently or promptly as U.S. domestic reporting companies. Our officers, directors and principal shareholders are exempt
from the requirements to report transactions in our equity securities and from the short-swing profit liability provisions contained
in Section 16 of the Exchange Act. As a foreign private issuer, we are not subject to the requirements of Regulation FD (Fair Disclosure)
promulgated under the Exchange Act. In addition, as a foreign private issuer, we are permitted to follow certain home country corporate
governance practices instead of those otherwise required under the NYSE American Listing Rules for domestic U.S. issuers (see &ldquo;<I>Risk
Factors &mdash; Risks Related to this Offering and the Ownership of Our Securities</I>&rdquo;). These exemptions and leniencies will
reduce the frequency and scope of information and protections available to you in comparison to those applicable to a U.S. domestic reporting
company. We intend to take advantage of the exemptions available to us as a foreign private issuer during and after the period we qualify
as an &ldquo;emerging growth company,&rdquo; until such time as we are no longer a foreign private issuer. We would cease to be
a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the
following three circumstances applies: (i) the majority of our executive officers or directors are U.S. citizens or residents; (ii) more
than 50% of our assets are located in the United States; or (iii) our business is administered principally in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to numerous risks, as more fully described in the section entitled &ldquo;<I>Risk Factors</I>&rdquo; immediately
following this prospectus summary. You should read these risks before you invest in the Ordinary Shares. In particular, our risks include,
but are not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Position and Capital Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not generated revenues from our continued activities, have incurred
significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future, and
we may never achieve or maintain profitability, which raise a substantial doubt about our ability to continue as a going concern and could
prevent us from obtaining new financing on reasonable terms or at all.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are a clinical stage biopharmaceutical company and we have incurred significant operating losses since our inception and anticipate
    that we will incur continued losses for the foreseeable future.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
    our legacy product and business activity, we have not generated revenue from any product candidate and may never be profitable, even
    if we receive regulatory approval to commercialize our products. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial
    doubt about our ability to continue as a going concern. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have identified material weaknesses in our internal control over financial reporting. If our remediations are not effective, or if
    we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls
    in the future, we may not be able to accurately or timely report our financial conditions or results or operations, or prevent fraud,
    which may adversely affect investor confidence in our Company and as a result, the market price of our Ordinary Shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Product Development, Regulatory Approval and Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend substantially on the success of our proprietary intranasal powder product candidates. We cannot give any assurance that any
    of our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    of our product candidates are in various stages of clinical development. Clinical drug development is a lengthy and expensive process
    with uncertain timelines and uncertain outcomes. If clinical trials of our product candidates are prolonged, delayed or not commercially
    viable, we or our collaborators may be unable to obtain required regulatory approvals, and therefore may be unable to commercialize
    our product candidates on a timely basis or at all, which will adversely affect our business. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    denial of regulatory approval for NS001 and NS002 could mean that we need to delay or even cease operations, and a delay in obtaining
    such approval would delay commercialization of our products and adversely impact our ability to generate revenue, business and results
    of operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    results of pre-clinical studies, early-stage clinical trials, data obtained from real-world use, and published third-party studies
    may not be indicative of results in future clinical trials and we cannot assure you that any planned or future clinical trials will
    lead to results sufficient for the necessary regulatory approvals.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    or others could discover that NS001 and NS002 or any product candidate we may pursue in the future lacks sufficient efficacy, or
    that it causes undesirable side effects that were not previously identified, which could delay or prevent regulatory approval or
    commercialization.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    clinical trials or the clinical trials of any of our current or potential future partners may encounter delays, suspensions or other
    problems.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if we obtain regulatory approval for a product candidate, our products will remain subject to ongoing regulatory oversight. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Reliance on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are dependent on manufacturers for Naloxone and Epinephrine. Any delay, price increase or unavailability of our manufacturers could
    materially adversely affect our ability to conduct clinical trials and, if this were to occur after we obtained commercialization
    and marketing approval, could materially impact our operations. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and
    may not be able to find replacements or immediately transition to alternative suppliers on a cost-effective basis, or at all.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    rely on third parties to conduct our pre-clinical and clinical studies and perform other tasks for us. If these third parties do
    not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be
    able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">We have limited manufacturing experience and could experience
    production problems that result in delays in our development or commercialization programs or otherwise adversely affect our business.
    We currently have no manufacturing facilities and anticipate reliance on third-party manufacturers for our products.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    own several issued patents but may require filing of additional patents in the future. There can be no assurance that all or some
    of our patent applications will result in issued patents. Consequently, our ability to protect our proprietary technology in the
    marketplace beyond the intellectual property already protected by our currently issued patents may be limited. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    proprietary position for our product candidates currently depends upon patents protecting the method of use, which may not prevent
    a competitor or other third party from using the same product candidate for another use.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
    if our patents are issued, because the patent status of pharmaceutical products can be complex and uncertain, we cannot predict the
    scope and extent of patent protection for our product candidates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to enforce our intellectual property rights throughout the world. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Business and Industry</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    product candidates for which we intend to seek approval may face competition sooner than anticipated.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    manage our business through a small number of employees and key consultants. We will need to significantly increase the size of our
    organization, and we may experience difficulties in managing growth.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to this Offering and the Ownership of Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    market price of our Ordinary Shares may be highly volatile, and you may not be able to resell your shares at or above the initial
    public offering price.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
    of a substantial number of our Ordinary Shares in the public market by our existing shareholders could cause our share
    price to fall.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Raising
    additional capital would cause dilution to our existing shareholders and may adversely affect the rights of existing shareholders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    principal shareholders and management own a significant percentage of our Ordinary Shares and will be able to exert significant influence
    over matters subject to shareholder approval.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
    will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Israeli Law and Our Operations in Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    conduct our operations in Israel. Conditions in Israel, including the recent attack by Hamas and other terrorist organizations and
    Israel&rsquo;s war against them, may affect our operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    expect to be exposed to fluctuations in currency exchange rates, which could adversely affect our results of operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    termination or reduction of tax and other incentives that the Israeli government provides to Israeli companies may increase our costs
    and taxes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 54%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus
    Pharma Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
    Shares issued and outstanding prior to this offering</B><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    Ordinary Shares</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
    Shares offered by us</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary
    Shares<SUP>(2)</SUP></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
    Shares to be outstanding after this offering</B><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary Shares or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary Shares if the underwriters exercise in full the over-allotment option to purchase additional Ordinary Shares.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-allotment
    option</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted the underwriters an option for a period of up to 45 days to purchase, at the public offering price less underwriting
    discounts and commissions, up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional Ordinary Shares, to cover over-allotments, if any.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representative&rsquo;s
    Warrants</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    will issue to ThinkEquity LLC, the representative of the underwriters, or its permitted designees, representative&rsquo;s warrants,
    or the Representative&rsquo;s Warrants, to purchase up to Ordinary Shares. The Representative&rsquo;s Warrants will have an exercise
    price equal to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , or 125% of the per Ordinary Share assumed public offering price, will be exercisable beginning on a date which
    is 180 days from the commencement of sales under the registration statement of which this prospectus forms a part and will expire
    four and a half years from such commencement of sales.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
    of proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0">We expect to receive approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million in net proceeds from the sale of Ordinary Shares offered by us in this offering (approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their over-allotment option in full), based upon an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">We intend to
                                            use the net proceeds from this offering, for our research and development efforts, sales
                                            and marketing activities, as well as general and administrative corporate purposes, including
                                            working capital and capital expenditures. We currently expect that such use of the net proceeds
                                            from this offering would specifically support the completion of our Intranasal Naloxone program,
                                            including the submission of our New Drug Application, or NDA, with the U.S. Food and Drug
                                            Administration, or the FDA, and for pre-commercial activities; the development of our Intranasal
                                            Epinephrine program, including, technology scale-up, pivotal trial, and the submission of
                                            our NDA to the FDA and pre-commercial activities; and the development of two additional early-stage
                                            indications, which we have not yet chosen and will be determined at a later date.</P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                              <P STYLE="margin-top: 0; margin-bottom: 0">The amounts and schedule of our actual expenditures will depend on multiple factors. As a result, our management will have broad discretion in the application of the net proceeds of this offering. See &ldquo;Use of Proceeds&rdquo; for more information about the intended use of proceeds from this offering.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock
    Up</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    directors and executive officers have agreed with the underwriters not to offer for sale, issue, sell, contract to sell, pledge
    or otherwise dispose of any of our Ordinary Shares or securities convertible into Ordinary Shares for a period of six months
    commencing on the date of this prospectus, and six months commencing on the date of this prospectus in the case of any other holder
    of outstanding securities. See &ldquo;<I>Underwriting</I>.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
    factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
    in our securities involves a high degree of risk. You should read the &ldquo;Risk Factors&rdquo; section starting on page <FONT>9
    </FONT>of this prospectus for a discussion of factors to consider carefully before deciding to invest in the Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed
    NYSE American symbol</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to apply to list the Ordinary Shares to be issued in this offering on the NYSE American under the symbol &ldquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .&rdquo;
    This offering is contingent upon the Ordinary Shares being listed on the NYSE American. There is no assurance  that such
    listing will be approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    actual number of Ordinary Shares that we will offer and that will be outstanding after this offering will be determined based on
    the actual public offering price.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            number of the Ordinary Shares to be outstanding immediately after this offering as shown
                                            above assumes that all of the Ordinary Shares offered hereby are sold, and is based on 1,444,359
                                            Ordinary Shares outstanding as of June 30, 2024. This number excludes:</FONT></P>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
     Ordinary Shares issuable upon the exercise of options, or share options, granted subsequent to June 30, 2024, at a weighted
    average exercise price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary
    share; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,688 </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary Shares issuable upon the exercise of
    share options to directors, employees and consultants under our 2019 Incentive Option Plan, or the 2019 Plan, outstanding as of June
    30, 2024, at a weighted average exercise price of $12.96, of which 37,054 were vested as of June 30, 2024, and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> &#9679; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 38,702 Ordinary Shares reserved for future grants under the 2019
                                                                              Plan as of February 5, 2025. </P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Unless
otherwise indicated, all information in this prospectus assumes or gives effect to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    automatic conversion of all outstanding existing classes of Ordinary Shares, including Class A, Class A-1, Class
    A-2, Class A-3 Ordinary Shares into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    Ordinary Shares, which will occur upon the consummation of this offering;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">35,243
                                            Ordinary Shares issuable upon the conversion of 35,243 Class A-3A Ordinary Shares that were
                                            issued upon the conversion of Simple Agreements for Future Equity, or SAFEs, entered into
                                            between February 2022 and April 2022, collectively the 2022 SAFEs, with approval at a special
                                            meeting of our shareholders on August 28, 2024; immediately prior to the consummation of this offering, such Class A-3A Ordinary Shares will automatically convert
into Ordinary Shares;</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0">63,958 Ordinary Shares issuable
                                            upon the conversion of 63,958 Class A-3B Ordinary Shares that were issued upon the conversion
                                            of SAFEs, entered into between March 2023 and April 2023, collectively the 2023 SAFEs, with
                                            approval at a special meeting of our shareholders on August 28, 2024; immediately prior to
                                            the consummation of this offering, such Class A-3B Ordinary Shares will automatically convert
                                            into Ordinary Shares;</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    Ordinary Shares issuable upon the conversion of SAFEs entered into between March 2024 and January 2025, or, collectively,
    the 2024 SAFEs, in the aggregate amount of $1,<FONT STYLE="background-color: white">757</FONT>,992, which will automatically convert into Ordinary Shares immediately prior to
    the consummation of this offering, based on an offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , which
    is the midpoint of the price range set forth on the cover page of this prospectus, assuming this offering occurs within 18 months
    of the execution of such SAFEs, otherwise such SAFEs will be converted into our securities on the basis of a previous round of equity
    financing consummated by the Company; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    adoption of our amended and restated articles of association prior to the closing of this offering, which will replace our amended
    and restated articles of association as currently in effect; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the underwriters&rsquo; over-allotment option <FONT STYLE="background-color: white">and the Representative&rsquo;s Warrants.</FONT></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUMMARY
FINANCIAL DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our financial data. We have derived the following statements of operations data for the years ended December
31, 2023 and 2022 from our audited financial statements, which are included elsewhere in this prospectus. We have derived the following
statements of operations data for the six months ended June 30, 2024 and 2023 and balance sheet data as of June 30, 2024 from our unaudited
interim consolidated financial statements, which are included elsewhere in this prospectus. Such financial statements have been prepared
in accordance with U.S. GAAP. Our historical results are not necessarily indicative of the results that may be expected in the future.
The following summary financial data should be read in conjunction with &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations</I>&rdquo; and our financial statements and related notes, which are included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements included in this prospectus were prepared in accordance with U.S. GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">Six Months Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic; text-align: left">U.S. dollars in thousands,
    except share and per share data</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">Consolidated statements of operations:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Unaudited</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 36%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</SUP></FONT></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">567</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,116</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">168</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">229</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General and administrative<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">580</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">926</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">315</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">327</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,147</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,042</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">483</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">Operating loss from continuing operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,147</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,042</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(483</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense<SUP STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(49</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in fair value of convertible securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">219</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(88</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(379</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">391</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left">Other income (expenses), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(28</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,005</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,152</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(885</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(184</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income (loss) from
discontinued operations</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(46</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">441</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,051</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1,711</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(871</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(214</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Per share data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss per share attributable to shareholders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.73</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(1.18</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.60</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.15</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.95</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.18</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.60</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.45</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average Ordinary Shares outstanding - basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,444,359</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,444,296</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,444,359</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,444,359</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average Ordinary Shares outstanding - diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,479,602</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,444,296</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,444,359</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,479,602</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development expenses includes $228 thousand and $231 thousand in expenses to related parties in the years ended December 31,
    2023 and 2022, respectively, and $103 thousand and $111 thousand in expenses to related parties in the six months ended June 30, 2024 and 2023,
respectively. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative expenses includes $288 thousand and $313 thousand in expenses to related parties in the years ended December 31,
    2023 and 2022, respectively, and $149 thousand and $140 thousand in expenses to related parties in the six months ended June 30, 2024 and 2023,
respectively. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expenses includes $27 thousand and $9 thousand in expenses to related parties in the years ended December 31, 2023 and 2022,
    respectively, and $12 thousand and $12 thousand in expenses to related parties in the six months ended June 30, 2024 and 2023,
    respectively. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt 0pt 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1pt solid">U.S. dollars in thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pro Forma</I> <SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pro Forma</I> As Adjusted <SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">Consolidated Balance Sheet Data:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center"><B>Unaudited</B></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">900</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,020</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,683</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,003</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total shareholders&rsquo; deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,663</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <I>pro forma</I> data gives effect to (i) the conversion of all outstanding Class A, Class A-1, Class A-2, Class A-3, Class A-3A
    and Class A-3B Ordinary Shares into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ordinary Shares; (ii) 37,688 Ordinary Shares
    issuable upon the exercise of share options held by directors, employees and consultants under our 2019 Plan, outstanding as of June
    30, 2024, at a weighted average exercise price of $12.96, of which 37,054 vested as of June 30, 2024 and 13,850 Ordinary Shares reserved
    for future grants under the 2019 Plan as of June 30, 2024; (iii) the issuance of&nbsp;&nbsp;&nbsp;35,243 and 63,958&nbsp;Class
    A-3A and Class A-3B Ordinary Shares, respectively, that were issued upon the conversion of the 2022 and 2023 SAFEs, respectively
    in August 2024 (iv) the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary Shares
    to be issued upon the conversion of the 2024 SAFEs into Ordinary Shares immediately prior to the consummation of this offering; and
    (v) our receipt in November 2024 through January 2025 of aggregate proceeds of $170,000 from the 2024 SAFEs
    we entered into with certain investors. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <I>pro forma</I> as adjusted data gives effect to the <I>pro forma</I> adjustments set forth above and the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary
    Shares in this offering, at an assumed public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per Ordinary
    Share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting the underwriting
    discounts and commissions and estimated offering expenses, as if the sale of the Ordinary Shares had occurred on June 30, 2024.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Da_002"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.5pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
investment in our securities involves a high degree of risk. We operate in a dynamic and rapidly changing industry that involves numerous
risks and uncertainties. You should consider carefully the risks and uncertainties described below, together with all of the other information
in this prospectus, including the financial statements and the related notes included elsewhere in this prospectus, before deciding whether
to invest in our securities. If any of the risks discussed below actually occur, our business, financial condition, operating results
or cash flows could be materially adversely affected. This could cause the trading price of our Ordinary Shares to decline, and you may
lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. Our
actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including
the risks faced by us described below and elsewhere in this prospectus. See &ldquo;Cautionary Note Regarding Forward-Looking Statements.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Position and Capital Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>We have not generated revenues from our continued activities, have incurred significant losses since our inception
and anticipate that we will continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability,
which raise a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining new financing on
reasonable terms or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated revenues from our continued activities, we have incurred substantial operating losses, and funded our
operations primarily through equity financing and the raise of outside capital. As of December 31, 2023 and June 30, 2024, we
incurred accumulated deficit of approximately $11.1 million and $12.0 million, respectively. Management expects us to
continue to generate substantial operating losses and to continue to fund our operations primarily through the utilization of our
current financial resources, and through additional raises of capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
we can generate significant revenues, we expect to satisfy our future cash needs through existing cash, debt or equity financing. We
expect to require additional financing to fund our operations in the near future. Because of the numerous risks and uncertainties associated
with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if,
we will be able to begin generating revenue from the commercialization of any products or achieve or maintain profitability. Our expenses
will also increase substantially if and as we proceed with development. We cannot be certain that additional funding will be available
to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate research
or development plans for, or commercialization efforts with respect to our products and it risks our ability to continue operating as
a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
events and conditions, along with other matters, indicated that a material uncertainty existed as of June 30, 2024, that raises
substantial doubt on our ability to continue as a going concern. The report of our auditors for our financial statements for the period
ended December 31, 2023 contains an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.
Our financial statements for the year ended December 31, 2023 and for the six months ended June 30, 2024 do not reflect any adjustments
that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are a clinical stage biopharmaceutical company and we have incurred significant operating losses since our inception and anticipate that
we will incur continued losses for the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an emerging pharmaceutical company with a limited operating history. We have funded our operations to date primarily through proceeds
from the private placement of securities, credit facilities, loans, convertible notes and revenues from our past legacy product and business
operations and activities. We expect to continue to incur substantial losses over the next several years during our clinical development
phase. To fully execute our business plan, which we estimate will cost between $18 and $22 million, we will need to complete Phase 2
clinical studies and certain development activities as well as manufacture the required clinical and commercial production batches in
the pilot manufacturing plant. Further, our product candidates will require regulatory approval prior to commercialization, and we will
need to establish sales, marketing and logistic infrastructures. These activities may span many years and require substantial expenditures
to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact us. Management plans
to seek additional equity financing through private and public offerings or strategic partnerships and, in the longer term, by generating
revenues from product sales. We have incurred losses in each year since our inception. Our net loss for the years ended December 31,
2023 and 2022 were $ 1.1 million and $1.7 million, respectively, and our net loss for the six months ended June 30, 2024 and 2023
were $0.8 million and $0.2 million, respectively. As of June 30, 2024, we had an accumulated deficit of approximately $12.0
million. Substantially all of our operating losses resulted from costs incurred in connection with epinephrine development, compensation
and general and administrative costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Until
we can generate significant revenues, if ever, we expect to satisfy our future cash needs through existing cash, debt or equity financing.
We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may
be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization efforts with respect
to our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our research and development expenses to increase in connection with our planned expanded clinical trials. In addition, if we
obtain marketing approval for Intranasal Naloxone and Intranasal Epinephrine or any other current or future product candidate, we will
likely incur significant sales, marketing and outsourced manufacturing expenses, as well as continued research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
in addition to such operating expenses, we expect to incur additional costs associated with operating as a public company subject to
the rules and regulations of the SEC, which we estimate will be at least $1 million dollars annually. As a result, we expect to continue
to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated
with developing a pharmaceutical candidate, we are unable to predict the extent of any future losses or when we will become profitable,
if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant losses until we are able to commercialize our product candidates, which we may not be successful
in achieving. We anticipate that our expenses will increase substantially if and as we:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    the research and development of our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    the scope of our current clinical studies for our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory and marketing approvals for our product candidates that successfully complete clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
    a sales, marketing, and distribution infrastructure to commercialize our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    to identify, assess, acquire, license, and/or develop other product candidates and subsequent generations of our current product
    candidates; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    to maintain, protect, and expand our intellectual property portfolio; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    to attract and retain skilled personnel; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create
    additional infrastructure to support our operations as a public company and our product candidate development and planned future
    commercialization efforts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Notwithstanding
our legacy product and business activity, we have not generated revenue from any product candidate and may never be profitable, even
if we receive regulatory approval to commercialize our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from our development
stage product candidates, other than from our legacy product and past business activities. In order to generate significant revenue,
we will need to obtain additional regulatory approvals in jurisdictions within which we already have certain regulatory approvals and
also in jurisdictions in which we currently have no regulatory approvals to market our products. Even if our current products or any
future products are approved for marketing and sale, we anticipate incurring significant incremental costs associated with commercializing
such products, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    favorable results from and progress the pre-clinical and clinical development of our product candidates, namely Intranasal Naloxone
    and Intranasal Epinephrine; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
    and obtaining regulatory approval for registration studies protocols for our product candidates, namely Intranasal Naloxone and Intranasal
    Epinephrine;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to successful completion of registration and clinical trials of Intranasal Naloxone and Intranasal Epinephrine, applying for and
    obtaining marketing approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and maintaining supply and manufacturing relationships with third parties that can provide adequate (in amount and quality) products,
    and at acceptable costs, to support market demand for our product candidates, if marketing approval is received;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying,
    assessing, acquiring and/or developing new product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">accurately
    identifying demand for our product candidates; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continued
    consumer interest in treatments for products for intranasal drug delivery; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    market acceptance of our product candidates, if approved for marketing, as viable treatment options;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating
    favorable terms in any collaboration, licensing or other arrangements into which we may enter; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;obtaining
    and maintaining CIV labelling (no FDA imposed boxed warning, commonly referred to as a &#8220;Black Box&#8221; warning) of our lead
    and follow-on product candidates, Intranasal Naloxone and Intranasal Epinephrine, respectively; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    and nurturing relationships with the leading physicians in the United States; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attracting,
    hiring and retaining qualified personnel.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial
doubt about our ability to continue as a going concern.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not believe that our current cash on hand will be sufficient to fund our projected operating requirements. This raises substantial
doubt about our ability to continue as a going concern. If we cannot continue as a going concern, our investors may lose their entire
investment in our securities. Until we can generate significant revenues, if ever, we expect to satisfy our future cash needs through
debt or equity financing. Even if we raise the proceeds from this offering, we do not believe that
such proceeds will be sufficient to complete all research and development activities necessary to commercialize our product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, if at all.
If funds are not available, we may be required to delay, reduce the scope of, or eliminate research or development plans for, or commercialization
efforts with respect to our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have identified material weaknesses in our internal control over financial reporting. If our remediations are not effective, or if we
experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the
future, we may not be able to accurately or timely report our financial conditions or results or operations, or prevent fraud, which
may adversely affect investor confidence in our Company and as a result, the market price of our Ordinary Shares.</I></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we will be required to maintain internal control over financial reporting and will be required to report any material
weaknesses in such internal control. Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, requires that we include
a report from management on the effectiveness of our internal control over financial reporting in our annual report on Form 20-F. In
addition, once we cease to be an EGC as such term is defined in the JOBS Act, our independent registered public accounting firm must
attest to and report on the effectiveness of our internal control over financial reporting. According to the U.S. Public Company Accounting
Oversight Board, a material weakness is a deficiency or combination of deficiencies in internal control over financial reporting such
that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on
a timely basis. If we fail to remediate the material weaknesses, or are otherwise unable to maintain effective internal control over
financial reporting, management could be required to expend significant resources and we could fail to meet our public reporting requirements
on a timely basis, and be subject to fines, penalties (including any penalties associated with late filing of tax returns), investigations
or judgements, all of which could negatively affect investor confidence and adversely impact our stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we identified a material weakness with our internal control over financial reporting as we had not designed or
maintained an effective control environment and associated control activities to meet our accounting and reporting requirements. Specifically,
we did not have a sufficient complement of personnel with an appropriate degree of internal controls and accounting knowledge, we have
not performed a documented risk assessment process to identify and analyze risks of misstatement due to error and/or fraud,
have not documented our financial reporting processes, have not implemented, documented, or tested internal controls over financial
reporting and, in certain cases, we did not have appropriate reviews over journal entries and third party reported information to
allow for reliable and timely financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">All of our existing material weaknesses may not have been identified, and we may in the future identify additional
material weaknesses. Our management did not perform an evaluation of our internal control over financial reporting during any period in
accordance with the provisions of Sarbanes-Oxley Act. Had we performed an evaluation of our internal control over financial reporting
in accordance with the provisions of Sarbanes-Oxley Act, additional control deficiencies amounting to material weaknesses may have been
identified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will take steps to develop a plan to remediate the material weakness identified above and to strengthen our internal control
over financial reporting. This involves assessing risk factors, understanding process gaps, and pinpointing areas that needed improvement.
We cannot assure investors that our future remediation plan will be sufficient to establish and maintain effective internal control over
financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if this offering is successful, we expect that we will need to raise substantial additional funding before we can expect to complete
the development of Intranasal Naloxone and Intranasal Epinephrine or any other product candidate. This additional financing may not be
available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate
our product candidate development efforts or other operations. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, our cash and cash equivalents were approximately $0.9 million, and we had a working capital deficit of $4.8 million
and an accumulated deficit of $12.0 million. Based upon our currently expected level of operating expenditures, we expect that our existing
cash and cash equivalents will be sufficient to fund operations through June 2025. Even if this offering is completed, we expect
that we will require substantial additional capital to commercialize our product candidates. In addition, our operating plans may change
as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future
funding requirements will depend on many factors, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    clinical trial results;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost, timing and outcomes of seeking marketing approval of Intranasal Naloxone and Intranasal Epinephrine;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of filing and prosecuting patent applications and the cost of defending our patents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    cost of prosecuting patent infringement actions against third parties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">development
    of other early-stage development product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with commercializing Intranasal Naloxone and Intranasal Epinephrine if we receive marketing approval, including
    the cost and timing of establishing sales and marketing capabilities to market and sell Intranasal Naloxone and Intranasal Epinephrine;
    </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to receipt of marketing approval, revenue received from sales of approved products, if any, in the future;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    product liability or other lawsuits related to our products; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    expenses needed to attract and retain skilled personnel; and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    costs associated with being a public company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 2.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to
develop and commercialize our product candidates. Moreover, the terms of any financing may adversely affect the holdings or the rights
of holders of our securities and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance,
may cause the market price of our common shares to decline. The incurrence of indebtedness could result in increased fixed payment obligations,
and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact
our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise
at an earlier stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or product
candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating
results and prospects. Even if we believe that we have sufficient funds for our current or future operating plans, we may seek additional
capital if market conditions are favorable or if we have specific strategic considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our
research or development programs or the development or commercialization, if any, of any product candidates or be unable to expand our
operations or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
agreements that we may enter into with lenders and future debt agreements may contain restrictions that may limit our flexibility in
operating our business. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may enter into credit facilities with certain lenders which contain restrictions, such as prohibiting that we merge into another company
or change our accounting standards, that could limit our flexibility in operating our business. Documents governing our future indebtedness,
or in connection with additional capital raises, if any, may contain, numerous financial and operating covenants that limit the discretion
of management with respect to certain business matters. Restrictive covenants included in the above-mentioned credit facility include
restrictions on, among others, our ability to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">create
    or permit to subsist any security interest over any of our assets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sell,
    transfer or otherwise dispose of any or our assets on recourse terms;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pay
    dividends;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">buy
    back our own securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur
    or permit additional indebtedness;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">merge
    or conduct any other corporate reconstruction; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">change
    the nature of our business.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to comply with these and other provisions of the existing debt agreements is dependent on our future performance, which will
be subject to many factors, some of which are beyond our control. The breach of any negative covenants in our current or future agreements
could result in an event of default, as may be defined in such agreements, thereby leading to a potential default interest rate or immediate
repayment of any borrowed amounts. These restrictive covenants which may be in place from time to time and a lack of compliance by us
could limit our flexibility in operating our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Unstable
market and economic conditions may have serious adverse consequences on our business, financial condition and share price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global economy, including credit and financial markets, has experienced extreme volatility and disruptions, including severely diminished
liquidity and credit availability, declines in consumer confidence, declines in economic growth, fluctuations in unemployment rates,
fluctuations in inflation rates and uncertainty about economic stability. For example, the ongoing conflicts between Ukraine and Russia
and in the Middle East have created volatility in the global capital markets and may have further global economic consequences, including
disruptions of the global supply chain and energy markets. Any such volatility and disruptions may have adverse consequences on us or
the third parties on whom we rely. If the equity and credit markets deteriorate, including as a result of political unrest or war, it
may make any necessary debt or equity financing more difficult to obtain in a timely manner or on favorable terms, more costly or more
dilutive. Inflation can adversely affect us by increasing our costs. Any significant increases in inflation and related increase in interest
rates could have a material adverse effect on our business, results of operations, financial condition and our ability to raise funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Product Development, Regulatory Approval and Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend substantially on the success of our proprietary intranasal powder product candidates. We cannot give any assurance that any of
our product candidates will receive regulatory approval, which is necessary before they can be commercialized.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have invested almost all of our efforts and financial resources in general and administrative costs and the research and development
of our intranasal powder product candidates. Our portfolio comprises a number of programs: Intranasal Naloxone (completed pivotal study)
and Intranasal Epinephrine (completed Phase 2) as well as a number of preclinical proof of concept (POC) programs. The process
to develop, obtain regulatory approval for and commercialize pharmaceutical product candidates is long, complex, costly and inherently
uncertain of outcome. We are not permitted to market any of our product candidates in the United States, European Union, or the EU, or
any other jurisdiction until we receive the requisite regulatory approvals. We cannot give any assurance that our current clinical development
plan will proceed as planned, or that our product candidates will receive regulatory approval, or that such regulatory approval, if received,
will be within a timeframe that allows us to effectively compete with our competitors, or be successfully marketed and commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have no product candidates approved for marketing and are investing the majority of our efforts and financial resources in
the development of NS001 and NS002 for the emergency treatment of opioid overdoses, allergic reactions and potential other indications.
Successful continued development and ultimate regulatory approval of NS001 and NS002 for our initial indication and potential additional
indications is critical to the future success of our business. We will need to successfully complete our clinical development of NS001
and NS002 for the emergency treatment of opioid overdoses, allergic reactions and other indications. The future regulatory and commercial
success of NS001 and NS002 and any future product candidates is subject to a number of risks, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    completion of nonclinical studies and clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    patient enrollment in clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    data from our nonclinical studies and clinical trials that support an acceptable risk-benefit profile of NS001 and NS002 or any future
    product candidates in the intended populations and indications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfaction
    of applicable regulatory requirements, including to satisfy applicable rules governing combination products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    unforeseen safety issues or adverse side effects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">receipt
    and maintenance of marketing approvals from applicable regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">remaining
    in compliance with post-marketing regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining patent and trade secret protection and regulatory exclusivity for NS001 and NS002, or any future product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">making
    arrangements or maintaining existing arrangements with third-party manufacturers, or establishing manufacturing capabilities, for
    both clinical and commercial supplies of NS001 and NS002 or any future product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">entry
    into collaborations to further the development of NS001 and NS002 or any future product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
    sales, marketing and distribution capabilities and launching commercial sales of any approved products, whether alone or in collaboration
    with others;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    launching commercial sales of NS001 and NS002 or any future product candidates, if and when approved;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of NS001 and NS002 or any future product candidates, if and when approved, by patients, the medical community and third-party payors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
    and maintaining third-party coverage and adequate reimbursement;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">products,
    following approval, maintaining a continued acceptable safety profile;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">effectively
    competing with other therapies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ensuring
    that we promote and distribute our products consistent with all applicable healthcare laws; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcing
    and defending intellectual property rights and claims.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of these risks are beyond our control, including the risks related to clinical development, the regulatory submission and review process,
potential threats to our intellectual property rights and the manufacturing, marketing and sales efforts of any current or future collaboration
partner. If we are unable to develop, receive regulatory approval for, or successfully commercialize NS001 and NS002 for the indications
we are developing it for, or if we experience delays as a result of any of these risks or otherwise, our business will be materially
harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, of the large number of products in development in the pharmaceutical industry, only a small percentage result in the submission
of an NDA to the FDA or a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, and even fewer are approved
for marketing and commercialization. Furthermore, even if we receive regulatory approval to market NS001 and NS002 for any indication,
any such approval may be subject to limitations on the indications or uses or the patient populations for which we may market the product.
Accordingly, even if we are able to obtain the requisite financing to continue to fund our development activities, we cannot assure you
that we will successfully develop or commercialize NS001 and NS002 for any indication. If we or any of our current or future licensing
and collaboration partners are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize NS001
and NS002 for its initial indication or potential additional indications, we may not be able to generate sufficient revenue to continue
our business. In addition, our failure to satisfy other regulatory requirements could adversely affect our development efforts for <I>NS001
</I>and <I>NS002</I> in other indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
</I></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>product candidates are in different
stages of clinical development. Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain
outcomes. If clinical trials of our product candidates are prolonged, delayed or not commercially viable, we or our collaborators may
be unable to obtain required regulatory approvals, and therefore may be unable to commercialize our product candidates on a timely basis
or at all, which will adversely affect our business. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain the requisite regulatory approvals to market and sell any of our product candidates, we or our collaborators for such candidates
must demonstrate through extensive preclinical studies and clinical trials that our products are safe, pure and potent or effective in
humans. Further, the process of obtaining regulatory approval is expensive, often takes many years following the commencement of clinical
trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target
indications and patient population. Prior to obtaining approval to commercialize a product candidate in the United States or abroad,
we or our potential future collaborators must demonstrate with substantial evidence from adequate and well-controlled clinical trials,
and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective
for their intended uses. Additionally, clinical testing is expensive and can take many years to complete, and its outcome is inherently
uncertain. Failure can occur at any time during the clinical trial process and our future clinical trial results may not be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to commence or complete the clinical trials that would support our submission of an NDA to the FDA or a MAA to
EMA. Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical
trials. Clinical trials can be delayed or prevented for a number of reasons, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    obtaining regulatory approval to commence a clinical trial or complying with conditions imposed by a regulatory authority regarding
    the scope or term of a clinical trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in reaching or failing to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and trial
    sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficient
    or inadequate supply or quality of a product candidate or other materials necessary to conduct our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the FDA or EMA elect to enact policy changes, as a result of the COVID-19 pandemic or otherwise;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">challenges
    recruiting and enrolling patients to participate in clinical trials for a variety of reasons, including fears resulting from the
    COVID-19 pandemic or due to government actions enacted and as a result of such pandemic, size and nature of patient population, proximity
    of patients to clinical sites, eligibility criteria for the trial, nature of trial protocol, the availability of approved effective
    treatments for the relevant disease and competition from other clinical trial programs for similar indications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended
or terminated by us, the FDA, IRBs, at the sites where the IRBs are overseeing a trial, a data safety
monitoring board overseeing the clinical trial at issue or by other regulatory authorities due to a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inspection
    of the clinical trial operations or trial sites by the FDA or other regulatory authorities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    safety issues or lack of effectiveness; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">lack
    of adequate funding to continue the clinical trial.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause,
or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval
of our product candidates or result in the development of our product candidates being stopped early.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
denial of regulatory approval for NS001 and NS002 could mean that we need to delay or even cease operations, and a delay in obtaining
such approval would delay commercialization of our products and adversely impact our ability to generate revenue, business and results
of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.75pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are not successful in commercializing NS001 and NS002, or are significantly delayed in doing so, our business will be materially harmed,
and we may need to curtail or cease operations. We currently have no pharmaceutical products approved for marketing, and we may never
obtain regulatory approval to market and commercialize NS001 and NS002 for any indication. The research, testing, manufacturing, labeling,
approval, sale, marketing and distribution of pharmaceutical products are subject to extensive regulation by the FDA, the EMA, and other
regulatory agencies in the United States, EU and other countries, and such regulations differ from country to country. We are not permitted
to market NS001 and NS002 until we receive approval or marketing authorization from the relevant regulatory authority. Of the large number
of pharmaceutical products in development, only a small percentage successfully complete the FDA, the EMA or other regulatory approval
processes and are commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we eventually complete clinical testing and receive approval of an NDA, MAA or other foreign marketing authorization for NS001 and
NS002, the FDA, the EMA or other applicable foreign regulatory agency may grant approval contingent on the performance of costly additional
clinical trials, which may be required after approval. The FDA, the EMA or other applicable foreign regulatory agency may also approve
NS001 and NS002 for a more limited indication and/or a narrower patient population than we originally request, and the FDA, the EMA or
any other applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful
commercialization of NS001 and NS002. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would delay or
prevent commercialization of NS001 and NS002 and would materially adversely impact our business and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
results of pre-clinical studies, early-stage clinical trials, data obtained from real-world use, and published third-party studies may
not be indicative of results in future clinical trials and we cannot assure you that any planned or future clinical trials will lead
to results sufficient for the necessary regulatory approvals.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
results of pre-clinical studies may not be predictive of the results of clinical trials, and the results of any completed clinical trials,
including studies derived from real-world use and studies in published literature, or clinical trials we commence may not be predictive
of the results of later-stage clinical trials. Additionally, interim results during a clinical trial do not necessarily predict final
results. Later clinical trial results may not replicate earlier clinical trials for a variety of reasons, including differences in trial
design, different trial endpoints (or lack of trial endpoints in exploratory studies), subject population, number of subjects, subject
selection criteria, trial duration, drug dosage and formulation and lack of statistical power in the earlier studies There can be no
assurance that any of our clinical trials will ultimately be successful or support further clinical development of any of our product
candidates. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development
even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a negative impact
on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
or others could discover that NS001 and NS002, or any product candidate we may pursue in the future, lacks sufficient efficacy,
or that it causes undesirable side effects that were not previously identified, which could delay or prevent regulatory approval or commercialization.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any FDA approved products and </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
product candidates have been tested in relatively small patient populations and for limited durations to date. Therefore, our
product candidates require additional clinical testing and it is possible that our clinical trials have or will indicate an apparent
positive effect that is greater than the actual positive effect, if any, or that additional and unforeseen side effects may be observed
as its development progresses. The discovery that NS001 or NS002 lacks sufficient efficacy, or that it causes undesirable side effects
(including side effects not previously identified in our completed clinical trials), could cause us or regulatory authorities to interrupt,
delay or discontinue clinical trials and could result in the denial of regulatory approval by the FDA or other non-U.S. regulatory authorities
for any or all targeted indications, including, but not limited to, a determination by the FDA that the 505(b)(2) regulatory pathway is not available
for a product candidate. The most common events reported to date have been tachycardia, hypertension, headache, anxiety,
apprehension, palpitations, diaphoresis, nausea, vomiting, weakness, and tremors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
discovery that NS001 or NS002, or any future product candidate, lacks sufficient efficacy or that it causes undesirable
side effects that were not previously identified could prevent us from commercializing such product candidate and generating revenues
from its sale. In addition, if we receive marketing approval for any of our current or future products and we or others later discover
that it is less effective, or identify undesirable side effects caused by them:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may withdraw their approval of the product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to recall the product, change the way this product is administered, conduct additional clinical trials or change
    the labeling or distribution of the product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    restrictions may be imposed on the marketing of, or the manufacturing processes for, the product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be subject to fines, injunctions or the imposition of civil or criminal penalties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    product may be rendered less competitive and sales may decrease; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    reputation may suffer generally both among clinicians and patients.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
one or a combination of these events could prevent us from achieving or maintaining market acceptance of the affected product or could
substantially increase the costs and expenses of commercializing the product, which in turn could delay or prevent us from generating
significant, or any, revenues from the sale of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
clinical trials or the clinical trials of any of our current or potential future partners may encounter delays, suspensions or other
problems.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
or our partners, may encounter problems in clinical trials that may cause us or the FDA or foreign regulatory agencies to delay, suspend
or terminate any such clinical trials at any phase. These problems could include the possibility that we may not be able to conduct clinical
trials at our preferred sites, enroll a sufficient number of patients for our clinical trials at one or more sites or begin or successfully
complete clinical trials in a timely fashion, if at all. Furthermore, we, our partners, the FDA or foreign regulatory agencies may suspend
clinical trials at any time if we or they believe the subjects participating in the trials are being exposed to unacceptable health risks
or if we or they find deficiencies in the clinical trial process or conduct of the investigation. If clinical trials of any of our products
fail, we will not be able to market the product which is the subject of the failed clinical trials. The FDA and foreign regulatory agencies
could also require additional clinical trials, which would result in increased costs and significant development delays. Our, or our
partners&rsquo;, failure to adequately demonstrate the safety and effectiveness of a product under development could delay or prevent
regulatory approval of the product and could have a material adverse effect on our business, prospects, financial condition and results
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
approval of an NDA or an MAA, even after clinical trials that are believed to be successful, is an uncertain process.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not permitted to market our products in the United States or the EU until we receive regulatory approval of an NDA from the FDA,
or MAA from the EMA, or in any foreign countries until we receive the requisite approval from regulatory authorities in such countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we complete our planned clinical trials and believe the results to be successful, all of which are uncertain, obtaining regulatory
approval is an extensive, lengthy, expensive and uncertain process, and the FDA and EMA, and other regulatory authorities may delay,
limit or deny approval of our products for many reasons, including, but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not be able to demonstrate to their satisfaction that the product candidate is a safe or effective treatment for a given indication;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    results of clinical trials may not meet the level of statistical significance or clinical significance required by the regulatory
    agencies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disagreements
    regarding the number, design, size, conduct or implementation of our clinical trials, or with our interpretation of data from pre-clinical
    studies or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    lack of acceptance of the accuracy or sufficiency of the data generated at our clinical trial sites to demonstrate, among others,
    that clinical and other benefits outweigh its safety risks or to support the submission of an NDA or MAA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    scheduling an advisory committee meeting in a timely manner or the advisory committee, or such other similar committee, may recommend
    against approval of our application or may recommend that such regulators require, as a condition of approval, additional pre-clinical
    studies or clinical trials, limitations on approved labeling, or distribution and use restrictions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    requirement that we develop a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval, which may or may not
    be feasible for us;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    identification of deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we enter into
    agreements for clinical and commercial supplies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in approval policies or the adoption of new regulations by such regulators; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be unable to be granted a pediatric investigation plan, or PIP, deferral which we intend to request from the EMA for delayed
    clinical trials and subsequent approval in children; this may delay our clinical trial program or approvals for adults, or we may
    have successful clinical trial results for adults but not children (if we were required to conduct pediatric studies prior to the
    receipt of an NDA or MMA for use of our product candidates in adults), or vice versa.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
before we can submit an NDA to the FDA, we must conduct Phase 3 trials (pharmacokinetic and bioavailability studies) that will be substantially
broader than our Phase 2 trials. An NDA must be supported by extensive clinical and pre-clinical data, as well as extensive information
regarding chemistry, manufacturing and controls to demonstrate the safety and effectiveness of the applicable product candidate. The
number and types of pre-clinical studies and clinical trials that will be required varies depending on the product candidate, the disease
or condition that the product candidate is designed to target and the regulations applicable to any particular product candidate. Obtaining
approval of an NDA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. The FDA review
processes can take years to complete and approval is never guaranteed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
this respect, we will also need to agree on a protocol with the FDA for the Phase 3 clinical trials before commencing those trials. Phase
3 clinical trials frequently produce unsatisfactory results even though prior clinical trials were successful. Therefore, the results
of the additional trials that we conduct may or may not be successful. The FDA may suspend all clinical trials or require that we conduct
additional clinical, nonclinical, manufacturing validation or drug product quality studies and submit those data before it will consider
or reconsider the NDA. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed
by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if
performed and completed, may not be considered sufficient by the FDA to approve the NDA. If any of these outcomes occur, we would not
receive approval at such time, if any, that we seek FDA approval. We may face similar risks with respect to obtaining regulatory approval
from the EMA at such time, if any, that we seek EMA approval. The risks that we face in obtaining applicable approvals from the FDA and
EMA Intranasal Naloxone and Intranasal Epinephrine, or any other product candidate that we may seek to develop, may also exist with other
regulatory authorities, such as those in Latin America or other regions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain FDA, EMA or other regulatory approval for Intranasal Naloxone and Intranasal Epinephrine, the approval might contain significant
limitations related to use restrictions, warnings, precautions or contraindications, or may be subject to significant post-marketing
studies or risk mitigation requirements. If we are unable to successfully commercialize Intranasal Naloxone and Intranasal Epinephrine,
we may be forced to cease operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Preliminary
data that we or others announce or publish from time to time with respect to our product candidates may change as more data become available
and are subject to audit and verification procedures that could result in material changes in the final data.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we, or our partners, may publish or seek to publish preliminary data from ongoing clinical trials, which are based on a
preliminary analysis of then-available data. Positive preliminary data may not be predictive of such trial&rsquo;s subsequent or overall
results. Preliminary data are subject to the risk that one or more of the results and related findings and conclusions may materially
change following a more comprehensive review of the data or as more data become available. Therefore, positive preliminary results in
any ongoing clinical trial may not be predictive of such results in the completed trial. We also make assumptions, estimations, calculations
and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. As a
result, preliminary data that we report may differ from future results from the same clinical trials, or different conclusions or considerations
may qualify such results, once additional data have been received and fully evaluated. Preliminary data also remain subject to audit
and verification procedures that may result in the final data being materially different from the preliminary data we previously published.
As a result, preliminary data should be viewed with caution until the final data are available. Material adverse changes in the final
data compared to preliminary data could significantly harm our business prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose
to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others
may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line
or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions
reached, our ability to obtain approval for, and commercialize, in scale, our product candidates may be harmed, which could harm our
business, operating results, prospects or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
results of clinical trials conducted at clinical sites outside the United States may not be accepted by the FDA and the results of clinical
trials conducted at clinical sites in the United States may not be accepted by international regulatory authorities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to conduct some of our clinical trials outside the United States. For example, we are planning to globally develop Intranasal Naloxone
in Canada. We performed our pivotal study for Naloxone in Canada in an FDA approved facility. However, although the FDA may accept data
from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA.
For example, the clinical trial must be well-designed and conducted and performed by qualified investigators in accordance with ethical
principles such as or IRB or ethics committee approval and informed consent. The study population must also adequately represent the
U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically
meaningful. Generally, the subject population for any clinical trials conducted outside of the United States must be representative of
the U.S. population. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will
be dependent upon its determination that the trials were conducted consistent with all applicable U.S. laws and regulations. There can
be no assurance the FDA or international regulatory authorities will accept data from trials conducted outside of the United States or
inside the United States, as the case may be, as adequate support of a marketing application. If the FDA does not accept the data from
sites in our globally conducted clinical trials, or if international regulatory authorities do not accept the data from our U.S. clinical
trials, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently
halt the development of one or more of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval,
limit the commercial potential or result in significant negative consequences following regulatory approval, if obtained. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the conduct of clinical trials, patients may experience changes in their health, including illnesses, injuries, discomforts or a fatal
outcome. It is possible that as we develop Intranasal Naloxone and Intranasal Epinephrine, or other product candidates that we may seek
to develop, in larger, longer and more extensive clinical trials as use of our product candidates becomes more widespread if they receive
regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier clinical trials, as well
as conditions that did not occur or went undetected in previous clinical trials, will be reported by subjects. Many times, side effects
are only detectable after investigational products are tested in larger scale, Phase 2 and 3 clinical trials or, in some cases, after
they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that Intranasal
Naloxone and Intranasal Epinephrine, or other product candidates that we may seek to develop, have side effects or cause serious or life-threatening
side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval,
such approval may be revoked or limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
if any of our product candidates receives marketing approval, the FDA or EMA could require us to adopt a REMS to ensure that the benefits
outweigh its risks, which may include, among other things, a medication guide outlining the risks of the product for distribution to
patients, a communication plan to health care practitioners, and restrictions on how or where the product can be distributed, dispensed
or used. Furthermore, if we or others later identify undesirable side effects caused by Intranasal Naloxone and Intranasal Epinephrine,
several potentially significant negative consequences could result, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may suspend or withdraw approvals of such a product candidate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may require additional warnings on the label;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    authorities may issue negative publicity regarding the affected product, including safety communications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may be required to change the way the product is distributed, dispensed or administered, or conduct additional pre-clinical studies
    or clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may need to voluntarily recall our products; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    could be sued and held liable for harm caused to patients.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could significantly
harm our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in methods of product candidate manufacturing or formulation may result in additional costs or delay. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
product candidates proceed through pre-clinical studies to late-stage clinical trials towards potential approval and commercialization,
it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way
in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any
of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other
future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing,
FDA or EMA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials
or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize
our ability to commence sales and generate revenue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to obtain FDA approval of any proposed names for our product candidates that gain marketing approval, and any failure or delay
associated with such naming approval may adversely impact our business. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
name we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal trademark
registration from the U.S. Patent and Trademark Office, or the U.S. PTO. The FDA typically conducts a review of proposed product names,
including an evaluation of whether proposed names may be confused with the names of other drug products. The FDA may object to any product
name we submit if it believes the name inappropriately implies medical claims. If the FDA objects to any of our proposed product names,
we may be required to adopt an alternative name for our product candidates, which could result in further evaluation of proposed names
with the potential for additional delays and costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, which may result in necessary changes
to clinical trial protocols, which could result in increased costs to us, delay our development timeline or reduce the likelihood of
successful completion of our clinical trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, as a result of which we may need
to amend clinical trial protocols. Amendments may require us to resubmit our clinical trial protocols to IRBs for review and approval,
which may impact the cost, timing or successful completion of a clinical trial. If we experience delays in completion of, or if we terminate,
any of our clinical trials, the commercial prospects for our products would be harmed and our ability to generate product revenue would
be delayed, possibly materially.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
development and regulatory strategy for our product candidates depends in part on published scientific literature and the FDA&rsquo;s
prior findings regarding the safety and efficacy of approved product candidates. If the FDA does not conclude that our product candidates
satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for our product candidates under
Section 505(b)(2) are not as we expect, the approval pathway would likely take significantly longer, cost significantly more and entail
significantly greater complications and risks than anticipated and in either case may not be successful. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Amendments, added Section 505(b)(2) to
the FFDCA, or Section 505(b)(2). Section 505(b)(2) permits the submission of an NDA where at least some of the information required
for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference.
We intend to seek FDA approval through the Section 505(b)(2) regulatory pathway for Intranasal Naloxone and Intranasal Epinephrine and
may seek this regulatory pathway for other product candidates that we seek to develop, <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">which we believe could expedite the development
program for Intranasal Naloxone and Intranasal Epinephrine by potentially decreasing the amount of preclinical and clinical data that
we would need to generate in order to obtain FDA approval. However, while we believe that Intranasal Naloxone and Intranasal Epinephrine
a reformulation of already-approved drugs and, therefore, will be eligible for submission of an NDA under Section 505(b)(2), the FDA may
disagree and determine that are not eligible for review under such regulatory pathway</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA does not allow us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical
trials, provide additional data and information and meet additional standards for regulatory approval. If this were to occur, the time
and financial resources required to obtain FDA approval, and complications and risks associated with FDA approval, would substantially
increase. We may need to obtain additional funding, which could result in significant dilution to the ownership interests of our then
existing shareholders to the extent we issue equity securities or convertible debt. We cannot assure you that we would be able to obtain
such additional financing on terms acceptable to us, if at all. Moreover, inability to pursue the Section 505(b)(2) regulatory pathway
could result in new competitive product candidates reaching the market faster than our product candidates, which could materially adversely
impact our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, we cannot assure
you that our product candidates will receive the requisite approvals for commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2) over the last few years, certain competitors
and others have objected to the FDA&rsquo;s interpretation of Section 505(b)(2). If the FDA&rsquo;s interpretation of Section 505(b)(2)
is successfully challenged, the FDA may be required to change its 505(b)(2) policies and practices, which could delay or even prevent
the FDA from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry is highly competitive,
and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved
drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval
of our potential future NDAs for up to 30 months depending on the outcome of any litigation. It is also not uncommon for a manufacturer
of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements
for, pending competing products. If successful, such petitions can significantly delay, or even prevent, the approval of the new product.
However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds
to the petition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Moreover, even if NS001 and NS002 or any future product candidates are approved under the Section 505(b)(2) pathway,
as the case may be, the approval may be subject to limitations on the indicated uses for which the products may be marketed or to other
conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy
of the products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may seek designations for our product candidates with the FDA and other comparable regulatory authorities that are intended to confer
benefits such as a faster development process or an accelerated regulatory pathway, but there can be no assurance that we will successfully
obtain such designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able
to realize the intended benefits of such designations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA, and other comparable regulatory authorities, offer certain designations for product candidates that are intended to encourage the
research and development of pharmaceutical products addressing conditions with significant unmet medical need. These designations may
confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory pathway and priority
review. There can be no assurance that we will successfully obtain any such designation for our products. In addition, while such designations
could expedite the development or approval process, they generally do not change the standards for approval. Even if we obtain such designations
for one or more of our product candidates, there can be no assurance that we will realize their intended benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, we may seek a Breakthrough Therapy designation from the FDA for one or more of our product candidates. A Breakthrough Therapy
designation is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or
life-threatening disease or condition, if preliminary clinical evidence indicates that the therapy may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. For therapies that have Breakthrough Therapy designation, interaction and communication between the FDA and the sponsor
of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in
ineffective control regimens. Therapies with Breakthrough Therapy designation from the FDA are also eligible for accelerated approval.
Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates
meets the criteria for Breakthrough Therapy designation, the FDA may disagree and instead determine not to make such designation. In
any event, the receipt of a Breakthrough Therapy designation for a product candidate may not result in a faster development process,
review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval
by the FDA. In addition, even if one or more of our product candidates qualify for Breakthrough Therapy designation, the FDA may later
decide that such product candidates no longer meet the conditions for qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
may also seek Fast Track designation from the FDA for some of our product candidates. If a therapy is intended for the treatment of a
serious or life-threatening condition and the therapy demonstrates the potential to address unmet medical needs for this condition, the
therapy sponsor may apply for Fast Track designation. The FDA has broad discretion whether or not to grant this designation, so even
if we believe a particular product candidate is eligible for this designation, there can be no assurance that the FDA would decide to
grant it. Even if we do receive Fast Track designation, we may not experience a faster development process, review or approval compared
to conventional FDA procedures, and receiving a Fast Track Designation does not provide assurance of ultimate FDA approval. The FDA may
withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
results of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of the results of later-stage
clinical trials. Initial success in our ongoing clinical trials may not be indicative of results obtained when these trials are completed
or in later stage trials.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through
preclinical studies and initial clinical trials. Furthermore, there can be no assurance that any of our clinical trials will ultimately
be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs and biologics
proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant
setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development
could harm our business and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Interim,
topline and preliminary data from our clinical trials that we announce or publish may change as more patient data become available and
are subject to audit and verification procedures that could result in material changes in the final data. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may publish interim, topline or preliminary data from our clinical trials. Preliminary and interim data from our clinical
trials may change as more patient data become available. Preliminary or interim data from our clinical trials are not necessarily predictive
of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change
as patient enrollment continues, more patient data become available, and we issue our final clinical trial report. Interim, topline and
preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different
from the preliminary data we previously published. As a result, preliminary and interim data should be viewed with caution until the
final data are available. Adverse changes in the final data compared to the interim data could significantly harm our business prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses
or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability
or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose
to publicly disclose regarding a particular preclinical study or clinical trial is based on what is typically extensive information,
and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure,
and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions,
views, activities or otherwise regarding a particular product, product candidate or our business. If the preliminary and interim data
that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our
ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results,
prospects or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain regulatory approval for a product candidate, our products will remain subject to ongoing regulatory oversight.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain any regulatory approval for our product candidates, they will be subject to ongoing regulatory requirements for manufacturing,
labeling, packaging, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information.
Any regulatory approvals that we receive for our product candidates also may be subject to a REMS, limitations on the approved indicated
uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing
testing, including Phase 4 clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. The holder of
an approved marketing application also must submit new or supplemental applications and obtain FDA approval for certain changes to the
approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are
subject to FDA review, in addition to other potentially applicable federal and state laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections
by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, requirements and adherence
to commitments made in the NDA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems
with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured
or disagrees with the promotion, marketing or labeling of that product, a regulatory authority may impose restrictions relative to that
product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to comply with applicable regulatory requirements, a regulatory authority may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issue
    an untitled letter or warning letter that we are in violation of the law; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    an injunction or impose administrative, civil or criminal penalties or monetary fines;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    or withdraw regulatory approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspend
    any ongoing clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to approve pending applications or supplements to applications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrict
    the marketing or manufacturing of the product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seize
    or detain the products or require the withdrawal of the product from the market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to permit the import or export of the products; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refuse
    to allow us to enter into supply contracts, including government contracts.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product
candidates and adversely affect our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>International
expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing
business outside of the United States, Israel or the EU.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our headquarters and other operations which are located in Israel, we currently have limited international operations, but our business
strategy incorporates potentially significant international expansion, particularly in anticipation of approval of our product candidates.
We may plan to maintain sales representatives and conduct physician and patient association outreach activities, as well as clinical
trials, outside of the United States, Israel and Europe. If our products are approved for commercialization outside the United States,
Israel, or the EU, we will likely enter into agreements with third parties to market the drugs in these additional global territories.
We expect that we will be subject to additional risks related to entering into or maintaining international business relationships, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">different
    regulatory requirements for drug approvals in foreign countries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">differing
    United States and foreign drug import and export rules, tariffs and other trade barriers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    protection for intellectual property rights in foreign countries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us to obtain regulatory approvals for the use of our products in various countries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">different
    reimbursement systems;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
    weakness, including inflation, or political instability in particular foreign economies and markets;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple,
    conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws,
    regulatory requirements and other governmental approvals, permits and licenses;</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
    associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises
    on demand and payment for our products and exposure to foreign currency exchange rate fluctuations, which could result in increased
    operating expenses and reduced revenues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">workforce
    uncertainty in countries where labor unrest is more common than in the United States;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">production
    shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the
    purview of the U.S. Foreign Corrupt Practices Act, or FCPA, its books and records provisions or its anti-bribery provisions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    liability resulting from development work conducted by these distributors; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
    interruptions resulting from a local or worldwide pandemic, such as COVID-19, geopolitical actions, including war and terrorism,
    or natural disasters.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if any of our product candidates receives marketing approval, they may fail to achieve the degree of market acceptance by physicians,
patients, third-party payors, pharmacists and others in the medical community necessary for commercial success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of our products will depend upon the acceptance of each product by the medical community, including physicians, patients
and third-party payors. The degree of market acceptance of any approved product will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    efficacy and safety of the product;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential advantages of the product compared to available therapies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    convenience and ease of administration compared to alternative treatments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
    or warnings, including use restrictions contained in the product&rsquo;s approved labeling;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">distribution
    and use restrictions imposed by the EMA, FDA or other regulatory authority or agreed to by us as part of a mandatory or voluntary
    risk management plan;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
    and cost effectiveness in relation to alternative treatments;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    the product is included under physician treatment guidelines as a first-, second,- or third-line therapy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    strength of sales, marketing and distribution support;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of third-party coverage and adequate reimbursement and the willingness of patients to pay out-of-pocket in the absence
    of coverage by third-party payors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    strength of sales, marketing and distribution support;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of patients to pay for drugs out of pocket in the absence of third-party coverage; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    willingness of the target patient population to try new therapies and of physicians to prescribe these therapies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our products are approved but do not achieve an adequate level of acceptance by physicians, third party payors and patients, we may not
generate sufficient revenue from the product, and we may not become or remain profitable. In addition, our efforts to educate the medical
community and third-party payors on the benefits of the product may require significant resources and may never be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may choose to collaborate with third parties that have direct sales forces and established distribution systems, either
to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we enter into
arrangements with third parties to perform sales, marketing and distribution services for our products, the resulting revenues or the
profitability from these revenues to us are likely to be lower than if we had sold, marketed and distributed our products ourselves.
If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize any
of our product candidates that receive regulatory approval. Depending on the nature of the third-party relationship, we may have little
control over such third parties, and any of these third parties may fail to devote the necessary resources and attention to sell, market
and distribute our products effectively. If we are not successful in commercializing our product candidates, either on our own or through
collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
currently have no marketing and sales organization. If we are unable to establish sales and marketing capabilities or enter into agreements
with third parties to market and sell our product candidates, we may be unable to generate any product revenue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no experience selling and marketing our product candidates, and we currently have no marketing or sales organization. To successfully
commercialize any product candidates that may result from our development programs, we will need to develop these capabilities, either
on our own or with others. If our product candidates receive regulatory approval, we intend to establish a sales and marketing organization
independently or by utilizing experienced third parties with technical expertise and supporting distribution capabilities to commercialize
our product candidates in major markets, all of which will be expensive, difficult and time consuming. Any failure or delay in the development
of our internal sales, marketing and distribution capabilities would adversely impact our ability to commercialize our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
given our lack of prior experience in marketing and selling pharmaceutical products, our initial estimate of the size of the required
sales force may be materially more or less than the size of the sales force actually required to effectively commercialize our product
candidates. As such, we may be required to hire sales representatives and third-party distributors to adequately support the commercialization
of our product candidates, or we may incur excess costs if we hire more sales representatives than necessary. With respect to certain
geographical markets, we may enter into collaborations with other entities to utilize their local marketing and distribution capabilities,
but we may be unable to enter into such agreements on favorable terms, if at all. We also may enter into collaborations with large pharmaceutical
companies to develop and commercialize product candidates. If our future collaborators do not commit sufficient resources to develop
and commercialize our future products, if any, and we are unable to develop the necessary marketing capabilities on our own, we will
be unable to generate sufficient product revenue to sustain our business. We may compete with companies that currently have extensive
and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales
functions, we may be unable to compete successfully against these more established companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
efforts to educate the medical community, including physicians, hospital pharmacists and third-party payors on the benefits of our product
candidates may require significant resources and may never be successful. If any of our product candidates are approved but fail to achieve
market acceptance among physicians, patients or third-party payors, we will not be able to generate significant revenues from such product,
which could have a material adverse effect on our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations or third-party
coverage and reimbursement policies, any of which could harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize any product candidates successfully will depend, in part, on the extent to which coverage and reimbursement
for these products and related treatments will be available from government health administration authorities, private health insurers
and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations,
decide which medications they will pay for and impact reimbursement levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining adequate reimbursement for our products may be difficult. We cannot be certain if and when we will obtain an adequate
level of reimbursement for our products by third party payors. Even if we do obtain adequate levels of reimbursement, third-party payors,
such as government or private healthcare insurers, carefully review and increasingly question the coverage of, and challenge the prices
charged for, drugs. Reimbursement rates from private health insurance companies vary depending on the company, the insurance plan and
other factors. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party
payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly,
third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the
prices charged for drugs. We may also be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement
or the level of reimbursement relative to other therapies. If coverage and reimbursement are not available or reimbursement is available
only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval,
and the royalties resulting from the sales of those products may also be adversely impacted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for
which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement
does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture,
sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may
not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may
be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services.
Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and
by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than
in the United States. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private
payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise
capital needed to commercialize products and our overall financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country.
Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause
delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be reimbursed. In many countries,
the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription drug
pricing remains subject to continuing governmental control, including possible price reductions, even after initial approval is granted.
As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that
delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate
from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more
product candidates, even if our product candidates obtain marketing approval. There can be no assurance that our product candidates,
if they are approved for sale in the United States or in other countries, will be considered medically necessary or cost-effective for
a specific indication, or that coverage or an adequate level of reimbursement will be available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face intense competition in an environment of rapid technological change and the possibility that our competitors may develop products
and drug delivery systems that are similar, more advanced or more effective than ours. As a result, we may be unable to effectively
compete in our industry, which may adversely affect our financial condition and our ability to successfully market or commercialize our
product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical industry in which we operate is intensely competitive and subject to rapid and significant technological change. We are
currently aware of various existing therapies in the market and in development that may in the future compete with our product candidates,
including other products that address opioid overdose or anaphylactic shock, as well as other drug delivery mechanisms. Other approaches
may also emerge for the prevention or treatment of any of the indications on which we focus, and new technologies may emerge in localized
drug delivery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have competitors both in the United States and internationally, including major multinational pharmaceutical companies and specialty
pharmaceutical companies. The major market players within the intranasal drug market and our primary competitors in the United States
and abroad include ADAPT Pharma, Inc., Teva Pharmaceuticals Ltd., Pfizer Inc., Viatris Inc., and Kal&eacute;o, Inc., among others. Some
of these companies hold significant market share. Their dominant market position and significant control over the market could significantly
limit our ability to introduce or effectively market and generate sales and capture market share. Many of our competitors have long histories
and strong reputations within the industry. They have significantly greater brand recognition, financial and human resources than we
do. They also have more experience and capabilities in researching and developing medical devices, obtaining and maintaining regulatory
clearances, manufacturing and marketing those products and other resources, than we do. There is a significant risk that we may be unable
to overcome the advantages held by our competition, and our inability to do so could lead to the failure of our business and the loss
of your investment. In addition, we may be unable to develop additional products in the future or to keep pace with developments and
innovations in the market and lose market share to our competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
competitors may succeed in developing, acquiring or licensing on products that are more effective or less costly than any product candidate
that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization and market penetration than
we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete,
and we may not be successful in marketing our product candidates against competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
competition in the pharmaceutical industry is intense, and can lead to, among other things, price reductions, longer selling cycles,
lower product margins, loss of market share and additional working capital requirements. To succeed, we must, among other critical matters,
gain consumer acceptance for our products, as compared to other solutions currently available in the market. For example, since the currently
accepted treatment for opioid overdose and anaphylactic shock are Narcan (Naloxone HCI) and the EpiPen (Epinephrine Injection USP), respectively,
we will need to invest resources in educating the medical community and consumers, and establish strategic collaborations before we will
be able to gain market acceptance for our Intranasal Naloxone and Intranasal Epinephrine as a treatment in severe acute emergency situations.
If our competitors offer significant discounts on certain products and solutions, we may need to lower our prices or offer other favorable
terms in order to compete successfully. Moreover, any broad-based changes to our prices and pricing policies could make it difficult
to generate revenues or cause our revenues to decline. Moreover, if our competitors develop and commercialize products and solutions
that are more effective or desirable than products and solutions that we may develop, we may not convince our customers to use our products
and solutions. Any such changes would likely reduce our commercial opportunity and revenues potential and could materially adversely
impact our operating results. See &ldquo;<I>Business Overview - Competition.</I>&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
FDA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses. The misuse
or off-label use of our products may harm our reputation in the marketplace, result in injuries that may lead to product liability suits
or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these
uses, any of which could be costly to our business. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become
subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about
prescription products, if approved. In particular, while the FDA permits the dissemination of truthful and non-misleading information
about an approved product, a manufacturer may not promote a product for uses that are not approved by the FDA or such other regulatory
agencies as reflected in the product&rsquo;s approved labeling. If we are found to have promoted such off-label uses, we may become subject
to significant liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion
of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter
into consent decrees, corporate integrity agreements or permanent injunctions under which specified promotional conduct must be changed
or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant
liability, which would materially adversely affect our business and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
advertising and promotion of our products that obtain marketing approval in the United States may be heavily scrutinized by the FDA,
the U.S. Department of Justice, or DOJ, U.S. Department of Health and Human Services, or HHS, state attorneys general, members of Congress,
and the public. In addition, advertising and promotion of any product that obtains approval outside of the United States may be heavily
scrutinized by comparable foreign regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that, if cleared or approved, our products, will be cleared by the requisite regulatory authorities for specific indications.
We expect to train our marketing personnel and direct sales force to not promote our devices for uses outside of the FDA-approved indications
for use, known as &ldquo;off-label uses.&rdquo; We cannot, however, prevent a physician from using our devices off-label, when in the
physician&rsquo;s independent professional medical judgment, he or she deems it appropriate. There may be increased risk of injury to
patients if physicians attempt to use our devices off-label. Furthermore, the use of our devices for indications other than those approved
by the FDA or approved by any foreign regulatory body may not effectively treat such conditions, which could harm our reputation in the
marketplace among healthcare providers and patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA or any state or foreign regulatory body determines that our promotional materials or training constitute promotion of an off-label
use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including
the issuance or imposition of an untitled letter, which is used for violators that do not necessitate a warning letter, injunction, seizure,
civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action
under other regulatory authority, such as false claims laws, if they consider our business activities to constitute promotion of an off-label
use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages,
fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations. We may become
subject to such actions and, if we are not successful in defending against such actions, those actions may have a material adverse effect
on our business, financial condition and results of operations. Equivalent laws and potential consequences exist in foreign jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if our products are cleared or approved, healthcare providers may misuse our products or use improper techniques if they are
not adequately trained, potentially leading to injury and an increased risk of product liability. If our products are misused or used
with improper technique, we may become subject to costly litigation by our customers or their patients. As described above, product liability
claims could divert management&rsquo;s attention from our core business, be expensive to defend and result in sizeable damage awards
against us that may not be covered by insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
product liability lawsuits are brought against us, we may incur substantial liabilities, even if we have appropriate insurance policies,
and we may be required to limit commercialization of our product candidates. Product liability or similar claims that could be expensive,
damage our reputation and harm our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing,
marketing and use of pharmaceutical products. Currently, we have no products that have been approved for marketing or commercialization;
however, the use of our product candidates in clinical trials, and the sale of these product candidates, if approved, in the future,
may expose us to liability claims. Product liability claims may be brought against us or our partners by participants enrolled in our
clinical trials, patients, health care providers, pharmaceutical companies, our collaborators or others using, administering or selling
any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities,
even if we have product liability or such other applicable insurance policies in effect. We may not be able to maintain adequate levels
of insurance for these liabilities at reasonable cost and/or reasonable terms. Excessive insurance costs or uninsured claims would add
to our future operating expenses and adversely affect our financial condition. As a result of such lawsuits and their potential results,
we may be required to limit commercialization of our product candidates. Regardless of the merits or eventual outcome, liability claims
may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for our product candidates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
    of clinical trial sites or entire trial programs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation and negative media attention;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls or increased warnings on product labels;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical trial participants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    of to defend the related litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of management and our resources;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to, or costly settlements with, clinical trial participants, patients or other claimants;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">higher
    insurance premiums;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of initiation of investigations by regulators or other authorities; and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to successfully commercialize our product candidates, if approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
our business exposes us to an inherent risk of potential product liability or similar claims. The pharmaceutical industry has historically
been litigious, and we face financial exposure to product liability or similar claims if the use of any of our products were to cause
or contribute to injury or death. There is also the possibility that defects in the design or manufacture of any of our products might
necessitate a product recall. Although we plan to maintain product liability insurance, the coverage limits of these policies may not
be adequate to cover future claims. In the future, we may be unable to maintain product liability insurance on acceptable terms or at
reasonable costs and such insurance may not provide us with adequate coverage against potential liabilities. A product liability claim,
regardless of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to our reputation, customer
dissatisfaction and frustration and a substantial diversion of management attention. A successful claim brought against us in excess
of, or outside of, our insurance coverage could have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to litigation for a variety of claims, including class actions, which could adversely affect our results of operations,
harm our reputation or otherwise negatively impact our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to litigation for a variety of claims, including class actions and contract claims, arising from our normal business
activities. These may include claims, suits, and proceedings involving labor and employment, wage and hour, commercial, contractual
and other matters. For example, on October 5, 2022, we received a termination notice from Aptar Group Inc., or Aptar, in connection
with an alleged breach of our contractual obligations with Aptar under a master services agreement, or </FONT>MSA, we entered into
with Aptar on September 6, 2019. We timely responded to such notice, exchanged correspondence with Aptar through February 2023 and
have been unable to resolve the claims and allegations made by each party. Since February 2023, we have continued to purchase
products from Aptar under our MSA and related schedules of work and,&nbsp;as of February 5, 2025, we have not received any
further notices, demands or claims from Aptar. Termination of the MSA with Aptar could result in significant delays to our
commercialization efforts and adversely harm our business, operating results, and financial condition. See
&ldquo;<I>Business&mdash;Our Solution&mdash;Aptar UDS and collaboration</I>&rdquo; for further information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> The
outcome of any litigation, regardless of its merits, is inherently uncertain. Further, we are unable to predict whether unknown
claims and lawsuits may be brought against us that could become material. Any claims and lawsuits, and the disposition of such
claims and lawsuits, could be time-consuming and expensive to resolve, divert management attention and resources, and lead to
attempts on the part of other parties to pursue similar claims. Any adverse determination related to litigation could adversely
affect our results of operations, harm our reputation or otherwise negatively impact our business. In addition, depending on the
nature and timing of any such dispute, a resolution of a legal matter could materially affect our operating results, cash flows and
our ability to raise capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions. Our failure to obtain regulatory approval in foreign jurisdictions
would prevent our product candidates from being marketed abroad, and any approval we are granted for our product candidates in the United
States would not assure approval of product candidates in foreign jurisdictions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements
of other countries regarding clinical trial design, safety and efficacy. The research, testing, manufacturing, labeling, approval, sale,
marketing and distribution of drugs are subject to extensive regulation by the FDA in the United States and other regulatory authorities
in other countries. These regulations differ from country to country. Even if we obtain and maintain regulatory approval of our product
candidates in one jurisdiction, such approval does not guarantee that we will be able to obtain or maintain regulatory approval in any
other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory
approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities
in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United
States, including additional nonclinical studies or clinical trials as investigations conducted in one jurisdiction may not be accepted
by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved
for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our
products is also subject to approval. These regulatory procedures can result in substantial delays in such countries. In other countries,
product approval depends on showing superiority to an approved alternative therapy. This can result in significant expense for conducting
complex clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we, or any third parties with whom we work, fail to comply with regulatory requirements in United States or international markets or
to obtain and maintain required approvals or if regulatory approvals in international markets are delayed, our target market may be reduced
and our ability to realize the full market potential of our products will likely be harmed. The inability to meet continuously evolving
regulatory standards for approval may result in our failing to obtain regulatory approval to market our current product candidates, which
could significantly harm our business, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
market is subject to intense competition, which may result in others commercializing products before or more successfully than us. If
we are unable to compete effectively, our products may be rendered non-competitive or obsolete, which may adversely affect our operating
results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development and commercialization of new products is highly competitive. Our potential competitors include major pharmaceutical companies,
specialty pharmaceutical companies and biotechnology companies worldwide with respect to our intranasal powder products or any future
product candidate that we may seek to develop or commercialize. Our competitors may succeed in developing, acquiring or licensing technologies
and products that are more effective, have fewer or more tolerable side effects or are more convenient or less costly than our products
or any future product candidate we may develop, which could render any product candidates obsolete and non-competitive. Our competitors
also may obtain FDA or other marketing approval for their products before we are able to obtain approval for ours, which could result
in competitors establishing a strong market position before we are able to enter the applicable market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of our potential competitors, alone or with their strategic partners, have significantly greater financial resources and expertise in
research and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining marketing approvals and commercializing
approved products than we do. There is a trend toward consolidation in the pharmaceutical and biotechnology industry, and additional
mergers and acquisitions in these industries may result in even more resources being concentrated among a smaller number of our competitors,
which may adversely affect us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and
established companies. These companies also compete with us in recruiting and retaining qualified scientific and management personnel
and establishing clinical trial sites and patient registration for clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if we enter the markets of our product candidates, with such entrance remaining subject to various additional regulatory approvals,
too late in the cycle, we may not achieve commercial success, or we may have to reduce our price in order to effectively compete, which
would impact our ability to generate revenue, obtain profitability and adversely affect our operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Legislative
or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or
approval of our product candidates and to produce, market and distribute our products after clearance or approval is obtained.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the
regulatory clearance or approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations
and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new
regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product
candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated,
enacted or adopted may have on our business in the future. Such changes could, among other things, require:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    to manufacturing methods;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">change
    in protocol design;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    treatment arm (control);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recall,
    replacement, or discontinuance of one or more of our products; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    recordkeeping.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in the United States, there have been a number of legislative and regulatory proposals to change the health care system in
ways that could affect our ability to sell our products profitably. The pharmaceutical industry in the United States, as an example,
has been affected by the passage of the Patient Protection and Affordable Care Act, or Affordable Care Act, which, among other things,
imposed new fees on entities that manufacture or import certain branded prescription drugs and expanded pharmaceutical manufacturer obligations
to provide discounts and rebates to certain government programs. There have been executive, judicial and Congressional challenges to
certain aspects of the Affordable Care Act. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural
grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &ldquo;individual mandate&rdquo; was repealed
by Congress. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things,
extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year
2025. The IRA also eliminates the &ldquo;donut hole&rdquo; under the Medicare Part D program beginning in 2025 by significantly lowering
the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is possible that the ACA will be subject
to judicial or Congressional challenges in the future. It is unclear how any such challenges and the healthcare reform measures of the
Biden administration will impact the Affordable Care Act and our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. These changes include,
among others, aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in 2013 and,
due to subsequent legislative amendments to the statute, will remain in effect until 2032 unless additional Congressional action is taken.
Congress is considering additional health reform measures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
there has been particular and increasing legislative and enforcement interest in the United States with respect to drug pricing practices
in recent years, particularly with respect to drugs that have been subject to relatively large price increases over relatively short
time periods. There have been several recent U.S. Presidential executive orders, Congressional inquiries and proposed bills designed
to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship
between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, in July 2021, the Biden administration released an executive order, &ldquo;Promoting Competition in the American Economy,&rdquo;
with multiple provisions aimed at prescription drugs. In response to President Biden&rsquo;s executive order, on September 9, 2021, the
Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles
for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative
actions HHS can take to advance these principles. Further, the IRA, among other things (i) directs HHS to negotiate the price of certain
high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare
Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023.
On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug
price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely
to have a significant impact on the pharmaceutical industry. Further in response to the Biden administration&rsquo;s October 2022 executive
order, on February 14, 2023, HHS released a report outlining three new models for testing by the Centers for Medicare &amp; Medicare
Services, or CMS, Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve
quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December
7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights
under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency
Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor
an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain
if that will continue under the new framework. Individual states in the United States have also become increasingly active in passing
legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and in some cases,
designed to encourage importation from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&rsquo;s
Section 804 Importation Program (SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear
how this program will be implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the
United States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation
plans, when implemented, may result in lower drug prices for products covered by those programs. In the future, there will likely continue
to be proposals relating to the reform of the U.S. healthcare system, some of which could further limit coverage and reimbursement of
drug products, including our product candidates. Any reduction in reimbursement from Medicare or other government programs may result
in a similar reduction in payments from private payors. Our results of operations could be adversely affected by the Affordable Care
Act and by other health care reforms that may be enacted or adopted in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the delivery of healthcare in the European Union, including the establishment and operation of health services, is almost exclusively
a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and
approaches to the delivery of health care and the pricing and reimbursement of products in that context. Coupled with ever-increasing
EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay additional marketing
approval of product candidates or any initial marketing approval for our current or any future product candidates, restrict or regulate
post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently unable to predict what additional legislation or regulation, if any, relating to the health care industry may be enacted
in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our
business. The pendency or approval of such proposals or reforms could result in a decrease in the price of our Ordinary Shares or limit
our ability to raise capital or to enter into collaboration agreements for the further development and potential commercialization of
our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might
require us to recall or withdraw a product from the market.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
after we achieve regulatory approvals to market our products in certain countries, we are still subject to ongoing and pervasive regulatory
requirements governing, among other things, the manufacture, marketing, advertising, sale, promotion, import, export, and registration.
In addition, if we receive additional regulatory approvals to market our products, we will likewise remain subject to ongoing regulation.
Failure to comply with these regulations could result in enforcement action by the FDA. Following its review of the periodic reports,
the FDA might ask for additional information or initiate further investigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations to which we are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions
on our ability to continue or expand our operations, higher than anticipated costs, or lower than anticipated sales. Even after we have
obtained the proper regulatory clearance to market a device, we have ongoing responsibilities under FDA regulations and applicable foreign
laws and regulations. The FDA, state and foreign regulatory authorities have broad enforcement powers. Our failure to comply with applicable
regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory authorities, which may include any
of the following sanctions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled
    letters or warning letters;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
    injunctions, consent decrees and civil penalties;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recalls,
    termination of distribution, administrative detention, or seizure of our products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">customer
    notifications or repair, replacement or refunds;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions or partial suspension or total shutdown of production;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in or refusal to grant our requests for future clearances or approvals or foreign marketing authorizations of new products, new intended
    uses, or modifications to existing products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawals
    or suspensions of product clearances or approvals, resulting in prohibitions on sales of our products;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    refusal to issue certificates to foreign governments needed to export products for sale in other countries; and criminal prosecution.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on
our reputation, business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the FDA or state or foreign authorities may change their clearance and approval policies, adopt additional regulations or revise
existing regulations, or take other actions, which may prevent or delay clearance or approval of our future products under development
on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain
new clearances or approvals, increase the costs of compliance or restrict our ability to maintain any approvals we are able to obtain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Environmental,
social and corporate governance (ESG) issues, including those related to climate change and sustainability, may have an adverse effect
on our business, financial condition and results of operations and damage our reputation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is an increasing focus from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally,
public interest and legislative pressure related to public companies&rsquo; ESG practices continue to grow. If our ESG practices fail
to meet regulatory requirements or investor, customer, consumer, employee or other stakeholders&rsquo; evolving expectations and standards
for responsible corporate citizenship in areas including environmental stewardship, support for local communities, Board of Director
and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate
governance and transparency, our reputation, brand and employee retention may be negatively impacted, and our customers and suppliers
may be unwilling to continue to do business with us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customers,
consumers, investors and other stakeholders are increasingly focusing on environmental issues, including climate change, energy and water
use, plastic waste and other sustainability concerns. Concern over climate change may result in new or increased legal and regulatory
requirements to reduce or mitigate impacts to the environment. Changing customer and consumer preferences or increased regulatory requirements
may result in increased demands or requirements regarding plastics and packaging materials, including single-use and non-recyclable plastic
products and packaging, other components of our products and their environmental impact on sustainability, or increased customer and
consumer concerns or perceptions (whether accurate or inaccurate) regarding the effects of substances present in certain of our products.
Complying with these demands or requirements could cause us to incur additional manufacturing, operating or product development costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we do not adapt to or comply with new regulations, or fail to meet evolving investor, industry or stakeholder expectations and concerns
regarding ESG issues, investors may reconsider their capital investment in our Company, and customers and consumers may choose to stop
purchasing our products, which could have a material adverse effect on our reputation, business or financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Reliance on Third Parties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are dependent on manufacturers for Naloxone and Epinephrine. Any delay, price increase or unavailability of our manufacturers could materially
adversely affect our ability to conduct clinical trials and, if this were to occur after we obtained commercialization and marketing
approval, could materially impact our operations. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA requires identification of raw material suppliers in applications for approval of drug products. If Naloxone and Epinephrine were
unavailable from a specified manufacturer, FDA approval of a new manufacturer, assuming one is found, could delay the manufacture of
the drug involved or delay any clinical trial we are then conducting or planning to conduct. Either such occurrence could have an adverse
effect on our operations and reputation and could materially impact our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
there is a risk of a sole approved manufacturer significantly raising prices. If prices for raw materials were to be significantly increased,
our profit margins and sales, if any, would be greatly reduced and, assuming our products were approved for commercialization or marketing,
delay product launches, or delay clinical trials at earlier stages of development. Such price increase occurrences could be resolved
by the successful FDA approval of an alternate supplier; however, such approval process can be lengthy and costly. There can be no guarantee
that a resolution would be reached in the event of a significant price increase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may
not be able to find replacements or immediately transition to alternative suppliers on a cost-effective basis, or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
source components of our technology from third parties and certain components are sole sourced. Obtaining substitute components may
be difficult or require us to re-design our products. For example, we rely on Aptar, a leading global manufacturer of inhalers,
as sole supplier for supply of its intranasal Unit Dose Spray product, or UDS, to be the delivery system for our Intranasal Naloxone
powder and Intranasal Epinephrine powder. If Aptar is <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unable to supply UDS to us
in the quantities we require, or at all, or otherwise default on their supply obligations to us, we may not be able to obtain alternative
supplies from other suppliers on acceptable terms in a timely manner. In addition, if we are required to change UDS manufacturers for
any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards
and with all applicable regulations and guidelines. We will also need to verify, such as through a manufacturing comparability study,
that any new manufacturer or manufacturing process for UDS will produce our product candidate according to the specifications previously
submitted to the FDA or another regulatory authority. A change in manufacturer may also require the conduct of additional clinical trials.
The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in
a timely manner or within budget.</FONT> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
any</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> natural or other disasters, epidemic or
pandemic, acts of war or terrorism, shipping embargoes, labor unrest or political instability or similar events at our third-party
suppliers&rsquo; facilities that cause a loss of manufacturing capacity or a reduction in the quality of the items manufactured
would heighten the risks that we face. Changes to, failure to renew or termination of our existing agreements or our inability to
enter into new agreements with other suppliers could result in the loss of access to important components of our tests and could
impair, delay or suspend our commercialization efforts. Our failure to maintain a continued and cost-effective supply of
high-quality components could materially and adversely harm our business, operating results, and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
rely on third parties to conduct our pre-clinical and clinical studies and perform other tasks for us. If these third parties do not
successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to
obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have relied upon and plan to continue to rely upon third-party CROs to monitor and manage data for our ongoing pre-clinical and clinical
programs. We rely on these parties for execution of our pre-clinical and clinical studies, and control only certain aspects of their
activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol,
legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and
our CROs and other vendors are required to comply with current cGMP, Good Clinical Practices, or GCP, quality system requirements, or
QSR, and Good Laboratory Practices, or GLP, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the
Member States of the European Economic Area, and comparable foreign regulatory authorities for all of our product candidates in clinical
development. Regulatory authorities enforce these regulations through periodic inspections of study sponsors, principal investigators,
study sites and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations, the clinical data
generated in our clinical studies may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require
us to perform additional clinical studies before approving our marketing applications. We cannot assure you that upon inspection by a
given regulatory authority, such regulatory authority will determine that any of our clinical studies comply with GCP regulations. In
addition, our clinical studies must be conducted with product candidates which are produced under cGMP regulations. Our failure to comply
with these regulations may require us to repeat clinical studies, which would delay the regulatory approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have limited manufacturing experience and could experience production problems that result in delays in our development or commercialization
programs or otherwise adversely affect our business. We currently have no manufacturing facilities and anticipate reliance on third-party
manufacturers for our products. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited experience manufacturing NS001 and NS002. We are currently only able to produce clinical trial material up to and including
Phase 2 studies of our products. We may be unable to produce commercial materials or meet demand for our product candidates if
we are unable to receive or maintain commercial regulatory approvals for our facility. Any such failure could delay or prevent our development
of our products and would have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
either of our product candidates is approved, we may need to increase the scale or capacity of our manufacturing process. We currently
do not have manufacturing facilities capable of producing our product candidates on a commercial scale and do not intend to develop facilities
for the manufacture of products for commercial purposes in the foreseeable future. We will rely on third-party manufacturers to produce
bulk drug products required for our Phase 3 clinical trials and commercial sales, if any. We plan to rely upon contract manufacturers
and, potentially, collaboration partners to manufacture commercial quantities of our drug product candidates if and when approved for
marketing by the applicable regulatory authorities. The use of new manufacturers may require obtaining new approvals. Our contract manufacturers
will need to complete process validation for the drug substance manufacturing process. Process validation involves a series of activities
taking place over the lifecycle of the product and process. If our contract manufacturers are not approved by the FDA, or other regulatory
bodies, our commercial supply of drug substance will be significantly delayed and may result in significant additional costs. If the
FDA does not consider the result of the process validation or required testing to be satisfactory, regulatory approval and/or commercial
supply after launch may be delayed. The FDA and similar foreign regulatory bodies may also implement new requirements, or change their
interpretation and enforcement of existing requirements, for manufacturers, packaging or testing of products at any time. If we, or our
contract manufacturers are unable to comply with such process validation or other requirements, we may be subject to regulatory, civil
actions or penalties which could harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business. In the event of a natural
disaster, business failure, strike or other difficulty, such as difficulties involving production yields, quality control and quality
assurance, we may be unable to replace a third-party manufacturer in a timely manner and the production of any product candidate or commercialized
drug would be interrupted, resulting in delays and additional costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we collaborate with contract manufacturers located outside of the United States, we may face difficulties in importing our drug substances
into the United States as a result of, among other things, FDA import inspections, incomplete or inaccurate import documentation or defective
packaging.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we may not be successful in producing sufficient quantities of our products, due to several factors, including equipment malfunctions,
facility contamination, technical process challenges, raw material shortages or contamination, natural disasters, disruption in utility
services, human error or disruptions in the operations of our suppliers. Problems with the manufacturing process, even minor deviations
from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product
liability claims or insufficient inventory. We may encounter problems achieving adequate quantities and quality of clinical- and commercial-grade
materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Slight
deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes
in the product that could result in lot failures or product recalls. There is no assurance we will not experience such failures at our
own manufacturing facility or that of a third party in the future. Lot failures or product recalls could cause delays in product supply
or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also may encounter problems hiring and retaining the experienced specialist scientific, quality assurance, quality control and manufacturing
personnel needed to operate our manufacturing process, which could result in delays in our production or difficulties in maintaining
compliance with applicable regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including biopharmaceutical
companies, which could limit our access to additional attractive development programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
and our potential collaborators and contract manufacturers are subject to significant regulation with respect to manufacturing our product
candidates. The manufacturing facilities on which we rely may not continue to meet regulatory requirements and have limited capacity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
and their facilities are required to comply with extensive regulatory requirements, including ensuring that quality control and manufacturing
procedures conform to cGMPs. These cGMP regulations cover all aspects of manufacturing relating to our product candidates. These regulations
govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control
and assure the quality of investigational product candidates and products approved for sale. Poor control of production processes can
lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates that may
not be detectable in final product testing. We, our potential collaborators or our contract manufacturers must supply all necessary documentation
in support of an NDA or MAA on a timely basis and must adhere to GLP and cGMP QSR regulations enforced by the FDA and other regulatory
authorities through their facilities inspection program. The facilities and quality systems of some or all of our potential and future
collaborators and third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition
of regulatory approval of our product candidates or any of our other potential product candidates. In addition, the regulatory authorities
may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential
product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted.
We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with
the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the product candidates
may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority,
if ever. Moreover, if our contract manufacturer&rsquo;s fail to achieve and maintain high manufacturing standards, in accordance with
applicable regulatory requirements, or there are substantial manufacturing errors, this could result in patient injury or death, product
shortages, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could
seriously harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
collaboration arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop
and commercialize our current and potential future product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization of our current
and potential future product candidates. We may enter into these arrangements on a selective basis depending on the merits of retaining
commercialization rights for ourselves as compared to entering into selective collaboration arrangements with other pharmaceutical or
biotechnology companies for each product candidate, both in the United States and internationally. We will face, to the extent that we
decide to enter into collaboration agreements, significant competition in seeking appropriate collaborators. Moreover, collaboration
arrangements are complex and time consuming to negotiate, document and implement. We may not be successful in our efforts to establish
and implement collaborations or other alternative arrangements should we so choose to enter into such arrangements. The terms of any
collaborations or other arrangements that we may establish may not be favorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disagreements
between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the
development process or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement.
These disagreements can be difficult to resolve if neither of the parties has final decision-making authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations
with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party.
Any such termination or expiration could adversely affect us financially and could harm our business reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them
or that our trade secrets will be misappropriated or disclosed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we rely on third parties to develop and manufacture our product candidates, we must, at times, share trade secrets with them. We seek
to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements,
collaborative research agreements, consulting agreements or other similar agreements with our collaborators, advisors, employees and
consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third
parties to use or disclose our confidential information, such as trade secrets. Despite the contractual provisions employed when working
with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become
known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these
agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&rsquo;s discovery
of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect
on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Intellectual Property </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
own several issued patents but may require filing of additional patents in the future. There can be no assurance that all or some of
our patent applications will result in issued patents. Consequently, our ability to protect our proprietary technology in the marketplace
beyond the intellectual property already protected by our currently issued patents may be limited. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed patent applications in many countries worldwide. These applications cover a range of technological areas including:, compositions
of matter, such as but not limited to pharmaceutical compositions and formulations, comprising multiple active pharmaceutical ingredient/s
(API/s), which may be known or novel, specific dosage forms such a dosage unit forms of the compositions of matter, methods of treatment
of various medical/physiological conditions using the compositions of matter, including treatment regimens, and process/es of manufacturing
the pharmaceutical compositions and formulations, and the dosage unit forms. While several patent applications have been granted, others
are still pending. Unless and until our pending patent applications are granted and patents thereon are issued, their protective scope
cannot be established . It is also not possible to predict whether or how many of our patent applications will mature into issued patents.
Even if patents on pending applications are issued, they may be issued with a scope significantly narrower than that we currently seek.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
proprietary position for our product candidates currently depends upon patents protecting the method of use, which may not prevent a
competitor or other third party from using the same product candidate for another use.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary patent based intellectual property protection for our product candidates will be patents granted on the formulation and/or pharmaceutical
composition, optionally in dosage unit form/s, and method/s of their use in treating specific medical/physiological conditions . We have
patents and patent applications covering our products as a composition of matter, specifically formulations and pharmaceutical compositions
comprising a desired API, such as, but not limited to epinephrine and naloxone. We also have patents and patent applications directed
to methods of preparing these compositions of matter, dosage unit forms of these compositions of matter and methods of treating medical
conditions using them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Composition
of matter patent claims on the active pharmaceutical ingredient (API), <I>per se</I> or comprised in pharmaceutical drug products are
generally considered to be the favored intellectual property protection for pharmaceutical products, as such patents provide protection
irrespective of any particular method of use, manufacture or formulation of the API used. Method of use patent claims protect the use
of a product, which may be the API or a composition/formulation comprising the same, for a defined indication, by the specified method,
which may be limited, for example, to route of administration/application and/or dosing regimen. These types of patent claims do not
prevent a competitor or other third party from making and marketing an identical API or composition comprising the API, for treating
an indication that is outside the scope of the method claims or from developing a different dosing regimen. Moreover, even if competitors
or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians
may recommend that patients use these products off-label, or patients may do so themselves. Although off-label use may infringe or contribute
to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if our patents are issued, because the patent status of pharmaceutical products can be complex and uncertain, we cannot predict the scope
and extent of patent protection for our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
patents that may be issued to us will not ensure the protection of our intellectual property for a number of reasons, including without
limitation the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
    issued patents may not be broad or strong enough to prevent competition by other drug products including identical or similar drug
    products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we are not issued patents or if issued patents expire, there would be no protection against competitors making generic equivalents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim throughout the patent
    term;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    may be other patents existing, now or in the future, in the patent landscape for PBI products, or any other product candidates that
    we seek to commercialize or develop, if any, that will affect our freedom to operate;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    our patents are challenged, a court could determine that they are not valid or enforceable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    court could determine that a competitor&rsquo;s technology or product does not infringe our patents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    court could determine we infringe a competitor&rsquo;s patents;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    patents could irretrievably lapse due to failure to pay fees or otherwise comply with regulations, or could be subject to compulsory
    licensing; and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if
    we encounter delays in our development or clinical trials, the period of time during which we could market our products under patent
    protection would be reduced.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by governmental or other patent authorities, and our patent protection could be reduced or eliminated for noncompliance with
these requirements. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodic
maintenance fees on any issued patent are due to be paid to the U.S. PTO and foreign patent authorities at several stages over the term
of the patent. The U.S. PTO and various foreign governmental or other patent authorities require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases
be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance
can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the
relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but
are not limited to, failure to respond to office actions within prescribed time limits, non-payment of fees and failure to properly legalize
and submit formal documents. In any such events, our competitors might be able to enter the market, which would have a material adverse
effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to enforce our intellectual property rights throughout the world. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing,
prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our
intellectual property rights in some countries outside the United States and Israel can be less extensive than those in the United States
and Israel. In addition, the laws of some foreign countries do not protect intellectual property to the same extent as laws in the United
States and Israel. Consequently, we may not be able to seek to prevent third parties from practicing our inventions in all countries
outside the United States and Israel, or from selling or importing products made using our inventions in and into the United States or
other jurisdictions. Competitors, for example, may use our technologies in jurisdictions where we have not obtained patents to develop
their own products and further, may export otherwise infringing products to territories where we have patents, but enforcement is not
as strong as that in the United States and Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal
systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade
secrets and other intellectual property, particularly those relating to medical devices and biopharmaceutical and biotechnology products,
which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary
rights generally. To date, we have not sought to enforce any issued patents in any jurisdictions. Proceedings to enforce our patent rights
in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could
put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke
third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded,
if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing
countries. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which
a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies
if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish
the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we
develop or license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to maintain effective proprietary rights for our product candidates, we may not be able to compete effectively in our markets.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the protection afforded by any patents currently owned and that may be granted, historically, we have relied on trade secret
protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes
that are not easily known, knowable, understood, analyzed or easily ascertainable, and for which patent infringement is difficult to
monitor and enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how,
information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our
proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific
advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data, trade secrets and intellectual property
by maintaining physical security of our premises and physical and electronic security of our information technology systems. Agreements
or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets and intellectual
property may otherwise become known or be independently discovered by competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot provide any assurances that our trade secrets and other confidential proprietary information will not be disclosed in violation
of our confidentiality agreements or that competitors will not otherwise gain access to our trade secrets or independently develop substantially
equivalent information and techniques. Also, misappropriation or unauthorized and unavoidable disclosure of our trade secrets and intellectual
property could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken
to maintain our trade secrets and intellectual property are deemed inadequate, we may have insufficient recourse against third parties
for misappropriating any trade secret.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would
be uncertain and could have a material adverse effect on the success of our business. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends upon our ability to develop, manufacture, market and sell our platform technology without infringing the proprietary
rights of third parties. There is considerable intellectual property litigation in the medical device and pharmaceutical industries.
While no such litigation has been brought against us to date and we have not been held by any court to have infringed a third party&rsquo;s
intellectual property rights, we cannot guarantee that our technology or use of our technology does not infringe third-party patents.
It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before
November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential
until patents issue. Patent applications in the United States and elsewhere are published approximately 18 months after the earliest
filing, which is referred to as the priority date. Therefore, patent applications covering our technology could have been filed by others
without our knowledge. Additionally, pending patent applications which have been published can, subject to certain limitations, be later
amended in a manner that could cover our technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect
to our technology, including inter parties review, interference, or derivation proceedings before the U.S. PTO and similar bodies in
other countries. Third parties may assert infringement claims against us based on existing intellectual property rights and intellectual
property rights that may be granted in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to infringe a third party&rsquo;s intellectual property rights, we could be required to obtain a license from such third
party to continue developing and marketing our technology. However, we may not be able to obtain any required license on commercially
reasonable terms or at all. Any inability to secure licenses or alternative technology could result in delays in the introduction of
our products or lead to prohibition of the manufacture or sale of products by us. Even if we were able to obtain a license, it could
be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court
order, to cease commercializing the infringing technology. In addition, we could be found liable for monetary damages, including treble
damages and attorneys&rsquo; fees if we are found to have wilfully infringed a patent. A finding of infringement could prevent us from
commercializing our technology or force us to cease some of our business operations, which could materially harm our business. Claims
that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our
business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims challenging the inventorship of our patents and other intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual
property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants
or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims
challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material
adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management and other employees. In addition, we may receive less revenue from future products if any of our employees
successfully claim for compensation for their work in developing our intellectual property, which in turn could impact our future profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Under
applicable employment laws, we may not be able to enforce covenants not to compete and therefore may be unable to prevent our competitors
from benefiting from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their
inventions irrespective of their agreements with us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
generally enter into non-competition agreements with our employees and certain key consultants. These agreements prohibit our employees
and certain key consultants, if they cease working for us, from competing directly with us or working for our competitors or clients
for a limited period of time. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees
work and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants
developed while working for us. For example, Israeli courts have required employers seeking to enforce non-compete undertakings of a
former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests
of the employer which have been recognized by the courts, such as the secrecy of a company&rsquo;s confidential commercial information
or the protection of its intellectual property. If we cannot demonstrate that such interests will be harmed, we may be unable to prevent
our competitors from benefiting from the expertise of our former employees or consultants and our ability to remain competitive may be
diminished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under Israeli law, if we wish to obtain ownership over inventions developed by our employees, which inventions were developed
while performing their employment activities, but outside the performance of their contractual duties, we are required to compensate
the employee for the rights to their respective inventions. There can be no guarantee that we will be able to obtain any such inventions
and the failure to obtain such ownership rights over employee inventions could have a material adverse effect on our operations and ability
to effectively compete.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Business and Industry</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future growth and success depend to a large extent on the continued services of members of our current management including, who each
have valuable and extensive experience and knowledge of the biopharmaceutical industry. In particular, Mr. Udi Gilboa, who is our co-founder
and Executive Chairman of the board of directors, Mr. Dan Teleman, who serves as our Chief Executive Officer, Dr. Dalia Megiddo,
who serves as our Chief Development Officer and Chief Medical Officer, Ms. Tair Lapidot, our Vice President of Research and Development
and Clinical Development, and Ms. Galia Temtsin Kryaz, who serves as our Director of Product, have been instrumental in formulating our
business strategies and spearheading the growth of our business and operations. We do not maintain &ldquo;key person&rdquo; insurance
for any of our executives or employees. Recruiting and retaining qualified scientific and clinical personnel and, if we progress the
development of our product pipeline toward scaling up for commercialization, manufacturing and sales and marketing personnel, will also
be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of
our development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore,
replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number
of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of
and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate
these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.
We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition,
we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development and commercialization
strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory
contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality
personnel, our ability to pursue our growth strategy will be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates for which we intend to seek approval may face competition sooner than anticipated.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an abbreviated approval pathway for biological products that
are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar
product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA.
In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference
product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference
product if the FDA approves a full BLA for the competing product containing the sponsor&rsquo;s own preclinical data and data from adequate
and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being
interpreted and implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
manage our business through a small number of part-time employees and key consultants. We will need to significantly increase
the size of our organization, and we may experience difficulties in managing our planned growth.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 5, 2025, we had one full-time employee (Mr. Dan Teleman), one part-time employee (Ms. Tair Lapidot),
three service providors (Dr. Dalia Megiddo, Mr. Udi Gilboa, and Mr. Oren Elmaliah) and one consultant (Ms. Galia Temtsin Kryaz). Our
future growth and success depend to a large extent on the continued services of members of our current management including, in particular,
Mr. Udi Gilboa, who is our co-founder and Executive Chairman of the board of directors, Mr. Dan Teleman, who serves as our Chief Executive
Officer, Dr. Dalia Megiddo who serves as our Chief Development Officer and Chief Medical Officer, Ms. Tair Lapidot, our Vice
President of Research and Development and Clinical Development, and Ms. Galia Temtsin Kryaz, who serves as our Director of Product. Any
of our employees and consultants may leave our company at any time, subject to certain notice periods. The loss of the services of any
of our executive officers or any key employees or consultants may adversely affect our ability to execute our business plan and harm
our operating results. Our operational success will substantially depend on the continued employment of senior executives, technical
staff and other key personnel, especially given the intense competition for qualified personnel. The loss of key personnel may have an
adverse effect on our operations and financial performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
we currently have a very limited number of employees, in order to commercialize our products, we will need to substantially increase
our operations, including expanding our employee base of managerial, operational and financial personnel. Any future growth will impose
significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional
employees. To that end, we must be able to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manage
                                            our clinical trials and the regulatory process effectively;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">develop
                                            our administrative, accounting and management information systems and controls;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire
                                            and train additional qualified personnel; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">integrate
                                            current and additional management, administrative, financial and sales and marketing personnel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Expansion
will place a significant strain on our financial, management and other resources, and will require us, among other things, to change,
expand and improve our operating, managerial and financial systems and controls and improve coordination between our various corporate
functions. Although we intend to hire a full-time Chief Financial Officer following the consummation of our initial public offering,
we presently rely entirely on one full-time employee, one part-time employee, three service providers and one consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our inability to effectively manage our growth, including the failure of any new personnel we hire to achieve
anticipated performance levels, would have a material adverse effect on our business, consolidated financial condition and results of
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 23.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 23.05pt"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations
may be directly or indirectly through our customers, subject to various federal and state fraud and abuse laws, including, without limitation,
the federal Anti-Kickback Statute, the federal False Claims Act and physician sunshine laws and regulations. These laws may impact, among
other things, our proposed sales, marketing and education programs. In addition, we may be subject to patient privacy regulation by both
the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly
                                            and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly,
                                            to induce, or in return for, the purchase or recommendation of an item or service reimbursable
                                            under a federal healthcare program, such as the Medicare and Medicaid programs;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal
                                            civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among
                                            other things, individuals or entities from knowingly presenting, or causing to be presented,
                                            claims for payment from Medicare, Medicaid or other third-party payors that are false or
                                            fraudulent;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new
                                            federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit
                                            program and making false statements relating to healthcare matters;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
                                            as amended by the Health Information Technology and Clinical Health Act, and its implementing
                                            regulations, which imposes certain requirements relating to the privacy, security and transmission
                                            of individually identifiable health information;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            federal physician sunshine requirements under Affordable Care Act, requires manufacturers
                                            of drugs, devices and medical supplies to report annually to the HHS information related
                                            to payments and other transfers of value to physicians, other healthcare providers and teaching
                                            hospitals and ownership and investment interests held by physicians and other healthcare
                                            providers and their immediate family members and applicable group purchasing organizations;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">state
                                            law equivalents of each of the above federal laws, such as anti-kickback and false claims
                                            laws that may apply to items or services reimbursed by any third-party payor, including commercial
                                            insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical
                                            industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated
                                            by the federal government, or otherwise restrict payments that may be made to healthcare
                                            providers and other potential referral sources; state laws that require drug manufacturers
                                            to report information related to payments and other transfers of value to physicians and
                                            other healthcare providers or marketing expenditures; and state laws governing the privacy
                                            and security of health information in certain circumstances, many of which differ from each
                                            other in significant ways and may not have the same effect, thus complicating compliance
                                            efforts; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">European
                                            and other foreign law equivalents of each of the laws, including reporting requirements detailing
                                            interactions with and payments to healthcare providers, and the European General Data Protection
                                            Regulation, or GDPR, which became effective in May 2018 and contains new provisions specifically
                                            directed at the processing of health information, higher sanctions and extra-territoriality
                                            measures intended to bring non-EU companies under the regulation, including companies like
                                            us that conduct clinical trials in the EU; we anticipate that over time we may expand our
                                            business operations to include additional operations in the EU and with such expansion, we
                                            would be subject to increased governmental regulation in the EU countries in which we might
                                            operate, including the GDPR.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform,
especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased
their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions,
convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business
practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare
laws and regulations. If our operations are found to be in violation of any of these laws or any other related governmental regulations
that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages,
fines, imprisonment, disgorgement, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid,
reputational harm, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar
settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of
the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable
laws, they may be subject to similar actions, penalties and sanctions. Efforts to ensure that our business arrangements comply with applicable
healthcare laws and regulations, as well as responding to possible investigations by government authorities, can be time- and resource-consuming
and can divert a company&rsquo;s attention from the business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Current
and future healthcare and other legislation and regulatory reform measures may have a material adverse effect on our business and results
of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and
regulatory changes to the healthcare system, including cost-containment measures that may reduce or limit coverage and reimbursement
for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In
particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare
costs and improve the quality of healthcare.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
industry is highly regulated and changes in law may adversely impact our business, operations or financial results. The Affordable Care
Act is a sweeping measure intended to, among other things, expand healthcare coverage within the United States, primarily through the
imposition of health insurance mandates on employers and individuals and expansion of the Medicaid program. Several provisions of the
law may affect us and increase certain of our costs. Among the provisions of the Affordable Care Act of importance to our potential product
candidates, the Affordable Care Act established an annual, nondeductible fee on any entity that manufactures or imports specified branded
prescription drugs and biologic agents; expands eligibility criteria for Medicaid programs; increased the statutory minimum rebates a
manufacturer must pay under the Medicaid Drug Rebate Program; created a new Medicare Part D coverage gap discount program; required certain
Affordable Care Act marketplace and other private payor plans to include coverage for preventative services, including vaccinations recommended
by the Advisory Committee on Immunization Practices without cost share obligations (i.e., co-payments, deductibles or co-insurance) for
plan members; established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative
clinical effectiveness research, along with funding for such research; and established a Center for Medicare and Medicaid Innovation
at the CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been adopted since the Affordable Care Act was enacted. These changes include aggregate reductions
in Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013. These reductions went into effect in
April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect until 2031.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare
payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to
providers from three to five years. These laws and new laws may result in additional reductions in Medicare and other healthcare funding,
which could have a material adverse effect on our customers and, accordingly, our financial operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that the Affordable Care Act, as well as other healthcare reform measures that may be adopted in the future, may result in
more rigorous coverage criteria and an additional downward pressure on the reimbursement our customers may receive for our products.
Further, there have been, and there may continue to be, judicial and Congressional challenges to certain aspects of the Affordable Care
Act. For example, the U.S. Tax Cuts and Jobs Act of 2017, or TCJA, includes a provision repealing, effective January 1, 2019, the tax-based
shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage
for all or part of a year that is commonly referred to as the &ldquo;individual mandate.&rdquo; On June 17, 2021, the U.S. Supreme Court
dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &ldquo;individual
mandate&rdquo; was repealed by Congress. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued
an executive order to initiate a special enrollment period from February 26, 2021 through August 15, 2021 for purposes of obtaining health
insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to
review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid
demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining
access to health insurance coverage through Medicaid or the Affordable Care Act. In addition, on August 16, 2022, President Biden signed
the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing
health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &ldquo;donut hole&rdquo;
under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly
established manufacturer discount program. Additional legislative and regulatory changes to the Affordable Care Act, its implementing
regulations and guidance and its policies, remain possible. However, it remains unclear how any new legislation or regulation might affect
the prices we may obtain for any of our product candidates for which regulatory approval is obtained. Any reduction in reimbursement
from Medicare and other government programs may result in a similar reduction in payments from private payers. The implementation of
cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize
our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing
and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and
health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of
products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions
on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory
burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict
or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently unable to predict what additional legislation or regulation, if any, relating to the health care industry may be enacted
in the future or what effect recently enacted federal legislation or any such additional legislation or regulation would have on our
business. The pendency or approval of such proposals or reforms could result in a decrease in the price of our securities or limit our
ability to raise capital or to enter into collaboration agreements for the further development and potential commercialization of our
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to securities litigation, which is expensive and could divert management attention.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the past, companies that have experienced volatility in the market price of their shares have been subject to securities class action
litigation. We may be the target of this type of litigation in the future. Litigation of this type could result in substantial costs
and diversion of management&rsquo;s attention and resources, which could seriously hurt our business. Any adverse determination in litigation
could also subject us to significant liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Unsuccessful
compliance with certain European privacy regulations could have an adverse effect on our business and reputation.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
collection and use of personal health data in the EU is governed by the provisions of the Data Protection Directive, and as of May 2018,
the GDPR. These directives impose several requirements relating to the consent of the individuals to whom the personal data relates,
the information provided to the individuals, notification of data processing obligations to the competent national data protection authorities
and the security and confidentiality of the personal data. The GDPR also extends the geographical scope of EU data protection law to
non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations for companies and
new rights for individuals. Failure to comply with the requirements of the Data Protection Directive, the GDPR, and the related national
data protection laws of the EU Member States may result in fines and other administrative penalties. The GDPR introduces new data protection
requirements in the EU and substantial fines for breaches of the data protection rules. The GDPR regulations impose additional responsibility
and liability in relation to personal data that we process, and we intend to put in place additional mechanisms ensuring compliance with
these and/or new data protection rules. In addition, other jurisdictions, including Switzerland, are currently discussing or implementing
regulations similar to GDPR. Changes to these European privacy regulations (and similar regulations in other jurisdictions) and unsuccessful
compliance may be onerous and adversely affect our business, financial condition, prospects, results of operations and reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>International
expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing
business outside of the United States or Israel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than our headquarters and other operations which are located in Israel, our business strategy incorporates significant international
expansion, particularly in anticipated expansion of regulatory approvals of our products. Doing business internationally involves a number
of risks, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">multiple,
    conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws,
    regulatory requirements and other governmental approvals, permits and licenses;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
    by us to obtain regulatory approvals for the use of our products and services in various countries;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
    potentially relevant third-party patent rights;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
    and difficulties in obtaining protection and enforcing our intellectual property;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in staffing and managing foreign operations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">complexities
    associated with managing multiple regulatory, governmental and reimbursement regimes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits
    in our ability to penetrate international markets;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">financial
    risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises
    on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">natural
    disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment
    of trade and other business restrictions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
    expenses including, among others, expenses for travel, translation and insurance; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
    and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the
    purview of the FCPA, its books and records provisions or its anti-bribery provisions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
management team has limited experience managing a U.S. reporting company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
members of our management team do not have experience or have limited experience managing a publicly traded company in the United States,
interacting with public company investors and complying with the increasingly complex laws pertaining to public companies in the United
States. Our management team may not successfully or efficiently manage our transition to being a public company in the United States
that is subject to significant regulatory oversight and reporting obligations under the U.S. federal securities laws and the continuous
scrutiny of securities analysts and investors. These new obligations and constituents will require significant attention from our senior
management and could divert their attention away from the day-to-day management of our business, which could adversely affect our business,
financial condition, results of operations and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business and operations might be adversely affected by security breaches, including any cybersecurity incidents.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
depend on the efficient and uninterrupted operation of our computer and communications systems, and those of our consultants, contractors
and vendors, which we use for, among other things, sensitive company data, including our intellectual property, financial data and other
proprietary business information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
certain of our operations have business continuity and disaster recovery plans and other security measures intended to prevent and minimize
the impact of IT-related interruptions, our IT infrastructure and the IT infrastructure of our consultants, contractors and vendors are
vulnerable to damage from cyberattacks, computer viruses, unauthorized access, electrical failures and natural disasters or other catastrophic
events. We could experience failures in our information systems and computer servers, which could result in an interruption of our normal
business operations and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents
or security breaches can cause interruptions in our operations and can result in a material disruption of our targeted phage therapies,
product candidates and other business operations. The loss of data from completed or future studies or clinical trials could result in
delays in our research, development or regulatory approval efforts and significantly increase our costs to recover or reproduce the data.
To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate
disclosure of confidential or proprietary information, we could incur regulatory investigations and redresses, penalties and liabilities
and the development of our product candidates could be delayed or otherwise adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
the implementation of security measures intended to secure our data against impermissible access and to preserve the integrity and confidentiality
of our data, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses,
malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet,
attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security
breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and
cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around
the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption
of our new products development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical
trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.
To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate
disclosure of confidential or proprietary information, we could incur material legal claims and liability, including under data privacy
laws such as the GDPR, damage to our reputation, and the further development of our new products could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
though we believe we carry commercially reasonable business interruption and liability insurance, we might suffer losses as a result
of business interruptions that exceed the coverage available under our insurance policies or for which we do not have coverage. For example,
we are not insured against terrorist attacks or cyberattacks. Any natural disaster or catastrophic event could have a significant negative
impact on our operations and financial results. Moreover, any such event could delay the development of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
it is possible that a cybersecurity attack might not be noticed for some period of time. The occurrence of a cybersecurity attack or
incident could result in negative publicity resulting in reputational damage with our shareholders and other stakeholders and/or increased
costs to prevent, respond to or mitigate cybersecurity events. In addition, the unauthorized dissemination of sensitive personal information
or proprietary or confidential information could expose us or other third parties to regulatory fines or penalties, litigation and potential
liability, or otherwise harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to this Offering and the Ownership of Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price of our Ordinary Shares may be highly volatile, and you may not be able to resell your shares at or above the initial public
offering price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has not been a public market for our Ordinary Shares. If an active trading market for our Ordinary Shares does
not develop following this offering, you may not be able to sell your shares quickly or at the market price. The initial public offering
price for the Ordinary Shares will be determined by negotiations between us and representative of the underwriters and may not be indicative
of prices that will prevail in the trading market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading price of each of our Ordinary Shares is likely to be volatile. The following factors, in addition to other risk factors described
in this section, may have a significant impact on the market price of such securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inability
                                            to obtain the approvals necessary to commence further clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unsatisfactory
                                            results of clinical trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                            of regulatory approval or the failure to obtain it, or specific label indications or patient
                                            populations for its use, or changes or delays in the regulatory review process;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                            of therapeutic innovations or new products by us or our competitors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
                                            actions taken by regulatory authorities with respect to our clinical trials, manufacturing
                                            supply chain or sales and marketing activities;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            or developments in laws or regulations applicable to the treatment of opioid overdose and
                                            anaphylactic shock, or any other indication that we may seek to develop;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            adverse changes to our relationship with manufacturers or suppliers;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            intellectual property infringement actions in which we may become involved;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
                                            concerning our competitors or the pharmaceutical industry in general;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            commencement of, or involvement in, litigation;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            major changes in our board of directors or management;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to recruit and retain qualified regulatory, research and development personnel;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">legislation
                                            in the United States relating to the sale or pricing of pharmaceuticals;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            depth of the trading market in our Ordinary Shares;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
                                            of the lock-up agreements or other restrictions limiting our ability or that of any of our
                                            existing shareholders to sell our common shares (or any other securities that we may issue,
                                            if any) after this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic
                                            weakness, including inflation, or political instability in particular foreign economies and
                                            markets;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">business
                                            interruptions resulting from a local or worldwide pandemic, such as COVID-19, geopolitical
                                            actions, including war and terrorism, or natural disasters</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            granting or exercise of employee share options or other equity awards; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in investors&rsquo; and securities analysts&rsquo; perception of the business risks and conditions
                                            of our business.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5.25pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock market in general, and the NYSE American in particular, have experienced extreme price and volume fluctuations that
have often been unrelated or disproportionate to the operating performance of small companies. Broad market and industry factors may
negatively affect the market price of our Ordinary Shares, regardless of our actual operating performance. Further, a systemic decline
in the financial markets and related factors beyond our control may cause our share price to decline rapidly and unexpectedly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sales
of a substantial number of our Ordinary Shares in the public market by our existing shareholders could cause our share price
to fall.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of a substantial number of our Ordinary Shares in the public market or the perception that these sales might occur, could depress the
market price of our common shares and could impair our ability to raise capital through the sale of additional equity securities. We
are unable to predict the effect that sales may have on the prevailing market price of our common shares. While the Ordinary Shares sold
to non-affiliates in this offering will be freely tradable, without restriction, in the public market, substantially all of the Ordinary
Shares owned prior to this offering or purchased in this offering by our existing shareholders are expected to be subject to lock-up
agreements with the underwriters of this offering that restrict the ability of these shareholders&rsquo; to transfer our common shares
held by them for at least six months from the date of this prospectus. These outstanding shares that are subject to lock-up agreements
are expected to become eligible for unrestricted sale upon expiration of the lockup period, as described in the section of this prospectus
entitled &ldquo;<I>Shares Eligible for Future Sale</I>.&rdquo; In addition, shares issued or issuable upon exercise of share options
vested as of the expiration of the lock-up period will be eligible for sale at that time. Sales of shares by these shareholders could
have a material adverse effect on the trading price of our common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Raising
additional capital would cause dilution to our existing shareholders and may adversely affect the rights of existing shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek additional capital through a combination of private and public equity offerings, debt financings and collaborations and strategic
and licensing arrangements. To the extent that we raise additional capital through the issuance of equity (such as this offering) or
otherwise including through convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation
or other preferences that adversely affect your rights as a shareholder. Future sales of our Ordinary Shares or of securities convertible
into our Ordinary Shares, or the perception that such sales may occur, could cause immediate dilution and adversely affect the market
price of our Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
principal shareholders and management own a significant percentage of our Ordinary Shares and will be able to exert significant influence
over matters subject to shareholder approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
executive officers, directors, five percent shareholders and their affiliates currently beneficially own approximately 78% of our Ordinary Shares as of February 5, 2025. <FONT>Following the completion of this offering, it is expected
that our executive officers, directors and principal shareholders will beneficially own &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our
Ordinary Shares, assuming no exercise of the underwriters&rsquo; over-allotment option to purchase additional Ordinary Shares. </FONT>Therefore,
these shareholders, and in particular, <FONT STYLE="background-color: white">our largest shareholders, </FONT>Ehud Gilboa and Dr.
Dalia Megiddo<FONT STYLE="background-color: white">, will have the ability to influence us through their ownership positions. These
shareholders may be able to determine all matters requiring shareholder approval. For example, these shareholders, acting together,
may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets
or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our securities
that you may believe are in your best interest as one of our shareholders. </FONT>See &ldquo;<I>Beneficial Ownership of Principal
Shareholders and Management</I>&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Management
will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management will have broad discretion in the allocation of the net proceeds and could use them for purposes other than those contemplated
at the time of this offering and as described in the section entitled &ldquo;<I>Use of Proceeds</I>.&rdquo; Our management could spend
the proceeds in ways that you do not agree with or that do not improve our results of operations or enhance the value of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
a foreign private issuer, we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise
applicable SEC and NYSE American requirements, which may result in less protection than is accorded to investors under rules applicable
to domestic U.S. issuers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
status as a foreign private issuer exempts us from compliance with certain SEC laws and regulations and certain regulations of the NYSE
American, including the proxy rules, the short-swing profits recapture rules, and certain governance requirements such as independent
director oversight of the nomination of directors and executive compensation. In addition, we will not be required under the Exchange
Act to file current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities
are registered under the Exchange Act and we will generally be exempt from filing quarterly reports with the SEC. Furthermore, as a foreign
private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These
exemptions and leniencies will reduce the frequency and scope of information and protections to which you are entitled as an investor.
See &ldquo;<I>Management &ndash; Differences between the Companies Law and NYSE American Requirements</I>&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
a foreign private issuer, we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise
applicable SEC and NYSE American requirements, which may result in less protection than is accorded to investors under rules applicable
to domestic U.S. issuers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
status as a foreign private issuer exempts us from compliance with certain SEC laws and regulations and certain regulations of the NYSE
American, including the proxy rules, the short-swing profits recapture rules, and certain governance requirements such as independent
director oversight of the nomination of directors and executive compensation. In addition, we will not be required under the Exchange
Act to file current reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose securities
are registered under the Exchange Act and we will generally be exempt from filing quarterly reports with the SEC. Furthermore, as a foreign
private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. These
exemptions and leniencies will reduce the frequency and scope of information and protections to which you are entitled as an investor.
See &ldquo;<I>Management &ndash; Differences between the Companies Law and NYSE American Requirements</I>&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we were to be characterized as a &ldquo;passive foreign investment company&rdquo; for U.S. tax purposes, U.S. holders of our securities
could have adverse U.S. income tax consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, we will be treated as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes in any taxable year
in which either (1) at least 75% of our gross income is &ldquo;passive income&rdquo; or (2) on average at least 50% of our assets by
value produce passive income or are held for the production of passive income. Passive income for this purpose generally includes, among
other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions and from the sale
or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary investment
of funds, including those raised in a public offering. In determining whether a non-U.S. corporation is a PFIC, a proportionate share
of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into
account. We do not expect to be a PFIC for 2023 and we do not expect to become a PFIC in the future, although there can be no assurance
in this regard. If we are a PFIC in any taxable year during which a U.S. taxpayer holds the securities, such U.S. taxpayer would be subject
to certain adverse U.S. federal income tax rules. In particular,, if the U.S. taxpayer did not make an election to treat us as a qualified
electing fund, or QEF, or make a &ldquo;mark-to-market&rdquo; election, then &ldquo;excess distributions&rdquo; to the U.S. taxpayer,
and any gain realized on the sale or other disposition of the securities by the U.S. taxpayer: (1) would be allocated ratably over the
U.S. taxpayer&rsquo;s holding period for the securities; (2) the amount allocated to the current taxable year and any period prior to
the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each
of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that
year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each
such other taxable year. In addition, if the U.S. Internal Revenue Service, or IRS, determines that we are a PFIC for a year with respect
to which we have determined that we were not a PFIC, it may be too late for a U.S. taxpayer to make a timely QEF or mark-to-market election.
U.S. taxpayers that have held the securities during a period when we were a PFIC will be subject to the foregoing rules, even if we cease
to be a PFIC in subsequent years, subject to exceptions for U.S. taxpayer who made a timely QEF or mark-to-market election. A U.S. taxpayer
can make a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions thereto.
We do not intend to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and to make and maintain
a valid QEF election for any year in which we are a PFIC. U.S. taxpayers that hold the securities are strongly urged to consult their
tax advisors about the PFIC rules, including tax return filing requirements and the eligibility, manner, and consequences to them of
making a QEF or mark-to-market election with respect to the securities in the event that we are a PFIC. See &ldquo;<I>Taxation&mdash;U.S.
Federal Income Tax Consequences&mdash;Passive Foreign Investment Companie</I>s&rdquo; for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have not paid, and do not intend to pay, dividends on our Ordinary Shares and, therefore, unless our traded securities appreciate in
value, our investors may not benefit from holding our Ordinary Shares. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid any dividends on our Ordinary Shares. We do not anticipate paying any dividends in the foreseeable future.
We currently intend to retain future earnings, if any, to finance operations and expand our business. Our board of directors has sole
discretion whether to pay dividends. If our board of directors decides to pay dividends, the form, frequency and amount will depend upon
our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other
factors that our directors may deem relevant. The Israeli Companies Law, 5759-1999, or the Companies Law, imposes restrictions on our
ability to declare and pay dividends. See &ldquo;<I>Dividend Policy</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
JOBS Act allows us to postpone the date by which we must comply with some of the laws and regulations intended to protect investors and
to reduce the amount of information we provide in our reports filed with the SEC, which could undermine investor confidence in our Company
and adversely affect the market price of our common shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
so long as we remain an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act, we intend to take advantage of certain exemptions
from various requirements that are applicable to public companies that are not &ldquo;emerging growth companies&rdquo; including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 23.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            provisions of the Sarbanes-Oxley Act requiring that our independent registered public accounting
                                            firm provide an attestation report on the effectiveness of our internal control over financial
                                            reporting;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
                                            107 of the JOBS Act, which provides that an &ldquo;emerging growth company&rdquo; can take
                                            advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities
                                            Act for complying with new or revised accounting standards. This means that an &ldquo;emerging
                                            growth company&rdquo; can delay the adoption of certain accounting standards until those
                                            standards would otherwise apply to private companies. We are electing to delay such adoption
                                            of new or revised accounting standards. As a result of this adoption, our financial statements
                                            may not be comparable to companies that comply with the public company effective date;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory
                                            audit firm rotation or a supplement to the auditor&rsquo;s report on the financial statements;
                                            and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to furnish two rather than three years of income statements and statements of cash
                                            flows in the registration statement on Form F-1 of which this prospectus is part.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to take advantage of these exemptions until we are no longer an &ldquo;emerging growth company.&rdquo; We will remain an emerging
growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the date of the completion
of this offering, (b) in which we have total annual gross revenue of at least $1.235 billion, or (c) in which we are deemed to be a large
accelerated filer, as defined in the rule under the Exchange Act, and (2) the date on which we have issued more than $1.0 billion in
non-convertible debt during the prior three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict if investors will find our ordinary less attractive because we may rely on these exemptions. If some investors find our
Ordinary Shares less attractive as a result, there may be a less active trading market for each such traded security, and the trading
price of each may be more volatile and may decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they
adversely change their recommendations or publish negative reports regarding our business or our shares, the trading prices of our shares
and trading volume of our shares could decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our Ordinary Shares will be influenced by the research and reports that industry or securities analysts may publish
about us, our business, our market or our competitors. We do not have any control over these analysts and we cannot provide any assurance
that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation
regarding our shares or provide more favorable relative recommendations about our competitors, the trading price of our shares would
likely decline. If any analyst who may cover us were to cease coverage of our Company or fail to regularly publish reports on us, we
could lose visibility in the financial markets, which in turn could cause the trading price of our shares and trading volume of our shares
to decline.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Israeli Law and Our Operations in Israel</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Potential
political, economic and military instability in Israel, where our headquarters, members of our management team, our production facilities,
and employees are located, may adversely affect our results of operations.</I></B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
headquarters and principal offices and most of our operations are located in the State of Israel. In addition, all of our key employees
and officers are residents of Israel. Accordingly, political, economic and military conditions in Israel may directly affect our business.
Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and countries in
the region or groups in neighboring countries. In addition, several countries, principally in the Middle East, restrict doing business
with Israel, and additional countries may impose restrictions on doing business with Israel and Israeli companies whether as a result
of hostilities in the region or otherwise. Any hostilities involving Israel, terrorist activities, political instability, violence in
the region or the interruption or curtailment of trade or transport between Israel and its trading partners could adversely affect our
operations and results of operations and the market price of our Ordinary Shares. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Our commercial insurance does not cover losses that may occur as a result of an event associated with war and terrorism. Although the
Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or
acts of war, we cannot assure you that this government coverage will be maintained or, if maintained, will be sufficient to compensate
us fully for any damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial
condition and results of operations. As of February 5, 2025, we have not incurred any direct losses or damages caused by terrorism
or war. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 7, 2023, an attack was launched against Israel by the Hamas terrorist organization. In response, the Security Cabinet
of the State of Israel declared war on Hamas and a military campaign ensued. To date, the State of Israel continues to
be at war with Hamas. To Israel&rsquo;s northern border, Israel has been engaged with Hezbollah in Lebanon, a terrorist organization
that has been launching missile, rocket, and shooting attacks against Israeli military sites, troops, and Israeli towns. In response
to these attacks, the Israeli army has carried out a number of targeted strikes on sites associated with Hezbollah in Lebanon. As of
the end of November 2024, Israel entered into a ceasefire agreement with Hezbollah, but there are no assurances as to whether the agreement
will hold or whether further hostilities with Hezbollah will resume. In addition, Iran has launched direct attacks on Israel involving
drones and missiles, has threatened to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also
believed to have a strong influence among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, and the Houthi
movement in Yemen and various rebel militia groups in Iraq. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
the war broke out on October 7, 2023, our operations have not been adversely affected. At this time, it is not possible to predict
the intensity or duration of the war, nor can we predict how this war will ultimately affect Israel&rsquo;s economy in general, which
may involve additional credit rating agencies downgrading Israel&rsquo;s credit rating score after Moody&rsquo;s downgrading of Israel&rsquo;s
credit rating from A1 to A2 and outlook rating from &ldquo;stable&rdquo; to &ldquo;negative&rdquo;, and we continue to monitor the
situation closely and examine the potential disruptions that could adversely affect our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
many Israeli citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until
they reach the age of 40 (or older for certain reservists) and, in the event of a military conflict, may be called to active duty. In
response to increases in terrorist activity, there have been periods of significant call-ups of military reservists.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
In connection with the Israeli security cabinet&rsquo;s declaration of war against Hamas, hostilities with Hezbollah and Iran,
and possible hostilities with other organizations, several hundred thousand Israeli military reservists were drafted to perform immediate
military service. Although many such military reservists have been discharged, they may be called up again depending on how events
unfold. As of February 5, 2025, none of our current employees in Israel have been called to active military duty.
Moreover, we rely on service providers located in Israel and have entered into certain agreements with Israeli counterparties.
Employees of such service providers or contractual counterparties may be called for service in the current or future wars or other armed
conflicts Israel may be engaged in and such persons may be absent from their positions for a period of time. Military service
call ups that result in absences of our personnel, service providers or contractual counterparties in Israel may disrupt our
operations and absences for an extended period of time may materially and adversely affect our business, prospects, financial condition
and results of operations. As of February 5, 2025, we have not been affected by any absences of personnel of our service providers
or counterparties located in Israel. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Any hostilities involving
Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and
results of operations. Our insurance policies do not cover losses that may occur as a result of events associated with war and terrorism.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war,
we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses
or damages incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region
would likely negatively affect business conditions and could harm our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Several
countries, principally in the Middle East, still restrict doing business with Israel and Israeli companies, and additional countries
may impose restrictions on doing business with Israel and Israeli companies, whether as a result of hostilities in the region or otherwise.
In addition, there have been increased efforts by certain countries, activists and organizations to cause companies,
research institutions and consumers to boycott Israeli goods and cooperation with Israeli-related entities based on Israeli government
policies. Such actions, particularly if they become more widespread, may adversely impact our ability to collaborate with other third
parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
political conditions within Israel may affect our operations. Many citizens and groups have responded strongly against the Israeli government&rsquo;s
pursuit of judicial reform. To date, these initiatives have been substantially put on hold. Actual or perceived instability in Israel
or any negative changes in the political environment may individually or in the aggregate adversely affect the Israeli economy and, in
turn, our business, financial condition, results of operations and growth prospects.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect to be exposed to fluctuations in currency exchange rates, which could adversely affect our results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incur expenses in the new Israeli shekel, or NIS, U.S. dollars, and Euros, but our functional currency is the U.S. dollar.
Accordingly, we face exposure to adverse movements in currency exchange rates. Accordingly, we face exposure to adverse movements in
the currency exchange rate of the U.S. dollars against these foreign currencies, which may have a negative effect on our revenue and
costs. If the U.S. dollar strengthens against any of these currencies, the translation of these foreign currency denominated
transactions will result in decreased revenue in U.S. dollars. Changes in currency exchange rates may have a negative effect on our
financial results. If the U.S. dollar weakens against the NIS and Euro, the translation of the NIS and Euro currency denominated
transactions to U.S. dollar will result in increased operating expenses. Similarly, if the U.S. dollar strengthens against NIS and
Euro denominated, the translation of these NIS and Euro denominated transactions to U.S. dollars will result in decreased expenses.
As exchange rates vary, sales and other operating results, when translated, may differ materially from our or the capital
market&rsquo;s expectations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
termination or reduction of tax and other incentives that the Israeli government provides to Israeli companies may increase our costs
and taxes.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli government currently provides tax and capital investment incentives to Israeli companies, as well as grant and loan programs
relating to research and development and marketing and export activities. In recent years, the Israeli government has reduced the benefits
available under these programs and the Israeli governmental authorities may in the future further reduce or eliminate the benefits of
these programs. While we have not previously received any such benefits or grants, we may take advantage of these benefits and programs
in the future; however, there can be no assurance that such benefits and programs will be available to us. If we qualify for such benefits
and programs and fail to meet the conditions thereof, the benefits could be canceled and we could be required to refund any benefits
we might already have enjoyed and become subject to penalties. Additionally, if we qualify for such benefits and programs and they are
subsequently terminated or reduced, it could have an adverse effect on our financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be required to pay monetary remuneration to our Israeli employees for their inventions, even if the rights to such inventions have
been duly assigned to us.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
enter into agreements with our Israeli employees pursuant to which such individuals agree that any inventions created in the scope of
their employment are either owned exclusively by us or are assigned to us, depending on the jurisdiction, without the employee retaining
any rights. A portion of our intellectual property has been developed by our Israeli employees during their employment for us. Under
the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee during the course of his or her employment
and within the scope of said employment are considered &ldquo;service inventions. Service inventions belong to the employer by default,
absent a specific agreement between the employee and employer otherwise. The Patent Law also provides that if there is no agreement regarding
the remuneration for the service inventions, even if the ownership rights were assigned to the employer, the Israeli Compensation and
Royalties Committee, or the Committee, a body constituted under the Patent Law, shall determine whether the employee is entitled to remuneration
for these inventions. The Committee has not yet determined the method for calculating this Committee-enforced remuneration. While it
has previously been held that an employee may waive his or her rights to remuneration in writing, orally or by conduct, litigation is
pending in the Israeli labor court is questioning whether such waiver under an employment agreement is enforceable. Although our Israeli
employees have agreed that we exclusively own any rights related to their inventions, we may face claims demanding remuneration in consideration
for employees&rsquo; service inventions. As a result, we could be required to pay additional remuneration or royalties to our current
and/or former employees, or be forced to litigate such claims, which could negatively affect our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to enforce covenants not-to-compete under current Israeli law that might result in added competition for our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have non-competition agreements with all of our employees, all of which are governed by Israeli law. These agreements prohibit our employees
from competing with or working for our competitors, generally during their employment and for up to 12 months after termination of their
employment. However, Israeli courts are reluctant to enforce non-compete undertakings of former employees and tend, if at all, to enforce
those provisions for relatively brief periods of time in restricted geographical areas, and only when the employee has obtained unique
value to the employer specific to that employer&rsquo;s business and not just regarding the professional development of the employee.
If we are not able to enforce non-compete covenants, we may be faced with added competition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Provisions
of Israeli law and our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition
of, us, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
corporate law regulates mergers, requires tender offers for acquisitions of securities above specified thresholds, requires special approvals
for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types
of transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date on which a merger proposal
is filed by each merging company with the Israel Registrar of Companies and at least 30 days have passed from the date on which the shareholders
of both merging companies have approved the merger. In addition, a majority of each class of securities of the target company must approve
a merger. Moreover, a tender offer for all of a company&rsquo;s issued and outstanding securities can only be completed if the acquirer
receives positive responses from the holders of at least 95% of the issued share capital. Completion of the tender offer also requires
approval of a majority of the offerees that do not have a personal interest in the tender offer, unless, following consummation of the
tender offer, the acquirer would hold at least 98% of the Company&rsquo;s outstanding securities. Furthermore, the shareholders, including
those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer,
claim that the consideration for the acquisition of the securities does not reflect their fair market value, and petition an Israeli
court to alter the consideration for the acquisition accordingly, unless the acquirer stipulated in its tender offer that a shareholder
that accepts the offer may not seek such appraisal rights, and the acquirer or the company published all required information with respect
to the tender offer prior to the tender offer&rsquo;s response date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not
have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free
share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances
but makes the deferral contingent on the fulfilment of a number of conditions, including, in some cases, a holding period of two years
from the date of the transaction during which sales and dispositions of securities of the participating companies are subject to certain
restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires,
the tax becomes payable even if no disposition of the securities has occurred. These provisions could delay, prevent or impede an acquisition
of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>It
may be difficult to enforce a judgment of a U.S. court against us and our executive officers and directors and the Israeli experts named
in this prospectus in Israel or the United States, to assert U.S. securities laws claims in Israel or to serve process on our executive
officers and directors and these experts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were incorporated in Israel. Substantially all of our executive officers and directors reside outside of the United States, and all of
our assets and most of the assets of these persons are located outside of the United States. Therefore, a judgment obtained against us,
or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be
collectible in the United States and may not be enforced by an Israeli court. It also may be difficult for you to effect service of process
on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Additionally,
it may be difficult for an investor, or any other person or entity, to initiate an action with respect to U.S. securities laws in Israel.
Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most
appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that
Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must
be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be
governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty
associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign
court (see &ldquo;<I>Enforceability of Civil Liabilities</I>&rdquo; for additional information on your ability to enforce a civil claim
against us and our executive officers or directors named in this prospectus).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Your
rights and responsibilities as a shareholder will be governed in key respects by Israeli laws, which differs in some material respects
from the rights and responsibilities of shareholders of U.S. companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
rights and responsibilities of the holders of our securities are governed by our amended and restated articles of association and by
Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders
in U.S. companies. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising
its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in such company,
including, among other things, in voting at a general meeting of shareholders on matters such as amendments to a company&rsquo;s amended
and restated articles of association, increases in a company&rsquo;s authorized share capital, mergers and acquisitions and related party
transactions requiring shareholder approval, as well as a general duty to refrain from discriminating against other shareholders. In
addition, a shareholder who is aware that it possesses the power to determine the outcome of a vote at a meeting of the shareholders
or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company.
There is limited case law available to assist us in understanding the nature of these duties or the implications of these provisions.
These provisions may be interpreted to impose additional obligations and liabilities on holders of our securities that are not typically
imposed on shareholders of U.S. companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
articles of association to be effective upon the consummation of this offering may be deemed to have an anti-takeover effect.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
provisions of our articles of association to be effective upon the consummation of this offering may make a change in control of us
more difficult to affect. Our articles of association will provide for a staggered board of directors consisting of three classes of
directors. Directors of each class are chosen for three-year terms upon the expiration of their current terms and each year one class
of our directors will be elected by our shareholders. This classified board provision could have the effect of making the replacement
of incumbent directors more time consuming and difficult. At least two annual meetings of shareholders, instead of one, will generally
be required to effect a change in a majority of our board of directors. Thus, the classified board provision could increase the likelihood
that incumbent directors will retain their positions. The staggered terms of directors may delay, defer or prevent an attempt to change
control of us, even though a change in control might be considered by our shareholders to be in their best interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>


<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="am_001"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
of the statements made under &ldquo;<I>Prospectus Summary</I>,&rdquo; &ldquo;<I>Risk Factors</I>,&rdquo; &ldquo;<I>Use of Proceeds</I>,&rdquo;
&ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</I>,&rdquo; &ldquo;<I>Business</I>&rdquo;
and elsewhere in this prospectus constitute forward-looking statements. In some cases, you can identify forward-looking statements by
terminology such as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential&rdquo; &ldquo;intends&rdquo; or &ldquo;continue,&rdquo;
or the negative of these terms or other comparable terminology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements
that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relating
to the research, development, completion and use of our products, and all statements (other than statements of historical facts) that
address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward-looking
statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements
on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current
conditions, expected future developments and other factors they believe to be appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Important
factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking
statements include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 23.05pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            regulatory pathways that we may elect to utilize in seeking EMA, FDA and other regulatory
                                            approvals;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
                                            EMA and FDA approval of, or other regulatory action in Europe or the United States and elsewhere
                                            with respect to Intranasal Naloxone, and Intranasal Epinephrine or other product candidates
                                            that we may seek to develop;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            commercial launch and future sales of Intranasal Naloxone, and Intranasal Epinephrine or
                                            any other future product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding the timing of commencing further clinical trials, the process entailed
                                            in conducting each such trial, including dosages, and the order of such trials with each
                                            of our product candidates or whether such trials will be conducted at all;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party
                                            payor reimbursement for Intranasal Naloxone, and Intranasal Epinephrine;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            estimates regarding anticipated expenses, capital requirements, and our needs for
                                            additional financing;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            to the patient market size and market adoption of Intranasal Naloxone, and Intranasal Epinephrine
                                            by physicians and patients;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            timing, cost, regulatory approvals or other aspects of the commercial launch of Intranasal
                                            Naloxone, and Intranasal Epinephrine;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
                                            of an MAA and NDA with the EMA and FDA for Intranasal Naloxone, and Intranasal Epinephrine,
                                            respectively;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
                                            and receiving favorable results of clinical trials for Intranasal Naloxone, and Intranasal
                                            Epinephrine;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            use of proceeds from this offering;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to raise capital through the issuance of additional securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuance
                                            of patents to us by the U.S. PTO and other governmental patent agencies and our ability to
                                            maintain, protect, and enhance our intellectual property;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            development and commercialization, if any, of any other product candidates that we may seek
                                            to develop;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability of our management team to lead the development of our product candidates;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            expectations regarding licensing, acquisitions, and strategic operations;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            market, political and economic conditions in the countries in which we operate, including
                                            those related to recent unrest and actual or potential armed conflict in Israel and other
                                            parts of the Middle East, such as the Israel&rsquo;s multi-front war;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">projected
                                            capital expenditures and liquidity;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            impact of competition and new technologies;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in our strategy; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our
or our industry&rsquo;s actual results, levels of activity, performance or achievements to be materially different from those anticipated
by the forward-looking statements. We discuss many of these risks in this prospectus in greater detail under the heading &ldquo;<I>Risk
Factors</I>&rdquo; and elsewhere in this prospectus. You should not rely upon forward-looking statements as predictions of future events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels
of activity, performance, or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking
statements, whether as a result of new information, future events or otherwise, after the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="am_002"></A>LISTING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to apply to list the Ordinary Shares on the NYSE American under the symbol &ldquo; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&rdquo;
No public market currently exists for our Ordinary Shares included in this offering. This offering is contingent upon the Ordinary Shares
being listed on the NYSE American; however, no assurance can be given that our application will be approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="am_003"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to receive approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million in net proceeds from the sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ordinary Shares offered by us in this offering (approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their over-allotment option in full), based upon an
assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Ordinary Share, which is the midpoint of the price
range set forth on the cover page of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
$1.00 increase or decrease in the assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Ordinary Share
would increase or decrease the proceeds from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million,
assuming that the number of Ordinary Shares offered by us, as set forth on the cover page of this prospectus, remains the same and
after deducting the estimated underwriting discounts and commissions. Similarly, each increase or decrease of 1,000,000 Ordinary
Shares offered would increase or decrease our proceeds by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million,
assuming the assumed public offering price remains the same, and after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the net proceeds from this offering for the following purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million for
                                            the completion of the development and approval of Intranasal Naloxone, including the submission
                                            of our NDA with the FDA, and for pre-commercial activities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            $&nbsp;&nbsp;&nbsp;&nbsp; million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million for the development
                                            of our Intranasal Epinephrine program, including, technology scale-up, pivotal trial, and
                                            the submission of our NDA to the FDA and pre-commercial activities for our research and development
                                            efforts;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to $ &nbsp;&nbsp;&nbsp;&nbsp; million for the
                                            development of two additional early-stage indications, <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">which we have not yet chosen and will
be determined at a later date;</FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approximately
                                            $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million for sales and
                                            marketing activities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            remainder for general and administrative corporate purposes, including working capital,
                                            and capital expenditures.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts and schedule of our actual expenditures will depend on multiple factors. As a result, our management will have broad discretion
in the application of the net proceeds of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Changing
circumstances may cause us to consume capital significantly faster than we currently anticipate. The amounts and timing of our actual
expenditures will depend upon numerous factors, including the progress of our global marketing and sales efforts, the development efforts,
and the overall economic environment. Therefore, our management will retain broad discretion over the use of the proceeds from this
offering. We may ultimately use the proceeds for different purposes than what we currently intend. Pending any ultimate use of any portion
of the proceeds from this offering, if the anticipated proceeds will not be sufficient to fund all the proposed purposes, our management
will determine the order of priority for using the proceeds, as well as the amount and sources of other funds needed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
our use of the net proceeds from this offering, we may invest the net proceeds in a variety of capital preservation investments, including
short-term, investment grade, interest bearing instruments and U.S. government securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="am_004"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
have never declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing
conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects
and other factors our board of directors may deem relevant. Under the Companies Law, repurchase of shares is considered a dividend distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Companies Law, we may declare and pay dividends only if, upon the determination of our board of directors, there is no reasonable
concern that the distribution will prevent us from being able to meet the terms of our existing and foreseeable obligations as they become
due. Under the Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over
the two most recent years legally available for distribution according to our then last reviewed or audited financial statements, provided
that the end of the period to which the financial statements relate is not more than six months prior to the date of distribution. In
the event that we do not meet such earnings criteria, we may seek the approval of the court in order to distribute a dividend. The court
may approve our request if it is convinced that there is no reasonable concern that the payment of a dividend will prevent us from satisfying
our existing and foreseeable obligations as they become due. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">However,
under the New Exemptions, an Israeli company whose shares are listed outside of Israel, is permitted to perform distribution in a way
of repurchasing its own shares, even if the Earnings Criteria is not met, without the need for court&rsquo;s approval. The exemption
is subject to certain conditions, including, among others: (i) The distribution meets the Solvency Criteria; and (ii) no rejection was
filed by any of the company&rsquo;s creditors to the court. If any creditor objects to the distribution, the company will be required
to obtain the court&rsquo;s approval for the distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Payment
of dividends may be subject to Israeli withholding taxes (see &ldquo;<I>Taxation&mdash;Israeli Tax Considerations and Government Programs</I>&rdquo;).
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="am_005"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and cash equivalents and our capitalization as of June 30, 2024:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            an actual basis;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            a <I>pro forma</I> basis to give effect to (i) the conversion of all Class A, Class A-1,
                                            Class A-2, Class A-3, Class A-3A and Class A-3B Ordinary Shares into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary
                                            Shares; (ii) 37,688 Ordinary Shares issuable upon the exercise of share options held by directors,
                                            employees and consultants under our 2019 Plan, outstanding as of June 30, 2024, at a weighted
                                            average exercise price of $12.96, of which 37,054 were vested as of June 30, 2024 and 13,850
                                            Ordinary Shares reserved for future grants under the 2019 Plan; <FONT STYLE="background-color: white">(iii)
                                            </FONT>the issuance of 35,243 and 63,958&nbsp;Class A-3A and Class A-3B Ordinary Shares,
                                            respectively, that were issued upon the conversion of the 2022 and 2023 SAFEs, respectively
                                            in August 2024; (iv)</FONT> the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary
                                            Shares to be issued upon the conversion of the 2024 SAFEs into Ordinary Shares immediately
                                            prior to the consummation of this offering; and (v) our receipt in November 2024 through
                                            January 2025 of aggregate proceeds of $170,000 from the 2024 SAFEs we entered
                                            into with certain investors; and.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
                                            a <I>pro forma</I> as adjusted basis to give effect to the issuance of Ordinary
                                            Shares in this offering, at an assumed public offering price of $ per Ordinary Share, which
                                            is the midpoint of the price range set forth on the cover page of this prospectus, and after
                                            deducting underwriting discounts and commissions and estimated offering expenses, as if the
                                            sale of the Ordinary Shares had occurred on June 30, 2024.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<I>pro forma</I> as adjusted information set forth in the table below is illustrative only and will be adjusted based on the actual public
offering price and other terms of this offering determined at pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this table in conjunction with the sections entitled &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations</I>&rdquo; and our financial statements and related notes included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1pt solid">U.S. dollars in thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid">Pro Forma</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD><TD STYLE="font-weight: bold; font-style: italic; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; font-style: italic; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pro Forma</I><BR> As<BR> Adjusted<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; font-style: italic">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Unaudited)</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">900</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Long term debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Shareholders&rsquo; equity (deficit):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Ordinary Shares par value NIS 0.01 per share; 2,681,000 shares authorized; 1,444,359 shares issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional Paid-In Capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,336</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accumulated deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(12,003</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total shareholders&rsquo; equity (deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,663</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Total capitalization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,663</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of Ordinary Shares purchased from us by existing shareholders is based on 1,444,359 Ordinary Shares issued and outstanding as
of June 30, 2024, and excludes the following as of such date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            Ordinary Shares issuable upon the exercise of share options granted subsequent to June 30, 2024, at a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            per ordinary share;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,688
                                            Ordinary Shares issuable upon the exercise of share options to directors, employees and consultants
                                            under the 2019 Plan outstanding as of June 30, 2024, at a weighted average exercise
                                            price of $12.96, of which 37,054 were vested as of June 30, 2024 and
                                            13,850 Ordinary Shares reserved for future grants under the 2019 Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
adjusted information discussed above is illustrative only and will be adjusted based on the actual initial public offering price and
other terms of our initial public offering determined at pricing. Each $1.00 increase (decrease) in the assumed initial public
offering price of $ per Ordinary Share, which is the midpoint of the price range set forth on the cover page of this prospectus,
would increase (decrease) the <I>pro forma</I> as adjusted amount of each of cash, cash equivalents and shareholders&rsquo; equity
(deficiency) by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of ordinary shares offered by us, as
set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and
commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0 million shares in the number
of Ordinary Shares offered by us at the assumed initial public offering price would increase (decrease) each of cash, cash
equivalents and shareholders&rsquo; equity (deficiency) by $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="am_006"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our Ordinary Shares, your interest will be diluted immediately to the extent of the difference between the public offering
price per Ordinary Share you will pay in this offering and the <I>pro forma</I> net tangible book value per Ordinary Share after this
offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, we had a net tangible book value of $(4.7) million, corresponding to a net tangible book value of $(3.23)
per Ordinary Share. Net tangible book value per share or per Ordinary Share represents the amount of our total tangible assets less
our total liabilities, divided by 1,444,359, the total number of Ordinary Shares issued and outstanding on June 30, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
<I>pro forma</I> net tangible book value as of June 30, 2024 was $&nbsp;&nbsp;&nbsp; million, representing approximately $&nbsp;&nbsp;&nbsp;&nbsp;
per Ordinary Share. <I>Pro forma</I> net tangible book value per Ordinary Share represents the amount of our total tangible assets less
our total liabilities, divided by &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, the total number of Ordinary Shares outstanding at June 30, 2024,
after giving effect to (i) the conversion of all outstanding Class A, Class A-1, Class A,2, Class A-3, Class A-3A and Class A-3B Ordinary
Shares into Ordinary Shares; (ii) the exercise immediately prior to the closing of this offering of share options to purchase Ordinary
Shares; (iii) the issuance of 35,243 and 63,958&nbsp;Class A-3A and Class A-3B Ordinary Shares, respectively, that were issued upon the
conversion of the 2022 and 2023 SAFEs, respectively in August 2024; (iv) <FONT STYLE="background-color: white">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Ordinary Shares to be issued upon the conversion of the 2024 SAFEs into Ordinary Shares immediately prior to the consummation
of this offering; and (v) our receipt in November 2024 of aggregate proceeds of $170,000 from the 2024 SAFEs we entered into with
certain investors. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the sale of the Ordinary Shares offered by us in this offering, assuming no exercise of the underwriter&rsquo;s option
to purchase additional Ordinary Shares and after deducting the estimated underwriting discounts and commissions and management fees and
estimated offering expenses payable by us, and after taking into account the automatic conversion of all outstanding Class A, Class A-1,
Class A-2, Class A-3, Class A-3A and Class A-3B Ordinary Shares into Ordinary Shares upon the consummation of this offering, the exercise
immediately prior to the closing of this offering of share options to purchase all classes of Ordinary Shares which will immediately
convert into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ordinary Shares; <FONT STYLE="background-color: white">the
issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ordinary Shares to be issued upon the conversion of the 2024 SAFEs
into Ordinary Shares immediately prior to the consummation of this offering; and our receipt of aggregate proceeds of $170,000
from the 2024 SAFEs we entered into between November 2024 and January 2025 with certain investors</FONT>, our <I>pro forma</I>
net tangible book value estimated at June 30, 2024 would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million,
representing $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Ordinary Share. At the assumed public offering price for this offering
of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Ordinary Share, which is the midpoint of the price range set forth on the cover page
of this prospectus, this represents an immediate increase in historical net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per Ordinary Share to existing shareholders and an immediate dilution in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per Ordinary Share to purchasers of Ordinary Shares in this offering. Dilution for this purpose represents the difference between the
price per Ordinary Share paid by these purchasers and <I>pro forma</I> net tangible book value per Ordinary Share immediately after the
completion of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table illustrates this dilution on a per Ordinary Share basis to purchasers of Ordinary Shares in this offering:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed
    public offering price per Ordinary Share</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pro
    Forma</I> net tangible book value per Ordinary Share as of June 30, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in <I>pro forma </I>net tangible book value per Ordinary Share attributable to new investors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pro
    forma</I> as adjusted net tangible book value per Ordinary Share after this offering</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution
    per Ordinary Share to new investors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    of dilution in net tangible book value per Ordinary Share for new investors</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
dilution information set forth in the table above is illustrative only and will be adjusted based on the actual public offering price
and other terms of this offering determined at pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35.45pt; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35.45pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
$1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Ordinary Share would
increase or decrease our <I>pro forma</I> net tangible book value per Ordinary Share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the dilution per Ordinary Share to new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming the number of Ordinary Shares offered by us, as set forth on the cover page of this
prospectus, remains the same, after deducting the estimated underwriting discounts and commissions and estimated offering expenses
payable by us. Similarly, each increase or decrease of 1,000,000 Ordinary would increase or decrease our <I>pro forma</I> net
tangible book value per Ordinary Share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and the dilution per Ordinary Share to
new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming the assumed initial offering price of $ per Ordinary Share, as set
forth on the cover page of this prospectus, remains the same, after deducting the estimated underwriting discounts and commissions
and estimated offering expenses payable by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes, on a <I>pro forma</I> basis as of June 30, 2024, the differences between the number of Ordinary
Shares acquired from us, the total amount paid and the average price per Ordinary Share paid by the existing holders of our Ordinary
Shares and by investors in this offering and based upon an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per Ordinary
Share, which is the midpoint of the price range set forth on the cover page of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Consideration</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Average<BR>
    Price Per<BR> Ordinary</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Percent</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Share</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Existing shareholders</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 35%; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">New investors</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; width: 9%; text-align: right"></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; width: 9%; text-align: right"></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; width: 9%; text-align: right"></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; width: 9%; text-align: right"></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 2%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; width: 9%; text-align: right"></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100.0</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<FONT STYLE="background-color: white">number</FONT> of Ordinary Shares purchased from us by existing shareholders is based on 1,444,359
Ordinary Shares issued and outstanding as of June 30, 2024, and excludes the following as of such date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            Ordinary Shares issuable upon the exercise of share options granted subsequent to June 30, 2024, at a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
                                            ordinary share;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,688
                                            Ordinary Shares issuable upon the exercise of share options to directors, employees and consultants
                                            under the 2019 Plan outstanding as of June 30, 2024, at a weighted average exercise price
                                            of $12.91, of which 34,248 were vested as of June 30, 2024; and </FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &#9679; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> 38,702
                                            Ordinary Shares reserved for future grants under the 2019 Plan as of February 5,
                                            2025. </TD></TR>
                                                                                                                                   </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Unless
otherwise indicated, all information in this prospectus assumes or gives effect to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the
                                            midpoint of the price range set forth on the cover page of this prospectus;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            automatic conversion of all outstanding Class A, Class A-1, Class A-2,
                                            Class A-3 Ordinary Shares into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ordinary Shares,
                                            which will occur upon the consummation of this offering;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,243
Ordinary Shares issuable upon the conversion of 35,243 Class A-3A Ordinary Shares that were issued upon the conversion of the 2022 SAFEs,
with approval at a special meeting of our shareholders on August 28, 2024; immediately prior to the consummation of this offering, such
Class A-3A Ordinary Shares will automatically convert into Ordinary Shares; immediately prior to the consummation of this offering, such Class A-3A Ordinary Shares will automatically convert
into Ordinary Shares;</FONT></P>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63,958
                                            Ordinary Shares issuable upon the conversion of 63,958 Class A-3B Ordinary Shares that were
                                            issued upon the conversion of the 2023 SAFEs, with approval at a special meeting of our shareholders
                                            on August 28, 2024; immediately prior to the consummation of this offering, such Class A-3B
                                            Ordinary Shares will automatically convert into Ordinary Shares;</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
                                            Ordinary Shares issuable upon the conversion of SAFEs entered into between April 2024 and
                                            August 2024, or, collectively the 2024 SAFEs, in the aggregate amount of $1,757,992,
                                            which will automatically convert into Ordinary Shares immediately prior to the consummation
                                            of this offering, based on an offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
                                            which is the midpoint of the price range set forth on the cover page of this prospectus,
                                            assuming this offering occurs within 18 months of the execution of such SAFEs, otherwise
                                            such SAFEs will be converted into our securities on the basis of a previous round of equity
                                            financing consummated by the Company; </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            adoption of our amended and restated articles of association prior to the closing of this
                                            offering, which will replace our amended and restated articles of association as currently
                                            in effect; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
                                            exercise of the underwriters&rsquo; over-allotment option and the Representative&rsquo;s
                                            Warrants.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
all of such issued and outstanding share options had been exercised as of </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 30, 2024,</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT>
the number of Ordinary Shares held by existing shareholders would increase to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, or %
of the total number of Ordinary Shares outstanding after this offering (in each case, not taking into account the conversion of SAFEs
as described above), and the average price per Ordinary Share paid by the existing shareholders would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the underwriters exercise their option to purchase additional Ordinary Shares in full in this offering, the number of Ordinary
Shares held by new investors will increase to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , or % of the total number of Ordinary Shares
issued and outstanding after this offering and the percentage of Ordinary Shares held by existing shareholders will decrease to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total Ordinary Shares issued and outstanding <FONT STYLE="background-color: white">(in
each case, not taking into account the conversion of SAFEs as described above)</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="am_007"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in
this prospectus. This discussion and other parts of the prospectus contain forward-looking statements based upon current expectations
that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated
in these forward-looking statements as a result of several factors, including those set forth under &ldquo;Risk Factors&rdquo; and elsewhere
in this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 23.1pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 23.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency
medical conditions. Intranasal administration is especially suitable for medical emergencies when prompt drug administration is critical,
since the nose is lined up with a very rich vascular bed enabling quick drug absorption. We are developing a unique PBI technology with
a specialized product portfolio to address acute medical conditions and public health threats. We believe that PBI may be superior
over liquid-based solutions due to potentially significantly higher dispersion of powder throughout the nasal cavity, thus creating
a larger absorption area and enabling more rapid and higher drug absorption. In addition, the uniform spherical powder particles of our
proprietary formulation may enhance the consistency and reliability of the delivered dose. The initial clinical trials
of our PBI products involving different molecules performed thus far have demonstrated quicker and higher drug absorption over
similar solution-based nasal products. However, to date we have only tested our product candidates on a relatively
small patient population and none of our products have been approved by the FDA. Prior to obtaining FDA approval of any of our product
candidates, we will need to perform additional clinical testing of our product candidates to confirm any benefits and advantages our products
may have over similar nasal products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective,
user-friendly and immediately active PBI specialized products. To help achieve this we are developing NS002, an intranasal powder
epinephrine nasal spray for the treatment of type 1 severe allergies and anaphylaxis, and NS001, an intranasal Naloxone powder nasal
spray for the treatment of opioid overdose. We will need to obtain regulatory approval for our products in order for us to grow
our business. We currently have no FDA approved products. Our products have been tested on relatively small patient populations thus
far.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining regulatory
approvals and developing NS001 and NS002 will require the incurrence of significant costs and our success will depend, in part, on gaining
market acceptance. In order to gain market acceptance in the United States, we will require specific approval from the FDA for our product
candidates. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We intend to seek approval of NS002 as an approved
molecule and a new delivery route (with EpiPen autoinjector as the reference device) under Section 505(b)(2) of the FFDCA which allows
the applicant to rely in part on previous studies conducted by unrelated parties, such as another drug manufacturer and, existing sources,
including published literature, for marketing approval by the FDA in the United States, and will seek approval under the comparable hybrid
application pathway in the European Union. The FDA may not agree that our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval. Such abbreviated approval pathways may not lead to a faster development or review
process compared to traditional approval pathways and do not increase the likelihood that NS001 and NS002 will receive regulatory approval
in the United States or the European Union. See &ldquo;<I>Business &ndash; Government Regulation</I>&rdquo; and &ldquo;<I>Risk Factors
&ndash; Risks Related to Product Development, Regulatory Approval and Commercialization</I>&rdquo; for additional information).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have conducted a twelve-patient pilot study of NS002, which included the testing of bioavailability of epinephrine under
&ldquo;allergenic challenge&rdquo; - the creation of severe acute allergic reaction in the nose by inserting ascending doses of
allergens to the nose of the healthy volunteers with known allergic rhinitis included in the study. The results showed that
epinephrine intranasal delivery of our NS002 followed the established characteristics of our platform technology&mdash;namely, there
were higher levels of the drug in the plasma in situations where immediate administration could be lifesaving. The Phase 2 study,
which is meant to optimize the dose that will be used in the Phase 3 study for registration, is conducted in limited patient
populations to identify possible adverse effects and safety risks, to preliminarily evaluate the dosage tolerance of the product for
specific targeted diseases or conditions and to determine dosage tolerance, optimal dosage and dosing schedule. Our Phase 2 study is
aimed at defining the final clinical dose to be used in our powder epinephrine product candidate, compared the bioavailability of
epinephrine following a various dosing of NS002 Microspheres Epinephrine powder. The pharmacokinetic results of our Phase 2 study
are in line with the known attributes of our nasal powder technology&mdash;namely: immediate absorption of epinephrine and reaching
higher peak plasma epinephrine levels quicker compared to IM Epinephrine injections. We intend to perform two additional Phase 2
studies of NS002. The first will be aimed at determining whether, if necessary, during a real-life anaphylaxis a
second dose of NS002 should be administered in the same nostril as the one used for the first administration of NS002 or whether it
should be in the other nostril. The second Phase 2 study will test the &ldquo;carry-over effect,&rdquo; or whether the first dose of
epinephrine changes the absorption of epinephrine of a following dose. Each study is currently planned to include at least 12
healthy volunteers with allergic rhinitis. Prior to submission to the FDA for marketing approval, we also intend to perform a
pivotal clinical, or Phase 3, study that will include a subsection of self-administration. We also intend to separately perform:
(1) stability testing which involves testing the product candidate under various temperature and humidity points; (2) a reliability
study, which is a subset of the stability study that tests the NS002&rsquo;s administration device in several potential conditions;
(3) a usability study, which tests how user friendly the device is; (4) preclinical studies or short animal safety studies in two
animal species; and (5) a pediatric study, the details of which will be agreed upon with the FDA as we progress with the
program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to NS001 Intranasal Naloxone, we have performed a pilot study, which is a first in human study aimed at safety and bioequivalence,
and pivotal clinical study, which is the Phase 3 registration study, in 14 and 42 healthy volunteers, respectively, with the
objective of evaluating the comparative bioavailability of naloxone between NS001 and certain competitor products. The pilot study results
were submitted to the FDA in support of the progression to the pivotal study. The results of the pilot study showed our technology having
a faster absorption rate in the immediate critical period after administration. The Phase 3 study is administered to an expanded patient
population to further evaluate dosage and clinical efficacy. Our pivotal clinical study consistently showed an
advantage in the first 30 minutes after administration. We intend to perform the following additional studies of NS001: (1) a stability study with reliability study; (2)
a usability study; and (3) short term preclinical studies in animals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
platform technology can also be incorporated into other products as it has been tested with several additional preclinical and invitro
molecules based on our proprietary nasal powder formulation and technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT>Competition
in the pharmaceutical industry is intense. Some of our competitors hold significant market share, have long histories and strong reputations
within the industry, greater brand recognition, and more financial and human resources than we do. They also have more experience and
capabilities in researching and developing testing devices, obtaining and maintaining regulatory clearances and other requirements, manufacturing
and marketing those products than we do. Their dominant market position and significant control over the market could significantly limit
our ability to introduce or effectively market and generate sales of NS001 and NS002.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To date, we have incurred significant operating losses, generated no revenues from existing products, and as
of June 30, 2024, our accumulated deficit was $12.0 million. We expect that we will need to raise substantial additional funding in the
future. See &ldquo;<I>Risk Factors&ndash;Risks Related to Our Financial Condition and Capital Requirements.</I>&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Components
of Operating Results </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Operating
Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current operating expenses consist of two components &ndash; research and development expenses and general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Expenses.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses consist primarily of costs incurred in connection with our research and development activities. This includes
conducting clinical trials and preclinical studies, manufacturing development efforts and activities related to regulatory filings for
product candidates, as well as overhead costs. Our research and development expenses primarily consist of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">salaries
                                            and personnel-related costs, including benefits and share-based compensation expense, for
                                            our scientific personnel for executing clinical trials, preclinical studies, regulatory activities
                                            and for performing research and development activities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            related to executing clinical trials and preclinical studies;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            of third-party clinical consultants and expenses related to conducting clinical and pre-clinical
                                            trials;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
                                            related to acquiring, developing and manufacturing materials for such clinical trials and
                                            preclinical studies; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                            related overhead costs.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are expensed as incurred. We record accrued expenses for research and development activities conducted, on our
behalf, by third-party service providers, which include the performance of clinical trials and the conduct of preclinical studies. We
record these accrued expenses based upon research and development activities performed by such third-party service providers and reported
to us, and we include these costs in accrued liabilities in the consolidated balance sheets and within research and development expense
in the consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
inception though June 30, 2024, we have incurred approximately $10 million in research and development expenses to advance
the development of our product candidates, as well as other preclinical research and development programs. Substantially all of our research
and development expenses for the years ended December 31, 2023 and 2022 and the six months ended June 30, 2024 were related to the development of NS001 and NS002.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our research and development expenses will materially increase as we enter into the Phase 2 and Phase 3 clinical development
stage of our product candidates, start Chemical Control and Manufacturing activity, or CMC, and recruit additional research and development
employees. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary
to complete the development of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence
from sales of our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries and related expenses, professional service fees for accounting, legal and bookkeeping,
facilities, travel expenses and other general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our general and administrative expenses will increase in the future to support continued research and development activities.
We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance and director and officer insurance costs,
as well as investor, public relations and compliance expenses, associated with operating as a public company. We expect increased expenses
if any of our product candidates receives regulatory approval and we determine to build a commercial infrastructure to support commercial
sales and marketing of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Comparison of the Six Months Ended June 30,
2024 to the Six Months Ended June 30, 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Results of Operations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The following
table presents our results of operations for the six months ended June 30, 2024 and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; font-style: italic; border-bottom: Black 1pt solid">U.S. dollars in thousands</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Consolidated statements of operations:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating Expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and
    development<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">168</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">229</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative<SUP>(2)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">315</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">327</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">483</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Operating loss from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(483</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(556</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense<SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in fair value of convertible securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(379</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">391</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(885</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(184</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net income (loss) from discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(30</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(871</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(214</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Research and development expenses includes $228 thousand and $231
    thousand in expenses to related parties in the years ended December 31, 2023 and 2022, respectively, and $103 thousand and $111 thousand
    in expenses to related parties in the six months ended June 30, 2024 and 2023, respectively.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">General and administrative expenses includes $288 thousand and $313
    thousand in expenses to related parties in the years ended December 31, 2023 and 2022, respectively, and $149 thousand and $140 thousand
    in expenses to related parties in the six months ended June 30, 2024 and 2023, respectively. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Interest expenses includes $27 thousand and $9 thousand in expenses
    to related parties in the years ended December 31, 2023 and 2022, respectively, and $12 thousand and $12 thousand in expenses to
    related parties in the six months ended June 30, 2024 and 2023, respectively.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses for the six months ended June 30, 2024, amounted to $168 thousand representing a decrease of $61 thousand, or 27%, compared
to $229 thousand for the six months ended June 30, 2023. The decrease was primarily attributable to the end of a clinical trial held
in 2023 for NS0002 and its related costs. For further information regarding our research and development activities, <I>see</I> &ldquo;<I>Business
&ndash; Research and Development</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>General and Administrative Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Our general
and administrative expenses totaled $315 thousand for the six months ended June 30, 2024, representing a decrease of $15 thousand,
or 4%, compared to $327 thousand for the six months ended June 30, 2023. The decrease was primarily attributable to a decrease in
legal and accounting related expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><I>Operating Loss from Continuing Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As a result
of the foregoing, our operating loss from continuing operations totalled $483 thousand for the six months ended June 30, 2024,
representing an decrease of $73 thousand, or 13%, compared to $556 thousand for the six months ended June 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><I>Change in Fair Value of Convertible Securities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Change
in fair value of convertible securities consist of changes in fair value as done from time to time. We recognized financial expense of
$379 thousand for the six months ended June 30, 2024, representing an increase of $770 thousand, or 197%, compared to financial income
of $391 thousand for the six months ended June 30, 2023. The increase in expense was primarily due to the change in the fair value of
the SAFEs.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><I>Net Loss (Income) from Discontinued Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Net income from
discontinued operations was $14 thousand for the six months ended June 30, 2024, representing an increase of $44 thousand, or
147%, compared to a net loss from discontinued operations of $30 thousand for the six months ended June 30, 2023. The net loss for
the six months ended June 30, 2024 was primarily due to changes in foreign currency exchange rates impacting current liabilities
related to discontinued operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Net Loss</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the foregoing,
our net loss totaled $871 thousand for the six months ended June 30, 2024, representing an increase of $657 thousand, or 307%, compared
to $214 thousand for the six months ended June 30, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comparison
of the Year Ended December 31, 2023 to the Year Ended December 31, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Results
of Operations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents our results of operations for the year ended December 31, 2023 and 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year
    Ended December 31,</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 12pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic"><FONT STYLE="font-family: Times New Roman, Times, Serif">U.S.
    dollars in thousands</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated statements
    of operations:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating Expenses:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">567</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,116</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative<SUP>(2)</SUP></FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">580</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">926</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total operating expenses</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,147</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,042</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating loss from continuing operations</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,147</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,042</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expense<SUP>(3)</SUP></FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(49</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change in fair value of convertible securities</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">219</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(88</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other income (expense),
    net</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(28</P></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss from continuing operations</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,005</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,152</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net income (loss) from
    discontinued operations</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(46</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">441</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,051</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,711</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
                                            and development expenses includes $228 thousand and $231 thousand in expenses to related
                                            parties in the years ended December 31, 2023 and 2022, respectively.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
                                            and administrative expenses includes $288 thousand and $313 thousand in expenses to
                                            related parties in the years ended December 31, 2023 and 2022, respectively.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
                                            expenses includes $27 thousand and $9 thousand in expenses to related parties in the
                                            years ended December 31, 2023 and 2022, respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses for the year ended December 31, 2023, amounted to $567 thousand representing a decrease of $549 thousand,
or 49%, compared to $1,116 thousand for the year ended December 31, 2022. The decrease was primarily attributable to a substantial reduction
in workforce as well as the end of CMC activity for NS001 in 2022, offset by clinical costs for the development of NS002. In
addition, in 2022, we offset research and development costs by $287 thousand in a non-recurring research and development arrangement
with a governmental body. In 2023, we had no such income. For further information regarding our research and development activities,
<I>see</I> &ldquo;<I>Business &ndash; Research and Development</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses totaled $580 thousand for the year ended December 31, 2023, representing a decrease of $346 thousand,
or 37%, compared to $926 thousand for the year ended December 31, 2022. The decrease was primarily attributable to a reduction in workforce,
as well a reduction in legal and accounting fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Loss from Continuing Operations</I></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the foregoing, our operating loss totaled $1,147 thousand for the year ended December 31, 2023, representing a decrease
of $895 thousand, or 56%, compared to $2,042 thousand for the year ended December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Change
in Fair Value of Convertible Securities </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
in fair value of convertible securities consist of changes in fair value as done from time to time. We recognized financial income of
$219 thousand for the year ended December 31, 2023, representing an increase of $399 thousand, or 453%, compared
to financial expense of $88 thousand for the year ended December 31, 2022. The increase was due to the change in fair value of the SAFEs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><I>Net
Loss (Income) from Discontinued Operations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
loss from discontinued operations totaled $46 thousand for the year ended December 31, 2023, representing a decrease of $487 thousand, or
110%, compared to $441 thousand in net income from discontinued operations for the year ended December 31, 2022. The decrease was
primarily attributable to the full stop of the discounted activity during 2022, during 2023 we only had storage costs and incidental
expenses related to the wind down.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
Loss</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the foregoing, our net loss totaled $1,051 thousand for the year ended December 31, 2023, representing a decrease
of $660 thousand, or 39%, compared to $1,711 thousand for the year ended December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception through June 30, 2024, we have funded our operations principally with approximately $10.6 million (net of
issuance expenses) through proceeds from equity financing and the issuance of convertible securities in the form of SAFEs. As
of June 30, 2024, we had approximately $0.9 thousand in cash and cash equivalents.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents our cash flows for the periods indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Year Ended December 31,</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; font-style: italic">U.S. dollars in thousands</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2022</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(1,029</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(1,211</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(180</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">(477</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(160</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,055</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,469</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">881</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,055</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase (decrease) in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">39</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(143</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">706</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
cash used in operating activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
cash used in operating activities amounted to $180 thousand during the six months ended June 30, 2024, compared to $477 thousand
during the six months ended June 30, 2023. The decrease is mainly due to a change in other current assets as of June 30, 2024 and higher
operational costs in 2023. Net cash used in operating activities during the six months ended June 30, 2024 was primarily
attributable to the net loss from continuing operations of $885 thousand and non-cash adjustments of $712 thousand, which includes a
$379 thousand loss from change in convertible securities, share-based compensation of $5 thousand and a net decrease in working
capital of $315 thousand. Net cash used in operating during the six months ended June 30, 2023 was primarily attributable to the net
loss from continuing operations of $184 thousand and non-cash adjustments of $248 thousand, which includes $391 thousand income from
change in convertible securities, share-based compensation of $25 thousand and a net decrease in working capital of $98
thousand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities of $1.0 million during the year ended December 31, 2023 compared to $1.2 million during the year ended
December 31, 2022. Net cash used in operating activities during the year ended December 31, 2023 was primarily attributable to our net
loss from continuing operations of $1,005 thousand, adjusted for non-cash expenses of $23 thousand, which includes a $219 thousand
income from change in convertible securities, stock-based compensation of $39 thousand, and a net decrease in working capital
of $167 thousand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating during the year ended December 31, 2022 was primarily attributable to our net loss from continued operations of
$2.2 million, adjusted for non-cash expenses of $121 thousand, which includes $88 loss from change in convertible securities,
stock-based compensation of $23 thousand, and a net decrease in working capital of $477 thousand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cash
used in investing activities </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had no net cash used in investing activities during the six months ended June 30, 2024 and June 30, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> no net cash used in investing activities during
the year ended December 31, 2023 and net cash used in investing activities of $160 thousand during the year ended December 31,
2022, as a result of a fixed asset purchase, offset by a sale of a fixed asset.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
cash provided by financing activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
cash provided by financing activities was $881 thousand for the six months ended June 30, 2024, as compared to $1,055 thousand for the
six months ended June 30, 2023. The decrease was mainly attributable to the deferred offering costs of $91 thousand related to this offering
and an additional $60 thousand loan from shareholders issued in February 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities was $1.1 million for the year ended December 31, 2023, as compared to $1.5 million for the year
ended December 31, 2022. The decrease was mainly attributable to $500 thousand in shareholder loans received in the year ended December
31, 2022 versus a $60 thousand loan received in the year ended December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Between
February</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2022 and April 2022, we entered into the
2022 <FONT STYLE="background-color: white">SAFEs</FONT> for aggregate proceeds of $966,000. Per the terms of the 2022 SAFEs, since an
initial public offering, merger, acquisition, equity financing other liquidity event or dissolution event did not take place within 15
months from the execution of such the 2022 SAFEs, on August 28, 2024, the subscription amounts under such SAFEs were converted into
Class A-3A Ordinary Shares. Immediately prior to the consummation of this offering, such Class A-3A Ordinary Shares will
automatically convert into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In July 2022, we received
a loan, or the July 2022 Loan, from Dr. Ronnie Hershman, a director and shareholder, and Michael Gibber, a shareholder, pursuant to which
we received a principal amount of $500,000, for a term of twelve (12) months, at an interest rate of 8% per annum. On August 28, 2024,
we and each of Dr. Ronnie Hershman and Michael Gibber entered into an exchange letter, or the July 2022 Loan Exchange Letter, according
to which our obligations in connection with the loan were discharged in consideration for the issuance of a SAFE under the same terms
as the 2024 SAFEs, under which it is deemed that Dr. Hershman invested an amount of $284,154 and Michael Gibber invested an amount of
$286,210.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
February 2023, we received a loan in an aggregate amount of $60,000 from Dr. Ronnie Hershman, Dr. Dalia Megiddo, and Mr. Udi Gilboa,
or the February 2023 Loan, under substantially the same terms as the July 2022 Loan</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
for a term of twelve (12) months, at an interest rate of 8% per annum. <FONT STYLE="background-color: white">A definitive agreement for
the February 2023 Loan was not executed. In August 2024, we and each of Dr. Ronnie Hershman, Dr. Dalia Megiddo, and Mr. Udi Gilboa entered
into an exchange letter, or the February 2023 Loan Exchange Letter, according to which our obligations in connection with the February
2023 Loan were discharged in consideration for the issuance of a SAFE under the same terms as the 2024 SAFEs, under which Dr. Ronnie
Hershman was deemed to have invested an amount of $43,954, Dr. Dalia Megiddo was deemed to have invested an amount of $11,286, and Mr.
Udi Gilboa was deemed to have invested an amount of $10,963 in said SAFEs. See &ldquo;<I>Related Party Transactions&mdash;SAFEs</I>&rdquo;
for information regarding  the terms of the 2024 SAFEs.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023 through April 2023, we entered into the 2023 SAFEs for aggregate proceeds of $995,000. Per the terms of the
2023 SAFEs, since an initial public offering, merger, acquisition, equity financing or other liquidity event or dissolution event did
not take place within 15 months from the execution of the 2023 SAFEs, on August 28, 2024, the subscription amounts under such SAFEs were
converted into Class A-3B Ordinary Shares. Immediately prior to the consummation of this offering, such Class A-3B Ordinary Shares will
automatically convert into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Current
Outlook</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, our cash and cash equivalents were approximately $0.9 million, and we had a working capital deficit of $4.8 million
and an accumulated deficit of $12.0 million. Based upon our currently expected level of operating expenditures, we expect that our existing
cash and cash equivalents will be sufficient to fund operations through June 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have financed our operations to date primarily through proceeds from equity financing and the issuance of convertible securities in the
form of SAFEs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024 through January 2025, we entered into the 2024 SAFEs <FONT STYLE="background-color: white">in the aggregate amount
</FONT>of $1,421,500, of which $300,000 were canceled and terminated in November 2024. In addition, pursuant to the terms of the
July 2022 Loan Exchange Letter and the February 2023 Loan Exchange Letter, the July 2022 Loan and February 2023 Loan were converted into
2024 SAFEs in the amount of $570,364 and $66,203, respectively; however, no additional proceeds were received pursuant to said exchanges.
Per the terms of the 2024 SAFEs, upon an initial public offering, merger, acquisition, qualified equity financing or other liquidity
event, the subscription amounts under such SAFEs will be converted into our Ordinary Shares upon consummation of this offering, at a
conversion price reflecting a discount of 35%. However, if such events do not occur within 18 months of the execution of such SAFEs,
such SAFEs will be converted into our securities of such class of shares having certain rights identical to the respective rights of
the most senior class of shares on the basis of a previous round of equity financing consummated by the Company at a conversion price
reflecting a discount of 35%, as prescribed in such SAFEs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to generate revenues from the sale of our products and other revenues in the future. However, we do not expect these revenues
to support all of our operations in the near future. We expect our expenses to increase in connection with our activities, particularly
as we continue the development of our products, and continue our commercialization efforts. Accordingly, we expect that we will require
substantial additional funding in connection with the growth of our operations, continuing our research and development activity, and
commercializing our products. Until we can generate recurring revenues and profit, we expect to satisfy our future cash needs through
debt and equity financings. However, there is no assurance that we will be successful accomplishing these plans. If we are unable to
obtain sufficient capital, we may need to reduce, delay, or adjust our operating expenses, including commercialization of our products
or be unable to expand our operations, as desired. We expect to continue incurring losses and negative cash flows from operations until
our products reach profitability. As a result of these expected losses and negative cash flows from operations, along with our current
cash position, our management has concluded that a material uncertainty exists that raises substantial doubt about our ability to continue
as a going concern. See &ldquo;<I>Risk Factors &ndash; Risks Related to Our Financial Position and Capital Requirements &mdash;
We have not generated revenues from our continued activities, have incurred significant losses since our inception and anticipate that
we will continue to incur significant losses for the foreseeable future, and we may never achieve or maintain profitability, which raise
a substantial doubt about our ability to continue as a going concern and could prevent us from obtaining new financing on reasonable
terms or at all.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Seasonality</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Seasonality
does not materially affect our business or the results of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for a standard short-term operating lease, we have not engaged in any off-balance sheet arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quantitative
and Qualitative Disclosure About Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial
position due to adverse changes in financial market prices and rates. Our current investment policy is to invest available cash in bank
deposits with banks that have a credit rating of at least A-. Accordingly, a substantial majority of our cash and cash equivalents is
held in deposits that bear interest. Our market risk exposure is primarily a result of foreign currency exchange rates, which is discussed
in detail in the following paragraph.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign
Currency Exchange Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate primarily in Israel, and part of our expenses are denominated in NIS. We are therefore exposed to market risk, which represents
the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. We are subject to
fluctuations in foreign currency rates in connection with these arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2024, we have not entered into any hedging transactions, but we may do so in the future. Even
if we do enter into such hedging transactions in the future, we cannot guarantee that such measures will effectively protect us
from adverse effects due to the impact of fluctuations in currency exchange rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
describe our significant accounting policies more fully in Note 2 to our financial statements for the year ended December 31, 2023. We
believe that the accounting policy below is critical in order to fully understand and evaluate our financial condition and results of
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
prepare our financial statements in accordance with U.S. GAAP. At the time of the preparation of the financial statements, our management
is required to use estimates, evaluations and assumptions which affect the application of the accounting policy and the amounts reported
for assets, obligations, income and expenses. Our management believes that the estimates, judgment and assumptions used are reasonable
based upon information available at the time they are made. These estimates, judgment and assumptions can affect reported amounts and
disclosures made. Actual results could differ from those estimates. Any estimates and assumptions are continually reviewed. The changes
to the accounting estimates are credited during the period in which the change to the estimate is made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
Value Measurements </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical
accounting estimates include the valuation of our convertible securities, including SAFEs, which are measured at fair value on a recurring
basis with changes in fair value reported in the consolidated statements of operations. We elected the fair value option in accordance
with ASC 825, Financial Instruments. The SAFEs are measured at fair value each period by using the probability-weighted
expected return model. In estimating the fair value of our SAFEs, we used the assistance of a third-party valuation specialist and considered
factors we believed are material to the valuation process, including, but not limited to, the likelihood of a SAFE mandatory conversion,
qualified equity finance or liquidity event or dissolution and fair value of Ordinary Shares, risk free rate, time to maturity and weighted
average cost of capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Share-based
compensation </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for share-based compensation in accordance with ASC Topic 718, &ldquo;Compensation-Stock Compensation.&rdquo; We calculate the
fair value of share options on the date of grant using the Black-Scholes option-pricing model, and the expense is recognized over the
requisite service period for awards expected to vest using the graded vesting method. This model requires various significant judgmental
assumptions in order to derive a final fair value determination for each type of award, including the expected term, expected volatility,
expected dividend yield, risk-free interest rate, and fair value of our share on the date of grant. The requisite service period for
share options is generally four years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
there is no public market for our Ordinary Shares, the fair value of our equity is being approved by our board of directors as of the
date share-based awards were granted. In estimating the fair value of our Ordinary Shares, we used the assistance of a third-party valuation
specialist and considered factors we believed are material to the valuation process, including, but not limited to, the price at which
recent equity was issued by us to independent third parties or transacted between third parties, risks, prospects, and economic and market
conditions, among other factors. We believe the combination of these factors provided an appropriate estimate of our expected fair value
and reflects the best estimate of the fair value of our Ordinary Shares at each grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of the Ordinary Shares underlying our option awards was determined by our board of directors, with input from management.
We believe that our board of directors has the relevant experience and expertise to determine the fair value of our Ordinary Shares as
of each respective grant date. The valuations of our Ordinary Shares were determined in accordance with the guidelines outlined in the
American Institute of Certified Public Accountants Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I>,
or the AICPA Practice Aid. The assumptions used in the valuation model are based on future expectations combined with management judgment.
Our board of directors, with input from management, exercised significant judgment and considered numerous objective and subjective factors
to determine the fair value of our Ordinary Shares as of the date of each option grant, including the following factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
</FONT></P>



<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">independent
                                            valuations performed at periodic intervals by independent third-party valuation specialist;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                            current business projections;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our
                                            stage of development;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            prices, rights, preferences and privileges of our convertible classes of Ordinary Shares;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">current
                                            business conditions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            likelihood of a liquidity event for the Ordinary Shares underlying these share options,
                                            such as an initial public offering or sale of our company, given prevailing market conditions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">any
                                            adjustments necessary due to the lack of marketability of our Ordinary Shares;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            purchase of our Ordinary Shares by third party investors in arms-length transactions; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            market performance of comparable publicly traded companies.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Impact
of Inflation and Currency Fluctuations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
functional and reporting currency is the U.S. dollar. We incur some of our expenses in other currencies. As a result, we are exposed
to the risk that the rate of inflation in countries in which we are active other than the United States will exceed the rate of devaluation
of such countries&rsquo; currencies in relation to the dollar or that the timing of any such devaluation will lag behind inflation in
such countries. To date, we have not been materially affected by changes in the rate of inflation or the exchange rates of other countries&rsquo;
currencies compared to the dollar, and we cannot assure you that we will not be adversely affected in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
annual rate of inflation in Israel was 3% in 2023 and 5.3% in 2022. The NIS weakened against the U.S. dollar by approximately 3.07 %
in 2023 and 13.15% in 2022. In the six months ended June 30, 2024, the NIS weakened against the U.S.
dollar by approximately 4%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>JOBS
Act Accounting Election</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company.&rdquo; Under the JOBS Act, an emerging growth company can delay adopting new or revised accounting
standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have irrevocably
elected to avail ourselves of this exemption from new or revised accounting standards, and, therefore, will not be subject to the same
new or revised accounting standards as public companies that are not emerging growth companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="am_008"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency
medical conditions. Intranasal administration is especially suitable for medical emergencies when prompt drug administration is critical,
since the nose is lined up with a very rich vascular bed enabling quick drug absorption. We are developing a unique PBI technology with
a specialized product portfolio to address acute medical conditions and public health threats. We believe that PBI may be superior
over liquid-based solutions due to potentially significantly higher dispersion of powder throughout the nasal cavity, thus creating
a larger absorption area and enabling more rapid and higher drug absorption. In addition, the uniform spherical powder particles of our
proprietary formulation may enhance the consistency and reliability of the delivered dose. The initial clinical trials
of our PBI products involving different molecules performed thus far have demonstrated quicker and higher drug absorption over
similar solution-based nasal products. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However, to date we have
only tested our product candidates on a relatively small patient population and none of our products have been approved by the FDA. Prior
to obtaining FDA approval of any of our product candidates, we will need to perform additional clinical testing of our product candidates
to confirm any benefits and advantages our products may have over similar</FONT> nasal products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly
and immediately active PBI specialized products. To help achieve this we are developing NS002, an intranasal powder epinephrine nasal
spray for the treatment of type 1 severe allergies and anaphylaxis, and NS001, an intranasal Naloxone powder nasal spray for the treatment
of opioid overdose. We will need to obtain regulatory approval for our products in order for
us to grow our business. We currently have
no FDA approved products. Our products have been tested on relatively small patient populations thus far.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Obtaining regulatory
approvals and developing NS001 and NS002 will require the incurrence of significant costs and our success will depend, in part, on gaining
market acceptance. In order to gain market acceptance in the United States, we will require specific approval from the FDA for our product
candidates. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We intend to seek approval of NS002 as an approved
molecule and a new delivery route (with EpiPen autoinjector as the reference device) under Section 505(b)(2) of the FFDCA which allows
the applicant to rely in part on previous studies conducted by unrelated parties, such as another drug manufacturer, and existing sources
including published literature, for marketing approval by the FDA in the United States, and will seek approval under the comparable hybrid
application pathway in the European Union. The FDA may not agree that our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval. Such abbreviated approval pathways may not lead to a faster development or review
process compared to traditional approval pathways and do not increase the likelihood that NS001 and NS002 will receive regulatory approval
in the United States or the European Union. <FONT STYLE="background-color: white">See &ldquo;<I>Business &ndash; Government Regulation</I>&rdquo;
and &ldquo;<I>Risk Factors &ndash; Risks Related to Product Development, Regulatory Approval and Commercialization</I>&rdquo; for additional
information).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have conducted a twelve-patient pilot study of NS002, which included the testing of bioavailability of epinephrine under
&ldquo;allergenic challenge&rdquo; - the creation of severe acute allergic reaction in the nose by inserting ascending doses of
allergens to the nose of the healthy volunteers with known allergic rhinitis included in the study. The results showed that
epinephrine intranasal delivery of our NS002 followed the established characteristics of our platform technology&mdash;namely, there
were higher levels of the drug in the plasma in situations where immediate administration could be lifesaving. The Phase 2 study,
which is meant to optimize the dose that will be used in the Phase 3 study for registration, is conducted in limited patient
populations to identify possible adverse effects and safety risks, to preliminarily evaluate the dosage tolerance of the product for
specific targeted diseases or conditions and to determine dosage tolerance, optimal dosage and dosing schedule. Our Phase 2 study is
aimed at defining the final clinical dose to be used in our powder epinephrine product candidate, compared the bioavailability of
epinephrine following a various dosing of NS002 Microspheres Epinephrine powder. The pharmacokinetic results of our Phase 2 study
are in line with the known attributes of our nasal powder technology&mdash;namely: immediate absorption of epinephrine and reaching
higher peak plasma epinephrine levels quicker compared to IM Epinephrine injections. We intend to perform two additional Phase 2
studies of NS002. The first will be aimed at determining whether, if necessary, during a real-life anaphylaxis a
second dose of NS002 should be administered in the same nostril as the one used for the first administration of NS002 or whether it
should be in the other nostril. The second Phase 2 study will test the &ldquo;carry-over effect,&rdquo; or whether the first dose of
epinephrine changes the absorption of epinephrine of a following dose. Each study is currently planned to include at least 12
healthy volunteers with allergic rhinitis. Prior to submission to the FDA for marketing approval, we also intend to perform a
pivotal clinical, or Phase 3, study that will include a subsection of self-administration. We also intend to separately
perform: (1) stability testing which involves testing the product candidate under various temperature and humidity points; (2) a
reliability study, which is a subset of the stability study that tests the NS002&rsquo;s administration device in several potential
conditions; (3) a usability study, which tests how user friendly the device is; (4) preclinical studies or short animal safety
studies in two animal species; and (5) a pediatric study, the details of which will be agreed upon with the FDA as we
progress with the program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to NS001 Intranasal Naloxone, we have performed a pilot study, which is a first in human study aimed at safety and bioequivalence,
and pivotal clinical study, which is the Phase 3 registration study, in 14 and 42 healthy volunteers, respectively, with the
objective of evaluating the comparative bioavailability of naloxone between NS001 and certain competitor products. The pilot study results
were submitted to the FDA in support of the progression to the pivotal study. The results of the pilot study showed our technology having
a faster absorption rate in the immediate critical period after administration. The Phase 3 study is administered to an expanded patient
population to further evaluate dosage and clinical efficacy. Our pivotal clinical study consistently showed an
advantage in the first 30 minutes after administration. We intend to perform the following additional studies of NS001: (1) a stability study with reliability study; (2)
a usability study; and (3) short term preclinical studies in animals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
platform technology can also be incorporated into other products as it has been tested with several additional preclinical and invitro
molecules based on our proprietary nasal powder formulation and technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT>Competition
in the pharmaceutical industry is intense. Some of our competitors hold significant market share, have long histories and strong reputations
within the industry, greater brand recognition, and more financial and human resources than we do. They also have more experience and
capabilities in researching and developing testing devices, obtaining and maintaining regulatory clearances and other requirements, manufacturing
and marketing those products than we do. Their dominant market position and significant control over the market could significantly limit
our ability to introduce or effectively market and generate sales of NS001 and NS002.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have incurred significant operating losses, generated no revenues from existing products, and as
of June 30, 2024, our accumulated deficit was $12.1 Million. We expect that we will need to raise substantial additional funding in the
future. See &ldquo;<I>Risk Factors&ndash;Risks Related to Our Financial Condition and Capital Requirements.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Split-Segment; Name: Spl_001 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Intranasal Drug Delivery Product Market</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal
administration is a non-invasive route for drug delivery, which was widely used for the local treatment of rhinitis or nasal polyposis.
Since drugs can be quickly absorbed into the systemic circulation through the nasal mucosa, this route can also be used in a range of
acute or chronic conditions requiring considerable or rapid systemic exposure. Indeed, such drug administration offers advantages such
as ease of administration, rapid onset of action, and avoidance of first-pass metabolism (in the liver).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
nasal mucosa is highly vascularized and enables quick and efficient drug delivery to the systemic circulation. The olfactory tissues
also provide a direct conduit to the central nervous system, bypass first-pass metabolism, and lead to an onset of action similar to
IV drug administration. The intranasal route of administration has also been shown to decrease delays in drug administration, especially
in the pre-hospital and community setting of emergency medical situations, which can have a profound impact in a variety of scenarios,
such as anaphylactic shock, opioid overdose, seizures, , acutely agitated or combative patients, and trauma management. Intranasal administration
of midazolam (Nazylam UCB pharma) lorazepam, flumazenil, ketamine, (Spravato, Jennssen) fentanyl, (Lazanda, Archimedes Pharma) Glucagon
(Baqsimi, Eli Lili) or sumatriptan (Sumatryptan nasal spray, Snadoz, Immitrex, SGK) has been shown to be an effective alternative
to the same molecules given as intramascular (IM) or intravenous (IV) administration. (The names referred to here in this paragraph are
the generic molecule and in parenthesis are the name of the commercial product).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal
drug delivery is especially suitable for potential medical emergency situations such as, anaphylaxis opioid overdose, seizures and the
like, most of which occur either at home or in the streets. While injectable drugs are available in the hands of professional health
personnel, immediate administration of the necessary drugs is essential for preservation of life. The availability of user-friendly,
non-invasive intranasal drug can significantly enhance the prospects of patients&rsquo; survival.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a Research and Markets report entitled &ldquo;Intranasal Drug Delivery - Global Market Trajectory &amp; Analytics,&rdquo; the intranasal
drug delivery market in the United States was estimated at $21.9 billion in 2021, currently accounting for a 42.05% share in the global
market. China, the world&rsquo;s second largest economy, is forecast to reach an estimated market size of $5.7 billion by the year 2026,
trailing a compound annual growth rate, or CAGR, of 8.4% from 2021-2026. Other noteworthy geographic markets include Japan and Canada,
each forecast to grow at 4.8% and 5% respectively over the same period. Within Europe, Germany is forecast to grow at approximately 5.9%
CAGR while the rest of the European market will reach $6.1 billion by the close of the analysis period. The following graphic depicts
the forecasted growth of the global market for intranasal drug delivery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formdrs_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">According
to a market monitoring report published in July 2023 entitled &ldquo;Nasal Drug Delivery Market: Global Industry Analysis and Forecast
(2023-2029),&rdquo; the total market, as depicted below, was estimated at $59 billion in 2022 and is expected to grow at CAGR of 6.9%
reaching $93.7 billion in 2029. The following graphic demonstrates the high estimated CAGR and that the major part of the market is in
the US and Europe: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_003.jpg" ALT="Z:\2024 OPERATIONS\EDGAR\08 AUGUST\Nasus Pharma Ltd\08-27-2024\Draft\Production"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Anaphylaxis
and Severe Allergy Type 1 </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anaphylaxis
is a severe, potentially life-threatening allergic reaction. It can occur within seconds or minutes of exposure to an allergen, such
as drugs peanuts or bee stings. Anaphylaxis causes the immune system to release a flood of cellular mediators that can cause shock, with
sudden blood pressure drops and airways narrowing, blocking breathing. Signs and symptoms include a rapid, weak pulse; a skin rash, nausea,
vomiting, respiratory distress and death. The World Allergy Organization anaphylaxis guidance in 2020 shows a global anaphylaxis incidence
of 50-112 episodes per 100,000 persons per year; recurrence <FONT STYLE="background-color: white">of reactions occurs in 26.5&ndash;54.0%
of anaphylaxis patients.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Epinephrine,
also called adrenaline, is the first-line therapy for anaphylaxis. It is an endogenous ligand of adrenergic receptors that is produced
in the adrenal glands. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to a summary review
entitled &ldquo;Update on the usage and safety of Epinephrine auto-injectors, 2017&rdquo; by Posner published in the Drug Health and
Patient Safety Journal in 2017 , <FONT STYLE="background-color: white">administration of exogenous Epinephrine can counteract some of
the most severe symptoms of anaphylaxis </FONT>through adrenergic (<FONT STYLE="background-color: white">alpha and beta) </FONT>receptor,
signaling <FONT STYLE="background-color: white">decreased vasoconstriction and peripheral vascular resistance, decreased upper airway
mucosal edema, increased bronchodilation, and decreased mediator release from mast cells and basophils. </FONT>Epinephrine has been in
use for more than 100 years, and it can be administered via different routes. A review entitled &ldquo;Adrenaline in the Acute Treatment
of Anaphylaxis,&rdquo; published in the Deuttsch Arztebl Int. 2018 stated that in accordance with FDA approval of autoinjectors (for
example EpiPen) and the many studies supporting this therapeutic mode the method of choice in the initial phase of anaphylaxis, especially
for self-medication, is intramuscular injection. The first Epinephrine auto-injector, EpiPen and EpiPen Jr., was approved by FDA in 1987.
Several generic versions of EpiPen have been in the market as well. Additional recent Epinephrine auto-injectors are now also FDA approved
(AUVI-Q, Adrenaclick), and the prescribed dosage is 0.3 mg per delivery for adults and 0.15 mg per delivery for children.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the last several decades, there has been a dramatic increase in anaphylactic episodes, especially among children with peanut allergies.
Anaphylaxis requires an immediate injection of epinephrine and an evacuation to an emergency room. Allergic people are required to carry
with them two Epinephrine autoinjectors at all times and make sure that injections are never more than a few feet away. According to
a study published in the World Allergy Organization Journal, the annual cost of Anaphylaxis in direct cost in the United States is over
$600 million and indirect annual costs are estimated at $1.2 billion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>The
unmet need for Anaphylaxis</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
many cases, adrenalin injections are not used readily or adequately, which contributes to fatality and severe morbidity cases. Lack of
availability of autoinjectors due to high prices, low availability and lack of education re treatment options of anaphylaxis are among
the leading causes. Other issues preventing prompt use of adrenaline injections concern patients and caregivers, hesitance and &ldquo;needle
fear&rdquo; since injection is perceived as &ldquo;aggressive,&rdquo; especially in young children.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Epinephrine
in solution form is widely known for its stability issues shortening its effective expiration date and necessitating frequent and expensive
change of the epinephrine injection. In addition, careful observation of the required storage condition is required in order to preserve
the effective dose within the autoinjectors. Further, the size and weight of a typical 2 autoinjector package is quite large and cumbersome,
requiring a special carrying bag.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Finally,
the price for a package containing 2 autoinjectors are high: the price for EpiPen ranges between $650 to $700 and the price for
generics are about half: $347-$481, according to a 2024 study by Leigh Ann Anderson,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">published
April 2024 on drugs.<FONT STYLE="background-color: white">com . This extremely high price and the need to acquire a new set every 12-18
months is a major obstacle in the treatment of the ever-expanding life-threatening condition of anaphylaxis.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rise
in prevalence</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lifetime prevalence of anaphylaxis is about 2% in the U.S. and up to 3% in Europe. Anaphylaxis accounts for up to 0.26% of overall hospital
admissions. A comprehensive study by Turner entitled &ldquo;Global Trends in Anaphylaxis Epidemiology and Clinical Implications,&rdquo;
published recently in the Journal of Allergy and Immunology practice (April 2020) reports that in recent decades, there have been multiple
reports from around the globe describing a dramatic increase in cases of Anaphylaxis, especially related to food allergy (mainly nuts)
and among younger children. The following graphics depict the rate of hospital admissions for anaphylaxis in various countries from 1995-2015,
including two United States data sources for each figure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="chart_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
1: Hospital admissions for anaphylaxis from all allergens</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mullins
    R.J., Wainstein B.K., Barnes E.H., Liew W.K., Campbell D.E. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin
    Exp Allergy. 2016;46:1099&ndash;1110. - <U>PubMed.</U></FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeppesen
    A.N., Christiansen C.F., Froslev T., Sorensen H.T. Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark
    from 1995 through 2012. J Allergy Clin Immunol. 2016;137:1143&ndash;1147. &ndash; <U>PubMed.</U></FONT> </TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 96%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tejedor-Alonso
    M.A., Moro-Moro M., Mosquera Gonzalez M., Rodriguez-Alvarez M., Perez Fernandez E., Latasa Zamalloa P. Increased incidence of admissions
    for</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> anaphylaxis in Spain 1998-2011. Allergy.
    2015;70:880&ndash;883. &ndash; PubMed. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yao
T.C., Wu A.C., Huang Y.W., Wang J.Y., Tsai H.J. Increasing trends of anaphylaxis-related events: an analysis of anaphylaxis using nationwide
data in Taiwan, 2001-2013. World Allergy Organ J. 2018;11:23. - <U>PMC</U> &ndash; <U>PubMed.</U> </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Turner
    P.J., Gowland M.H., Sharma V., Ierodiakonou D., Harper N., Garcez T. Increase in anaphylaxis-related hospitalizations but no increase
    in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J&nbsp;Allergy Clin Immunol. 2015;135:956&ndash;963.e1.
    doi: 10.1016/j.jaci.2014.10.021.&nbsp;[<U>DOI</U>] [<U>PMC free article</U>] [<U>PubMed</U>] [<U>Google Scholar</U>].</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motosue
    M.S., Bellolio M.F., Van Houten H.K., Shah N.D., Campbell R.L. Increasing emergency department visits for anaphylaxis,
    2005-2014. J Allergy Clin Immunol Pract. 2017;5:171&ndash;175.e3. &ndash; PubMed. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motosue
    M.S., Bellolio M.F., Van Houten H.K., Shah N.D., Li J.T., Campbell R.L. Outcomes of emergency department anaphylaxis visits</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    from 2005 to 2014. J Allergy Clin Immunol Pract. 2018;6:1002&ndash;1009.e2. &ndash; PubMed. </FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Source: Turner PJ, Campbell DE, Motosue MS, Campbell
RL. Global Trends in Anaphylaxis Epidemiology and Clinical Implications. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1169-1176. doi:
10.1016/j.jaip.2019.11.027. Epub 2019 Nov 28. PMID: 31786255; PMCID: PMC7152797. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="chart_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
2: Prevalence of hospitalization for food allergy</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 97%; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mullins
    R.J., Wainstein B.K., Barnes E.H., Liew W.K., Campbell D.E. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin
    Exp Allergy. 2016;46:1099&ndash;1110. doi: 10.1111/cea.12748.&nbsp;[<U>DOI</U>] [<U>PubMed</U>] [<U>Google Scholar</U>].</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kivisto
    J.E., Protudjer J.L., Karjalainen J., Wickman M., Bergstrom A., Mattila V.M. Hospitalizations due to allergic reactions in Finnish
    and Swedish children during 1999-2011. Allergy. 2016;71:677&ndash;683. &ndash; PubMed. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wang
    Y., Koplin J.J., Ho M.H.K., Wong W.H.S., Allen K.J. Increasing hospital presentations for anaphylaxis in the pediatric population
    in Hong Kong. J Allergy Clin Immunol Pract. 2018;6:1050&ndash;1052.e2. &ndash; PubMed. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nocerino
    R., Leone L., Cosenza L., Berni Canani R. Increasing rate of hospitalizations for food-induced anaphylaxis in Italian children: an
    analysis of the Italian Ministry of Health database. J Allergy Clin Immunol. 2015;135:833&ndash;895.e3. &ndash; PubMed. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Turner
    P.J., Gowland M.H., Sharma V., Ierodiakonou D., Harper N., Garcez T. Increase in anaphylaxis-related hospitalizations but no increase
    in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J&nbsp;Allergy Clin Immunol. 2015;135:956&ndash;963.e1.
    doi: 10.1016/j.jaci.2014.10.021.&nbsp;[<U>DOI</U>] [<U>PMC free article</U>] [<U>PubMed</U>] [<U>Google Scholar</U>].</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ma
    L., Danoff T.M., Borish L. Case fatality and population mortality associated with</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
    anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133:1075&ndash;1083. - PMC &ndash; PubMed. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Motosue
    M.S., Bellolio M.F., Van Houten H.K., Shah N.D., Campbell R.L. National trends in emergency department visits and hospitalizations
    for food-induced anaphylaxis in US children. Pediatr Allergy Immunol. 2018;29:538&ndash;544. &ndash; PubMed. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> Source: Turner PJ, Campbell DE, Motosue
MS, Campbell RL. Global Trends in Anaphylaxis Epidemiology and Clinical Implications. J Allergy Clin Immunol Pract. 2020 Apr;8(4):1169-1176.
doi: 10.1016/j.jaip.2019.11.027. Epub 2019 Nov 28. PMID: 31786255; PMCID: PMC7152797. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Current
treatment limitations</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Needle
fear:</I> Perception of the current injections as invasive and risky leads to a delay in prompt administration. Parents have reservations
about administering Epinephrine to their children due to concerns over injury, incorrect use, and poor outcomes. A more user-friendly
treatment is required. Despite the potentially life-saving benefits of using Epinephrine auto-injectors, Epinephrine is not used to treat
the majority of anaphylactic reactions. A major obstacle to prompt the Epinephrine administration in the community setting is the availability
of an auto-injector, partially caused by price issues and misleading information regarding side effects and risks of injections. Analysis
of fatal and near fatal anaphylaxis both in children, teenagers and adults consistently showed that delay or hesitancy in timely administering
IM injection was the root cause in all cases. In the case of teenagers, a UK-based study showed that the current injection dose of 0.3
was inadequate and larger doses were required to create effective plasma levels. The NHS has encouraged Epinephrine manufacturer to produce
larger dosage auto-injectors (0.5 mg instead of the 0.3) with little success. It is widely agreed by professional organizations that
failure to administer the adequate dose or doses of epinephrine immediately and up to 30 minutes following an event is the single most
important risk factor associated with fatal or near fatal incidences of anaphylaxis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Needle
size: </I>A review by Dreborg published in Allergy Asthma Clin Immunol in 2016 entitled &ldquo;Do epinephrine auto-injectors have an
unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy points out that one of the major limitation
in the use of autoinjectors is needle size. The current indication for autoinjectors calls for injecting in the lateral side of the thigh
muscle. Absorption of drugs from muscle is significantly quicker than its absorption from the fat tissue. Since the amount of fat covering
the thigh differs widely between men and women, and differs in relation to the body mass of the user, it cannot be expected that a single
size needle will ensure the injected epinephrine will indeed reach the muscle in all people&mdash;yet all autoinjectors have one single
needle size (one of adults and one for children- irrespective of age). <U>In a recent formal publication of the Royal</U> College of
Physicians of Ireland in June 2022, the College stated that while the required length of a needle to reach the thigh muscles is between
25 mm up to 38-40mm for those weighing more than 100 kg, <I>none of the currently approved autoinjectors carries an adequate length needle.
</I>As a result, the opinion of the <U>Royal College of Physicians of Ireland was</U> that the epinephrine injected into the fat tissue
below the skin creates a delay of 10-15 minutes in epinephrine absorption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, absorption of Epinephrine from the muscle is not immediate and may not always promptly create therapeutic levels of epinephrine
in the blood. Most studies averaged a period of approximately 15 minutes for &ldquo;time to 100pg/ml&rdquo; &ndash; the time for reaching
the start of the clinical effect. This major limitation is reviewed and discussed by Sclar in &ldquo;Bioequivalence evaluation of epinephrine
autoinjectors with attention to rapid delivery&rdquo; &ndash; published in Ther Clin Risk Management journal in 2013. This major limitation
further shortens the therapeutic window for intervention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stability
and price</I>: The auto-injectors consisting of Epinephrine in an aqueous solution suffer from severe issues of instability and loss
of the active ingredient of the Epinephrine due to creation of enantiomers. Despite the addition of many stabilizers and lowering the
acidity of the Epinephrine solution, multiple independent studies have shown that the stability of Epinephrine as a solution is highly
volatile and unpredictable. After the use-by date, and oftentimes even before the expiration date, the solution gradually loses effectiveness,
even though it stays clear and colorless.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epinephrine
was found to lose about 30% of its active compound after 12 weeks of a heat cool cycle. The molecule is highly sensitive to light and
should not be exposed to light. It can also be easily oxidized and therefor all epinephrine solutions contain low acidity and bisulphites.
Due to the known stability issues of Epinephrine in solution autoinjectors, injectors need to be replaced every 18-24 months. The cost
of EpiPen 2 -injectors package (the leading brand and largest market share) can reach up to $ 650-700, and the cost of generic autoinjectors
is about 50-60% of that amount. Despite many government investigations and political pressure, the cost did not change significantly
even after the introduction of generics into the market and still poses an economic burden. The volatility of epinephrine thus necessitates
frequent restocking, and given the high prices of new Epinephrine package, further contributes to the lower availability of proper treatment
options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Opioid
overdose</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opioid
overdose can occur in both drug abusers and patients treated with prescribed medications for pain. Opioid intoxication is manifested
by reduced consciousness and respiratory depression, which may deteriorate to cardiac arrest and death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the U.S. Center for Disease Control, or CDC, press release dated November 17, 2021, misuse and abuse of opioids has evolved into a
worldwide epidemic, particularly in the U.S. where it is declared a national public health emergency. According to a CDC Morbidity and
Mortality Weekly report from 2021 entitled &ldquo;Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Death,&rdquo;
overdose deaths involving synthetic opioids were nearly 12 times higher in 2019 than in 2013. More than 36,000 people died from overdoses
involving synthetic opioids in 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nearly
108,000 Americans died of drug overdoses in 2022, according to final federal figures released on March 2024. Over the last two decades,
the number of <U>U.S. overdose deaths</U> has risen almost every year and continued to break annual records &mdash; making it the worst
overdose <U>epidemic</U> in U.S. history.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following graphic depicts age-adjusted rate of drug overdose deaths by gender in the United States from 2002&ndash;2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_006.jpg" ALT="Z:\2024 OPERATIONS\EDGAR\08 AUGUST\Nasus Pharma Ltd\08-27-2024\Draft\Production">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source:
Spencer, M.R, M.P.H., Garnett, M.F, M.P.H. and Mini&ntilde;o, A.M., M.P.H. Drug Overdose Deaths in the United States, 2002&ndash;2022.
- <U>CDC.</U></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the U.S. Substance Abuse and Mental Health Service Administration, has reported that the immediate treatment for opioid overdose is rapid
administration of Naloxone. Naloxone is a medication approved by the FDA, designed to rapidly reverse opioid overdose. It is an opioid
antagonist, or in other words, it binds to opioid receptors and can reverse and block the effects of other opioids, such as heroin, morphine,
and oxycodone.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to a CDC publication from April 2021 entitled &ldquo;State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose
&mdash; United States, 2017&rdquo; Naloxone is currently available in injections (auto injectors or solution for injection),
intranasal or intravenous solutions. In 2017, the FDA approved the first liquid based intranasal Naloxone (Narcan 4 mg, by Adapt
Pharma) and has since approved generic versions, and an 8 mg Naloxone nasal solution (Kloxxado, Hikkma). The U.S. economic cost of
opioid use disorder ($471 billion) and fatal opioid overdose ($550 billion) during 2017 totalled $1.021 billion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>The
Unmet Need for Opioid Overdose Treatment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unparalleled increase in the use of synthetic opioids such as Fentanyl, Isotonitazene, or ISO, and other extremely dangerous New Synthetic
Opioids, or NSOs, have changed the scope of immediate treatment of opioid overdose. While Narcan (solution based intranasal naloxone)
was approved in 2017 in a 4 mg dosage, the FDA approved label for Narcan indicated that if respiratory depression is not improved within
2-3 minutes, then there is a need for an additional dose, followed by a third one until emergency health professionals have reached the
victim. According to reports by the FDA Advisory Committee on the Most Appropriate Dose or Doses of Naloxone to Reverse the Effects of
Life-threatening Opioid Overdose in the Community Settings (2016) a third of opioid overdose victims required two doses of Narcan and
about 16% required a third dose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two
conclusions can be reached from the changing landscape of opioid overdose in recent years:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            amount of Naloxone needed to overcome the new highly potent synthetic opioids is higher according
                                            to a review article entitled &ldquo;Naloxone dosage for opioid reversal: current evidence
                                            and clinical implications,&rdquo; published by Dr. Lyn and colleagues from the University
                                            of Denver in &ldquo;Therapeutic Advances in Drug Safety&rdquo; Journal in 2018; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            first few minutes are the critical period for effective intervention since, in these first
                                            few minutes, the maintenance of high plasma levels of Naloxone is imperative, attested by
                                            the need for repeat dosages in the prehospital and community setting.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Current
treatment limitation:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
intranasal Naloxone administration is most suitable for out of hospital opioid overdose and offers non-invasive, easy to use, immediately
available first aid, the currently approved liquid based products such as Narcan and Kloxxado (Naloxone HCI Nasal Spray) do not create
sufficient plasma levels of Naloxone, especially in the first few minutes (10-15 -30) where maintaining adequate levels of Naloxone in
the plasma is vital for restoration of respiration and life as reflected in the high percentage of victims, requiring a second and third
dose. Notably, Narcan and Kloxxado are distributed in a 2-inhaler package.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Solution</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently developing a number of intranasal powder products aimed at assisting patients in severe acute emergency situations
such as anaphylactic shock, opioid overdose and other medical emergencies. Intranasal administration is most suitable for those situations
in which rapid drug delivery is required and offers multiple advantages such as rapid drug delivery, ease of use and non-invasiveness.
Our portfolio comprises a number of programs: NS002 Intranasal Epinephrine (completed Phase 2); NS001 Intranasal Naloxone (completed
pivotal study) and a number of preclinical proof of concept programs, such as Midazolam (acute seizures); Atropine (organophosphate
poisoning); high dose Naloxone (for counteracting incidents relating to chemical warfare and severe opioid overdose);
Metoclopramide (intractable vomiting). and others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
technology provides an inexpensive, non-invasive, needle-free, and user-friendly solution to the limitations described above through
the administration of a <I>powder-based</I> nasal spray to treat opioid overdose and anaphylaxis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our cost structure enables us to compete in the market and maintain extremely high margins. Our powder epinephrine nasal
spray is stable and devoid of the stability issues of liquid-based epinephrine products in the market. Due to the inherent advantage
of drug delivery through the highly vascularized nasal tissue, our results show a dramatic advantage in bringing clinical levels of epinephrine
into the plasma much higher and quicker compared to IM Injections especially in the first critical 30 minutes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
in our limited clinical studies with small patient sample sizes, our product candidates have been shown to maintain, and even increase,
the absorption rate as compared</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> to the currently
known results of our potential competitors developing liquid based epinephrine nasal sprays, even with the presence of nasal
congestion common in anaphylaxis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nasus&rsquo;s
Well Differentiated and Diversified Technology Platform &ndash; Intranasal Powder</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
intranasal emergency drugs approved by the FDA in recent years are liquid based. Powder nasal spray products are extremely rare since
the proper technology for the creation of nasal powder is not obvious or simple and requires deep understanding and proprietary knowledge.
Nasus&rsquo; proprietary powder composition for intranasal delivery is comprised of uniform spherical active pharmaceutical ingredients,
or API, and carriers approved for inhalations. The active compound&rsquo;s particles&rsquo; shape, size, and morphology, in combination
with a carrier and a device provide rapid and precise delivery of the drug to the blood stream and brain. Our patented technology (manufacturing
device and process) creates a unique combination of two homogenous particle populations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Small,
                                            unified API particles ensure stable and repeatable absorption of the drug</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
                                            lactose particles serve as disaggregants and carriers for the powder into the nose.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following graphic depicts the size distribution of the powder particles showing two distinct populations: the active ingredient and the
carrier molecule. The ability to control the size of the active pharmaceutical ingredient, or API, particles is critical for effective
absorption.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_008.jpg" ALT="Z:\2024 OPERATIONS\EDGAR\08 AUGUST\Nasus Pharma Ltd\08-27-2024\Draft\Production"></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
3: Nasus powder technology: Particle size and shape</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
has been long established that powder spray into the nose covers a significantly larger surface area of the nasal cavity compared to
liquid nasal spray. The liquid particles are heavier and tend to accumulate at the lower area of the nasal cavity (an area that is covered
by an epithelium that is less absorbent compared to the respiratory epithelium at the upper parts of the nasal cavity). According to
a review by Djupesland from 2013 in Drug Delivery and Translational Research entitled &ldquo;Nasal drug delivery devices: characteristics
and performance in a clinical perspective&mdash;a review,&rdquo; due to the significantly larger absorbent area after powder nasal administration,
drug absorption is more rapid and larger compared to liquid nasal spray. This phenomenon was also found in our clinical studies when
compared head-to-head with similar liquid nasal products. The following graphic depicts the drug liquid nasal spray distribution versus
powder drug distribution in the nasal cavity:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_009.jpg" ALT="Z:\2024 OPERATIONS\EDGAR\08 AUGUST\Nasus Pharma Ltd\08-27-2024\Draft\Production"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
4: Powder nasal spray achieves significantly larger absorption area compared to liquid spray.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
creation of uniform and spherical powder particles ensures that drug absorption will be stable without the known volatility of
absorption when particles with different sizes and shapes are used&mdash;therefore reducing the reproducibility of results. The
following graphic depicts powder particles as seen under scanning electron microscopy. On the left, irregular sizes of
different third-party particles that are used in the pharmaceutical industry. The top three images on left side of the
graphic show examples of various nasal powder formulations produced by adding different polymers using common milling technology.
The bottom three images on the left side of the graphic show particles of the same three compounds depicted above them, after
processing them again for two hours, using the same common milling technology. The powders on the left have various shapes and
un-controlled particles. The right side of the graphic depicts the uniform particles created by our PBI technology, as seen under
scanning electron microscopy. Spheric drug-loaded particles are seen, among large &ldquo;rocky shape&rdquo; lactose carrier
particles. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="formdrs_010.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
5: Powder morphology -commercial and Nasus Pharma.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"> &nbsp; </TD>
  <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
  <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source for left side of
  Figure 5: Gieszinger P, Cs&oacute;ka I, Pallagi E, Katona G, J&oacute;j&aacute;rt-Laczkovich O, Szab&oacute;-R&eacute;v&eacute;sz P,
  Ambrus R. Preliminary study of nanonized lamotrigine containing products for nasal powder formulation. Drug Des Devel Ther. 2017 Aug
  23;11:2453-2466. doi: 10.2147/DDDT.S138559. PMID: 28860716; PMCID: PMC5574602.</FONT> </TD></TR>
</TABLE>


<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Proven
Tech Transfer, Scalability and Nasal Inhaler</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
successfully completed our scalability and technology transfer to a European GMP FDA approved manufacturing facility and succeeded in
manufacturing three commercial batches as required for NDA submission and filling the nasal inhaler device with powder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>Aptar
UDS and collaboration<SUP></SUP></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We have a
collaboration agreement with Aptar, a leading global manufacturer of inhalers. On September 6, 2019, we entered
into the MSA with Aptar for services, including the performance of certain work, studies and
analytical services in connection with our drug device product development program. The MSA provides that the work and services to
be performed are to be enumerated in schedules of work signed by the parties for fees set forth in such schedules. Pursuant to the
MSA, Aptar is required to use reasonable commercial efforts to meet agreed upon timelines for providing the services to us. The MSA
remains in effect for the later of a period of three years and the completion of the services or other obligations set forth in
executed schedules, unless earlier terminated in accordance with the terms and conditions set forth therein. The rights and
obligations of the parties under the MSA are ongoing and the MSA is in effect as of the date of this prospectus. In addition, there
are rights and obligations under the existing schedules that remain in effect for seven years following the future launch of our
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Concurrently
with signing of the MSA, on September 6, 2019, we entered into a schedule of work related to Naloxone with Aptar, or the Naloxone
SOW, which provides that, for a fee of $1,350 thousand, comprising of $200 thousand in development stage, $350
thousand upon submission of an NDA with the FDA (or equivalent) and $800 thousand at market launch, Aptar will provide support to us
for the use and submission of its intranasal UDS to be the delivery system for our Intranasal Naloxone
powder. Any additional services requested by us, not included in the Naloxone SOW, will be negotiated by us and Aptar in good faith
on a fee for services basis. The Naloxone SOW also provides for tier-based royalty payments upon commercialization of Intranasal
Naloxone using Aptar&rsquo;s UDS for a period of up to seven years following the first commercial sale which are as follows: 1% for up to $30 million; 1.2% for $30 million to $60 million; 1.4% for $60 million to $100
million; and 1.6% for over $100 million. The Naloxone SOW has a
termination fee of $450 thousand to be paid to Aptar if our Intranasal Naloxone program is terminated for whatever reason, other
than Aptar&rsquo;s breach of the agreement, or if we do not make applicable filings to regulatory authorities within three years of
the effective date of the agreement (which may be extended upon mutual agreement for a period of six months). Through December 2020,
we made a pre-IND filing with the FDA, and an additional filling related to Type C meetings to review questions related to drug
development. In addition, we made an equivalent IND filing with Health Canada before conducting a registration study in Canada. As
of the date of this prospectus, we have paid $200 thousand to Aptar in connection with the Naloxone SOW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On April 20, 2020,
we entered into a schedule of work related to Epinephrine, or the Epinephrine SOW, with Aptar governed under the same terms and conditions
set forth in the Naloxone SOW, the purpose of which was to extend Aptar&rsquo;s services to Intranasal Epinephrine. For a fee of $675
thousand, comprising of $150 thousand in the development stage, $225 thousand upon
a submission of an NDA with the FDA (or equivalent) and $300 thousand at market launch. Aptar will provide support to us for the use and submission of its intranasal UDS product to be the delivery system for our
Intranasal Epinephrine powder. Any additional services requested by us, not included in the Naloxone SOW, will be negotiated by us and
Aptar in good faith on a fee for services basis. The Epinephrine SOW provides for certain tiered-based royalty payments upon commercialization
of Intranasal Epinephrine using Aptar&rsquo;s UDS for a period of up to seven years following the first commercial sale. The Epinephrine
SOW has a termination fee of $450 thousand to be paid to Aptar if our Intranasal Epinephrine program is terminated for whatever reason,
other than Aptar&rsquo;s breach of the agreement, we do not make applicable filings to regulatory authorities within three years of the
effective date of the agreement (which may be extended upon mutual agreement for a period of six months). We made a pre-IND with the
FDA, as well as equivalent filings with Health Canada and the Israeli Health Ministry before performing our Phase 2 and Phase
3 studies of Intranasal Epinephrine. As of the date of this prospectus, we have paid $150 thousand to Aptar in connection with the Epinephrine
SOW.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On August 16, 2021,
we entered into a change order with respect to the Naloxone SOW, for the provision of additional services and deliverables by Aptar related
to Intranasal Naloxone, including but not limited to, the authoring of a reliability protocol (excludes execution of the protocol), drafting
of a fault tree analysis, data analysis post-execution of the reliability protocol, and authoring of the reliability report, for a fee
of &euro;100 thousand ($107), of which &euro;40 ($43) thousand was paid to Aptar prior to January 1, 2022, and the remaining amounts will
be paid upon NDA submission and FDA approval of Intranasal Naloxone. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> For the services
received under the agreement by April 2022, there is an amount of $529 thousand outstanding to be paid to Aptar, which has not been paid
to date. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">On October 5, 2022,
we received a written notice from Aptar, or the Notice, based on our alleged breach of our contractual obligations under the MSA concerning
failure to cooperate with and outstanding payments in connection with services rendered by Aptar&rsquo;s subdivision, NextBreath, in
an aggregate amount of $1 million (which also includes termination fees of $450,000 in connection with the Naloxone SOW), which set forth
a period to cure the alleged breach within 15 days. We responded to the Notice on October 13, 2022 and on October 19, 2022, contesting
Aptar&rsquo;s allegations set forth in the Notice and rejecting any grounds for termination by Aptar. Since our response letters were
sent in October 2022, we and Aptar discussed and exchanged further correspondence regarding the Notice through February 2023 and were
unable to resolve the claims and allegations made by each party. Since February 2023, we have continued to purchase UDS products from
Aptar and, as of February 5, 2025, we have not received any further notices, demands or claims from Aptar concerning the
Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">We believe that
we have operated and continue to operate in accordance with our contractual obligations under the MSA, Naloxone SOW and Epinephrine SOW,
or the Aptar Agreements. We further believe that Aptar and we are still operating based on the terms of the Aptar Agreements.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Aptar has collaborated,
supported and performed the development of our drug device program with appropriate information and studies to support the device information
part submission to the FDA. The MSA calls for certain services to be performed to support our future NDA submission. Aptar&rsquo;s UDS
is a single-use, ready-to-use one-step nasal delivery device that can deliver a powder formulation in an emergency situation quickly
and easily. During such an event, the patient or caregiver presses a small plunger on the bottom of the device to release the drug in
a single powder puff into the nose, where the drug can be quickly absorbed via the nasal mucosa. Aptar&rsquo;s nasal UDS is an alternative
to injectable kits that may require assembly, including multistep, time-consuming steps. The UDS powder system we use, depicted below,
was recently approved by the FDA in conjunction with Eli Lilly and Company&rsquo;s emergency use glucagon for hypoglycaemia (Baqsimi).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_012.jpg" ALT="Z:\2024 OPERATIONS\EDGAR\08 AUGUST\Nasus Pharma Ltd\08-27-2024\Draft\Production"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
6: Aptar&rsquo;s powder unidose system</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Products</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intranasal
Epinephrine (NS002)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NS002
Intranasal Epinephrine, our primary product, is aimed at assisting in severe allergic reaction emergency situations. Clinical data has
shown that our product offered faster and quicker epinephrine absorption by needle-free treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Development
status</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
powder based intranasal epinephrine, NS002 or Intranasal Epinephrine, is being developed for acute intervention in cases of severe allergy
and anaphylactic shock. We are developing NS002 as a Section 505(b)(2) program. Our reference device is the EpiPen Autoinjector 0.3 mg
(EpiPen, Mylan Specialty L.P., USA). Our pilot study was prepared by a proprietary spray drying and blending process using the final
nasal inhaler that will be used in our commercial product. We have developed stable clinical trial material and performed a proof of
concept/pilot study for NS002 followed by a dose finding/safety Phase 2 study. We have completed a 2-year stability study
for our clinical trial material proving complete stability of our powder that remained 100% pure without the characteristic enantiomeric
conversion that usually develops in liquid-based epinephrine formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
pilot study (NP002)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted a pilot study of NS002 which we called NP002. Developing a successful intranasal product for anaphylaxis requires testing under
conditions of nasal congestions to reflect the status of the nasal mucosa during an anaphylaxis. To that end, our NP002 pilot study included
the testing of bioavailability of epinephrine under &ldquo;allergenic challenge&rdquo;- the creation of severe acute allergic reaction
in the nose by inserting ascending doses of allergens to the nose of the healthy volunteers with known allergic rhinitis included in
the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NP002
was an open-label, single-dose, two-period, three-treatment and fixed-sequence clinical study that compared epinephrine
bioavailability in 12 adults with seasonal allergic rhinitis. All participants received all treatments. NS002 (1.6 mg and 3.2 mg
Epinephrine) was administered intranasally to adults with and without a nasal allergenic challenge and compared to intramuscular, or
IM, epinephrine (0.3 mg) injection (EpiPen, Mylan Specialty L.P., USA). Epinephrine pharmacokinetics were evaluated based on 21
plasma samples from each subject on each dosing day. Clinical and safety assessments were done at screening, on dosing days and at
the end of the study visit. The study was performed at Hadassah Medical Center, Jerusalem, and approved by the hospital ethics
committee, in accordance with GCP (NCT04696822 on clinicaltrials.gov.). The results showed that epinephrine intranasal delivery of
our NS002 followed the established characteristics of our platform technology&mdash;namely, there were significantly higher levels
of the drug in the plasma in situation where immediate administration could be lifesaving. Specifically, time to plasma concertation
of 100pg/ml is considered crucial since it is accepted that at this plasma level a clinical effect is starting. Our 3.2 mg dosage
under allergenic challenge was three times shorter compared to IM EpiPen.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify; text-indent: 31pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NS002
(3.2 mg) Epinephrine administered following an allergen challenge had the shortest median time to, the highest concentration of drug
in the blood, or Cmax, and the shortest median time to reach the clinical plasma threshold of 100 pg/mL. Both results reached statistical
significance compared to all other administrations. Mean epinephrine total amount of drug absorbed, or AUC, 0-8 hours following administration
of NS002 3.2 mg with and without an allergen challenge were similar but not significantly to higher than mean AUC0-8hr for EpipPen in
all other administrations. Analysis showed that NS002 was well tolerated at both concentrations and most treatment-emergent adverse
events, or AEs, were mild and resolved spontaneously. Intranasal absorption of epinephrine was faster compared to that with EpiPen, offering a clinical advantage in the short therapeutic
window for the treatment of anaphylaxis while total epinephrine exposure was comparable. The below graphic depicts the pharmacokinetics,
or PK, results of our Phase 1 study, which was aimed to test the safety of NS002 and evaluate the PK versus the reference product:</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="formdrs_028.jpg" ALT=""style="width:800px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
7: NS002 PK results vs EpiPen, first 30 minutes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formdrs_029.jpg" ALT="" style="width:720px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have published the detailed results of our pilot study in a prestigious scientific journal, the Journal of Allergy and Clinical Immunology,
in June 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
Phase 2 dose-finding/safety study - NP006</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 2 portion of our NS002 study, or NP006, aimed at defining the final clinical dose to be used in our powder epinephrine product.
The NP006 study compared the bioavailability of epinephrine following a single nasal dose of NS002 Microspheres Epinephrine powder either
3.6 mg, or 4 mg with EpiPen 0.3 mg intramuscular injection in healthy adult volunteers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NP006
was an open-label, single-dose, three-treatment, randomized, three-sequence, comparative bioavailability study. Twelve healthy
volunteers were randomized to receive intranasal 3.6 mg, 4.0 mg and Epinephrine IM 0.3 mg at weekly intervals. Epinephrine
pharmacokinetics were evaluated based on 13 plasma samples of the first two hours after administration from each subject on each
dosing day. Clinical and safety assessments were done at screening, on dosing days and at the end of the study visit. The study was
performed at Hadassah Medical Center, Jerusalem, and approved by the hospital ethics committee, in accordance with GCP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmacokinetic results of our Phase 2 study are in line with the known attributes of our nasal powder technology&mdash;namely:
immediate absorption of epinephrine and reaching higher peak plasma epinephrine levels quicker compared to IM Epinephrine injections.
No less significant are the pharmacodynamic results that are fully comparable to those of our reference product&mdash;IM Epinephrine&mdash;reflecting
the actual effect of Epinephrine in the body.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is well established that the therapeutic window in anaphylactic shock is very short and ranges between a few minutes up to 25 minutes.
The immediate creation of clinically significant levels of epinephrine in the plasma could well mean saving lives. In this context the
results of our Phase 2 study, these results potentially indicate the advantages of our nasal powder Epinephrine
over IM injection as well as other competing technologies below. Further clinical testing will need to be performed
to confirm these results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
that context it is worth noting the following: the levels of Epinephrine in the plasma after 3.6 mg and 4 mg in the first 4, 10, 20 and
30 minutes was consistently higher compared to those after IM Epinephrine administration . Although the Phase 2 study was not powered
for statistical significance, the result of the study indicated a very strong and robust effect of NS002 compared to EpiPen, resulting
in reaching statistical significance after four minutes. The following graphic depicts the area under the curve, or AUC, of Epinephrine
concentration in the plasma in the first 30 minutes after administration showing higher amounts of Epinephrine in the plasma after intranasal
administration of either 3.6 mg and 4 mg Epinephrine compared to intramuscular injection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="formdrs_030.jpg" ALT=""style="width:720px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
8: AUC after dosing Phase 2 study</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
significant results observed in the NP006 study were:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            time to reach a clinical threshold level in the plasma (T100pg) was about a third compared
                                            to IM injections (3.6 minutes compared to 9 minutes or 0.15h compared to 0.067h)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            time until maximums amounts of Epinephrine were absorbed (T max) was shorter after nasal
                                            administration (10 minutes or 0.17h compared to 14.6 minutes or 0.245 h)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            total amount of Epinpehrine absorbed was higher compared to IM administration (477pg/ml vs
                                            360pg/ml)</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following graphic depicts that in additional pharmacokinetic parameters NS002 was better compared to intramuscular injection: the time
to maximum concentration of epinephrine in the blood, or T max, and the time to the clinical threshold (T100pg) was shorter and the Cmax
(maximum concentration) was higher.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: center; text-indent: -0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<IMG SRC="formdrs_038.jpg" ALT=""style="width:720px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
9: PK results Phase 2 study</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
less important are the pharmacodynamic results which point to the potential biological activity of the absorbed epinephrine compared
to the injected reference product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
two main pharmacodynamics, or PD, and safety parameters reflect the biological effect of epinephrine: systolic blood pressure and heart
rate. These two hemodynamic parameters are the mainstay of the epinephrine activity in the body and potentially safety indicators. As
can be seen there is no significant difference in the effect of epinephrine on blood pressure and heart rate and more importantly (as
will be discussed in the competitor analysis) the PD characteristics of our intranasal epinephrine follow the same trend of the IM reference
EpiPen). The following graphics depicts the changes in heart rate and blood pressure following administration of either intranasal doses
(3.6 mg and 4 mg) compared in intramuscular injection (EpiPen). As can be seen the pharmacodynamic changes follow closely
the pattern of EpiPen and all changes from base line still remain within normal limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="formdrs_032.jpg" ALT=""style="width:800px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="formdrs_033.jpg" ALT="" STYLE="width: 800px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
10: PD parameters systolic BP and HR</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our studies of NS002, the primary objective was to evaluate the comparative bioavailability of NS002 against the reference product, EpiPen,
and the secondary objective was to evaluate the safety and tolerability of NS002. None of the studies of NS002 were powered for statistical
significance, but a statistically significant difference was found nonetheless. The result of the study indicated a very strong
and robust effect of NS002 compared to EpiPen, resulting in reaching statistical significance. Specifically, the NP002 study
showed comparable or superior PK profile especially during the first 30 minutes in a simulation of the real-life nasal congestion that
occurs in severe allergic reactions, while the NP006 study indicated that 4mg of NS002 is absorbed faster and achieves the clinical threshold
faster than the reference product. There were no significant adverse events and NS002 was tolerated at both concentrations tested whether
it was with or without an allergen test. No unexpected safety signals were observed in the NP002 studies we performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intranasal
Naloxone (NS001)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our Naloxone has the answer to the issues of slower and lower absorption of naloxone in currently approved products
during medical emergencies that necessitate immediate drug administration. It is able to create significantly higher plasma levels
of Naloxone in the blood starting from first minutes and up to one hour against the 4 mg Narcan and even against the 8 mg dosage of
Narcan and Kloxxado.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
explained above, our powder technology enjoys an inherent advantage over liquid nasal products based on larger absorption area achieved
by powder and a rapid and repeatable absorption based on the uniform spherical powder particles of our proprietary formulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Development
status of NS001 &ndash; Powder Naloxone program.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing NS001 Intranasal Naloxone, NS001 or Intranasal Naloxone, to treat opioid overdose. NS001 is being developed under a Section
505(b)(2) application under the FFDCA as an approved molecule and a similar delivery route. The reference device is Narcan. The following
are the steps that need to be completed in order to submit our NDA dossier for marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
                                            scale up of manufacturing and manufacturing of three commercial batches;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filling
                                            up the devices; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting
                                            a stability study.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
pilot study and a pivotal clinical study of NS001, NP001 and NPNAL004, were performed in 14 and 42 healthy volunteers, respectively,
according to a similar protocol. The primary objective in both studies was to evaluate the comparative bioavailability of naloxone between
NS001 (FMXIN001) Naloxone Microspheres Powder 4 mg for Nasal Application (Nasus Pharma, Israel) and Narcan&reg; (naloxone HCl) nasal
spray 4 mg (Adapt Pharma, Inc., USA) after a single dose in healthy subjects under fasting conditions. The secondary objective was to
evaluate the safety and tolerability of the study treatments (NCT04713709). The pilot study results were submitted to the FDA in support
of the progression to the pivotal study. The results of the pilot study showed our technology having a significantly faster absorption
rate in the immediate critical period after administration and that it was well tolerated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            partial AUC0-4 minutes was approximately 7-fold higher;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            partial AUC0-10 minutes was approximately 4-fold higher;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            partial AUC10-30 minutes was approximately 1.6-fold higher;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            total systemic exposure was approximately 1.26-fold higher;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            peak systemic exposure was approximately 1.6-fold higher; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            median Tmax occurred approximately 5 minutes earlier.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following graphic depicts the levels of Naloxone in the blood after administration of either our NS001 Intranasal Naloxone or Narcan.
Our NS001 creates higher levels of Naloxone in the blood as well as creates higher levels in the first few minutes &ndash; the important
therapeutic window,</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="formdrs_034.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
11: NSOO1 (FMXIN001) pilot study PK profile compared to Narcan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pivotal study comprised of 42 healthy volunteers and consistently showed the same characteristics: significant advantage in the first
30 minutes after administration. We have completed a majority of the development plan and will need to establish a full stability study
before submitting to FDA. If our management so decides, based on market conditions, demand for the product candidate and our ability
to obtain appropriate financing, we believe we will be able to complete the program within the next 24 months. The following graphic
depicts the results of the pivotal study of NS001 versus Narcan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Table
1: Results of pivotal study NS001 (FMXIN001) vs Narcan</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><IMG SRC="formdrs_020.jpg" ALT="">&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="formdrs_035.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
12: NS001 Pivotal study results</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="formdrs_036.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Figure
13: NS001 vs Narcan Pivotal study- significant higher absorption</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both NS001 and Narcan were well tolerated by the volunteers in the study. The incidence of mild side effects that resolved spontaneously
before the study ended (within a few hours) was similar between the study treatments. The most common side effect was nasal congestion.
No serious side effects were found, and all volunteers completed the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In our studies of NS001,
NP001 and NPNAL004, the primary objective was to evaluate the comparative bioavailability of NS001 against the reference product,
Narcan, and the secondary objective was to evaluate the safety and tolerability of NS001. Only the NPNAL004 study of NS001 was
powered for statistical significance, but a statistically significant difference was found in both studies. Specifically, 14 subjects
were enrolled into this study (NP001). The sample size chosen for this study was not based on any formal calculation or published literature
but was considered to be adequate for this explorative PK bioequivalence study. The study was not expected to demonstrate statistical
power, or the means to learn the statistical significance, but to provide preliminary assessment of the PK and safety profiles for Naloxone.
Nonetheless, the result of the study indicated a very strong and robust effect of NS001 compared to Narcan, resulting in reaching
statistical significance. Overall, the results were specifically significant in that 4mg of NS001 displayed greater peak and total
systemic exposure, with earlier onset of action when compared to the reference product after a single dose in healthy subjects with allergic
rhinitis. In NPNAL004, the results were statistically significant in the working assumption that the NS001 drug delivery system is either
comparable or superior to the reference product while maintaining the effectiveness of the treatment. There were no significant adverse
events in these studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our powder intranasal technology showed consistent advantage, including quicker and higher absorption, over the current
market leader in intranasal naloxone. This advantage is highly meaningful clinically since it creates higher plasma levels of the antidote
in the most critical first few minutes of overdose rescue. We have published our results in a highly respected journal in an article
named &ldquo;A Novel Faster-Acting, Dry Powered-Based, Naloxone, Intranasal Formulation for Opioid Overdose,&rdquo; published in Pharmacy
Res in 2022, providing a scientific overview our NS001 product, NS001 was named as having a high (4.2) impact factor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
we receive FDA input on our suggested protocols, we will complete a reliability study, usability study and a short two-week preclinical
safety study in rats to study the effects of the products in histology of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing a unique intranasal powder technology that has been tested in multiple clinical studies as well as in preclinical
work in multiple molecules. This technology enables quick and efficient absorption of the drug through the nasal cavity, making it
especially suitable for the treatment of medical emergencies. Using a nasal inhaler for immediate rescue of a patient is simple and
does not require waiting for medical professionals to reach the patient. </FONT>Our PBI technology has been scaled up for commercial
uses and passed successfully both the tech transfer and the commercial scaleup.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
leadership and executives are highly experienced biotech executives that have accumulated precious experience with regards to our technology
as well as relevant industry experience. Further, we maintain a strong IP position with multiple patents already approved and many others
in different stages of examination worldwide. We have developed a strong strategy covering further development and product commercialization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Commercialization Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
strategic objective is to develop and commercialize our PBI products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to further advance our breakthrough technologies and commercialization efforts. To achieve these objectives, we plan to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Seek
    partnerships to accelerate and maximize the potential for our advanced programs.</I> As we continue to generate data, we will seek
    partnering opportunities with pharmaceutical companies that have established development and sales and marketing capabilities to
    potentially enhance and accelerate the development and commercialization of our products</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Explore
    building in-house capabilities to potentially commercialize our products in the United States. </I>As NS001 progresses towards marketing
    approval, in addition to partnering opportunities, we intend to evaluate the development of our own specialty sales force and marketing
    capabilities to allow us to directly market NS001 in the United States, if approved by the FDA.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Explore
    regulatory approval of our products outside the United States</I>. We are working on getting scientific advice from several European
    countries to advance our products approval in the European Union. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use
    our platform technology and accumulated knowledge and experience to further develop additional pipeline programs. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Competitors
and Market for NS001</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
Emergent BioSolutions Inc.&rsquo;s acquisition of Narcan in 2017, its sales of Narcan consistently beat the market expectation as well
as the company&rsquo;s own estimation. The intranasal Naloxone Narcan sales since first launched showed a CAGR above 23%:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Table
2: Narcan sales 2018 &ndash; 2021 (U.S. dollars in millions)</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 83%; border-collapse: collapse; margin-left: 1in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sales</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">280</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">373</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">434</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">374</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">488</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reached
    119 in first quarter</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the end of 2021, several new players entered the market. Teva and Sandoz Inc. recently won an intellectual property legal battle against
Emergent, the sole manufacturer of Narcan in the last 4 years. Given this, they are allowed to distribute authorized generics of Narcan
at a price around $40-80 compared to the $130-140 market price for Narcan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notably,
however, according to a market study by Vantage Market Research in 2022 entitled &ldquo;Naloxone Spray Market,&rdquo; intranasal Naloxone
is gradually replacing the $2 billion injectable Naloxone market, and therefore, the whole market is estimated to reach $785 million
in 2025 at a CAGR of 22.3%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2024, the FDA approved Summit Biosciences Inc.&rsquo;s Rozeopy, which is a 10 mg nasal solution for emergency treatment of known
or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients.
Another recent entrant to the market is Hikma Pharmaceuticals, with its product, Kloxxado. This product recently received emergency use
authorization from the FDA for an 8 mg liquid nasal spray, compared to 4 mg of Narcan. Our NS001 creates high plasma levels in
the first minutes after administration, the critical therapeutic window in our clinical studies performed thus far, which have had small
patient sample sizes. As depicted in the graphic below, 4 mg of NS001 has shown equivalence to double doses of the current market players:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_037.jpg" ALT="">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Figure
14: Comparison with competitor&rsquo;s double dose</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Competitors
and Market for NS002</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there are no approved PBI epinephrine products in the market. According to market research by Fortune Business Insights, the global
epinephrine market size was valued at $1.75 billion in 2022 and is projected to grow from $1.92 billion in 2023 to $4.08 billion by 2030.
Most of the growth is attributed to growth of the autoinjector sections and anaphylaxis. There are a number of companies working on alternative
administration routes and formulas of Epinephrine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Epinephrine
IM injections are currently considered the standard of care for severe allergic reaction and anaphylactic shock. We believe our PBI
technology is superior to the reference product used in our studies, EpiPen, because it had a higher nasal absorption rate in head-to-head
studies (albeit in small patient populations) due to the physical properties of powder particles versus solution particles. Absorption
area of powder in the nose is larger and, therefore, the initial absorption rate is quicker and higher.  At this time there are a
number of programs in development aiming to find an alternative to injections. Two programs are developing intranasal liquid-based epinephrine&mdash;ARS
Pharmaceuticals, Inc. (whose product, Neffy, was recently approved by the FDA) and Bryn Pharma. There
is another program that is developing PBI epinephrine (Orexo). Another program that is competing in this field is Aquestive Therapeutics
Inc., which is developing a sublingual film of epinephrine. The below graphic depicts the results from our trials (which have
been tested in small patient sample sizes and have not yet been approved by the FDA) as compared to those of our competitors.</FONT></P>

<P STYLE="text-align: center; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="chart_003.jpg" ALT=""></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Table
3: PK parameters competitor analysis</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            following graphic depicts our PBI products in terms of long-term stability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="formdrs_025.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Figure:
Enantiomeric stability Nasus vs EpiPen and EpiPen Junior</B></FONT></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legacy
Product</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
legacy product, Taffix, an innovative personal powder nasal spray which is used to block viruses within the nasal cavity, has been discontinued
in order for us to focus on our current products and activities. We started the wind-down of operations with respect to Taffix in December
2021, and ceased all operations by end of 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
Property</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
seek patent protection as well as other effective intellectual property rights for our products and technologies in the United States
and internationally. Our policy is to pursue, maintain and defend intellectual property rights developed internally and to protect the
technology, inventions and improvements that are commercially important to the development of our business</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intranasal powder-based Naloxone technology is covered by a granted U.S. patent, US 11,202,757 B2, with a priority date of December 1,
2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current intellectual property portfolio consists of two patent families. Patents of the first family relate to dry powder formulations
for intranasal delivery, and cover our basic powder formulation for intranasal administration of active pharmaceutical ingredients, or
APIs. In this family we have four granted patents in the U.S. (one of which is specifically covering Naloxone), one granted patent in
India, one granted patent in Japan and one granted patent in Israel. We have pending applications under examination in Europe by the
European Patent Office, or EPO, Australia, Canada and China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
second family of patents relates to dry powder formulations for intranasal delivery of epinephrine. In this family we have one granted
patent in the U.S., and pending applications in the U.S., Argentina, Taiwan, Australia, Brazil, Canada, China, Europe, India, Israel,
Japan, Mexico, New Zealand and South Korea.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tables below provide certain information regarding our intellectual property portfolio, all of which we owned as of February 5,
2025. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dry
powder compositions for intranasal delivery</I></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; width: 22%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; width: 16%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    No./</B></FONT></P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
    No.</FONT></P></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
                                            Date/</B></FONT></P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pub.
    Date</FONT></P></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: bottom; width: 22%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; vertical-align: top; width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date<SUP>(2)</SUP> </B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/20/2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    Ended</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT<SUP>(1)</SUP></FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WO</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019/038756
    A1</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    Phase entered</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    Fee Paid</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office
    Action due: 10/22/2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN 110996912 A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/10/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination in progress</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3668490</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/24/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination requested</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">416927</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/05/2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proof
    of Use due: 9/30/ 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">272220</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/02/2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7334145</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/18/2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA
                                            NP of PCT/IL2018/050914</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,331,270</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/17/2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA
                                            CIP of 11,331,270</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/19/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,844,859</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/19/2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted
                                            Specific to opioid receptor antagonists (naloxone etc.)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA
                                            CON of 11,844,859</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,202,757</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/21/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA
                                            CON of 11,331,270</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,116,723</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/14/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/19/2038</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent
    Cooperation Treaty, or PCT.</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    dates for pending patents or PCT applications are estimated.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT>&nbsp;</P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Treatment
with powdered intranasal Epinephrine</I></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 12pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    No./ </B>Publication No.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grant
    Date/ Publication Date</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Status</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date<SUP>(1)</SUP> </B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    Ended</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,400,045</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/02/2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Argentina</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AR121593
    A1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/22/2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination
    requested</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/28/2040</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.05in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WO
                                                                              2021/186437</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/23/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    Phase entered</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> 12/28/2040 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request
    for Exam: 11/16/2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> 12/28/2040 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination requested</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> 12/28/2040 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Request
    for Exam: Mar 16, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> 12/28/2040 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN
    115279340 A</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/01/2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination
    in progress</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> 12/28/2040 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EPO</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4121005</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/25/2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination
    in progress</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> 12/28/2040 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination requested</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> 12/28/2040 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awaiting
    Examination</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> 12/28/2040 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examination
    requested</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> 12/28/2040 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mexico</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/16/2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MX/a/2022/011
    464</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/13/2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    Phase entered</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> 12/28/2040 </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration
    dates for pending patents or PCT applications are estimated.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sustained-release
intranasal pharmaceutical composition</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 12pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
  <TR>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Filed</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.45pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    No./</B></FONT></P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4.45pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Publication
    No.</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Grant
    Date/</B></FONT></P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pub.
    Date</B></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 8%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>
    <P STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US Provisional</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/15/2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convention
    due 4/15/2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">04/15/2045</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in"> &nbsp; </TD>
  <TD STYLE="text-align: left; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT> </TD>
  <TD STYLE="text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration dates for pending
  patents or PCT applications are estimated.</FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on trade secrets, know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain
that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed
by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially
useful in protecting our technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends, in part, on an intellectual property portfolio that supports future revenue streams and erects barriers to our competitors.
We are maintaining and building our patent portfolio through filing new patent applications, prosecuting existing applications, and licensing
and acquiring new patents and patent applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite
these measures, any of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or
misappropriated. Intellectual property and proprietary rights may not be sufficient to permit us to take advantage of current market
trends or otherwise to provide competitive one (see &ldquo;<I>Risk Factors&mdash;Risks Related to our Intellectual Property</I>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&ldquo;<I>Related Party Transactions&mdash;Formulex License Agreement</I>&rdquo; for information regarding our license agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Production
and Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on prior work already completed for our Naloxone product, we identified and were successful in building a manufacturing process through
FDA and EMA approved vendors in Europe and the U.S. We have succeeded in scaling up the manufacturing process for commercial quantities
as well as collaborating with a filling and packaging FDA approved vendor for adaptation of a specific filling line to our specific needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
described herein, we are developing NS002 Intranasal Epinephrine to treat anaphylactic shock and severe allergic reaction. NS002 is being
developed under a Section 505(b)(2) application under the FFDCA Act as an approved molecule and a new delivery route. The reference device
is EpiPen autoinjector. The following are the steps, based on discussions with the FDA, that need to be completed in order to submit
our NDA dossier for marketing approval, all of which is subject to us obtaining sufficient funding<U>:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scaling
                                            up of powder production to commercial size batches.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical
                                            studies, or short two-week animal safety studies in two animal species. These studies will
                                            entail giving several doses of Intranasal Epinephrine to the animals and later estimating
                                            via histology if there is potential damage to the relevant tissues such as the nose, pharynx
                                            or lungs.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            effect of two concurrent doses and the effect of prior dose on the absorption of the next
                                            dose, or the Carry-Over Effect study (Phase 2). We intend to perform two additional Phase
                                            2 studies of NS002. The first will be aimed at determining whether, if necessary,
                                            during a real-life anaphylaxis a second dose of NS002 should be administered in the
                                            same nostril as the one used for the first administration or whether it should be in the
                                            other nostril as it is important to learn which method of administration is more effective
                                            and safer for use in case a second dose is deemed necessary. The second Phase 2 study will
                                            test the &ldquo;carry-over effect,&rdquo; or whether the first dose of epinephrine changes
                                            the absorption of epinephrine of a following dose. In other words, this study will test how
                                            efficiently the absorption was after a first dose was already administered. The primary objective
                                            will be to make sure that Intranasal Epinephrine did not lower the absorption of a second
                                            dose. These studies have been agreed upon with the FDA as required studies for submission.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion
                                            of our Phase 3 study, or pivotal clinical study, prior to submission to the FDA for marketing approval.
                                            The study will be conducted in healthy volunteers where NS002 or EpiPen will be administered
                                            by health care professionals. The study will also include a subsection of self-administration
                                            by the subjects to collect information on self-use. This study has also
                                            been agreed upon with the FDA as a required study for submission. </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pediatric
                                            study, the details of which will be agreed upon with the FDA as we progress with the program.
                                            </FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stability
                                            testing that will test the product under various temperature and humidity points.</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Reliability
                                            testing, which is a subset of the stability study that tests the products administration
                                            device in several potential conditions.</TD></TR>
                                                                                                                                                            <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Usability
                                            study, which tests how user friendly the device is.</TD></TR>
                                                                                                                                                            </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on prior work already completed for our Intranasal Naloxone product, we identified and were successful in building a manufacturing process
through FDA and EMA approved vendors in Europe and the U.S. We have succeeded in scaling up the manufacturing process for commercial
quantities as well as collaborating with a filling and packaging FDA approved vendor for adaptation of a specific filling line to our
specific needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing NS001 Intranasal Naloxone to treat opioid overdose. NS001 is being developed under a Section 505(b)(2) application under
the FFDCA, which allows the applicant to rely in part on previous studies conducted by unrelated parties, such as another drug manufacturer
and virtually any source including published literature, for marketing approval by the FDA in the United States, as an approved
molecule and a similar delivery route. The reference device is Narcan. The following are the steps that need to be completed in order
to submit our NDA dossier for marketing approval:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
                                            scale up of manufacturing and manufacturing of three commercial batches;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Pre-clinical
                                            study, or short two-week animal safety studies in one animal species (we have already completed
                                            one such study in a second animal species). This study will entail giving several doses of
                                            Intranasal Naloxone to the animals and later estimating via histology if there is a potential
                                            damage to the relevant tissues such as the nose, pharynx or lungs.</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filling
                                            up the devices; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Starting
                                            a stability study.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">To perform the above steps,
we will need to manufacture three batches of NS001 in quantities that are equivalent to the quantities that will be needed for commercial
use in the future (i.e. commercial batches) and fill the nasal inhalers with the powder. We will then test NS001 at various temperature
(room temperature or accelerated conditions) and humidity points (40% and 75%) to determine whether they continue to function in terms
of the characteristics of the powder emitted and quality and activity of the molecules. The room temperature program is a two-year program,
during which devices are tested every three months in the first year and later twice a year until the 24<SUP>th</SUP> month. The accelerated
program is for six months only.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following studies will be completed after we receive FDA input on our suggested protocols:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reliability
                                            study, which is a subset of the stability study that tests the products administration device
                                            in several potential conditions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Usability
                                            study, which tests how use-friendly the device is; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            short preclinical study in rats that will involve a one-time administration of NS001 to
                                            animals and follow up at different time points up to two weeks to study the histology.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We estimate approximately
two years for submission of NS001 to the FDA for marketing approval, subject to our commercialization strategy. However, our submission
of NS001 and NS002 may not lead to a faster development or review process compared to traditional approval pathways and does not increase
the likelihood that NS001 and NS002 will receive regulatory approval in the United States or the European Union. For further information,
see &ldquo;<I>Risk Factors&mdash;Our product candidates are in different stages of clinical development. Clinical drug development
is a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical trials of our product candidates are
prolonged, delayed or not commercially viable, we or our collaborators may be unable to obtain required regulatory approvals, and therefore
may be unable to commercialize our product candidates on a timely basis or at all, which will adversely affect our business</I>&rdquo;
and &ldquo;<I>Risk Factors&mdash;Our development and regulatory strategy for our product candidates depends in part on published scientific
literature and the FDA&rsquo;s prior findings regarding the safety and efficacy of approved product candidates. If the FDA does not conclude
that our product candidates satisfy the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for
our product candidates under Section 505(b)(2) are not as we expect, the approval pathway would likely take significantly longer, cost
significantly more and entail significantly greater complications and risks than anticipated and in either case may not be successful</I>.&rdquo;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, we entered into a non-recurring research and development arrangement with a governmental body. As part of the arrangement,
we performed certain research and development activities in connection with NS001. We no longer provide services under this arrangement
and do not have any future obligations or other contractual commitment to repay the amounts received or otherwise under this
arrangement in the future, and intellectual property and know-how, if any, resulted from the performance of such research and
development activities will remain with the Company. Additionally, we do not provide research and development services as part of our
central operations. </FONT>For further information, see &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and
Results of Operations&mdash;Research and Development Expenses</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our two main products, Intranasal
Naloxone and Intranasal Epinephrine, we are exploring other potential indications for which our PBI technology may be applicable, including
Midazolam (acute seizures), Atropine (organophosphate poisoning) and Metoclopramide (intractable vomiting).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon
the clinical development, manufacturing and marketing of pharmaceutical products. These agencies and other federal, state and local entities
regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage,
packaging, recordkeeping, tracking, approval, import, export, distribution, advertising and promotion of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S.
Government Regulation of Drug Products</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, the FDA regulates drugs under the FFDCA and its implementing regulations. The process of obtaining regulatory approvals
and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of
substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development
process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the
FDA&rsquo;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product
recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement or civil or criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process required by the FDA before drug product candidates may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">nonclinical
    laboratory and animal tests that must be conducted in accordance with good laboratory practices;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    of an IND, which must become effective before clinical trials may begin;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">ethical approval of the clinical research by an independent
    institutional review board, or IRB, for each clinical site or centrally before each trial may be initiated;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
    and well-controlled human clinical trials to establish the safety and efficacy of the proposed product candidate for its intended
    use, performed in accordance with good clinical practices, or GCPs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    to the FDA of an NDA and payment of user fees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of an FDA advisory committee review, if applicable;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">satisfactory pre-approval inspection of manufacturing
    facilities and selected clinical investigators for their compliance with cGMP and GCPs;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">manufacturing of the drug product in accordance with
    good manufacturing practices;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory
    completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    approval of an NDA to permit commercial marketing for particular indications for use; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy,
    or REMS, and the potential requirement to conduct post-approval studies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
testing and approval process requires substantial time, effort and financial resources. Preclinical studies include laboratory evaluation
of drug substance chemistry, pharmacology, toxicity and drug product formulation, as well as animal studies to assess potential safety
and efficacy. Prior to commencing the first clinical trial in the U.S. with a product candidate, we must submit the results of
the preclinical tests and preclinical literature, together with manufacturing information, analytical data and any available clinical
data or literature, among other things, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted.
The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety
concerns or questions about the conduct of the clinical trial or information in the IND, which may result in a clinical hold. In such
a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND does
not result in FDA authorization to commence a clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators
in accordance with GCP requirements. A separate submission of the clinical protocol to the existing IND must be made for each
successive clinical trial conducted during product development, as well as amendments to previously submitted clinical trials. Further,
an independent IRB for each study site proposing to conduct the clinical trial must review and approve the plan for any clinical trial,
its informed consent form and other communications to study subjects before the clinical trial commences at that site. The IRB must continue
to oversee the clinical trial while it is being conducted, including any changes to the study plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
authorities, an IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that
the subjects are being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the FDA&rsquo;s
or the IRB&rsquo;s requirements, if the drug has been associated with unexpected serious harm to subjects, or based on evolving business
objectives or competitive climate. Some studies also include a data safety monitoring board, which receives special access to unblinded
data during the clinical trial and may advise the study sponsor to halt the clinical trial if it determines that there is an unacceptable
safety risk to subjects or other grounds, such as no demonstration of efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, for purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    1&mdash;Studies are initially conducted to test the product candidate for safety, dosage tolerance, structure-activity relationships,
    mechanism of action, absorption, metabolism, distribution and excretion in healthy volunteers or subjects with the target disease
    or condition. If possible, Phase 1 clinical trials may also be used to gain an initial indication of product effectiveness.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    2&mdash;Controlled studies are conducted with groups of subjects with a specified disease or condition to provide enough data to
    evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded evidence of safety. Multiple Phase 2 clinical
    trials may be conducted to obtain information prior to beginning larger and more expansive Phase 3 clinical trials.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase
    3&mdash;These clinical trials are undertaken in larger subject populations to provide statistically significant evidence of clinical
    efficacy and to further test for safety in an expanded subject population at multiple clinical trial sites. These clinical trials
    are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. These
    clinical trials may be done globally to support global registrations so long as the global sites are also representative of the U.S.
    population and the conduct of the study at global sites comports with FDA regulations and guidance, such as compliance with GCPs.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 studies may
be made a condition to be satisfied after approval. The results of Phase 4 studies can confirm the effectiveness of a product candidate
and can provide important safety information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials must be conducted under the supervision of qualified investigators in accordance with GCP requirements, which includes the requirements
that all research subjects provide their informed consent in writing for their participation in any clinical trial, and the review and
approval of the study by an IRB. Investigators must also provide information to the clinical trial sponsors to allow the sponsors to
make specified financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives
of the trial, the trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical
analysis plan. Information about some clinical trials, including a description of the trial and trial results, must be submitted within
specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacture of investigational drugs for the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs
and active pharmaceutical ingredients imported into the United States are also subject to regulation by the FDA relating to their labeling
and distribution. Further, the export of investigational drug products outside of the United States is subject to regulatory requirements
of the receiving country as well as U.S. export requirements under the FFDCA. Progress reports detailing the results of the clinical
trials must be submitted at least annually to the FDA and the IRB and more frequently if serious adverse effects occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent
with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry
and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities
in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product
candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product.
Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Orange
Book Listing</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims
cover the applicant&rsquo;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published
in Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
applicant who files a 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA (1) that no patent information
on the drug product that is the subject of the application has been submitted to the FDA; (2) that such patent has expired; (3) the date
on which such patent expires; or (4) that such patent is invalid or will not be infringed upon by the manufacture, use or sale of the
drug product for which the application is submitted. This last certification is known as a Paragraph IV certification. Generally, the
505(b)(2) NDA cannot be approved until all listed patents have expired, except where the 505(b)(2) NDA applicant challenges a listed
patent through a Paragraph IV certification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification
to the holder of the NDA for the reference listed drug and the patent owner once the application has been accepted for filing by the
FDA. The applicant may also elect to submit a &ldquo;section viii&rdquo; statement certifying that its proposed label does not contain
(or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. The NDA holder
or patent owner may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing
of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification prevents the FDA from approving the application
until the earlier of 30 months from the date of the lawsuit, expiration of the patent, settlement of the lawsuit, a decision in the infringement
case that is favorable to the applicant or such shorter or longer period as may be ordered by a court. This prohibition is generally
referred to as the 30-month stay. In instances where a 505(b)(2) NDA applicant files a Paragraph IV certification, the NDA holder or
patent owner regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many months
or years to resolve. Thus, approval of a 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification
the applicant makes and the reference drug sponsor&rsquo;s decision to initiate patent litigation. To our knowledge, we will not need
to challenge intellectual property rights via a Paragraph IV certification in connection with our 505(b)(2) NDA filing. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusivity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA provides periods of non-patent regulatory exclusivity, which provides the holder of an approved NDA limited protection from new competition
in the marketplace for the innovation represented by its approved drug for a period of three or five years following the FDA&rsquo;s
approval of the NDA. Five years of exclusivity are available to new chemical entities, or NCEs. An NCE is a drug that contains no active
moiety that has been approved by the FDA in any other NDA. An active moiety is the molecule or ion, excluding those appended portions
of the molecule that cause the drug to be an ester, salt, including a salt with hydrogen or coordination bonds, or other noncovalent,
or not involving the sharing of electron pairs between atoms, derivatives, such as a complex (<I>i.e.</I>, formed by the chemical interaction
of two compounds), chelate (<I>i.e.</I>, a chemical compound), or clathrate (<I>i.e.</I>, a polymer framework that traps molecules),
of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA may not accept
for review or approve an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA submitted by another company that contains the
previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires
if a Paragraph IV certification is filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product is not eligible for the NCE exclusivity, it may be eligible for three years of exclusivity. Three-year exclusivity is available
to the holder of an NDA, including a 505(b)(2) NDA, if one or more new clinical trials, other than bioavailability or bioequivalence
trials, was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity
period protects against FDA approval of ANDAs and 505(b)(2) NDAs for the particular condition of the new drug&rsquo;s approval or the
change to a marketed product, such as a new formulation for a previously approved drug. Five-year and three-year exclusivity will not
delay the submission or approval of a 505(b)(1) NDA; however, an applicant submitting a 505(b)(1) NDA would be required to conduct or
obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate
safety and efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Generating Antibiotic Incentives Now Act, or GAIN Act, which was enacted as part of the Food and Drug Administration
Safety and Innovation Act, or FDASIA, which was signed into law in July 2012, the FDA may designate a product as a Qualified Infectious
Disease Product, or QIDP. In order to receive this designation, a drug must qualify as an antibiotic or antifungal drug for human
use intended to treat serious or life-threatening infections, including those caused by either (1) an antibiotic or antifungal resistant
pathogen, including novel or emerging infectious pathogens, or (2) a so-called &ldquo;qualifying pathogen&rdquo; found on a list of potentially
dangerous, drug-resistant organisms to established and maintained by the FDA. A sponsor must request such designation before submitting
a marketing application. Upon approving a marketing application for a QIDP-designated product, the FDA will extend by an additional five
years any non-patent marketing exclusivity period awarded, such as a three-year exclusivity period awarded for new clinical investigations
of previously approved products. This extension is in addition to any pediatric exclusivity extension awarded, and the extension will
be awarded only to a drug first approved on or after the date of enactment of the GAIN Act. The GAIN Act prohibits the grant of an exclusivity
extension where the application is a supplement to an application for which an extension is in effect or has expired, is a subsequent
application for a specified change to an approved product, or is an application for a product that does not meet the definition of QIDP
based on the uses for which it is ultimately approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Hatch
Waxman Amendments and the 505(b)(2) Regulatory Approval Process</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
505 of the FFDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization
for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A Section
505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy, but where at least some of the information
required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained
a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant
to rely, in part, on the FDA&rsquo;s prior findings of safety and efficacy for an existing product, or published literature, in support
of its application. Specifically, the applicant may rely upon the FDA&rsquo;s prior findings of safety and efficacy for an approved product
that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also require 505(b)(2) applicants to perform additional
studies or measurements to support any changes from the reference listed drug. The FDA may then approve the new product candidate for
all or some of the labeled indications for which the referenced product has been approved, as well as for any new indication sought by
the 505(b)(2) applicant. Lastly, the FDA permits marketing applications through Section 505(j), which establishes an abbreviated approval
process for a generic version of approved drug products through the submission of an ANDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration,
labeling, performance characteristics and intended use, among other things, to a previously approved product. ANDAs are termed &ldquo;abbreviated&rdquo;
because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead,
generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator
drug through in vitro, in vivo, or other testing. The generic version must deliver the same amount of active ingredients into a subject&rsquo;s
bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written
for the reference listed drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Special
FDA Expedited Review and Approval Programs</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has various programs, including Fast Track Designation, breakthrough therapy designation, accelerated approval, and priority review,
which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment
of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these
programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the fast track program, the sponsor of a new drug candidate may request that FDA designate the drug candidate for a specific indication
as a fast track drug concurrent with, or after, the filing of the IND for the drug candidate. To be eligible for a Fast Track Designation,
the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life threatening disease
or condition and demonstrates the potential to address an unmet medical need, or that the drug qualifies as a QIDP under the GAIN Act.
The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy
that may be potentially superior to existing therapy based on efficacy or safety factors. Fast Track Designation provides additional
opportunities for interaction with the FDA&rsquo;s review team and may allow for rolling review of NDA components before the completed
application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept
sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the
first section of the NDA. However, the FDA&rsquo;s time period goal for reviewing an application does not begin until the last section
of the NDA is submitted. The FDA may decide to rescind the Fast Track Designation if it determines that the qualifying criteria no longer
apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a sponsor can request breakthrough therapy designation for a drug if it is intended, alone or in combination with one or more
other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment
effects observed early in clinical development. Drugs designated as breakthrough therapies are eligible for intensive guidance from the
FDA on an efficient drug development program, organizational commitment to the development and review of the product including involvement
of senior managers, and, like fast track products, are also eligible for rolling review of the NDA. Both fast track and breakthrough
therapy products are also eligible for accelerated approval and/or priority review, if relevant criteria are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDA&rsquo;s accelerated approval regulations, the FDA may approve a drug for a serious or life threatening illness that provides
meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict
clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably
likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity,
or prevalence of the condition and the availability or lack of alternative treatments. A drug candidate approved on this basis is subject
to rigorous post marketing compliance requirements, including the completion of Phase 4 or post approval clinical trials to confirm the
effect on the clinical endpoint. Failure to conduct required post approval studies, or confirm a clinical benefit during post marketing
studies, will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates
approved under accelerated approval regulations are subject to prior review by the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
an NDA is submitted for a product intended to treat a serious condition, the FDA may assign a priority review designation if FDA determines
that the product, if approved, would provide a significant improvement in safety or effectiveness. A priority review means that the goal
for the FDA to review an application is six months, rather than the standard review of ten months under current The Prescription Drug
User Fee Act, or PDUFA, guidelines. Under the current PDUFA agreement, for new molecular entities, these six and ten months review
periods are measured from the 60-day filing date rather than the receipt date for NDAs for non-new molecular entities, which typically
adds approximately two months to the timeline for review from the date of submission. Most products that are eligible for fast track
breakthrough therapy designation are also likely to be considered appropriate to receive a priority review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for
qualification or decide that the time period for FDA review or approval will not be shortened. In addition, the manufacturer of an investigational
drug for a serious or life threatening disease is required to make available, such as by posting on its website, its policy on responding
to requests for expanded access. Furthermore, fast track designation, breakthrough therapy designation, accelerated approval and priority
review do not change the standards for approval and may not ultimately expedite the development or approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>NDA
Submission and Review by the FDA</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
successful completion of the required clinical and preclinical testing, among other items, the results of product development, including
chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling,
as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the FDA. These user fees must be filed at the
time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions
are available in some circumstances. One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees,
including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced
or delivered for introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing
application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA for a new active ingredient, indication, dosage form,
dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy of the drug for the claimed
indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which
the product is safe and effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until
after approval of the product for use in adults or full or partial waivers from the pediatric data requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA must refer applications for drugs that contain active ingredients, including any ester or salt of the active ingredients, that have
not previously been approved by the FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring
it to an advisory committee. The FDA may also refer drugs which present difficult questions of safety, purity or potency to an advisory
committee. An advisory committee is typically a panel that includes clinicians and other experts who review, evaluate and make a recommendation
as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory
committee, but it considers such recommendations carefully when making decisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the
manufacturing controls are adequate to assure and preserve the product&rsquo;s identity, strength, quality and purity. Before approving
an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless
it determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with
cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving
an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit a
substantive review, before it accepts the application for filing. Once the submission is accepted for filing, the FDA begins an
in-depth review of the NDA. The FDA&rsquo;s NDA review times may differ based on whether the application is a standard review or
priority review application. The FDA may give a priority review designation to drugs that are intended to treat serious conditions
and provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious
conditions. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has set the review goal of 10 months from the
60-day filing date to complete its initial review of a standard NDA for a new molecular entity, or NME, and make a decision on the
application. For non-NME standard applications, the FDA has set the review goal of 10 months from the date that the FDA receives the
application to complete its initial review and to make a decision on the application. For priority review applications, the FDA has
set the review goal of reviewing NME NDAs within six months of the 60-day filing date and non-NME applications within six months of
the date that the FDA receives the application. Such deadlines are referred to as the PDUFA date. The PDUFA date is only a goal and
the FDA does not always meet its PDUFA dates. The PDUFA date may be extended by the FDA in certain circumstances. These include
circumstances such as a &lsquo;major amendment,&rsquo; for example, where data submitted to a final study report is updated or data
inadvertently omitted is supplied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Once
the FDA&rsquo;s review of the application is complete, the FDA will issue either a Complete Response Letter, or CRL, or approval letter.
A CRL indicates that the review cycle of the application is complete and the application is not ready for approval. A CRL generally contains
a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical
or preclinical testing, or other information or analyses in order for the FDA to reconsider the application. Upon completion of the
deficient information, the updated NDA is resubmitted. The FDA has the goal of reviewing 90% of application resubmissions in either
two or six months of the date that the FDA receives the application, depending on the FDA classification of resubmission. Even
with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria
for approval. If and when those conditions have been met to the FDA&rsquo;s satisfaction, the FDA may issue an approval letter. An approval
letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information
and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product, or impose other conditions, including
distribution restrictions or other risk management mechanisms. For example, the FDA may require a REMS as a condition of approval or
following approval to mitigate any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit
further marketing of a product, or impose additional post-marketing requirements, based on the results of post-marketing studies or surveillance
programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional
labeling claims, are subject to further testing requirements, FDA notification and FDA review and approval. Further, should new safety
information arise, additional testing, product labeling or FDA notification may be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be
marketed or may include contraindications, warnings or precautions in the product labeling, which has resulted in a Black Box warning.
A Black Box warning is the strictest warning put in the labeling of prescription drugs or drug products by the FDA when there is reasonable
evidence of an association of a serious hazard with the drug. The FDA also may not approve the inclusion of labeling claims necessary
for successful marketing. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory
standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase 4
post-marketing studies to monitor the effect of approved products, and may limit further marketing of the product based on the results
of these post-marketing studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-approval
Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including manufacturing,
periodic reporting, product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval
requirements imposed as a conditional of approval such as Phase 4 clinical trials, REMS and surveillance, recordkeeping and reporting
requirements, including adverse experiences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review
and approval. There also are continuing, annual user fee requirements for any approved products and the establishments at which such
products are manufactured, as well as new application fees for supplemental applications with clinical data. Drug manufacturers and their
subcontractors are required to register their establishments with the FDA and certain state agencies and to list their drug products,
and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with cGMPs and other
requirements, which impose procedural and documentation requirements upon us and our third-party manufacturers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
to the manufacturing process are strictly regulated and often require prior FDA approval, or FDA notification, before being implemented.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA regulations also require investigation and correction
of any deviations from cGMPs and specifications, and impose reporting and documentation requirements upon the sponsor and any third-party
manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area
of production and quality control to maintain cGMP compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Later
discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing
processes, or failure to comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to
the approved labeling to add new safety information or other limitations, imposition of post-market studies or clinical trials to assess
new safety risks, or imposition of distribution or other restrictions under a REMS program, among other consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA closely regulates the marketing and promotion of drugs. A company can make only those claims relating to safety and efficacy, purity
and potency that are approved by the FDA. Physicians, in their independent professional medical judgement, may prescribe legally available
products for uses that are not described in the product&rsquo;s labeling and that differ from those tested by us and approved by the
FDA. We, however, are prohibited from marketing or promoting drugs for uses outside of the approved labeling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the distribution of prescription pharmaceutical products, including samples, is subject to the Prescription Drug Marketing
Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration
and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical
product samples and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act also imposes obligations
on manufacturers of pharmaceutical products related to product tracking and tracing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to comply with any of the FDA&rsquo;s requirements could result in significant adverse enforcement actions. These include a variety of
administrative or judicial sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of
an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification
of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or
partial suspension of production or distribution, debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals
of government contracts and new orders under existing contracts, exclusion from participation in federal and state healthcare programs,
restitution, disgorgement or civil or criminal penalties, including fines and imprisonment. It is also possible that failure to comply
with the FDA&rsquo;s requirements relating to the promotion of prescription drugs may lead to investigations alleging violations of federal
and state healthcare fraud and abuse and other laws, as well as state consumer protection laws. Any of these sanctions could result in
adverse publicity, among other adverse consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Healthcare Regulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business activities, including but not limited to, research, sales, promotion, distribution, medical education and other activities are
subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the FDA, including the
Department of Justice, the HHS and its various divisions, including CMS and the Health Resources and Services Administration, the Department
of Veterans Affairs, the Department of Defense and state and local governments. Our business activities must comply with numerous healthcare
laws and regulations, including those described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting
or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for,
the referral of an individual for, or purchasing, leasing, ordering, or arranging for the purchase, lease or order of, any good, facility,
item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The Anti-Kickback Statute has been interpreted
to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on
the other hand. The term remuneration has been interpreted broadly to include anything of value. There are a number of statutory exceptions
and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and
require strict compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to induce
prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to
meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se
illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based
on a cumulative review of all of its facts and circumstances. Additionally, the Patient Protection and Affordable Care Act of 2010, as
amended by the Health Care and Education Reconciliation Act of 2010, or collectively the Affordable Care Act, amended the intent requirement
of the federal Anti-Kickback Statute, and other healthcare criminal fraud statutes, so that a person or entity no longer needs to have
actual knowledge of the federal Anti-Kickback Statute, or the specific intent to violate it, to have violated the statute. The Affordable
Care Act also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower to assert
that a claim for payment of items or services resulting from such violation constitutes a false or fraudulent claim for purposes of the
federal civil False Claims Act, or FCA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal civil and criminal false claims laws, including the FCA, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false claim for payment to, or approval by, the U.S. federal government, including the Medicare and Medicaid
programs, or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim
or to avoid, decrease or conceal an obligation to pay money to the federal government. As a result of a modification made by the Fraud
Enforcement and Recovery Act of 2009, a claim includes &ldquo;any request or demand&rdquo; for money or property presented to the U.S.
government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors
if they are deemed to &ldquo;cause&rdquo; the submission of false or fraudulent claims. The FCA also permits a private individual acting
as a &ldquo;whistleblower&rdquo; to bring actions on behalf of the federal government alleging violations of the FCA and to share in
any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages
and mandatory penalties. Government enforcement agencies and private whistleblowers have investigated pharmaceutical companies for or
asserted liability under the FCA for a variety of alleged promotional and marketing activities, such as providing free products to customers
with the expectation that the customers would bill federal programs for the products; providing consulting fees and other benefits to
physicians to induce them to prescribe products; engaging in promotion for &ldquo;off-label&rdquo; uses; and submitting inflated best
price information to the Medicaid Rebate Program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition of receiving Medicaid coverage for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to calculate
and report to CMS their Average Manufacturer Price, or AMP, which is used to determine rebate payments shared between the states and
the federal government and, for some multiple source drugs, Medicaid payment rates for the drug, and for drugs paid under Medicare Part
B, to also calculate and report their average sales price, which is used to determine the Medicare Part B payment rate for the drug.
In January 2016, CMS issued a final rule regarding the Medicaid Drug Rebate Program, or MDRP, effective April 1, 2016, that, among other
things, revised the manner in which the AMP is calculated by manufacturers participating in the program and implemented certain amendments
to the Medicaid rebate statute created under the Affordable Care Act. In addition, the MDRP requires pharmaceutical manufacturers to
enter into and have in effect a National Drug Rebate Agreement, or NDRA, with the Secretary of HHS as a condition for states to receive
federal matching funds for the manufacturer&rsquo;s outpatient drugs furnished to Medicaid patients. On March 23, 2018, CMS finalized
updates to the NDRA, or the Updated NDRA, to incorporate a number legislative and regulatory changes, including changes to align with
certain provisions of the Affordable Care Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
that are approved under a biologics license application, or BLA, or an NDA, including a 505(b)(2) NDA, are subject to an additional requirement
to calculate and report the manufacturer&rsquo;s best price for the drug and inflation penalties which can substantially increase rebate
payments. For BLA and NDA drugs, the Veterans Health Care Act requires manufacturers to calculate and report to the Department of Veterans
Affairs a different price called the Non-Federal AMP, offer the drugs for sale on the Federal Supply Schedule, and charge the government
no more than a statutory price referred to as the Federal Ceiling Price, which includes an inflation penalty. A separate law requires
manufacturers to pay rebates on these drugs when paid by the Department of Defense under its TRICARE Retail Pharmacy Program. Knowingly
submitting false pricing information to the government creates potential federal False Claims Act liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
created additional federal criminal statutes that prohibits, among other things, knowingly and willfully executing, or attempting to
execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or
promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether
the third-party payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully
obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any
trick, scheme or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery
of, or payment for, healthcare benefits, items or services relating to healthcare matters. Additionally, the Affordable Care Act amended
the intent requirement of some of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge
of the statute, or the specific intent to violate it, to have committed a violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under Section 6002 of the Affordable Care
Act and its implementing regulations, requires some manufacturers of drugs, devices, biologicals and medical supplies for which payment
is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program (with specified exceptions) to report annually
information related to specified payments or other transfers of value provided to physicians (defined to include doctors, dentists, optometrists,
podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners) and teaching
hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to
report annually specified ownership and investment interests held by physicians and their immediate family members. Failure to submit
timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests
may result in civil monetary penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct
our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing
regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information held
by covered entities, their business associates and covered subcontractors. Among other things, HITECH makes HIPAA&rsquo;s security standards
directly applicable to business associates, defined as independent contractors or agents of covered entities that create, receive, maintain
or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also created
new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates,
and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal
HIPAA laws and seek attorneys&rsquo; fees and costs associated with pursuing federal civil actions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services
reimbursed by any third-party payor, including commercial insurers. We may also be subject to state laws that require pharmaceutical
companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government, and/or state laws that require drug manufacturers to report information related to payments and other transfers
of value to physicians and other healthcare providers or marketing expenditures and pricing information, state and local laws that require
the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information in
certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance
efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will
likely be costly. It is possible that governmental authorities will conclude that our business practices do not comply with current or
future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
were found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant
civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from government
funded healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations
and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with
these laws, and curtailment of our operations, any of which could substantially disrupt our operations. If the physicians or other providers
or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant
criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage
and Reimbursement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to commercialize any products successfully will also depend in part on the extent to which coverage and adequate reimbursement
for the procedures utilizing our product candidates, performed by health care providers, once approved, will be available from government
health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors,
such as private health insurers and health maintenance organizations, determine which procedures, and the products utilized in such procedures,
they will cover and establish reimbursement levels. Assuming coverage is obtained for procedures utilizing a given product, by a third-party
payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high.
Patients who undergo procedures for the treatment of their conditions, and their treating physicians, generally rely on third-party payors
to reimburse all or part of the costs associated with the procedures which utilize our products. When used in connection with surgical
and certain other procedures, our product candidates may not be reimbursed separately but their cost may instead be bundled as part of
the payment received by the provider for the procedure only. Treating physicians are unlikely to use and order our products unless coverage
is provided and the reimbursement is adequate to cover all or a significant portion of the cost of the procedures which utilize our products.
A decision by a third-party payor not to cover or adequately reimburse for our product candidates or procedures using our product candidates,
could reduce physician utilization of our products once approved. Therefore, coverage and adequate reimbursement for procedures which
utilize new products is critical to the acceptance of such new products. Coverage decisions may depend upon clinical and economic standards
that disfavor new products when more established or lower cost therapeutic alternatives are already available or subsequently become
available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government
authorities and other third-party payors are developing increasingly sophisticated methods of cost containment, such as including price
controls, restrictions on coverage and reimbursement and requirements for substitution of less expensive products and procedures. Government
and other third-party payors are increasingly challenging the prices charged for health care products and procedures, examining the cost
effectiveness of procedures, and the products used in such procedures, in addition to their safety and efficacy, and limiting or attempting
to limit both coverage and the level of reimbursement. Further, no uniform policy requirement for coverage and reimbursement exists among
third-party payors in the United States, which causes significant uncertainty related to the insurance coverage and reimbursement of
newly approved products, and the procedures which may utilize such newly approved products. Therefore, coverage and reimbursement can
differ significantly from payor to payor and health care provider to health care provider.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be sure that coverage and reimbursement will be available for any product that we commercialize, or the procedures which utilize
such product, and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the
demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available
or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain
marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Healthcare
Reform Measures</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and some non-U.S. jurisdictions are considering or have enacted a number of legislative and regulatory proposals designed
to change the healthcare system. Among policy makers and payors in the United States and elsewhere, there is significant interest in
promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access.
In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by
major legislative initiatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
example, the pharmaceutical industry in the United States has been affected by the passage of Affordable Care Act, which, among other
things: imposed new fees on entities that manufacture or import certain branded prescription drugs; expanded pharmaceutical manufacturer
obligations to provide discounts and rebates to certain government programs; implemented a licensure framework for follow-on biologic
products; expanded health care fraud and abuse laws; revised the methodology by which rebates owed by manufacturers to the state and
federal government under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including products that are
inhaled, infused, instilled, implanted or injected; imposed an additional rebate similar to an inflation penalty on new formulations
of drugs; extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care
organizations; expanded the 340B program which caps the price at which manufacturers can sell covered outpatient pharmaceuticals to specified
hospitals, clinics and community health centers; and provided incentives to programs that increase the federal government&rsquo;s comparative
effectiveness research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act. For example, on June 17, 2021,
the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety
because the &ldquo;individual mandate&rdquo; was repealed by Congress. Further, on August 16, 2022, President Biden signed the IRA into
law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act
marketplaces through plan year 2025. The IRA also eliminates the &ldquo;donut hole&rdquo; under the Medicare Part D program beginning
in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is
possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any such
challenges and the healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the
Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2.0% per fiscal year,
which went into effect in April 2013, and due to subsequent legislative amendments, including the BBA, will remain in effect until 2032,
unless additional U.S. Congressional action is taken. In addition, in January 2013, President Obama signed into law the American Taxpayer
Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, the
Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, ended the use of the statutory formula for clinician payment and established
a quality payment incentive program, also referred to as the Quality Payment Program. This program provides clinicians with two ways
to participate, including through the Advanced Alternative Payment Models, or APMs, and the Merit-based Incentive Payment System, or
MIPS. Under both APMs and MIPS, performance data collected each performance year will affect Medicare payments in later years, including
potentially reducing payments. At this time, the full impact to overall physician reimbursement as a result of the introduction of the
Quality Payment Program remains unclear. Any reduction in reimbursement from Medicare or other government programs may result in a similar
reduction in payments from private payors. Congress is considering additional health reform measures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, there has been particular and increasing legislative and enforcement interest in the United States with respect to drug pricing
practices in recent years, particularly with respect to drugs that have been subject to relatively large price increases over relatively
short time periods. Specifically, there have been several recent U.S. Presidential executive orders, Congressional inquiries and proposed
and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship
between pricing and manufacturer patient programs, reduce the cost of prescription drugs under Medicare and reform government program
reimbursement methodologies for pharmaceutical products. For example, in July 2021, the Biden administration released an executive order,
&ldquo;Promoting Competition in the American Economy,&rdquo; with multiple provisions aimed at prescription drugs. In response to President
Biden&rsquo;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines
principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential
administrative actions HHS can take to advance these principles. Further, the IRA, among other things (i) directs HHS to negotiate the
price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part
B and Medicare Part D to penalize price increases that outpace inflation. These provisions took effect progressively starting in fiscal
year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the
Medicare drug price negotiation program is currently subject to legal challenges. Further in response to the Biden administration&rsquo;s
October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation
Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is
unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the Biden administration
announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December
8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering
the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding
to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the
new framework. In addition, individual states in the United States have become increasingly active in passing legislation and implementing
regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation
from other countries and bulk purchasing. For example, on January 5, 2024, the FDA approved Florida&rsquo;s Section 804 Importation Program
(SIP) proposal to import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be implemented,
including which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other states
have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans, when implemented, may result
in lower drug prices for products covered by those programs. In the future, there will likely continue to be proposals relating to the
reform of the U.S. healthcare system, some of which could further limit coverage and reimbursement of products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
Foreign Corrupt Practices Act</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering or authorizing payment or offering
of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any
act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also
obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the companies to
maintain books and records that accurately and fairly reflect all transactions of the companies, including international subsidiaries,
and to devise and maintain an adequate system of internal accounting controls for international operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-U.S.
Government Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that any of our product candidates, once approved, are sold in a country outside of the United States, we will be subject
to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance,
anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to
healthcare professionals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to market our future products in the EEA (which is comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein)
and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can
only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: .25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee
    for Medicinal Products for Human Use of the EMA, and which is valid throughout the entire territory of the EEA. The Centralized Procedure
    is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products and medicinal products
    indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized
    Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute
    a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">National
    MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are
    available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized
    for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition
    Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously
    in various Member States through the Decentralized Procedure.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an
assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Data
and Marketing Exclusivity</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional
two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from
relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or
biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized
in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the
EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period
can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the marketing authorization holder obtains
an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are
held to bring a significant clinical benefit in comparison with existing therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pediatric
Investigation Plan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EEA, marketing authorization applications for new medicinal products not authorized have to include the results of studies conducted
in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the EMA&rsquo;s Pediatric Committee,
or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing
authorization is being sought. The PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until
there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric
clinical trial data can be waived by the PDCO when these data are not needed or appropriate because the product is likely to be ineffective
or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product
does not represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the marketing authorization
is obtained in all Member States of the EU and study results are included in the product information, even when negative, the product
is eligible for six months&rsquo; supplementary protection certificate extension.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Environmental,
Health and Safety Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: justify; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to extensive environmental, health and safety laws and regulations in a number of jurisdictions, primarily Israel, governing,
among other things: the use, storage, registration, handling, emission and disposal of chemicals, waste materials and sewage; chemicals,
air, water and ground contamination; air emissions and the cleanup of contaminated sites, including any contamination that results from
spills due to our failure to properly dispose of chemicals, waste materials and sewage. Our operations use chemicals and produce waste
materials and sewage and require permits from various governmental authorities including, local municipal authorities, the Ministry of
Environmental Protection and the Ministry of Health. The Ministry of Environmental Protection and the MOH, local authorities and the
municipal water and sewage company conduct periodic inspections in order to review and ensure our compliance with the various regulations.
These laws, regulations and permits could potentially require the expenditure by us of significant amounts for compliance or remediation.
If we fail to comply with such laws, regulations or permits, we may be subject to fines and other civil, administrative or criminal sanctions,
including the revocation of permits and licenses necessary to continue our business activities. In addition, we may be required to pay
damages or civil judgments in respect of third-party claims, including those relating to personal injury (including exposure to hazardous
substances we use, store, handle, transport, manufacture or dispose of), property damage or contribution claims. Some environmental,
health and safety laws allow for strict, joint and several liability for remediation costs, regardless of comparative fault. We may be
identified as a responsible party under such laws. Such developments could have a material adverse effect on our business, financial
condition and results of operations. In addition, laws and regulations relating to environmental, health and safety matters are often
subject to change. In the event of any changes or new laws or regulations, we could be subject to new compliance measures or to penalties
for activities that were previously permitted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Organizational
Structure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have any subsidiaries. Until February 2023, we had a United Kingdom incorporated subsidiary, Nasus Pharma UK Ltd., which
was never active.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property
and Facilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
offices are located in Israel. We currently lease one facility located at Yigal Alon 65, Tel Aviv, Israel from Top Notch Ltd.
for a monthly fee of NIS 12,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consider that our current office space is sufficient to meet our anticipated needs for the foreseeable future and is suitable for the
conduct of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 5, 2025, we have five members of senior management (including our Chief Executive Officer), of which
one is a full-time employee, one is a part-time employee, and three are service providers. As of February 5, 2025,
we also have one consultant. </FONT> During the years 2023 and 2022, we reduced
our workforce by two and five employees, respectively, due to discontinued operations and a slowdown of our NS001 program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None of our employees are represented by labor unions or covered by collective bargaining agreements.
However, in Israel, we are subject to certain Israeli labor laws, regulations and national labor court precedent rulings, as well as
certain provisions of collective bargaining agreements applicable to us by virtue of extension orders issued in accordance with relevant
labor laws by the Israeli and Industry of Economy and which apply such agreement provisions to our employees even though they are not
part of a union that has signed a collective bargaining agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our employment and consulting agreements include employees&rsquo; and consultants&rsquo; undertakings with respect to non-competition
and assignment to us of intellectual property rights developed in the course of employment and confidentiality. The enforceability of
such provisions is limited by Israeli law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not
currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our
business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management
resources and other factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U><A NAME="p_013"></A></U>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Directors
and Senior Management</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding our executive officers and directors as of February 5, 2025: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 58%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Dan Teleman </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> 52 </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"> Chief Executive Officer </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Udi
    Gilboa <SUP>(2)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Founder
    and Executive Chairman of the Board</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Dalia Megiddo<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Founder,
    Director, Chief Development Officer and Chief Medical Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tair
    Lapidot, Pd.D.<SUP>(3)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President of Research and Development and Clinical Development </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Galia
    Temtsin Kryaz, Ph.D.<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of Product Development</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren
    Elmaliah<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of Finance</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dr. Ronnie Hershman</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">65</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Director</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">(1)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Consultant</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(2)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Service Provider</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(3)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0">Part-Time Employee</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>Dan Teleman<FONT STYLE="background-color: white">,
Chief Executive Officer</FONT></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT>Mr.
Dan Teleman has served as our Chief Executive Officer since January 2025. Prior to this appointment Mr. Teleman served as Pharma Two
B Ltd.&rsquo;s Chief Executive Officer from May 2023 to January 2025, and as its President from October 2022 to May 2023. Mr.&nbsp;Teleman
brings over 20&nbsp;years of experience in the biotechnology industry. From May 2022 to May 2023, Mr.&nbsp;Teleman was an Executive Partner
at Israel Biotech Fund, a life science venture capital firm. From January 2023 to November 2023, Mr.&nbsp;Teleman also served as a board
member of 4C Biomed, an early stage immune-oncology&nbsp;company developing a novel antibody. From July 2021 to May 2023, Mr.&nbsp;Teleman
served as the chairman of Tamarix Pharma Ltd, an early-stage ophthalmology company developing novel anti apoptotic molecules. From January
2010 to May 2022, Mr.&nbsp;Teleman was the chief executive officer of Atox Bio Ltd., where he led the company through an NDA submission
for Reltecimod, the first immunomodulator developed for NSTI.&nbsp;Previously, Mr.&nbsp;Teleman was the co-founder&nbsp;and chief executive
officer of PainReform Ltd. (NASDAQ: PRFX), head of business development for Pharmos Corporation and held marketing and sales roles at
Amgen (NASDAQ: AMGN). Mr.&nbsp;Teleman holds an MBA from the Fuqua School of Business at Duke University and an MSc in Biochemical engineering
from Ben Gurion University in Israel.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Udi
Gilboa<FONT STYLE="background-color: white">, Co-Founder and Executive Chairman</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>Mr.
</I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Udi Gilboa </FONT></I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white">has
served as our Co-Founder and Executive Chairman since 2019. Since January 2012, Mr. Gilboa has been serving as a director, Senior Vice
President of Operations and the Chief Financial Officer of Bioblast Pharma Ltd. (NASDAQ:ORPN). Mr. Gilboa is the founder and managing
partner of TopNotch Capital Ltd., a prominent Israeli life sciences investment bank. He is also the founder of a number of medical device
and pharmaceutical companies. Mr. Gilboa is Chairman of the Board of Samson NeuroSciences Ltd. Mr. Gilboa has served as a director of
InsuLine Medical Ltd. (TASE: INSL) until 2014 and served, until 2010 as a director and chairman of the board of directors of Topspin
Medical Ltd. Mr. Gilboa holds a Bachelor&rsquo;s degree and M.B.A. from Tel Aviv University. We believe Mr. Gilboa&rsquo;s skills
and experiences in the pharmaceutical and medical device industry as a founder, board member and in management positions, specifically
in publicly traded companies, make him a beneficial addition to our board of directors.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Dr.
Dalia Megiddo, Co-Founder, Chief Development Officer and Chief Medical Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Dalia Megiddo</I> is one of our Co-Founders and has served as our Chief <FONT STYLE="background-color: white">Development Officer
and Chief Medical Officer</FONT> since June 2019. Dr. Megiddo also served as our Chief Executive Officer from March 2020 to
January 2025. She has founded and served as management or a director for multiple biopharma and medtech companies, including Chiasma
Inc. (<FONT STYLE="background-color: white">NASDAQ</FONT>: CHMA) from 2002 to 2008 as co-founder and director; Medingo Ltd. (sold to
Roche Holding AG) from 2005 to 2007 as co-founder and director; Alcobra Pharmaceuticals Ltd. (<FONT STYLE="background-color: white">NASDAQ</FONT>:ADHD)
from 2008 to 2013 as co-founder and director; and Bioblast Pharma Ltd. (<FONT STYLE="background-color: white">NASDAQ</FONT>:ORPN) from
February 2012 through its public offering in February 2015 as CEO and director from February 2012 to March 2019. Dr. Megiddo managed
two venture capital funds: 7 Health Ventures from 2006 through 2010 and <I>InnoMed Ventures</I>, since 2000. Dr Megiddo has been involved
in the Life Science Venture Capital Industry since 1999 and is well recognized as one of the leaders in the healthcare investment and
entrepreneurial community both in Israel and internationally. She is a frequent speaker at local and international meetings and served
as a board member at Given Imaging Ltd. (<FONT STYLE="background-color: white">NASDAQ</FONT>:GIVN), Elron Ventures Ltd. (<FONT STYLE="background-color: white">NASDAQ</FONT>:
ELRN), Alcobra, and Bioblast. Dr. Megiddo is member of the scientific-investment advisory boards to several academic institutes in Israel
including the Technion and Tel Aviv University. Dr. Megiddo holds an MBA from Kellogg-Recanati School of Business, and teaches at various
entrepreneurial programs in Israeli universities. She completed her medical studies at the Hebrew University&rsquo;s Hadassah Medical
School and a specialty program in Family Medicine. After spending a few years as a faculty member in the Family Medicine department at
the Hebrew University in Jerusalem, Dr. Megiddo founded and sold two successful businesses in the medical field: <I>The Journal Club
</I>- Israel&rsquo;s leading provider of Continuing Medical Education for physicians, and <I>Academia Medica</I> &ndash; a medical multimedia
developer and worldwide distributor for Continuing Medical Education programs for physicians. We believe Dr. Megiddo&rsquo;s skills and
experiences as an investor, board member, <FONT STYLE="background-color: white">Chief Development Officer</FONT> and <FONT STYLE="background-color: white">Chief
Medical Officer</FONT>, as well as her professional experience as a practicing physician with drug development capabilities make
her a beneficial addition to our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Tair
Lapidot, Pd.D., Vice President of Research and Development and Clinical Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dr.
Tair Lapidot</I> has served as our Vice President of R&amp;D and Clinical Development since 2019. Since 2002 Dr. Lapidot has been managing
scientific projects and product development activities in the Israel Life-Science industry, from early preclinical research, clinical
trials, and regulatory approval. Dr. Lapidot served as Chief Scientific Officer of Algatech Ltd. (sold to Solabia) from 2016 to 2019.
She served as Director of Product Development &amp; RA at Epitomee Medical (TLV: EPIT) 2010- 2016. She managed analytical and research
activities in Chiasma Inc. (<FONT STYLE="background-color: white">NASDAQ</FONT>: CHMA), BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), and
Compugen Ltd. (NASDAQ: CGEN; TASE: CGEN). Dr. Lapidot received her Ph.D. in Biochemistry from the Hebrew University of Jerusalem and
had graduated Cum Laude Food Technology, B.Sc.Agri, also from the Hebrew University.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Galia
Temtsin Kryaz, Ph.D., Director of CMC and Product Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>Dr.
Galia Temtsin Kryaz, Ph.D. </I>has served as our Director of CMC and Product Development since 2019. Dr. Kryaz serves as CEO of Formulex
Pharma Innovations Ltd., or Formulex, where she has worked for the past 15 years. Dr. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kryaz
<FONT STYLE="background-color: white">received her Ph.D. in chemistry with specialization in organic chemistry and nanomaterials from
Ben-Gurion University of the Negev.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Oren
Elmaliah, Director of Finance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>Mr.
</I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oren Elmaliah</FONT></I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
<FONT STYLE="background-color: white">has served as our Director of Finance since 2019. In September 2015, Oren Elmaliah founded Accounting
Team Ltd., a financial consultancy and service provider to public companies traded in Israel and abroad, and has acted as Account
Manager since then. Since February 2017, Mr. Elmaliah has served as controller of Ayala Pharmaceuticals Inc. (NASDAQ:AYLA), and since
Februray 2022 he has served as Chief Financial Officer of Igentify. In addition, since September 2015, Mr. Elmaliah has served as an
Israel Authorities Reporting Officer of LG Electronics Israel and since September 2015 he has served as Local Financial Report Consultant
of Chiasma Inc. (NASDAQ: CHMA). From May 2017, Oren has served as chairman of the audit committee of Mysize, Inc (NASDAQ: MYSZ).
From July 2011 until August 2015, Mr. Elmaliah served as CPA, Financial Director of CFO Director Ltd. and from June 2010 until July 2011
he served as Risk Management Consultant of RSM International Limited. Mr. Elmaliah holds a Bachelor of Arts in Accounting/Economics and
a Msc. in Finance/Accounting from Tel Aviv University, Israel. He is a licensed Certified Public Accountant in Israel.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Dr. Ronnie Hershman<FONT STYLE="background-color: white">,
Director</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><I>Dr.
</I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif">Ronnie Hershman</FONT></I><FONT STYLE="font-family: Times New Roman, Times, Serif">
is a cardiologist and has served on our board of directors since January 2019. For the last 15 years Dr. Hershman has also been an active
Angel Investor. As an Angel Investor, he is the Founder and Principal Owner of Hershman Holdings LLC, a company he founded in 2004. He
has also been co-founder of several other companies, including HealthEffect in August 2015 and InvestEffect in 2017. Dr. Hershman holds
an M.D. from Icahn School of Medicine at Mount Sinai and a B.S. from Sophie Davis CCNY Center for Biomedical Education. <FONT>We
believe Dr. Hershman&rsquo;</FONT></FONT>s skills and experiences as an active physician and as an experienced healthcare investor combined
with his intimate familiarity with the US healthcare industry make him a beneficial addition to our board of directors.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Family
Relationships</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no family relationships between any members of our executive management and our directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Arrangements
for Election of Directors and Members of Management</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">There
are currently no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our
executive management or our directors were selected (see &ldquo;<I>Related Party Transactions</I>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents in the aggregate all compensation we paid to all of our directors and senior management as a group for the year
ended December 31, 2024. The table does not include any amounts we paid to reimburse any of such persons for costs incurred in
providing us with services during this period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Salary,
                                            Bonuses and Related Benefits</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pension,
                                            Retirement and Other Similar Benefits</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share
                                            Based Compensation </B></FONT></P></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">All directors and senior management
    as a group, consisting of 5 persons</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">513,578</FONT> </TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">16,619</FONT> </TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 14%; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif">4,135</FONT> </TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
so long as we qualify as a foreign private issuer, we will not be required to comply with the proxy rules applicable to U.S. domestic
companies regarding disclosure of the compensation of certain executive officers on an individual basis. Pursuant to Israeli Law, we
will be required, after we become a public company, to disclose the annual compensation of our five most highly compensated officers
on an individual basis. This disclosure will not be as extensive as that required of a U.S. domestic issuer. We intend to commence providing
such disclosure, at the latest, in the annual proxy statement for our first annual meeting of shareholders following the closing of this
offering, which will be filed under cover of a report on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Services
Agreements with Executive Officers</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into written services agreements with each of our executive officers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition
provisions may be limited under applicable law. In addition, we have entered into agreements with each executive officer and director
pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent that these liabilities are not covered
by directors and officers insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">For
a description of the terms of our share options and share option plan (see &ldquo;<I>Management&mdash;Equity Incentive Plan</I><FONT STYLE="font-variant: small-caps">&rdquo;
</FONT>below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"> <I>Employment Agreement with Dan
Teleman, our Chief Executive Officer</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.05pt; text-align: justify"> <I>&nbsp;</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"> On January 6, 2025, we entered
into an agreement with Mr. Dan Teleman, pursuant to which, Mr. Teleman provides us with services as our Chief Executive Officer. Pursuant
to the terms of the services agreement, Mr. Teleman is entitled to a gross monthly salary in the amount of NIS 30,000 ($7,981) as of
the commencement date of January 7, 2025 and until March 2025. As of April 1, 2025, Mr. Teleman is entitled to a gross monthly salary
of NIS 40,000 ($10,641), to be increased to NIS 70,000 ($18,622) as of and subject to consummation of this offering until the first anniversary
of this offering, and thereafter to NIS 75,000 ($19,952) until the second anniversary of this offering and to NIS 80,000 ($21,282) thereafter.
The services agreement also provides for other benefits such as reimbursement of expenses and certain bonus payments, including a one-time
bonus payment of NIS 120,000 ($31,923) upon and subject to consummation of this offering. Both parties may terminate the services agreement
for any reason with 30 days&rsquo; written notice during the first 12 months of employment or with 60 days&rsquo; written notice thereafter.
In addition, pursuant to an option agreement entered into in January 2025, Mr. Teleman was granted share options, with a grant date of
January 16, 2025, to purchase up to 66,845 Ordinary Shares under our 2019 Plan at an exercise price of $28.8409, vesting over a period
of 36 months commencing on January 7, 2025. Mr. Teleman&rsquo;s option grant letter agreement contains an acceleration clause, whereby
the options will become fully vested immediately prior to the closing of any transaction, as defined under the 2019 Plan to mean any
merger in which we no longer continue to exist as a legal entity, or sale of all, or substantially all, of our issued and outstanding
shares to a third party or the sale of all or substantially all of our assets. A transaction, for the avoidance of doubt, does not include
an initial public offering. Any unexercised options will expire ten years from the date they were granted, in accordance with the 2019
Plan. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Services
Agreement with Udi Gilboa, our Co-Founder and Executive Chairman</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify; text-indent: 0.5in">On June 1, 2019,
we entered into an agreement with TopNotch Ltd., a company beneficially owned by Mr. Udi Gilboa, pursuant to which Mr. Gilboa
provides us with services as our Executive Chairman. Pursuant to the terms of the services agreement, Mr. Gilboa is entitled to a monthly
salary in the amount of NIS 20,000 ($5,321), which was increased to NIS 45,000 ($11,971) on May 1, 2020 per an amendment
to the services agreement. In February 2022, Mr. Gilboa agreed to a voluntarily reduction in his monthly salary to NIS 36,000 ($9,577).
In November 2022, Mr. Gilboa again agreed to a voluntarily reduction in his monthly salary to NIS 18,000 ($4,789). The services
agreement also provides for other benefits such as reimbursement of expenses and certain bonus payments. Both parties may terminate the
services agreement for any reason with 90 days&rsquo; written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"><I>Services Agreement with Dr. Dalia Megiddo,
our Co-Founder, Chief Development Officer and Chief Medical Officer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify; text-indent: 0.5in">On June 1, 2019,
we entered into a services agreement with D.M. Medica Ltd., a company beneficially owned by Dr. Dalia Megiddo, pursuant to which
Dr. Megiddo provides us with services as our Chief Executive Officer. Pursuant to the terms of the services agreement, Dr. Megiddo is
entitled to a monthly salary in the amount of NIS 20,000 ($5,321), which was increased to NIS 45,000 ($11,971) on May 1,
2020, per an amendment to the services agreement. In February 2022, Dr. Megiddo agreed to a voluntarily reduction in her monthly salary
to NIS 36,000 ($9,577). In November 2022, she again agreed to a voluntarily reduction in her monthly salary to NIS 18,000 ($4,789)
per month. The services agreement also provides for other benefits such as reimbursement of expenses. The amendment to the services
agreement additionally provides for an annual bonus which is paid out for any top line revenues. Both parties may terminate the services
agreement for any reason with 90 days&rsquo; written notice. On January 7, 2025, Dr. Dalia Megiddo&rsquo;s service as our Chief Executive
Officer has terminated with the appointment of Mr. Dan Teleman as our new Chief Executive Officer. Dr. Dalia Megiddo continues to serve
as our Chief Development Officer and Chief Medical Officer, in addition to her service as our director. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Employment
Agreement with Tair Lapidot, Pd.D., our Vice President of Research and Development and Clinical Development</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify; text-indent: .5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 2, 2019, we entered into an employment agreement with Dr. Tair Lapidot<I>,</I> pursuant to which Dr. Lapidot provides us with services
as our Vice President of Research and Development and Clinical Development. Pursuant to the terms of the services agreement, Dr. Lapidot
is entitled to a monthly salary in the amount of NIS 35,000 ($9,311), which was decreased to NIS 28,000 ($7,449) on March
13, 2022 pursuant to an amendment to the employment agreement. The agreement also provides for other benefits such as reimbursement of
expenses. In addition, pursuant to an option agreement entered into on January 30, 2020, Dr. Lapidot was granted share options (with
a grant date of November 28, 2019) to purchase up to 14,509 Ordinary Shares under our 2019 Plan, with 11,607 options having an exercise
price of $5.85 and 2,902 options having an exercise price of $20.50, vesting over a period of four years commencing on July 17, 2019
and January 30, 2020. Both parties may terminate the services agreement for any reason with 30 days&rsquo; written notice. Pursuant
to an option agreement entered into on January 23, 2023, Dr. Lapidot was granted additional options to purchase 1,915 Ordinary Shares
under our 2019 Plan, with a grant date of January 23, 2023, at an exercise price of $0.01, vesting over a period of 18 months commencing
on January 31, 2023. Dr. Lapidot&rsquo;s option grant letter agreement contains an acceleration clause, whereby the options will become
fully vested after the consummation of an initial public offering or after any transaction, as defined under the 2019 Plan to mean any
merger in which we no longer continue to exist as a legal entity, or sale of all, or substantially all, of our issued and outstanding
shares to a third party or the sale of all or substantially all of our assets. Any unexercised options will expire ten years from the
date they were granted, in accordance with the 2019 Plan. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Services
Agreement with Oren Elmaliah, our Director of Finance</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.05pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 13, 2019, we entered into a consulting services agreement with Accounting Team Ltd., or Accounting Team, a company beneficially
owned by Mr. Oren Elmaliah, pursuant to which Accounting Team provides us with part-time accounting services in consideration for a
monthly fee of NIS 2,000 ($532). Pursuant to an amendment dated December 5, 2024, we have ratified the agreement to reflect
that as of February 1, 2021, Accounting Team has been entitled to a monthly fee of NIS 8,000 ($2,128). Accounting Team is also entitled to receive an aggregate amount of NIS 325,000 ($86,459) in connection with accounting
services related to this offering and will be entitled to a one-time payment of NIS 250,000 ($66,507) upon and subject to consummation
of this offering. On December 5, 2024,
we have also entered into a separate consulting agreement directly with Mr. Elmaliah, reflecting that since August 1, 2020, we have
engaged Mr. Elmaliah directly as our part time external Director of Finance. Under such agreement, Mr. Elmaliah is entitled to an
additional monthly fee of NIS 2,000 ($532) with effect from such date. In addition, pursuant to an option agreement entered
into in January 2020, Mr. Elmaliah was granted share options, with a grant date of November 28, 2019, to purchase up to 5,803
Ordinary Shares under our 2019 Plan at an exercise price of $5.85, vesting over a period of four years commencing on June 13, 2019.
Mr. Elmaliah&rsquo;s option grant letter agreement contains an acceleration clause, whereby the options will become fully vested six
months after the consummation of an initial public offering or six months after any transaction, as defined under the 2019 Plan to
mean any merger in which we no longer continue to exist as a legal entity, or sale of all, or substantially all, of our issued and
outstanding shares to a third party or the sale of all or substantially all of our assets. Pursuant to an option agreement
entered into in January 2025, Mr. Elmaliah was granted additional share options, with a grant date of January 16, 2025, to purchase
up to 5,803 Ordinary Shares under our 2019 Plan at an exercise price of $28.8409, vesting over a period of 36 months commencing on
January 7, 2025. Mr. Elmaliah&rsquo;s option grant letter agreement contains an acceleration clause, whereby the options will become
fully vested immediately prior to the closing of any transaction, as defined under the 2019 Plan to mean any merger in which we no
longer continue to exist as a legal entity, or sale of all, or substantially all, of our issued and outstanding shares to a third
party or the sale of all or substantially all of our assets. A transaction, for the avoidance of doubt, does not include an initial
public offering. Any unexercised options will expire ten years from the date they were granted, in accordance with the 2019
Plan. Both parties may terminate the services agreement for any reason with 60 days&rsquo; written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Directors&rsquo;
Service Contracts</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than with respect to our directors that are also executive officers, we do not have written agreements with any director providing for
benefits upon the termination of his employment with our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Differences
between the Companies Law and NYSE American Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Sarbanes-Oxley Act, as well as related rules subsequently implemented by the SEC, require foreign private issuers, such as us, to comply
with various corporate governance practices. In addition, following the listing of the Ordinary Shares on the NYSE American, we will
be required to comply with NYSE American rules. Under those rules, we may elect to follow certain corporate governance practices permitted
under the Companies Law in lieu of compliance with corresponding corporate governance requirements otherwise imposed by the NYSE American
rules for U.S. domestic issuers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Israeli law and practice and subject to the exemption set forth in NYSE American Section 110, we have elected to follow
the provisions of the Companies Law, rather than the NYSE American rules, with respect to the following requirements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &#9679; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quorum.
                                            While NYSE American Section 123 recommends a quorum of at least 33.33%, under Israeli law,
                                            a company is entitled to determine in its articles of association the number of shareholders
                                            and percentage of holdings required for a quorum at a shareholders meeting. Our amended and
                                            restated articles of association will provide that a quorum of two or more shareholders holding
                                            at least 25% of the voting rights in person or by proxy is required for commencement of business
                                            at a general meeting. However, the quorum set forth in our amended and restated articles
                                            of association with respect to an adjourned meeting consists of at least one shareholders
                                            present in person or by proxy.</FONT> </TD></TR>
                                                                                                                                      <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nomination
of our directors. With the exception of directors elected by our board of directors and external directors, our directors are elected
by an annual meeting of our shareholders (i) to hold office until the next annual meeting following his or her election or (ii) for three-year
term, as described below under &ldquo;<I>Management&mdash;Board Practices&mdash;External Directors</I>.&rdquo; The nominations for directors,
which are presented to our shareholders by our board of directors, are generally made by the board of directors itself, in accordance
with the provisions of our amended and restated articles of association and the Companies Law. Nominations need not be made by a nominating
committee of our board of directors consisting solely of independent directors, as required under NYSE American Section 804.</FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation
                                            of officers. Israeli law and our amended and restated articles of association do not require
                                            that the independent members of our board of directors (or a compensation committee composed
                                            solely of independent members of our board of directors) determine an executive officer&rsquo;s
                                            compensation, as is generally required under NYSE American Section 805 with respect to the
                                            chief executive officer and all other executive officers. Instead, compensation of executive
                                            officers is determined and approved by our compensation committee and our board of directors,
                                            and in certain circumstances by our shareholders, either in consistency with our office holder
                                            compensation policy or, in special circumstances in deviation therefrom, taking into account
                                            certain considerations stated in the Companies Law (see &ldquo;<I>Management&mdash;Board
                                            Practices&mdash;Approval of Related Party Transactions under Israeli Law</I>&rdquo;).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent
                                            directors. Israeli law does not require that a majority of the directors serving on our board
                                            of directors be &ldquo;independent,&rdquo; as defined under NYSE American Section 803(A),
                                            and rather requires we have at least two external directors who meet the requirements of
                                            the Companies Law, as described above under &ldquo;<I>Management &mdash; Board Practices
                                            &mdash; External Directors,</I>&rdquo; as opposed to NYSE American Section
                                            802(a) that prescribes that a majority of the directors sitting on the board of directors
                                            must be independent. We are required, however, to ensure that all members of our Audit Committee
                                            are &ldquo;independent&rdquo; under NYSE American Section 803(B)(1) and under the SEC criteria
                                            for independence and we must also ensure that a majority of the members of our Audit Committee
                                            are &ldquo;independent directors&rdquo; as defined in the Companies Law. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
                                            approval. We will seek shareholder approval for all corporate actions requiring such approval
                                            under the requirements of the Companies Law, rather than seeking approval for corporation
                                            actions in accordance with NYSE American rules. In particular, under NYSE American Section
                                            711, shareholder approval is required in accordance with respect to the establishment or
                                            material amendment to a stock option or purchase plan or other equity compensation arrangement
                                            pursuant to which options or stock may be acquired by officers, employees, or consultants,
                                            regardless of whether or not such authorization is required by law or by the company&rsquo;s
                                            charter, with certain exceptions. By contrast, under the Companies Law, shareholder approval
                                            is required for, among other things: (i) transactions with directors concerning the terms
                                            of their service or indemnification, exemption and insurance for their service (or for any
                                            other position that they may hold at a company), for which approvals of the compensation
                                            committee, board of directors and shareholders are all required, (ii) extraordinary transactions
                                            with controlling shareholders of publicly held companies, which require the special approval,
                                            and (iii) terms of employment or other engagement of the controlling shareholder of us or
                                            such controlling shareholder&rsquo;s relative, which require special approval. In addition,
                                            under the Companies Law, a merger requires approval of the shareholders of each of the merging
                                            companies.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual
                                            Shareholders Meeting. As opposed to NYSE American Section 704, which mandates that a listed
                                            company hold its annual shareholders meeting within one year of the company&rsquo;s fiscal
                                            year-end, we are required, under the Companies Law, to hold an annual shareholders meeting
                                            each calendar year and within 15 months of the last annual shareholders meeting.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
                                            Structure. As opposed to NYSE American Section 802(d), which mandates that the board of directors
                                            may not classified into more than three classes of approximately equal size and tenure, with
                                            no individual director&rsquo;s term exceeding three years, and with a majority of the directors
                                            standing for re-election within every consecutive two-year period, it is required, under
                                            the Companies Law and our articles of association, that each director, except external directors
                                            (if applicable), will hold office until the following annual general meeting of our shareholders
                                            following their appointment, or until they resign or are removed by a majority vote of our
                                            shareholders at a general meeting of our shareholders or upon the occurrence of certain events.
                                            The directors are classified, with respect to the term for which they each severally hold
                                            office, into three classes, as equal in number as practicable, and designated as Class I,
                                            Class II and Class III. The board of directors may assign members of the board of directors
                                            already in office to such classes at the time such classification becomes effective. If the
                                            number of directors is changed, any newly created directors or decrease in directors must
                                            be apportioned by the board of directors among the classes to make them equal in number.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating
                                            Committee. As opposed to NYSE American Section 804(a) that mandates that the board of director
                                            nominations must be either selected, or recommended for the board&rsquo;s selection, by either
                                            a Nominating Committee comprised solely of independent directors or by a majority of the
                                            independent directors and that a company must adopt a formal written charter or board resolution
                                            addressing the nominations process and such related matters, we are required, under the Companies
                                            Law and our articles of association, with the exception of directors elected by our board
                                            of directors and external directors, to elect directors in an annual meeting of our shareholders
                                            (i) to hold office until the next annual meeting following their election or (ii) for a three-year
                                            term. The nominations for directors, which are presented to our shareholders by our board
                                            of directors, are generally made by the board of directors.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
                                            Notice. As opposed to NYSE American Section 703, that mandates each issuer to provide shareholders
                                            with written notice at least 10 days in advance of all shareholder meetings and to provide
                                            for such notice in its by-laws, we are required, under Companies Law and our articles of
                                            association, to provide either 14 or 21 days written notice. If the agenda of the meeting
                                            involves the appointment or removal of directors, the approval of transactions with office
                                            holders, interested or related parties, the approval of the general manager to serve as the
                                            chairman of the board of directors, or an approval of a merger, notice must be provided at
                                            least 35 days prior to the meeting. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Practices</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Introduction</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors presently consists of three members, as the Companies Law does not mandate the appointment of external
directors to the board. Immediately following the completion of this offering, our board is expected to consist of seven directors.
Based upon information requested from and provided by each director concerning such director&rsquo;s background, employment and affiliations,
including family relationships, our board of directors determined that, four members of our directors following the completion of this
offering, are &ldquo;independent directors&rdquo; as defined under the listing standards of the NYSE American rules. Our amended and
restated articles of association provide that the number of board of directors&rsquo; members (including external directors) shall be
set by the general meeting of the shareholders provided that it will consist of not less than two and not more than nine. Pursuant to
the Companies Law, the management of our business is vested in our board of directors. Our board of directors may exercise all powers
and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible
for our day-to-day management and have individual responsibilities established by our board of directors. Our Chief Executive Officer
is appointed by, and serves at the discretion of, our board of directors, subject to the employment agreement that we have entered into
with him. All other executive officers are appointed by our Chief Executive Officer. Their terms of employment are subject to the approval
of the board of directors&rsquo; compensation committee and of the board of directors, and are subject to the terms of any applicable
employment agreements that we may enter into with them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
director, except external directors, will hold office until the next annual general meeting of our shareholders following his or her
appointment, or until he or she resigns or unless he or she is removed by a majority vote of our shareholders at a general meeting of
our shareholders or upon the occurrence of certain events, in accordance with the Companies Law and our amended and restated articles
of association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under certain circumstances, our amended and restated articles of association allow our board of directors to appoint directors
to fill vacancies on our board of directors or in addition to the acting directors (subject to the limitation on the number of directors),
until the next annual general meeting or special general meeting in which directors may be appointed or terminated. External directors
may be elected for up to two additional three-year terms after their initial three-year term under the circumstances described below,
with certain exceptions as described in &ldquo;External Directors&rdquo; below. External directors may be removed from office only under
the limited circumstances set forth in the Companies Law (see &ldquo;<I>Management&mdash;Board Practices&mdash;External Directors</I>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law and regulations promulgated thereunder, any shareholder of the Company holding at least five percent of our outstanding
voting power may nominate a director. However, any such shareholder may make such a nomination only if a written notice of such shareholder&rsquo;s
intent to make such nomination has been given to our board of directors. Any such notice must include certain information, including
the consent of the proposed director nominee to serve as our director if elected, and a declaration that the nominee signed declaring
that he or she possesses the requisite skills and has the availability to carry out his or her duties. Additionally, the nominee must
provide details of such skills, and demonstrate an absence of any limitation under the Companies Law that may prevent his or her election,
and affirm that all of the required election-information is provided to us, pursuant to the Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, our board of directors must determine the minimum number of directors who are required to have accounting and financial
expertise. In determining the number of directors required to have such expertise, our board of directors must consider, among other
things, the type and size of the company and the scope and complexity of its operations. Our board of directors has determined that the
minimum number of directors of our company who are required to have accounting and financial expertise is two.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors must elect one director to serve as the chairman of the board of directors to preside at the meetings of the board
of directors, and may also remove that director as chairman. Pursuant to the Companies Law, neither the chief executive officer nor any
of his or her relatives is permitted to serve as the chairman of the board of directors, and a company may not vest the chairman or any
of his or her relatives with the chief executive officer&rsquo;s authorities. In addition, a person who reports, directly or indirectly,
to the chief executive officer may not serve as the chairman of the board of directors; the chairman may not be vested with authorities
of a person who reports, directly or indirectly, to the chief executive officer; and the chairman may not serve in any other position
in the company or a controlled company, but he or she may serve as a director or chairman of a controlled company. However, the Companies
Law permits a company&rsquo;s shareholders to determine, for a period not exceeding three years from each such determination, that the
chairman or his or her relative may serve as chief executive officer or be vested with the chief executive officer&rsquo;s authorities,
and that the chief executive officer or his or her relative may serve as chairman or be vested with the chairman&rsquo;s authorities.
Such determination of a company&rsquo;s shareholders requires either: (1) the approval of at least a majority of the shares of those
shareholders present and voting on the matter (other than controlling shareholders and those having a personal interest in the determination)
(shares held by abstaining shareholders shall not be considered); or (2) that the total number of shares opposing such determination
does not exceed 2% of the total voting power in the company. Currently, we have a separate chairman and chief executive officer. In accordance
with the Companies Law regulations, such determination of a company&rsquo;s shareholders that was made after a company first offered
its securities to the public, or that the company described in the prospectus, will be for a period not exceeding five years from the
date the company became public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors may, subject to the provisions of the Companies Law, delegate any or all of its powers to committees of the board,
and it may, from time to time, revoke such delegation or alter the composition of any such committees, subject to certain limitations.
Unless otherwise expressly provided by the board of directors, the committees shall not be empowered to further delegate such powers.
The composition and duties of our audit committee, financial statement examination committee and compensation committee are described
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors oversees how management monitors compliance with our risk management policies and procedures, and reviews the adequacy
of the risk management framework in relation to the risks faced by us. The board of directors will be assisted in its oversight
role by an internal auditor. The internal auditor will undertake both regular and ad hoc reviews of risk management controls
and procedures, the results of which are reported to our audit committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>External
Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Companies Law, an Israeli company whose shares have been offered to the public or whose shares are listed for trading on a stock
exchange in or outside of Israel is required to appoint at least two external directors to serve on its board of directors. External
directors must meet stringent standards of independence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to regulations promulgated under the Companies law, at least one of the external directors is required to have &ldquo;financial and
accounting expertise,&rdquo; unless another member of the audit committee, who is an independent director under NYSE American rules,
has &ldquo;financial and accounting expertise,&rdquo; and the other external director or directors are required to have
&ldquo;professional expertise.&rdquo; An external director may not be appointed to an additional term unless: (1) such director has
&ldquo;accounting and financial expertise;&rdquo; or (2) he or she has &ldquo;professional expertise,&rdquo; and on the date of
appointment for another term there is another external director who has &ldquo;accounting and financial expertise&rdquo; and the
number of &ldquo;accounting and financial experts&rdquo; on the board of directors is at least equal to the minimum number
determined appropriate by the board of directors. We have determined that both &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have accounting and financial expertise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
director with accounting and financial expertise is a director who, due to his or her education, experience and skills, possesses a high
degree of proficiency in, and an understanding of, business &ndash; accounting matters and financial statements, such that he or she
is able to understand the financial statements of the company in depth and initiate a discussion about the manner in which financial
data is presented. A director is deemed to have &ldquo;professional expertise&rdquo; if he or she holds an academic degree in certain
fields or has at least five years of experience in certain senior positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">External
directors are elected by a majority vote at a shareholders&rsquo; meeting, as long as either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
                                            least a majority of the shares held by shareholders who are not controlling shareholders
                                            and do not have personal interest in the appointment (excluding a personal interest that
                                            did not result from the shareholder&rsquo;s relationship with the controlling shareholder)
                                            have voted in favor of the proposal (shares held by abstaining shareholders shall not be
                                            considered); or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            total number of shares voted by non-controlling shareholders and by shareholders who do not
                                            have a personal interest in the election of the external director, against the election of
                                            the external director, does not exceed 2% of the aggregate voting rights of the company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;control&rdquo; is defined in the Companies Law as the ability to direct the activities of the company, other than by virtue
of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder &ldquo;holds&rdquo; (within the
meaning of the Companies Law) 50% or more of the voting rights in a company or has the right to appoint 50% or more of the directors
of the company or its general manager. With respect to certain matters, a controlling shareholder is deemed to include a shareholder
that holds 25% or more of the voting rights in a public company if no other shareholder holds more than 50% of the voting rights in the
company, but excludes a shareholder whose power derives solely from his or her position as a director of the company or from any other
position with the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law provides for an initial three-year term for an external director. Thereafter, an external director may be reelected by
shareholders to serve in that capacity for up to two additional three-year terms, provided that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">his
                                            or her service for each such additional term is recommended by one or more shareholders holding
                                            at least one percent of the company&rsquo;s voting rights and is approved at a shareholders
                                            meeting by a disinterested majority, where the total number of shares held by non-controlling,
                                            disinterested shareholders voting for such reelection exceeds two percent of the aggregate
                                            voting rights in the company and subject to additional restrictions set forth in the Companies
                                            Law with respect to the affiliation of the external director nominee, herein a Special Majority,
                                            as described below;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">his
                                            or her service for each such additional term is recommended by the board of directors and
                                            is approved at a shareholders meeting by the same disinterested majority required for the
                                            initial election of an external director (as described above); or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            external director offered his or her service for each such additional term and was approved
                                            by a Special Majority.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of office for external directors for Israeli companies traded on certain foreign stock exchanges, including the NYSE American, may
be extended indefinitely in increments of additional three-year terms, in each case provided that the audit committee and the board of
directors of the company confirm that, in light of the external director&rsquo;s expertise and special contribution to the work of the
board of directors and its committees, the reelection for such additional period(s) is beneficial to the company, and provided that the
external director is reelected subject to the same shareholder vote requirements as if elected for the first time (as described above).
Prior to the approval of the reelection of the external director at a general shareholders meeting, the company&rsquo;s shareholders
must be informed of the term previously served by him or her and of the reasons why the board of directors and audit committee recommended
the extension of his or her term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law provides that a person is not qualified to serve as an external director if (i) the person is a relative of a controlling
shareholder of the company, or (ii) if that person or his or her relative, partner, employer, another person to whom he or she was directly
or indirectly subordinate, or any entity under the person&rsquo;s control, has or had, during the two years preceding the date of appointment
as an external director: (a) any affiliation or other disqualifying relationship with the company, with any person or entity controlling
the company or a relative of such person, or with any entity controlled by or under common control with the company; or (b) in the case
of a company with no shareholder holding 25% or more of its voting rights, had at the date of appointment as an external director, any
affiliation or other disqualifying relationship with a person then serving as chairman of the board or chief executive officer, with
a holder of 5% or more of the issued share capital or voting power in the company or with the most senior financial officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;relative&rdquo; is defined under the Companies Law as a spouse, sibling, parent, grandparent or descendant; spouse&rsquo;s
sibling, parent or descendant; and the spouse of each of the foregoing persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the term &ldquo;affiliation&rdquo; and the similar types of disqualifying relationships include (subject to certain
exceptions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            employment relationship;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            business or professional relationship even if not maintained on a regular basis (excluding
                                            insignificant relationships);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">control;
                                            and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">service
                                            as an office holder, excluding service as a director in a private company prior to the initial
                                            public offering of its shares if such director was appointed as a director of the private
                                            company in order to serve as an external director following the initial public offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term &ldquo;office holder&rdquo; is defined under the Companies Law as a general manager, chief business manager, deputy general manager,
vice general manager, any other person assuming the responsibilities of any of these positions regardless of that person&rsquo;s title,
a director and any other manager directly subordinate to the general manager.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, no person may serve as an external director if that person&rsquo;s position or professional or other activities create, or
may create, a conflict of interest with that person&rsquo;s responsibilities as a director or otherwise interfere with that person&rsquo;s
ability to serve as a director or if the person is an employee of the Israel Securities Authority or of an Israeli stock exchange. A
person may furthermore not continue to serve as an external director if he or she received direct or indirect compensation from the company
including amounts paid pursuant to indemnification and/or exculpation contracts or commitments and insurance coverage, other than for
his or her service as an external director as permitted by the Companies Law and the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the termination of an external director&rsquo;s service on a board of directors, such former external director and his or her spouse
and children may not be provided a direct or indirect benefit by the company, its controlling shareholder or any entity under its controlling
shareholder&rsquo;s control. This includes engagement as an office holder or director of the company or a company controlled by its controlling
shareholder or employment by, or provision of services to, any such company for consideration, either directly or indirectly, including
through a corporation controlled by the former external director. This restriction extends for a period of two years with regard to the
former external director and his or her spouse or child and for one year with respect to other relatives of the former external director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">External
directors may be removed only by a special general meeting of shareholders called by the board of directors after the board has determined
the occurrence of circumstances allow such dismissal, at the same special majority of shareholders required for their election or by
a court, and in both cases only if the external directors cease to meet the statutory qualifications for their appointment or if they
violate their duty of loyalty to our company. In the event of a vacancy created by an external director which causes the company to have
fewer than two external directors, the board of directors is required under the Companies Law to call a shareholders meeting as soon
as possible to appoint such number of new external directors in order that the company thereafter has two external directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">External
directors may be compensated only in accordance with regulations adopted under the Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
at the time at which an external director is appointed all members of the board of directors who are not controlling shareholders or
relatives of controlling shareholders of the company are of the same gender, the external director to be appointed must be of the other
gender. A director of a company may not be appointed as an external director of another company if at the same time a director of such
other company is acting as an external director of the first company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
regulations promulgated pursuant to the Companies Law, a company with no controlling shareholder whose shares are listed for trading
on specified exchanges outside of Israel, including NYSE American, may adopt exemptions from various corporate governance requirements
of the Companies Law, so long as such company satisfies the requirements of applicable foreign country laws and regulations, including
applicable stock exchange rules, that apply to companies organized in that country and relating to the appointment of independent directors
and the composition of audit and compensation committees. Such exemptions include an exemption from the requirement to appoint external
directors and the requirement that an external director be a member of certain committees, as well as exemption from limitations on directors&rsquo;
compensation. We may use these exemptions in the future if we do not have a controlling shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Independent
Directors Under the Companies Law</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
&ldquo;independent director&rdquo; is either an external director or a director who meets the same non-affiliation criteria as an external
director (except for (i) the requirement that the director be an Israeli resident (which does not apply to companies such as ours whose
securities have been offered outside of Israel or are listed outside of Israel) and (ii) the requirement for accounting and financial
expertise or professional qualifications), as determined by the audit committee, and who has not served as a director of the company
for more than nine consecutive years. For these purposes, ceasing to serve as a director for a period of two years or less would not
be deemed to sever the consecutive nature of such director&rsquo;s service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulations
promulgated pursuant to the Companies Law provide that a director in a public company whose shares are listed for trading on specified
exchanges outside of Israel, including NYSE American, who qualifies as an independent director under the relevant non-Israeli rules and
who meets certain non-affiliation criteria, which are less stringent than those applicable to independent directors as set forth above,
would be deemed an &ldquo;independent&rdquo; director pursuant to the Companies Law provided: (i) he or she has not served as a director
for more than nine consecutive years; (ii) he or she has been approved as such by the audit committee; and (iii) his or her remuneration
shall be in accordance with the Companies Law and the regulations promulgated thereunder. For these purposes, ceasing to serve as a director
for a period of two years or less would not be deemed to sever the consecutive nature of such director&rsquo;s service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
pursuant to these regulations, such company may reappoint a person as an independent director for additional terms, beyond nine years,
which do not exceed three years each, if each of the audit committee and the board of directors determine, in that order, that in light
of the independent director&rsquo;s expertise and special contribution to the board of directors and its committees, the reappointment
for an additional term is in the company&rsquo;s best interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Alternate
Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
amended and restated articles of association provide, as allowed by the Companies Law, that any director may, subject to the conditions
set thereto including approval of the nominee by our board of directors, appoint a person as an alternate to act in his place, to remove
the alternate and appoint another in his place and to appoint an alternate in place of an alternate whose office is vacated for any reason
whatsoever. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who is already serving as
a director or a person who is already serving as an alternate director for another director, may not be appointed as an alternate director.
Nevertheless, a director who is already serving as a director may be appointed as an alternate director for a member of a committee of
the board of directors so long as he or she is not already serving as a member of such committee, and if the alternate director is to
replace an external director, he or she is required to be an external director and to have either &ldquo;financial and accounting expertise&rdquo;
or &ldquo;professional expertise,&rdquo; depending on the qualifications of the external director he or she is replacing. A person who
does not have the requisite &ldquo;financial and accounting experience&rdquo; or the &ldquo;professional expertise,&rdquo; depending
on the qualifications of the external director he or she is replacing, may not be appointed as an alternate director for an external
director. A person who is not qualified to be appointed as an independent director, pursuant to the Companies Law, may not be appointed
as an alternate director of an independent director qualified as such under the Companies Law. Unless the appointing director limits
the time or scope of the appointment, the appointment is effective for all purposes until the appointing director ceases to be a director
or terminates the appointment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Committees
of the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors will establish three standing committees, the audit committee, the compensation committee and the Financial
Statement Examination Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Audit
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, we are required to appoint an audit committee. The audit committee must be comprised of at least three directors,
including all of the external directors (one of whom must serve as chairman of the committee). The audit committee may not include the
chairman of the board; a controlling shareholder of the company or a relative of a controlling shareholder; a director employed by or
providing services on a regular basis to the company, to a controlling shareholder or to an entity controlled by a controlling shareholder;
or a director who derives most of his or her income from a controlling shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a majority of the members of the audit committee of a publicly traded company must be independent directors under the
Companies Law. Our audit committee will be comprised of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, our audit committee is responsible for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
                                            whether there are deficiencies in the business management practices of our company, and making
                                            recommendations to the board of directors to improve such practices;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
                                            whether to approve certain related party transactions (including transactions in which an
                                            office holder has a personal interest and whether such transaction is extraordinary or material
                                            under Companies Law) and establishing the approval process for certain transactions with
                                            a controlling shareholder or in which a controlling shareholder has a personal interest (see
                                            &ldquo;<I>Management&mdash;Board Practices&mdash;Approval of Related Party Transactions under
                                            Israeli law</I>&rdquo;);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
                                            the approval process for transactions that are &ldquo;non-negligible&rdquo; (i.e., transactions
                                            with a controlling shareholder that are classified by the audit committee as non-negligible,
                                            even though they are not deemed extraordinary transactions), as well as determining which
                                            types of transactions would require the approval of the audit committee, optionally based
                                            on criteria which may be determined annually in advance by the audit committee;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining
                                            our internal controls and internal auditor&rsquo;s performance, including whether the internal
                                            auditor has sufficient resources and tools to dispose of its responsibilities;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">examining
                                            the scope of our auditor&rsquo;s work and compensation and submitting a recommendation with
                                            respect thereto to our board of directors or shareholders, depending on which of them is
                                            considering the appointment of our auditor;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing
                                            procedures for the handling of employees&rsquo; complaints as to deficiencies in the management
                                            of our business and the protection to be provided to such employees; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">where
                                            the board of directors approves the working plan of the internal auditor, examining such
                                            working plan before its submission to the board of directors and proposing amendments thereto.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audit committee may not conduct any discussions or approve any actions requiring its approval (see &ldquo;<I>Management&mdash;Board Practices&mdash;Approval
of Related Party Transactions under Israeli law</I>&rdquo;), unless at the time of the approval a majority of the committee&rsquo;s members
are present, which majority consists of independent directors under the Companies Law, including at least one external director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors intends to adopt an audit committee charter to be effective upon the listing of our Ordinary Shares on NYSE American
setting forth, among others, the responsibilities of the audit committee consistent with the rules of the SEC and NYSE American Rules
(in addition to the requirements for such committee under the Companies Law), including, among others, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">oversight
                                            of our independent registered public accounting firm and recommending the engagement, compensation
                                            or termination of engagement of our independent registered public accounting firm to the
                                            board of directors in accordance with Israeli law;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            the engagement or termination of the person filling the office of our internal auditor, reviewing
                                            the services provided by our internal auditor and reviewing effectiveness of our system of
                                            internal control over financial reporting;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            the terms of audit and non-audit services provided by the independent registered public accounting
                                            firm for pre-approval by our board of directors; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
                                            and monitoring, if applicable, legal matters with significant impact, finding of regulatory
                                            authorities&rsquo; findings, receive reports regarding irregularities and legal compliance,
                                            acting according to &ldquo;whistleblower policy&rdquo; and recommend to our board of directors
                                            if so required.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>NYSE
American Requirements for Audit Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the NYSE American rules, we are required to maintain an audit committee consisting of at least three members, each of whom is independent
and financially literate, and at least one of whom has accounting or related financial management expertise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
noted above, the members of our audit committee include &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who are external directors, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; who is an independent director,
each of whom is &ldquo;independent,&rdquo; as such term is defined in under NYSE American rules. serves as the chairman of our audit
committee. All members of our audit committee meet the requirements for financial literacy under the NYSE American rules. Our board
of directors has determined that each member of our audit committee is an audit committee financial expert as defined by the SEC
rules and has the requisite financial experience as defined by the NYSE American rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financial
Statement Examination Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the board of directors of a public company incorporated in Israel must appoint a financial statement examination committee,
which consists of members with accounting and financial expertise or the ability to read and understand financial statements. Our financial
statement examination committee will be comprised of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The function of a financial statements examination committee is to discuss
and provide recommendations to its board of directors (including the report of any deficiency found) with respect to the following issues:
(1) estimations and assessments made in connection with the preparation of financial statements; (2) internal controls related to the
financial statements; (3) completeness and propriety of the disclosure in the financial statements; (4) the accounting policies adopted
and the accounting treatments implemented in material matters of the company; and (5) value evaluations, including the assumptions and
assessments on which evaluations are based and the supporting data in the financial statements. Our independent registered public accounting
firm and our internal auditor are invited to attend all meetings of our financial statements examination committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compensation
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the board of directors of any public company must establish a compensation committee. The compensation committee must
be comprised of at least three directors, including all of the external directors, who must constitute a majority of the members of the
compensation committee. Each compensation committee member that is not an external director must be a director whose compensation does
not exceed an amount that may be paid to an external director. The compensation committee is subject to the same Companies Law restrictions
as the audit committee as to: (a) who may not be a member of the committee; and (b) who may not be present during committee deliberations
as described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee will act pursuant to a written charter, and will be comprised of&nbsp;&nbsp;&nbsp;, and&nbsp;&nbsp;&nbsp;.
Our compensation committee will comply with the provisions of the Companies Law, the regulations promulgated thereunder, and our
amended and restated articles of association, on all aspects referring to its independence, authorities and practice. Our
compensation committee will follow home country practice as opposed to complying with the compensation committee membership and
charter requirements prescribed under the NYSE American rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation committee will review and recommend to our board of directors: with respect to our executive officers&rsquo; and directors&rsquo;:
(1) annual base compensation (2) annual incentive bonus, including the specific goals and amounts; (3) equity compensation; (4) employment
agreements, severance arrangements, and change in control agreements and provisions; (5) retirement grants and/or retirement bonuses;
and (6) any other benefits, compensation, compensation policies or arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duties of the compensation committee include the recommendation to the company&rsquo;s board of directors of a policy regarding the terms
of engagement of office holders, to which we refer as a compensation policy. Such policy must be adopted by the company&rsquo;s board
of directors, after considering the recommendations of the compensation committee. The compensation policy is then brought for approval
by our shareholders, which requires a special majority (see &ldquo;<I>Management&mdash;Board Practices&mdash;Approval of Related Party
Transactions under Israeli law</I>&rdquo;). Under the Companies Law, the board of directors may adopt the compensation policy if it is
not approved by the shareholders, provided that after the shareholders oppose the approval of such policy, the compensation committee
and the board of directors revisit the matter and determine that adopting the compensation policy would be in the best interests of the
company. Our compensation policy was approved by our shareholders on January 23, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of executive officers
and directors, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment
or engagement. The compensation policy must relate to certain factors, including advancement of the company&rsquo;s objectives, the company&rsquo;s
business and its long-term strategy, and creation of appropriate incentives for executives. It must also consider, among other things,
the company&rsquo;s risk management, size and the nature of its operations. The compensation policy must furthermore consider the following
additional factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            education, skills, expertise and accomplishments of the relevant director or executive;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            director&rsquo;s or executive&rsquo;s roles and responsibilities and prior compensation agreements
                                            with him or her;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            relationship between the cost of the terms of service of an office holder and the average
                                            median compensation of the other employees of the company (including those employed through
                                            manpower companies), including the impact of disparities in salary upon work relationships
                                            in the company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            possibility of reducing variable compensation at the discretion of the board of directors;
                                            and the possibility of setting a limit on the exercise value of non-cash variable compensation;
                                            and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            to severance compensation, the period of service of the director or executive, the terms
                                            of his or her compensation during such service period, the company&rsquo;s performance during
                                            that period of service, the person&rsquo;s contribution towards the company&rsquo;s achievement
                                            of its goals and the maximization of its profits, and the circumstances under which the person
                                            is leaving the company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation policy must also include the following principles:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
                                            the exception of office holders who report directly to the chief executive officer, the link
                                            between variable compensation and long-term performance and measurable criteria;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            relationship between variable and fixed compensation, and the ceiling for the value of variable
                                            compensation at the time of its grant;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            conditions under which a director or executive would be required to repay compensation paid
                                            to him or her if it was later shown that the data upon which such compensation was based
                                            was inaccurate and was required to be restated in the company&rsquo;s financial statements;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            minimum holding or vesting period for variable, equity-based compensation; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">maximum
                                            limits for severance compensation.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation policy must also consider appropriate incentives from a long-term perspective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation committee is responsible for: (1) recommending the compensation policy to a company&rsquo;s board of directors for its approval
(and subsequent approval by the shareholders); and (2) duties related to the compensation policy and to the compensation of a company&rsquo;s
office holders, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            whether a compensation policy should continue in effect, if the then-current policy has a
                                            term of greater than three years (approval of either a new compensation policy or the continuation
                                            of an existing compensation policy must in any case occur every three years);</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
                                            to the board of directors periodic updates to the compensation policy;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assessing
                                            implementation of the compensation policy;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
                                            whether the terms of compensation of certain office holders of the company need not be brought
                                            to approval of the shareholders; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determining
                                            whether to approve the terms of compensation of office holders that require the committee&rsquo;s
                                            approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation policy is designed to promote our long-term goals, work plan and policy, retain, motivate and incentivize our directors
and executive officers, while considering the risks that our activities involve, our size, the nature and scope of our activities and
the contribution of an officer to the achievement of our goals and maximization of profits, and align the interests of our directors
and executive officers with our long-term performance. To that end, a portion of an executive officer compensation package is targeted
to reflect our short and long-term goals, as well as the executive officer&rsquo;s individual performance. On the other hand, our compensation
policy includes measures designed to reduce the executive officer&rsquo;s incentives to take excessive risks that may harm us in the
long-term, such as limits on the value of cash bonuses and equity-based compensation, limitations on the ratio between the variable and
the total compensation of an executive officer and minimum vesting periods for equity-based compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation policy also addresses our executive officer&rsquo;s individual characteristics (such as his or her respective position,
education, scope of responsibilities and contribution to the attainment of our goals) as the basis for compensation variation among our
executive officers, and considers the internal ratios between compensation of our executive officers and directors and other employees.
Pursuant to our compensation policy, the compensation that may be granted to an executive officer may include: base salary, annual bonuses,
equity-based compensation, benefits and retirement and termination of service arrangements. All cash bonuses are limited to a maximum
amount linked to the executive officer&rsquo;s base salary. In addition, our compensation policy provides for maximum permitted ratios
between the total variable (cash bonuses and equity based compensation) and non-variable (base salary) compensation components, in accordance
with an officer&rsquo;s respective position with the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
annual cash bonus may be awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The
annual cash bonus that may be granted to executive officers other than our chairman or Chief Executive Officer may be based entirely
on a discretionary evaluation. Our Chief Executive Officer will be entitled to recommend performance objectives to such executive officers,
and such performance objectives will be approved by our compensation committee (and, if required by law, by our board of directors).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
performance measurable objectives of our chairman and Chief Executive Officer will be determined annually by our compensation committee
and board of directors. A less significant portion of the chairman&rsquo;s and/or the Chief Executive Officer&rsquo;s annual cash bonus
may be based on a discretionary evaluation of the chairman&rsquo;s or the Chief Executive Officer&rsquo;s respective overall performance
by the compensation committee and the board of directors based on quantitative and qualitative criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
equity-based compensation under our compensation policy for our executive officers (including members of our board of directors) is designed
in a manner consistent with the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives
being to enhance the alignment between the executive officers&rsquo; interests with our long-term interests and those of our shareholders
and to strengthen the retention and the motivation of executive officers in the long term. Our compensation policy provides for executive
officer compensation in the form of share options or other equity-based awards, such as restricted shares and phantom, options, in accordance
with our equity incentive plan then in place. Share options granted to executive officers shall be subject to vesting periods in order
to promote long-term retention of the awarded executive officers. The equity-based compensation shall be granted from time to time and
be individually determined and awarded according to the performance, educational background, prior business experience, qualifications,
role and the personal responsibilities of the executive officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our compensation policy contains compensation recovery provisions which allows us under certain conditions to recover bonuses
paid in excess, enables our Chief Executive Officer to approve an immaterial change in the terms of employment of an executive officer
(provided that the changes of the terms of employment are in accordance our compensation policy) and allows us to exculpate, indemnify
and insure our executive officers and directors subject to certain limitations set forth thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
compensation policy also provides for compensation to the members of our board of directors either: (i) in accordance with the amounts
provided in the Companies Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by
the Companies Regulations (Relief for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be
amended from time to time; or (ii) in accordance with the amounts determined in our compensation policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Internal
Auditor </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, the board of directors of an Israeli public company must appoint an internal auditor nominated by the audit committee.
We intend to appoint our internal auditor within 90 days following the consummation of this offering. The role of the internal auditor
is to examine, among other things, whether a company&rsquo;s actions comply with the law and proper business procedure. The audit committee
is required to oversee the activities, and to assess the performance of the internal auditor as well as to review the internal auditor&rsquo;s
work plan. An internal auditor may not be an interested party or office holder, or a relative of any interested party or office holder,
and may not be a member of the company&rsquo;s independent accounting firm or its representative. The Companies Law defines an interested
party as a holder of 5% or more of the outstanding shares or voting rights of a company, any person or entity that has the right to appoint
at least one director or the general manager of the company or any person who serves as a director or as the general manager of a company.
Our internal auditor is not our employee, but partner of a firm which specializes in internal auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Remuneration
of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, remuneration of directors is subject to the approval of the compensation committee, thereafter by the board of directors
and thereafter, unless exempted under the regulations promulgated under the Companies Law, by the general meeting of the shareholders.
In case the remuneration of the directors is in accordance with regulations applicable to remuneration of the external directors then
such remuneration shall be exempt from the approval of the general meeting. Where the director is also a controlling shareholder, the
requirements for approval of transactions with controlling shareholders apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fiduciary
Duties of Office Holders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law imposes a duty of care and a duty of loyalty on all office holders of a company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duty of care requires an office holder to act with the level of care with which a reasonable office holder in the same position would
have acted under the same circumstances. The duty of care of an office holder includes a duty to use reasonable means to obtain:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information
    on the advisability of a given action brought for his approval or performed by him by virtue of his position; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
    other important information pertaining to these actions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
duty of loyalty of an office holder requires an office holder to act in good faith and for the benefit of the company, and includes a
duty to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from any conflict of interest between the performance of his duties in the company and his performance of his other duties or personal
    affairs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from any action that is competitive with the company&rsquo;s business;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refrain
    from exploiting any business opportunity of the company to receive a personal gain for himself or others; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclose
    to the company any information or documents relating to the company&rsquo;s affairs which the office holder has received due to his
    position as an office holder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Insurance</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, a company may obtain insurance for any of its office holders against the following liabilities incurred due to acts
he or she performed as an office holder, if and to the extent provided for in the company&rsquo;s articles of association:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">breach
    of his or her duty of care to the company or to another person, to the extent such a breach arises out of the negligent conduct of
    the office holder;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    breach of his or her duty of loyalty to the company, provided that the office holder acted in good faith and had reasonable cause
    to assume that his or her act would not prejudice the company&rsquo;s interests; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    financial liability imposed upon him or her in favor of another person.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have directors&rsquo; and officers&rsquo; liability insurance, providing total coverage of $3.0 million for the benefit of
all of our directors and officers, in respect of which we paid an 18-month premium of approximately $5,250, which expires on April 1,
2025. We are currently in the process of obtaining directors&rsquo; and officers&rsquo; liability insurance that will be in place upon
completion of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Indemnification</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law and the Israeli Securities Law, 5728-1968, or the Securities Law, provide that a company may indemnify an office holder
against the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking
made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            financial liability imposed on him or her in favor of another person by any judgment concerning
                                            an act performed in his or her capacity as an office holder, including a settlement or arbitrator&#8217;s
                                            award approved by a court;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
                                            litigation expenses, including attorneys&#8217; fees, expended by the office holder (a) as
                                            a result of an investigation or proceeding instituted against him or her by an authority
                                            authorized to conduct such investigation or proceeding, provided that (1) no indictment (as
                                            defined in the Companies Law) was filed against such office holder as a result of such investigation
                                            or proceeding; and (2) no financial liability as a substitute for the criminal proceeding
                                            (as defined in the Companies Law) was imposed upon him or her as a result of such investigation
                                            or proceeding, or, if such financial liability was imposed, it was imposed with respect to
                                            an offense that does not require proof of criminal intent; or (b) in connection with a monetary
                                            sanction;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
                                            litigation expenses, including attorneys&#8217; fees, expended by the office holder or imposed
                                            on him or her by a court,: (1) in proceedings that the company institutes, or that another
                                            person institutes on the company&#8217;s behalf, against him or her; (2) in a criminal proceedings
                                            of which he or she was acquitted; or (3) as a result of a conviction for a crime that does
                                            not require proof of criminal intent; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
                                            incurred by an office holder in connection with an Administrative Procedure under the Securities
                                            Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees. An &#8220;Administrative
                                            Procedure&#8221; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by
                                            the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative
                                            Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures
                                            subject to conditions) to the Securities Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law also permits a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates
to financial liability imposed on him or her, as described above, then the undertaking should be limited and shall detail the following
foreseen events and amount or criterion:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            events that in the opinion of the board of directors can be foreseen based on the company&#8217;s
                                            activities at the time that the undertaking to indemnify is made; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            amount or criterion determined by the board of directors, at the time of the giving of such
                                            undertaking to indemnify, to be reasonable under the circumstances.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into indemnification agreements with all of our directors and with all members of our senior management. Each such indemnification
agreement provides the office holder with indemnification permitted under applicable law and up to a certain amount, and to the extent
that these liabilities are not covered by directors and officers insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exculpation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, an Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but
may exculpate in advance an office holder from his or her liability to the company, in whole or in part, for damages caused to the company
as a result of a breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such
exculpation is included in its articles of association. Our amended and restated articles of association provide that we may exculpate,
in whole or in part, any office holder from liability to us for damages caused to the company as a result of a breach of his or her duty
of care, but prohibit an exculpation from liability arising from a company&rsquo;s transaction in which our controlling shareholder or
officer has a personal interest. Subject to the aforesaid limitations, under the indemnification agreements, we exculpate and release
our office holders from any and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted
by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limitations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law provides that we may not exculpate or indemnify an office holder nor enter into an insurance contract that would provide
coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty of loyalty
unless (in the case of indemnity or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable basis
to believe that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was carried
out intentionally or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive an illegal
personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation
committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of association permit us to exculpate (subject to the aforesaid limitation), indemnify and insure our office
holders to the fullest extent permitted or to be permitted by the Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing descriptions summarize the material aspects and practices of our board of directors. For additional details, we also refer
you to the full text of the Companies Law, as well as of our amended and restated articles of association, which are exhibits to this
registration statement of which this prospectus forms a part, and are incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no service contracts between us or our Subsidiary, on the one hand, and our directors in their capacity as directors, on the other
hand, providing for benefits upon termination of service.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Approval
of Related Party Transactions under Israeli Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Companies Law, we may approve an action by an office holder from which the office holder would otherwise have to refrain, as described
above, if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            office holder acts in good faith and the act or its approval does not cause harm to the company;
                                            and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            office holder disclosed the nature of his or her interest in the transaction (including any
                                            significant fact or document) to the company at a reasonable time before the company&#8217;s
                                            approval of such matter.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Disclosure
of Personal Interests of an Office Holder</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Companies Law requires that an office holder disclose to the company, promptly, and, in any event, not later than the board meeting at
which the transaction is first discussed, any direct or indirect personal interest that he or she may have and all related material information
known to him or her relating to any existing or proposed transaction by the company. If the transaction is an extraordinary transaction,
the office holder must also disclose any personal interest held by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            office holder&#8217;s relatives; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            corporation in which the office holder or his or her relatives holds 5% or more of the shares
                                            or voting rights, serves as a director or general manager or has the right to appoint at
                                            least one director or the general manager.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">An
office holder is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of his or her
relative in a transaction that is not considered an extraordinary transaction. Under the Companies Law, an extraordinary transaction
is a transaction:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            in the ordinary course of business;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            on market terms; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that
                                            is likely to have a material effect on the company&#8217;s profitability, assets or liabilities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Companies Law does not specify to whom within us nor the manner in which required disclosures are to be made. We require our office holders
to make such disclosures to our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Companies Law, once an office holder complies with the above disclosure requirement, the board of directors may approve a transaction
between the company and an office holder, or a third party in which an office holder has a personal interest, unless the articles of
association provide otherwise and provided that the transaction is in the company&rsquo;s interest. If the transaction is an extraordinary
transaction in which an office holder has a personal interest, first the audit committee and then the board of directors, in that order,
must approve the transaction. Under specific circumstances, shareholder approval may also be required. Generally, a person who has a
personal interest in a matter which is considered at a meeting of the board of directors or the audit committee may not be present at
such a meeting unless the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present
in order to present the transaction that is subject to approval. A director who has a personal interest in a transaction, which is considered
at a meeting of the board of directors or the audit committee, may not be present at this meeting or vote on this matter, unless a majority
of members of the board of directors or the audit committee, as the case may be, has a personal interest. If a majority of the board
of directors has a personal interest, then shareholder approval is generally also required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Disclosure
of Personal Interests of a Controlling Shareholder</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Companies Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public company.
Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a
private placement in which a controlling shareholder has a personal interest, as well as transactions for the provision of services whether
directly or indirectly by a controlling shareholder or his or her relative, or a company such controlling shareholder controls, and transactions
concerning the terms of engagement and compensation of a controlling shareholder or a controlling shareholder&rsquo;s relative, whether
as an office holder or an employee, require the approval of the audit committee or the compensation committee, as the case may be, the
board of directors and a majority of the shares voted by the shareholders of the company participating and voting on the matter in a
shareholders&rsquo; meeting. In addition, the shareholder approval must fulfill one of the following requirements:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at
                                            least a majority of the shares held by shareholders who have no personal interest in the
                                            transaction and are voting at the meeting must be voted in favor of approving the transaction,
                                            excluding abstentions; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            shares voted by shareholders who have no personal interest in the transaction who vote against
                                            the transaction represent no more than 2% of the voting rights in the company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
addition, any extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest
with a term of more than three years requires the abovementioned approval every three years; however, such transactions not involving
the receipt of services or compensation can be approved for a longer term, provided that the audit committee determines that such longer
term is reasonable under the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Companies Law requires that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction
with a controlling shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in
the vote in question. Failure to so indicate will result in the invalidation of that shareholder&rsquo;s vote. However, according to
the Companies Law Regulations (exemptions for companies whose securities are listed for trading on a stock exchange outside of Israel)
5760-2000, by signing and submitting a proxy card, a shareholder declares and approves that he has no personal interest in the approval
of any of the items on a general meeting agenda that requires such declaration under the Companies Law, with the exception of a personal
interest that the shareholder positively informed the Company about.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
term &ldquo;controlling shareholder&rdquo; is defined in the Companies Law as a shareholder with the ability to direct the activities
of the company, other than by virtue of being an office holder. A shareholder is presumed to be a controlling shareholder if the shareholder
holds 50% or more of the voting rights in a company or has the right to appoint 50% or more of the directors of the company or its general
manager. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder
who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company.
For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Approval
of the Compensation of Directors and Executive Officers</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
compensation of, or an undertaking to indemnify, insure or exculpate, an office holder who is not a director requires the approval of
the company&rsquo;s compensation committee, followed by the approval of the company&rsquo;s board of directors, and, if such compensation
arrangement or an undertaking to indemnify, insure or exculpate is inconsistent with the company&rsquo;s stated compensation policy,
or if the said office holder is the chief executive officer of the company (subject to a number of specific exceptions), then such arrangement
is subject to the approval of our shareholders, subject to a special majority requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Directors</I>.
Under the Companies Law, the compensation of our directors requires the approval of our compensation committee, the subsequent approval
of the board of directors and, unless exempted under the regulations promulgated under the Companies Law, the approval of the general
meeting of our shareholders. If the compensation of our directors is inconsistent with our stated compensation policy, then, provided
that those provisions that must be included in the compensation policy according to the Companies Law have been considered by the compensation
committee and board of directors, shareholder approval by a special majority will be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Executive
officers other than the chief executive officer.</I> The Companies Law requires the approval of the compensation of a public company&rsquo;s
executive officers (other than the chief executive officer) in the following order: (i) the compensation committee, (ii) the company&rsquo;s
board of directors, and (iii) only if such compensation arrangement is inconsistent with the company&rsquo;s stated compensation policy,
the company&rsquo;s shareholders by a special majority. However, if the shareholders of the company do not approve a compensation arrangement
with an executive officer that is inconsistent with the company&rsquo;s stated compensation policy, the compensation committee and board
of directors may override the shareholders&rsquo; decision if each of the compensation committee and the board of directors provide detailed
reasons for their decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
executive officer.</I> Under the Companies Law, the compensation of a public company&rsquo;s chief executive officer is required to be
approved by: (i) the company&rsquo;s compensation committee; (ii) the company&rsquo;s board of directors, and (iii) the company&rsquo;s
shareholders by a special majority. However, if the shareholders of the company do not approve the compensation arrangement with the
chief executive officer, the compensation committee and board of directors may override the shareholders&rsquo; decision if each of the
compensation committee and the board of directors provides detailed reasons for their decision. In addition, the compensation committee
may exempt the engagement terms of a candidate to serve as the chief executive officer from shareholders&rsquo; approval, if the compensation
committee determines that the compensation arrangement is consistent with the company&rsquo;s stated compensation policy, that the chief
executive officer did not have a prior business relationship with the company or a controlling shareholder of the company, and that subjecting
the approval to a shareholder vote would impede the company&rsquo;s ability to attain the candidate to serve as the company&rsquo;s chief
executive officer (and provide detailed reasons for the latter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
approval of each of the compensation committee and the board of directors, with regard to the office holders and directors above, must
be in accordance with the company&rsquo;s stated compensation policy; however, under special circumstances, the compensation committee
and the board of directors may approve compensation terms of a chief executive officer that are inconsistent with the company&rsquo;s
compensation policy provided that they have considered those provisions that must be included in the compensation policy according to
the Companies Law and that shareholder approval was obtained by a special majority requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Duties
of Shareholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Companies Law, a shareholder has a duty to refrain from abusing his power in the company and to act in good faith and in an acceptable
manner in exercising his rights and performing his obligations toward the company and other shareholders, including, among other things,
in voting at general meetings of shareholders (and at shareholder class meetings) on the following matters:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendment
                                            of the articles of association;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
                                            in the company&#8217;s authorized share capital;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">merger;
                                            and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            approval of related party transactions and acts of office holders that require shareholder
                                            approval.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">A
shareholder also has a general duty to refrain from oppressing other shareholders. The remedies generally available upon a breach of
contract will also apply to a breach of the above mentioned duties, and in the event of oppression of other shareholders, additional
remedies are available to the injured shareholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
addition, any controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any
shareholder that, under a company&rsquo;s articles of association, has the power to appoint or prevent the appointment of an office holder,
or has another power with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not
describe the substance of this duty except to state that the remedies generally available upon a breach of contract will also apply in
the event of a breach of the duty to act with fairness, taking the shareholder&rsquo;s position in the company into account.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Equity
Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2019 Plan was adopted by our board of directors, or the &ldquo;board,&rdquo; in July 2019. The 2019 Plan provides for the grant of share
options to our directors, officers, employees, office holders, service providers and their employees, or charitable entities (collectively,
&ldquo;optionees&rdquo; or &ldquo;participants&rdquo;). On January 6, 2025, the Company increased the maximum number of Ordinary Shares
reserved for issuance under the 2019 Plan from 51,607 Ordinary Shares to 151,607 Ordinary Shares. As of February 5, 2025,
the total number of Ordinary Shares reserved for future grants of share options under our 2019 Plan was 38,702. As of February
5, 2025, the total number of Ordinary Shares issuable upon the exercise of share options to directors, employees and consultants
under our 2019 Plan was 74,921. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
2019 Plan is administered by our board or our Compensation Committee; however, the board is empowered to alter, amend, or rescind
any act taken by the Compensation Committee. The power to administer the 2019 Plan includes, but is not limited to: (i) approval
of option grants, or &ldquo;Option Grants,&rdquo; and the determination of the terms and provisions of the respective Option Grants,
including, the vesting schedules of the share options the Exercise Price thereof; provisions concerning the time or times when
and the extent to which Options may be exercised; the nature and duration of restrictions as to transferability; or any other special
conditions relating to an Option Grant; (ii) the acceleration of any participant&rsquo;s right to exercise Options, in whole or in part;
(iii) the interpretation of the provisions of the 2019 Plan; (iv) altering, amending or rescinding any resolution or act previously
taken by the Compensation Committee; and (v) the determination of any other matter which is necessary or desirable for, or incidental
to, the administration of the 2019 Plan. The board has the exclusive discretion and power to grant Options. The board also has
the power to grant optionees a cashless exercise mechanism for all or part of the Option Grants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise determined by the board with the consent of at least one investor director, Option Grants vest over four years&mdash;25% of
which vests on the first anniversary of the Option Grant, and each additional one twelfth (1/12) balance vests on the last day of each
three-month period following the first anniversary of the Option Grant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eligible
employees, officers and directors would qualify for provisions of Section 102 of the Israeli Income Tax Ordinance of 1961 (New Version),
or the Tax Ordinance. Section 102 of the Tax Ordinance allows employees, directors and officers who are not controlling shareholders
and are considered Israeli residents to receive favorable tax treatment for compensation in the form of shares or share options. Section
102 includes two alternatives for tax treatment involving the issuance of share options or shares to a trustee for the benefit of the
grantees and also includes an additional alternative for the issuance of share options or shares directly to the grantee. Section 102(b)(2)
of the Tax Ordinance, the most favorable tax treatment for the grantee, permits the issuance to a trustee under the &ldquo;capital
gain track.&rdquo; However, under this track we are not allowed to deduct an expense with respect to the issuance of the share options
or shares. Non-employees may only be granted share options under section 3(i) of the Tax Ordinance, which does not provide for similar
tax benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a default, our 2019 Plan provides that upon termination of a an optionee&rsquo;s employment or service with us or any of our affiliates,
other than in the event of death, disability or cause, all unvested share options will terminate and the underlying Options will
immediately expire, and all vested share options will generally be exercisable for 90 days following such termination, subject
to the terms of the 2019 Plan and the governing option agreement. Notwithstanding the foregoing, in the event the engagement is
terminated for cause (including, inter alia, due to breach of his/her employment agreement (whether written or oral) including without
limitation, a breach of non-compete obligations, or breach of his/her fiduciary duties towards us or a related entity as determined by
the Compensation Committee, in its sole discretion, or any other termination for &ldquo;cause&rdquo; or in the case that competent court
or other authority resolves that such employee is not entitled to discharge compensation), all share options granted to such optionee,
whether vested or unvested, will not be exercisable and will terminate on the date of the termination. Upon termination of a service
agreement due to death or disability, all the share options vested at the time of termination will generally be exercisable for
six months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a merger or consolidation with or into another corporation resulting in such other corporation being the surviving entity,
an acquisition of all or substantially all of our outstanding capital stock, or the sale of substantially all of our assets, each outstanding
option shall be assumed for an equivalent option or right substituted by the successor corporation or a parent or subsidiary of the successor
corporation, and appropriate adjustments shall be made in the number of share options in order to reflect such an action. In the event
that the successor corporation refuses to assume or substitute for the option, the vesting periods defined in the Option Grants may be
fully or partially accelerated by the Compensation Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any variation in our share capital, including a share dividend, share split, combination or exchange of shares, recapitalization,
or any other like event, the number, class and kind of shares subject to the 2019 Plan and outstanding options, and the exercise
prices of the share options, will be appropriately and equitably adjusted so as to maintain the proportionate number of shares
without changing the aggregate exercise price of the share options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><A NAME="Z_001"></A>BENEFICIAL
OWNERSHIP OF PRINCIPAL SHAREHOLDERS AND MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding beneficial ownership of our Ordinary Shares as of February 5, 2025 by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            person, or group of affiliated persons, known to us to be the beneficial owner of more than
                                            5% of our outstanding Ordinary Shares;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
                                            of our directors and executive officers; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all
                                            of our directors and executive officers as a group.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership is determined in accordance with the rules of the SEC, and includes voting or investment power with respect to Ordinary Shares.
Ordinary Shares issuable under share options that are exercisable within 60 days after February 5, 2025, are deemed outstanding
for the purpose of computing the percentage ownership of the person holding the share options but are not deemed outstanding for the
purpose of computing the percentage ownership of any other person. Percentage of shares beneficially owned before this offering is based
on 1,543,560 shares outstanding on February 5, 2025. The number of Ordinary Shares deemed outstanding after this offering is based on Ordinary Shares which does not assume
exercise of the underwriters&rsquo; over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
are not controlled by another corporation, by any foreign government or by any natural or legal persons except as set forth herein, and
there are no arrangements known to us which would result in a change in control of our company at a subsequent date. Except as indicated
in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to
all securities shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise noted
below, each beneficial owner&rsquo;s address is: Nasus Pharma Ltd., Yigal Alon 65, Tel Aviv, 6744317, Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Shares<BR> Beneficially<BR> Owned<BR>
    Prior to this<BR> Offering***</TD><TD STYLE="text-align: left; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Owned<BR>
                                            Prior to this<BR> Offering***</B></FONT></P></TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="text-align: left; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left; font-weight: bold">Shares<BR> Beneficially<BR> Owned<BR> After this<BR> Offering</TD><TD STYLE="text-align: left; padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Owned<BR> After this</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offering</B></FONT></P></TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Holders of more than 5% of our voting securities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 36%">Udi Gilboa*(1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">392,613</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">25</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Dalia Megiddo*(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">392,630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Ronnie Hershman*(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 284,256 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Capital Point Ltd.(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">89,124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Phoenix Solutions Ltd (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">90,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Hershman Holdings LLC (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Directors and senior management who are not 5% holders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <TD STYLE="font-style: normal; font-weight: normal; text-align: left"> Dan Teleman </TD><TD STYLE="font-style: normal; font-weight: normal"> &nbsp; </TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal"> &nbsp; </TD><TD STYLE="font-style: normal; text-align: right; font-weight: normal"> - </TD><TD STYLE="font-style: normal; text-align: left; font-weight: normal"> &nbsp; </TD><TD STYLE="font-style: normal; font-weight: normal"> &nbsp; </TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal"> &nbsp; </TD><TD STYLE="font-style: normal; text-align: right; font-weight: normal"> - </TD><TD STYLE="font-style: normal; text-align: left; font-weight: normal"> &nbsp; </TD><TD STYLE="font-style: normal; font-weight: normal"> &nbsp; </TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal"> &nbsp; </TD><TD STYLE="font-style: normal; text-align: right; font-weight: normal"> &nbsp; </TD><TD STYLE="font-style: normal; text-align: left; font-weight: normal"> &nbsp; </TD><TD STYLE="font-style: normal; font-weight: normal"> &nbsp; </TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal"> &nbsp; </TD><TD STYLE="font-style: normal; text-align: right; font-weight: normal"> &nbsp; </TD><TD STYLE="font-style: normal; text-align: left; font-weight: normal"> &nbsp; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Galia Temtsin Krayz(7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">36,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Tair Lapidot, Pd.D.(8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 16,424 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Oren Elmaliah(9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"> 6,287 </TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left"> % </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">All directors and senior management as a group (5 persons)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right"> 1,128,210 </TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right"> 73 </TD><TD STYLE="font-weight: bold; text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"></TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    director of the Company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    than 1%.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***
    </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
    conversion of the 2024 SAFE at $28.84 into 93,782 Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 387,000 Ordinary Shares; (ii) 1,272 Class A-3A Ordinary Shares; (iii) 3,252 Ordinary Shares issuable upon conversion
    2024 SAFEs; and (iv) 1,089 Class A-3A Ordinary Shares held by Formulex. Mr. Gilboa is a beneficial
    owner. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 387,000 Ordinary Shares; (i) 1,272 Class A-3A Ordinary Shares; (ii) 3,269 Ordinary Shares issuable upon conversion
    2024 SAFEs; and (iii) 1,089 Class A-3A Ordinary Shares held by Formulex of which Dr. Megiddo is a beneficial owner. Dr. Megiddo
    does not have sole nor share voting and investment power over the shares held by Formulex. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 100,000 Ordinary Shares held by Hershman Holdings LLC, which Dr. Hershman beneficially owns; (ii) 28,016 Class A-1 Ordinary
    Shares held by Hershman Holdings LLC; (iii) 14,637 Class A-3A Ordinary Shares held by Hershman Holdings LLC; (iv) 5,451 Class A-3A
    Ordinary Shares held by Hershman Holdings LLC; (v) 6,347 Class A-3B Ordinary Shares held by Hershman Holdings LLC; (vi) 25,505
    Ordinary Shares issuable upon conversion of 2024 SAFEs held by Hershman Holdings LLC; (vii) 90,000 Ordinary Shares held by Phoenix
    Solutions Ltd. Dr. Hershman is the controlling shareholder of Phoenix Solutions Ltd. Phoenix Solutions Ltd. is also a non-beneficial
    owner of Formulex; and (viii) 13,211 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable
    within 60 days. Dr. Hershman has sole voting and investment power over the shares held by Hershman Holdings LLC but not over those
    held by Phoenix Solutions Ltd. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (i) 85,470 Ordinary Shares; (ii) 3,654 Class A-3A Ordinary Shares. Capital Point Ltd. is a public company on the Tel Aviv
    Stock Exchange with an address of Azreli Tower 1, Floor 22, Tel Aviv Israel.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(5)</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Consists of 90,000 Ordinary Shares. Dr. Hershman
    is the beneficial owner of Phoenix Solutions Ltd. and has shared voting and investment power over the shares held by Phoenix Solutions Ltd. The address of Phoenix Solutions Ltd is Remez David 19, Tel Aviv, Israel.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(6)</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">Consists of 100,000 Ordinary Shares. These Ordinary
    Shares are also included in Dr. Hershman&rsquo;s shares under footnote (3). Dr. Hershman is the beneficial owner of Hershman
    Holdings LLC and has sole voting and investment power over the shares held by Hershman Holdings LLC. The address of Hershman Holdings LLC is 1999 Marcus Ave, # 220, New Hyde Park, New York 11042.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 36,000 Ordinary Shares. Dr. Galia Temtsin Krayz is the chief executive officer of Formulex.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 16,424 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</FONT> </TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 6,287 Ordinary Shares issuable upon exercise of outstanding share options that are exercisable within 60 days.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Record
</I></B></FONT><B><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 5, 2025, there were 77 shareholders of record of our Ordinary Shares, all of which are located in
Israel. These <FONT STYLE="background-color: white">numbers </FONT>are not representative of the number of beneficial holders of our
shares nor is it representative of where such beneficial holders reside, since many of these shares were held of record by brokers or
other nominees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Z_002"></A>RELATED
PARTY TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Services
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into written services agreements with each of our executive officers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition
provisions may be limited under applicable law. In addition, we have entered into agreements with each executive officer and director
pursuant to which we have agreed to indemnify each of them up to a certain amount and to the extent that these liabilities are not covered
by directors and officers insurance. Members of our senior management are eligible for bonuses each year. The bonuses are payable upon
meeting objectives and targets that are set by our Chief Executive Officer and approved annually by our board of directors that also
set the bonus targets for our Chief Executive Officer. For more information on the written services agreements with each of our executive
officers, please see &ldquo;Management&mdash;Compensation&mdash;Services Agreements with Executive Officers.&rdquo; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Options
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have granted share options to purchase our Ordinary Shares to our officers and certain of our directors. Such
option agreements may contain acceleration provisions upon certain merger, acquisition, or change of control transactions. We describe
our option plans under &ldquo;Management&mdash;Equity Incentive Plan.&rdquo; If the relationship between us and an executive officer
or a director is terminated, except for cause (as defined in the various option plan agreements), share options that are vested will
generally remain exercisable for three months after such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Loan
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, we received the July 2022 Loan from Dr. Ronnie Hershman, a director and shareholder, and Michael Gibber, a shareholder, pursuant
to which we received a principal amount of $500 thousand, for a term of twelve (12) months, at an interest rate of 8% per annum.
On August 28, 2024, we and each of Dr. Ronnie Hershman and Michael Gibber entered into an exchange letter, or the July 2022 Loan Exchange
Letter, according to which our obligations in connection with the loan were discharged in consideration for the issuance of a SAFE under
the same terms as the 2024 SAFEs, under which it is deemed that Dr. Hershman invested an amount of $284,154 and Michael Gibber invested
an amount of $286,210.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
February 2023, we received a loan in an aggregate amount of $60 thousand from Dr. Ronnie Hershman, Dr. Dalia Megiddo, and Mr.
Udi Gilboa, or the February 2023 Loan, under substantially the same terms as the July 2022 Loan</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
for a term of twelve (12) months, at an interest rate of 8% per annum. <FONT STYLE="background-color: white">A definitive agreement for
the February 2023 Loan was not executed. On August 28, 2024, we and each of Dr. Ronnie Hershman, Dr. Dalia Megiddo, and Mr. Udi Gilboa
entered into </FONT>the February 2023 Loan Exchange Letter<FONT STYLE="background-color: white">, according to which our obligations
in connection with the February 2023 Loan were discharged in consideration for the issuance of a SAFE with the same terms as the 2024
SAFEs, under which Dr. Ronnie Hershman was deemed to have invested an amount of $43,954, Dr. Dalia Megiddo was deemed to have invested
an amount of $11,286, and Mr. Udi Gilboa was deemed to have invested an amount of $10,963 in said SAFEs. See &ldquo;<I>&mdash;SAFEs</I>&rdquo;
below for information regarding the terms of the 2024 SAFEs.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Formulex
License Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2019, we entered into a license agreement with Formulex. Formulex is an Israeli corporation, owned by our co-founders<FONT STYLE="background-color: white">,
Mr. Ehud Gilboa, Dr. Dalia Megiddo, and director Dr. Ronnie </FONT>Hershman. Ms. Galia Temtsin Kryaz, our director of product
development, is the chief executive officer of Formulex. Pursuant to the license agreement, Formulex granted the company an
exclusive license for the development, manufacture and commercialization of Formulex&rsquo;s patent for dry powder compositions for
intranasal delivery and rights in the know-how of its intranasal and inhaled formulations, combination products, and particle
engineering, together, the Licensed Products. Pursuant to the License Agreement, we pay Formulex royalties of the Licensed Products
in the amount of 0.5% of net sales of the licensed products, which are capped at $100,000 in the aggregate. The royalty payment
period commenced on the effective date of the agreement and will continue on a country-by-country, product-by-product basis for the
longer of: (i) 15 years from the date of the first commercial sale of such Licensed Product in such country, or (ii) until the
licensed patent expires in such country. We may terminate the license agreement for any reason upon 60 days prior written notice. The
agreement does not provide for termination by Formulex. In the event of termination by us, we have the right to acquire
the Licensed Technology in an amount equal to the balance between the amount actually paid to Formulex prior to the date of
termination and the amount of $100,000. Termination of the agreement does not relieve the parties of obligation accrued prior to
such termination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Formulex
Service Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
June 3, 2019, w</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e entered into a services agreement with
Formulex, as amended in March 2020, for the provision of certain services by Formulex. Formulex provides us with services relating
to chemical manufacturing and controls for our PBI products, including preclinical formulation development of dry intranasal powder,
development and validation of analytical methods, packaging in an intranasal device, preparation of clinical batches for bioavailability
studies, stability studies, and quality assurance, for a fixed monthly cost of $5,000. The services agreement was for a term of three
years from the amendment date, and automatically renews every year for a period of one year, unless terminated by either party upon
30 days&rsquo; written notice, in accordance with the terms and conditions set forth therein. We may also terminate the agreement
for any reason upon 30 days&rsquo; written notice to Formulex. In connection with the same, Formulex has provided the Company
with one-time development services in 2023 and 2022 for additional fees of $22,000 and $11,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Formulex
Subcontractor Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 5, 2024, we entered into a subcontractor agreement with Formulex. Under the terms of the agreement, we may retain the services
of Formulex as a subcontractor, on a non-exclusive basis, in connection with our potential participation in tenders to render certain
services to end-clients. The services provided by Formulex shall be decided by the parties on a case-by-case basis, and may include,
among other services, assisting us with applying to, and participating in, certain tenders, and performing certain tasks for the projects
underlying tenders for which we are selected. Payment for services would be dependent upon the project and, pursuant to the contract,
would need to be pre-itemized in the form of a budget before a project commences. However, the maximum consideration paid to Formulex
in the aggregate under the agreement shall not exceed $800,000. The term of the subcontractor agreement is thirty-six months from its
effective date, unless terminated by either party upon 30 days&rsquo; written notice at any time and for any reason. Each subcontract
under the agreement terminates upon the earlier of completion of the services provided thereunder or the expiration or termination of
the subcontractor agreement, unless otherwise provided by the parties in any specific subcontract with respect thereto. The agreement
is subject to ratification and approval by our shareholders, which we expect to obtain prior to the closing of this offering. In 2024,
Formulex has provided the Company with subcontractor services for a total amount of $117,000.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Secretarial Services</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2019, we entered into an agreement with <FONT STYLE="background-color: white">Topnotch Consultancy (2009) Ltd., or </FONT>Topnotch,
a company owned by our co-founder and Executive Chairman of the Board of Directors, Mr. Udi Gibloa, pursuant to which Topnotch will provide
us with secretarial and administrative services incurred in connection with Mr. Gilboa&rsquo;s services to the Company, in the amount
of NIS 5,000 per month ($1,330), which was raised to NIS 15,000 ($3,990) in December 2024. Per the agreement, Mr. Gilboa
is not entitled to any further compensation, reimbursement of expenses, fees, or commissions that are not in connection with the performance
of office or secretarial services. <FONT STYLE="background-color: white">The agreement shall continue until terminated by either party
upon 30 days&rsquo; written notice.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Property
Lease and Office Services</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 1, 2019, we entered into a services agreement with Topnotch, pursuant to which we receive certain office services and the lease
of our office space in return for a monthly fee of NIS 12,000 ($<FONT STYLE="background-color: white">3,192</FONT>). Per the agreement,
Mr. Gilboa is not entitled to any further compensation, reimbursement of expenses, fees, or commissions that are not in connection with
the performance of office or secretarial services. The agreement shall continue until terminated by either party upon 30 days&rsquo;
written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>SAFEs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022 through April 2022, we entered into the 2022 SAFEs for aggregate proceeds of $966,000. Our co-founders, a member of our
board of directors, several shareholders at that time, and Formulex participated in these 2022 SAFEs. Specifically, Mr. Udi Gilboa participated
in the amount of $35,000, Dr. Dalia Megiddo participated in the amount of $35,000, Dr. Ronnie Hershman (through Hershman Holdings
LLC) participated in the amount of $150,000 and Formulex participated in the amount of $30,000. Per the terms of the 2022 SAFEs, since
an initial public offering, merger, acquisition, equity financing other liquidity event or dissolution event did not take place within
15 months from the execution of the 2022 SAFEs, on August 28, 2024, the subscription amounts under such SAFEs were converted into Class
A-3A Ordinary Shares. Immediately prior to the consummation of this offering, such Class A-3A Ordinary Shares will automatically convert
into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023 through April 2023, we entered into the 2023 SAFEs for aggregate proceeds of $995,000. A member of our board of directors,
Dr. Hershman (through Hershman Holdings LLC) participated in the amount of $100,000. Gabriel Hershman, a relative of Dr. Hershman, also
participated in the amount of $25,000. Per the terms of the 2023 SAFEs, since an initial public offering, merger, acquisition, equity
financing other liquidity event or dissolution event did not take place within 15 months from the execution of the 2023 SAFEs, in August
28, 2024, the subscription amounts under such SAFEs were converted into Class A-3B Ordinary Shares. Immediately prior to the consummation
of this offering, such Class A-3B Ordinary Shares will automatically convert into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024 through January 2025, we entered into the 2024 SAFEs <FONT STYLE="background-color: white">in the aggregate amount
</FONT> of $1,421,500, of which $300,000 were canceled and terminated in November 2024. In addition, pursuant to the terms of
the July 2022 Loan Exchange Letter and the February 2023 Loan Exchange Letter, the July 2022 Loan and February 2023 Loan were converted
into 2024 SAFEs in the amount of $570,364 and $66,203, respectively; however, no additional proceeds were received pursuant to said exchanges.
Our co-founders and members of our board of directors participated in the 2024 SAFEs. Specifically, Mr. Gilboa participated in the amount
of $60,963, Dr. Megiddo participated in the amount of $61,286 and Dr. Hershman participated in the amount of $478,108. Per the
terms of the 2024 SAFEs, upon an initial public offering, merger, acquisition, qualified equity financing other liquidity event, the
subscription amounts under such SAFEs will be converted into our Ordinary Shares upon consummation of this offering at a conversion price
reflecting a discount of 35%. However, if such events do not occur within 18 months of the execution of such SAFEs, such SAFEs will be
converted into our securities of such class of shares having certain rights identical to the respective rights of the most senior class
of shares on the basis of a previous round of equity financing consummated by the Company at a conversion price reflecting a discount
of 35%, as prescribed in such SAFEs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="Z_003"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF SHARE CAPITAL AND GOVERNING DOCUMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF SHARE CAPITAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>General</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 40pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of February 5, 2025, our authorized share capital consisted of 2,780,201 Ordinary Shares, par value NIS 0.01 per share,
comprised of: 2,000,000 Ordinary Shares, 171,000 Class A Ordinary Shares; 300,000 Class A-1 Ordinary Shares; 100,000 Class A-2 Ordinary
Shares; 110,000 Class A-3 Ordinary Shares, 35,243 Class A-3A Ordinary Shares and 63,958 Class A-3B Ordinary Shares, of which 1,543,560
shares were issued and outstanding as of such date. All our outstanding Ordinary Shares have been validly issued, fully paid and non-assessable.
Our Ordinary Shares are not redeemable and are not subject to any preemptive right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 28.35pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 28.35pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
registration number with the Israeli Registrar of Companies is 516022712.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Conversion
of Classes of Ordinary Shares </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the consummation of this offering, all of our Class A, Class A-1, Class A-2, Class A-3, Class
A-3A, and Class A-3B Ordinary Shares outstanding will automatically convert into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Ordinary
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the last three years, we have issued an aggregate of 69 Ordinary Shares for share options exercised as part of our option plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Our
Articles of Association</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Purposes
and Objects of the Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
purpose is set forth in Article 1 of our articles of association and includes every lawful purpose. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>The
Powers of the Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors shall direct our policy and shall supervise the performance of our Chief Executive Officer and his actions.
Our board of directors may exercise all powers that are not required under the Companies Law or under our amended and restated
articles of association to be exercised or taken by our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Rights
Attached to Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
Ordinary Shares shall confer upon the holders thereof:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equal
                                            right to attend and to vote at all of our general meetings, whether regular or special, with
                                            each Ordinary Share entitling the holder thereof, which attend the meeting and participate
                                            at the voting, either in person or by a proxy or by a written ballot, to one vote;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equal
                                            right to participate in distribution of dividends, if any, whether payable in cash or in
                                            bonus shares, in distribution of assets or in any other distribution, on a per share pro
                                            rata basis; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">equal
                                            right to participate, upon our dissolution, in the distribution of our assets legally available
                                            for distribution, on a per share pro rata basis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Election
of Directors</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to our amended articles of association to be in effect upon the consummation of this offering, our directors are elected at an annual
general meeting of our shareholders and serve on the board of directors until the next annual general meeting (except for external directors)
or until he or she resigns or unless he or she is removed by a majority vote of our shareholders at a general meeting of our shareholders
or upon the occurrence of certain events, in accordance with the Companies Law and our articles of association. The directors are classified,
with respect to the term for which they each severally hold office, into three classes, as nearly equal in number as practicable, and
designated as Class I, Class II and Class III. The Board may assign members of the Board already in office to such classes at the time
such classification becomes effective. If the number of directors is changed, any newly created directors or decrease in directors must
be apportioned by the board among the classes to make them equal in number. Pursuant to our articles of association, other than the external
directors, for whom special election requirements apply under the Companies Law, the vote required to appoint a director is a simple
majority vote of holders of our voting shares, participating and voting at the relevant meeting. In addition, our articles of association
allow our Board of Directors to appoint directors to fill vacancies and/or as an addition to the Board of Directors (subject to the maximum
number of directors) to serve until the next annual general meeting. External directors are elected for an initial term of three years,
may be elected for additional terms of three years each under certain circumstances, and may be removed from office pursuant to the terms
of the Companies Law. See &ldquo;<I>Management&mdash;Board Practices&mdash;External Directors</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Annual
and Special Meetings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Under
the Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year, at such time and place
which shall be determined by our board of directors, that must be no later than 15 months after the date of the previous annual
general meeting. All meetings other than the annual general meeting of shareholders are referred to as special general meetings. Our
Board of Directors may call special meetings whenever it sees fit and upon the request of: (a) any two of our directors or such number
of directors equal to one quarter of the directors then at office; and/or (b) one or more shareholders holding, in the aggregate, (i)
5% or more of our outstanding issued shares and 1% of our outstanding voting power or (ii) 5% or more of our outstanding voting power.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Subject
to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general
meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four and forty days prior
to the date of the meeting. Resolutions regarding the following matters must be passed at a general meeting of our shareholders:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amendments
                                            to our amended and restated articles of association;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            exercise of our board of director&#8217;s powers by a general meeting if our
                                            board of directors is unable to exercise its powers and the exercise of any of its powers
                                            is required for our proper management;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment
                                            or termination of our auditors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointment
                                            of directors, including external directors;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
                                            of acts and transactions requiring general meeting approval pursuant to the provisions of
                                            the Companies Law (mainly certain related party transactions) and any other applicable law;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases
                                            or reductions of our authorized share capital; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            merger (as such term is defined in the Companies Law).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Notices</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Companies Law and our amended and restated articles of association require that a notice of any annual or special shareholders meeting
be provided at least 21 days prior to the meeting, and if the agenda of the meeting includes the appointment or removal of directors,
the approval of transactions with office holders or interested or related parties, approval of the company&rsquo;s general manager to
serve as the chairman of the board of directors or an approval of a merger, notice must be provided at least 35 days prior to the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Quorum</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
permitted under the Companies Law, the quorum required for our general meetings consists of at least two shareholders present in person,
by proxy, written ballot or voting by means of electronic voting system, who hold or represent between them at least 25% of the total
outstanding voting rights. If within half an hour of the time set forth for the general meeting a quorum is not present, the general
meeting shall stand adjourned the same day of the following week, at the same hour and in the same place, or to such other date, time
and place as prescribed in the notice to the shareholders and in such adjourned meeting, if no quorum is present within half an hour
of the time arranged, any number of shareholders participating in the meeting, shall constitute a quorum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
a special general meeting was summoned following the request of a shareholder, and within half an hour a legal quorum shall not have
been formed, the meeting shall be canceled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Adoption
of Resolutions</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Our
amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless
otherwise required under the Companies Law or our amended and restated articles of association. A shareholder may vote in a general meeting
in person, by proxy, by a written ballot.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Changing
Rights Attached to Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Unless
otherwise provided by the terms of the shares and subject to any applicable law, any modification of rights attached to any class of
shares must be adopted by the holders of a majority of the shares of that class present a general meeting of the affected class or by
a written consent of all the shareholders of the affected class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
enlargement of an existing class of shares or the issuance of additional shares thereof, shall not be deemed to modify the rights attached
to the previously issued shares of such class or of any other class, unless otherwise provided by the terms of the shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Limitations
on the Right to Own Securities in Our Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">There
are no limitations on the right to own our securities. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Provisions
Restricting Change in Control of Our Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">There
are no specific provisions of our amended and restated articles of association that would have an effect of delaying, deferring or preventing
a change in control of the Company or that would operate only with respect to a merger, acquisition or corporate restructuring involving
us (or our Subsidiary). However, as described below, certain provisions of the Companies Law may have such effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Companies Law includes provisions that allow a merger transaction and requires that each company that is a party to the merger have the
transaction approved by its board of directors and, unless certain requirements described under the Companies Law are met, a vote of
the majority of shareholders, and, in the case of the target company, also a majority vote of each class of its shares. For purposes
of the shareholder vote of each party, unless a court rules otherwise, the merger will not be deemed approved if shares representing
a majority of the voting power present at the shareholders meeting and which are not held by the other party to the merger (or by any
person or group of persons acting in concert who holds 25% or more of the voting power or the right to appoint 25% or more of the directors
of the other party) vote against the merger. If, however, the merger involves a merger with a company&rsquo;s own controlling shareholder
or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same Special Majority
approval that governs all extraordinary transactions with controlling shareholders. Upon the request of a creditor of either party to
the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that as a result
of the merger the surviving company will be unable to satisfy the obligations of any of the parties to the merger, and may further give
instructions to secure the rights of creditors. If the transaction would have been approved by the shareholders of a merging company
but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still
approve the merger upon the petition of holders of at least 25% of the voting rights of a company. For such petition to be granted, the
court must find that the merger is fair and reasonable, taking into account the value of the parties to the merger and the consideration
offered to the shareholders. In addition, a merger may not be completed unless at least (1) 50 days have passed from the time that the
requisite proposals for approval of the merger were filed with the Israeli Registrar of Companies by each merging company and (2) 30
days have passed since the merger was approved by the shareholders of each merging company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Companies Law also provides that, subject to certain exceptions, an acquisition of shares in an Israeli public company must be made by
means of a &ldquo;special&rdquo; tender offer if as a result of the acquisition (1) the purchaser would become a holder of 25% or more
of the voting rights in the company, unless there is already another holder of at least 25% or more of the voting rights in the company
or (2) the purchaser would become a holder of 45% or more of the voting rights in the company, unless there is already a holder of more
than 45% of the voting rights in the company. These requirements do not apply if, in general, the acquisition (1) was made in a private
placement that received shareholders&rsquo; approval, subject to certain conditions, (2) was from a holder of 25% or more of the voting
rights in the company which resulted in the acquirer becoming a holder of 25% or more of the voting rights in the company, or (3) was
from a holder of more than 45% of the voting rights in the company which resulted in the acquirer becoming a holder of more than 45%
of the voting rights in the company. A &ldquo;special&rdquo; tender offer must be extended to all shareholders. In general, a &ldquo;special&rdquo;
tender offer may be consummated only if (1) at least 5% of the voting power attached to the company&rsquo;s outstanding shares will be
acquired by the offeror and (2) the offer is accepted by a majority of the offerees who notified the company of their position in connection
with such offer (excluding the offeror, controlling shareholders, holders of 25% or more of the voting rights in the company or anyone
on their behalf, or any person having a personal interest in the acceptance of the tender offer). If a special tender offer is accepted,
then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity
may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target
company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an
offer or merger in the initial special tender offer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If,
as a result of an acquisition of shares, the acquirer will hold more than 90% of an Israeli company&rsquo;s outstanding shares or of
certain class of shares, the acquisition must be made by means of a tender offer for all of the outstanding shares, or for all of the
outstanding shares of such class, as applicable. In general, if less than 5% of the outstanding shares, or of applicable class, are not
tendered in the tender offer and more than half of the offerees who have no personal interest in the offer tendered their shares, all
the shares that the acquirer offered to purchase will be transferred to it by operation of law. However, a tender offer will also be
accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company
or of the applicable class of shares. Any shareholders that was an offeree in such tender offer, whether such shareholder accepted the
tender offer or not, may request, by petition to an Israeli court, (i) appraisal rights in connection with a full tender offer, and (ii)
that the fair value should be paid as determined by the court, for a period of six months following the acceptance thereof. However,
the acquirer is entitled to stipulate, under certain conditions, that tendering shareholders will forfeit such appraisal rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Lastly,
Israeli tax law treats some acquisitions, such as stock-for-stock exchanges between an Israeli company and a foreign company, less favorably
than U.S. tax laws. For example, Israeli tax law may, under certain circumstances, subject a shareholder who exchanges his Ordinary Shares
for shares in another corporation to taxation prior to the sale of the shares received in such stock-for-stock swap.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Changes
in Our Capital</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
general meeting may, by a simple majority vote of the shareholders attending the general meeting:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
                                            our registered share capital by the creation of new shares from the existing class or a new
                                            class, as determined by the general meeting;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cancel
                                            any registered share capital which have not been taken or agreed to be taken by any person;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">consolidate
                                            and divide all or any of our share capital into shares of larger nominal value than our existing
                                            shares;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subdivide
                                            our existing shares or any of them, our share capital or any of it, into shares of smaller
                                            nominal value than is fixed; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduce
                                            our share capital and any fund reserved for capital redemption in any manner, and with and
                                            subject to any incident authorized, and consent required, by the Companies Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Z_004"></A>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, no public market existed for our Ordinary Shares. Sales of substantial amounts of our Ordinary Shares following this
offering, or the perception that these sales could occur, could adversely affect prevailing market prices of our Ordinary Shares and
could impair our future ability to obtain capital, especially through an offering of equity securities. Assuming that the underwriters
do not exercise their over-allotment option with respect to this offering and assuming no exercise of options outstanding following the
offering, we will have an aggregate of Ordinary Shares outstanding upon completion of this offering. Of these shares, the Ordinary Shares
sold in this offering will be freely tradable without restriction or further registration under the Securities Act, unless purchased
by &ldquo;affiliates&rdquo; (as that term is defined under Rule 144 of the Securities Act), who may sell only the volume of shares described
below and whose sales would be subject to additional restrictions described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
remaining Ordinary Shares will be held by our existing shareholders. Because substantially all of these shares were sold outside the
United States to persons residing outside the United States at the time, they also will be freely tradable without restriction or further
registration, except that shares held by affiliates must be sold pursuant to Rule 144 or another available exemption, and except for
the lock-up restrictions described below. Further, substantially all of our Ordinary Shares outstanding prior to this offering are subject
to lock-up agreements described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
and our executive officers, directors, and certain shareholders have agreed not to offer, sell, agree to sell, directly or indirectly,
or otherwise dispose of any Ordinary Shares or any other securities convertible into or exchangeable for Ordinary Shares except for the
Ordinary Shares offered in this offering without the prior written consent of the representative for a period of six months after
the date of this </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prospectus without the prior written
consent of ThinkEquity LLC. <FONT STYLE="background-color: white">After the expiration of such day period, the Ordinary Shares held by
our directors, executive officers or certain of our other existing shareholders may be sold outside of the United States subject to the
restrictions under applicable Israeli securities laws or by means of registered public offerings. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144, any person who is not our affiliate (and has not been an affiliate of ours for the last three months) and has
held their shares for at least six months, including the holding period of any prior owner other than one of our affiliates, may sell
shares without restriction as long as we continue to file required public information with the SEC. In addition, under Rule 144, any
person who is not an affiliate of ours (and has not been an affiliate of ours for the last three months) and has held their shares for
at least one year, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited
number of shares immediately upon the completion of this offering without regard to whether current public information about us is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
person who is our affiliate or who was our affiliate at any time during the preceding three months and who has beneficially owned restricted
securities for at least six months, including the holding period of any prior owner other than one of our affiliates, is entitled to
sell a number of shares within any three-month period that does not exceed the greater of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">one
                                            percent of the number of ordinary shares then outstanding; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            average weekly trading volume of our Ordinary Shares on the NYSE American during the four
                                            calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an affiliate acquires &ldquo;restricted securities,&rdquo; those securities will also be subject to holding period requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->154<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our outstanding Ordinary Shares are expected to be either unrestricted or to be eligible for sale under Rule 144. We cannot estimate
the number of our Ordinary Shares that our existing shareholders will elect to sell.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulation
S</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulation
S under the Securities Act provides that securities owned by any person may be sold without registration in the United States, provided
that the sale is affected in an offshore transaction and no directed selling efforts are made in the United States (as these terms are
defined in Regulation S), subject to certain other conditions. In general, this means that our Ordinary Shares may be sold in some manner
outside the United States without requiring registration in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, Rule 701 under the Securities Act, provides that each of our employees, consultants or advisors who received our Ordinary Shares
from us in connection with a compensatory share plan or other written agreement executed prior to the completion of this offering is
eligible to resell such Ordinary Shares in reliance on Rule 144, but without compliance with some of the restrictions, including the
holding period, contained in Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
S-8 Registration Statement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
the completion of this offering, we intend to file one or more registration statements on Form S-8 under the Securities Act to register
Ordinary Shares issued or reserved for issuance under our 2019 Plan. The registration statement on Form S-8 will become effective
automatically upon filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
shares issued upon exercise of a share option and registered under the Form S-8 registration statement will, subject to vesting and lock-up
provisions and Rule 144 volume limitations applicable to our affiliates, be available for sale in the open market immediately unless
they are subject to a lock-up, in which case, immediately after the term of the lock-up expires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 22.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
DISCUSSION ABOVE IS A GENERAL SUMMARY. IT DOES NOT COVER ALL SHARE TRANSFER RESTRICTION MATTERS THAT MAY BE OF IMPORTANCE TO A PROSPECTIVE
INVESTOR. EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN LEGAL ADVISOR REGARDING THE PARTICULAR SECURITIES LAWS AND TRANSFER RESTRICTION
CONSEQUENCES OF PURCHASING, HOLDING, AND DISPOSING OF THE ORDINARY SHARES INCLUDING THE CONSEQUENCES OF ANY PROPOSED CHANGE IN APPLICABLE
LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->155<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Z_005"></A>TAXATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>The
following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition
of our Ordinary Shares. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well
as any tax consequences that may arise under the laws of any state, local, foreign, including Israeli, or other taxing jurisdiction.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ISRAELI
TAX CONSIDERATIONS AND GOVERNMENT PROGRAMS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following is a description of the material Israeli income tax consequences of the ownership of our Ordinary Shares. The following also
contains a description of material relevant provisions of the current Israeli income tax structure applicable to companies in Israel,
with reference to its effect on us. To the extent that the discussion is based on new tax legislation which has not been subject to judicial
or administrative interpretation, there can be no assurance that the tax authorities will accept the views expressed in the discussion
in question. The discussion is not intended, and should not be taken, as legal or professional tax advice and is not exhaustive of all
possible tax considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership or disposition
of our Ordinary Shares. Shareholders should consult their own tax advisors concerning the tax consequences of their particular situation,
as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>General
Corporate Tax Structure in Israel</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Israeli
companies are generally subject to corporate tax. As of January 2016, the corporate tax rate was 25%. As of January 1, 2017, the corporate
tax rate was reduced to 24% and as of January 1, 2018, the corporate tax rate is 23%. However, the effective tax rate payable by a company
that derives income from a Preferred Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli company
are generally subject to the prevailing corporate tax rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Capital
gains derived by an Israeli resident company are subject to tax at the prevailing corporate tax rate. Under Israeli tax legislation,
a corporation will be considered as an &ldquo;Israeli resident company&rdquo; if it meets one of the following: (i) it was incorporated
in Israel; or (ii) the control and management of its business are exercised in Israel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Law
for the Encouragement of Industry (Taxes), 5729-1969</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax
benefits for &ldquo;Industrial Companies.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
Industry Encouragement Law defines an &ldquo;Industrial Company&rdquo; as an Israeli resident-company, of which 90% or more of its income
in any tax year, other than income from defense loans, is derived from an &ldquo;Industrial Enterprise&rdquo; owned by it. An &ldquo;Industrial
Enterprise&rdquo; is defined as an enterprise whose principal activity in a given tax year is industrial production.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
following corporate tax benefits, among others, are available to Industrial Companies:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">amortization
                                            of the cost of purchased a patent, rights to use a patent, and know-how, which are used for
                                            the development or advancement of the company, over an eight-year period, commencing on the
                                            year in which such rights were first exercised;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">under
                                            limited conditions, an election to file consolidated tax returns with related Israeli Industrial
                                            Companies; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
                                            related to a public offering are deductible in equal amounts over three years.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Eligibility
for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>




<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->156<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Tax
Benefits for Research and Development</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israeli
tax law allows, under certain conditions, a tax deduction for expenditures, including capital expenditures, for the year in which they
are incurred. Expenditures are deemed related to scientific research and development projects, if:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            expenditures are approved by the relevant Israeli government ministry, determined by the
                                            field of research;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            research and development must be for the promotion of the company; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            research and development is carried out by or on behalf of the company seeking such tax deduction.&#9;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of such deductible expenses is reduced by the sum of any funds received through government grants for the finance of such scientific
research and development projects. No deduction under these research and development deduction rules is allowed if such deduction is
related to an expense invested in an asset depreciable under the general depreciation rules of the income Tax Ordinance, 1961. Expenditures
not so approved are deductible in equal amounts over three years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time we may apply the Israel Innovation Authority for approval to allow a tax deduction for all research and
development expenses during the year incurred. There can be no assurance that such application will be accepted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Taxation
of our Shareholders</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital
Gains Taxes Applicable to Non-Israeli Resident Shareholders. A non-Israeli resident who derives capital gains from the sale of shares
in an Israeli resident company might be exempt from Israeli tax upon meeting the following terms: (1) the shares sold were purchased
after 1/1/2009; (2) the capital gain is not derived from the permanent establishment of the foreign resident in Israel; (3) the purchase
of shares was not from a relative; (4) and the shares are not traded on the Israeli stock exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax
treaty. For example, under Convention Between the Government of the United States of America and the Government of the State of Israel
with respect to Taxes on Income, as amended, or the United States-Israel Tax Treaty, the sale, exchange or other disposition of shares
by a shareholder who is a United States resident (for purposes of the treaty) holding the shares as a capital asset and is entitled to
claim the benefits afforded to such a resident by the U.S.-Israel Tax Treaty, or a Treaty U.S. Resident, is generally exempt from Israeli
capital gains tax unless: (i) the capital gain arising from such sale, exchange or disposition is attributed to real estate located in
Israel; (ii) the capital gain arising from such sale, exchange or disposition is attributed to royalties; (iii) the capital gain arising
from the such sale, exchange or disposition is attributed to a permanent establishment in Israel, under certain terms; (iv) such Treaty
U.S. Resident holds, directly or indirectly, shares representing 10% or more of the voting capital during any part of the 12-month period
preceding the disposition, subject to certain conditions; or (v) such Treaty U.S. Resident is an individual and was present in Israel
for 183 days or more during the relevant taxable year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
all instances where our shareholders may be liable for Israeli tax on the sale of their Ordinary Shares, the payment of the consideration
may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax
on their capital gains in order to avoid withholding at source at the time of sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->157<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxation
of Non-Israeli Shareholders on Receipt of Dividends. Non-Israeli residents are generally subject to Israeli income tax on the receipt
of dividends paid on our Ordinary Shares at the rate of 25%, which tax will be withheld at source, unless relief is provided in a treaty
between Israel and the shareholder&rsquo;s country of residence. With respect to a foreign resident who is a &ldquo;substantial shareholder&rdquo;
at the time of receiving the dividend or on any time during the preceding twelve months, the applicable tax rate is 30%. A &ldquo;substantial
shareholder&rdquo; is generally a person who alone or together with such person&rsquo;s relative or another person who collaborates with
such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the &ldquo;means of control&rdquo; of the corporation.
&ldquo;Means of control&rdquo; generally include the right to vote, receive profits, nominate a director or an executive officer, receive
assets upon liquidation, or order someone who holds any of the aforesaid rights how to act, regardless of the source of such right. However,
a distribution of dividends to non-Israeli residents is subject to withholding tax at source at a rate of 20% if the dividend is distributed
from income attributed to a Preferred Enterprise, unless a reduced tax rate is provided under an applicable tax treaty. For example,
under the United States-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our
Ordinary Shares who is a Treaty U.S. Resident is 25%. However, generally, the maximum rate of withholding tax on dividends, not generated
by a Preferred Enterprise, that are paid to a United States corporation holding 10% or more of the outstanding voting capital throughout
the tax year in which the dividend is distributed as well as during the previous tax year, is 12.5%, provided that not more than 25%
of the gross income for such preceding year consists of certain types of dividends and interest. Notwithstanding the foregoing, dividends
distributed from income attributed to a Preferred Enterprise are not entitled to such reduction under the tax treaty but are subject
to a withholding tax rate of 15% for a shareholder that is a U.S. corporation, provided that the condition related to our gross income
for the previous year (as set forth in the previous sentence) is met. If the dividend is attributable partly to income derived from a
Preferred Enterprise, and partly to other sources of income, the withholding rate will be a blended rate reflecting the relative portions
of the two types of income. We cannot assure you that we will designate the profits that we may distribute in a way that will reduce
shareholders&rsquo; tax liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>U.S.
FEDERAL INCOME TAX CONSIDERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
FOLLOWING SUMMARY IS INCLUDED HEREIN FOR GENERAL INFORMATION AND IS NOT INTENDED TO BE, AND SHOULD NOT BE CONSIDERED TO BE, LEGAL OR
TAX ADVICE. EACH U.S. HOLDER SHOULD CONSULT WITH HIS OR HER OWN TAX ADVISOR AS TO THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES
OF THE PURCHASE, OWNERSHIP AND SALE OF ORDINARY SHARES, INCLUDING THE EFFECTS OF APPLICABLE STATE, LOCAL, FOREIGN OR OTHER TAX LAWS AND
POSSIBLE CHANGES IN THE TAX LAWS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the limitations described in the next paragraph, the following discussion summarizes the material U.S. federal income tax consequences
to a &ldquo;U.S. Holder&rdquo; arising from the purchase, ownership and sale of the Ordinary Shares. For this purpose, a &ldquo;U.S.
Holder&rdquo; is a holder of Ordinary Shares that is: (1) an individual citizen or resident of the United States, including an alien
individual who is a lawful permanent resident of the United States or meets the substantial presence residency test under U.S. federal
income tax laws; (2) a corporation (or entity treated as a corporation for U.S. federal income tax purposes) or a partnership (other
than a partnership that is not treated as a U.S. person under any applicable U.S. Treasury regulations) created or organized under the
laws of the United States or the District of Columbia or any political subdivision thereof; (3) an estate, the income of which is includable
in gross income for U.S. federal income tax purposes regardless of source; (4) a trust if a court within the United States is able to
exercise primary supervision over the administration of the trust and one or more U.S. persons have authority to control all substantial
decisions of the trust; or (5) a trust that has a valid election in effect to be treated as a U.S. person to the extent provided in U.S.
Treasury regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->158<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
summary is for general information purposes only and does not purport to be a comprehensive description of all of the U.S. federal income
tax considerations that may be relevant to a decision to purchase our Ordinary Shares. This summary generally considers only U.S. Holders
that will own our Ordinary Shares as capital assets. Except to the limited extent discussed below, this summary does not consider the
U.S. federal tax consequences to a person that is not a U.S. Holder, nor does it describe the rules applicable to determine a taxpayer&rsquo;s
status as a U.S. Holder. This summary is based on the provisions of the Internal Revenue Code of 1986, as amended, or the Code, final,
temporary and proposed U.S. Treasury regulations promulgated thereunder, administrative and judicial interpretations thereof, (including
with respect to the Tax Cuts and Jobs Act of 2017), and the U.S./Israeli Income Tax Treaty, all as in effect as of the date hereof and
all of which are subject to change, possibly on a retroactive basis, and all of which are open to differing interpretations. We will
not seek a ruling from the IRS with regard to the U.S. federal income tax treatment of an investment in our Ordinary Shares by U.S. Holders
and, therefore, can provide no assurances that the IRS will agree with the conclusions set forth below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion does not address all of the aspects of U.S. federal income taxation that may be relevant to a particular U.S. holder based
on such holder&rsquo;s particular circumstances and in particular does not discuss any estate, gift, generation-skipping, transfer, state,
local, excise or foreign tax considerations. In addition, this discussion does not address the U.S. federal income tax treatment of a
U.S. Holder who is: (1) a bank, life insurance company, regulated investment company, or other financial institution or &ldquo;financial
services entity;&rdquo; (2) a broker or dealer in securities or foreign currency; (3) a person who acquired our Ordinary Shares in connection
with employment or other performance of services; (4) a U.S. Holder that is subject to the U.S. alternative minimum tax; (5) a U.S. Holder
that holds our Ordinary Shares as a hedge or as part of a hedging, straddle, conversion or constructive sale transaction or other risk-reduction
transaction for U.S. federal income tax purposes; (6) a tax-exempt entity; (7) real estate investment trusts or grantor trusts; (8) a
U.S. Holder that expatriates out of the United States or a former long-term resident of the United States; or (9) a person having a functional
currency other than the U.S. dollar. This discussion does not address the U.S. federal income tax treatment of a U.S. Holder that owns,
directly or constructively, at any time, Ordinary Shares representing 10% or more of our voting power. Additionally, the U.S. federal
income tax treatment of partnerships (or other pass-through entities) or persons who hold Ordinary Shares through a partnership or other
pass-through entity are not addressed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
prospective investor is advised to consult his or her own tax adviser for the specific tax consequences to that investor of purchasing,
holding or disposing of our Ordinary Shares, including the effects of applicable state, local, foreign or other tax laws and possible
changes in the tax laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Taxation
of Dividends Paid on Ordinary Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not intend to pay dividends in the foreseeable future. In the event that we do pay dividends, and subject to the discussion under
the heading &ldquo;<I>Passive Foreign Investment Companies</I>&rdquo; below and the discussion of &ldquo;qualified dividend income&rdquo;
below, a U.S. Holder, other than certain U.S. Holder&rsquo;s that are U.S. corporations, will be required to include in gross income
as ordinary income the amount of any distribution paid on Ordinary Shares (including the amount of any Israeli tax withheld on the date
of the distribution), to the extent that such distribution does not exceed our current and accumulated earnings and profits, as determined
for U.S. federal income tax purposes. The amount of a distribution which exceeds our earnings and profits will be treated first as a
non-taxable return of capital, reducing the U.S. Holder&rsquo;s tax basis for the Ordinary Shares to the extent thereof, and then capital
gain. We do not expect to maintain calculations of our earnings and profits under U.S. federal income tax principles and, therefore,
U.S. Holders should expect that the entire amount of any distribution generally will be reported as dividend income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, preferential tax rates for &ldquo;qualified dividend income&rdquo; and long-term capital gains are applicable for U.S. Holders
that are individuals, estates or trusts. For this purpose, &ldquo;qualified dividend income&rdquo; means, inter alia, dividends received
from a &ldquo;qualified foreign corporation.&rdquo; A &ldquo;qualified foreign corporation&rdquo; is, among others, a corporation
that is entitled to the benefits of a comprehensive tax treaty with the United States which includes an exchange of information program.
The IRS has stated that the Israeli/U.S. Tax Treaty satisfies this requirement and we believe we are eligible for the benefits of that
treaty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->159<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, our dividends will be qualified dividend income if our Ordinary Shares are readily tradable on the NYSE American or another
established securities market in the United States. Dividends will not qualify for the preferential rate if we are treated, in the year
the dividend is paid or in the prior year, as a PFIC, as described below under &ldquo;<I>Passive Foreign Investment Companies</I>.&rdquo;
A U.S. Holder will not be entitled to the preferential rate: (1) if the U.S. Holder has not held our Ordinary Shares for at least 61
days of the 121 day period beginning on the date which is 60 days before the ex-dividend date, or (2) to the extent the U.S. Holder is
under an obligation to make related payments on substantially similar property. Any days during which the U.S. Holder has diminished
its risk of loss on our Ordinary Shares are not counted towards meeting the 61-day holding period. Finally, U.S. Holders who elect to
treat the dividend income as &ldquo;investment income&rdquo; pursuant to Code section 163(d)(4) will not be eligible for the preferential
rate of taxation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of a distribution with respect to our Ordinary Shares will be measured by the amount of the fair market value of any property
distributed, and for U.S. federal income tax purposes, the amount of any Israeli taxes withheld therefrom. Cash distributions paid by
us in NIS will be included in the income of U.S. Holders at a U.S. dollar amount based upon the spot rate of exchange in effect on the
date the dividend is includible in the income of the U.S. Holder, and U.S. Holders will have a tax basis in such NIS for U.S. federal
income tax purposes equal to such U.S. dollar value. If the U.S. Holder subsequently converts the NIS into U.S. dollars or otherwise
disposes of it, any subsequent gain or loss in respect of such NIS arising from exchange rate fluctuations will be U.S. source ordinary
exchange gain or loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Taxation
of the Disposition of Ordinary Shares</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as provided under the PFIC rules described below under &ldquo;<I>Passive Foreign Investment Companies</I>,&rdquo; upon the sale, exchange
or other disposition of our Ordinary Shares, a U.S. Holder will recognize capital gain or loss in an amount equal to the difference between
such U.S. Holder&rsquo;s tax basis for the Ordinary Shares in U.S. dollars and the amount realized on the disposition in U.S. dollar
(or its U.S. dollar equivalent determined by reference to the spot rate of exchange on the date of disposition, if the amount realized
is denominated in a foreign currency). The gain or loss realized on the sale, exchange or other disposition of Ordinary Shares will be
long-term capital gain or loss if the U.S. Holder has a holding period of more than one year at the time of the disposition. Individuals
who recognize long-term capital gains may be taxed on such gains at reduced rates of tax. The deduction of capital losses is subject
to various limitations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Passive
Foreign Investment Companies</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Special
U.S. federal income tax laws apply to U.S. taxpayers who own shares of a corporation that is a PFIC. We will be treated as a PFIC for
U.S. federal income tax purposes for any taxable year that either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">75%
                                            or more of our gross income (including our pro rata share of gross income for any company,
                                            in which we are considered to own 25% or more of the shares by value), in a taxable year
                                            is passive; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
                                            least 50% of our assets, averaged over the year and generally determined based upon fair
                                            market value (including our pro rata share of the assets of any company in which we are considered
                                            to own 25% or more of the shares by value) are held for the production of, or produce, passive
                                            income.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
this purpose, passive income generally consists of dividends, interest, rents, royalties, annuities and income from certain commodities
transactions and from notional principal contracts. Cash is treated as generating passive income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->160<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
tests for determining PFIC status are applied annually, and it is difficult to make accurate projections of future income and assets
which are relevant to this determination. In addition, our PFIC status may depend in part on the market value of our Ordinary Shares.
We do not expect to be a PFIC for 2023 and we do not expect to become a PFIC in the future, although there can be no assurance in
this regard.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we currently are or become a PFIC, each U.S. Holder who has not elected to mark the shares to market (as discussed below), would, upon
receipt of certain distributions by us and upon disposition of our Ordinary Shares at a gain: (1) have such distribution or gain allocated
ratably over the U.S. Holder&rsquo;s holding period for the Ordinary Shares, as the case may be; (2) the amount allocated to the
current taxable year and any period prior to the first day of the first taxable year in which we were a PFIC would be taxed as ordinary
income; and (3) the amount allocated to each of the other taxable years would be subject to tax at the highest rate of tax in effect
for the applicable class of taxpayer for that year, and an interest charge for the deemed deferral benefit would be imposed with respect
to the resulting tax attributable to each such other taxable year. In addition, when shares of a PFIC are acquired by reason of death
from a decedent that was a U.S. Holder, the tax basis of such shares would not receive a step-up to fair market value as of the date
of the decedent&rsquo;s death, but instead would be equal to the decedent&rsquo;s basis if lower, unless all gain were recognized by
the decedent. Indirect investments in a PFIC may also be subject to these special U.S. federal income tax rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
PFIC rules described above would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder has
held the Ordinary Shares while we are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder
who has made such a QEF election is required for each taxable year that we are a PFIC to include in income such U.S. Holder&rsquo;s pro
rata share of our ordinary earnings as ordinary income and such U.S. Holder&rsquo;s pro rata share of our net capital gains as long-term
capital gain, regardless of whether we make any distributions of such earnings or gain. In general, a QEF election is effective only
if we make available certain required information. The QEF election is made on a shareholder-by-shareholder basis and generally may be
revoked only with the consent of the IRS. We do not intend to notify U.S. Holders if we believe we will be treated as a PFIC for any
tax year. In addition, we do not intend to furnish U.S. Holders annually with information needed in order to complete IRS Form 8621 and
to make and maintain a valid QEF election for any year in which we are a PFIC. Therefore, the QEF election
will not be available with respect to our Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the PFIC rules described above would not apply if we were a PFIC and a U.S. Holder made a mark-to-market election. A U.S. Holder
of our Ordinary Shares which are regularly traded on a qualifying exchange, including the NYSE American, can elect to mark the Ordinary
Shares to market annually, recognizing as ordinary income or loss each year an amount equal to the difference as of the close of the
taxable year between the fair market value of the Ordinary Shares and the U.S. Holder&rsquo;s adjusted tax basis in the Ordinary Shares.
Losses are allowed only to the extent of net mark-to-market gain previously included income by the U.S. Holder under the election for
prior taxable years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders who hold our Ordinary Shares during a period when we are a PFIC will be subject to the foregoing rules, even if we cease to be
a PFIC. U.S. Holders are strongly urged to consult their tax advisors about the PFIC rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tax
on Net Investment Income</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.
Holders who are individuals, estates or trusts will generally be required to pay a 3.8% Medicare tax on their net investment income (including
dividends on and gains from the sale or other disposition of our Ordinary Shares), or in the case of estates and trusts on their net
investment income that is not distributed. In each case, the 3.8% Medicare tax applies only to the extent the U.S. Holder&rsquo;s total
adjusted income exceeds applicable thresholds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->161<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tax
Consequences for Non-U.S. Holders of Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as provided below, an individual, corporation, estate or trust that is not a U.S. Holder referred to below as a non-U.S. Holder, generally
will not be subject to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the disposition of,
our Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
non-U.S. Holder may be subject to U.S. federal income tax on a dividend paid on our Ordinary Shares or gain from the disposition of our
Ordinary Shares if: (1) such item is effectively connected with the conduct by the non-U.S. Holder of a trade or business in the United
States and, if required by an applicable income tax treaty is attributable to a permanent establishment or fixed place of business in
the United States; or (2) in the case of a disposition of our Ordinary Shares, the individual non-U.S. Holder is present in the United
States for 183 days or more in the taxable year of the disposition and other specified conditions are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, non-U.S. Holders will not be subject to backup withholding with respect to the payment of dividends on our Ordinary Shares if
payment is made through a paying agent, or office of a foreign broker outside the United States. However, if payment is made in the United
States or by a U.S. related person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S. Holder provides an applicable
IRS Form W-8 (or a substantially similar form) certifying its foreign status, or otherwise establishes an exemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of any backup withholding from a payment to a non-U.S. Holder will be allowed as a credit against such holder&rsquo;s U.S. federal
income tax liability and may entitle such holder to a refund, provided that the required information is timely furnished to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Information
Reporting and Withholding</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Holder may be subject to backup withholding at a rate of 24% with respect to cash dividends and proceeds from a disposition of Ordinary
Shares. In general, backup withholding will apply only if a U.S. Holder fails to comply with specified identification procedures. Backup
withholding will not apply with respect to payments made to designated exempt recipients, such as corporations and tax-exempt organizations.
Backup withholding is not an additional tax and may be claimed as a credit against the U.S. federal income tax liability of a U.S. Holder,
provided that the required information is timely furnished to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Holder with interests in &ldquo;specified foreign financial assets&rdquo; (including, among other assets, our Ordinary Shares, unless
such Ordinary Shares are held on such U.S. Holder&rsquo;s behalf through a financial institution) may be required to file an information
report with the IRS if the aggregate value of all such assets exceeds $50,000 on the last day of the taxable year or $75,000 at any time
during the taxable year (or such higher dollar amount as may be prescribed by applicable IRS guidance); and may be required to file a
Report of Foreign Bank and Financial Accounts, or FBAR, if the aggregate value of the foreign financial accounts exceeds $10,000 at any
time during the calendar year. You should consult your own tax advisor as to the possible obligation to file such information report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->162<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Z_006"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ThinkEquity
is acting as representative of the underwriters, or the Representative. On&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, we entered into an underwriting agreement with the Representative,
or the Underwriting Agreement. Subject to the terms and conditions of the Underwriting Agreement, we have agreed to sell, and each underwriter
named below has severally agreed to purchase, the number of Ordinary Shares listed next to each underwriter&rsquo;s name in the following
table, at the public offering price less the underwriting discounts set forth on the cover page of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1pt solid">Underwriters</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number <BR> of Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; text-align: justify; padding-bottom: 2.5pt">ThinkEquity LLC</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; border-bottom: Black 2.5pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"></TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right"></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters have committed to purchase all of the Ordinary Shares offered by us in this offering other than those covered by the over-allotment
option described below. The obligations of the underwriters may be terminated upon the occurrence of certain events specified in the
Underwriting Agreement. Furthermore, pursuant to the Underwriting Agreement, the underwriters&rsquo; obligations are subject to customary
conditions, representations, and warranties, such as receipt by the underwriters of officers&rsquo; certificates and legal opinions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters are offering Ordinary Shares subject to prior sale when, as, and if issued to and accepted by them, subject to approval
of legal matters by their counsel and other conditions. The underwriters reserve the right to withdraw, cancel, or modify offers to the
public and to reject orders in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters propose to offer the Ordinary Shares to the public at the public offering price set forth on the cover of the prospectus.
After Ordinary Shares are released for sale to the public, the underwriters may from time to time change the offering price and other
selling terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-Allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted to the underwriters an option, exercisable for 45 days from the date of this prospectus, to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional Ordinary Shares (15% of the Ordinary Shares sold in
this offering) at the initial public offering price, less the underwriting discounts and commissions. The underwriters may exercise
the option solely for the purpose of covering over-allotments, if any, in connection with this offering. To the extent that the
option is exercised, each underwriter must purchase additional Ordinary Shares in an amount that is approximately
proportionate to that underwriter&rsquo;s initial purchase commitment (set forth in the table above). Any Ordinary
Shares issued or sold under the option will be issued and sold on the same terms and conditions as the other Ordinary
Shares that are the subject of this offering. If this option is exercised in full, the total offering price to the public will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and the total net proceeds to us, before expenses, will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discounts
and Commissions </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative has advised that the underwriters propose to offer the Ordinary Shares to the public at the public offering price per
share set forth on the cover page of this prospectus. The underwriters may offer the Ordinary Shares to securities dealers at that
price less a concession of not more than $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, of which up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; may be re-allowed to other dealers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->163<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the public offering price, underwriting discounts and commissions, and proceeds to us before expenses, assuming
both no exercise and full exercise by the underwriters of the over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Share</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Without <BR> Over-<BR> Allotment</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">With <BR> Over-<BR> Allotment</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; text-align: justify">Public offering price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting discount (7%) <SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Proceeds, before expenses, to us</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to pay a non-accountable expense allowance to the Representative equal to 1% of the gross proceeds received in this offering
    (excluding proceeds received from exercise of the underwriters&rsquo; over-allotment option) which is not included in the underwriting
    discounts and commission.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have paid an expense deposit of $20,000 to the Representative, which will be applied against the Representative&rsquo;s accountable out-of-pocket
expenses (in compliance with FINRA Rule 5110(f)(2)(C)) that are payable by us in connection with this offering. We have agreed to reimburse
the Representative for the fees and expenses of its legal counsel in connection with the offering in an amount not to exceed $125,000,
the fees and expenses related to the use of Ipero&rsquo;s book building, prospectus tracking and compliance software for the offering
in the amount of $29,500, up to $15,000 for background checks of our officers and directors, the costs associated with bound volumes
of the offering materials as well as commemorative mementos and lucite tombstones in an amount not to exceed $3,000, data services and
communications expenses up to $10,000, the actual accountable &ldquo;road show&rdquo; expenses up to $10,000 and the costs of market
making and trading and clearing firm settlement expenses up to $30,000; provided however that the aggregate accountable expenses
reimbursement will not exceed $175,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the expenses of this offering payable by us, not including underwriting discounts and commissions, will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Representatives&rsquo;
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to issue to the Representative, upon the consummation of this offering, warrants to purchase up to an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Ordinary Shares (5% of the Ordinary Shares sold in this offering), or the Representative&rsquo;s Warrants. The Representative&rsquo;s
Warrants are exercisable at a per share price equal to 125% of the public offering price per share in this offering. The Representative&rsquo;s
Warrants are exercisable at any time and from time to time, in whole or in part, commencing on the six-month anniversary of the
effective date of the registration statement of which this prospectus is a part and expiring on the date that is five years following
the commencement of sales of Ordinary Shares in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Representative&rsquo;s Warrants are deemed underwriter compensation by FINRA and are therefore subject to a 180-day lock-up pursuant
to FINRA Rule 5110(g)(1). The Representative (or permitted assignees under Rule 5110(g)(1)) will not sell, transfer, assign, pledge,
or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative,
put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a period
of 180 days from commencement of sales in this offering. In addition, the Representative&rsquo;s Warrants provide for registration rights
upon request, in certain cases. The one-time demand registration right provided will not be greater than five years from the commencement
of sales of this offering in compliance with FINRA Rule 5110(f)(2)(G)(iv). The piggyback registration right provided will not be greater
than seven years from the commencement of sales of this offering in compliance with FINRA Rule 5110(g)(8. We will bear all fees and expenses
attendant to registering the securities issuable on exercise of the Representative&rsquo;s Warrants other than underwriting commissions
incurred and payable by the holders. The exercise price and number of shares issuable upon exercise of the Representative&rsquo;s Warrants
may be adjusted in certain circumstances including in the event of a stock dividend or our recapitalization, reorganization, merger,
or consolidation. However, neither the Representative Warrant exercise price, nor the number of Ordinary Shares underlying such warrants,
will be adjusted for issuances of Ordinary Shares by us at a price below the exercise price of the Representative&rsquo;s Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->164<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters do not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to certain &ldquo;lock-up&rdquo; agreements, we for a period of 6 months and our executive officers and directors as of the date of this
prospectus have agreed, for a period of 8 months from the date of this prospectus, and as for any other holder of our outstanding securities
for period of 6 months, not to engage in any of the following, whether directly or indirectly, without the Representative&rsquo;s consent:
offer, pledge, sell, contract to sell, grant, lend, or otherwise transfer or dispose of, our Ordinary Shares or any securities convertible
into or exercisable or exchangeable for our Ordinary Shares, or the Lock-Up Securities; enter into any swap or other arrangement that
transfers to another, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities; make any demand for
or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration
of any Lock-Up Securities; enter into any transaction, swap, hedge, or other arrangement relating to any Lock-Up Securities, subject
to customary exceptions; or publicly disclose the intention to do any of the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
18 months from the closing date of this offering, the Representative will have an irrevocable right of first refusal to act as sole investment
banker, sole book-runner, and/or sole placement agent, at the Representative&rsquo;s sole discretion, for each and every future public
and private equity and debt offering, including all equity linked financings, during such 18 month period, for us, or any successor to
or any subsidiary of us, on terms customary for the Representative. The Representative will have the sole right to determine whether
any other broker-dealer shall have the right to participate in any such offering and the economic terms of any such participation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pricing
of the Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there was no established public market for our Ordinary Shares. The public offering price was negotiated between us
and the underwriters. In determining the price, we considered our history and prospects, our business potential and earnings prospects,
an assessment of our management, general securities market conditions at the time of the offering, and such other factors that we deemed
relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
active trading market for our Ordinary Shares may not develop. It is also possible that the Ordinary Shares will not trade in the public
market or above the initial public offering price following the closing of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify the underwriters against liabilities relating to this offering that may arise under the Securities Act and from
any breach of the representations and warranties contained in the Underwriting Agreement. We have further agreed to contribute to payments
that the underwriters may be required to make for these liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->165<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale and Distribution of Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus in electronic format may be made available on websites or through other online services maintained by one or more of the underwriters,
or by their affiliates. Other than this prospectus in electronic format, the information on any underwriter&rsquo;s website and any information
contained in any other website maintained by an underwriter is not part of this prospectus or the registration statement of which this
prospectus forms a part, has not been approved or endorsed by us or any underwriter in its capacity as underwriter, and should not be
relied upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer
Restrictions Outside of the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken that would permit a public offering of our Ordinary Shares in any jurisdiction where
action for the purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor
may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be
distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and
regulations of that country or jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about
and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute
an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an
offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Australia</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian
Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter
6D of the Australian Corporations Act. Accordingly, (i) the offer of the securities under this prospectus is only made to persons to
whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions
set out in section 708 of the Australian Corporations Act, (ii) this prospectus is made available in Australia only to those persons
as set forth in clause (i) above, and (iii) the offeree must be sent a notice stating in substance that by accepting this offer, the
offeree represents that the offeree is such a person as set forth in clause (i) above, and, unless permitted under the Australian Corporations
Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its transfer
to the offeree under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Canada</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Ordinary Shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted
clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale
of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements
of applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by
the purchaser within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser
should refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars
of these rights or consult with a legal advisor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 170; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->166<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>China</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People&rsquo;s
Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region
and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly
to &ldquo;qualified domestic institutional investors.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>European
Economic Area&mdash;Belgium, Germany, Luxembourg and Netherlands</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under
the Directive 2003/71/EC, or the Prospectus Directive, as implemented in Member States of the European Economic Area, each, a Relevant
Member State, from the requirement to produce a prospectus for offers of securities. An offer to the public of securities has not been
made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions under the Prospectus Directive
as implemented in that Relevant Member State:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose
    corporate purpose is solely to invest in securities;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    any legal entity that has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total balance
    sheet of more than &euro;43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an
    annual net turnover of more than &euro;50,000,000 (as shown on its last annual unconsolidated or consolidated financial statements);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive)
    subject to obtaining the prior consent of the company or any underwriter for any such offer; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall
    result in a requirement for the publication by the company of a prospectus pursuant to Article 3 of the Prospectus Directive.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>France</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers)
in France within the meaning of Article L.411-1 of the French Monetary and Financial Code (Code Mon&eacute;taire et Financier) and Articles
211-1 et seq. of the General Regulation of the French Autorit&eacute; des march&eacute;s financiers, or AMF. The securities have not
been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document and any other offering material relating to the securities have not been, and will not be, submitted to the AMF for approval
in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifi&eacute;s)
acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&deg; and D.411-1 to D.411-3, D.744-1, D.754-1
;and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified
investors (cercle restreint d&rsquo;investisseurs) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2&deg;
and D.411-4, D.744-1, D.754-1; and D.764-1 of the French Monetary and Financial Code and any implementing regulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 171; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->167<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly
or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3
of the French Monetary and Financial Code.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ireland</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed
with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities
in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005, or the Prospectus Regulations. The securities
have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering,
except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii) fewer than 100 natural or legal
persons who are not qualified investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Israel</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), nor have such
securities been registered for sale in Israel. The Ordinary Shares may not be offered or sold, directly or indirectly, to the public
in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering
or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered
an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities
offered by this prospectus is subject to restrictions on transferability and must be made effective only in compliance with the Israeli
securities laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Italy</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione
Nazionale per le Societ&agrave; e la Borsa, or &ldquo;CONSOB&rdquo;) pursuant to the Italian securities legislation and, accordingly,
no offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in
a public offer within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998, or Decree No. 58, other than:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    Italian qualified investors, as defined in Article 100 of Decree no.58 by reference to Article 34-ter of CONSOB Regulation no. 11971
    of 14 May 1999, or Regulation no. 1197l as amended, or Qualified Investors; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Article 34-ter of
    Regulation No. 11971 as amended.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements
    where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">made
    by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative
    Decree No. 385 of 1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007 and any other applicable
    laws; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
    compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules
provided under Decree No. 58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply
with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring
the securities for any damages suffered by the investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 172; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->168<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Japan</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan
(Law No. 25 of 1948), as amended, or the FIEL, pursuant to an exemption from the registration requirements applicable to a private placement
of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations
promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit
of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities
may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities
is conditional upon the execution of an agreement to that effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Portugal</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is not being distributed in the context of a public offer of financial securities (oferta p&uacute;blica de valores mobili&aacute;rios)
in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (C&oacute;digo dos Valores Mobili&aacute;rios). The
securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document
and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market
Commission (Comiss&amp;abreve;o do Mercado de Valores Mobili&aacute;rios) for approval in Portugal and, accordingly, may not be distributed
or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify
as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to
persons who are &ldquo;qualified investors&rdquo; (as defined in the Portuguese Securities Code). Only such investors may receive this
document and they may not distribute it or the information contained in it to any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Sweden</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority).
Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances
that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel
med finansiella instrument). Any offering of securities in Sweden is limited to persons who are &ldquo;qualified investors&rdquo; (as
defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the
information contained in it to any other person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Switzerland</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock
exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for
issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses
under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland.
Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly
available in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial
Market Supervisory Authority (FINMA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 173; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->169<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
document is personal to the recipient only and not for general circulation in Switzerland.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>United
Kingdom</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services
Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as
amended, or the FSMA, has been published or is intended to be published in respect of the securities. This document is issued on a
confidential basis to &ldquo;qualified investors&rdquo; (within the meaning of section 86(7) of FSMA) in the United Kingdom, and the
securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document,
except in circumstances which do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not
be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in
the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the
issue or sale of the securities has only been communicated or caused to be communicated and will only be communicated or caused to be
communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to the company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters
relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial
Promotions) Order 2005, or FPO, (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth
companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together &ldquo;relevant
persons&rdquo;). The investments to which this document relates are available only to, and any invitation, offer or agreement to purchase
will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any
of its contents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to section 3A.3 of National Instrument 33-105 Underwriting Conflicts, or NI 33-105, the underwriters are not required to comply with
the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stabilization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate-covering
transactions, penalty bids, and purchases to cover positions created by short sales. Stabilizing transactions permit bids to purchase
shares so long as the stabilizing bids do not exceed a specified maximum and are engaged in for the purpose of preventing or retarding
a decline in the market price of the Ordinary Shares while the offering is in progress.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotment
transactions involve sales by the underwriters of shares in excess of the number of shares that the underwriters are obligated to purchase.
This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position,
the number of shares over-allotted by the underwriters is not greater than the number of shares that the underwriters purchase in the
over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares that the underwriters
purchase in the over-allotment option. The underwriters may close out any short position by exercising their over-allotment option and/or
purchasing shares in the open market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 174; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->170<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syndicate
covering transactions involve purchases of shares in the open market after the distribution has been completed in order to cover syndicate
short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things,
the price of shares available for purchase in the open market as compared with the price at which they may purchase shares through exercise
of the over-allotment option. If the underwriters sell more shares than could be covered by exercise of the over-allotment option and,
therefore, have a naked short position, the position can be closed out only by buying shares in the open market. A naked short position
is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the
Ordinary Shares in the open market that could adversely affect investors who purchase in the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
bids permit the representative to reclaim a selling concession from a syndicate member when the Ordinary Shares originally sold by that
syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price
of our Ordinary Shares or preventing or retarding a decline in the market price of our Ordinary Shares. As a result, the price of our
Ordinary Shares in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor the
underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our
Ordinary Shares. These transactions may be affected in the over-the-counter market or otherwise and, if commenced, may be discontinued
at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
underwriters and their affiliates may in the future provide various advisory, investment and commercial banking and other services for
us in the ordinary course of business, for which they may receive customary fees and commissions. However, we have not yet had, and have
no present arrangements with any of the underwriters for any further services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 175; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->171<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="Z_007"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPENSES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is an itemization of the total expenses, excluding underwriting discounts, expected to be incurred in connection with the
offer and sale of our Ordinary Shares by us. With the exception of the SEC registration fee and the FINRA filing fee, all amounts are
estimates:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 80%; text-align: justify">SEC registration fee</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">NYSE American listing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">FINRA filing fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Transfer agent fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Printer fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Legal fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Miscellaneous</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 176; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->172<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="Z_008"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
legal matters concerning this offering will be passed upon for us by Sullivan &amp; Worcester LLP, New York, New York. Certain legal
matters with respect to the legality of the issuance of the securities offered by this prospectus and other legal matters concerning
this offering relating to Israeli law will be passed upon for us by Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), Tel Aviv,
Israel. Certain legal matters related to the offering will be passed upon for the underwriters by Blank Rome LLP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 177; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->173<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><A NAME="Z_009"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements of Nasus Pharma Ltd. as of December 31, 2023 and 2022 and for each of the two years in the period ended December
31, 2023, included in this prospectus, have been audited by Brightman Almagor Zohar &amp; Co., a firm in the Deloitte Global Network,
an independent registered public accounting firm, as stated in their report appearing herein. Such financial statements are included
in reliance upon the report of such firm given their authority as experts in accounting and auditing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Z_010"></A>ENFORCEABILITY
OF CIVIL LIABILITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and senior management
and the Israeli experts named in the registration statement of which this prospectus forms a part, a substantial majority of whom reside
outside of the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets
and a substantial of our directors and senior management are located outside of the United States, any judgment obtained in the
United States against us or any of our directors and senior management may not be collectible within the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been informed by our legal counsel in Israel, Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), that it may be difficult to
assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on a violation
of U.S. securities laws because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court
agrees to hear a claim, if U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can
be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have irrevocably appointed Puglisi &amp; Associates as our agent to receive service of process in any action against us in any U.S. federal
or state court arising out of this offering or any purchase or sale of securities in connection with this offering. Subject to specified
time limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain exceptions,
is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including
a monetary or compensatory judgment in a non-civil matter, provided that among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            judgment is obtained after due process before a court of competent jurisdiction, according
                                            to the laws of the state in which the judgment is given and the rules of private international
                                            law currently prevailing in Israel;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            judgment is final and is not subject to any right of appeal;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevailing law of the foreign state in which the judgment was rendered allows for the enforcement
                                            of judgments of Israeli courts; however, the court may enforce a foreign judgment, even without
                                            reciprocity, based on the request of the Attorney General, under certain circumstances;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adequate
                                            service of process has been affected and the defendant has had a reasonable opportunity to
                                            be heard and to present his or her evidence;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            liabilities under the judgment are enforceable according to the laws of the State of Israel
                                            and the judgment and the enforcement of the civil liabilities set forth in the judgment is
                                            not contrary to the law or public policy in Israel nor likely to impair the security or sovereignty
                                            of Israel;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            judgment was not obtained by fraud, there was reasonable opportunity for the defendant to
                                            present their case, the judgment was given by an authorized court to issue it under the applicable
                                            international private law rules in Israel, and the judgement does not conflict with any other
                                            valid judgments in the same matter between the same parties;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            action between the same parties in the same matter is not pending in any Israeli court at
                                            the time the lawsuit is instituted in the foreign court;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            judgment is enforceable according to the laws of Israel and according to the law of the foreign
                                            state in which the relief was granted; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enforcement
                                            may be denied if it could harm the sovereignty or security of Israel.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a foreign judgment is declared enforceable by an Israeli court, it generally will be payable in Israeli currency. The conversion to Israeli
currency will be based on the latest official exchange rate published by the Bank of Israel before the payment date. However, the obligated
party will fulfill its duty by the judgment even if they choose to make the payment in the same foreign currency, subject to the laws
governing the foreign currency applicable at that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending
collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli CPI plus
interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable
exchange rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 178; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->174<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="Z_011"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form F-1 under the Securities Act relating to this offering of our Ordinary Shares.
This prospectus does not contain all of the information contained in the registration statement. The rules and regulations of the SEC
allow us to omit certain information from this prospectus that is included in the registration statement. Statements made in this prospectus
concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized,
but are not complete descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the registration
statement, you may read the document itself for a complete description of its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically with the SEC.
Our filings with the SEC are also available to the public through the SEC&rsquo;s website at www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those
requirements are filing reports with the SEC. Those other reports or other information may be inspected without charge at the locations
described above. As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content
of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly
and current reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered
under the Exchange Act. However, we will file with the SEC, within 120 days after the end of each fiscal year, or such applicable time
as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting
firm, and intend to submit to the SEC, on Form 6-K, unaudited interim financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain a corporate website at www.nasuspharma.com. Information contained on, or that can be accessed through, our website does not
constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.
We will post on our website any materials required to be so posted on such website under applicable corporate or securities laws and
regulations, including, posting any XBRL interactive financial data required to be filed with the SEC and any notices of general meetings
of our shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 179; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->175<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ch_001"></A>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audited
consolidated financial statements of Nasus Pharma Ltd. and its subsidiary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#xc_001">Report of Independent Registered Public Accounting Firm</A> (PCAOB ID 1197)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#xc_002">Consolidated Balance Sheets</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#xc_003">Consolidated Statements of Operations</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#xc_004">Consolidated Statements of Shareholders&rsquo; Deficit</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#xc_005">Consolidated Statements of Cash Flows</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-6</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#xc_006">Notes to Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Unaudited interim condensed consolidated financial
statements of Nasus Pharma Ltd. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><B></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ach_001">Unaudited
    Interim Condensed Consolidated Balance Sheets</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-29</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ach_002">Unaudited
    Interim Condensed Consolidated Statements of Operations</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-30</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ach_003">Unaudited
    Interim Condensed Consolidated Statements of Shareholders&rsquo; Deficit</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ach_004">Unaudited
    Interim Condensed Consolidated Statements of Cash Flows</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-32</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ach_005">Notes
    to Unaudited Interim Condensed Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-33</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"></P>


<!-- Field: Page; Sequence: 180; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="xc_001"></A>Report
of Independent Registered Public Accounting Firm</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>To
the Shareholders and the Board of Directors of Nasus Pharma Ltd</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Nasus Pharma Ltd. and its subsidiary (the &ldquo;Company&rdquo;) as of December
31, 2023 and 2022, the related consolidated statements of operations, changes in shareholders&rsquo; deficit, and cash flows, for each
of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December
31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023,
in conformity with accounting principles generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
1.B to the financial statements, the Company&rsquo;s lack of revenues and accumulated operating losses raise substantial doubt about
its ability to continue as a going concern. Management&rsquo;s plans in regard to these matters are also described in Note 1.B. The financial
statements do not include any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>/s/
    Brightman Almagor Zohar &amp; Co.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certified
    Public Accountants</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A
    Firm in the Deloitte Global Network</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv,
    Israel</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    30, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have served as the Company&rsquo;s auditor since 2024.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 181; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="xc_002"></A>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
BALANCE SHEETS</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Amounts
    in thousands, except share and per share amounts)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    assets:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">193</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">154</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">234</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">246</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">444</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">417</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Assets</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>444</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>417</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities
    and Shareholders&rsquo; Deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable (of which $0 and $6 are to related parties as of December 31, 2023 and December 31, 2022, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">655</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">771</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expense and other current liabilities (of which $451 and $147 are to related parties as of December 31, 2023, and December
    31, 2022, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">616</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">345</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    securities (of which $365 and $382 are to related parties as of December 31, 2023 and December 31, 2022, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,830</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,054</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
    debt from shareholders (of which $344 and $259 are to related parties as of December 31, 2023, and December 31, 2022, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">627</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">518</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities related to discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">513</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">514</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,241</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,202</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
                                            Liabilities</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,241</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,202</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
    and contingencies (see Note 7)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders&rsquo;
    deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    Shares(&#42;), par value ILS 0.01 per share; 2,681,000 shares authorized; 1,444,359 shares issued and outstanding</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,331</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,292</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,132</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,081</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Shareholders&rsquo; Deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,797</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,785</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Liabilities and Shareholders&rsquo; Deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">444</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>417</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
  otherwise stated, the term Ordinary Shares in these financial statements refers to all classes of shares, including Class Ordinary
  Shares, Class A Ordinary Shares, Class A-1 Ordinary Shares, Class A-2 Ordinary Shares and Class A-3 Ordinary Shares.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.&lrm;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 182; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="xc_003"></A>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF OPERATIONS</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Amounts
    in thousands, except share and per share amounts)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    expenses:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development (of which $228 and $231 are with related parties in 2023 and 2022, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">567</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,116</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative (of which $288 and $313 are with related parties in 2023 and 2022, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">580</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">926</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    operating expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,147</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,042</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    loss from continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,147</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,042</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense (of which $27 and $9 are with related parties in 2023 and 2022, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(49</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of convertible securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">219</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(88</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    expense, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(28</P></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    from continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,005</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,152</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    income (loss) from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(46</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">441</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,051</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,711</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per
    share data:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    per share attributable to shareholders:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.73</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.18</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.95</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.18</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><P STYLE="font-style: normal; margin: 0; font-weight: normal"><FONT STYLE="font-style: normal; font-weight: normal">)</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average Ordinary Shares outstanding - basic</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444,359</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444,296</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average Ordinary Shares outstanding - diluted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,479,602</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444,296</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.&lrm;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 183; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="xc_004"></A>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF CHANGES IN SHAREHOLDERS&rsquo; DEFICIT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
    Shares**</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional<BR>
Paid- in</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholders&rsquo;</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capital</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</FONT></TD><TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    as of January 1, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444,290</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,266</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,370</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1,100</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance
    of Class Ordinary Shares for share options exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,711</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,711</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    as of December 31, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444,359</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,292</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10,081</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,785</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    -based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    as of December 31, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444,359</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,331</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,132</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,797</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represent
  amounts less than $ 1.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
  otherwise stated, the term Ordinary Shares in these financial statements refers to all classes of shares, including Class Ordinary
  Shares, Class A Ordinary Shares, Class A-1 Ordinary Shares, Class A-2 Ordinary Shares and Class A-3 Ordinary Shares.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.&lrm;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 184; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="xc_005"></A>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF CASH FLOWS</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Amounts
    in thousands)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    flows from operating activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(1,051</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,711</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    Net loss (income) from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(441</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Loss from continuing operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,005</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,152</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    to reconcile loss from continuing operations to net cash used in operating activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based
    compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of convertible securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(219</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of exchange rates</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    interest on short-term debt from shareholders</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in operating assets and liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">174</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(116</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">150</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expense and other current liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">271</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">153</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    used in operating activities from continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(982</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,536</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by (used in) operating activities from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(47</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">325</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in operating activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,029</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,211</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    flows from investing activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    used in investing activities from continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    used in investing activities from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(160</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    used in investing activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(160</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
                                            flows from financing activities:</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of convertible securities (of which $100 and $350 are with related parties in 2023 and 2022, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">995</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">966</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from short-term debt from shareholders (of which $60 and $250 are with related parties in 2023 and 2022, respectively)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from the exercise of share options</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,055</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,469</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    used in financing activities from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(231</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    provided by financing activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,055</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,238</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of exchange rate changes on cash, cash equivalents and restricted cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    increase (decrease) in cash and cash equivalents</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(143</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
    cash equivalents and restricted cash at beginning of year</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">314</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
    cash equivalents and restricted cash at end of year</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">210</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.&lrm;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets
to the total of the same such amounts shown on the consolidated statements of cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;193</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;154</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
    cash equivalents and restricted cash at end of year</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">210</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 185; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="xc_006"></A>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  1:</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORGANIZATION
  AND NATURE OF THE BUSINESS</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
                                            of the Business</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus
Pharma Ltd. (the &ldquo;Company&rdquo;) was incorporated in May 2019 under the laws of the State of Israel. The Company is a clinical stage
specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions. The
Company is developing a powder-based intranasal technology with a specialized product portfolio to address acute medical conditions and
public health threats. The Company&rsquo;s lead product candidates are NS002, an intranasal powder Epinephrine nasal spray for the treatment
of type 1 severe allergies and anaphylaxis, and NS001, an intranasal Naloxone powder nasal spray for the treatment of opioid overdose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had a wholly-owned subsidiary in the United Kingdom which had no operations since its incorporation in September 2020
through its dissolution in February 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
                                            and Going Concern</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (&ldquo;U.S.
GAAP&rdquo;) on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course
of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company has devoted most of its efforts to business planning, research and development, clinical trials and raising
capital. The Company is still in its development and clinical stage and has not yet generated revenues from its existing products
under development and, accordingly, the extent of the Company&rsquo;s future operating losses and the timing that the Company will
become profitable are uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2023, the Company incurred a net loss of $1,051 (and a loss of $1,005 from continuing operations)
and used net cash flows from operations of $1,029 (and cash used in continuing operations was $982). Additionally, as of
December 31, 2023, the Company had cash and cash equivalents of $193 to fund its operations and an accumulated deficit of $11,132.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has funded its operations to date primarily through equity financing and the issuance of convertible securities in the form of
simple agreement of future equity (&ldquo;SAFE&rdquo;) (see Note 4 and Note 13). Additional funding will be required to complete the
Company&rsquo;s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts
of the Company&rsquo;s products and to achieve a level of sales adequate to support the Company&rsquo;s cost structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
conditions raise substantial doubts about the Company&rsquo;s ability to continue as a going concern. Management&rsquo;s plans include,
but are not limited to, an initial public offering (&ldquo;IPO&rdquo;) in the United States. While the Company has been able to raise
outside capital in the past, there can be no assurance that it will be able to successfully consummate an IPO or obtain additional financing
on a timely basis in terms acceptable to the Company, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
expects that the Company will continue to generate losses from the clinical development and regulatory activities of its product candidates,
which would result in negative cash flow from operating activity. This has led management to conclude that there is substantial doubt
about the Company&rsquo;s ability to continue as a going concern.&nbsp; The Company&rsquo;s consolidated financial statements do not
reflect any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 186; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  2:</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT
  ACCOUNTING POLICIES</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>a.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
                                            of presentation and principles of consolidation:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements are prepared in accordance with U.S. GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements include accounts of the Company&rsquo;s wholly-owned subsidiary in the United Kingdom that was dissolved
in February 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
                                            of estimates:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from
those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
items subject to such estimates and assumptions include identifying the existence of embedded derivatives, share-based compensation and
the determination of the fair value of the Company&rsquo;s Ordinary Shares and share options and the fair value of convertible
securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
believes that the estimates, and judgments they made, are reasonable based upon information available to them at the time that these
estimates and judgments are made. To the extent that there are material differences between these estimates and actual results, the Company&rsquo;s
consolidated financial statements will be affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>c.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
                                            statements in U.S. dollars:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
functional and reporting currency of the Company is the United States dollar (&ldquo;USD&rdquo; or &ldquo;U.S. dollar&rdquo;) as the
U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate
in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company balances and transactions denominated in U.S. dollars are presented at their original amounts. Non-U.S. dollar transactions and
balances have been remeasured to U.S. dollars in accordance with Accounting Standards Codification (&ldquo;ASC&rdquo;) 830 of the Financial
Accounting Standards Board (&ldquo;FASB&rdquo;). All transaction gains and losses from remeasurement of monetary balance sheet items
denominated in non-U.S. dollar currencies are included within other expense (income), net in the consolidated statements
of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>d.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
                                            equivalents:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, and restricted
cash. The Company&rsquo;s cash and cash equivalents consist of demand deposits with financial institutions. The associated risk
of concentration is mitigated by banking with creditworthy institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
equivalents are short-term highly liquid investments that are readily convertible to cash with maturities of three months or less as
of the date acquired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>e.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restricted
                                            cash:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash consists of amounts used to secure for the Company&rsquo;s corporate credit cards, and are invested in highly liquid deposits, with
maturities of three months or less.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 187; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>f.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Severance
                                            pay:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">According
to the Israeli Severance Pay Law, 1963 (&ldquo;Severance Pay Law&rdquo;), all of the Company&rsquo;s employees are entitled to severance
payment, following the termination of their employment. Under the Severance Pay Law, the severance payment is calculated as one-month
salary for each year of employment, or a portion thereof. The Company&rsquo;s liability for severance pay is covered by the provisions
of Section 14 of the Severance Pay Law (&ldquo;Section 14&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 14 employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, contributed on their behalf to their
insurance funds. Payments in accordance with Section 14 release the Company from any future severance payments in respect of those employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Therefore,
the Company does not recognize a liability for severance pay due to its employees beyond the monthly deposits they are required to make
and, accordingly, the amount deposited under Section 14 are not recorded as an asset in the Company&rsquo;s balance sheets. Severance
expenses for the years ended December 31, 2023 and 2022 amounted to $10, and $74, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>g.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
                                            value measurement:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures and discloses the fair value of financial assets and liabilities in accordance with ASC Topic 820, &ldquo;Fair Value
Measurement.&rdquo; Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly
transaction between market participants at the measurement date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value
into three broad levels, which are described below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">quoted
    prices (unadjusted) in active markets for identical assets or liabilities.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs
    other than quoted prices included within Level 1 that are observable directly or indirectly.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">inputs
    that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balances
included in the consolidated financial statements measured at fair value on a recurring basis include convertible securities. When developing
fair value measurements, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. However, for
estimating the fair value of convertible securities the Company utilizes unobservable inputs in determining fair value due to
the lack of observable inputs in the market, which requires greater judgment in measuring fair value. In instances where there is limited
or no observable market data, fair value measurements for assets and liabilities are based primarily upon the Company&rsquo;s own estimates,
and the measurements reflect information and assumptions that management believes a market participant would use in pricing the asset
or liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>h.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
                                            and Administrative</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of compensation-related expenses for management and other employees. Also, it consists
of expenses for facilities, professional services fees, management fees, insurance costs, and other general overhead costs. General and
administrative expenses are expensed as incurred with the exception of share-based compensation, which is recognized over the requisite
service period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>i.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
                                            and development costs:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses include compensation-related expenses, consulting costs, external contract research and development expenses,
clinical trial costs, raw materials, third party manufacturing costs. Research and development costs are expensed as incurred, except
for share-based compensation, which is recognized over the requisite service period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 188; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -28.35pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2022, the Company entered into a non-recurring research and development arrangement with a governmental body. As part of the
arrangement, the Company performed certain research and development activities in connection with NS001 and reported on the results of such research and development activities to the governmental body. The Company does not
have an obligation or other contractual commitment to repay the amounts received under this arrangement, and intellectual property
and know-how, if any, resulting from the performance of such research and development activities will remain with the Company.
Additionally, the Company does not provide research and development services as part of its central operations. The amounts received
under the arrangement of $287 were recorded as a reduction to research and development expenses within the consolidated statements
of operations during the year ended December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>j.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
                                            Costs</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
and related patent costs are expensed as incurred as their realization is uncertain. Costs related to patent registration are classified
as general and administrative expenses, and costs related to acquired patents are recorded in research and development expenses within
the consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>k.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contingent
                                            liabilities</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its contingent liabilities in accordance with ASC No. 450, &ldquo;Contingencies&rdquo;. A provision is recorded
when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. With respect to legal
matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of
legal counsel and other information and events pertaining to a particular matter. See Note 6.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>l.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
                                            tax</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future
tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities
and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and
liabilities of a change in tax rates is recognized in income or expense in the period that includes the enactment date. A valuation allowance
is established when necessary to reduce deferred income tax assets to the amount expected to be realized based on management&rsquo;s
consideration of all positive and contradictory evidence available. As of December 31, 2023, and 2022, a full valuation allowance was
established by the Company to reduce the deferred tax assets to the amount supported by future reversals of existing taxable temporary
differences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates uncertainty in income tax positions based on a more-likely-than-not recognition standard. If that threshold is met,
the tax position is then measured at the largest amount that is greater than 50% likely of being realized upon ultimate settlement. If
applicable, the Company records interest and penalties as a component of income tax expense. The Company applies a more-likely-than-not
recognition threshold to uncertain tax positions based on the technical merits of the income tax positions taken. The Company does not
recognize a tax benefit unless it is more likely than not that the tax position will be sustained upon examination, including resolution
of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these
positions is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The
Company believes that its tax positions are all highly certain of being upheld upon examination. As such, as of December 31, 2023 and
2022, the Company has not recorded any liability for unrecognized tax benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>m.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share-based
                                            compensation:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company measures and records the expense related to share-based compensation awards made to employees, directors, and non-employee service
providers based on estimated fair values of those awards as determined on the date of grant. The Company recognizes share-based compensation
expenses based on the accelerated attribution method over the requisite service period. The Company recognizes forfeitures of awards
as they occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 189; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes-Merton (&ldquo;Black-Scholes&rdquo;) option-pricing model to determine the fair value of share options.
The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions, which determine the fair value
of share-based compensation awards, including the Class Ordinary Share price, expected volatility of the underlying Class Ordinary
Share, expected option term (the time from the grant date until the share options are exercised or expire), and expected divided
yield. The Company calculates the fair value of share options granted using the following assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
                                            </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ordinary
                                            Share Price &ndash; Since the Company&rsquo;s Class Ordinary Shares are not publicly
                                            traded, the expected volatility is based on the historical and implied volatility of similar
                                            companies whose stock or option prices are publicly available, after considering the industry,
                                            stage of life cycle, size, market capitalization, and financial leverage of the other companies.
                                            The Company estimated its Ordinary Share price based on third party valuation.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
                                            Volatility &ndash; The Company estimated volatility for share option grants by evaluating
                                            the average historical volatility of a peer group of companies for the period immediately
                                            preceding the share option grant for a term that is approximately equal to the share
                                            options&rsquo; expected term.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
                                            Term&mdash;The expected term of the Company&rsquo;s share options represents the period
                                            that the share options are expected to be outstanding. The Company has elected to
                                            use the &ldquo;simplified&rdquo; method for share options granted to employees and
                                            directors, as the Company does not have sufficient historical information to develop reasonable
                                            expectations about future exercise patterns and post-vesting employment termination behavior.
                                            Under this approach, the midpoint of the share options vesting term and contractual
                                            expiration period to compute the expected term. The simplified method makes the assumption
                                            that the employee will exercise share options evenly over the period when the share options
                                            are vested and ending on the date when the share options expire. The expected term for share
                                            options granted to non-employees is based on the contractual term.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-Free
                                            Interest Rate&mdash;The risk-free interest rate is based on the implied yield currently available
                                            on US Treasury zero-coupon issues with a term that is equal to the share options&rsquo;
                                            expected term at the grant date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
                                            Yield&mdash;The Company has not declared or paid dividends to date and does not anticipate
                                            declaring dividends. As such, the dividend yield has been estimated to be zero.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>n.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basic
                                            and diluted net loss per share</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
loss per share attributable to holders of Ordinary Shares is computed by dividing the net loss by the weighted average number
of Ordinary Shares outstanding during the period. Diluted loss per share attributable to holders of Ordinary Shares is computed
by dividing the net loss attributable to holders of Ordinary Shares and assumed conversions by the weighted average number of
Ordinary Shares outstanding together with the number of additional Ordinary Shares that would have been outstanding if all potentially
dilutive Ordinary Shares had been issued. Diluted net loss per share is the same as basic net loss per share in periods when the effects
of potentially dilutive Ordinary Shares are anti-dilutive. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 190; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>o.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
                                            and Uncertainties</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical
studies and clinical trials, the need to obtain marketing approval for any product candidate that it may identify and develop, the need
to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary
technology, compliance with government regulations, development by competitors of technological innovations and reliance on third parties
to assist in discovery and development activities, and conducting the Company&rsquo;s clinical trials and performing data collection
and analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>p.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Concentrations
                                            of Risk</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. Bank
deposits are held by financial institutions and these deposits may at times not be insured. The Company limits its credit risk associated
with cash and cash equivalents by placing them with financial institutions that it believes are of high-quality credit rating. The Company
has not experienced any losses on its deposits of cash or cash equivalents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>q.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Segment
                                            information</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has one operating and reportable segment. The Company&rsquo;s chief operating decision maker, the Chief Executive Officer, reviews
financial information presented on a company-wide basis for purposes of allocating resources and evaluating financial performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>r.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Emerging
                                            Growth Company Status</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an emerging growth company (&ldquo;EGC&rdquo;), as defined in Section 2(a) of the United States Securities Act of 1933, as
modified by the Jumpstart Our Business Startups Act of 2012 (the &ldquo;JOBS Act&rdquo;). Section 102(b)(1) of the JOBS Act exempts EGCs
from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not
had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act)
are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an EGC can elect to opt out
of the extended transition period and comply with the requirements that apply to non-EGCs but any such election to opt out is irrevocable.
The Company has not elected to opt out of such extended transition period which means that when a financial accounting standard is issued
or revised and it has different application dates for public or private companies, the Company, as an EGC, can adopt the new or revised
standard at the time private companies adopt the new or revised standard. The Company will be eligible to use this extended transition
period under the JOBS Act until the earlier of the date it (i) is no longer an EGC or (ii) affirmatively and irrevocably opts out of
the extended transition period provided in the JOBS Act. As a result, the Company&rsquo;s financial statements may not be comparable
to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that
are applicable to public companies, which may make comparison of the Company&rsquo;s financials to those of other public companies more
difficult.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will cease to be an EGC on the date that is the earliest of (i) the end of the Company&rsquo;s fiscal year in which its total
annual gross revenue exceeds $1.235 billion, (ii) the last day of the Company&rsquo;s fiscal year following the fifth anniversary of
the date on which initial public offering has been consummated, (iii) the date on which the Company has issued more than $1.0 billion
in non-convertible debt during the preceding three-year period or (iv) the last day of the Company&rsquo;s fiscal year in which the market
value of the Company&rsquo;s Ordinary Shares held by non-affiliates exceeds $700 million as of the last business day of its most recently
completed second quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>s.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
                                            Adopted Accounting Standards</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an &ldquo;emerging growth company,&rdquo; the JOBS Act allows the Company to delay adoption of new or revised accounting pronouncements
applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this
extended transition period under the JOBS Act. The adoption dates discussed below reflects this election.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 191; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &ndash; Credit Losses (Topic 326): Measurement of Credit Losses on
Financial Instruments, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial
asset measured at amortized cost to be presented at the net amount expected to be collected. The new guidance was adopted for
the Company on January 1, 2023 and the adoption did not have a material impact on the Company&rsquo;s consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>t.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
                                            Issued Accounting Standards Not Yet Adopted</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, <I>Segment Reporting (Topic 280) &ndash; Improvements to Reportable Segment Disclosures</I>.
This ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses.
This ASU is effective for our annual fiscal year 2024, and interim periods starting in fiscal year 2025. Early adoption is permitted.
A public entity should apply the amendments in this ASU retrospectively to all prior periods presented in the financial statements. As
of December 31, 2023, the Company does not expect ASU 2023-07 will have a material impact on the segment disclosures within the consolidated
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  3:</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHORT-TERM
  DEBT FROM SHAREHOLDERS</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July 2022, the Company received a loan in the amount of $500 from two existing shareholders, including a director of the Company,
for a term of twelve (12) months, at an interest rate of 8% per annum (the &ldquo;July 2022 Loan&rdquo;). As of December 31, 2023,
the July 2022 Loan was outstanding. On August 28, 2024, the Company and each of said shareholders entered into an exchange letter
(the &ldquo;July 2022 Loan Exchange Letter&rdquo;), according to which the Company&rsquo;s obligations in connection with the loan
were discharged in consideration for the issuance of a SAFE. The July 2022 Loan balance was $560 as of December 31 2023, and after
considering interest accrued during 2024 through the date the July 2022 Loan Exchange Letter was executed and withholding taxes to
be paid on behalf of the said shareholders, it was deemed that Dr. Hershman invested an amount in the SAFE of $284 and Michael
Gibber invested an amount in the SAFE of $286. The July 2022 Loan, including accrued interest, was $560 and $518 as of December 31, 2023 and 2022, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, the Company received a loan in an aggregate amount of $60 from its co-founders, Mr. Udi Gilboa and Dr. Dalia Megiddo,
and director, Dr. Ronnie Hershman, or the February 2023 Loan, under substantially the same terms as the July 2022 Loan, for a term of
twelve (12) months, at an interest rate of 8% per annum. As of December 31, 2023, the February 2023 Loan was outstanding. On August 28,
2024, the Company and each of these investors entered into an exchange letter (the &ldquo;February 2023 Loan Exchange Letter&rdquo;),
according to which the Company&rsquo;s obligations in connection with the February 2023 Loan were discharged in consideration for the
issuance of a SAFE under the same terms as the 2024 SAFEs, as described below, under which Dr. Ronnie Hershman was deemed to have invested
an amount in the SAFE of $44, Dr. Dalia Megiddo was deemed to have invested an amount in the SAFE of $11, and Mr. Udi Gilboa
was deemed to have invested an amount in the SAFE of $11 in said SAFE. The February 2023 Loan, including interest accrued, was $67 and $0 as of December
31, 2023 and 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  4:</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONVERTIBLE
  SECURITIES</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company has raised funds through the issuance of Simple Agreement for Future Equity (&ldquo;SAFE&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
SAFE requires conversion into shares of the Company upon the occurrence of certain events, or at the maturity date of the SAFE. The number
of shares to be issued upon conversion of the SAFE are not fixed and will be dependent upon the nature of the event that occurred
that resulted in its conversion, the fair value of shares as of the event&rsquo;s date, and other factors as defined in the related agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SAFEs
are classified as a liability and the Company elected the fair value option in accordance with ASC 825, Financial Instruments (&ldquo;ASC
825&rdquo;). Accordingly, the liability is adjusted to fair value at each balance sheet date, with the change in fair value being recorded
as change in fair value of convertible securities within the consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 192; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            February 17, 2022, the shareholders approved the issuance of SAFE (the &ldquo;2022 SAFEs&rdquo;)
                                            to certain shareholders and third parties up to a maximum aggregate amount of $1,000. In
                                            March 2022 and April 2022, the Company raised $966 under the 2022 SAFE.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 SAFE investors are entitled to the rights and privileges set forth in the agreement, which include the issuance of the most senior
shares outstanding upon conversion of the 2022 SAFEs in the event of an equity financing or liquidity event occurs prior to the termination
of the 2022 SAFEs as defined in the related agreement. The investors shall receive a 40% discount on the share price in any of such event.
If a dissolution event occurs prior to the termination of the 2022 SAFE, each SAFE investor will be entitled to receive, prior to consummation
of the dissolution event, a portion of the related proceeds equal to its investment amount, or in case the applicable proceeds upon dissolution
are insufficient to permit a full payment of the amounts invested under the 2022 SAFEs, a prorated amount in par with the other SAFE
investors. In the event that the 2022 SAFEs mature after 15 months from its issuance, all amounts invested under the 2022 SAFEs are converted
into the Company&rsquo;s outstanding most senior shares based on a $41,000 valuation divided by number of outstanding shares including
any outstanding share options. The 2022 SAFEs will expire and terminate immediately upon the earliest to occur of (1) the issuance of
shares upon its conversion due to equity financing or liquidity event, or upon maturity; or (2) the payment, or setting aside
for payment, of amounts due to the occurrence of dissolution event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June, and July 2023, the 2022 SAFEs matured and accordingly, it should have been converted into 35,243 most senior outstanding shares. As of December 31, 2023 the shares have not been issued and therefore, the 2022 SAFEs remained
outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 28, 2024, the 2022 SAFEs were converted into 35,243 Class A-3A Ordinary Shares (see Note 7c) and accordingly, the 2022
SAFEs were terminated on that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            March 15, 2023, the shareholders approved the issuance of additional SAFEs to certain shareholders
                                            and third parties up to the maximum aggregate amount of $1,000 (the &ldquo;2023 SAFEs&rdquo;).
                                            In March and April 2023, the Company raised $995 under the 2023 SAFEs. In
                                            addition, the Company paid $15 as finder fees for issuance of the 2023 SAFEs which was recorded
                                            as other expense (income), net within the consolidated statements of operations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 SAFEs investors are entitled to the rights and privileges set forth in the agreement, which include the issuance of the most senior
shares outstanding upon conversion of the 2023 SAFEs in the event of an equity financing or liquidity event occurs prior to the termination
of the 2023 SAFEs as defined in the related agreement. The investors shall receive a 40% discount on the share price in any of such event.
If a dissolution event occurs prior to the termination of the 2023 SAFEs, each SAFE investor will be entitled to receive, prior to consummation
of the dissolution event, a portion of the related proceeds equal to its investment amount, or in case the applicable proceeds upon dissolution
are insufficient to permit a full payment of the amounts invested under the 2023 SAFEs, a prorated amount in par with the other SAFE
investors. In the event the 2023 SAFEs mature after 15 months without a conversion prior to 15 months from its issuance, all amounts
invested under the 2023 SAFEs are converted into the Company&rsquo;s outstanding most senior shares based on a $24,600 valuation divided
by number of outstanding shares including any outstanding share options. The 2023 SAFEs will expire and terminate immediately upon the
earliest to occur of (1) the issuance of shares upon its conversion due to equity financing or liquidity event, or upon maturity;
or (2) the payment, or setting aside for payment, of amounts due to the occurrence of dissolution event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June, July and August 2024, the 2023 SAFEs have matured. In August 28, 2024, the 2023 SAFE were converted into 63,958 Class A-3B Ordinary
Shares (see Note 7c) and accordingly, the 2023 SAFEs were terminated on that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company measured the 2022 SAFEs and the 2023 SAFEs upon issuance and on each period end
                                            at its fair value in accordance with ASC 825-10. Accordingly, the SAFEs are measured
                                            at fair value each period with changes in fair value reported in the consolidated statements
                                            of operations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SAFEs were valued at the end of the year using a probability-weighted expected return model, which incorporated significant unobservable
inputs. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 193; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the following significant inputs in measuring the SAFEs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 56%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value of Ordinary Share*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.63</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    average cost of capital</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.70</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22.80</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    free rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.06</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.75</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time
    to maturity</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.48</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.46</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center; width: 1in"></TD>
    <TD STYLE="text-align: center; width: 0.25in">*</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Including inputs and assumptions
  on the likelihood of a SAFE mandatory conversion, qualified equity financing or liquidity event or dissolution.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  5:</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FAIR
  VALUE MEASUREMENTS</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provide the liabilities carried at fair value measured on a recurring basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measured as of December 31, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
    liabilities at fair value:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,054</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,054</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    financial liabilities at fair value</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,054</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,054</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measured as of December 31, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
    liabilities at fair value:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,830</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,830</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    financial liabilities at fair value</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,830</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,830</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
changes in the fair value of the Company&rsquo;s Level 3 financial liabilities, which are measured on a recurring basis are as follows:</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January
    1, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 82%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of 2022 SAFE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">966</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of convertible securities</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">88</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,054</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from issuance of 2023 SAFE</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">995</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of convertible securities</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(219</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,830</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between fair value measurement levels during the years ended December 31, 2023 and 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of the Company&rsquo;s cash and cash equivalents, restricted cash, other current assets, accounts payable,
accrued expense and other current liabilities and short-term debt from shareholders approximates their carrying values as these financial
instruments are highly liquid or short-term in nature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -56.7pt"></P>


<!-- Field: Page; Sequence: 194; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -56.7pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  6:-</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTINGENT
  LIABILITIES AND COMMITMENTS</B></FONT></TD></TR>
</TABLE>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Litigation</B></FONT></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may be involved in various claims and legal
proceedings. The Company reviews the status of each matter and assesses its potential financial exposure. If the potential loss from any
claim or legal proceeding is considered probable and the amount can be reasonably estimated, the Company accrues a liability for the estimated
loss. The Company discloses pending claims and legal proceedings litigation if the Company believes a possibility exists that the claims
and legal proceedings litigation will have a material effect on its financial results. Legal costs are accounted for as they are incurred.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            May 2022, the Company received a demand letter from a supplier associated with the Taffix
                                            business, which demanded that the Company pay professional fees billed to the Company in
                                            connection with services provided by the supplier. In August 2022, the supplier commenced
                                            legal proceedings in the magistrate court of Tel Aviv, in an amount of $85. The Company
                                            recorded the entire contractual expenses prior to January 1, 2022 and a liability of $85
                                            is recorded as current liabilities related to discontinued operations within the Company&rsquo;s
                                            consolidated balance sheets as of December 31, 2023 and 2022.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commitments</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            May 2019, the Company entered into a license agreement (&ldquo;License Agreement&rdquo;)
                                            with Formulex Pharma Innovations Ltd. (&ldquo;Formulex&rdquo;). Formulex is an Israeli corporation,
                                            owned by the Company&rsquo;s shareholders, Mr. Ehud Gilboa, Dr. Dalia Megiddo and Dr.
                                            Ronnie Herschman. Pursuant to the License Agreement, Formulex granted the Company a license
                                            for the development, manufacture and commercialization of Formulex&rsquo;s patent for dry
                                            powder compositions for intranasal delivery and rights in the know-how of its intranasal
                                            and inhaled formulations, combination products, and particle engineering, together, the Licensed
                                            Products. Also pursuant to the License Agreement, the Company pay Formulex royalties of the
                                            Licensed Products in the amount of 0.5% of net sales of the licensed products, which are
                                            capped at $100 in the aggregate. The royalty payment period commenced on the effective date
                                            of the agreement and will continue on a country-by-country, product-by-product basis for
                                            the longer of: (i) 15 years from the date of the first commercial sale of such Licensed
                                            Product in such country, or (ii) until the licensed patent expires in such country. The Company
                                            may terminate the License Agreement for any reason upon 60 days prior written notice. In
                                            the event of such termination, the Company has the right to acquire the Licensed Technology
                                            in an amount equal to the balance between the amount actually paid to Formulex prior to the
                                            date of termination and the amount of $100. Termination of the agreement does not relieve
                                            the parties of obligation accrued prior to such termination.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2019, the Company entered into a service agreement with Formulex, as subsequently amended in March 2020, to facilitate the
flow of information and know how, as well as help develop the Company products. The Company pays $5 a month under the service agreement.
The services agreement automatically renews every year for a period of one year, unless terminated by either party upon 30 days&rsquo;
written notice, in accordance with the terms and conditions set forth therein. In connection with the same, Formulex provided the Company with one-time development services in 2023 and 2022 for additional fees of $22 and $11, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            September 2019, the Company entered into a master service agreement and schedules of work
                                            (&ldquo;Aptar Agreement&rdquo;), with Aptar Group Inc. (&ldquo;Aptar&rdquo;), under which
                                            Aptar granted the Company technology access to co-development and support for the development
                                            and submissions to regulatory bodies of intranasal to deliver NS001 and NS002 using Aptar&rsquo;s
                                            technology.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 195; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NASUS PHARMA LTD. AND ITS SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Amounts in thousands, except share and per
share amounts)</B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in">In
connection with NS001, the Company is required to pay Aptar up to $1,350 in the aggregate comprising of $200 in development
stage, $350 upon submission of New Drug Application (&ldquo;NDA&rdquo;) with the Food and Drug Administration (&ldquo;FDA&rdquo;)
(or equivalent) and $800 at market launch. The Company paid $200 to Aptar prior to January 1, 2022. In August
2021, the Company entered into a change order with respect to NS001, for the provision of additional services and deliverables to be
provided by Aptar for an additional fee of 100 thousand Euro, out of which 40 thousand Euro paid to Aptar prior to January 1, 2022,
and the remaining amounts will be paid upon NDA submission and FDA approval of NS001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in">In
connection with NS002, the Company is required to pay Aptar up to $675 in the aggregate comprising of $150 in development
stage, $225 upon submission of NDA with the FDA (or equivalent) and $300 at market launch. The Company paid $150 to Aptar prior to January 1, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in">The Company is also obligated to pay Aptar for
each final product that achieves certain sales-based milestone events and tiered royalties on net sales of each final product by the
Company or its affiliates or sublicensees at rates ranging from a low single-digit percentage, depending on the total annual worldwide
net sales of each such final product up to seven years after first commercial sale. The Aptar Agreement has an early termination fee
in case the Company terminate NS001 or NS002 programs for whatever reason, other than a breach of the agreement by Aptar, of $450 for
each product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in">In April 2021, the Company entered into an agreement
with Aptar&rsquo;s subdivision, NextBreath, which is subject to terms and conditions of the Aptar Agreement, to perform laboratory and
development services in connection with NS001. For the services received under the agreement by April 2022, there is an amount of $529
outstanding to be paid to Aptar, which has not been paid to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in">On
June 15, 2022, Aptar sent Nasus a Notice of Default Letter, which followed by Notice of Termination Letter sent on October 5, 2022,
in which Aptar claimed for alleged breach of the contractual obligations of the Aptar Agreement made by Nasus and stated the
outstanding amounts of $529 and in addition a termination fee of $450 relates to NS001. The Company rejected the alleged breach made
by Aptar and the existence of any grounds for termination of the Aptar&rsquo;s Agreement. Since then, the Company and Aptar
discussed and exchanged further correspondence, but were unable to resolve the claims and allegations made by each party. There is
no legal proceeding between Nasus and Aptar. As of December 31, 2023 and 2022 a liability of $529 is recorded as accounts payable
within the consolidated balance sheets. The Company has not recorded a liability for the termination fees of $900 ($450 for NS001
and $450 for NS002), as the Company believes it is not probable that it will be required to pay such amounts in the future.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 196; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  7:</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHAREHOLDERS&rsquo;
  DEFICIT</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Company&rsquo;s authorized capital shares consist of 2,681 thousand shares of Ordinary Shares,
                                            comprised of: 2,000 thousand Class Ordinary Shares, 171 thousand Class A Ordinary Shares;
                                            300 thousand Class A-1 Ordinary Shares; 100 thousand Class A-2 Ordinary Shares; and 110 thousand
                                            Class A-3 Ordinary Shares. Holders of each share class have the right to one vote per share.
                                            All share classes have the similar rights attached to them (noting that there are certain
                                            shareholders rights which are triggered based on a holding rate&nbsp;), except that, (i)
                                            Class A Ordinary Shares, Class A-1 Ordinary Shares, Class A-2 Ordinary Shares, Class A-3
                                            Ordinary Shares differ in Original Issue Price (as prescribed in the Company&rsquo;s Articles
                                            of Association and noted below), (ii) while the Class A Ordinary Shares, Class A-1 Ordinary
                                            Shares, Class A-2 Ordinary Shares and Class A-3 Ordinary Shares are entitled to certain conversion
                                            ratio adjustments, such adjustment is affected by split or reverse split of such shares (with
                                            no special rights provided as down-round protection) and (iii) the appointment of board members
                                            is not determined at a general meeting, but rather through a specific mechanism of nomination,
                                            as detailed in the Company&rsquo;s Articles of Association. Subject to the forgoing, each
                                            Ordinary Shares are treated equally, identically and rateably, on a per share basis,
                                            with respect to any dividends or distributions as may be declared and paid from time to time.
                                            Upon the liquidation, dissolution or winding up of the Company, whether voluntary or involuntary,
                                            holders of Ordinary Shares will be entitled to receive rateably all assets of the Company
                                            available for distribution to its shareholders. None of the shares have preferred rights
                                            in liquidation preferences or redemption rights. Class A Ordinary Shares, Class A-1 Ordinary
                                            Shares, Class A-2 Ordinary Shares, and Class A-3 Ordinary Shares will be converted into Class
                                            Ordinary Shares upon completion of an IPO.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            of Class A Ordinary Shares; Class A-1 Ordinary Shares; Class A-2 Ordinary Shares;
                                            and Class A-3 Ordinary Shares is convertible, at the option of the holder at any time, into
                                            the number of Class Ordinary Shares as is determined by dividing the original issue price
                                            for such series of shares by the conversion price for such series of shares that is in effect
                                            at the time of conversion. The initial and current conversion price for Class A Ordinary
                                            Shares; Class A-1 Ordinary Shares; Class A-2 Ordinary Shares; and Class A-3 Ordinary Shares
                                            is the original issue price for such class of shares. The original issue price was $5.85,
                                            $14.2775, $20.4947 and $28.8409 per share for Class A Ordinary Shares; Class A-1 Ordinary
                                            Shares; Class A-2 Ordinary Shares; and Class A-3 Ordinary Shares, respectively. The applicable
                                            conversion price of each is subject to adjustment upon share splits or combinations, recapitalizations,
                                            or upon the issuance of any new securities at a price per share lower than the applicable
                                            conversion price of the Class A Ordinary Shares; Class A-1 Ordinary Shares; Class A-2 Ordinary
                                            Shares; and Class A-3 Ordinary Shares, as applicable, in effect immediately prior to such
                                            issuance.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of Class A Ordinary Shares; Class A-1 Ordinary Shares; Class A-2 Ordinary Shares; and Class A-3 Ordinary</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Shares will automatically be converted into Class Ordinary Shares, at the then effective conversion price, upon the closing of the sale
of Ordinary Shares to the public in a firm commitment underwritten public offering or the affirmative consent of the holders of majority
of the Class A Ordinary Shares with respect to the Class A Ordinary Shares; (iii) the affirmative consent of the holders of majority
of the Class A-1 Ordinary Shares with respect to the Class A-1 Ordinary Shares; (iv) the affirmative consent of the holders of majority
of the Class A-2 Ordinary Shares with respect to the Class A-2 Ordinary Shares and (v) the affirmative consent of the holders of majority
of the Class A-3 Ordinary Shares with respect to the Ordinary A-3 Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 28, 2024 the shareholders of the Company approved the issuance of Class A-3A Ordinary Shares and Class A-3B Ordinary Shares,
which have similar rights to other classes of Ordinary Shares (see Note 7a and 7b).</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"></P>


<!-- Field: Page; Sequence: 197; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
    and outstanding</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
    and outstanding</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="14" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,069</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,000,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000,069</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    A Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">160,684</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">171,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">160,684</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    A-1 Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77,044</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77,044</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    A-2 Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97,583</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97,583</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
    A-3 Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108,979</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">110,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108,979</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,681,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444,359</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,681,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444,359</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  8:</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHARE-BASED
  PAYMENTS</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity
Incentive Plan</B> &ndash; The Company has established the 2019 Incentive Option Plan (the &ldquo;2019 Plan&rdquo;) whereby
the Company may grant share options to purchase its Class Ordinary Shares, for the purpose of providing incentives to employees,
officers, directors, consultants and service providers of the Company. Share options granted under the 2019 Plan generally have
10-year terms and vest over a four-year period starting from the date specified in each agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum number of share options of Class Ordinary Shares that may be issued under the 2019 Plan is 51,607 shares. As of
December 31, 2023, there were 13,850 share options available for issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents a summary of share options activity for the years ended December 31, 2023 and 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Exercise Price Per Share Option</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Remaining Contractual Life</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
    Intrinsic Value</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of January 1, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,438</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.97</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(69</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,510</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.71</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,671</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.81</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43,188</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.58</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,915</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expired</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7,577</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.03</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(838</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20.49</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,688</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.91</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.36</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">278</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested
    and Exercisable as of December 31, 2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,248</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.72</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.28</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">240</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 198; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
                                            PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate intrinsic value was calculated as the difference between the exercise price of the share options and the fair value of the
underlying Class Ordinary Shares as December 31, 2023 and 2022. The weighted-average grant-date fair value of share options granted during
the years ended December 31, 2023 and 2022 was $11.1 and $9.8, respectively. There was no intrinsic value to the share options exercised
in the year ended December 31, 2022, and there were no share option exercises during the year ended December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the total share-based compensation expense resulting from share options granted to employees, directors
and service providers included in the Company&rsquo;s consolidated statements of operations:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year
                                                                                                                         ended December 31,</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss (income) from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    share-based compensation expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, and 2022, unamortized share-based compensation expense was $6 and $14, respectively, related to non-vested share
options, which is expected to be recognized over weighted average period of 0.46 and 0.7 years, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value of Share Options</B>&ndash; The Company estimates the fair value of share option awards on the date of grant using the Black-Scholes
option-pricing model. The Black-Scholes option-pricing model requires estimates of highly subjective assumptions, which affect the fair
value of each share option. The assumptions used to estimate the fair value of share options granted are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 89%; margin-left: 0.75in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Amounts
    in dollars, except percentages)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66%-68</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    dividends</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term (in years)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-5.47</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.70</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
    free rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.59%-3.66</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.82</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value of Class Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$14.41-$12.6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 199; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
                                            PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
                                            Value of Class Ordinary Shares</B> &ndash; Since the Company&rsquo;s Class
                                            Ordinary Shares are not publicly traded, the fair value of the Company&rsquo;s Class
                                            Ordinary Shares was approved by the Company&rsquo;s Board of Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
estimating the fair value of the Company&rsquo;s Class Ordinary Shares, management uses the assistance of third-party valuation
specialist and consider factors management believes are material to the valuation process, including, but not limited to, the price at
which recent equity was issued by the Company to independent third parties or transacted between third parties, actual and projected
financial results, risks, prospects, and economic and market conditions, among other factors. Management believes the combination of
these factors provides an appropriate estimate of the expected fair value and reflects the best estimate of the fair value of the Company&rsquo;s
Class Ordinary Shares at each grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expected
                                            Volatility</B> &ndash; The expected volatility is based on the historical and implied volatility
                                            of similar companies whose stock or share option prices are publicly available, after
                                            considering the industry, stage of life cycle, size, market capitalization, and financial
                                            leverage of the other companies.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk-Free
                                            Interest Rate</B> &ndash; The risk-free interest rate assumption is based on observed U.S.
                                            Treasury yield curve interest rates in effect at the time of grant appropriate for the expected
                                            term of the share options granted.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expected
                                            term (years) </B>&ndash; Expected term represents the period that the Company&rsquo;s share
                                            option grants are expected to be outstanding. There is not sufficient historical share
                                            exercise data to calculate the expected term of the share options. Therefore, the
                                            Company elected to utilize the simplified method to value share option grants. Under
                                            this approach, the weighted-average expected life is presumed to be the average of the shortest
                                            vesting term and the contractual term of the share option.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expected
                                            dividend yield</B> &ndash; The Company does not anticipate paying any dividends in the foreseeable
                                            future.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  9:-</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TAXES
  ON INCOME</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>a.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tax
                                            rates applicable to the income of the Company:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli corporate income tax rate was 23% in 2023 and 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 79%; margin-left: 0.75in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    tax assets:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    operating loss carryforward</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,476</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,963</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">172</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">505</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vacation
    accrual</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    deferred tax assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,649</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,476</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation
    allowance</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,649</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,476</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    deferred tax</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 200; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
                                            PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -18pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>b.</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>A
  reconciliation of the Company&rsquo;s Israeli tax statutory rate to effective tax rate is as follows:</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 79%; margin-left: 1in">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    Ended December 31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Israel
    tax statutory rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-deductible
    share-based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.85</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.94</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Effect of change in fair value of convertible securities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20.97</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5.20</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effect
    of other permanent differences</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.80</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in valuation allowance and temporary differences</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(47.92</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16.81</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
    tax rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>c.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carry
                                            forward losses for tax purposes and other temporary differences:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the Company&rsquo;s Israeli tax loss carryforward was approximately $10 million. Such losses can be carried forward
indefinitely to offset against future taxable income of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the available evidence, management believes that it is more likely than not that its deferred tax assets will not be realized and
accordingly, a full valuation allowance has been provided.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>d.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Final
                                            tax assessments:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, all of Company&rsquo;s tax assessments in Israel are not final.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>e.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Uncertain
                                            tax positions:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by a
taxation authority. As of December 31, 2023, and 2022, the Company has not recorded any uncertain tax position liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  10:-</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NET
  LOSS PER SHARE ATTRIBUTABLE TO SHAREHOLDER</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed using the weighted average number of shares of Ordinary Shares outstanding for the period. Diluted net
loss per share reflects the effect of the assumed exercise of any share options, and the conversion of any convertible securities, in
each case only in the periods in which such effect would have been dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, net loss per share amounts were the same for Class Ordinary Shares, Class A Ordinary
Shares, Class A-1 Ordinary Shares, Class A-2 Ordinary Shares and Class A-3 Ordinary Shares because the holders of each class are entitled
to equal per share dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 201; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
                                            PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the computation of basic and diluted net loss per share:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerator:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">from continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,005</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,152</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss (income) from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(441</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss attributable to holders of Ordinary Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,711</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Effect of dilutive securities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of convertible securities related to dilutive effect*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">361</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">from continuing operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,366</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,152</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss (income) from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(441</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss attributable to holders of Ordinary Shares and assumed conversions</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,412</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,711</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average
    number of Ordinary Shares used to compute net loss per share, basic</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444,359</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444,296</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Effect of dilutive securities:</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">2022 SAFE**</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">35,243</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average
    number of Ordinary Shares used to compute net loss per share, diluted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,479,602</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,444,296</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
                                            loss (income) per share, basic:</B></FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuing
    operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.70</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.49</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discontinued
    operations</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.31</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share, basic</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.73</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss (income) per share, diluted:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuing
    operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.92</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.49</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Discontinued
    operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.03</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(0.31</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss per share, diluted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.95</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The dilutive effect on
  the numerator (net loss) in calculating the diluted net loss per share for the year ended December 31, 2023 represents the change in
  fair value in connection with the 2022 SAFEs.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">**</TD>
  <TD STYLE="text-align: justify">The dilutive effect on the denominator (the weighted average number of Ordinary Shares) in calculating
  the diluted net loss per share for the year ended December 31, 2023 is based on the assumption the conversion of the 2022 SAFE into
  shares will occur upon its maturity.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the number of securities that were excluded from the calculation of diluted net loss per share as the effect would
have been anti-dilutive:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Year ended</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2023</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2022</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; font-size: 10pt">Share options</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">37,688</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font-size: 10pt; text-align: right">43,188</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">2022 SAFE*</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">35,243</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">2023 SAFE**</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">63,958</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 0.25in">*</TD>
  <TD STYLE="text-align: justify">The weighted average number of Ordinary Shares in connection with the 2022 SAFE for the year ended December 31, 2022 is based on the assumption
the conversion of the 2022 SAFE into shares will occur upon its maturity.</TD></TR>
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify">**</TD>
  <TD STYLE="text-align: justify">The weighted average number of Ordinary Shares in connection with the 2023 SAFE <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
  the year ended December 31, 2023 is based on the assumption the conversion of the 2023 SAFE into shares will occur upon its maturity.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  11:-</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELATED
  PARTIES</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Ehud Gilboa and Dr. Dalia Meggido are shareholders of the Company and
each hold approximately 25% of the Company&rsquo;s issued and outstanding Ordinary Shares. Mr. Gilboa is the Chairman of the Board of
Directors and Dr. Meggido is a member of the Board of director Directors and Chief Executive Officer.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Ronnie Hershman is a member of the Board of Directors director of the
Company and holds approximately 10% of the Company&rsquo;s outstanding Ordinary Shares.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            Gilboa and Dr. Meggido are each entitled to management fee of ILS 45 (approximately $13)
                                            plus customary social benefits of additional 25% of the management fee. In February 2022,
                                            both Mr. Gilboa and Dr. Meggido agreed to a voluntary deferral of such fee of ILS 9 (approximately
                                            $3), and an additional deferral of ILS 18 (approximately $5) in November 2022. As of December
                                            31, 2023, and 2022 the aggregate deferred liability amounted to $318 and $92, respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 202; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
                                            PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            Gilboa subleases office space for a fee of ILS 12 (approximately $3) and his company provides
                                            the Company with secretarial services for a monthly fee of ILS 5 (approximately $2).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            Gilboa, Dr. Megiddo and Dr. Ronnie Hirshman have all participated in SAFEs (see Note 4) rounds
                                            and the short-term debt from shareholders (see Note 3). Mr. Gilboa, Dr. Megiddo and Dr. Ronnie
                                            Hirshman invested $35, $35 and $250 respectively in the SAFEs and $10, $10 and $290 in the
                                            short-term debt from shareholders.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
                                            Gilboa, Dr. Megiddo and Dr. Ronnie Hirshman are major shareholders of Formulex which granted
                                            services and additional services and license to the Company (see Notes 6).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            following related party balances are included in the consolidated balance sheets:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
    LIABILITIES:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term
    debt from shareholders</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">344</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">259</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    securities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">365</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">382</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Account payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expense and other current liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">451</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">147</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            following related party transactions are included in the consolidated statements of operations:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;228</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;231</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">General and administrative</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">288</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">313</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss (income) from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  12:-</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISCONTINUED
  OPERATIONS</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2020, the Company&rsquo;s research and development team in Israel developed a nasal powder that creates a hostile microenvironment in
the nose where many airborne viruses can&rsquo;t survive, which was marketed as Taffix (&ldquo;Taffix&rdquo;). The Company got Conformit&eacute;
Europ&eacute;enne, a European union regulatory marketing approval (&ldquo;CE&rdquo;) and Israel health authority approval for Taffix.
The Company started production of Taffix in late 2020 and marketed it through distributors around the world and through direct sales
on website.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the end of 2021, the Company started the wind-down of Taffix by selling of all the manufacturing equipment, ceasing marketing efforts,
seeking alternatives, fulling final orders but not accepting new orders, disposal of inventory and terminating of engagements with employee
contractors and manufacturers. As of December 2022, the Company was no longer engaged in the development, production, marketing or sales
of Taffix.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
disposal of a business is classified as discontinued operations if the cessation of operations represents a strategic shift that will
have a major effect on the entity&rsquo;s operations and financial results. When a business is identified for discontinued operations
reporting: (i) results for prior periods are retrospectively reclassified as discontinued operations; (ii) results of operations are
reported in a single line, net of tax, in the consolidated statements of operations; and (iii) assets and liabilities are reported
as held for sale in the consolidated balance sheets in the period in which the business is classified as held for sale.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 203; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
                                            PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with applicable accounting guidance, the results of Taffix are presented as net loss (income) from discontinued operations
in the consolidated statements of operations. Further, the Company reclassified
the liabilities of Taffix current liabilities related to discontinued operations on the consolidated balance sheets as of December 31,
2023 and 2022. The consolidated statements of cash flows are presented on a consolidated basis for both continuing operations and discontinued
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents key components of &ldquo;Net loss (income) from discontinued operations&rdquo;:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -56.7pt"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year
    ended December 31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 56%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,066</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of revenue</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">366</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">256</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> (income) from discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 2.5pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(441</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents liabilities that are classified as discontinued operations on the consolidated balance sheets:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2023</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">160</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expense and other current liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">93</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advances
    from customers</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">270</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">261</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities related to discontinued operations</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">513</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">514</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
  13:</B></FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSEQUENT
  EVENTS</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated subsequent events from the date of the consolidated balance sheet of December 31, 2023 through August 30, 2024,
the date the consolidated financial statements were available to be issued, and has determined that, there have been no subsequent events
that require recognition or disclosure in the consolidated financial statements, except as described in Note 3, Note 4 and as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            April 9, 2024 the Board of Directors approved a SAFE (the &ldquo;2024 SAFE&rdquo;)
                                            with certain current shareholders and third parties who may join the SAFE.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 204; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
                                            PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
maximum amount that can be raised by the Company under the SAFE is $2,000. The 2024 SAFE was approved by the Board of Directors, and
as of August 30, 2024, the Company entered into agreements in the amount of $1,301 under the 2024 SAFEs, of which $951
was received as of that date. In addition, see note 13 (b) additional 2024 SAFE have been issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investors under the SAFEs are entitled to the rights and privileges set forth in the SAFE. Under the terms of the 2024
SAFEs, upon an initial public offering, merger, acquisition, qualified equity financing other liquidity event, the subscription amounts
under such SAFEs will be converted into the Company&rsquo;s most senior outstanding shares &nbsp;upon completion of this offering, at
a conversion price reflecting a discount of 35%. In the event that such events had not occurred within 18 months of the execution of
such SAFEs, such SAFEs will be converted into our securities on the basis of a previous round of equity financing consummated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            August 28, 2024, the investors in the July 2022 Loan and February 2023 Loan (see Note 3)
                                            agreed to convert the then outstanding balance of short-term debt of $588 and $68, respectively,
                                            into SAFEs. Pursuant to the terms of the July 2022 Loan Exchange Letter and the February
                                            2023 Loan Exchange Letter, the then outstanding balance of the July 2022 Loan and the February
                                            2023 Loan converted, after deduction of applicable withholding taxes, into 2024 SAFEs in
                                            the amount of $570 and $66, respectively.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            August 28, 2024, the Company issued the 35,243 Class A-3A Ordinary Shares and accordingly,
                                            the 2022 SAFEs were terminated on that date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            August 28, 2024, the Company issued the 63,958 Class A-3B Ordinary Shares and accordingly,
                                            the 2023 SAFEs were terminated on that date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            August 8, 2024, the Company granted three of its scientific advisory board members 2,500
                                            options to exercise 2,500 Class Ordinary Shares. The share options vest quarterly over a
                                            period of three years, commencing in July 2024 at an exercise price of $17.71.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 205; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>




<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NASUS PHARMA LTD. AND ITS SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONDENSED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS OF JUNE 30, 2024</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNAUDITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>U.S. DOLLARS IN THOUSANDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 206; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ach_001">Unaudited
    Interim Condensed Consolidated Balance Sheets</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-29</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ach_002">Unaudited
    Interim Condensed Consolidated Statements of Operations</A> </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-30</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ach_003">Unaudited
    Interim Condensed Consolidated Statements of Shareholders&rsquo; Deficit</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ach_004">Unaudited
    Interim Condensed Consolidated Statements of Cash Flows</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-32</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ach_005">Notes
    to Unaudited Interim Condensed Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-33</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 207; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ach_001"></A>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">(Amounts in thousands, except share and per share amounts)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">900</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">193</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Prepaid expenses and other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">234</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">929</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">444</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,020</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">444</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Liabilities and Shareholders&rsquo; Deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">652</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">655</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Accrued expense and other current liabilities (of which $557 and $451 are to
    related parties as of June 30, 2024 and December 31, 2023, respectively)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">735</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">616</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Convertible securities (of which $575 and $365 are to related parties as
    of June 30, 2024 and December 31, 2023, respectively)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,830</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Short-term debt from shareholders (of which $356 and $344 are to related parties
    as of June 30, 2024 and December 31, 2023, respectively)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">645</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">627</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Current liabilities related to discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">492</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">513</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,683</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,241</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total Liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,683</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,241</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Contingent liabilities and commitments (see Note 6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Shareholders&rsquo; deficit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Ordinary Shares (*), par value ILS 0.01 per share; 2,681,000 shares authorized; 1,444,359 shares
    issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,336</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,331</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,003</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,132</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total Shareholders&rsquo; Deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,663</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,797</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Shareholders&rsquo; Deficit</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,020</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">444</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise stated, the term Ordinary Shares in these condensed consolidated financial statements refers to all classes of shares,
    including Class Ordinary Shares, Class A Ordinary Shares, Class A-1 Ordinary Shares, Class A-2 Ordinary Shares and Class A-3 Ordinary
    Shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.&lrm;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 208; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ach_002"></A>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">(Amounts in thousands, except share and per share amounts)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; padding-left: 10pt">Research and development (of which $103 and $111 are with related
    parties in 2024 and 2023, respectively)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">168</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">229</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">General and administrative (of which $149 and $144 are with
    related parties in 2024 and 2023, respectively)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">315</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">327</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">483</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">556</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating loss from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(483</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(556</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Interest expense (of which $12 and $12 are with related parties in 2024 and 2023,
    respectively)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Change in fair value of convertible securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(379</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">391</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">3</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Loss from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(885</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(184</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net income (loss) from discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(30</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(871</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(214</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Per share data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss per share attributable to shareholders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.60</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.15</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.60</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.45</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average Ordinary Shares outstanding - basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,444,359</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,444,359</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Weighted average Ordinary Shares outstanding - diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,444,359</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,479,602</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.&lrm;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"></P>


<!-- Field: Page; Sequence: 209; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ach_003"></A>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&rsquo; DEFICIT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Ordinary Shares**</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">Additional<BR> Paid- in</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholders&rsquo;</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; padding-bottom: 2.5pt">Balance as of December 31, 2022</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right">1,444,359</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right">4</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right">7,292</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right">(10,081</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2,785</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(214</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(214</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Balance as of June 30, 2023</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,444,359</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,317</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(10,295</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,974</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Ordinary Shares**</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">Additional<BR> Paid- in</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1pt; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shareholders&rsquo;</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Shares</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Capital</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Deficit</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; padding-bottom: 2.5pt">Balance as of December 31, 2023</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right">1,444,359</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right">4</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right">7,331</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right">(11,132</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="width: 2%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 2.5pt double; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3,797</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net loss</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(871</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(871</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Balance as of June 30, 2024</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,444,359</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">7,336</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(12,003</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(4,663</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represent
    amounts less than $ 1.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
    otherwise stated, the term Ordinary Shares in these condensed consolidated financial statements refers to all classes of shares,
    including Class Ordinary Shares, Class A Ordinary Shares, Class A-1 Ordinary Shares, Class A-2 Ordinary Shares and Class A-3 Ordinary
    Shares.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.&lrm;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 210; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ach_004"></A>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNAUDITED
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">(Amounts in thousands)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left">Net loss</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 14%; font-weight: bold; text-align: right">(871</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 14%; font-weight: bold; text-align: right">(214</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">Less: Net loss (income) from discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(14</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">30</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Loss from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(885</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(184</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Adjustments to reconcile loss from continuing operations to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Share-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in fair value of convertible securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">379</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(391</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Effect of exchange rates</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued interest on short-term debt from shareholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Change in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid expenses and other current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">28</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(23</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Accrued expense and other current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">98</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">93</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash used in operating activities from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(173</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(432</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net cash used in operating activities from discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(7</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(45</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(180</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(477</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash used in investing activities from continuing operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash used in investing activities from discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash used in investing activities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds from issuance of convertible securities (of which $150 and $100 are with related parties
    in 2024 and 2023, respectively)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">951</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">995</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from short-term debt from shareholders (of which $0 and $60 are with related parties in
    2024 and 2023, respectively)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Deferred offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(70</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash provided by financing activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">881</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,055</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Cash used in financing activities from discontinued operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash provided by financing activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">881</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,055</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Effect of exchange rate changes on cash, cash equivalents and restricted cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net increase (decrease) in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">706</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Cash, cash equivalents and restricted cash - Beginning of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">210</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">171</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash, cash equivalents and restricted cash - End of period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">916</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">751</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Supplemental disclosure of noncash financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Deferred offering costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">21</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these condensed consolidated financial statements.&lrm;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance
sheets to the total of the same such amounts shown on the condensed consolidated statements of cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Cash and cash equivalents, end of period</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">900</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">734</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Restricted cash, end of period</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">16</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">17</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Cash, cash equivalents and restricted cash - End
    of period</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">916</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">751</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 211; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ach_005"></A>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    1:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ORGANIZATION
    AND NATURE OF THE BUSINESS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description
    of the Business</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 1in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus
Pharma Ltd. (the &ldquo;Company&rdquo;) was incorporated in May 2019 under the laws of the State of Israel. The Company is a clinical
stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions.
The Company is developing a powder-based intranasal technology with a specialized product portfolio to address acute medical conditions
and public health threats. The Company&rsquo;s lead product candidates are NS002, an intranasal powder Epinephrine nasal spray for the
treatment of type 1 severe allergies and anaphylaxis, and NS001, an intranasal Naloxone powder nasal spray for the treatment of opioid
overdose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had a wholly-owned subsidiary in the United Kingdom which had no operations since its incorporation in September 2020 through
its dissolution in February 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
    and Going Concern</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S.
(&ldquo;U.S. GAAP&rdquo;) on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the
normal course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, the Company has devoted most of its efforts to business planning, research and development, clinical trials and raising capital.
The Company is still in its development and clinical stage and has not yet generated revenues from its existing products under development
and, accordingly, the extent of the Company&rsquo;s future operating losses and the timing that the Company will become profitable are
uncertain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the six months ended June 30, 2024, the Company incurred a net loss of $871 (and a loss of $885 from continuing operations) and used
net cash flows from operations of $180 (and cash used in continuing operations was $173). Additionally, as of June 30, 2024, the Company
had cash and cash equivalents of $900 to fund its operations and an accumulated deficit of $12,003.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has funded its operations to date primarily through equity financing and the issuance of convertible securities in the form of
Simple Agreement of Future Equity (&ldquo;SAFE&rdquo;) (see Note 4 and Note 10). Additional funding will be required to complete the
Company&rsquo;s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts
of the Company&rsquo;s products and to achieve a level of sales adequate to support the Company&rsquo;s cost structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such
conditions raise substantial doubts about the Company&rsquo;s ability to continue as a going concern. Management&rsquo;s plans include,
but are not limited to, an initial public offering (&ldquo;IPO&rdquo;) in the United States. While the Company has been able to raise
outside capital in the past, there can be no assurance that it will be able to successfully consummate an IPO or obtain additional financing
on a timely basis in terms acceptable to the Company, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
expects that the Company will continue to generate losses from the clinical development and regulatory activities of its product candidates,
which would result in negative cash flow from operating activity. This has led management to conclude that there is substantial doubt
about the Company&rsquo;s ability to continue as a going concern. The Company&rsquo;s condensed consolidated financial statements do
not reflect any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 212; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    2:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT
                                            ACCOUNTING POLICIES</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of presentation and principles of consolidation</B> - The accompanying interim condensed consolidated financial statements of the Company
are unaudited. These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting
principles in the United States of America (&ldquo;U.S. GAAP&rdquo;) and the applicable rules and regulations of the Securities and Exchange
Commission (&ldquo;SEC&rdquo;) for interim financial information. Accordingly, they do not include all of the information and footnotes
required by U.S. GAAP for complete financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
December 31, 2023 condensed consolidated balance sheet was derived from the audited financial statements as of that date, but does not
include all of the information and footnotes required by U.S. GAAP for complete financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated
financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to
state fairly the Company&rsquo;s consolidated financial position, results of operations, and cash flows for the interim periods. The
condensed consolidated financial statements include accounts of the Company&rsquo;s wholly-owned subsidiary in the United Kingdom that
was dissolved in February 2023. The interim results for the six months ended June 30, 2024 are not necessarily indicative of the results
that may be expected for the year ending December 31, 2024, or for any other future annual or interim period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unaudited interim condensed financial statements should be read in conjunction with the audited consolidated financial statements and
accompanying notes of the Company for the year ended December 31, 2023. The significant accounting policies applied in the annual financial
statements of the Company as of December 31, 2023, are applied consistently in these interim condensed financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of estimates</B> - The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
items subject to such estimates and assumptions include identifying the existence of embedded derivatives, share-based compensation and
the determination of the fair value of the Company&rsquo;s Ordinary Shares, share options and the fair value of convertible securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred
offering costs <I>- </I></B>Deferred offering costs, which consist of direct incremental legal, accounting, and consulting fees relating
to the planned IPO, are capitalized. The deferred offering costs shall be reclassified to shareholders&rsquo; equity and offset against
the proceeds of the offering upon the consummation of the IPO. In the event the planned IPO is terminated, the deferred offering costs
will be expensed. As of June 30, 2024, there were $91 deferred offering costs recorded on the unaudited condensed consolidated balance
sheets. There were no offering costs recorded as of December 31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Jumpstart Our Business Startups Act of 2012 (&ldquo;JOBS Act&rdquo;), emerging growth companies can delay adopting new or revised
accounting standards until such time as those standards would otherwise apply to private companies. While the Company has not historically
delayed the adoption of new or revised accounting standards until such time as those standards would apply to private companies, the
Company has elected to take advantage of this extended transition period and, as a result, its operating results and financial statements
in the future may not be comparable to the operating results and financial statements of companies who have adopted the new or revised
accounting standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Issued Accounting Standards Not Yet Adopted</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2023, the FASB issued ASU 2023-07, <I>Segment Reporting (Topic 280) &ndash; Improvements to Reportable Segment Disclosures</I>.
This ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses.
This ASU is effective for our annual fiscal year 2024, and interim periods starting in fiscal year 2025. A public entity should apply
the amendments in this ASU retrospectively to all prior periods presented in the financial statements. The adoption of ASU 2023-07 will
impact the Company&rsquo;s disclosures only and the Company is evaluating the effect of adopting the new disclosure requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 213; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    3:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SHORT-TERM
    DEBT FROM SHAREHOLDERS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
July 2022, the Company received a loan in the amount of $500 from two existing shareholders, including a director of the Company, for
a term of twelve (12) months, at an interest rate of 8% per annum (the &ldquo;July 2022 Loan&rdquo;). As of June 30, 2024, the July 2022
Loan was outstanding. On August 28, 2024, the Company and each of said shareholders entered into an exchange letter (the &ldquo;July
2022 Loan Exchange Letter&rdquo;), according to which the Company&rsquo;s obligations in connection with the loan were discharged in
consideration for the issuance of a SAFE. The July 2022 Loan balance was $578 as of June 30 2024, and after considering interest accrued
during July and August 2024 through the date the July 2022 Loan Exchange Letter was executed and withholding taxes to be paid on behalf
of the said shareholders, it was deemed that Dr. Hershman invested an amount in the SAFE of $284 and Michael Gibber invested an amount
in the SAFE of $286. The July 2022 Loan, including accrued interest, was $578 and $560 as of June 30, 2024 and December 31, 2023, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2023, the Company received a loan in an aggregate amount of $60 from its co-founders, Mr. Udi Gilboa and Dr. Dalia Megiddo,
and director, Dr. Ronnie Hershman, or the February 2023 Loan, under substantially the same terms as the July 2022 Loan, for a term of
twelve (12) months, at an interest rate of 8% per annum. As of June 30, 2024, the February 2023 Loan was outstanding. On August 28, 2024,
the Company and each of these investors entered into an exchange letter (the &ldquo;February 2023 Loan Exchange Letter&rdquo;), according
to which the Company&rsquo;s obligations in connection with the February 2023 Loan were discharged in consideration for the issuance
of a SAFE under the same terms as the 2024 SAFEs, as described below, under which Dr. Ronnie Hershman was deemed to have invested an
amount in the SAFE of $44, Dr. Dalia Megiddo was deemed to have invested an amount in the SAFE of $11, and Mr. Udi Gilboa was deemed
to have invested an amount in the SAFE of $11 in said SAFE. The February 2023 Loan, including interest accrued, was $67 and $67 as of
June 30, 2024 and December 31, 2023, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    4:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONVERTIBLE
    SECURITIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company has raised funds through the issuance of Simple Agreement for Future Equity (&ldquo;SAFE&rdquo;).</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
SAFE requires conversion into shares of the Company upon the occurrence of certain events, or at the maturity date of the SAFE. The number
of shares to be issued upon conversion of the SAFE are not fixed and will be dependent upon the nature of the event that occurred that
resulted in its conversion, the fair value of shares as of the event&rsquo;s date, and other factors as defined in the related agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SAFEs
are classified as a liability and the Company elected the fair value option in accordance with ASC 825, Financial Instruments (&ldquo;ASC
825&rdquo;). Accordingly, the liability is adjusted to fair value at each balance sheet date, with the change in fair value being recorded
as change in fair value of convertible securities within the condensed consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 214; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    February 17, 2022, the shareholders approved the issuance of SAFE (the &ldquo;2022 SAFEs&rdquo;) to certain shareholders and third
    parties up to a maximum aggregate amount of $1,000. In March 2022 and April 2022, the Company raised $966 under the 2022 SAFE.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 SAFE investors are entitled to the rights and privileges set forth in the agreement, which include the issuance of the most senior
shares outstanding upon conversion of the 2022 SAFEs in the event of an equity financing or liquidity event occurs prior to the termination
of the 2022 SAFEs as defined in the related agreement. The investors shall receive a 40% discount on the share price in any of such event.
If a dissolution event occurs prior to the termination of the 2022 SAFE, each SAFE investor will be entitled to receive, prior to consummation
of the dissolution event, a portion of the related proceeds equal to its investment amount, or in case the applicable proceeds upon dissolution
are insufficient to permit a full payment of the amounts invested under the 2022 SAFEs, a prorated amount in par with the other SAFE
investors. In the event that the 2022 SAFEs mature after 15 months from its issuance, all amounts invested under the 2022 SAFEs are converted
into the Company&rsquo;s outstanding most senior shares based on a $41,000 valuation divided by number of outstanding shares including
any outstanding share options. The 2022 SAFEs will expire and terminate immediately upon the earliest to occur of (1) the issuance of
shares upon its conversion due to equity financing or liquidity event, or upon maturity; or (2) the payment, or setting aside for payment,
of amounts due to the occurrence of dissolution event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June, and July 2023, the 2022 SAFEs matured and accordingly, it should have been converted into 35,243 most senior outstanding shares.
As of June 30, 2024 the shares had not been issued and therefore, the 2022 SAFEs remained outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 28, 2024, the 2022 SAFEs were converted into 35,243 Class A-3A Ordinary Shares (see Note 10) and accordingly, the 2022 SAFEs were
terminated on that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    March 15, 2023, the shareholders approved the issuance of additional SAFEs to certain shareholders and third parties up to the
    maximum aggregate amount of $1,000 (the &ldquo;2023 SAFEs&rdquo;). In March and April 2023, the Company raised $995 under
    the 2023 SAFEs. In addition, the Company paid $15 as finder fees for issuance of the 2023 SAFEs which was recorded as other expense
    (income), net within the condensed consolidated statements of operations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2023 SAFEs investors are entitled to the rights and privileges set forth in the agreement, which include the issuance of the most senior
shares outstanding upon conversion of the 2023 SAFEs in the event of an equity financing or liquidity event occurs prior to the termination
of the 2023 SAFEs as defined in the related agreement. The investors shall receive a 40% discount on the share price in any of such event.
If a dissolution event occurs prior to the termination of the 2023 SAFEs, each SAFE investor will be entitled to receive, prior to consummation
of the dissolution event, a portion of the related proceeds equal to its investment amount, or in case the applicable proceeds upon dissolution
are insufficient to permit a full payment of the amounts invested under the 2023 SAFEs, a prorated amount in par with the other SAFE
investors. In the event the 2023 SAFEs mature after 15 months without a conversion prior to 15 months from its issuance, all amounts
invested under the 2023 SAFEs are converted into the Company&rsquo;s outstanding most senior shares based on a $24,600 valuation divided
by number of outstanding shares including any outstanding share options. The 2023 SAFEs will expire and terminate immediately upon the
earliest to occur of (1) the issuance of shares upon its conversion due to equity financing or liquidity event, or upon maturity; or
(2) the payment, or setting aside for payment, of amounts due to the occurrence of dissolution event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June, July and August 2024, the 2023 SAFEs had matured. On August 28, 2024, the 2023 SAFE were converted into 63,958 Class A-3B Ordinary
Shares (see Note 10) and accordingly, the 2023 SAFEs were terminated on that date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    April 9, 2024, the Board of Directors approved the issuance of additional SAFEs to certain shareholders and third parties up to the
    maximum aggregate amount of $1,500 (the &ldquo;2024 SAFEs&rdquo;). The Company raised $951 under the 2024 SAFEs during the six months
    period ended June 30, 2024. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2024 SAFEs investors are entitled to the rights and privileges set forth in the agreement, which include the issuance of the most
senior shares outstanding upon conversion of the 2024 SAFEs in the event that an initial public offering, merger, acquisition,
qualified equity financing or other liquidity event occurs prior to the termination of the 2024 SAFEs as defined in the related
agreement. The investors shall receive a 35% discount on the share price in any of such event. If a dissolution event occurs prior
to the termination of the 2024 SAFEs, each SAFE investor will be entitled to receive, prior to consummation of the dissolution
event, a portion of the related proceeds equal to its investment amount, or in case the applicable proceeds upon dissolution are
insufficient to permit a full payment of the amounts invested under the 2024 SAFEs, a prorated amount in par with the other SAFE
investors. If such events had not occurred within 18 months of the execution of the 2024 SAFEs, all amounts invested under the 2024
SAFEs are converted into the Company&rsquo;s outstanding most senior shares based on the previous round of equity financing
consummated discounted in 35% and divided by number of outstanding shares including any outstanding share options. The 2024 SAFEs
will expire and terminate immediately upon the earliest to occur of (1) the issuance of shares upon its conversion due to a
qualified equity financing or liquidity event as aforesaid, or upon maturity; or (2) the payment, or setting aside for payment, of amounts due
to the occurrence of a dissolution event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company measured the 2022 SAFEs, the 2023 SAFEs and 2024 SAFEs upon receiving the cash and on each period end at its fair value in
    accordance with ASC 825-10. Accordingly, the SAFEs are measured at fair value each period with changes in fair value reported in
    the condensed consolidated statements of operations. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SAFEs were valued at the end of the period using a probability-weighted expected return model, which incorporated significant unobservable
inputs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 215; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company used the following significant inputs in measuring the SAFEs:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">June 30,</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">December 31,</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Fair value of Ordinary Share*</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">21.56</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">19.63</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Weighted average cost of capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21.80</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21.70</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Risk free rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.48</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.06</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Time to maturity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.29</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.48</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Including
    inputs and assumptions on the likelihood of a SAFE mandatory conversion, qualified equity financing or liquidity event or dissolution.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    5:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FAIR
    VALUE MEASUREMENTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table provide the liabilities carried at fair value measured on a recurring basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measured as of June 30, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Financial liabilities at fair value:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1pt">Convertible securities</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">3,159</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">3,159</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total financial liabilities at fair value</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,159</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,159</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measured as of December 31, 2023</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid">Financial liabilities at fair value:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding-bottom: 1pt">Convertible securities</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">1,830</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 11%; border-bottom: Black 1pt solid; text-align: right">1,830</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">Total financial liabilities at fair value</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,830</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">1,830</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
changes in the fair value of the Company&rsquo;s Level 3 convertible securities, which are measured on a recurring basis are as follows:</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended <BR>
June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; font-weight: bold">December 31, 2023</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 14%; font-weight: bold; text-align: right">1,830</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issuance of 2024 SAFE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">950</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in fair value of convertible securities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">379</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">June 30, 2024</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">3,159</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 93%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended <BR>
June 30, 2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 82%; font-weight: bold">December 31, 2022</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 14%; font-weight: bold; text-align: right">1,054</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from issuance of 2023 SAFE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">995</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Change in fair value of convertible securities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(391</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">June 30, 2023</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">1,658</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between fair value measurement levels during the six months ended June 30, 2024 and the year ended December 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated fair value of the Company&rsquo;s cash and cash equivalents, restricted cash, other current assets, accounts payable, accrued
expense and other current liabilities, and short-term debt from shareholders approximates their carrying values as these financial instruments
are highly liquid or short-term in nature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 216; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    6:-</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTINGENT
    LIABILITIES AND COMMITMENTS </B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Litigation</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
    time to time, the Company may be involved in various claims and legal proceedings. The Company reviews the status of each matter
    and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and
    the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. The Company discloses pending claims
    and legal proceedings litigation if the Company believes a possibility exists that the claims and legal proceedings litigation will
    have a material effect on its financial results. Legal costs are accounted for as they are incurred.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    May 2022, the Company received a demand letter from a supplier associated with the Taffix business, which demanded that the Company
    pay professional fees billed to the Company in connection with services provided by the supplier. In August 2022, the supplier commenced
    legal proceedings in the magistrate court of Tel Aviv, in an amount of $85. The Company recorded the entire contractual expenses
    and a liability of $85 is recorded as current liabilities related to discontinued operations within the Company&rsquo;s consolidated
    balance sheets as of June 30, 2024 and December 31, 2023.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commitments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    May 2019, the Company entered into a license agreement (&ldquo;License Agreement&rdquo;) with Formulex Pharma Innovations Ltd. (&ldquo;Formulex&rdquo;).
    Formulex is an Israeli corporation, owned by the Company&rsquo;s shareholders, Mr. Ehud Gilboa, Dr. Dalia Megiddo and Dr. Ronnie
    Herschman. Pursuant to the License Agreement, Formulex granted the Company a license for the development, manufacture and commercialization
    of Formulex&rsquo;s patent for dry powder compositions for intranasal delivery and rights in the know-how of its intranasal and inhaled
    formulations, combination products, and particle engineering, together, the Licensed Products. Also pursuant to the License Agreement,
    the Company pay Formulex royalties of the Licensed Products in the amount of 0.5% of net sales of the licensed products, which are
    capped at $100 in the aggregate. The royalty payment period commenced on the effective date of the agreement and will continue on
    a country-by-country, product-by-product basis for the longer of: (i) 15 years from the date of the first commercial sale of such
    Licensed Product in such country, or (ii) until the licensed patent expires in such country. The Company may terminate the License
    Agreement for any reason upon 60 days prior written notice. In the event of such termination, the Company has the right to acquire
    the Licensed Technology in an amount equal to the balance between the amount actually paid to Formulex prior to the date of termination
    and the amount of $100. Termination of the agreement does not relieve the parties of obligation accrued prior to such termination.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0pt 0pt 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2019, the Company entered into a service agreement with Formulex, as subsequently amended in March 2020, to facilitate the flow
of information and know how, as well as help develop the Company products. The Company pays $5 a month under the service agreement. The
services agreement automatically renews every year for a period of one year, unless terminated by either party upon 30 days&rsquo; written
notice, in accordance with the terms and conditions set forth therein. In connection with the same, Formulex provided the Company with
one-time development services in the six months ended 2024 and 2023 for additional fees of $0 and $22, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 217; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    September 2019, the Company entered into a master service agreement and schedules of work (&ldquo;Aptar Agreement&rdquo;), with Aptar
    Group Inc. (&ldquo;Aptar&rdquo;), under which Aptar granted the Company technology access to co-development and support for the development and submissions to regulatory bodies of intranasal to deliver NS001 and NS002 using Aptar&rsquo;s technology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">In connection with NS001,
the Company is required to pay Aptar up to $1,350 in the aggregate comprising of $200 in development stage, $350 upon
submission of New Drug Application (&ldquo;NDA&rdquo;) with the Food and Drug Administration (&ldquo;FDA&rdquo;) (or equivalent) and
$800 at market launch. The Company paid $200 to Aptar prior to January 1, 2022. In August 2021, the Company
entered into a change order with respect to NS001, for the provision of additional services and deliverables to be provided by Aptar
for an additional fee of 100 thousand Euro, out of which 40 thousand Euro paid to Aptar prior to January 1, 2022, and the remaining
amounts will be paid upon NDA submission and FDA approval of NS001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">In connection with NS002,
the Company is required to pay Aptar up to $675 in the aggregate comprising of $150 in development stage, $225 upon
submission of NDA with the FDA (or equivalent) and $300 at market launch. The Company paid $150 to Aptar prior
to January 1, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">The Company is also obligated
to pay Aptar for each final product that achieves certain sales-based milestone events and tiered royalties on net sales of each final
product by the Company or its affiliates or sublicensees at rates ranging from a low single-digit percentage, depending on the total
annual worldwide net sales of each such final product up to seven years after first commercial sale. The Aptar Agreement has an early
termination fee in case the Company terminate NS001 or NS002 programs for whatever reason, other than a breach of the agreement by Aptar,
of $450 for each product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">In April 2021, the Company entered
into an agreement with Aptar&rsquo;s subdivision, NextBreath, which is subject to terms and conditions of the Aptar Agreement, to perform
laboratory and development services in connection with NS001. For the services received under the agreement by April 2022, there is an
amount of $529 outstanding to be paid to Aptar, which has not been paid to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify">On June 15, 2022, Aptar sent
Nasus a Notice of Default Letter, which followed by Notice of Termination Letter sent on October 5, 2022, in which Aptar claimed for
alleged breach of the contractual obligations of the Aptar Agreement made by Nasus and stated the outstanding amounts of $529 and in
addition a termination fee of $450 relates to NS001. The Company rejected the alleged breach made by Aptar and the existence of any grounds
for termination of the Aptar&rsquo;s Agreement. Since then, the Company and Aptar discussed and exchanged further correspondence, but
were unable to resolve the claims and allegations made by each party. There is no legal proceeding between Nasus and Aptar. As of June
30, 2024 and December 31, 2023 a liability of $529 is recorded as accounts payable within the consolidated balance sheets. The Company
has not recorded a liability for the termination fees of $900 ($450 for NS001 and $450 for NS002), as the Company believes it is not
probable that it will be required to pay such amounts in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 218; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    7:-</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NET
    LOSS PER SHARE ATTRIBUTABLE TO SHAREHOLDER</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per share is computed using the weighted average number of shares of Ordinary Shares outstanding for the period. Diluted net
loss per share reflects the effect of the assumed exercise of any share options, and the conversion of any convertible securities, in
each case only in the periods in which such effect would have been dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the six months ended June 30, 2024 and 2023, net loss per share amounts were the same for Class Ordinary Shares, Class A Ordinary Shares,
Class A-1 Ordinary Shares, Class A-2 Ordinary Shares and Class A-3 Ordinary Shares because the holders of each class are entitled to
equal per share dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the computation of basic and diluted net loss per share:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font-weight: bold">Numerator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left">Loss from continuing operations</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">(885</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">(184</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net income (loss) from discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(30</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss attributable to holders of Ordinary Shares</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(871</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(214</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Effect of dilutive securities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in fair value of convertible securities related to dilutive effect*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(449</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Loss from continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(885</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(184</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Net income (loss) from discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(30</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net loss attributable to holders of Ordinary Shares and assumed conversions</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(871</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(663</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font-weight: bold">Denominator:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted-average number of Ordinary Shares used to compute net loss per share, basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,444,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,444,359</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Effect of dilutive securities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2022 SAFE**</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,243</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Weighted-average number of Ordinary Shares used to compute net loss per share, diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,444,359</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,479,602</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net loss (income) per share, basic:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.61</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.13</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.01</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Net loss per share, basic</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.60</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.15</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Net loss (income) per share, diluted:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Continuing operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.61</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.43</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">0.01</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(0.02</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; font-weight: bold; padding-bottom: 2.5pt">Net loss per share, diluted</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.60</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.45</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    dilutive effect on the numerator (net loss) in calculating the diluted net loss per share for the six months ended June 30, 2023
    represents the change in fair value in connection with the 2022 SAFEs.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    dilutive effect on the denominator (the weighted average number of Ordinary Shares) in calculating the diluted net loss per share
    for the six months ended June 30, 2023 is based on the assumption the conversion of the 2022 SAFE into shares will occur upon its
    maturity.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 219; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below presents the number of securities that were excluded from the calculation of diluted net loss per share as the effect would
have been anti-dilutive:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six
                                            Months Ended June 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Share options</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">37,688</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">37,688</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>2022 SAFE*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,243</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>2023 SAFE**</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,958</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,958</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>2024 SAFE***</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,756</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.35in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    weighted average number of Ordinary Shares in connection with the 2022 SAFE for the six months ended June 30, 2024 is based on the
    assumption the conversion of the 2022 SAFE into shares will occur upon its maturity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    weighted average number of Ordinary Shares in connection with the 2023 SAFE for the six months ended June 30, 2024 and 2023 is based
    on the assumption the conversion of the 2023 SAFE into shares will occur upon its maturity.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">***</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    weighted average number of Ordinary Shares in connection with the 2024 SAFE for the six months ended June 30, 2024 is based on the
    assumption the conversion of the 2024 SAFE into shares will occur upon its maturity.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    8:-</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELATED
    PARTIES</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Ehud Gilboa and Dr. Dalia Meggido are shareholders of the Company and each hold approximately 25% of the Company&rsquo;s issued and
    outstanding Ordinary Shares. Mr. Gilboa is the Chairman of the Board of Directors and Dr. Meggido is a member of the Board of Directors
    and Chief Executive Officer.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ronnie Hershman is a member of the Board of Directors of the Company and holds approximately 10% of the Company&rsquo;s outstanding
    Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gilboa and Dr. Meggido are each entitled to a monthly management fee of ILS 45 (approximately $13) plus customary social benefits
    of additional 25% of the management fee. In February 2022, both Mr. Gilboa and Dr. Meggido agreed to a voluntary deferral of such
    fee of ILS 9 (approximately $3), and an additional deferral of ILS 18 (approximately $5) in November 2022. As of June 30, 2024, and
    December 31, 2023, the aggregate deferred liability amounted to $407 and $318, respectively. For the six months ended June 30, 2024 and 2023, management fees in the amount of $181 and $196, respectively, recorded
as operating expense within the Company&rsquo;s consolidated statements of operations.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 220; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gilboa subleases office space for a monthly fee of ILS 12 (approximately $3) and Topnotch Consultancy (2009) Ltd., a company owned
    by Mr. Gibloa provides the Company with secretarial services for a monthly fee of ILS 15 (approximately $4), which increased from
    a monthly fee of ILS 5 (approximately $2) starting April 2024.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gilboa, Dr. Megiddo and Dr. Ronnie Hirshman have all participated in SAFEs (see Note 4) rounds and the short-term debt from shareholders
    (see Note 3). Mr. Gilboa, Dr. Megiddo, Formulex and Dr. Ronnie Hirshman invested $35, $35 $30 and $250 respectively in the 2023 SAFEs,
    Mr. Gilboa, Dr. Megiddo and Dr. Ronnie Hirshman invested $50, $50 and $100 respectively in the 2024 SAFEs and $10, $10 and $290 in
    the short-term debt from shareholders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Gilboa, Dr. Megiddo and Dr. Ronnie Hirshman are major shareholders of Formulex which granted services and additional services and
    license to the Company (see Note 6 to the Company&rsquo;s audited financial statements as of and for the two years ended December
    31, 2023).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following related party balances are included in the condensed consolidated balance sheets:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left">Short-term debt from shareholders</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">356</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">344</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Convertible securities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">575</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">365</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued expense and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">557</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">451</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    following related party transactions are included in the condensed consolidated statements of operations:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Six
                                            Months Ended June 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Research and development</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">103</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">111</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">General and administrative</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">149</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">144</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    9:-</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DISCONTINUED
    OPERATIONS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the end of 2021, the Company started the wind-down of Taffix by selling of all the manufacturing equipment, ceasing marketing efforts,
seeking alternatives, fulling final orders but not accepting new orders, disposal of inventory and terminating of engagements with employee
contractors and manufacturers. As of December 2022, the Company was no longer engaged in the development, production, marketing or sales
of Taffix.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"></P>


<!-- Field: Page; Sequence: 221; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with applicable accounting guidance, the results of Taffix are presented as net loss (income) from discontinued operations
in the condensed consolidated statements of operations. Further, the Company reclassified the liabilities of Taffix current liabilities
related to discontinued operations on the condensed consolidated balance sheets as of June 30, 2024 and December 31, 2023. The condensed
consolidated statements of cash flows are presented on a condensed consolidated basis for both continuing operations and discontinued
operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents key components of &ldquo;Net loss (income) from discontinued operations&rdquo;:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">General and administrative expense</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">(34</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Other income (expense), net</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">4</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net income (loss) from discontinued operations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(30</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents liabilities that are classified as discontinued operations on the condensed consolidated balance sheets:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2024</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2023</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left">Accounts payable</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">147</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">158</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrued expense and other current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Advances from customers</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">262</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">270</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Current liabilities related to discontinued operations</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">492</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">513</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
    10:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSEQUENT
    EVENTS</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated subsequent events from the date of the condensed consolidated balance sheet of June 30, 2024 through December 31, 2024, the date the condensed consolidated financial statements were available to be issued, and has determined that, there have been
no subsequent events that require recognition or disclosure in the condensed consolidated financial statements, except as described in
Note 3, Note 4 and as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 222; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NASUS
PHARMA LTD. AND ITS SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Amounts
in thousands, except share and per share amounts)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 28, 2024, the Board of Directors and the Company&rsquo;s shareholders approved the 2024 SAFE agreements and approved an
    aggregate of $2,000 to be raised in the 2024 SAFE, which is $500 more than previously approved on April 9, 2024 (see Note 4). The
    Company entered into agreements to raise $1,301 under the 2024 SAFEs, out of which $951 in proceeds were received during April 2024,
    $50 in proceeds were received during November 2024 and 2024 SAFEs in the amount of $300 were canceled and terminated during November
    2024 according to mutual agreement between the investors and the Company. In addition, see Note 10 (b) for additional 2024 SAFEs
    that have been issued.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 28, 2024, the investors in the July 2022 Loan and February 2023 Loan (see Note 3) agreed to convert the then outstanding
    balance of short-term debt of $588 and $68, respectively, into 2024 SAFEs. Pursuant to the terms of the July 2022 Loan Exchange
    Letter and the February 2023 Loan Exchange Letter, the then outstanding balance of the July 2022 Loan and the February 2023 Loan
    converted, after deduction of applicable withholding taxes, into 2024 SAFEs in the amount of $570 and $66,
    respectively.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 28, 2024, the Company issued the 35,243 Class A-3A Ordinary Shares and accordingly, the 2022 SAFEs were terminated on that
    date.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 28, 2024, the Company issued the 63,958 Class A-3B Ordinary Shares and accordingly, the 2023 SAFEs were terminated on that
    date.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    August 8, 2024, the Company granted three of its scientific advisory board members 2,500 options to exercise 2,500 Class Ordinary
    Shares. The share options vest quarterly over a period of three years, commencing July 2024 at an exercise price of $17.71.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 5, 2024, the Company entered into a subcontractor agreement with Formulex. Under the terms of the agreement, the Company
    may retain the services of Formulex as a subcontractor, on a non-exclusive basis, in connection with potential participation in
    tenders to render certain services to end-clients. The services provided by Formulex shall be decided by the parties on a
    case-by-case basis, and may include, among other services, assisting us with applying to, and participating in, certain tenders, and
    performing certain tasks for the projects underlying tenders for which we are selected. Payment for services would be dependent upon
    the project and, pursuant to the contract, would need to be pre-itemized in the form of a budget before a project commences. The
    maximum consideration to be paid to Formulex in the aggregate under the agreement shall not exceed $800,000. The term of the
    subcontractor agreement is thirty-six months from its effective date, unless terminated by either party upon 30 days notice. As of
    December 31, 2024, Formulex has provided the Company with subcontractor services for a total amount of $117,000 under this
    agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 223; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></FONT></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>Ordinary
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="formdrs_027.jpg" ALT=""></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Nasus
Pharma Ltd.</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRELIMINARY
    PROSPECTUS</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>ThinkEquity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2025 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025 (the
25<SUP>th</SUP> day after the date of this offering), all dealers effecting transactions in these securities, whether or not participating
in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation to deliver a prospectus
when acting as an underwriter and with respect to an unsold allotment or subscription.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 224 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
6. Indemnification of Directors, Officers and Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Indemnification</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Israeli Companies Law 5759-2999, or the Companies Law, and the Israeli Securities Law, 5728-1968, or the Securities Law, provide that
a company may indemnify an office holder against the following liabilities and expenses incurred for acts performed by him or her as
an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association
include a provision authorizing such indemnification:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            financial liability imposed on him or her in favor of another person by any judgment concerning
                                            an act performed in his or her capacity as an office holder, including a settlement or arbitrator&#8217;s
                                            award approved by a court;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
                                            litigation expenses, including attorneys&#8217; fees, expended by the office holder (a) as
                                            a result of an investigation or proceeding instituted against him or her by an authority
                                            authorized to conduct such investigation or proceeding, provided that (1) no indictment (as
                                            defined in the Companies Law) was filed against such office holder as a result of such investigation
                                            or proceeding; and (2) no financial liability as a substitute for the criminal proceeding
                                            (as defined in the Companies Law) was imposed upon him or her as a result of such investigation
                                            or proceeding, or, if such financial liability was imposed, it was imposed with respect to
                                            an offense that does not require proof of criminal intent; or (b) in connection with a monetary
                                            sanction;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reasonable
                                            litigation expenses, including attorneys&#8217; fees, expended by the office holder or imposed
                                            on him or her by a court,: (1) in proceedings that the company institutes, or that another
                                            person institutes on the company&#8217;s behalf, against him or her; (2) in a criminal proceedings
                                            of which he or she was acquitted; or (3) as a result of a conviction for a crime that does
                                            not require proof of criminal intent; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expenses
                                            incurred by an office holder in connection with an Administrative Procedure under the Securities
                                            Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees. An &#8220;Administrative
                                            Procedure&#8221; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by
                                            the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative
                                            Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures
                                            subject to conditions) to the Securities Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law also permits a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates
to financial liability imposed on him or her, as described above, then the undertaking should be limited and shall detail the following
foreseen events and amount or criterion:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
                                            events that in the opinion of the board of directors can be foreseen based on the company&#8217;s
                                            activities at the time that the undertaking to indemnify is made; and</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            amount or criterion determined by the board of directors, at the time of the giving of such
                                            undertaking to indemnify, to be reasonable under the circumstances.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into indemnification agreements with all of our directors and with all members of our senior management. Each such indemnification
agreement provides the office holder with indemnification permitted under applicable law and up to a certain amount, and to the extent
that these liabilities are not covered by directors and officers insurance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 225; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exculpation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, an Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but
may exculpate in advance an office holder from his or her liability to the company, in whole or in part, for damages caused to the company
as a result of a breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such
exculpation is included in its articles of association. Our amended and restated articles of association provide that we may exculpate,
in whole or in part, any office holder from liability to us for damages caused to the company as a result of a breach of his or her duty
of care, but prohibit an exculpation from liability arising from a company&rsquo;s transaction in which our controlling shareholder or
officer has a personal interest. Subject to the aforesaid limitations, under the indemnification agreements, we exculpate and release
our office holders from any and all liability to us related to any breach by them of their duty of care to us to the fullest extent permitted
by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Limitations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Law provides that the Company may not exculpate or indemnify an office holder nor enter into an insurance contract that would
provide coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty
of loyalty unless (in the case of indemnity or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable
basis to believe that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was
carried out intentionally or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive
an illegal personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation
committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended and restated articles of association permit us to exculpate (subject to the aforesaid limitation), indemnify and insure our office
holders to the fullest extent permitted or to be permitted by the Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7. Recent Sales of Unregistered Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below are the sales of all securities by the Company since February 2022, which were not registered under the Securities
Act. The Company believes that each of such issuances was exempt from registration under the Securities Act in reliance on Section 4(a)(2)
of the Securities Act, Rule 701 and/or Regulation S under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2022 through May 2022, we entered into certain investment agreements, which we refer to as Simple Agreements for Future Equity,
or <FONT STYLE="background-color: white">SAFEs,</FONT> for aggregate proceeds of $966,000, collectively, the 2022 SAFEs. Per the terms
of the 2022 SAFEs, since an initial public offering, merger, acquisition, equity financing other liquidity event or dissolution event
did not take place within 15 months from the execution of the 2022 SAFEs, on August 28, 2024, the subscription amounts under such
SAFEs were converted into 35,243 Class A-3A Ordinary Shares. Immediately prior to the consummation of this offering, such Class
A-3A Ordinary Shares will automatically convert into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2022, we received a loan, or the July 2022 Loan, from Dr. Ronnie Hershman, a director and shareholder, and Michael Gibber, a shareholder,
pursuant to which we received a principal amount of $500 thousand, for a term of twelve (12) months, at an interest rate of 8%
per annum. On August 28, 2024, we and each of Dr. Ronnie Hershman and Michael Gibber entered into an exchange letter, or the July 2022
Loan Exchange Letter, according to which our obligations in connection with the loan were discharged in consideration for the issuance
of a SAFE under the same terms as the 2024 SAFEs, under which it is deemed that Dr. Hershman invested an amount of $284,154 and Michael
Gibber invested an amount of $286,210.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
February 2023, we received a loan in an aggregate amount of $60 thousand from Dr. Ronnie Hershman, Dr. Dalia Megiddo, and Mr.
Udi Gilboa, or the February 2023 Loan, under substantially the same terms as the July 2022 Loan</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
for a term of twelve (12) months, at an interest rate of 8% per annum. <FONT STYLE="background-color: white">A definitive agreement for
the February 2023 Loan was not executed. On August 28, 2024, we and each of Dr. Ronnie Hershman, Dr. Dalia Megiddo, and Mr. Udi Gilboa
entered into an exchange letter, or the February 2023 Loan Exchange Letter, according to which our obligations in connection with
the February 2023 Loan were discharged in consideration for the issuance of a SAFE under the same terms as the 2024 SAFEs, under which
Dr. Ronnie Hershman was deemed to have invested an amount of $43,954, Dr. Dalia Megiddo was deemed to have invested an amount of $11,286,
and Mr. Udi Gilboa was deemed to have invested an amount of $10,963 in said SAFEs.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2023 through April 2023, we entered into SAFEs for aggregate proceeds of $995,000, collectively, the 2023 SAFEs,
Per the terms of the 2023 SAFEs, since an initial public offering, merger, acquisition, equity financing other liquidity event or dissolution
event did not take place within 15 months from the execution of the 2023 SAFEs, on August 28, 2024, the subscription amounts under such
SAFEs were converted into 63,958 Class A-3B Ordinary Shares. Immediately prior to the consummation of this offering, such Class
A-3B Ordinary Shares will automatically convert into Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2024 through January 2025, we entered into SAFEs <FONT STYLE="background-color: white">in the aggregate amount</FONT> of
$1,421,500, or the 2024 SAFEs, of which $300 thousand were canceled and terminated during November 2024. In addition, pursuant
to the terms of the July 2022 Loan Exchange Letter and the February 2023 Loan Exchange Letter, the July 2022 Loan and February 2023 Loan
were converted into 2024 SAFEs in the amount of $570,364 and $66,203, respectively; however, no additional proceeds were received pursuant
to said exchanges. Per the terms of the 2024 SAFEs, upon an initial public offering, merger, acquisition, qualified equity financing
or other liquidity event, the subscription amounts under such SAFEs will be converted into our Ordinary Shares upon consummation of this
offering at a conversion price reflecting a discount of 35%. However, if such events do not occur within 18 months of the execution of
such SAFEs, such SAFEs will be converted into our securities of such class of shares having certain rights identical to the respective
rights of the most senior class of shares on the basis of a previous round of equity financing consummated by the Company at a conversion
price reflecting a discount of 35%, as prescribed in such SAFEs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Since February 2022, we
granted our directors, officers, consultants and employees options to purchase 79,063 Ordinary Shares under our <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019
Incentive Option Plan, </FONT> at an exercise price ranging between $0.01 and $42.00 per Ordinary Share<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Further, since February 2022, 69 Ordinary Shares were issued upon exercise of options at an exercise price of $42.0, and
options to purchase 16,596 Ordinary Shares were forfeited and expired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 226; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8. Exhibits and Financial Statement Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits:</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Number</B></FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 0.1in; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Underwriting Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles
    of Association of Nasus Pharma Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Articles
    of Association of Nasus Pharma Ltd. to be in effect upon the consummation of this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&amp;+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Indemnification Agreement.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Representative&rsquo;s Warrants.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4&amp;+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus
    Pharma Compensation Policy.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), Israeli counsel to Nasus Pharma Ltd. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Sullivan &amp; Worcester LLP, U.S. counsel to Nasus Pharma Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasus
    Pharma 2019 Incentive Option Plan. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License
    Agreement, dated May 1, 2019, by and between Nasus Pharma Ltd. and Formulex Pharma Innovations Ltd.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Master
    Services Agreement, dated September 6, 2019, by and between Nasus Pharma Ltd. and Aptar France SAS.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">10.4&amp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">Schedule of Work, dated September
    6, 2019, by and between Nasus Pharma Ltd. and Aptar France SAS.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">10.5&amp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">Schedule of Work, dated April
    20, 2020, by and between Nasus Pharma Ltd. and Aptar France SAS.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">10.6&amp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify">Schedule of Work, dated August
    26, 2021, by and between Nasus Pharma Ltd. and Aptar France SAS.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of 2022 SAFE.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of 2023 SAFE.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of 2024 SAFE.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Brightman Almagor Zohar &amp; Co., a firm in the Deloitte Global Network. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Sullivan &amp; Worcester Tel Aviv (Har-Even &amp; Co.), (included in Exhibit 5.1).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power
    of Attorney (included on the signature page of this Registration Statement).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> 99.1&amp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"> Financial Statement Representation
    pursuant to Instruction 8.A.4 of Item 8 of Form 20-F. </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing
    Fee Table. </FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously
                                            filed.</FONT> </P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&amp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    be filed by amendment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or any compensatory plan, contract or arrangement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Statement Schedules:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
financial statement schedules have been omitted because either they are not required, are not applicable or the information required
therein is otherwise set forth in the Company&rsquo;s financial statements and related notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9. Undertakings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned Registrant hereby undertakes:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
    post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
    forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
    the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
    of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b)
    if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set
    forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    include any material information with respect to the plan of distribution not previously disclosed in the registration statement
    or any material change to such information in the registration statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 227; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
    be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
    termination of the offering.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F
    at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required
    by Section 10(a)(3) of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective
    amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other
    information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with
    respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and
    information required by Section 10(a)(3) of the Act or Rule 3-19 of this chapter if such financial statements and information are
    contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d)
    of the Securities Exchange Act of 1934 that are incorporated by reference in the Form F-3.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the registrant is relying on Rule 430B:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the
    date the filed prospectus was deemed part of and included in the registration statement; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
    prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on
    Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information
    required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement
    as of the earlier of the date such form of prospectus is first used after effectiveness of the date of the first contract or sale
    of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
    person that is at that date and underwriter, such date shall be deemed to be a new effective date of the registration statement relating
    to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time
    shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement
    or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into
    the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract
    sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that
    was part of the registration statement or made in any such document immediately prior to such effective date; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 228; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the registrant is subject to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating
    to an offering, other than registration statements relying on Rule 430B or other prospectuses filed in reliance on Rule 430A, shall
    be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided,
    however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a
    document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
    statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that
    was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
    prior to such date of first use.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
    of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
    to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
    are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller
    to the purchaser and will be considered to offer or sell securities to such purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 96px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
    424;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 96px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
    the undersigned registrant;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 96px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
    or its securities provided by or on behalf of the undersigned registrant; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 96px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements,
    certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each
    purchaser.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
    as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
    persons of the registrant pursuant to the provisions described in Item 6 hereof, or otherwise, the registrant has been advised that
    in the opinion of the SEC such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.
    In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
    or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
    is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will,
    unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction
    the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final
    adjudication of such issue.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    undersigned registrant hereby undertakes that:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
    for purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
    as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
    to Rule 424(b)(1) or (4), or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the
    time it was declared effective.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 72px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That
    for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form
    of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of
    such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 229; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form F-1 and has duly caused this registration statement on Form F-1 to be signed on its behalf by
the undersigned, thereunto duly authorized, in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2025. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasus
    Pharma Ltd.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 62%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; white-space: nowrap; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
    Teleman</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned officers and directors of Nasus Pharma Ltd. hereby constitute and appoint each of Mr. Udi Gilboa and Mr. Dan Teleman
 with full power of substitution, each of them singly our true and lawful attorneys-in-fact and agents to take any
actions to enable the Company to comply with the Securities Act, and any rules, regulations and requirements of the SEC, in connection
with this registration statement on Form F-1, including the power and authority to sign for us in our names in the capacities indicated
below any and all further amendments to this registration statement and any other registration statement filed pursuant to the provisions
of Rule 462 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this amendment to the registration statement on Form F-1 has been signed by the following
persons in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 46%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt; width: 2%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> , 2025 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Dan Teleman </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> Chief Executive Officer </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> (Principal Executive Officer) </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Founder
    and Executive Chairman of the</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
    of Directors</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;,
    2025 </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Udi
    Gilboa </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Co-Founder, Director </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;,
    2025 </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Dalia Megiddo</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Director of Finance</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;&nbsp;&nbsp;, 2025 </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Oren Elmaliah</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial and Accounting Officer)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;,
    2025 </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Ronnie Hershman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 230; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE
OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Act of 1933, as amended, the undersigned, Puglisi &amp; Associates, the duly authorized representative in the United
States of Nasus Pharma Ltd., has signed this registration statement on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2025. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald
    J. Puglisi</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing
    Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 231; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>formdrs_001.jpg
<TEXT>
begin 644 formdrs_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "& .T# 2(  A$! Q$!_\0
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M1D_-W]* /L&BOR3_ &9_^"G'QA^.'[2W@+PCJAT73M U;41!=V]G8C<R;&.
M[$D=!R*_3?XO?&+PE\"O ][XL\9ZM'I.CVHQN;F29S]V.->K.>P'Z#F@#M:*
M_)WXK?\ !:G5KW4)++X:^!H8+8N4CO=;=I9I/[I6)" I/H2U>:?\-R?MI^+/
M])T[2-76W^\@L?"9V8/^UY9S^= '[6T5^)-K_P %3/VE_AGJL-KXOL;29N#]
MCUS1#:.P!YY4(Q^M?6'[.O\ P5^\#_$K6+/0OB!H[>!M1N"L::DDOG6+2'LQ
M(W1#/<[ASR1UH _0:BF0S1W,,<T,BRQ2*'21""K*1D$$=013+FX6WCR?\^]
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M LT3$'()5@0<'FBB@!E]X3T34_#W]@W>D6-UHGE+#_9LUNCV_EKC:OED;<#
MP,<8J70?#NE^%=+ATS1M.M=*TZ'(BM+.%8HDR<G"J !S110!HT444 9GB+PS
MI'B[2Y-,US2[/6-.D(+VE] LT3$'()5@0<5;L+"VTNR@L[.WCM;2W01100H$
M2-0,!5 X  [444 9FK>"] U[6-/U;4=%L;[5=/;=9WMQ;JTUN<YRCD97GT-;
M=%% !1110!AV?@?P[I_B2Y\06VA:=;Z[<KLGU**U1;B5>.&D W$<#J>U/U3P
E;H.N:Q8:MJ&C6%]JFGG-I>W%LCS6^?[CD97\*** -FBBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>formdrs_002.jpg
<TEXT>
begin 644 formdrs_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (6 R # 2(  A$! Q$!_\0
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M_P */[&L_P#GTL_^_2_X5=\H>_YT>4/?\Z *7]C6?_/I9_\ ?I?\*/[&L_\
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M[_G1Y0]_SH I?V-9_P#/I9_]^E_PH_L:S_Y]+/\ []+_ (5=\H>_YT>4/?\
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M-9_\^EG_ -^E_P */[&L_P#GTL_^_2_X5=\H>_YT>4/?\Z *7]C6?_/I9_\
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M/H: &X]A1CV%.VGT-&T^AH ;CV%&/84[:?0T;3Z&@!N/848]A3MI]#1M/H:
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M_P#;#_98UGPWJ4GA'6/'.B6US:WR1B8Z/-.6+LBG[S1_O /?!KM?!E[\1O\
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MC]'_ -EOXL7GQW_9U\&^,M1M+2QO_$FF)>W%O;9,,3-N^5<\XX[U\Y?M3_\
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M]GK5/'%YIS:K);2QVMI9AP@N)Y"0H9C]U1@DG&<#I7S3_P $$?A#)I'[,_\
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M[MJ_P3YM--K7^=[6>_0TAQ)'ZL\2H;-+XX<NNN][?*U[K8^ROVI/BI>? O\
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M?%/X!-X:U*T\=+NUKPWKEPD0MY6.]UW,=CJ&Y5@P89(Y!S7M/P0^"WQE\;_
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MO#GQ-LI[GPUX@T/Q#;VK^7-)IE_%=K"W]UC&QP?K4:_%?PL_C8^&1XF\._\
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M#'QYN?AI\8?#G@^VU^X\/3^)M(U7P;=7,]A?00L5FA>*X42)*IVD9)5LUG?
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M_K0 WRA[_G1Y0]_SIVUO[OZT;6_N_K0 WRA[_G1Y0]_SIVUO[OZT;6_N_K0
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M>ZN-55(1=W"#=':A\&3"G(&W!S7Z#:7\&?"VB_%75/'-KH6GP>+M;LXM/O\
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MF?\ A'-.X_Y=8O\ T!:NY^M #?+]S1Y?N:=GZT9^M #?+]S1Y?N:=GZT9^M
M#?+]S1Y?N:=GZT9^M #?+]S1Y?N:=GZT9^M #?+]S1Y?N:=GZT9^M #?+]S1
MY?N:=GZT9^M #?+]S1Y?N:=GZT9^M #?+]S1Y?N:=GZT9^M #?+]S1Y?N:=G
MZT9^M #?+]S1Y?N:=GZT9^M #?+]S1Y?N:=GZT9^M #?+]S1Y?N:=GZT9^M
M#?+]S1Y?N:=GZT9^M #?+]S1Y?N:=GZT9^M #?+]S1Y?N:=GZT9^M #?+]S1
MY?N:=GZT9^M #?+]S1Y?N:=GZT9^M #?+]S1Y?N:=GZT9^M #?+]S1Y?N:=G
MZT9^M #?+]S1Y?N:=GZT9^M #?+]S1Y?N:=GZT9^M #?+]S1Y?N:=GZT9^M
M#?+]S1Y7/7IS3L_6C/UH 9Y6!C)QSQ_GI2^5[G/K3L_6C/UH ;Y?N:/+]S3L
M_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH
M ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:
M/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L
M_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH
M ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:
M/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L
M_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH ;Y?N:/+]S3L_6C/UH
M ;Y?N:I^($VZ!?\ .?\ 1I?_ $!JO9^M4O$1QX>O_P#KVE_]%M0 _P ,?\BW
MI_\ UZQ?^@+5ZJ7AA WAG3NN?LL7_H"U>\@>IH 2BE\@>IH\@>IH 2BE\@>I
MH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>
MIH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2
MBE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@
M>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\
M@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH
M 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE
M\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>I
MH\@>IH 2BE\E<]31Y*^IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@
M>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH
M2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\
M@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2BE\@>IH\@>IH 2J/B;CPW
MJ/\ UZR_^@-5_P @>IJCXE0#PUJ/7_CUE_\ 0&H ?X6!_P"$8T[C_EUB_P#0
M%J]@^AJGX4_Y%G3_ /KVB_\ 0%K0H CP?0T8/H:DHH CP?0T8/H:DHH CP?0
MT8/H:DHH CP?0T8/H:DHH CP?0T8/H:DHH CP?0T8/H:DHH CP?0T8/H:DHH
M CP?0T8/H:DHH CP?0T8/H:DHH CP?0T8/H:DHH CP?0T8/H:DHH CP?0T8/
MH:DHH CP?0T8/H:DHH CP?0T8/H:DHH CP?0T8/H:DHH CP?0T8/H:DHH CP
M?0T8/H:DHH CP?0T8/H:DHH CP?0T8/H:DHH CP?0T8/H:DHH CP?0T8/H:D
MHH CP?0T8/H:DHH CP?0T8/H:DHH CP?0T8/H:DHH CP?0T8/H:DHH CP?0U
MD^*?'FA^!A9G6]9TK1_[0G6UM?MMW';_ &F5CA8TWD;F)/ '-;5?G=_P7YMT
MF;]FO<BMM^*>FD9 .W]]$.X]_K[B@#[W\4^/=#\#"S.MZSI6CC4)Q:VOVV[C
MM_M,IZ1IN(W,?0<TSQE\1?#WPZM8Y_$.NZ-H4$S;(Y-0O8[99&] 7(!/TKX,
M_P""_5NDS?LUF1$<+\4]/(W+T.].E>7?\%%?A/:?#S_@HKK'Q"_:!^%WBGXP
M_ _5M(AM=$;2_,N;;PS*H7>TMNK*/X7R2P&'W#)&* /U'F\>Z';^$VU^36=*
M30DC\YM1:[C%HJ9QN,N=N/?-4/!_QH\'?$/4&M/#_BSPUKETB[VAT_4X+F0+
MZ[48G'O7YDW7PY^%/AO_ ())?M+ZU\%_B5J_BWX>>)+'[1!X;U!<+X2D\Q,P
M(KCS4RI (DSG8".^>7\=_L$?#_X2_P#!'7PM\?\ X?:6_@3XN>$M$L/$@U[2
MKF6*6_E\Q$DCF7?M9&#$X &"!CJ00#]?KV^ATVTEN+F6.W@@0R22RL$2-0,E
MB3P !W-<1_PU1\,/^BC^!/\ P?6O_P 7[5G_ +._C-/VFOV3O"6N:_913)XT
M\.02ZE:M]R7SH0)1QCY3EO3@U^?7_!67]@7X"_![X<^#OA[\-?A)X0L?BE\7
M]>@T/19X(7,^FP!@US=J"QQM7:F2",R^U 'ZBZ)X@L/$NC0:CIU[:7^GW2>;
M#=6\RRPRI_>5U)!'N#3M)URRU^V,]A=VU]"KM$9+>59$#J2&7()&0001VQ7R
M7^V!^P$VK?L;:%X1T'XB^,O GA/X9>&[KS].\/21VY\0/';KY2SRE2PC4I)E
M5 W>;R>*SO\ @@/(TW_!,;P6[%F9KW4"68Y+'[5)R3U/;D\T ?8^IZO::)I\
MUW>W-O9VENI>6>>01QQ*.I9CP!]:S?!OQ(\._$6UEG\/:]HVO0P-LEDTZ]CN
MEC/H2C'!^M>2?M\_LA:'^V'\);32?%&L^,;/PYX>NSK5]I6@2QHWB%8D)%K+
MO5BR'^ZI4EL<U\%_\$X;;P7K7_!6I+CX3>$-6^ GA/3/"#IJ?A#7V:TO_%$S
M%P)HK3>XV)\A+;F_U>>": /U5\6^-]%\ :1_:&O:OIFB6 =8C<W]TEM"'8X5
M=[D#)[#-9W@_XS^#OB%?M:Z!XK\-ZY=(N]H;#4X;F0#U*HQ.*^-/^#C&W6Z_
MX)PSHT0F4^*=)^0KNWCSN@'?/3_"OBOQ5X7^&>G_ +0G[/<?PO\ A%XM_9JU
MJ7Q#;MJ/BGQ%&=-L]40(I,"8FE$C.02,E>&Q@AB5 /V;D^-?@]/%FMZ"WB;1
MO[;\.60U'5+ 72&XL+8KN$LB [E7'.3[>M<A%^W-\()?AYX>\6K\1/#+>&O%
MNHG2-'U$7'[C4KL,4\B,]WW*1CVKY?C^)>E:Y_P4O_:;\,P^ O"&G:OI/PV$
M\WBBVBE75]41K>/$,Q+F/8N[@J@)VKG-?%>E?\HG/V3NG_)77QQ_T^3T ?M9
MIGQ5\,ZO\0-0\)VFO:1<^)](@2YO=*BND:[M8GQM=X\[E4Y&"1W%;^[C/:OA
M30?VE?"_PU_X*I_M$S:IX'\)Z2/ O@>TUC4O%=I%+_;.IP+%"_D2;G,6!G V
MJ"<+DUPUI_P6/^-FB_#?2?C7XC^!^CV/[/>N7B0P7MMK)EURUMWD,2W$D9.T
MKN5CCRU!XYY!H _23<* V3QR:^&_CO\ \%)OBU:_MNM\(_A#\/?"/CU=3\(6
M_B32[J^U)[ KYHW&65RVPQ;,850K$GK7I?\ P3&_;HUW]M3P5XR@\8^&+'PI
MXX^'>O2^']<L[&9I;1IHRPWQ%B6 ^4CEF^[D'!% 'TU@^AHP?0U)10!'@^AH
MP?0U)10!'@^AHP?0U)10!'@^AHP?0U)10!'@^AHP?0U)10!'@^AHP?0U)10!
M'@^AHP?0U)10!'@^AHP?0U)10!'@^AHP?0U)10!'@^AHP?0U)10!'@^AHP?0
MU)10!'@^AHP?0U)10!'@^AHP?0U)10!'@^AJAXI!_P"$9U+C'^BR_P#H#5IU
MG^*_^19U#_KVE_\ 0&H /"G_ "+.G_\ 7M%_Z M:%9_A3_D6=/\ ^O:+_P!
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M+N%(/4 9&<U\0_$_]I7Q[\9[II/$GBK5KZ-CN%LDOV>V3G.!%'A,?49XKZ'
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MD:F4_P#0D-?$Y0$YQ0% /  _"LI</9>]Z:^5_P#,UCQ#F"VJ/YV_R/T!T/\
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MW%P4L14OW?YO_(Y\'-%=K'I]K=NOG6MO,1DX*;3D]RRD%C]3^%2K\/M-O8F
M2>%V.=RRY"^P!'\S6SQ$5N8K#2>QPM%=VWP8BN9%^SZC(B]_-C#$_ETJ._\
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MJ #PI_R+.G_]>T7_ * M:%9_A3_D6=/_ .O:+_T!:T* "BBB@ HHHH ****
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M+.G_ /7M%_Z M:%9_A3_ )%G3_\ KVB_] 6M"@ HHHH **** "BBB@ HHHH
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M\D_X)J^&K[Q+^WY\,4LK:6X-CK4=W<E%W+!$BMEW/8<XK^@Q1NZ<@]#7Y_\
M[(GP?\-_!?XA^&]-\-Z7%I\#WR&63[\URP!^:1S\S'^7:OO^,_,??_ZU?D^#
M\2Z'&=:MC,)2<*5)\D>:W-)6YKM+1;V2NW;?4_5<)P55X:H1PV)J*=2:YI6V
MB_ALGUVO<D7BEIJ4ZO13OJ;^H4444P"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *S_ !7_ ,BSJ'_7M+_Z U:%9_BO_D6=
M0_Z]I?\ T!J #PI_R+.G_P#7M%_Z M:%9_A3_D6=/_Z]HO\ T!:T* "BBB@
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M/PJ[=?Q50N>ASZU\7C<57JMNM4E)^<F_S9]#A\/2@DH12]$OT2*-R2H//?\
M*J-R< 'W-7;OI^/^-4;H97\37S.(?8]>F[FY\%?^2P^&_P#K^3^1K[8CZ_C7
MQ/\ !;GXQ>&_^OY?Y&OMB/K^-?T+X&_\BO%?]?%_Z2C\R\0/][I?X?\ VYDB
M?=%+2)]T4M?N9\(PHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5G^*_P#D6=0_Z]I?_0&K0K/\5_\ (LZA_P!>TO\
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M=0_Z]I?_ $!JT*S_ !7_ ,BSJ'_7M+_Z U !X4_Y%G3_ /KVB_\ 0%K0K/\
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M_/I6?<_=_#_&O Q)Z-$H7?WJW?@E_P EE\-?]?J?R-85W]ZMWX)?\EE\-?\
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MZHJVW\/U_K6C:_=-9UM_#]?ZUHVOW37Y=A#ZRJ:=K_#]36K:=!_O?XUE6O\
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M1110 5G^*_\ D6=0_P"O:7_T!JT*S_%?_(LZA_U[2_\ H#4 'A3_ )%G3_\
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M\BSI_P#U[1?^@+6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "L_Q7_R+.H?]>TO_ * U:%9_BO\ Y%G4/^O:7_T!J &>%_\
MD6--_P"O6+_T!:OX^M9WAA\>&=._Z]8O_0%J_P"9[&@!V/K1CZTWS/8T>9[&
M@!V/K1CZTWS/8T>9[&@!V/K1CZTWS/8T>9[&@!V/K1CZTWS/8T>9[&@!V/K1
MCZTWS/8T>9[&@!V/K1CZTWS/8T>9[&@!V/K1CZTWS/8T>9[&@!V/K1CZTWS/
M8T>9[&@!V/K1CZTWS/8T>9[&@!V/K1CZTWS/8T>9[&@!V/K1CZTWS/8T>9[&
M@!V/K1CZTWS/8T>9[&@!V/K1CZTWS/8T>9[&@!)>A .#Z^E>6_%'X*3ZGJL^
MJZ4P>2<[Y;=SC<W3*GIVZ5ZBS;NQ%)@9Z'Z=J\C.,EPV94?J^*C>-[JVC3VN
MGZ'7@L;5PM3VM)ZGS=<Z1=Z-+MN[::V9#SYBD#\^E6+4]!QR1TYKZ'GMXKJ,
MI+$DBGJ&4'-8FH_#71-0)9M/CB?^]$?+_EQ^E? 5?#JK2_W6LGZJWXH^BAQ+
M&>E6'W'DUH3D<8&:U+-L[?KG^==I+\'M/_Y=Y;N(^^' _2H&^%,D!_=WB$#I
MO3!_2IAPQF%)V<$_1W'+-L-+9_@<U+_JV_SVJA.>&^O]:["?X:W^SY9;9L_[
M1&:SKGX::K@XCA//:3K6>)R7'K_EU+^OF72QV'_G1Q]Q]S]?YU2G;:3[?XUU
MUQ\+]988%LA_[:BJ,OPIUUR?]#7_ +^K7@8C)<P>U"7W'HTL=A[?&OO.1EX5
MOI6?.,5VTGP=\02 @6L8S_TU%1GX$>(;CK%:QY_O3"O'J\.YI/2.'G]QW1S/
M"+>HOO//;HXC'TK/N?O'ZUZD/V;-=N  ]Q81C_?)Q^E6+;]E2ZER;G5X%'I'
M$2?U-<3X'SRL[0P[7K9?J;?V_E]-:U5\KO\ 0\9NAM7/'-9UR,?ES[5]%6?[
M*&D@C[3?ZA<8[*RQ#^1K<TO]G7PSI3!ETNWF<=&G8S8_!LC/X5U4?"3.J[7M
MI0IK_%?\(K]3.?&F!@OW:E+Y)+\3Y6M-$O->N!'96L]TS''[M"P'U/05Z1\+
M/@#>Z9JD.J:L#%+!\\-LIR5..&;M^%?0EGX,M;&,)%%'$@XPHP/RJTGA^W10
M,>_7K7W/#?A#E^7XB&-Q<_;5(--*W+%-:WTU>MOB^YGS^9\9XG$TW1H1Y(M-
M7W=F<;9Z*X/0FM:QT:1<?*:Z6/3HHNB?G4JQH@P$%?KI\:9=AI<B\@8^M:=K
M:F$<FI ^/X:7S/8T .Q1CZTWS/8T>9[&@!V/K3,D>O6E\SV-,;Y@00:+=P:O
MHSR[XI?!6?4]5GU32F\R6?YYK=CC<?[RGIGVKSZXT>[TB;9=6TULRG_EHA /
MT/>OI%D#*00>?I39K:.YC*2Q)(I[,H(KX#-O#_"8FM+$X>7LY2U:LFK]^_W'
MT&#XBKTJ:I55S);>2/GJWSVY!-:5K]X#OGGFO6-0^&6AZ@VYK!(V]8CY?Z+@
M5GS_  >T[.89[N$=@6#C^5>&^"<QHOW91EZ.WX-7._\ MZA-6::^1QEH<@'_
M #VJ>XZ?E_2NE_X53)"?W5ZC#MN0_P!*BN/AM?,/EEMS_P "(K9Y#CX1:=-O
MT(_M##2?QI>IR$QP#[U0FZ?C777/PUU0,0J0OSVD K/F^&.M'I;1G_MJ*\C$
MY+C^E&7W'?2QN'_G7WG)7'RL3^-49SAS[UV$_P )]=<G%FO_ ']%5I/@WX@D
M;BS3\90*\.OD68O:A/[F=M/,,,MZB^\X>X^[^']*HS_<;Z5Z ?@/XAGX\NU7
MZS#BE3]FW7;C(:XT^,'K\Y)'Z5Y=3A7-ZKM##R^[_@G9#-\#'>K'[_\ @'E]
MUT;Z50N1SC/7GCM7M%O^RI=2DFYU:%0>T<))_6M&Q_91TG&;F^U"X]E81K_(
MU,?#;/Z[_A*/^*27^8WQ3EU/[?-Z)O\ R/G:Z((SQ@U'::)>:Y.([*UGNF)X
M\N,L/SZ5]4Z5^SMX9THATTR&:0?Q3NTI_(G'Z5TMEX-M;"'9%%#$H[1J$_EB
MO7P?@EB*K7U_$QC'JHIM_>[+Y_@SCK\=TX.^&I-O^\]/NW/GOX5_ *\T[5;?
M5-5'E20'?#;J<D'U8_TKUFQT.0*!@G%=K'H$$?!'7TJQ'IL,71*_:>'.&L#D
MF$^J8&+2W;;NV[6NWZ>2/A\RS2OCZOM<0_)+HEO9>1S-EH[J?NGDUKV6DNHZ
M8%:J(B#A!3@^.BU[J/.&6EOY(.3DFIL4SS/:E\SV-,!V/K1CZTWS/8T>9[&@
M!V/K1CZTWS/8T>9[&@!V/K1CZTWS/8T>9[&@!V/K1CZTWS/8T>9[&@!V/K1C
MZTWS/8T>9[&@!V/K1CZTWS/8T>9[&@!V/K1CZTWS/8T>9[&@!V/K1CZTWS/8
MT>9[&@!V/K1CZTWS/8T>9[&@!V/K1CZTWS/8T>9[&@!V/K1CZTWS/8T>9[&@
M!V/K5#Q3G_A&=1YX%K+_ .@-5WS/8U0\3N3X:U+_ *]9?_0&H 9X;?'AO3O^
MO6+_ - 6KWFCW_*J'AL?\4YIW_7K%_Z M7: '>:/?\J/-'O^5-HH =YH]_RH
M\T>_Y4VB@!WFCW_*CS1[_E3:* '>:/?\J/-'O^5-HH =YH]_RH\T>_Y4VB@!
MWFCW_*CS1[_E3:* '>:/?\J/-'O^5-HH =YH]_RH\T>_Y4VB@!WFCW_*CS1[
M_E3:* '>:/?\J/-'O^5-HH =YH]_RH\T>_Y4VB@!WFCW_*CS1[_E3:* '>:/
M?\J/-'O^5-HH =YH]_RH\T>_Y4VB@!WFCW_*@R CO3:",T *' __ %4$@CCB
MFA<'O2X'I0 ;MM'FC'4U1\2>(M/\'Z%>:KJMY:Z=IFGPM<75U<2".*WC7EF9
MCP!@5X%\$O\ @JY\ ?VAOBL?!7A/XC:5J'B)W,5M \;PK>N"<K$[@*Y.#C!R
M<<9I-=@:ON?18?GM2^9CCG\Z\/\ VIO^"B_P;_8OUC3]-^(OC.RT/5=44206
M2QO/<"/) D9$!*H2#@MC-==)^U1\.8_@0/B>?&.ACP"T N5ULW(%LR9P!GKO
MW<;<9SVH:ON*R['H!//W1BG;_K7@_P"R_P#\%*/@M^V-XHN]#^'WCFQUG6;-
M&D-D\3P3RHO)=%<#> .3M]>15#XY?\%4/@)^SC\6D\$>,/B'I>E>)-P2:V6-
MYA9L2,+,Z*5C/()!Y -,=CZ'+@=C^5)Y@8\=ZJ:-K-IXDTFVU#3[J"]L+V)9
MK>XA8/'-&PRK*PX((Y!JT%Q2MK<!4(7/?-+O'O\ E28Q13 7>/0_E2^8/?\
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MM0 [>??]*-Y]_P!*;O7VHWK[4 .WGW_2C>??]*;O7VHWK[4 .WGW_2C>??\
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MH_.C>/4?G0 [S#Z"CS#Z"F[QZC\Z-X]1^= #O,/H*/,/H*;O'J/SHWCU'YT
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MP?6@"7 ]!1@>@J/'UHQ]: ),#T%&!Z"H\?6C'UH DP/048'H*CQ]:,?6@"3
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M;75=#B@U#37WA6GA9,P3V[89 1N(/Y5I_$+Q';7'Q=CNKYUET7X6:3)KMZ7
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MFZ#\/-"\+W\UUI6@:+IMY*I$DMGI\4,I!Y.650<'KUYZFI-5\%Z/XBNO.O\
M1=)U&X4!?,N+"*XD4#MEE)P/2MX\44U5@U3DU&,HZRO.TK?:Y;>[;W>JZLP_
MU5J.E4C[2*<Y1EI"T+Q7\M[MN_O=.R/C/]C;]KK]E7X<:=\0;CX-:=<Z/-IF
MAOKVLQRVTT*W4-J&\M=TKD;BT@4#U>OC[]D#]G+X]?M5_"GXG^+O!=GX+O\
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M[;?(^9=7D7_AD[2 ",#6I,DG@\.,?GBMWXB_%FQ^)GPUTSPGH$%Y?W\S6XE
MA($7EC]1N KWHZ1;_91&UI;^2&W>7Y*E0<^F.#2PZ=#9.6CMK>!AG/EQ*A[>
M@]Q^8K*'AMCH4WAJ>+2ISHTZ,_<;DU!6;B^9<O-Y\UEZFD^)L/*?M)46Y1J2
MFGS*R<GI=6UL>-?M@:.?#'_!/[Q]82E%>R\*7$;G(P"(QGGTS7Y>^&;75?@W
M_P $[O@I\>_"SJFK^!O$FLZ+>3!2R_9[F:;RBY'!59-Z^YN!W%?M3<V274#P
MSVZ3PRC:\<L6Y9!TP0W!]\\53_X0O25T?^RQH^E?V<3O%G]BC-OG.<^7MV\D
MYSCJ*_<\AS>&68..&A#F@G%[VO%1Y''YH_,,ZR6IF6*=>53EDTUM?WN924EK
MT:/QJ^,GP5_X43X%_9#AOU\G6_%6I7OB+4RYP\DUU>6+@'/7"!1^ KV/_@J;
MK?B+]KC_ (*/^!?A+X"&EW^J^![1KU8+N4+:B]DVW,S2D9.U(H85(Q_>SC-?
MIKJ'A/3-5:V-YI>FW3VO%M]HM(Y#;=/N!E.SMPN.@I;?PQI]OJ[ZC'I=A'J,
MH(:[6TC$[@C!!D W'CCD\BO4?%3=2%:5.\X*I9MW5ZDKW^4=-SSO]58NG.C"
MI:$W3;25G:FFFM^KUVT/RG\#:M\1_P!BW_@K1X2\0_%J/P[IVH?%-&AOGT:3
M_09X9CY'&0/F26.)BOKM/>I? ?[+'@O]L#_@L#\</"?C:WN;S3;0WEZD=K=F
M"2.820*#D=1AVX/!K]4M5\*Z?KDD,FH:5IUZ]L<Q/=6L<K1'/52X.WIG ],T
MMKX;L+'4IK^WTS3X+V<%9;F*T1)I,D<,X4,<GL3R1[5,N*G[TJ<.2I*'L[Q=
MDK2332L]HIIZ^>A4.%8IQIRGSTU4Y[-7;O%IINZW=FG;IUW/SK_X)1:_<_L_
M_ME?&[X$0:D7\*:'!>7VF6UTJ"X$\4D:9R "<PR%B.GR BOE/]E[]BN+]JG]
MD_XQ>)M!6>7QQX#UF*XT[[/*2;BW"/)-"%'&\_>4]<J!7[?+X2TV+57U-=*T
MY+^4%6O%LXQ.X.,YD"[CGCOSBGZ3X=L/#JR#3],L=.$IW2"UM8X/,.,;FVJ,
M\D]??WJH<63A5J5:4+3GR7=^L4^;_P "6_J2^$H3IPHU9WA3Y[*W2;5O_ 6?
MGO\ #/\ ;JM_VN_^"1_Q/L-9U&!_'7@SP^UCJ\;R 2W<(*K!=[3TWJ"K\<.K
M9Y-?.W[%7Q?_ &.?"'[/^BCXN:#/J'C^TN+B>[NHK2XE78)2T)!1PI*IM[=J
M_8BT\!Z+IR3K!H.BQ"=3'/Y6GPJ)5Z[7PHR.^"#5<?#'PRZG_BF/#A4\9_LF
MW*G/_ *5+/L-3C4HPI3C&<E)*,U%K36-TMAU.'\3.5*O.K"3A!Q;E!R3UTE9
MO<\=_;I\96'CC_@FWXZU[37;^RM;\)KJ-JS@H?)E$3QD@]/D8''4$UQO_!$F
M?S/^"<GA%HF1R;_40ASD$_:"!^!KZIETB"?2OLDEG ]DT8C-NUNIAV #"[,;
M<8 XQP *33-%M=!T]+>QLK2QM0"4BMXEAB&<DD*H Y[^OO7BQS!?498.$7K-
M3N_*^C[ON>U++W]=CC)26D'"R\[:KLM-%Y'Y=_$K]J7X+?M >*?&?AS]K+X=
M0_#OQUHDK6MGJ.E:?<F[NE3*_P"L53OZ HS QLIZXKU?_@@KK?C'4/@SXQM]
M4DURZ\"6NHHGA:;4E<%X\-O$1.1LV^62%)4,Q K[C\1> M&\7RPMK&AZ1JTD
M7$;7UA%.RX[*64G'XXJ[!:QV%FD,$,=M!"H6...(1HBCHJJ!@ #L!^%>EBL\
MIU,&\+"DTG;1S;C&W\J>L;]=6>;A<AJ4\8L7.JFU?51492O_ #-?%;T1,'Y/
M4\FJ^M28T2]Z_P#'O)_Z :G)P<<'''!S5;6R/[%O?^O>3_T$U\WY'TY'H@_X
MDMED?\N\?4?[(JR5'_ZNM4]%=CHMESTMX_\ T 5:W-ZC\J ,W7O!FF^*-3T>
M\OK83W&@W7VVR?<1Y,VTINQW^5B,'CFL?Q!\#_#'BC2M4L[[36EAUB_CU2Z*
MSR(YND "RJX.4("KC''%=5N;U'Y4;F]1^5 'E_QT_9SL_'W@?Q:NC6\4/B3Q
M)ID6FM/<7,BV\Z(Z%?-4;@6"J1NVEJW?#_[//@_P_I^JVZ:+'<QZ[:K97XO)
MGNC/ /\ ECF0G;&.H5<#(!KL]S>H_*C<WJ/RH XG1?V<_".@Z/J=E;V%YY6L
MP):W<DE_/).T*,&6-9&8LB@@<*<5-?\ P-T74M%U>PF:_DAU_48M3OR9LM.\
M9C*QDX_U6(U7;W&>:[#<WJ/RHW-ZC\J ,GQWX T?XFZ&FFZ[81:A8QW,-XD3
MY 66)M\;C']U@/S-&E> ](T3QGJOB&UL8H=9UQ(8[ZZ4?-.L08(,=!C/;K6M
MN;U'Y4;F]1^5 '('X ^$&\,R:.=#MO[.EU4:VT.XX-X)/,\[/7.[G'3%;6H^
M M'U;QQIGB2XL8Y=;T>WGM;*Z/WH(YL>8H'0YV@<].<=ZU=S>H_*C<WJ/RH
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M#++;DDP!66,(^!][%?H?+\-_#EQ=P7$OAOP[+<6JHL,KZ7 TD2H $"L4RH4
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M+%L/^>=Y_P!^U_\ BJ** #_A8MA_SSO/^_:__%4?\+%L/^>=Y_W[7_XJBB@
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M+%L/^>=Y_P!^U_\ BJ** #_A8MA_SSO/^_:__%4?\+%L/^>=Y_W[7_XJBB@
M_P"%BV'_ #SO/^_:_P#Q5'_"Q;#_ )YWG_?M?_BJ** #_A8MA_SSO/\ OVO_
M ,51_P +%L/^>=Y_W[7_ .*HHH /^%BV'_/.\_[]K_\ %4?\+%L/^>=Y_P!^
MU_\ BJ** #_A8MA_SSO/^_:__%4?\+%L/^>=Y_W[7_XJBB@ _P"%BV'_ #SO
M/^_:_P#Q5'_"Q;#_ )YWG_?M?_BJ** #_A8MA_SSO/\ OVO_ ,51_P +%L/^
M>=Y_W[7_ .*HHH /^%BV'_/.\_[]K_\ %4?\+%L/^>=Y_P!^U_\ BJ** #_A
M8MA_SSO/^_:__%4?\+%L/^>=Y_W[7_XJBB@ _P"%BV'_ #SO/^_:_P#Q5'_"
MQ;#_ )YWG_?M?_BJ** #_A8MA_SSO/\ OVO_ ,54&I>/K&XTRY41W>6@<<HO
(H1_>HHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>formdrs_003.jpg
<TEXT>
begin 644 formdrs_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" )J R # 2(  A$! Q$!_\0
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M',!F;M4_O:?^34;M4_O:?^35I[!Z#\J-@]!^5',!F;M4_O:?^34;M4_O:?\
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M,>WK1<"ENU3^]I_Y-1NU3^]I_P"35HAE YQQ[4;DR1QD=>*.8#.W:I_>T_\
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MV_Z_(OYBM%?O"L[Q+_JK;_K[B_G6BGWA3E\(?:'*VX9%+38O]6*=4E!1110
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MJ?B"^M(Y-ZL\3PDM<%<+YC$D'G=D9KWG]HW_ ()\_M"?#S_@M+:_M(_!C3_
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M(T5YFR3RY)Y-=A2;0.PH C>U!'8^Q%)]G;<3QDC'/-344 0K:_-R3CTR3_\
MJI7M0Y4DDE3G.3G\ZEHH B^RCGYCSU]^W-(MN47:,% , >U344 1"VPOWFYZ
MTHMPH.,?-R3C[WUJ2B@"(VH(P#C/H*1K0.22QR>I''\JFHH K7FFQWUL\,RI
M-#*A22*10R2J1@A@>H(/0\5Y?\.OV$?@E\(/')\4>$O@Y\*?"_B<LS-J^C^$
MM/L;_+'+'SXHEDR3R3NYKUG'-&.:=P..U#]G_P #ZQ\5;/Q[=^#?"=SX\T^V
M-E:^))='MWU:V@.<Q)=%/-5#EOE#!?F/'-=4+78 %^ZHP!T 'I@5/12N!";7
M*C+'(&,]_P _\*4VV3]]L>G3']:EHH A:UX."1[#C^5 MR_W\,/?G'YU-10!
M%]E  Y(P<T?9%X[ $]!CCTJ6B@" 6I08!S[FG-;%T +$8S[U+10!&+=0P;G(
M[^M2444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110>E #6_U=?A9
M_P 'IES/+X?_ &>;1&D%M/J.JLR\A"VVV )[9&3C\:_= 2Y![8%?E[_P=:?L
MG7?[0'_!..W\8Z9:R7NI_";6X];F2,9<V4BM%/QU^4M$Q'H">U>CDRC+'4H3
M^TU^+)DKJQ_/-\']"^PW,DTL;+!;@JB@\Y.!D>OK7UI^SM\(_P"U[NS@#@S7
MK!V93M)YP,^X&37SC\('AN[;2K9T+Q3MO5@P)4<$/GN,$U]A_LYI9CQ;%=/(
MDT5L"X8$JXP-H!_/-?Z>Y#2EEW#5/#X=^[RW7S7EYGXEXI8RO#+:D:+LVFCZ
MMT/1]=T+PK=V^N1G7-#>S^Q_9[J,-+'$Q7<(Y0-Z\#H#@YKPOQ!^P7X@^*GA
M22^\/W/AZ#3XBUO:0WZ^<=@<\!Y,E" 1^5?0GCSQU9Z)\(=]G>3K<A=KJS$A
M\<_T_/%:/A#Q\-9\%:==V-Q;"UD@!411#C/!&>Q)ZU^883-,PP+>*PB49.79
MVT\GI=]S^*L)Q5Q%D$/KE*3^*RT:6G1W_,_'#]JGX?:Q\'-7N/#GB/2Y[+5+
M*<P*LBGRG4_QJ_1DQS[5]S?\&<EW+!_P4*^)%K$S/"_@IQ,5)VDB[@VGZ#M]
M:Z/_ (*-_"3PC\;/@5?W?C'5KO3$\-6\MU9W2SY5'P<1[#D,7?:O3O7#?\&U
MW[7_ ,/?V ?B=K^K^-+/6&N_BI<6GAW2=2M[8?8[:+SE#>83C_EH(\@=!7Y=
MXOT<ZXGQ:J8>E[2<:=Y0ATMKS)?)]]C^Z_"'CN/%>4QQ;AR5(/EFNE^Z?6Y^
M\O\ P4F\1Z)X._82^*EWK,<,UG/X=NK%8Y>1<33H8HH^>3F1EX_&OPJ_X(U?
M\$M]8_:S_:_T'5M0L)HOAYX"O8=4U:Y93Y-U<1,)(;1?[V6"A_1<CO7Z^_MR
M?!O6OVGK6\U+QKJ5QX7^#?@NWDU2>*W8_;=8$:%B5'0;A\J]\MQSS7,?\$NO
M^"F_PR_:)U*?X7_!?X9^(-!TWPE!Y]V+E([5(EW!0[GJ\C'&2>><FOFN!^)L
MUX=X+S*CDL)5)UFE6FM(4(M.*OKK.5WTT[]#]A5U&TC[WL5%LBHJJL<8VJ%
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M%W/?SK;06_ (4%NF,\X%?0E[_P $2?BQX$DAM/AW!\(]#1$VC5;VS>ZO(?9
M<XP?6K?P\_X-J)?BOXIAUG]HSXR>)_B5'#('70M.+6&FD=XV .0O^X5KT,^\
M<<KQ>'Y:$52BFW;XI/MLDE\S\USOP7P.:4%A<1.48<UW:WW'Q#\/?V9M1_X+
M"?'*W^&^G:_>ZMX#TF_^TZY?>&83'IFGQ+G)FO9@1+*>BQH,98>E>[_\%%_^
M";NB:=^QC\5]/^'FD?8#\!/$5I<:;%  LTEH852=BPYW9<RDYZI7[#?!CX ^
M"_V7?AK:>%_ 'A32_"WAW3(R(;#2[<1 G')..9'/]YB6)/6O"/V</#.N^+_B
MU\;-+\8?#W7=&\,_$&[D%I<W@C:&[M3 875P&)4G)P".?6OQ[*O$;,(9R\]A
M*WLG!J-U[T5-<T;=;Q<KKL?K7#G#^ R7!PP&74U"G'HO35M]6SP/]AW]L(_\
M%)_V0O@MX-%VTMZMPLOCC# NMKI9$J*P/59IH[=#G[RL]> _\&TL_F?MX_M#
M';M7=.!&#\J 7AP !QP !^%?6'_!*#_@F[/_ ,$R?A]\5]1OM)N-8UKQ!KEP
MNFPV062XDTU6_P!'2,G&,ALD>J"O#?\ @B=^QU\8OV,_VL_B?XB\>_#C6]/T
M;QX9?L4\$L<OV?-P91YOS9&0>H[U]K/-\CCEG$V#RJJE1JQINE&32<Y.K[2?
M*FU\-[+^ZCV]+6.+_P""S_[)UQ\=O@A\=/'.CPS/K_PL\9QZBK0DA_L;0J)C
MQR F=_\ P&O?_P!BO]K7_AY5^S#\#/"YN#-=031W_C0*Q)2/3'5X4?OB69(A
M[KNKW+]FWPGK/CSQY\<M'\:_#[7M%\.?$>^G2"6]1/*OK-X/(<-M.5+ MP>W
M->;_ /!)O_@G5<?\$Q?@E\1+N^T>?7?$OB#6[@V\-E&KS36"';;JN3QD'YAT
MXKPL;Q/@JO#DLMQ<N;$X:=.6'::>E2DHU%>[24)+FWT:7F4FCY0_X-A9/M'[
M5_[0)<;<SM\I&"!]I? _ 5RE[\3A\&?^#E?QMXHDT;6==30[*]NI;32H!-=/
M&MFY<JI(R N>!_.O:/\ @AA^Q[\7_P!BC]H?XEZQ\0?AYK6F:5XX9I;.>&6.
M;R?WK2!9 &R"0?7K5?P%^RE\8M"_X+C:E^T!<?"WQ"OP_OFN+<-OC^U;7A,8
MD,>[IGGKTK[G,,^RU\39UC*E:$Z=3 QA%\\5SR4*=X)I_$VI+;<2LG<\\^")
M/_!;G_@KYHGQD\*20>'/ _P?N+*>5+N01ZM?M"^]<PCG8S#:>>,XK]LX>5R
M,'ICFOR-^/?_  37^,?[#7_!3?3?CA^S1X8;7O"WB20W'B'P[%<):QJKOF>
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M_0S:!V%*1D4,#R?X-?L8_"O]G^"./PAX"\.:,R8(F%H)IU/KYDFY_P C7J"
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MX04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB$"-+.^]EBB!(BB!^Z@)QSS7OHC .1D?CTI57;Z_B: %HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ /2A>@H/2A>@I+X@,SPK_ ,BY9?\
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M_P 0/V8OAOKNJW#W6J:UX6TS4+R=\;III;2*1W.!U+,3^- 'H%%%% !1110
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M=7MM/UGPU' VI75J;.QLXYHI+>9%A43W#NX!(**X)%?5O_!./_@E=\/OV&O
M_A_4G\&^%%^*-K:2P:IXCL/.E:Y,DKLQ0RG*DJ5!(5<XQTKB/#W_  3#\::5
M^S!X>\"3:YX<.HZ3\:7^(\T\<DJQ&P;5)[ORE_=_Z_RY0,$;<@\]Z8'I<O\
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M_M)_\$R_&WQF\._M'6>G:YX;MIOC#KGA_4](:X:;_0X]/EB>19L*>2$;9MR
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M<1-[DU_)/CG_ ,CZ'_7M?J?UKX$?\B&I_P!?'^2)>]%'>BOQEL_;PHHSU]J
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MFI-/T^#1[9;:UMH+6&/[J0H(T3/)  &* +T?W:=3(<@$'M3Z "BBB@ HHHH
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MPFMU-I^EP3"4F\G-RBR/*TC1DQC*JJ8#$DL>,^)W_!.7XV_&;X7?!JU\70?
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MA:?@7=?$9-<NW\)V?B"7PQ+='3YO,6_CNC:O%Y>W?@3*5W8QQGH14FE_M]^
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MZ^G?VB_^2-ZK_P!=(/\ T:M?,1^[^ K[;AEMX6?J?'\0K_:5;L>[_P#!,/\
MY/T^&O\ V$1_*OWR3HWT/\S7X&_\$Q?^3\_AM_V$?Z5^^:]&^E?TMX9?\B^I
M_C?Y(_E_Q3US2F_[B_-CX_N4M)']REK]*/S,**** "BBB@ HHHH **** "FR
M_P"K-.ILF0C<CVSVH YT_#[03X]'BAM%TMO$R6AL$U06R_;!;%@QA$A&X)N
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M^M '8?#_ /X)^_ WX4:9K6G^&/A'\/M LO$=M]AU6WL-$@@BU"#.1'*JJ R
M\X((KOE^%GA8>+=)\0?\(]HQUKP_82:;I=_]C07%A:2;=\$3XW)&P1,J#@[!
MQQ3?A+\5?#_QQ^&&A^,/#&HQ:KH'B.SCO+"[C) EC?ID<$,#P0>000>E?/7[
M8_[37QE\*_M=_#;X1_!ZT^%B7_C'P_JNOWNH>,TOY8H5LY;:,1Q):NIRWGDD
ML<?+32 ].^&G["'P6^"OQ$?Q;X/^%G@'PQXGE:4OJFF:+!:W69&)D.]5R-Q)
M)]234O@S]AGX-_#MO$;>'_A7X!TAO&5M+::Z;/1+>$:O#*#YD4V%^=&W'(/!
MSTKY[_X>6>*_ /PV\?:#\1[/P;X(^+GPIU;0+#79EM[[4O#VJ6VJW:P6MY9)
M"WVE$F(= LIW1. 9,K7LGBS_ (*(_#OP9\<Y/A]*/%>K:K8WEIIFK7^DZ!=7
MVD:)=73;88;N[C4QP.Q(^5VR P)Q0T!UGP1_8_\ A7^S1(\_P\^'7@SP5,\+
M6[2Z+I,-D[1E@Q0LBYVY520>,@>E=?IOPWT#2O&^I^)+?1=+M_$.L6\5K?ZC
M';*MU=PPEO*C>3[S(F]BH)(&XXZU\I?L2_\ !1)O&.F0Z'\0M5N];\:^)_B#
MK>@:%:Z1I EDAL+650DTZP+B*",,%:>0#)8<UH> O^"JGA#1O@]X-U?QEJ1U
M_P 0^/+[4;/0K7P7X8U*=M2:S<J\45O*K3&1%ZYX;DKQ2 ^@/CA^S=\/OVF-
M!L]*^(?@GPQXWTVQF^TVMOK6FQ7L5N^,;T#@[21QD5O_  N^&7ASX->"+#PS
MX3T/2O#7A[28Q#9:;IULMM;6J?W410 /7IU->%'_ (*H_"6;X):'XUM)O%.H
M1^(==F\,6>@VN@7,WB%M5@#FXL6L OG+/$J,70C*A236A\1_^"BW@7X::/X,
M>_TCXC7GB#Q[8OJ&F^$M/\*W=UXCBMD&)9Y[!$\V&-"55FD  9U'4T ?0NX>
MHHW#U%?,NJ_\%7/@W8?#+X?^*K?5?$&JVOQ0N;G3_#UAIVB75UJ-Q>6\;//9
MO;(OF1W,>QE:-P&5ABO3?V9OVGO"?[5_PVN/$OA1]42SLM1NM(O[/5-/DL+_
M $N]MI#'<6]Q!( \4B,#E6 ]>AH ]-W CJ*-X/<?G7SY;_\ !1SX>/\ '?3/
M 4L'C*RN=;U.71]-UVX\.W4/A[4KV-2S6\-^4\EY/D90 >6!'6N<TG_@KI\'
M-7\;C1;>?QDT,/BF?P5=:TWAJ\&CV&KQ3_9_LL]WL\M':3A23\V10!]3;P>X
M_.E!![BOA?\ X*7?\%9]$_9W^"WQBTKP+=^(SX_\ Z>(O[=M_#,NHZ#HNIRA
M7AM[FY*FW$I# &-CD%@#@XK[-^'VJ7&N^"=#OKMU>YO=/@GF8*%#.\:LQXZ<
MD\=.?:@#;HHHH **** "N.^.?BS4/ ?P7\7ZUI,)N-3T?1+R^LXP =\T<#L@
MP>#R!QWKL:;/$D\+I(JNCJ596&0P/4$>E 'YH_!S]B3X/_&3_@E1!\9O$=E9
MZC\3O$O@V7Q?>_$B:X;^W[/5C"TWFPWI/FPB&8>6D:, BQA,54^!'Q__ &E/
MVK_B-X4\ Z9\5].^&0/P$\->.]2U)O#UGJ.JMJUS>:A"[HMS&\?DRI;IYP<$
MH%7R]K.S5]*7_P#P2(^"FI^()Y3IGC&WT"ZOSJ$WA*V\8ZG!X6FF+>8V[24G
M%F4=\LR&/:Q))&37(_%W_@F5;?M"?\%&/$?CCQ-::SIG@.3X7:1X2TJ_\-^)
MKK0;^.YAU'4I;JU!LY(YA;O!<0!E+;&Z8.#A@?+W@OQO\6?VU/VW/V//%UQ\
M6+_P1KNL>$O&UG>1Z+H&G75D9=-O-/M[N6'[3$Y*7H5&.X$Q!%\LKO:LS]L'
MP]'^U/\  '4O ^IIIF@6&M?M8:?X=:?0["/39E1[-2LTA@P99E=E8R-EF" 9
MX&/T,\7_ /!.KX5^)[#X8V\>CZYX?_X4XLL7A6?P]K][I%QIT,HB6:%I+:5'
MFCE\F/S$D+!MOS9R:N:A_P $_OA9J,,<4GA^\VIX[A^)0"ZG<C&N1((TN>'Y
M4*!^Z^X>I6@#\_=%_:X\31?M@_ *R\?JUW\3_P!G_P .?$O2?%5JLI4ZN]GI
M^BS6M^!WCNH#&^\<!VE4<J:]3\'_ +2GQ\^%N@?LY?&'Q/\ %+3?&WA7X_\
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MLG\EL>*?%#_@G=\&_C/\1=3\5^)/"<NH:_K+B2\NDU:[@\Y@H4';'(%7A1G
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MW4PMPB[XBA#,Q5B!7TA^T1^RUX&_:Q\(6^B^.-';4H+&Y6\LKFVNYK&_TV<
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MGF$X[4Z@ HILDGEX[YI!-TR.O3!S0 ^BHFN-K#CY6[^E+]H'U'^>U $E%%%
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M)]P?2LWPK_R+EE_UQ7^5:2?<'TIR^*1,/A1F>)?]5;?]?<7\ZT4^\*SO$O\
MJK;_ *^XOYUHI]X4Y?"'VA8O]6*=38O]6*=2*"BBB@ HHHH **** &R9"'%?
M,7_!4L_\6+L/0:E&*^G9?N>M>#_M[_![7OC/\*;33O#UJEW>17T<K1L^W"C.
M3TKY+CK#UJ^0XJC0@Y3<'9+=[=#ZK@?$T</G^$K5Y*,%-7;T2WZGYNC))(RI
M''-(JD+C<?RKV<?L#?%$CG08QQS_ *0/I_=]J/\ A@+XG@\:!&3_ -?('_LM
M?QLN#<\M_ND_N9_9JXXR'7_;*?\ X$CQC9U^:C:1_'7L_P#PP-\4?^A?C_\
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M?WC8^\['!XP!SGVO]D+]A[P-^QCX.&G>%[ 3:E<*#?ZK= -=WK8YRW9<]%&
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M0_:"\+6/Q[^&7@SPIX'U[X?_ +1]]>ZI<^*=2\1&ROO!$FJV,5C?0M9+ XU
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MT'6=1U43^'))+S5#9W$H#17$,T=O;;$ !1X'W\8*$&N<_P""?/\ P33^*?\
MP3V^)^F>+O#T'AV\?XCZM<V_Q1TF?569#;^<[V.IV4K(2LL",\;6H C<2D@J
MRBK_ .QQ_P $X?B;\"_!G[,6GZZGAP7'PG\->(-+UXV^I&18IKV5VA\G,>9
M0PW$XQSP>M 'KG[/'_!8#X7?M'^)O ]CH6D?$6QTGXD[X_#7B+5?#<EIHVKW
M"+(SVL<Y;_7*(G^4J =IP36KX0_X*I_#OQM\4;+0K/2O'L?A_5=7?0M-\;SZ
M$T?A/4[U2R>3!?EMKEG1T0XP[J0I->5? O\ 8"^)'PS_ &//V//!=T- &O\
MP/U.RNO$HBU!C!Y44$T<@@?9^\/SC ( QGK7B7[,O_!'S7OV>/'?@[P=KGP4
MT[XB>$/ WB--0TSQO+\8-3L-R1W37%O=OH#1R0">(L,QK*$8KD!<XH ^Q?\
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M,KJ"L/\ :**[*T@01JY1C$0"I /UQ@^7C &!C'I[?K4G ':ORS^+G[3?QC^
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M3J,.L:;;WMLQDM[J)9HF*%-RL 1\IY'!'!&12 O4444 %%%% !1110 4444
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M)%M:!3,/M26UU(]QF1"L*PG<H<[AMYT_'_[>?@S]G;X4>&M>^,$S_#C6=?\
M,A_L(Q3:M>">(LLOE);1O)+"-NY9?+4%'C+!&;: #L=4_9@\":EJ'CVZN/#U
MM)<?$[3_ .RO$TF]R=5MO):'RWYX'ENR_+CJ?:F?#S]EOP%\)_$.FZOX?\.6
M>F7VD^'+7PG:SI(Y\G2[88AMAD_=4=^ON:X_X@?\%+_@9\+O GAOQ'K'Q$TB
M#2?&-C-J.ARP13W,NK10L%F\F*)&D=T9L-&%WKAL@;6QMV/[;_PIU;X.>(OB
M!#XVTM?"'A6Z2QUC4)(Y8AIUPX@*PR(RAUD/VB$!=N<R*.O% '':[_P2H^!?
MB3P=X:\.3>#[B+P[X1CF@TW2[76;VVLUCFN9+F9)88Y5297EED+"0,"'93P<
M5J?&;_@FM\%_CYXPL=?\3>"[2XU/3[."PW6=W<6$-W;0X\JWN(X9%6>)0-H2
M0,H4E<$$@LTG]OKP=H?@OXD>*/&>N>$M!\-> /$B^'GN].U&YU&9G>&WDCCG
M@-K$\=TWVA?W$0FP"#O/S!9+G_@I=\#[#X*V7Q#D\<6Z>%]2U%M(MG_L^[-W
M+>*H9K<6@B^T>8JD,5\O(4Y/'- 'HFE? /PAX>^*(\96.A6=EXECTF/0DN[=
M=GEV$;%H[=4!V*BD\  =/PH^"_P(\)?L]?"33O ?@W1;31?">D)+%::;'EX8
M5EE>60?,26#/*[8/J>U>>>(?^"F'P1\+_ ;PY\2[OQW:CP=XON#::1=0V%U/
M/>S#=NB%LD9G#J%.Y6C!7OBO6O 7CG3/B)X(TWQ#HT\MSI.K6ZW5K.\#P-)&
MPR"4D"LN?1@#[4[ >"^%/^"1'[.W@U]06S^&UA-8W\,]L=+O;NXO--M5F+%_
M(M99&A@.6;!C52NXX(S7H6O?L;> _$/[.-G\)KK3M2;P+IMM%:6]FFL7<5PL
M<9RBFZ643$#IRQ)'7-<_\1/VV=+^%7[5%W\/M;TP6&B:9X%O?'6I>(GO"4LH
M+:15EC, C+-A"S[@QX7&VI/@3_P48^"W[2_Q.?P=X'\=Z=X@U\6;:A#!':W$
M45[;J5W2V\TB+'.HWKDQLV,\]*0"^-_^"=GP=^(?P=\(^ ;[P79P^%_ (5?#
MT-C<S64^C@*5_<S0NLJ9!.<-SGG-:/A3]A[X6>"O!W@7P_IG@[3[;2?AO?\
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M+M7TV/2+O40S>9-:QL'2,C.W 89X&:[,=*:4!8'N*=0 4444 %%%% !1110
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MX/:_^T%X(^(WB#X37WBGX6:)HOB;2?$QM+KP_HIL]3ENH0ES TMW(9+=K1V
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M<3,""(_O$$<4 =?149G 'OW]J//^7."1]* )**:C[P#Z_I3J "BBB@ HHHH
M**** "BBB@ HHHH *CF("'<,BI*;*N4.#@T ?*/_  4FT'3/&UCHNA>+OV<?
M&?QS\*R+)<VM[X/N+,:QH%XN "/M%S:/"K(S8EAG+9&TICFOD74?V*/VAOAW
MH_P2\?>+;OXS>(-7T#PWJ?AO4[7X9ZOIS^*](@GO3<:?#,^H"."Y2.V6&&=E
M=6$L*D>:#NK]8-YW!L'G!/S>OM_GM343S PVXSVZ=_\ )H _/3]ES]B2]\ ?
M&C]FC6="\#_$BQ\)^$8/%.H:E)X_ET^37-$O]0D4[IA;RO&K2LTQ'DEN)#G[
MQ%6/CI^PE\0/$W_!0]]&TG08IO@!\4-=TSQ]XUOOM*!8=3TQ3BU:(G<WVB6.
MP<,!@?9FSU%?H%)&I;!7YL$G![GUI[HN<$Y8CIUH _-7Q5^R5\5O WC_ ,9?
M$FU^'^H^)D\*?M&3?$6U\-PW%O\ ;O%.CRZ-;:?YMD'D$1GBD9Y529XA^X^\
M#BKO[87P?^*?[1WB?X8?&_2?AU\8/AU#X9U#5;>]\->#]2TJ'QS+;7=O#'%?
MR),QLA,7B:.2+[0S"$HPE))B7]%]2OH-*TR:ZN9X[:U@1Y9I9WV)#&H)9F8\
M  <DDCI4>D:Q9^)-&AO["Z@OK&\430SV\JRQ3(>C*RG!!]0>]-,#\QK_ /9<
MLO"'[-5KJ^E?"G]MN?XC:KXOU?Q/:Z_'=>'6\8:!J5S:Q6\US)F^6T%O-&JJ
M$7>3M?<%)!/U#^RC^U1\2+_XJ^#?@[\0O#NE:MXWTSP#%XA\<^(=-O-EKI%]
M+-LMK-H"GS2S1JSLRN%#1O@$%37OWQ1^,_@_X):5!>^,/%7A[PI9W4GDPSZO
MJ$5G',^,[5:1@"<#.!Z5H^&(]&U* ZWI*:9,NMQ1S-J%GL?[?& ?+8RH/W@
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M_!3QKX1\3:#JGPYT"[TKQAKW_"4ZO%AT-YJNU4%YO5PR2[40;D(^Z* /SO\
M!G_!9+]H'X@_LN>%#;0^%-#^(EU\>;CX.ZE?:QHZ!)($MHIA=26L%Q+%%.AG
MP8XYY$)AP)#N)'#?$K]KKQU^Q[_P6O\ BIX9TB^\.+XK^*$/@CPU?^/-9TUH
M-!T,_P"GL\LL$;.1/<8$<,9;86W;I$P ?T]\#_\ !,[X#_#3P?I>@Z!\,/#6
MGZ1HWB4^,;&W579;?63&D1O@2Y)EV(BY.>%%:WQ)_8%^#OQDU'QA>^*?A[X>
MUN\^($=E%XAFN8F+:HMDS-:[\'@Q,[%2N#R>: /B.?\ X*/?M3?%W]LGQ[I7
MPI^&=]XE\%_"OQO;>#-5TL:?I<5OJ,21Q27=Y/J$^H175I*4G#I#'8SQXC'[
MTEF"ZW_!'2T^)UW_ ,% /VS_ /A)OB/#XA\/:'\0?L3Z3)H;1,TSVL<D,L,Q
MN'$$<<9V&%$;>WSY7.VOK7Q-_P $WO@IXM^,,/CZ]^'^F?\ "8Q&V+:K;W5Q
M:RSFV_U#2B.0"5D'0R!B1P2:ZGPE^R1\.O GQ\U[XHZ-X3TS2_'WBBW^RZOJ
M]N9$DU!!MQYB!MC-\B_,5W8&,XI@?G#^U/\ V_\ L@_\%(=9^,GQ)M-4^*WP
MN\9^*=+\/:#XG\+>+3;:G\'[B)EC739M-<I%.EQ+=AF*,T@19-R\(&PO"G[:
MOC'X,_LA?'OQ-\,[KX?_  X\16/QZU7PYHVC:1X+.H?\)UJ5PEN(HV62ZB*W
M$I^>689(2(GR_EP?T>U__@GO\&?%7QRC^)6H_#W0[SQI%=IJ*ZA,)&4W2KM%
MP8-_E&4+@;RI;@<\"L/QU_P2Q_9_^)&A3:=K?PN\/7EE-XAG\6-'OGB!U:95
M66^RD@(F95 W#D<XQDT@/CO]H?\ X*!_M8:5^TG9?!/X?^&4\0_$7P)\/+#Q
M3XH?1]!TV[MM?U&\8*(<7NI69L[.-HWC,T7VERT@)C& #ZU_P6-^,&L>&_\
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M\SD#-=1\+?\ @GMX$^#/Q-\'>+?#<_B#2]8\'^'!X5=HK\K'K]BN3"M^N/\
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MW!^8(O I >$>"?@KHW_!1/\ ;;^.R_%EK[7O#OPGU.T\->&O#,6J7-G9V*-
M9I;V5(71GEG)4!F)&V+ K4DU/XQ:O\>-2_9Z^#/C_2_"%G\&O"6FZAJ'BOQA
MI9\4:GKDM^UR+2W\OS(0J1I;/OF+ECE %/)KUSXZ_P#!/#PU\9OC%-\0-)\6
M?$'X9>,M0L$TS5-4\%ZL--DUN",LT*W2E'64Q%WV,1D;R,XXK%\??\$M?!?B
M:[T"]\.>*_B;\.-;T'P^/#)UCPKXA>SO]4L5<R)%=RL',Q1V=E<\J9&P13 Z
MK_@G?^U+J7[8G[(?A3QYK6DVNC>(-026UU6RM9O-MX[N"5H93$Y )C8IN'&1
MNQSC->V0S!Y5Z\_YS^>:\%7]@_PW\,(?!.I_#:WFT/5?A)X=U#1?!^BMJUQ;
M>'Y6N%!!OHHPQD_>H"9-K.-SD DUT'["?[-=[^R%^RKX1\ ZCX@O/%>L:);,
MVIZM=7$L[W]W([22N&D)8)N8A0>B@<"D!\#?L(_M&?&)/V)?V-_ /@3Q)H6G
MZK\4='U=M6\0^);2;6)[06TLKK*D9=3.QZ;'D3(_B&,5Z-X+_P""B'Q@^('@
M'0?AC:W_ (/L_C'J'Q7UWX63^+VTMGTF-=(C:>74AI^\'?-$H"P>;M5V/SD#
MGZ0^#'_!-WX=_ 32?A%9Z#_;[0_!.TO+/P[]IOS*Q2Y+>;YW \T_,=I.,5E>
M*_\ @E=\-O$GA#7]/@O/%FB:EK/CV\^),&N:;JAAU31-9NB/.ELYMI\E&4%"
MF"-K$=Z /6/V;]-^(N@?#9;/XHZMX7U[Q1:7MQ"NJZ';R6L&I6BR'R)Y+=Q^
MXF:/!DB5Y$1L@2..:]!BDW*,]?KG\*\&^''[ 7A7X>>*_ 6N1>)/B#J>K^ 9
M=3N8[C4-?EF&MW.H'-S/>H,),Y(RO 5,?*HKW>%2"..,=<\T 2T444 %%%%
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MQZ\=^*/#VM^'OBE;2V.I>"M*T98+2SE-N#;7,%TP,Y<NI:56)C^8A,8%;_[
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MT<?\PZU_[XH_X0/1O^@;:_\ ?%'_ !#/ >?_ ($'_$1<P[K[C[I_XB"/A_\
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M9]B_\/U? O\ T)OBK_O[#_C1_P /U? O_0F^*O\ O[#_ (U\=?\ "$Z1_P!
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M%_JQ0[[1FF@XC ]^:CED4<9 J6[%!)/M7)%4[B[ 4_6F7-TBJ<MTK)U'55C
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M3-5W#@\9['(K;L[L.P;=SFOD4].9]=3ZQQM*R-F)LC'7%.JI;7-65DW'_"F
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M6?\ \T/_  +_ ( ?\1SR+^2I]R_S/SMVG^^:-I_OFOT2_P"':/PU'_+KJ/\
MX$O1_P .T?AI_P ^NH_^!+T?\02S_P#FA_X%_P  /^(YY%_)4^Y?YGYV[3_?
M-&T_WS7Z)?\ #M'X:?\ /KJ/_@2]+_P[0^&O_/KJ7_@2]+_B"6?]X?\ @7_
M#_B.>1?R5/N7^9^=@7GELTF#\W-?HI_P[0^&O_/KJ7_@2]-7_@F;\-\<VVHG
M)_Y^&XIKP1X@VYH?^! _'3(DK\E3[E_F?E%^U<IC^&UINZF_!)'8>6U?HQ_P
M0\\!:UX'_8T!UG3+S2CJNJ3WMJES$8S+ ^W;(H/\# <&O2-%_P"";WPMTSQ%
MIVH76B2ZK)I%P+NWANY6FA60 @,4/#$9R,].O6O>[.VCM88TC7RE4 !5'  &
M .*_6O#CP_Q.2-U\;)<UK:.Y^2>(_B)0SV*P^$@U"]]58G495<U)%T/UI%7=
MU'%."A>@Q7Z\?D0M%%%  >E"]!0>E"]!27Q 9GA7_D7++_KBO\JTD^X/I6;X
M5_Y%RR_ZXK_*M)/N#Z4Y?%(F'PHS/$O^JMO^ON+^=:(.#GTK.\2',-J?6[B_
MF*O.^U:<OA0?:&.^TG)JE<700DYJ2[G"IG(-8NIZB(U."/<^E+3J40ZKJ@4M
MG\LUP7Q(^)UGX(TQI[F4/,W^J@!YE/8'V]:L_$;Q[:>$='EO+N141/N#/S2G
MZ>E?,7B[Q3<^,M;FO[M\RR,2(^H@7L![8YR/6OP3QF\8*/"N&^I9?:6*FO7D
MWU:\NA]EPKPU+,)^TK+W%MYDWC+QM>^.-6:ZOG9>3LA4Y6(=,#VK(' ^E!7S
M"3D8[4F=H%?YW9MFV+S+$2QF-J.=23NV_P!/+R/V_#8:E0IJE05DA34&HZ9#
MK6G7%I=*)+:YC:*5''WE(QCZ5*QR.*=M#MAN5;BL,#BZN$K1Q5"7+.#4D^S3
M3T\]/S'7I1JTY4JBO&2L_F?G3\4? <WPR^(FK:%<!]UC*?*)Z/$W*$?\!('U
M!K S@ 'KU-?4/[?OPQ^TV6G^++>,^9"!:WQ R,,248_R_*OEW.3D @&O^@OP
M(\1*?&G!V#S=R7M.2,:B3VG%)/[VKH_@WCGAV>39O5P37NW;B^C3N]/3;Y"]
MZ1_N-]/Z&ESS22'$;?3^AK]?Z7/CI;.W8]QT?_D$67_7O'_Z *G_ (O\^M0:
M1QI%G[01_P#H J?'->:]V?&5%:K*_F.7H*#TH7H**1F'>D)S[TIZ4A.10&JV
M#H?RK4\&>.=4^'7B6VU?1KR:SO[5LQNAP".I!'<'^@K+QP*3/7@5G7HTJT73
MK1YHOIT-*56I2DJE*5FNJW/T:_90_:^TOX^Z5]DF:/3O$EE&//M&^5;E>\L?
MMZCM7O\ I6HDLJEAD\CGK7XZ>'/$M_X0\06NJ:9=2V=_9/YD$J,04/\ @>X[
MU^C'[(_[3]E^T#X19G*6FO:6%2_MRW4GI*H[(<'GUXK\$XVX,EE]26,PRYJ3
MW2V7_ /W'@SC!8Z*PF*?[Q;/JU_F?25K="1.ZDU>MY ,'!^M<UI.I"7&3CZU
MN6URK+P:_.KM_$?H2V--7)8 @<TZH4D 8 YXJ4'<,T#%HI"V*02@G'>@!V!1
M31(#WI=W7KQ0'F+10#D44 %%)NZ>]&[K[4 +12 Y]>:6@ HHHH **** "BBB
M@ HHHH **** # ]**** # HHHH ***1FVB@ ) Z]J:74'M4=W/Y<?<9/)[#\
M:IS:]9VTQ2:\M8W7@J\JJP]L$YII.7NQW0G)+5LT"H+?=XI/+/O^=9X\2Z<3
M_P A"Q_\"$_QI_\ PE6G_P#/_8?^!"?XU7L9OH_N?^1/M(?S+[U_F7O+/O\
MG1Y9]_SJC_PE6G_\_P#8?^!"?XT?\)5I_P#S_P!A_P"!"?XT>PJ=G]S_ ,@]
MI#^9?>O\R]Y9]_SH\L^_YU1_X2K3_P#G_L/_  (3_&C_ (2K3_\ G_L/_ A/
M\:/85.S^Y_Y![2'\R^]?YE[RS[_G1Y9]_P ZH_\ "5:?_P _]A_X$)_C1_PE
M6G_\_P#8?^!"?XT>PJ=G]S_R#VD/YE]Z_P R]Y9]_P Z/+/O^=4?^$JT_P#Y
M_P"P_P# A/\ &C_A*M/_ .?^P_\  A/\:/85.S^Y_P"0>TA_,OO7^9>\L^_Y
MT>6??\ZH_P#"5:?_ ,_]A_X$)_C1_P )5I__ #_V'_@0G^-'L*G9_<_\@]I#
M^9?>O\R]Y9]_SI"A]ZI?\)5I_P#S_P!A_P"!"?XTH\4Z>?\ E_L/_ A/\:/8
MU.S^Y_Y![2'\R^]?YEQUVI@\\TKH2<CFJ#>)].+?\A"PR?\ IX3_ !IJ>)M/
MZ'4+''_7PG^-'LY_RO[G_D'M(=U]Z_S- DJ.211O;VK.;Q)IRM\]_9+Z?Z0G
M^-2_\))IA_Y?K+_O^O\ C7/*M3B[2DE\U_F;*E-ZJ+^Y_P"1<WM[4;V[X-4_
M^$CTS_G^LO\ O^O^-+_PD6F?\_UC_P!_T_QI?6*7\Z^]?YC]C4_E?W/_ "+F
MX^BT;C["J7_"1Z8/^7ZR_P"_Z?XT?\))IG_/]9?]_P!?\:/K%+^=?>O\P]C4
M_E?W/_(N[F]1^5&YO4?E5+_A(],/_+]9?]_T_P :7_A(M,_Y_K'_ +_I_C1]
M8I?SK[U_F'L:G\K^Y_Y%S<WJ/RHW-ZC\JI?\)'IG_/\ 67_?]?\ &C_A)-,_
MY_K+_O\ K_C1]8I?SK[U_F'L:G\K^Y_Y%W<WJ/RI-Q]1^54_^$BTW_G_ +/_
M ,"$_P :'\1Z:%XO[$?]MT_QI^WI?S+[U_F'L:G\K^Y_Y%PDGJ:1AFJ#>*M-
M0<ZA8CG'_'PG^-26^L6VH$BVN8)ROWO+D5]OUP>*<:U-OE4E]Z_S$Z<XKF<7
M]S_R+JC<>2,CK3ZCB."<C':I*T>CL0%%%% "8^F:-H]!2T4 &>?:BBB@ HHH
MH #TH7H*#TH7H*2^(#,\*_\ (N67_7%?Y5I)]P?2LWPK_P BY9?]<5_E6DGW
M!]*<OBD3#X49?B0XM[3_ *_(A_X]BK4\NP'\A5;Q.-MO:>UY$?\ QZB]F"'G
MGD_C3E\*!?$5+^Z*H<D' KD?%&OPZ;;3S3SK%#"I:1G.% 'J>U:^L7V0V,AC
MV_I]:^7OVV/BV;:TC\*V<NY[R,3WK(>D9Y5?Q'/XTBCS?XG?M%7'C[QQ/= ;
M]%1]MI'R#M''F?4CJ#4EAJ$&IVZRP2*R$#D?P^QKS ,6;=N&3SP.QJSI>KW&
MB7/F6[[">J]0_J*_ _%KP1P?%,99C@Y>RQ5M[Z3MLGY^:/L>&>*YY:_8U%>F
M>F/D,.1] *"03P*R_#WBB#7D"\Q70X,+8!;Z5J#&6).?<#C-?Y^\0<.9CDN+
ME@<QI.$XZ:K?S7='[3E^.H8RE[7#RNA".1]:<ZX7.<X%)S[4* 6QWKPXM[KH
M=J?-MT,KQWX2M?'G@W4-&NP3!J,#0GV./E/U!Q7YV^)/#MSX1\17VEWJ-'>:
M=,UO,IZY4D9_$<_0BOTH8$G\,=*^7/VR_P!G_6/$OQ)T_5?#6C7NKW6M*()X
M+2(NYE0 !CV^YL'X5_H!]!+Q1_LK.\1PEC9?N<3'GA=Z*<=TO\2/P;QNX:6,
MP4,TH+WZ;Y7W?-_D?-@'!I)00A&">/Z&OJ+X;?\ !)#XJ>,XHI]7_LKPK;3@
M$"ZF\VX4$9^:,8(_.O7=%_X(BP"!4U3QS<22,/F^S6.U>G;<37^H6,XYR:@W
M[6NI2\KO\NVQ_-D.',?6@U&'WNQ\XZ.V=)M/^N$?!./X!5G=BOL!_P#@E;9V
M]E%#:>+;I##&(\S6H(X '8^U<5XT_P""9_C;1$=]'U#2M:503L+FWD;Z Y!_
M.O.H<<9-B*G*JJ7K=?F?,8W@W-J;<U1;]-3YT!XHW5N^.OAAXD^&6HM::_H>
MIZ5,IP//@*J_^T#T(]ZP]I+$=^N,?-C'4CL/YU]-1K4JT/:4I<R\M3YBM2JT
MI^SJQY7YA130^?Y"E!K<SZV88H[^U!Y&:#[XHM?0$[; OS$?2NC^$OQ5U/X-
M^/K#7]*D(GM\)+'NXFB_B0CN"/7H>:YOOGUI5&%5?3H>XK&OAZ=>FZ-97B]&
M71KU*$E5I.TD[H_63X-_%33_ (I^!=-U[3&#VFH1A@/^>;#[Z'W!(^N:](TN
M],D9K\X/^"=O[0+^ ?'I\*:C/_Q)]?(>V9C\EO=C./IO''U(K]!M(OSC& IR
M1R>AST^O6OYDXGR*>5XZ6'?PMNS/Z4X:SJ.9X&-=:/9KS.QBFW@<]>*L@D'@
MXS6593 H,\G'Y5HQ-D9SVX%?.=+GT!E^._&-MX#\+ZAK-\9/L6E6[W-P8UW,
M$49) [\"O!E_X*A_#60J5/B+:2/F.F$#'K][ITKUK]H?0[SQ)\%/%%C86\MU
M>WFF3Q0P1C+R.4.% ]2:_-JU_90^)Y,!_P"$"\3A@R#)ME 7GOEN@K\PXZXC
MSO+L90HY52YXS^)V;MK;?T/TC@CA[(LQPN(K9O7]G*G\"YDKZ=GOKV/O#]MW
M]K^;]D']F]?'FF^%9?&=Y>ZQH^B:?I U)-.^TW&I7UO91;IV1UC57N%))4\
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M]*_2TVF^7J>#ZLY]]%#C&..]03Z%M  'W>E=3]B'M3);!2,$#BD[[WO_ %Z
M[6LE8\[\7> +'Q7I<MCJEA;ZC9S##0W$8D7\!V_"OC?]I3_@G7-I;7.K^!09
MH5)>;27.&3N3"W\7^Z:^_KS3O,Z "L35M*R2P)!' SU4=_S[5[N3\1XW+*L9
MT9MQZKH>)G'#N#S*E*%2*4NDNI^-MQ$]M/)')&T<D;F-D(PRN#@J0>0PI .^
M<CM_GM7V]^W#^QS'XTMKGQ=X=@$&LVT;->6\:X%Y&O.0!_&!D^]?#^-F!@J>
M3SU/U]".:_HKA[/Z&:X=5:;M+JC^?\_R.MEF)=*HKQ>S'?P?A1D FD'3&<^_
MK3J]UZGA)6$ZXZT8QBEHIO56"*2=T.L;R72[^&[MW:*ZMY%F213@JR\@_A7Z
MC_LR_%Y/C)\)-'UQ64SSP^5<J.JS1X#Y]^_OFORU/ KZM_X)>_%#[#X@UWPE
M.[;+R-;^S!. KH2&4?[RL2?]VOSWQ'RCZW@/K,(^]!K[C[_P]S9X7'K#-^[/
M\T??>FW190/;KZUNVSA@,GWKD]&G9AD]JZ6S?*#)S7\^1TBD?O*:>A=,2N0>
M_P#(U$+='D(QR.<XZ5,B\KGG.?QJ38*&K[@M-B$VY;ITI!9 K@XZ8QVJP!BB
MA!8A6TV8P<8H%H <\]<8SQC/I4U&!3 XKXT?L_\ A;]H'2M$L?%>FC4[;P]K
MMAXEL%\UXS;W]C.L]M,"I!.R10<'@]"".*Z\6:C/O[U-CG-% $$=DJ(.!G.<
MXYSZU+''L!]2<]:=10 4444 %%%% !1110 4444 %,E;"GJ0.U/ILB%AQUH
M_.C]I7]F;]HOXN?\%*=-^)6N?#7PC\1_A=\,66;X=^'7\?G1[>VOF3;)JM[
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M'_#K[XNG_F&Z+_X,#_\ $5^H^T'L:=E??\Z]-^)F;_W?N/-_XASEG>1^6O\
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M<U_3>Z3\D_O/YP=NGFON%HHHI (W0]Z[S]F#QD? 'Q]\,:D)&"?;1;R<<%)
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M[>1^I1!)SFG>:?05^6?_  ^C^+G_ $+7A_\ \ I_\:7_ (?1?%S_ *%KP_\
M^ 4_^-'_ !%/(.M27_@#_P Q?\0GXB_Y]Q_\"7^1^IGFGT%'FGT%?EE_P^D^
M+?\ T+7A_P#\ I_\:/\ A]'\7/\ H6O#_P#X!3_XT?\ $4\@_GE_X"_\P_XA
M/Q%_S[C_ .!+_(_4WS3Z"CS3Z"ORR_X?1_%P?\RUX?\ _ *?_&C_ (?2?%O_
M *%KP_\ ^ 4_^-'_ !%/(/YY?^ O_,/^(3\1?\^X_P#@2_R/U,\TCL*43>U?
MEE_P^C^+A'_(M>'_ /P"G_QIDG_!:;XL0C=)X<\.I&@W,QLYP /7KQ37BED#
M^W+_ ,!?^8+PGXB?_+N/_@:_R/U0\Y>N<8ZBG@Y&:^!O^"<W_!3OQ=^V)^T?
M>>$=8TO0K?3K?19]0,UI&ZR>8DL*J 22"I$A)]P*^\E7&0!7V.59MALQH?6,
M,WR^:L?$YME&)RW$O"XM)279W)Z",T45Z9Y@U@ O3-,"[B<# ^M2T4 -C3;G
M@ FG444 %%%% !1110 4444 %%%%  >E"]!0>E"]!27Q 9GA7_D7++_KBO\
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MA8_6N0UT_,1D?,N/I54])Q?9HRJQO"7FC\C_ !]HC>&_'&L6#?\ +K>RH/\
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M[[%'V^#_ )[)_P!]BESP_F_K[PY:G9_<3?:I/^>C_G1]I?\ YZ-^=0_;X/\
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M?"W14\/^$-*LD&$M;.) /3"KG]0:] TTD#.!GI7\E9C5]KBJE1;.3?XL_JK
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MA5\._P#@OB_^)KLJ*?US$?SO[W_F']GX7_GW'[D<;_PH/P1_T*OAW_P7Q?\
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M(\&?]"[HW_@*G^%'_"B/!G_0NZ-_X"I_A75Y+>OXT-P,^E']C8#_ )\0_P#
M5_D']I8O_G[+_P "E_F<G_PHCP:#QX=T;\;1/\*%^!?A!)E=?#6A$KT+649_
MF*ZP\'_Z]*@W-WH63X!.ZH1_\!0GF&*>]67_ ($_\QD-DL$:(BJB1@!0HP%
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MJ:_8'V/RA"T@I:3.1^-%NH 2"*[[]E[P2WQ"^/OAC32NY4O%G<?PA8PSD_\
MCN/QK@6Y'%?6'_!+WX8"_P!:UKQ;/&Q2UC&FV+'@%F.Z5A],;?\ @5?/<3YD
ML'EE:M>SM9>K/>X9RZ6,S*E22TO=^B/MO0[<(/E&U.P'89-=9IT>!UZ<UAZ1
M!A0 O;O726<9102."/UK^797;DOZ[_J?TRDE&+78M9("CM4N_CK^E5KV]AL(
MC+/)'#%$"S.[!54>I)K%'Q2\->=M_P"$AT3<W;[='D_AFN.OCL-1:C6JQ@WT
ME))OTNU^!I"E.:O&+?HF_OLM#I(F++DTZO-?VFOVK? G['/P5U#XA?$+7/[
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MO_C5+_P]6^ 7_11+#_P"NO\ XU7Y"_\ "D="'\%Y_P!_O_K4?\*2T+^Y>?\
M?[_ZU'_$+:'_ #]?_DH?\1+K_P#/M?\ DQ^O)_X*K? (?\U%L/\ P"NO_C5'
M_#U;X!?]%$L/_ *Z_P#C5?D-_P *1T(_P7G_ '^_^M2_\*1T+^Y=_P#?[_ZU
M'_$+:'_/Q_\ DH?\1*K_ //M?^3'Z\_\/5O@%_T42P_\ KK_ .-4A_X*J_ (
MC_DHEA_X!77_ ,:K\A_^%):%_<N_^_W_ -:D_P"%):$?X+O_ +_?_6I?\0MH
M_P#/U_\ DH?\1+K_ //M?^3'Z[_\/4?@&,_\7$T__P  ;K_XW37_ ."JGP#4
M _\ "Q+#J/\ ERNO_C=?D6?@GH>>EY_W^'^%7_#WP'\/W>I 2+>X"EL>8/\
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M&3WLQG_T*E_X=./G_D;O_)(?_%5_FG'PGXFLFJ"^_P!3_27_ (C!PQM[9_\
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M&"3*49ELP2 1@]3_ )Q5TO"CB;VD>:BK777;\3.KXO<,RA)*L[V?V7J?%/\
MP0N5O^&]+4HI=8O#6H>80,A 6@ZGM7[518QZGISUKR/]E#]C;P7^Q]X$71O"
M>EB*XE4&^U&90UU?N,9:1^O/91P!7KD1('0\<=*_JKA+)JN69?'#5I7=[ORT
M/Y4XNSNEFN93Q5*-HVLOO?0F7H*6D3[HI:^D6Q\V%%%%, HHHH **** "BBB
M@ HHHH **** "BBB@ /2A>@H/2A>@I+X@,SPK_R+EE_UQ7^5:2?<'TK-\*_\
MBY9?]<5_E6DGW!]*<OBD3#X49GBH_P"CVG_7W%_Z$*L3Q )P.M5O$XS#:_\
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M ^MX5*J0>F>*?3(#F,>U/H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (*^-X:34+F#X1>+;W3? VB:5JWQ%N/[4LH7\#R7]I%>1V;1.P>[G2WF21A
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M?#S]C3XL?$CXDVWC+XV^)/ =_K?A7PO>^&?"UKX4M;F*TADO(C'<W]P9QO\
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M);>'O"T4L<*?8=.BDPT<&Z,RE<#+S2<<U]&8HQ0 B'*"EHHH **** "BBB@
MHHHH **** "BBB@ HHHH ****  ]*%Z"@]*%Z"DOB S/"O\ R+EE_P!<5_E6
MDGW!]*S?"O\ R+EE_P!<5_E6DGW!]*<OBD3#X49GB3F&V/\ T]P_SK24$&LW
MQ$0+:URRJ%NXLDG X85>-]"PQYT?_?8JVKJP[:W)(^$ -+N'K4'VF$?\MH_^
M^A1]JA/_ "WC_P"^Q46D,L9'J*,CU%5_M,/_ #WC_P"^Q1]IA_Y[Q_\ ?8HY
M6!8R/449'J*K_:8?^>\?_?8H^TP_\]X_^^Q1RL"QD>HHR/457^TP_P#/>/\
M[[%'VF'_ )[Q_P#?8HY6!,RJQSWIIC&>H_&H_M,/_/>/_OL4?:8?^>\?_?8H
MY6!(1M]#]*,^QJ/[3#_SWC_[[%'VF'_GO'_WV*.5@29]C29]J9]IA_Y[Q_\
M?8H^TP_\]X_^^Q1RL"41@#DCZ"E\M?;\ZA^TP_\ />/_ +[%'VF'_GO'_P!]
MBCE8$Y;! I<CU%5_M,/_ #WC_P"^Q1]IA_Y[Q_\ ?8HY6!8R/449'J*K_:8?
M^>\?_?8H^TP_\]X_^^Q1RL"QD>HHR/457^TP_P#/>/\ [[%'VF'_ )[Q_P#?
M8HY6!8R/449'J*K_ &F'_GO'_P!]BC[3#_SWC_[[%'*P+&1ZBC(]15?[3#_S
MWC_[[%'VF'_GO'_WV*.5@6,CU%&1ZBJ_VF'_ )[Q_P#?8H^TP_\ />/_ +[%
M'*P+&1ZBC(]15?[3#_SWC_[[%'VF'_GO'_WV*.5@6,CU%&1ZBJ_VF'_GO'_W
MV*/M,/\ SWC_ .^Q1RL"QD>HHR/457^TP_\ />/_ +[%'VF'_GO'_P!]BCE8
M%C(]11D>HJO]IA_Y[Q_]]BC[3#_SWC_[[%'*P+&1ZBC(]15?[3#_ ,]X_P#O
ML4?:8?\ GO'_ -]BCE8%C(]11D>HJO\ :8?^>\?_ 'V*/M,/_/>/_OL4<K L
M9'J*,CU%5_M,/_/>/_OL4?:8?^>\?_?8HY6!8R/449'J*K_:8?\ GO'_ -]B
MC[3#_P ]X_\ OL4<K L9'J*,CU%5_M,/_/>/_OL4?:8?^>\?_?8HY6!8R/44
M9'J*K_:8?^>\?_?8H^TP_P#/>/\ [[%'*P+&1ZBC(]15?[3#_P ]X_\ OL4?
M:8?^>\?_ 'V*.5@6,CU%&1ZBJ_VF'_GO'_WV*/M,/_/>/_OL4<K L9'J*,CU
M%5_M,/\ SWC_ .^Q1]IA_P">\?\ WV*.5@6,CU%&1ZBJ_P!IA_Y[Q_\ ?8H^
MTP_\]X_^^Q1RL"QD>HHR/457^TP_\]X_^^Q1]IA_Y[Q_]]BCE8%C(]11D>HJ
MO]IA_P">\?\ WV*/M,/_ #WC_P"^Q1RL"QD>HHR/457^TP_\]X_^^Q1]IA_Y
M[Q_]]BCE8%C(]11D>HJO]IA_Y[Q_]]BC[3#_ ,]X_P#OL4<K L9'J*,CU%5_
MM,/_ #WC_P"^Q1]IA_Y[Q_\ ?8HY6!8R/449'J*K_:8?^>\?_?8H^TP_\]X_
M^^Q1RL"QD>HHR/457^TP_P#/>/\ [[%'VF'_ )[Q_P#?8HY6!8R/449'J*K_
M &F'_GO'_P!]BC[3#_SWC_[[%'*P+&1ZBC(]15?[3#_SWC_[[%'VF'_GO'_W
MV*.5@6,CU%&1ZBJ_VF'_ )[Q_P#?8H^TP_\ />/_ +[%'*P+&1ZBC(]15?[3
M#_SWC_[[%'VF'_GO'_WV*.5@6,CU%&1ZBJ_VF'_GO'_WV*/M,/\ SWC_ .^Q
M1RL"QD>HHR/457^TP_\ />/_ +[%'VF'_GO'_P!]BCE8%C(]11D>HJO]IA_Y
M[Q_]]BC[3#_SWC_[[%'*P+&1ZBC(]15?[3#_ ,]X_P#OL4?:8?\ GO'_ -]B
MCE8%C(]11D>HJO\ :8?^>\?_ 'V*/M,/_/>/_OL4<K L9'J*,CU%5_M,/_/>
M/_OL4?:8?^>\?_?8HY6!8R/449'J*K_:8?\ GO'_ -]BC[3#_P ]X_\ OL4<
MK L9'J*,CU%5_M,/_/>/_OL4?:8?^>\?_?8HY6!.2/6@, ,5!]IA_P">\?\
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;1%5$C&%51@**>C;B<TK_ '#]*2/J:3U=P/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>chart_001.jpg
<TEXT>
begin 644 chart_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $7 A\# 2(  A$! Q$!_\0
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M:>(_%&E77Q!T73M2T#PN5O[VWT_2SXB;3 VJ.54+RS_T?^(?V^/V-?A5JA\
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MMI>E7W]DMJI8EV /[(HM0CFAAFB,$B2?ZJ2.;SX)P>/]&NAA3_WS[=J_-/\
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M\=_"^\O;*S;Q5X=T'P5H>J:A?6&FK>6NH:K>;0--TK_B:,ZHQQ\U?LD_L?\
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MC%K'@O\ X1S5OBWI?[/VAZ'I]]XD^(GB+0K,Z?JVHV&I ?Z9?:L-*SP?Z5Z
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M(P?\CY_P5@_[28_&#_U%O!]?N;0 4444 %%%% !1110 4444 %%%% !1110
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MI"6L/BF#QCX%U'XPVFLG2[KXE:JUHWA^ZT/QI?VEH/"/_"/LVU;._75R/O
M_1ORT8YR"<+A@<G) ))/7U )//.,9%?'WP?_ &ZOV.OC_P#&+Q_\!?@S\?\
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M2]2U0Q17-7E3=1Z1E?I9V;ZWT35L=IHVDW@792F?N8?$5&GM%W?;6W35O_F
MZ7MW37]"7V>'/W.>N>W^&?\ ]="VZK_MD_\ /3D__KJQ15E#57;GG.:=110
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M::9;6?A;4OB#I'QZ_MJU\+75W;$&[UW3O"I-\H; CTH[54!0*_6]6W#/^?\
M.*;L3_GG_+_&G*NW/.<T .HICNJCYVV_C_\ 6_S^=/H **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%,W'^X?U_P *3S/;]?\
MZU9RFH:=D@(F8(,;5P<]^.?Q(/\ ('WJN;J--^X2?N^2?+)XQV]3^ ]<<5\E
M_M)?MF_!K]FRQ-OXIU&X\6_$&]^SP^&/A!\/D_X2OXI^*+ZZW%+>R\(V!:]M
M+(MM_P")CJ.S3"AR7#(J'X\/@7]LG]MB[T[6OBUXEU7]C7]G;4)#;3?!'POJ
M5K/\:/B1H]X3A?&WC<#'@S^T+('3AIOAYBP &X[FW'Y;'<3X;#8F66990EG6
M;6O_ &7EFJC9:_VEF=GEV6+J^=N3VY>AC[>[]G2LWWU_7MMT?D>D?M _\%&/
M"/@W4/$WPV_9O\#^(_VJ/CMX8@FEUCX>_#*VNK_3?"L'5KGQ;XKM8SIUB 3:
MD:?I_P#:>K?,P,:XW-\\_ S]E?X@_MY:?X2_:)_;YD\9:;>Z?JE_'I'[)L>C
MZIX(^'7A6WL]3(LQXLL[TMJOC?4/D%\+_P#M+^RSE0A;:P7]1O@C^SE\%?V=
M/#!\)_!GP#H7@K2Y)3=7[6$1FU76=0(XNO$&L71;4M9O<XRVHZA(PR<!1DU[
MNB*,J",GJ!U_H/?.?IV%<2X<QN9XC#8GB7,5CDE_R*8I1RM-J^JT_M*V_O))
M/6W?#ZO5J574Q.JMLKVOM=][/OI?HCG?#OAC1/#&E:;H/AO1[#0M$T>UM[#2
M](TJTM;'2M-MK7I:V=I9 +9@#/0'L#EB<]-Y:;ON=L9[=?\ /^'>G[%]/U/^
M-.K[+#X>GAZ?LJ6B7I?8[0HHHKH **** "BBB@ HHHH **** "J_VA/3]15B
MORO_ &^_V9O^"A_Q[U[X?7O[#W_!0:V_8IT;P]INKVOCO1KSX#^"_B[_ ,)Q
MJUY=6ATC4OMWBFS+:.=-L0+ V-@54DJ<D[L 'ZCO-M;&R1_]P'!SG'&<_P"<
M4]71AD;\X^YSG'T[_G7\F7[0_P#P2O\ ^#B;QWX-TK2?"W_!<+0_$NHV_B*W
MO9;-_@YI7P \JW-M>6K77_"6?"[PKJGB&^)^UD'P_J'_ !*B3E6+=/3O G_!
M-'_@X+TKPAX<TS4?^"\.F65_IVEVUK<VLG[)_P -_'0BGM@<VW_"6>)=$T_Q
M%XE7Y2&U+5%74N,9[T ?U 1SQR?=;/UXKP;]H#]H[X6_LP^ U^)?Q=U/Q!I7
MA)]9T[0OMOAOP9XS\?7JZCK!NS:#^QO!6A>(M>6SS:-NO_[-.GJ"N2NY0O _
ML9?"_P#:3^$'P2T#P1^UA^T?!^U/\9=/U35[K6?B_;_#W0?AC!J^FWER?[)T
MH>$O#.-.LO[/ *_;QEM3R"17UK)"C-&[?\LZ /S$^"O_  5^_8-_:&^(MA\+
M/@]\5/%WB_QIJ'BZ?P'+I\?P7^,VE66C^,+.V-W?:'XCUG6O VFZ!X;O]-C*
M_P!IKJFI:8%:Y7)X#+]\_$?XE>$OA#X#\7?$KX@:A/H_@WP-H5[XB\3ZHECJ
M>K2:?I%DH>\NDLK"SO\ 4+QD.0++3X[]\ ;05 -?S&^'/B]K'P5_9N_X+9>)
MO"OQ6\>_!?Q9J?\ P5[\<>"/"/BSX6>"=+^(_P 5+OQ!X[U/X):-9^#/AGX?
MUL_V WCGQH+R[\/Z3J.I Z5X6.KG6"0=-!/+WW[3G[6OPMN_VX]$DU[]L?X,
MV.C_ /!+KQ?^T/\ #[P=^UM\7_A'\4_BSX6^)_@_XB:/X.L_B-I-IX+_ +2U
M#X??VC8W=T-5\/\ B#5/[+U750-7T;2=+4$4 ?U@:/X@T[7M'TK7--DDN]-U
MNQL-4TZX-M<6_G:?JULMY:7 M[I00K6DZLW4]0R# 0; O8"F[>,?S_SWZ]#7
M\J/[1'[2?[8\NG_&3]B+X(?M$^+_  ]^U=\93^SA\?OV:O'^J?8[C7/#GP8\
M2?!&[^(WQ9T+2L6))T33O&WPE\6>'?\ D&ZH=)7Q[8*PR*@UC_@I9\0_C_X%
M^/\ \7_!WQU^+WPV^%NF6/[$/[,/PETSX(^#]"\7_$SXP?M+_%.W'CSX[>#?
M@G:7Q?P]9?%>_75]&^%NE>(=28:5X#U==0?5D0?(H!_5HUU"H'[P?O/]7_GG
M '''\J@O+Z.UMWN?+N)UCB,GV>TC,]S*#V%L!N('USU]J_B?^+_[<G[<'PAU
MC_@HM\.]$\;?M7? :V\)?L"_#+X]_"KP;^TW\2_AQ\5/CA\*OB!>?&_1_ 6L
M^,;35_#']I_V)8^(=$U0!O!WB+4]4YL?[7T@#2-1X_8[X?7OQO\ V;O^"DO[
M%/P,D_:;^-_QN^&_[4G[*7QX\<_%#0/C?XBTSQA#9_$;X4'X<:OH_C'X?&ST
M/3/^$-_M$^.-8L-5\/Z=C21I=K8J,G+, ?+_ /P5U_;BTRP^*VC?"3Q?X0_;
M"\+>#/V>?VD/V./$^EW7P]_9C^._B/X>?'CQ9=?&3X<>)==N;OXK^#_"FH>$
M]9\*>#?"5W=:#X4^'MCJ;:OX]^*]WL;39I/#7AC3]7_IFLKA+_3[*^B2XAAN
M;*.>.*\M[BQNE%U$L^VYM+M$N[2==Y#6DJ!T^XX[)S?C;P/X'^(^EVGA[QWX
M<TCQ7HMAKOA?Q9::5K5BNH6</B#P=X@TSQ/X3URVMW#JM_X=\3Z1I6NZ9>J/
M,T_4;*SFC9'52.UWHX(7/.%&,#JLG] /P'I1"<88'ZJXM+Z_/,'*]_XF7Y;&
M22MI=9=S>2O:^MHKI5<1[6"4;Y?'+[6W:ECI<ST6K<M;W>GEI>HHHH+"BBB@
M HHHH HWD<TMK<1PW'V2:2VGCBN4B67[-,58"X /!*D[MIP,C&<U_/YX&\.?
MM@?$#]JC]H[X(^,/^"GEIH.F? '2_AQ':P>*_P!EG]E2'XE^*=1\>:#>>)?^
M$Q/]LZ']@'PKL!]FT#2#IVE_VGJNK6.H ZQI3:>@;^@]_NG\/YBOY?/^"C4G
MQ#_: _:1\9V>B_!G]@H^#?@G\9?V>?V7[_QS^U'\&M4^(GQ-FUCX\VQUFR\9
M?\)!HNN^'1HOP>TV]U;2/#VEZ!J)U,:MJXU]@%R  #]4/^"9/Q1^)/Q'^#WQ
M3LOBG\4M+^-6N_"S]I#XP?"2S^,OA?P=X.\#^!_B1I/@W4[.ULM=\*:1X)M(
M]!:PTXW1\/ZQ>J^I;O%&C:B#K&IY./7OVS/C7^PU\+_A[#HW[<WCWX%^'_A_
MXDOK>:Q\*_&J[T&]L?$NHV3%K>XTCPGJ(O[_ %MK%B3YFGZ7J']G$Y8KP:\9
M_P""8VO>/G^!OC/X8?%0?!&Q^(?[/OQR^)'P.\0^&?V</APWPK^#WA:#P?/9
MWGAZT\)>$GOM1\NQU'0=5TC7^634]]\0V&T\Y^-_VV;W7?V./VL_B5^V5XY_
M8[\$?ME?"KXI_#KX4^!-"U-_'OPGT7XM? G5_ D'B2U\0:'X=\/_ !IOM,T&
M\\+>,QJO_"0:K?\ @S5-,U%=4M2NL+(@0T ?0?[.O@K_ ((J?M91ZO:?LU?#
MW]ASXO7FB6MM=:]X?\(> _ ,^OZ7;&XQ:76K^';O0K#7;.TWG'V^_P!,V],$
MX ;]4?!G@[PSX!\-Z)X0\&>&M'\(>$_#>GKI6A>&O#]A::3HFD:?&=RVFE:5
M88L;.R#%F50,@EAA=W/\[7P"UW7/^"B'[4/[+OQU^$?[&WAC]C#P3^RQX[U?
MQY\1OB1JGC?X,WWQ3^)ND>(_"NL>#[3X.67A/X%ZYJ;?\(KJ5_=VGB'5M0\;
M:J^E_P#$GL/['TG^U\Y_I6H **** &[%]/U/^-.HHH _#+_@C!_R/G_!6#_M
M)C\8/_46\'U^YM?AE_P1@_Y'S_@K!_VDQ^,'_J+>#Z_<V@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **:_W3^'\Q3!)\V&/7D<?Y_QX].:SYU[3E\K
M?U\P'*5P3TQC/'Y>OX<\4R29(E!<Y!XZ=>W.?6N=U_Q+H?AG2+[7?$6K:;H6
MBZ7;&[O]8U:^M=+TNPMP"#/>7EX8X[,#. TI"C@9R>?Q^_:3_P""CWQ+\5Z5
MXD\$?\$]/@EXS_:0\<:=)!:W?Q7T31UG^#OALEB;Q]+UF] T[QIJ-A_QXOIV
MFG =F^9QAJ\3->(,KR5+Z[B(O$.*<,N@XRS"I?\ DBFVUY_"_LM],JE:G3W>
MMVK6U]+6O^!^GGQA^.7PN^ W@K5/B#\5_%VD>#O"FCPM-<:EJLY5YIP!BUT[
M3 'O[^]8@8L=/623DD @2%?S.TC]J']IO]O>WM1^Q?HUA\)?V=M0NM0TS7?V
MEOB%:V]SXJUBWL[N[L[RV^&7@87W^B7H) _M+Q&N%X.%KT7X)?\ !.[2=9OK
M/XP_M?\ C/Q!^TU\6=7T\7<>F?$2T\CP!\/O[8TPF\\/^'/AZ+[4_#]F=/%T
M]@;\ L0#@ X:OT ^%WP<^&'P7\/OX7^%/@3PM\._#,]U<:G-X?\ "&C6NAZ6
M=1O"/M5R;*Q L0S8SA4P#D@<8/S5/#\4<02P[Q\O]6<J2;>6Y?/_ (5'_BE;
MEBG?6T=%K;6QC!XG$/\ >V^JRZ+XFOR7Y]WKI^<G[+W_  2_MOV7OVH?%7[1
MNE?&;Q9\2CXT\+GPWKVF?$G3],UWQ4+I?LC'7K/QJ0NI6E_J%\MV=4POS:5C
M2ER*^H/VK_V>/B%^T/9_"[3O!/QDOOA!;_#WXF>'_B;JUQI6@KJ=QXKU#P=J
M"7GA_0KLM?H+70OMOVC^UK(9&J A#@+Q]G!!]XY&1C(]<]_;@<_J*7:<Y*@\
M8(R.>,?_ %Z][+^&LHRO XG 9=A(X/"XNK_:,DI:K,'KSZOT=MG9V-J>'HTO
MX>EOS_KT*UK&ZJGG+F;ROWO<$Y_4]OY>UZBBOIC4**:QPO'T'^?I3%DW?['U
MYS_+CWH EHI.&'M^H/\ C_GI2T %%%-WKZ_H?\* '45$TH';_/\ GWH:1%7\
M,8Z?G_GKWYK/VE/NON0 <<#@'TP #P>A(SQ^'/2H?XQRV,$<*,9[$MG(P<<*
M",CZXA>X5%^5 ^/0C'/? SC!],?6OR*N?^"LW@8?\%-]'_X)K:5\(O&/B3Q%
M?^&_[:U/XO:!K.EZOX4T&Y70+SQ');:II-BM]J%E8:>+(Z?J>H7U_&NF:M=K
MI93<Q)]KASA#B3C+^VUPYETLP?#'#>9<6\1J%7 TO[,X9R=+^TLTJ/,:N7)T
MX72<(.6/J77U"C4:=M%!K1+NOF]NK=^WYG[";U]?T/\ A3JHQS.V/D&R3IQV
M]?3W_P \7$^Z/Q_F:\*%13J/R1F.J+"'/R9\L\?7'Y_SXI[-MQQG-0M)]P_3
MK^'/\OU^M74J*FK@2_*1_>V?0XX_ =*-Q_N']?\ "HO,V<?CC'Z]O3UI_FCV
M_P"^A_A2YWV7X_Y@.VKN^[SUSV_G^&/Z4K+NQSC%,5AM_N8_']/8?TZ=*S]2
MU33])M)=0U&]L["QM@6N+W4+RVL;"U''-W=7;*MLI!'7@9 P,C+IU/:(#X?\
M:_\ !.?]DOX@?#']H+X0^*?AC]O\"_M/_%VX^.WQ?LTUS7[?4-7^+-_=:+>C
MQWX?U>TODU+PMKNGWWA[1]0TJ^\/ZA&=-:S!"*!MKS3P1_P20_8A\":?XRMM
M-^&GB;7-8^)WPN\2_!;XE^-O&'Q*\:^,?B#\0/ACXFNK.]O/"_B[Q9XGUO4=
M2UFQTZ\M;0Z0&OE_L@JQTLJ#@?I/>:QINGVS7E]?6EA: 0#[;>W-O9VQ%T<6
MV;FZ95W'M[] <$!MOK%A=2WEM975I>7%A(+:]M[2ZM[VYLI\<6U[:VK,UHW8
M[QQ_$.*T ^:3^Q[\!7^._P +/VE9/A];O\9?@O\ "75O@9\-O%[7UV;C0OAE
MJW-WH'V+<^GWNX$J+S4%9\,=K;B#7C]Q_P $O?V+V_9GU;]DFT^$-MHWP5UG
MX@ZQ\6/[#T/6M6TKQ!H/Q0UGQ!_PDEQ\1O"7BNSO_P"WO#/BO3M=87VDZEIN
MI Z;PO& %^]-,UO2M62Y;3-3T[4Q9W36-]]@U"VOC9WJ%?M%I>"T:0VM\I/S
M69PV[!VC=FLZ^\7>'=*%S_;.MZ)I#V,8N=035-7TRR-E;75S]FLKJ[^UWA^Q
MV5^5.QF Y.T$L0& /S)TC_@C+^P1I<'CF.?X4^)?$&K_ !-^%]W\'_B5XP\6
M_$CQIXJ\8_$+P/<^*='\7VVF>+/%.MZ[?ZEKE]IVN>'=(&D:A?D_V9I5JNE+
ME"#7V]K7[-OPF\0_&3X0?'K5/"QNOBC\#/!GCCP#\-?$@U"\#:!X7\?6NC6?
MBS2Q:J?L5Y_:7_"/Z2 U_P @V@(.0<>E:=\2OA]K%Y:Z=I/COP9JNHW8)M=/
MT_Q;H-[?7!QPMI:6EZ[W8]=O( )ZUW*MN7/W>WTZ?3_/H: %V+Z?J?\ &EX4
M>WZD_P"/^>E(S;1G_/\ G%9EK?V=[)>16MQ!<SV,_P!FNXK>:"6:SN?LRW M
M[M48BUNRMSNVM_"1DC<: -6BBB@!H(/ XQVX_IQ3JYK4O$6BZ3.+?4M8TC3)
MC:7%]&FH:I:64K6MFR_:[H"ZD3%I8KDZA("5C'+!>C4M8\7:'I/AK4_%EQ>1
MS:%I.@7_ (EDU6UE@GLI=(L+1[ZXN[:[W+9.HM4+ [U#*20=I+'*I.G"G[6H
MTD.G#GG[."N_+U2V^:.RHK\A?^";7_!1GXA_MWZKXRO=9\+_ +(_ASP?H7A/
MP[XBM=+^!O[8]M^T+\8?"]]XP:SU7P[H/QA^&UG\*O!EE\--0/AB[>\U)%\3
M^)_[/URTOM$)+6,C+^O76MYTZE)M5++T,J=2G->X_/8:S;1G_/\ G%?GW^T#
M^PW^Q9^TQJWQ1UWXM:!I^J:_\8_A5H/P6^(6L:+\1=7\*WVL^#_"/BH>,/"-
MRIT/7+$67BKP5KQ^V^%O&-@$\4:4"VFQZHL2".OOJZM8;RWGL[E$FMKJ*>VN
M(GZ2070*LH[<@E?7N""*_E!_:/\ @-\$?#/QG\?>!/V>_P#@G#^PI+\/_AM\
M;O@/^S=K/C?X^>*/BSH=[/\ $CXV:4-8L]>M?#W@RPU.PLO _AS^UO#VGC4+
M_5%U75=6U@_V/D:;4FA_0[^RC^S'\%/V2O@_IOP?^ T.K?\ "&V.L:]KUWK?
MB7QEJWQ$\7^*O$_B.Z:^U_Q1XK\:ZW?:EKOB/7=1+,KZA?7X<BT16 ")C\?_
M -N;X/?!JR_;?\9_M$?MS_L8_'/]L;X!-\)?A?X3_9TU/X<^!->_: \ _";Q
M!:7/B7_A9MKXA^!'AF_.HV'BOQ'J%UI.HZ1\0CX8U<#25.CC5-,[?=/_  2T
MD.G_   \;_#K5_AE\%/@CXU^#_QW^*/PU^(OPH^ <GB"]\ >#_$^CZG9WEK]
MFU7Q0!KNLMX@T.]T?Q@M^XTW.EZQ8_N_DR/@W]MG0?@!KO[?'C9_^"D?BS]I
M#PO^RSH_P7^%\7[,UKX?U3XQ>%OV7=>\87E[XD_X6U=^-O$/P6*ZA??&'3[X
M^'['1[#QGJ8TS_A%#NTE"^4(!Y[^S[\(/@MX[_;%_9>^,W_!-O\ 8=^-7[''
MACP/XQ\43?M9_$GQO\(/%7[+O@?X@_":[\+W5EI7PZO/AGXS.FZE\6_%.H>+
M#I.H^%=3TWPR!X2%I?:P=7']H_V6?Z>*_EZ^".C_ +-7A[]MO]E#5/\ @DIX
ME^/'BKP5JOBKQAIG[9>FVOB?X[>.OV;=+^$/_"*WI\/:IXNN_C-J>I:9X9^(
MW_"5?8A\/5\%NNJ:JUUJ/]KZ<4*L/Z@O,0L4##=Z#K^HQ0 ^LBXU.PM+FTM+
MO4+.VN=0E,5A;7%S#;SW<UKS<"U1B&NF (+(!D>BY%:K_=/X?S%?R8_M>_!#
MXT?#K_@O_P#\$Q?C#\2OVD_%GQ9\-_&;XE_M$6/PD^#-SH5KX9\ _ 7X?>$/
MAK8$:#H%G97Q/B3Q1X@O]6-[K'B_5(TDU-K*SRA4(: /ZO)-5TZ*[BTU[ZS3
M49X_-BL)+JWCOIAC^&V8AF!!QD#&>F1S6D&'.6!^HQ_^NO\ /+_X*-7NHZMX
M#_X+,?MZ:AJFOZ3^V'^RW_P4Z_9Q^%'[/OC1/$?B"'7/A5\-_#B^!++2/ OA
MVTL=04V?A?QA_:^JZEJNG_V;C5F #!EW*?Z//BC_ ,%2O^"@'PR\8S>"_ /_
M  1J_:>_:,\):3I'@]]+^-/@SQYX,T/PW\06U7P?HFL:GJNDZ5?:?J6H65D-
M1N[S35&H.65[-MP!V&@#K?\ @C!_R/G_  5@_P"TF/Q@_P#46\'U^YM?SN?\
M&^?CSQG\3?#G_!1?Q_\ $'X8ZY\&/&WB_P#X*"_%'7?$_P */$US;WWB/X?:
MQ>>%O"'VKPOK]Y9!=/N[[3R ,V( Z@@9%?T1T %%%% !1110 4444 %%%% !
M1110 444U_NG\/YB@!H* $9R#UZ_X#_.:7" \_EUQ^'^-5V9%Z_\M/3K_P#K
MQW_.OF#X^_M>_ ?]FZS"_$OQQIEGXCO+7S=!\ Z8RZKX]\4W!(%K:>'O"=DS
M:E?R7Y!Q\@3!V[QBO/QF.PN7X;ZWCL0L'ADMY67X_P"7_#*4Z<?M6[WL?4#M
M&BC)7C)Y!QCKZ =C_P#JZ?G[\=?^"@WPN^%OCB3X+_#W1_%'QV_:#EM ;'X3
M?#/2VU:>RGO!FTN?%GB%MN@>%[$'DG4M2# 9!"MROS=>Z-^VM^WS8))JM[XD
M_8:_9]N)#]FT>TB&J_'#XJ:!>8/_ !-R+W31\/;$V-KP/^0KB]X! K[U_9R^
M _P'^!'A,>$?@EH6A6EAIM]J6GZ]K=E=0:WXCU'7[1Q_:B^+/%%WNU&]US[6
MP$EKJ+_*P+A40D)\HLRSC/:CI9-A?['RNUO[6S2*YYV6G]FY;97=OM2:7D<O
MM\34TIV6KUMOZ7[]W;H? =E^S3\7_P!J_P 4Z'9?\%!/B;I.C0:A'<>,O!W[
M)'PDUDZ7X<FT#1[JS-W_ ,+$\0C_ (F7C<Z;?7EGI^JKI[#2B#@, :_6;P1\
M/_!_PZ\+Z3X,\#>'-+\+^%=$M?LFEZ!H=A:V.E65N.0MK:*,+@G/0DYP>U>!
M^)OV2?AYXL_:8\!_M5:IJGCE/B?\._#^H>$O#<=GXHN++PK!X>UEKW^UM+O-
M M+0)?VE]]J9I/[0D8X2P8X^P*#]91[%8A",=,#.3V') SVR<X_/GLR/(L+E
MF*Q%6>&<\7)V>:YBXRS/,M-7*5](K;:_]TTAAJ=._??7M\U?\EH.6,1KL0O]
M>V?\_6IJ**^O-PHHHH *;O7U_0_X4ZJL_1O\_P )H C#*J$H05"X/8G/3)XS
MG_/;'G7BOXI> O!.LZ%H/BKQ-IFA:IXED\C0K._F$%QJ]SC'V:S4X^U,!U '
MOUXKSKP-JWQJNOBK\3=*\::5H&G_  ST6XTX> -8L[:Y_M;Q$;VT^UWANQ]M
M*_\ $M/_ !+QA0&[@UWGBOPKX&\5^(?!M]XCLM-O->\(:I<:SX32\-N;V'4!
MIE[8W-S:9)(/V"[[# QD]J^7GF>)Q^4_7<LPSPC69*#_ +5OEJ:CF*BVVW=\
MUF[OXKZ]3OIX.E0Q7L\5?&85Y=S/^S6VTVKI:Q:5M$UM'76Z3?J:9<!B^5YR
M#R">Q)P<<8 /&.O:GG;_ ,!Q@J 3^ QCCOU'<UXS\1_C5\)/@AX=/B/XO_$[
MP+\-M"CBFE&I^-?%&E^'+$P+T^S-K-[IQOL=,6 /TYK\N/B5_P %O?V7DNI_
M"W[*7@OXT?MV_$'E!H'[,WP_USQ)X=M^<7)U7XA7MGIWANR_L_"MJ0;4B0"<
MC+%!^C\.\!\;<64ZE;(N%<UQN$IRC@JV:O+I0RFBVE9YIF];V6395!J[?]I9
MS"$8WE)I/7BIIU.6UW?9+J_*UW?SM?M?I^U&,C[Y!(7G@DD9X(.0 >F!_C5&
M[N['3[:6[O[JVLK5!E[F[N+:V@BYYS.[!5/'&2/8]J_EW_9U_P""E_\ P4A_
MX*F>./BY\(_V7OA/\+?V(=/^#\MOI7Q/^(OQFB\9?$7QOH=QK-S>65IIGA_P
M]8:?X9T"Q\;6!M+MFL-1_M-1WPH-?/\ \3_^"+__  43^(?[;?P+A^/O[2_C
MC]LS]DW5+^QUWXXZWXK\>:E\--#TS[&+W^U?#.E?#+PQKN!9$?8FT>^TX,#J
M;9UEABOV?"_1SP&19_FO#_BUXL<!>&7$&29+F/$LLG=67%N:U84LI_M6&5PS
M#AJ<N%(9KF\7&GE>7U>*).I.475:22-7%=VDWVM:[^_STV5[+4_:+]H[_@M_
M_P $V_V9K_4-&\=_M$Z'XH\4:5&3=^%/A18W7Q+U:*X P+.[N?#0?0K*^))S
M8ZAJ<3# *GJ#\]1?\%)?^"@O[67@:S\<?\$[_P!@F0_#C7=.N=8\-_&S]JGQ
MGIG@?1?$FA-;;M+U+PKX(T"^U'7];_M 8 W:B"!RWWLU^BMI_P $Y?V&-.^&
M&H_!NR_91^!UM\-]9BAAUGP_#X%T.!]2-KM*W-WJB62Z[>7P^S@+?-J0D(P0
M3@L?K/P/X*\+_#SPCX;\"^!]"TWPQX0\)Z-9:%X7\-Z-:I8Z7H>C:5;+96>E
MV=J"#]BLU4!>1QMW9P!7R,>*O S(<DRZMPKX;\2\3\7+-I^TS/Q0S>-3AC^R
M7&U.4>%>$GE.80S268.2E#-,WS3+,MIN-I5:J<G3LFU_PVF^KO?IZZZ=%_+I
M^Q-X#_X*+?\ !6KPK\4]7_;[^-W[0W[+G@3P5XZ;P?I?PB^"_@ZU^!,7C7[%
M;#^U;JZU^^LM2\87EC87Q:PX=4U(\#(X'[7?L<_\$Q?V._V'M5USQ7\"/AS?
MVOQ&\66/]G>*?B=XT\4:]XV^(7B"V>Y^UW8OO$6M7DK+_:-Z?MVIC3_+623@
M\, /T14GABN-QX7(9>/[I' !]?P!]7$8SDEOFR 6YP,Y /;/H<?3BL>/?&;B
M/C&MG6#R/"Y;X><#9FX?\:RX$4<HX4HTX0I\D)T\!&G5S7FE&6/YLXJ9M54I
M[V48J'-MV:6GKJ[Z^7W66@U4"K_RT<X]A]<?SS^56***_*:=-01B563> >I!
M[$9Y/<XYSD]N>0.U?!?[7'QI_;7^%^M^$;/]E7]D;0/VDM(U33-2NO%FI:Q\
M7]!^'7_".ZC9W2C2],M;36<M?&_M";S[<&V+P-N=H'WXH(&"3S^GT_G41'49
MX[GG _+^?Y5V91C<-E68X7,,=DF5\2X?")_\).;?VC_9E1N+C[_]EYEE>9:7
M4O=S**NK/30T4^EE;U??^EL?SN?M"?MR_P#!;3P7\-=2\0>!O^"7GA&QUR"]
MTZ&.YM/B]IOQ3DAM[JZ0W6/!7AF]T[4KO*C!O ^S3@6+(^68^M:#^V%_P6,O
M= TBZU/_ ()8^"#J4^EZ?+>HW[2W@ZQ"SW%N/MC"RO0&M"K8S9$LV2,M@X'[
MD$;< D8;&2=V\D^I '&1W[=*-G<Y)P>,Y7C/4XZ]"<@G..>>/T^IXH\*/*\+
M@*7@+X4X7&8/,<?F%3,T_$?GQ\:L8\M*<7QV[PIV<ERM*=_=IPY4Y7S+?ITU
M>K^[2^W==6?.W[-GCCX[?$#X7Z9XD_:)^#5A\"OB5=WVH0ZE\/-*\9:;X\M-
M/L;6XQ9ZB/$.G*+(_P!H(,_9.7C4$YP"R_ G_!?:\O;'_@CW^W/?6%[>V-];
M?"S0IK:[T^XN+>]MYQ\1_ X5K:ZM<2*Q!QE1DY.1MZ?L(%((Y&/[NT+D<=\\
MCCN3]/3Q3]HCX'>!_P!I;X)?$[X _$VPEU+P)\7/!^L>!_$L%N_V:\@L-9M2
MHU&RN@<VFH:7>):ZCI;X.W4[.R8D+G'Y-B*U/%8S$8FCA,!@,-BIRDLLR]-9
M9EL9:VA]>G4Q[A%:)5*DI-7N[V9F]+V]%W_X?T_X!^5/_!:V^N['_@EO8WUA
M>7=G>_\ "U?V*3]LL[JYMY_^2\_"HY^U6?//<CY2>>ZU^-'CG]MKXY?L]?MF
M?\%D/AK\']'\8Z-X?\;_ +:O[,VE_'C]J>XT:[\2>!OV,_@/X]^#?@[P'>?$
M;2;4WHL;[QP-<NKL:3IYVZ5X6'_%7ZTO]CZ;Q^T^C?\ !,O]JWQW'\!_AK^U
MI^WG:_M!_LT_ 7QOX'\>6OPUT[]G?0/ASXQ^+6L?"JYM;WX8VWQ:^(EAXYU/
M[98>'=;LM)\0:K8>'_#6EKXJU725&KGYL#Z:^#__  3[\'?#WXD?\%#_ !9X
MV\0)\4?!W_!0WQWHWBGQS\/]:\-VUCIOACP_9_"VR^%>J>#?M:W^HGQ)9ZE9
MVUU?_;G32VTTW;!8\8840>V?L=_LM?!S]D'X(^'/A%\%&UW5/"XNKWQ9?^-/
M%?BF]\<>,/B-X@\2'[=JOCSQ;XMNV!US6O$;XOWOU TLJ4&EKY>#7\U7QTOM
M0_:!_P"":'[7'[:GQ,M/$/CS4OVJ_P!M3X=>"-'\$^&[ZYAOHOV:?@I^TPOP
ML^'?PF\*:8=0TUK*_P#$5C9^+]0U<?VEIG]KZMXF+,5*C/\ 0K_P3^_8]\0?
ML+_ Q/V=[GXT^*/C=X"\)>,?$][\'+[QI8FW\4_#[X7ZQ>)>^'OAAJNK&_U(
M^*++P<3=:=I/B"_8:F^F,$8#"JGYE_#+]@[XL^+?V</VNO\ @FGJWB3Q#\&+
M+X<?M46WQ^_9E_: /@C_ (2GPKXC^&WCOXH_\+M\/Z9I.CWU]IFG7E_X*\;V
MOB+PAXOT_P#M3.+NPU?!_M+D [/]DS]E/]ASP;^T'X/\8_"__@D]^T-^S1X^
M\*Q:_K'ASXP_$C1],TCP/X;OK30KO=]JO;#XX^-S]OU&-KJPCQX9U/YL'=AA
MCS/]FW_@IA_P4.^,7PS_ &;?VN?%/P8_9?\ "_[*?QB_:2T?]GO6O#.A^*?'
MVN?'&+2/$?QC\0_!VT^)^D'/_"'62Z?XIL+$/X,U#^U-3.E"_P!8;5<G^RJ_
M0/X:_LX_\%(O#WC[PQKWQ1_X*%>!_B7X!T^_\WQ3X#TO]DO0/!%QXDT[[.1_
M9=IXALOB/J0T89_Y?QIA8$@$!C6+\(O^";$/PI_8F^!/['L'Q<O=1@^!_P <
M] ^-$/C_ /X1.SLI]?G\._'S5_CNFB76@C43'9J][JHT);_^TS($M5U;:KGR
MR ?%WQF_X*+?\%(-*^#7Q\_;8^"/P5_9<\6?LD_##XD^,/!/@?PAXI\4^/\
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M\#?LMZ3^TW\']1_9NUKQ1!8^*=9UCXC:1\*;7X.>(;3X@DW]G?'Q5XATD_\
M"7V(;2/[,%\S LHQW>I?\$:?&OCB#]K35/B?^UA+XB\7_M>W?[+]_P")[GP[
M\&M#\&>#OAN/V8_B)9^,?#WA?X?^$K7Q1J)7PMJ-C:-X?*ZCJ9U9?M8U9]6U
M)]R+](?M:_\ !+7X=?MC?&GXD?$CXI^-M9B\(_$K]CK7_P!DJ_\ !ND:9:V>
MJZ#/J_Q&T?XCZ1\6_#_BYI&DL_%?@_6])M3H]BVG/IA()<[N& /S9U6]_;7\
M8?\ !63_ ()CZ5^V]X:^ B:!X_\ V?/VN=4TO2O@M>^,[C1(?^$C\!^#_P#A
M+/A=\0=(\9\ZW?>'+&[M /%^F_\ $KU8?;\:1I?%?HS^P7:32?!O]KC]B71M
M?N[=OV4/C)\4/V;_  )XB\6:7:>/VTKX<>,?!>C_ !&^#O\ :VE>)"UAXUM/
M!OA3XBZ7X=&G:\S:=K&F^&UT?5"4\QJ\V\!?\$\/CUX2_:<_9O\ VNOVE?VR
M5^,=M^QG\'/B5\,?!OA/PS\%%\'_ -N>&?$GA>RT?5O&'BN[L?%OB?4-9^(S
MV&D6TFJW^E:9IB:J%?2M)TE6U,[OI?\ X)O^!O$EM\/?C+^T%XZ\%ZU\/?'G
M[8/[07C[X_ZIX%\2VOV'Q'X3\+7EMHW@/X8Z%XAL@"+36U^''@?PIJ6I<$>9
MJHZ$';%2G[2E[+^OZW*A/DJ.IZ?@U_P#S7]DS]EW]I[3?C=X)^,'[3/A3]E3
MX9S? 7X.^,?@%\--(_90N/$XTGXHZ+XOU7P%?:MX[\<Z3K7@7P/I_P /M.TY
M?A]9CPA\(O#Z^+-,\+ZEK6O2GQ7,@TW=^L&TDC'/(/YI_GW]NM(6 R,=#S[_
M "YS^A'7\NE*C@L,?Q$'TZH2,#Z=J4JM2J\/&44HP4MW\,'*>83LK=<;CIRU
M;=W:YA"-*DG*FFK<LOG%+"7^2A82XD>&":5(FF>..5T@0C,Q'( ]R<8Y[G@F
MOYK_ !MKU]^TU\3OVM[+XM_\$COVP;:7Q?%\*/ &L:QX-^*/PQ\(:KXDT_P(
MUIX^^'WCRZS\<=-T"R^(O@OQ7:D>$?'W@LZGJ::2!HVKZJ%4:0/Z2+ZRM]0M
M+RPO%#VU[;7%I=(',8EMKJ VUR#CU1B,GIQCMG^7O]K?]@S2/VP_VMOB9X5_
M9Z_8U^ ?C6+]G/P1\*?A?\0/B_\ M%?M+?M0^ O[3U\>#O[7\._#KP/X)^$>
MM WMEX>\)W>D'5O'WB')U35[TJIU<:9N.AJ?K/\ \$S?A1XU^%/P+\8Z?XW^
M$7B'X.:EXL^,_P 0?&>GZ7\0_B!;_%3XX>,- U>ZL1I'CSX\^.;'7?$FFZS\
M1_$0M3_:R:?J9TO3-*L[#2EQL)%K]K3_ (*9_LW_ +(/C_1/@SXJT7XV_&+X
MS^)-!@\6Q?!C]F_X.>*_C5X_TWP?>7=[9VOBGQ7I/AFS.G^%]#U&_M+NPCO_
M !%J>F#43]W*\GC?^"3FD> _!O[-GB#X5>$O@Q#^SWXD^#OQC^(_PU^,/PLT
M;XA^-?BYX6T'XLZ1=V5SXBNO!7Q"\:71U_Q'X6\0V-]H_B#2-W.E+>2:25&J
MQ2,/D7]O7]H'4/\ @G_^U+XQ^-WPP_::_9.TGQ]^TGX&^&]EXI_9A_:/TSXG
M7/BK6+;X6?VQX<TKXC_#[Q!\"M!\:_$#3]%^Q:N^FZMI_B+P,WA4ZG9AO[9T
MMF95 .OTG]M[X:?M]?&'X2_!WX:?&W]N7_@GA\2O#%SXN\0V'PQ^)O[.EO\
M!RX_:/TX:&+4Z;I%W\3O"OB70/$]C\.K^U@\0:IIG@[5=/U,+?$:L!I)RO[C
MZ9:W-K:6D%Y>2:A=P6EO%<W\D-O ;NY49NKHVBG%L;]@244X!.."-S?S<?LL
M?M"ZA_P4^_:6_9_U/XT?M,?L>:#XA_9.\<ZO\<_!/[._[/6G_&9_B/\ $/6G
M\,WG@T:]XBU7]H+PI\.O$-EX4\.6/B*ZOS8?#SPQJJZEJ5W8?VSJRQ)@?TO[
M%]/U/^- #J^6/BU^R#\%OC7\<OV>/VB?'FCZQ>?%']ES4/&&J?"'5+#7KW3K
M'1[OQYIEIH_B+^U=(MG^PZTKV-G:B,7JL%()!85]3T4 ?E=\7/\ @CK^PY\;
MOV@-5_:)^('@/QA?^(/%?BSP1\0?B)\/M,^(7BC2?@O\5/B+\-VV>!_'GQ*^
M%]E>C0/%/BCPXN3IFH7^,K\NIB7//ZAVMK!9PQ6T$4<-M!'Y5M%& (88!M @
M&<\<#\ /3!O44 ?A=_P1=C2/QU_P5?QU3_@I;\7\^W_%+^#_ .GO7[HU^&7_
M  1@_P"1\_X*P?\ :3'XP?\ J+>#Z_<V@ HHHH **** "BBB@ HHIK-MQQG-
M #J*:Q"CE@GOQ_6L?4-3LM+L[K4M3U"TT^QL+:>[O[R\N;>VL;."V!-U<W=W
M=DK:V:A1N8\(!N) !-9^T79_@!JL<8ZYYY/4=<@C'3Z^OX5YQ\0OB9X%^%'A
M75?&OQ(\4:%X,\+Z/:SWNHZUK^H6]E;P6]JNYB1N#7;MG=]DLPSD' !+ 'X!
M^(G_  4'N?&>NWOPN_8?\ O^U!\2;+45T_7_ !1IUU<:3\%/ ,!(%U<>(?B'
M)OL-7O;%B-FFZ6^_4SM"29'/S=^RQ^QS^T5\8OC=X]^-W_!2KP@OB7QCX2\1
MZ?)\"M&LO&&E>(O@YIV@ WH^T6O@"Q#%+W3]0_T_3'\0JS@7C?VLI;%?#XSB
MG$5\6LMX=RUYSBW?FS):93ESMKS9DDU*7E'7NV8?6/WOLJ>M^MG96\_GLK]-
M5NO1_$7[5_[1W[9D#^&?V$M#'PL\!R:A<6-U^U!\:-)%CI6NV-F"MVWPF\$7
MH.I>)B4/VX^(=1TW^R=@V@ 9KO8?@1^S1^P9\./&/[6WQLFU?XK_ !$\%Z.?
M$7CSX\_$/'BSXC:@;NYM+06WA;[<4L-%#7MVFGZ3IFF#2R"2"Q7D>^?%S]DM
MOB=\;O@)\9K/XL>._ <?[/UYJ-WX;\ >$+?38/!^O7&LVK6>K_\ "06A5BUE
M?Z,#INPE!&AP" %1OJO7?"7A?Q9I$N@>+/#FB>(]&N,?:=)US2K+5M+NPI'D
M_:;.]LGL789 P8N&P &!XC"9!BJ]7$XO.FL9FJ3_ +-<M,K2MO\ V9>RL]6W
M>Z[/4SIT_:-U*NOZ=_Q^_0R/"'BG1OB1X-\.^,O"U_'=>'O&?AO3O$>@:O!(
M)\V'B+3%O+.[M.V1978(Z#->)?LR_LLZ#^S%H?CC0_#GCWXA>,K7Q[XVUCXB
M:F_CS6+;5[BR\4>)06\0W.EE+&P^PV.HWP^W-8@LH;(!/&?HJSTS1_#.C66E
MZ-IMEI&BZ39K;6.F:7:BRLK*QM5&+:RM;*-$ME'1+15 .&&,[A7GWPM^,'@[
MXNVNN7_@RZU6[MM UG4-!U)]0TC4]*\C6++B\T[_ $U$):Q+*&'(4E0#DG=]
M!4GE]/'9-2Q^)7]JM2>7)];_ !:;/3XKGH0PM6O2Q&)^K/ZKA.J5TK[7=U:[
MV[OYGL2JF%#8P/3//\^WI@\9["HY"8^0HR?7(_R/I[^E#.B!"7'3''7\LD8(
MY]?I7A'[04'Q@F\$13? S4=-M/%\&MZ.9(]2M[2>VNM#DO?LFK@_;?E#V5I(
M;\$,26M"H)+ 'KQN)J8/ 8C%4L-+&.S:67?$[?/=;MW>G86%IK%8J.%]NL+K
M9N=N57O9NRT5U;YJ]MSW2/S-@R%##'S#D,!CC\2<9R/TJH;ET63 V,AYX)!&
M.A]6XXSQQUR*\<\9?'/X4_"30XKCXF_%'PCX<:RL/.O[K6=9LK>6?[):_P"E
MW!M ^\<_.V%P.V6KY/TS_@HW\$/B7X>O]=_9M35OVD-)TNZN;"_\2>!?W'@?
M2=0M,EDU7QKK!33K$H!@'+<9.,\UY\\\PM+!2S51S3&X3 ^SAF7]F9<\UY,R
MS*+6697F"RWVBAF>9)_\)N6_%4:U:4;GI8/(<\QTKX#+Y2=TN9J4<O>K7Q-0
M2U[/73E3;2/IS3OCG9ZM\9M:^"=IX1\5Q:MH/A[3_$5WXHFMK-?#$NGWW-O)
M9W?VTWEVWF"XM"/+&'0Y/.!U'Q!^,_PM^%0T1OB9\1_ OP^A\3ZK;Z#X;E\;
M^*=)\-_\)!K=P0%TO3#K5[IXO;[-P,62?.!C:,8-?R=:_P#\%9/VAO"7_!07
MXC7'CS]JOX,>"OV=-6\)6^C>&_@Y\,[:V_:,^(^@ZQ_9=G]DM=)\/?#'1-1\
M0CQ4-<^UC5O[1U,:5V&!T^8/V[/!?[2W[>&N?![7=8_90_::UC2-%^(,&E?#
M;XL?M/>*+/X/>%I-1\2:I9W5W:Z5\)M%L=3U\:)J%CI%K?C.I:7JN0?0U^[9
M+X&<39/Q'PA#Q1SW*LB\*N*>%\NX]S#Q@S.>4<*Y;P/EO$\'_JUPMF64\5YK
MPOF><<4Y3F7)EO$ZRFG*-%YG&I-)*Y[,>&L-C%^[Q668+&7AEBRM/,\TS+,7
MK?,XVC_9JB]N7FL[62/Z_OC_ /MR_LV_LT>"?$_C;XB?$/1VL_">C7&LZEI/
MANX'B+6YK:T !%I96)!.2.X'H#P-WYLO_P %\_V5/%/PED^+G@&XATCPV!J%
MI)?_ !<\0:%X&N+74K,68^S_ /")VFI:KXQUG)O+/C0-,EXN_O9.:\:C_P""
M,'[0_P"T#X.MO#'[4G[7Z_#GP+JVE06.N_ S]DGX>Z3X&\*'3Q;8&E:I\0/$
MO]J^-/%5E(H+ZC_;Z,CZD"0?NAOOW]E?_@CK_P $^OV0XM.O?AO^S]X8UWQ7
MILD-S'XZ^)-N/'_BU=05/LKW-G=^)1)8Z.]Z,G_B5Z;IHXXXP*PAP=X.99P;
MBZ/%_B?Q1Q1X@K.&LNRSP:RJ.5<+1X;MS2RS->*./,M3>;J5E/,^&,JS++_[
M/?\ PG1NFR'C.&,OJX?ZMDLLZL[N6:YFX:J]D\MRM6MHT[YHUT;T/Q)T3_@M
M!^TA^V+\4M:^$/[(/@_XG?%CQII\$^J2^&/A;X8\/^ M$TCP_&+2R_M_6?&_
MQ!OCJ1T5;VYM#\VF:6Q%YNZ8-?,'[1?C3]O'X#?M/_LX^%?VQ?VJ9_V3?$7Q
M\O[>S\'M^SUI^O?'WQYX=TV]U,>#[RXU;QKXH33O#^C+J5Y>?V<=/TX:JNF
MWVK< 5_:5X3^#'PB\#^+_%7Q"\%_#+P1X4\<>.HK&+QCXK\.^&='TGQ!XJM[
M$%;*WU_5;2T%[?"QY93*X )&<8XW/%7PZ^'/B_4_#>O>+O!/@[Q+K/A&_&I>
M%M5\1^'M)U?5/#M^%XNM OK^SFO=&O"6),FG&-@.N2:]'AGBWP.X,XGP^:9#
MX%K-L LIS6,LTX\XF7'O'[XHS7*'3AF65YIQ/E=3@/*<MRK-G#,XQRO@' 9I
M.&71@LQ3=I+$\6YE7HXK#X7"Y5D^$QBUR[*\LBH\BV7/)_VDUW3J65FWU:_"
M+X\_\&^?[/'QN^!'CO1-?^*/Q=^*/[3_ (GT3S?"W[2/Q]\=>)_'E]X;\4<7
M7]K6G@BQO]+\.Z)8:A_QY:KI^F:8&*@8&X -^FG_  3M_8YB_88_9.^&7[-T
MOBJ#QSK'@FSU&37O&UKHEGH:^(]1UK5+K6+MA:V@W&QT\7W]F:2;YCJ TNSL
MPY+*:^YU\E$1,QH/^>?ICOCT'7G/'TH$UL"=DB'TQ^@Y_+WKP,]\8O$OBS@Z
M/ >?\5YCF_",.)H\44\FS&,(TZ6:+*_[*A[&G"G!4J<,LO&GE5*G3RJ"MR99
M"237S%2K=MMMMO65]7UW=[]W=W\][XVF>%O#^CW6H7>D:)H^EW.L7AO]8N-+
MTRTL+G5[\ 9N]5N;1(S?78)&&O\ S"Q)'..-W[-CR_G_ -7S_/\ #W_.CSH6
MV?/'_G_(_7.*GB^X/P_D*^ J+VR_>)OYZ_?J9C'C!ZG"^G)Y_(].?\BE1 .A
MX!SWY/X@>W2G,5/4,,?2DRG]T_Y_&LOJ]/VGM>OX?F'-4MNOO=OR_4EHHHK<
M HHHH K,YWA2><9YZC\.W;ZU$)0V=FUL]<GMWZY [8Q_@*67"IEG("]QW/IV
MKY$_:*_;"^$/[,NH^&;'XG2>-8YO%4$]WI/_  BW@#QIXVMA!9'[+<&\N_"N
MA:I]CPV"?MY'(R".,98BO1PU-5:NBYK;62VZO3;[NIU9?E^/S?'8?+,GPLL=
MF>+7NY=#WISLM>5)IW\KZW^[Z^\W X!7'0 \?B>_Y>U1^:<NJC#CG(SP/J,]
MNO3M7XM_&S_@M]^RG\)O#%IXAT[0?C!XRGN-8MM.&FR?#KQ3X*:*.[M[P_:C
MJ?C73=+TX ?9,BRWEMQS@8!/H/@O_@L7^R5XK\*>'_$MY%\8M%N=;TRUU"32
M!\%/B1K;:>+L BV;5M#T'4O#][@EA]MT_5'#  YR2*\+_6K(/K7U/^TH_6=W
M'I]UK7\O^&/T*IX*^*U# 8?-*OA_Q4L(VTF\IENNZO>VUGL]EJ?K,A?!R/FY
MSL.01TYYS^'L*F)!7ITXP/?\^#_.O"?@M\:/!_Q[\&:7\1? $NNR^&=2DN+>
M#_A(/#VN^$-462URMQ]IT#7M.T[4%^8@!FCQSP#R!\A?\%@?CI\5/V:/^";?
M[5WQU^"7B8^#?BC\./ &DZ[X0\2I96NK3:1J1\<^$-+NI_L-_9W^GWC2:?>W
MEF5O8FC NGW8*@K[].I3G356GJK]WKUW[=4U;;4_-\1A\5A,5B,#B\/+!XG"
MNSC);/2Z:=[275-NQ^FR?='X_P S29']P_\ ?(K\F/\ @J9^T5\8OV>_V!;7
MXS_"7Q?)X2^)9^('[+.D?\)'_96EZL/L'Q%^+G@'PWXLM?[)OM/U+3\ZCHFL
M:KIX_P");@?:QM&%)K\Y_P!J?]L'XF_\-J?''X2_M-?\%!/%O_!*3X5?#34?
M -I^R1XBM?AWX6N? W[4&G^)/!NCZOXL^(GBSXF_$'0]2\'WJ>'/'%S=>'?^
M%>KJ7A<_V:,N"QDDJS,_J 9MOU-4X;4).\V^4L1_'R"#Q_+TQBOQ6\>?MA_M
M4? G_@F%-\7?BA?_  A^)'[5WC'7[+X,? ?6?@?J-IXB\ ?&7QW\2_&8\"_!
M/QGI%K8'4-.L[S4[.[M_&>M>';#47TS3I-*O]+WJ%P?2_P#@E5^T_P#&GXN>
M!_B]^SS^U3JEKK/[8/[&_P 5;[X0_'C5(M*M-#/C#2-6TT^)OA1\6[32;('3
MK31?B)X49GC&G@J'LMQ(SP ?/_P(_P""DOCKXX?MU+\,+/\ :2_9%\/> [WX
M@_%KX>Z%^R;J_@CXGCX]7_AGX7Z_XE\('XD']H&PUO4?A8/BEXAU[PI=:YI7
M[.FH^%--UE?AU>'6)M8.K:=*Y_>4*'R 2.N<<<Y&>-JC/3)YX/4]:_*:R_X)
MS^,K;XV^%=1G_:2D_P"&0/A_\=;K]J'P'^ROI_P2\&:1XBT3XZW6N^(/&<EY
M=?'NPUXZYK/PZ3QSXN\1>+H_"$W@6'Q2TMU9Z/JGQ$U'0;(:<_ZMK@9R3@<#
M/7:",="<C/0X'3G'?.'^Z8"[3K^S?/9:*7,WNDGK'763Z/ECS?4,!%3E^LU_
M9?[M=<MWK;E6ZLM>CT5FFK2Y?[0Q\/V;C/G7&['_ #V.?3\O?/\ A3H8A$K)
MG?D^8/<__7(X[59HK0L**** *\UNLIR<>_\ G_&GK& V_P#BQCZ?C_.I:* "
MBBB@ K^9']OF/X'Z?^T+^U-\:/"[?M_1_%OP6/V9O@%JL7[-G[4EW\$/ _QA
M^,_Q4O%T?X9_!'2-)L;34?\ B>>'="\0VOB_Q9XQU'3"-)TN^4_,%PW]-U?S
M._M@^ ?'_B__ (*):E\2/V)_V0/'_P"U%\1/@'J'@;QE\;/[8_:NT'X ?LRZ
M-\=[3P9J]E\/-2_X5YK=EJ0^(/QQ\.?#KQ#:Z@/$&!I6E"\\/C6!D$L >^_\
M$J_V4OA-X?D\1?$3PGXY_;5\ _$CX3?&/XH^ ?C9^SG\6/VL=7^,GPTTWXRW
MF+OQ9J=Z+6T70?'UKX@L=9L?$.E>(2 Q^U68\M&TT8]K^)WPC_:D^"O[;7Q2
M_:U^"7[.GPD_:C\*?&#X4_"[P)?Z1J7Q TGX6?'#X5ZA\+E\36=U;>$?$7BG
M0=4\.7_@CQG9>(+74M6\/_VEIFK#5K'+ J>>]_X):WG@N[_9MUVPTKPMX\\!
M?%O2/C)\3X/VHO!?Q4\:6OQ&^(V@?M(WFO'6/B';^*O&VC Z;XGL]06\TO4?
M"GB#3E_LMO"=WH(TC@8KQ[]M7]@3XW?'7]JCX%_%_P"'W[4W[87@?X.ZBUU\
M/OV@/@_\#?VA;KX.Z)HVC'0-8;PE\8O!)7"F]TSQ4;33?B#H0.IZIXJTF[75
M-)TMI-,9F *&L_!O]KG]L/\ :G_9"^-_Q9_9K^&W[)7@?]E#QYXA^(MUKEY\
M2]!^+OQN^)%SJ_A>_P##6E> O#]UX+T73-,\&>"%?5'U#Q>OB#5-2.J_8K :
M5I((W5^UM?F=\%/^":WAKX+?$OP?\3[+]L/_ (*#_$:Y\*W=S>Q^#?B_^U7X
M@\>_#GQ +RRN[1K?Q1X1N]#L;#6K/=>"_$;.C+J:VDN\B/!_3&@ HHIC?=;;
MUY_/OUXZ?YS0 ^BOCGXN?M]?L7? +Q]'\*_C;^U/\"?A3\2_L.GZF? ?COXD
M^%_#OBK^SM98#2;LZ/?WXOB-249TL ?\3,<("3Q]:V-W;W]I:7EM/'<6MY;P
M75M/!CR)[>[3[1;7$&=V0R%67)Y!#'H 0#\0_P#@C!_R/G_!6#_M)C\8/_46
M\'U^YM?AK_P1@_Y'K_@J_P#]I,/C#_ZC'@ZOW*H **** "BBB@ HIJMNSQC%
M,:0;3V]>_'M_^J@!    ,=<=/ESZ\CC@]@<XJ":<1G@%CS@Q@$]?3T_&OGSX
M\_M1?!7]FOPXOB/XQ>/=(\+0WF8M)TQFN+[Q#KUP?^7/P_X?L=VHZU>GD :=
M&WT VU^6.B_&_P#;/_;X^,7C#X6:%X0^)/['?[+%MH%OJD7Q,\0> ]5L?B-\
M8= O+H6=WI?AWQ!>DZ!X+OM1L[K^T<Z>6U8:5_$>37QV;<599EU3ZIAF\ZS:
MR2RO+6IU+VM[\[M9?>]^:5GHTU8YZF(I4W[.ZNW:VGX^7K^A]U?M%_MX_"#X
M$:A:^!M/AUSXQ?&?7&,7AWX,?"J&'Q'XSO6#G?=:JMH[6'AG3;$;CJ.H:FZ^
M4NTA)%P*^'/C'^SY^W5^TKX \?\ CWXXZI;:5I%KX-U>[^%?['7P@\1W=C#X
ME\47]KCP[:?&_P 7G^SO[<LM.O\ [%?:IING-_98 O0 %"BO>(O^"=I^$.H?
M!YOV1?'6B_!FQ\%>/#XV^)6H>*O#5W\1/&_QAE-H-'_L#Q;XMO=1T_4&T3^P
M[S5_]"7 _M4Z?JP .F9/Z=1N)(HW3@/QSV''4>N?7OBO(JY1F7$2Q>&XM:C@
M]7EN698[*R2NY-M?VI:VMU%)*_F^/ZOB:E6V-T6UH[-=-5J]7M:VS['SK^QY
MX-U#P=^SM\+-*\1?"/PS\$O&</A+3HO&OP_\+V.E6.EZ1XGM01JYM?[%'V&Z
ML]0OM]^K*>5O#R3P/J)@V3]ULG[K,H48]RI_3\^E9KWT5M;RS74T2);#S99Y
M\"$#CG@Y '3CIG@9Z_*>J_MT_LN:7>:EIDWQ9TF;5=*N_P"S[K3K33M?O[UK
M[[2+3[/:VMGIS->OO(R+$N#][)/%>[7SSAGA/#8?#9KG>4Y*K62S/,\MRQ^K
MO)+[K===3Z+*<BSG.?W.0Y+FN<_4]'_9669AF=NE_P#A/C-:];K5VTW/KU-J
MC8RJ!G@'/!/?!!'<#M^&>:\I4MMD<*1TW1HP ('9P0/\<<5^=?C#]NKQ%>ZU
MX<\*?!GX&>/_ !?K7C"ZN+7PIJOBO3+KP?HNM_9+;S+K4[9;S_B8?8=-!7^T
MAJ4>EL$QM/)S\A_M._M>^,O@[X5URY_:/_;4_9S_ &9O$,^E7$NE?#G0+NWU
M3Q1>7!&+2U()U'Q!N]?[/7=GTKR\FXRJ\8YHLA\-N$N._$O-M%R\*\+9IF<&
MY:I?VA)9=#7R6JU;:/IO]1<RH+#5,]S'*.&HXV5E'-,RC+,ERMQE_P )65^U
MS+W6FFFE9KEERM-+]K]=\1Z!HEL)];U[1]&MHR)//U34;*P@&#GD75T@ Y.2
M<C' '6OBR[_;5_9=\!-JNB> -4D^(VL3ZQJ%SJFE?!70O^$SQX@N\&Z-[=:*
M?[.M+_4#WW ^^1D_A\_[17PL^-FFSQ_L@?L;?M8_\%"?'&H:6+#7OB?XPFUW
MX5_""SUF\TS[)=ZI;:OXU/AL7E@UY=<C3=*&F?Z(=K# :O/?^"9O_!&[_@IS
M^SWX;^)&DWG[3/AC]C;P-\8O$=MXG\6^%OAUIVC?%SXLVW]E?;;/2=,TKQKK
M"OX>\- 6%V =3T]-5U)2,$A]Q/[]EG@3Q5C^#>).(/%/C;@/P XOR6IE=/AC
MA;B9_P"M/%6;9;F6G%*_LK*%4XHX8S;*8K+G&&:Y9#+,VMRWA>+?-]6X8RRM
M[+ZQFF<1T_M"+4<IC=7:M9YG*S=NFB=^5H^W/C[_ ,%I/&_P]_:P^'7[*4?[
M/-W\';3XG>'#K%C\</C]XCTSPKX0\-Z?]EN[TZ[>V8)S8Z=]D&GZH-1U+*ZI
M>6( VLV?RB_X*._MQ?%GX_\ @ZT^$W['G[9WQB^.7QS7QWH\NI>%?V2/AGXY
M_P"%:3:./MMG=:6WQ$T2QTX&]TZ^-KJ'WCI(^Q]P:_9GPK_P1U_X)K^&?C/H
M#_'O7/B%^U#^T#K2MJMK=?M+_%'7/'%]XBF6UN_M5S:^$<Z;X>%D5L[P_8!I
MC(N" &XS^T/@;X:?#[X9:'9^&OAOX-\+^!O#=A:BUT_0_"ND:3H-C%;@Y 6U
ML[-%&#SERQS^ 'V^4<3_ $=.!N)O#?C7A').-_$SC'PTRC+<OXGCG&:9=PMX
M?\3\>97/-;\4YOPQ%<59MF5-9;F<+\,S>4KX6G%M<G/7S>&%I>SPN2+ _6Y6
MCSI9E?+FE9J4XZ-IM*46EK)-MII_S&67[+7_  4I_:?^%"_#;P[^R=\ /V2-
M%\6^ [?P;\1?B]^U#XGU+XM?'7Q'<7F@_P!C^(-=TKPKHQU'3=$;4@;K&_5E
MU73#>?*!G ]C_9*_X-P/@G\%?!$'A#XY_M _&3XX>'+FZM]6U[X4Z'XIUSX9
M?!C4?$&TVFK3ZIX4\-Z@NH^*+*^1?L93Q#J;;44D+T!_H^U6XFLK"^O;:T;4
MKRUMIIK:T640_:;CE5MP3]TDA<,<@'/K7DWP3^*>K_%GPO)XEU3P3K'@&3^T
M]0L;;2M<GMIM0FAL[IK.YN3]A_X]0;RV?Y6] <9&1\O2^D%Q)PO@\7P1X?X'
MAGPEX=XES-9N\JX"REY;/,<SRI-PGF?%&9+-<ZEF>6O,Y?V9?-*<^2\:7O)M
M\^(QN<9AAL1CL5B?KF%P;L[M:.5VK)O79[*UTWJD[>?_  /_ &%_V1_V:X;5
M?@9^SG\(_AE=64?E6VJ>&_!NE#78AZ#7[RSO==X]3J1/KDBOHC6_"6A>)(]/
MMM>TRSU>'2M4TW6;&*_B6:*#5])NOM5CJEKGD7UB^2A. 3Q_":ZIF*(6)SCN
M.1_GUZ\53>Z7)R/F3@YQS,><_0C/N,^V*_-,UQN:9[B:^/S_ ##,LXQ4KREF
M6;9G4S6;D^KEFM2J^9;.[?D[GCO$.%3VKQ.MK*S[^G](NHNTYWY/7Y^,_B?7
MU/'XT]P5&-HX]?\ #H?P]NM9=UJ":?#-=WDZ)#'$)9?^F/KGN?QZGUKP[5/V
M@?A3-X>\.:O9_%GP/I-I\0K2WA^'^LZOJNFP0Z]?ZN/LFE-H^F7NH:8VMN;Q
MO^/!27/0G(S64ZE+#O\ >XB_KI^37YE8?"8['I/#8"6*_P *;O97>T9/;7;9
M/L>WW$UO&#*H \M=I9<$A, A5)SM#=^GY=?ECXS?MG?L_P#P'\;^!_A_\2/B
M!X;T/Q/XWUC^S(-.OM9TNSN="M?[)U?6+37?$"WMZ/L.BWQTC^SDOB"#JEY8
M*0"[;?P3^%O[;O\ P4PN?VQ/B]H/@#X80_M"^!O$?Q /A?3[I/#-U\.O!-UI
M_P .;7^R+RY\*:OXFU!M-T4BR^UZAJN#JPU0C"'@&ONW]JK_ ()1R_MP?&A_
MBE\?OC'?67AK2O"5OH/@'P#X)\/Z7I%]X:^V6JW=VWB#Q7MU*^UDG7,D@;5&
MF?+G))KX?_63,<YR^O/A?*LR>*CF48*.:Q_LSW:;OF,;RYK\J7N[ZNZ5VF_W
M)>$F0\#<19;2\7>*\KP/#V.X8GF_-PKF4<VS9SGEB>69;+*E&,LMF\TDN99J
MLL?+&TK:Q7M_[;W_  4^^!7[)'@.._CUBW\<>/?%^@WTO@GPWX:NM+U2:+4+
MO3+N\\*Z[XALA?"_L_"NHWHM0-1*XYX&<UX%IG[7'[;W[8WP \*?$7]BKX9^
M#_!NDZQHVH?V]\3/BUJ]K!)_;WAUS9:]IO@OPI9+J;W]F;U;P:9J.I-I:8LS
ME,?,?T!L?V*?V=[S1_AG%XI^'?A_Q-K'PUT;P=I.F:_K%DL^J:A_P@=K]A\/
MOJEZH\S6+'3W:>^TRRU#S$C+AMH.YC[3X-^#/PZ^'6B>(O"_@GP[:>'M \3:
MQK'B#5M&TMC;6!U?Q%!LUBZTJVW$:0;[.9%L"N2#QD!AZ-3!\18K'8BI4S)8
M+!RRWE]V.TI.[N[>ZT_B>Z6K:3U\+#\2>&&19#E?]C\$RSCC; YO_:>99MQ5
M-9GD\\M3LLL7#$91B[JTTYSLI.2<7)7/Q=_X)#_MT_&3X\W/Q'^"?Q?B\9?$
MCQ5\.?$>H:A?_%?5[;POH8CT"]N[RVM-+U32M.V_:KW3];LKS3],'AX:LC*J
MEM6 4[OW]M,&%"1)D1@;I#V(_P XZGTKQWPO\"OA9X-U7P]K7A/PAI'AG4_#
M/A^Z\*:+>:'"-,FB\.WQLWNM+NC:A1>QB[LK?4%6]5R-07S,[R<^SKA1\S'&
M> /YGW//'..N2.OHY+@\PP& P^$QV*^NR2MS6^=WW\]7?=]#YKQ&XBX<XKXM
MS3B+A;AJ/!N48Z2E'*(OFC!I6?*_AC'W4TH1A&-VE&[;=FBBBO8/B@HHHH *
M*** (G0,=^>V?P _SZ>]9DUBDVQYH8YGC_U0DB''X#..?\],ZKL1@"F,<)DO
MCZ\]S^/;OQ^54IM*V@KJFW4ZH\T\8_##X>_$+3(M(\<^"O"OB[2X[K[=%8>(
M]"TK7;"*_'/VH6=]9.!>G/! #=JZ'1?"_A_P_IEEH^BZ1I6D:3IEN+6QTW3K
M"VL+"RMS@?9[.SM-B6BKGHG'7UKH=PYVA4_VCZ=!WS[# QW'J9 %E7#!3GT/
M3\SC/'TX!Z\US^QH^U]LZ"6(MJ[Z:;*[TM\]S9XK$NDL//$9@\.G=*4I63:U
M:2>[6[MKM?<A@MX[?Y(4V?\ 7/'Z_A_+OUKY#_;^_9@'[:'['/[0_P"RXNMP
M>&[GXS?#G4/"FFZ_=0W-Q9:3K"W5IK'AZZO+:T&]K!-=TO2_[5"$-_9F_AB0
M*^R]B^GZG_&FO$DGWQGVSWK8R/P.^,?P?_X* _MO?"CX+?LB_'+]F?P'\#O
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M^*FE?%H>#E;1[7XQZ1X(\3MINOVGBGP[H0MO#VJ>(M,_XE!%IIZZP6.G@O\
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M/WMY=:8UB&(5;%=JAMU?3_Q5_P""3G_!/OXZ_M,Z3^U[\6?V:?!'C;X[:/\
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M8_@US/Q9TKX86OQ1NK9W#6_]FW=]=VKZ0,@$:Y9Z>+37GLN@TF\$@7*YK/\
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MD)KWZT^[\^B_KUW):***U&%%%% !1110 4444 %0K"J]#(/JY[_0_P ZFHH
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M.0<CN< 'I%%%% !1110!^&7_  1@_P"1\_X*P?\ :3'XP?\ J+>#Z_<O^/\
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M>F>$[JQL=,O]:_M'//B_4 ='TL*"0W./IS6?@1_P63_;6\':CH_QQ^.GP?\
M^"?_ ,/?$FE7-K?^"OV=-(U+XF?%R:VO;9[-M+UCQ_K%]I6F:?9/9W##/A]$
MU%6&W<H''[P:=IEEHUG;V&GVEIIVGVMO;VMG9:?:)865K!:@@06EM9IMMK7
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M[JXO+W.IZK>6VEJ,AR&*X;319LIW;6 _+#]EW_@J_P#M,?'GXG_&GX<^*?\
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MS_T1ET\\@?ZP1MA1WGP;^"_@;X,>&;GPYX+^/&GVUEX@UZ[\6Z_JS:YX5O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0R-MC=ODX'7M_\
MKSC%34UFVC/^?\XH ^'_ !__ ,%%OV(_A3\<[+]FGXA_M-?"KP9\=;^Y\/6D
M7PX\1>(#INK0W_C LWA32[R\>R_L'2-0\0AC_9&GZKJFG:GJ1*E%X-?;-O-Y
ML:.Z;&(Z=O3\!R>#Q7^=O_P4=O+"U^ '_!=CX7>(+O1YOVMO&G_!6;]F"_\
MAGH=S=6MM\5/$GA_6#X!;X9:I\/]'8KXAO=%TZPM-7T[2+_P^ITS(U  J3M;
M^G#XB?!#_@O-K?B?^U/V>OVSOV+OAQ\(9_#_ (/7P=X'^*/[/_BCQ7X^T&VM
M?!^BV^K6OBGQ!9AEUB^_MX:K(S@G NERJM&%H L?\$:_F\9_\%82AC4C_@IA
M\8<'H!GPQX.R.V>N>G)%>$?\%'/V._VM?VQ/^"EO[)/A#5?#'C#5O^"=NC>$
MKC_A;S^$OB%KG@C1;W4#<ZQ=Z_:^-;31=<TW4+Z^-]:^'M/T@_V:0-+.H9(&
M37D_P!_X)K?\%]/V:M0^-FJ_"_\ ;Y_8.M;[]H/XO^(?CC\1CKG[//C+5$N/
MB#XFM+&RU:YTE38K_9-@]EIEF$L0&4'(+#K7T:?V>?\ @Y/"_P#*0;_@GD
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MO-MDM]J5I8M81M?9"LPVY8,]>/2X(X3P_P#"R/*OEEJ_R.GZ_CO^@F7W_P#
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M#_PM<V?VCRXX+GQ39*/MAYR++7E)![<C'!(/2O!!^SY_P<HGI_P4+_X)X?\
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M6ZQJNF:!K]XOV#2-8OXW*+>L0%?YP<  _N4GW1^/\S0 ZBBB@ HHHH ****
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MQL-(\':>P.J:KJY"J5&1_,=>?"_XK6/[$7[&/PR\>>!/B'^S;^RC_P %#_\
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M-^)^NZ)\;].^, U2^UBZ^(MS\3$SJ5[XLU*^U6\.JW]^K_VH+EAMSMK]9:*
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M-_CMXG\1?%3X>_$[P?;A/#GB'X??$"\4:EX8_LX _P"@Z=\K$EF+??K]G:*
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MM0"2-V,#+<G]A]/MELK>*T2&.WM[:*&SM8DY\JWM +:U7W^4 CT&!CG%:E%
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M*>#=(U?61G2?"NG?:AMTU4WYM%8*.#7Z344 -3[H_'^9IU%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5OLL':/;]#_
M /KHHH F9%=2C)E3V.,9_ U']G3=O[_T]/\ /'M110!*J*B[%&%]*=110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>chart_002.jpg
<TEXT>
begin 644 chart_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #S A\# 2(  A$! Q$!_\0
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M)F4*6+# ]F(_I5NL[0?^07#]7_\ 0S6C0 4444 %%%% !1110 4444 %%%%
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MN+?0/ ^EW*QS2QE4N[^\ 4A#_$(XD.2.,R >M>X#I2;1G.*=0 4444 %%%%
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M)F@?]@^W_P#12UXO_P % _\ DS7XK?\ 8)_]JQU[1X&_Y$S0/^P?;_\ HI:
M-VBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI-P
M% "$B@,#TJM>/,EK*8%#SA"41C@%L< GL,UY5\"] ^(?A^;Q(OCB2SN4O[UK
MZTDM;EI?)W_>BP1PHXQ^-<\JG+.,>5Z]>B%?6Q[!12+]T4M= PHHHH ****
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M&"Y!YKZ)\#_\B9H'_8/M_P#T6M &[1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !2$T'I6?K&KVFAZ9<ZA?W"6MG;1M++-(V%10,DD_2HE)
M1U8&;XW\9Z9\/_"^H:]J\_D6%C&9)"HRQ]%4=R>PKR[P%X?O_C#X@M/B!XIA
M,>DP_O/#NB.=R11GE;J5>GG'M_=%9MIX:F_:;U ZQXDMY[?X=0$C2='9FC;4
M3VNY<88#&=B^^:]L\+>&;#P=H5GHVEQ&#3K./RH(F=G*+G@98DFO-CSXFIS-
M>XMO-]_0S3<G?H:R?=&>M24G/M2UZ:- HHHJ@"BBB@ HHHH **** "BBB@ I
M& 88-+10!7%I"K[A$@?^\%&?SJE8>'M*TN:^ELM-M;62^G^TW3PPJIGEP%,C
MD#YFP ,GGBM3FEHN]P(HX8X\;45/91BN"_:#!/P,\? =]#O/_135Z%4%Q;QW
M4+PRHLD3C:R,,A@>H(]* /G#P/X<\>>'/@ FK:A\0Y=7T]/!;26^G)H\-J\+
M_8@8V69#NRF/QZUXGH-EJGCO0_C%JNJ^)/$@O/#W@W0[W2A;ZI/"EO=-IAF>
M<*K -(SJ,DYSSZU]\BUB%K]G\I/(V;/*VC;MQC;CIC'&*K1:)8PB=4L[>,3H
ML<H6)1YB@8"MQR . /2@#X&U+QQ+8^-/'WVM]0DOO$.J^%X]L.H?V9:W$G]D
M>8Z7=W@F&%L'.W!8@*.M4_#OB'7O$.LV7A"3Q!<66D-\3+2P:'PWKES<PI:2
M::TLMO'=. [1&0'/8'.#7W[?>$M&U.RNK6\TFRNK6Z55GAFMT=)0HPH8$<X'
M STI]OX:TRU,9BTZTB:(J8RD"C85!"D<<8!('H#0!\>.Z^'_ !?_ ,(;K'B/
M5K+X<P>/[JSN);K4Y5"1?V7%/;VLEP6W+ 9W? + 9 &:]/\ V6;=&^'OQ'B\
M):Z^JH?%6K)INJZFS7(+80(S-D&1%;C.?F Z]Z]UU'PYINJV5U:7FGVMW:W1
MW7$,T*NDQP!EU(PQX'7T%6M/TVVTR$Q6MO%;19SY<*!%Z =![ ?E2>JL-::G
MBGP ^%_Q2^'>L:A)XT\3>%O$MM?*TMW?Z?I-S!J=W<Y 1Y99+ATV*NY1&J*J
M\;0!G/NB9P?K3Z*INX@HHHI %%%% !1110 4444 >#?M)>)M3\)_!NTO[35;
M_0-+75[9=<UG2XS)<V&G&<^?*@56/0!20"0&)KY]^&GCWQ5XF^*G@KQ@FN>)
M#K?C+Q1<BS\/RB3[%_PB,*M&MQ)&R[8R659 S8<F3%>]?&B>/P5X"U+6+CQ1
MXPBEUJ\MK#3M*\-M"US]I,C*L-JKQD RD_-O)&!VKSCX27WCR;XF:"NI:%\;
MK6Q,^V6;Q'>:8^GHN#_KA$H<ITX4]: /L1STXR*_/W4[GX/WGQ9^*J?&SPAK
MGBSQ%!KMPFG:A+HM]>VXT_8ODPVIC7:FP9!QU;G-?H%)P!DX[5\5B'PW\8/B
M-\3O^%G_ !4U?PEJ7AG6YK'3=#L=?.C)8Z>J*T-QM!7SS)DOO.X?P]L4 =9^
MQ=\<=%U_PW:^!XXO$EMJ-K+>2V-KKFEW2-;Z>LS&"*2XD7:SK&RC&XGMSBOJ
MM?NCO7C?[*GBS4O&_P '=/U'4-9F\21K=W5M8Z]-&(WU2SCG=(+E@ .60#D
M9Z]Z]D'2@!:*** "BBB@#YZ_X*!_\F:_%;_L$_\ M6.O:/ W_(F:!_V#[?\
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M\#_#":[E\)>%-)\.2785;AM-M5A,H4Y4-M'.*R/VEU#?L^?$0$$C^PKS@?\
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M&T*(MC:NB22LQQU8X '4GGCM67X-^.5[\8_!>@:QX)\/7L5GXATBXNX-8U1
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M\"N7^-'Q*\8ZOX+^(7A#Q/<>(+O388/#VJ6?_"4Z=:65ZCOJL<<A"VYQY9V
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MH6DVFDQ3,&DCM(A&KGL2!WJZ<7%QY'[MOFQQZ6V-\'BD+;>M>3?%G]ICP/\
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M,[C9Y@) >,G)7ITH ]GTW]IOPYKGBK3;O3=5M)O $OA[4M9N=9D5T,3VEU#
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MH5N/#]Y#%O$J<-(\84#@\DXK[?\  _\ R)F@?]@^W_\ 1:T ;M%%% !1110
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MHLT\D^H:ED-& PPHB0'# Y).,]*]-_9^^!VA_L__  TTSPAHH:<0#S+S49E
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M;W'FH@E=F* *-S C.: /K#XJ^*=0\$^ ]7US3/#-QXON[*$R_P!CVDJ1RW"
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M:KA0Q/H%'S$_05X=;_L[?%+XA^#,_$GXK:F=4GLSG1]!1+&UBG*_*'EC&^0
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MU)\-_P!C+0?AAXAT75M,\?\ Q'OH])*^1I>I^)Y;BQ*JNU8VA(VE .B]!@4
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MMWT3L^C\OQ/M\ 8X-.Z]Z_//P)_P54LI=*U>'6O#=]XEU"VN'%K/X;LG\J:
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M_P"%4(^FE7:*6OF3_AA#0O\ HK'Q?_\ "TG_ ,*/^&$-"_Z*Q\7_ /PM)_\
M"@#Z;HK\_P#]H7]FD?##4_A9;Z/\5_BH4\2>+[70[XW7B^X<BWDCD9RGHV4'
M/->R+^P?H(SCXK_&#K_T.D_^% 'TY17S)_PPAH7_ $5CXO\ _A:3_P"%'_#"
M&A?]%8^+_P#X6D_^% 'TW17S)_PPAH7_ $5CXO\ _A:3_P"%>M_"#X36WP=\
M.SZ-9^(?$GB2*:Y:Y-UXFU-[^X4E0-BR-R$&WIZD^M 'H%%%% !1110 4W;Z
M4ZB@! ,4M)@4M !28%+10 4444 %%%% !1110 4444 %%%% !1110 4444 9
MNA9&EPXY^9__ $,UXMXA_;H^!/A37=0T;5_B1I-CJFGSO;75M)YFZ*1"0RG"
M]0017M.@_P#(+B_WG_\ 0S7XF> -:^#.A_MR?&.X^-]E:WOA=M0U);:.[MWF
M3[3]JXX3G.W=0!^L/@;]K[X,_$K6+?2?#?Q'T'4M5N#MALEN@DLK=@JMC)/H
M.:]AC8NH.,5^(W[39^ GQ2\=?#;0_P!F+2)+#QK-JL:/<6,$EM;@$CRSF0YW
MJX#9'0 U^U>@6]W9Z'I]O?S_ &J_BMXX[B?_ )Z2!0';\3D_C0!HT444 %%%
M% !354*,"G44 %%%% !65XC\1Z;X2T2]UC5[ZWTS2[*)I[F\NY!'%#&O5F8\
M "M6J6J:99ZS92V.H6<%]93KMEM[F,21R#T92""/K0!\_:1^V[X)USX.Z_\
M$>SL-7N-(T[6VT"UM$@!NM3NMR+&L$>?XRXQNP<=:YNX_:[^'UU:+XQU#P%K
MT/Q(TS5QX.@\.3V<?]LI<W"B184^?;Y<BKNW;L'::Y.W^!7B:+]GWXRZ1?\
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M_P#".:UXLO\ 4KZ/3K+2M!MQ-<33,"1G)"JH .68@"O2*\'_ &O/$_Q.\/\
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M&,'D>]244 -V#OR:3R_<XI]% "!<4M%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G:#_R"X?J_P#Z&:T:
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>formdrs_006.jpg
<TEXT>
begin 644 formdrs_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #K <,# 2(  A$! Q$!_\0
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MF3\K=1@<<5Z;0 5XC^QY_P D:'_88U'_ -*I*]NKQ']CS_DC0_[#&H_^E4E
M'MU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>4?
M'_XV6_PF\.I#9K]N\3:B?)T^QC^9BQXWD>@KGQ%>GAJ;JU79(B4E!<TCGOVB
M/C==^'9+;P3X.W7OC352(U$/S&T0\%SZ'^76L"Q_9;\7ZM;0GQ'\2M5NBR O
M#&^-I(Y7=WQ73?LX_!.?P9:S^*O$Y^V^,M6_>S32?,8%;G8":]QKQ:6"ECKX
MC&WUVC=I)>=MV^IS1INK[]3[CY[L_P!BGP?&VZ\U;7+YNI\R]8 FO4_AK\*=
M!^%.F3V&@QS1P3/YC^=(7)/U-=C17I4,OPN&EST::3[]3>-&G!WB@HHHKT#4
M**** "O)_P!I+16U3X?O<07.I0WEC*MS%#IET('GQ_ V1\R^U>L5Y_\ ')K&
MS^'.K:A>W%W9BTBWK<6$8DG0Y ^13PQ]J .>_9<U!M5^'<][);:A:RS7TK.F
MHMF0M@#(]JQ/%7[4UO9_%/7? OAZPM=8U/3-)-Z6DO%BWW!<*L(![8.2W08Q
M72_LUW%_>?#YY[[4Y=422[D-NUU$(KB*/ PDRC@..X]Q70>(O@KX*\4:E=ZC
M?>'[,ZC=6;V$MY"@BE:%FW,NY<'.1G/6@"]\._%MQXMT65[^T^Q:I9S-:WD"
MG<JRJ 3M/<<CFOGO]D3XU:+!X>@\&_V9KS:E)K>HQ_:AI<GV,'[3(<^=]W&.
M]?2_A?POIW@W0[72-+A,-G;+L0.Y=C[LQY8^YKRC]CUBWP97)SC5]1 _\"I*
M /;:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XOXM?
M%+2_A+X1N=9U)\O@I;6Z\M-)CA0*\A^ ?PLU3QEK\GQ3\?(TVL7C;]-L9>5M
M(OX3CUQT]*RKZ+_AH;]I VDD?G>$_"(^9@<Q3S9SGZ@\5]2HBQHJ(H55& JC
M  ]*^?I1_M+$.M/^'3=HKNUO)^FR^\Y(KVT^9_"MO7N.HHHKZ ZPHHHH ***
M* "BBB@ KS/]HP(OPEUR6::6Q@AB\R34K?F6R (/G*O\1'I7IE>;_'FZT<^!
MY;#5O%#^$6O76.WU*.#SF5P<XV$$-D<8- ')_LGZ'$G@VZ\0Q:MJ>L+J\QD^
MVWDG[J]Q@?:4BQ^[+="/]FO=*\C_ &>?#4&BZ7K%UI_CNZ\9Z9>7;/''-:K
MED^ &C10!M'0XQWKUR@ KQ']CS_DC0_[#&H_^E4E>W5XC^QY_P D:'_88U'_
M -*I* /;J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS7]H
M+XF)\+_AKJ6HI)MU&9?L]FH/S>8W ('< UZ57RQXED;]H#]I*UT)0L_A3PB?
M-N6'(>X[HW]/I7E9E7G2H^SI?'-\L?5]?DM3"M)QC:.[T/2OV8OAF_PZ^&ML
MU]'LUK56-]?'=N_>/S@'TQ_.O7:;&BQHJ*-JJ, #L*=7;AZ$<-1C1AM%6-(1
M4(J*Z!16=X@TN'6M%O;*X5VAFB966-RC'CL1R*^9M$L?%WP]M8=/T"UU2![Z
M\:*..21K@S1\YD9GSMV=L=:Z"SZJJO9ZA;:@LC6MQ'<+&YC<QL&VL.H/O7RK
M;^//B;_:WA?P]%%J&IZ?<>=;ZI>7D CE"KEDN$*]BWR8]J]Y^$_A/4?#&CW#
M:M]G:_NY/->2W)PP[9!Z$=\=: .YHHHH **** "O-?VAH86^%^J32PB<P!9$
MC6<03%@1_JI"/D?W^M>E5YC^T)#J<GP_NGL8[&>T0@WT5^<*8<_,0>Q% %7]
MFVXLK_P+<WUI93V+W5[)+<+<W8N9&DPH+%P/8<5ZQ7D'[,6DPZ/X!NH;.RM[
M736OY'M);>1G%Q&0N)#NY!)R,>U87Q*^-'BWP/X\U'1XET"33[C36FTZXFG8
M-!=!PH2X ^ZA!)W=.* /?*\1_8\_Y(T/^PQJ/_I5)7?_  O\57WBKPZTNI"W
M:_M9FMII[-MUO.P )>(]U.>OM7AG[(_Q U*V\)VN@CP;K#6,VM:BO]M#8;8?
MZ2YW'G(';I0!]14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1144]U!:[?.FCAW
M'"^8P7)]LT 2T4@(8 CD4M !115/4]9L-%MVFO[R"SB4;BTT@7C\:3:BKL#B
M_CG\2K?X6_#G4]6<;[IHS#:PJ<,\C#  ^G7\*Y?]E;X<S>"?ATFHZDPFUS7'
M^W74V,,0W**?< UYOXOU:W_:5^.VA^'])NQ?>$-!47MY)#]UI0>#GZ\5]71Q
MK#&J(H1%& JC  KP<,UCL9+$K6$/=CYO[3_3[SDA^\J.?1:+]1U%%<#XP^(3
MPW3:-H$?VW5W^0E.1%[_ %KZ&,7)V1TRDHJ[+_C;X@0>&56TM4^VZK+\L=NG
M.#ZFL)+[XE74:21V>G1@C/[PX/Y5K>"?AS%H,G]I:C*;[6)1N>63D(3U"UVU
M:<T8Z15R.64M6['G&SXCR+@G34SW&,BNH\(PZY%9R_V])$]R6^7R>@%;]%2Y
MW5K%*-G>X4445F6%%%% !7F_[0UF+_X3ZW!_94VM2,@,=C%+Y0E8$$!G_A7W
MKTBO,OVA/"[^(_ ,DUOI%[KM_I\RW-K86,YB>60< <'Y@,Y(/'% %3]FG6I]
M<^'0FN-$&@21W+Q?9%DW@8 Y!KK;_P"%/A#5-4U74;SP[87-]JMO]DOKB2(%
MKB+^XQ[BN;_9[\.ZOX9\%W-MKFCQZ/J+WDDKK%*9%ER!A^>GICVKT^@"AH.@
MZ=X7TBUTK2;.*PTZU3RX;:!=J1J.P%>0?L>_\D:7_L,:C_Z525[=7B/['G_)
M&A_V&-1_]*I* /;J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D9@JDDX Y)-4-?UZQ\,
MZ/=ZIJ4ZVUE:QF221S@ "OER/6/B%^U7?W*:/>GPG\/5E:)KB+(GN4!['^]]
M.*\[%8V.&:IQBY3EM%?F^R\S&I44-$KM]#O_ (I?M1:7X;OO^$?\(VS>*_%,
MQ*1VUG\T<;=,DCK@]JY/1_V>O&_Q6F_MWXF>)KBTN67=:Z9ICE([9NS<=/I7
ML/PP^"'A7X3V831K!&O6 \Z_F&Z:5N[$GH3[5W]<2P%7%OGQ\KKI!?"O7JW^
M!G[*536J_ET_X)\SK\%?C%X%D:;PS\0FUR-?]79ZL,(OHM);?&SXO> V>/QE
MX#.M!3S<:-]T?XU],TE7_9GL]<-6E#RO=?=*X_8<OP2:_'\SYCD^*'QF^+$P
MB\(>%D\*::1B2[U?AROJGO5O3_V1;CQ1<?:_B-XQU/Q-*2'2WBE,21G^[GN*
M^D0 HP!@4M"RJG4?-BINH_-Z?^ K0/8*6M1W_KL<WX+^'/ASX?6AM] TJWT\
M,H5WC7YY,=V/>NDHKE_'WC!/">CL\9#WTWR6\?<L>]>S3I1BE3IJR\C?2"\C
M#\=>++Z\U:+PSH+8OI>)Y@,^4O\ 0UO^#? ]GX1M3LS/?2<S7+\LS=\>@K/^
M&O@]]#LI-1O\R:O??O)F;DH#SM%=K71.27N1V(C&_O2"BBBL34**** "BBB@
M HHHH *\._:>U'5+31]-BT^\U*19)1OTG0KK[-J%QU^:-_0=UKW&O'?V@O#=
MSX@E\,$:'-J-E;WGF37]@Y6ZLN"-Z8ZCGI0!H_L[W6I7'@-UU/4YKZ>*Z=%M
M[R;SKNQ7C$%P_P#%(O<^XKU&O,/@#I<NB^&=3M)-%CT55U&5H@9?,GN8SC$T
MQSD2-WSZ5Z?0 5XC^QY_R1H?]AC4?_2J2O;J\1_8\_Y(T/\ L,:C_P"E4E '
MMU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,X9%!Z\_G7/V?QFM]0T3PQJ=OI4[IKD[P+ TT:RP[6*DE2<MR#TH ]'HHHH
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MP!]P=UYZUZ+7E_P+\.^*/"FE7^F:TFBQZ/'-NTJ'1@0D$) _=GUP<\^]>H4
M%>(_L>?\D:'_ &&-1_\ 2J2O;J\1_8\_Y(T/^PQJ/_I5)0![=1110 4444 %
M%%% !1161KWB[1?#%I-<ZIJEK8Q1*7;SI5!P/;.34RE&"O)V0FTMS7ILDBQ*
M6=E11U9C@5\[>)?VOK/4KI=-^'FAW?BZ_E;9'=1QL+96]&;M63'\%OBA\9VC
MNOB!XD?P_I3/O_L;36*NGMN''YUXTLTA4ER82#J/R^'YR>GW7.=UT]*:YOR^
M\^DVUW3E4DW]L .3^]7_ !J'_A*-(/\ S$[3_O\ +_C7AX_8L\);@3K.N,O=
M3=G!JQ_PQEX)_P"?O5?_  +:J]OF/_/B/_@?_P!J'-6_E7WG5_%G2?#'Q0T:
MTTNZ\26=D+6\CN@ZRJ6#)TQSP?>O-=6^!GAO4--MK*/Q]!%&FJ?VE*S%&:4@
M8"D[OUKIH_V./ 2J RWTC=V:Y;)_6G?\,=> /^>5[_X$M_C2]MF7_/J/_@3_
M ,@YJW\J^\Y/1?V>_"=CXYT_7V\=K<M#J*Z@]F95\MI%^X%&?EZ\^M>V?V/X
M&;4-.O#'I376GNTEDY9,V[-]XISP3GFO/9/V./ 3*0JW\;?WEN6R/UJ#_AC+
MP3_S]ZMG_K[:G[;,>M&/_@7_ -J'-6_E7WGM_P#;>G_\_P!;_P#?U?\ &HY/
M$6E0L ^HVJD\\S+_ (UX8?V+/"98D:UK@'I]K-20_L7^#E4B74M8G/8O=MQ1
M[?,?^?$?_ _^ '-6_E_$]?NOB%X9LEW3Z[81+G;EKA1SZ=:PM<^/'@'PZ"+O
MQ1I_F 9\J*4._P"0KBH_V.?A]@"6WNYP.OF7#')]:V]"_9:^&F@SK<1^&K>Y
MNEZ3W)+M^II<^9RT4(+YM_H@O7?1'(:C^V?X<O;A[3PIHNK>);U.&CBMR@]L
M'O6>OQ6^.'C"8R:'X$BT&!?X-4/+>X->^V6F>'_#JJEK;:?IX4<;%1#^=5+K
MXC>'+*3RYM5A5O8DTU@<;6_BUWZ127XN[)Y)OXY_=H>)?\)!^T;_ - /0_\
MOH4?\)#^T;_T ]#_ .^A7M,?Q/\ #$C!5U:')^M3?\+$\._]!6#\ZK^RZO\
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MG&Y9(V#*P]01UH DHHKG]&\=:/KWBC7/#]G<&35-%\K[;$4($?F*63GOD T
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? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>formdrs_008.jpg
<TEXT>
begin 644 formdrs_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %  X0# 2(  A$! Q$!_\0
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M24444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1_P\@\.?]$W^/?\ X;?5?_C5'_#R#PY_T3?X]_\ AM]5_P#C5 !_PJK]IO\
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M (;NY_\ EG1_P\@\.?\ 1-_CW_X;?5?_ (U1_P /(/#G_1-_CW_X;?5?_C5
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M .&WU7_XU1_P\@\.?]$W^/?_ (;?5?\ XU0 ?\*J_:;_ .BP_"K_ ,-W<_\
MRSH_X55^TW_T6'X5?^&[N?\ Y9T?\/(/#G_1-_CW_P"&WU7_ .-4?\/(/#G_
M $3?X]_^&WU7_P"-4 '_  JK]IO_ *+#\*O_  W=S_\ +.C_ (55^TW_ -%A
M^%7_ (;NY_\ EG1_P\@\.?\ 1-_CW_X;?5?_ (U1_P /(/#G_1-_CW_X;?5?
M_C5 !_PJK]IO_HL/PJ_\-W<__+.C_A57[3?_ $6'X5?^&[N?_EG1_P /(/#G
M_1-_CW_X;?5?_C5'_#R#PY_T3?X]_P#AM]5_^-4 '_"JOVF_^BP_"K_PW=S_
M /+.C_A57[3?_18?A5_X;NY_^6='_#R#PY_T3?X]_P#AM]5_^-4?\/(/#G_1
M-_CW_P"&WU7_ .-4 '_"JOVF_P#HL/PJ_P##=W/_ ,LZ/^%5?M-_]%A^%7_A
MN[G_ .6='_#R#PY_T3?X]_\ AM]5_P#C5'_#R#PY_P!$W^/?_AM]5_\ C5 !
M_P *J_:;_P"BP_"K_P -W<__ "SH_P"%5?M-_P#18?A5_P"&[N?_ )9T?\/(
M/#G_ $3?X]_^&WU7_P"-4?\ #R#PY_T3?X]_^&WU7_XU0 ?\*J_:;_Z+#\*O
M_#=W/_RSH_X55^TW_P!%A^%7_AN[G_Y9T?\ #R#PY_T3?X]_^&WU7_XU1_P\
M@\.?]$W^/?\ X;?5?_C5 !_PJK]IO_HL/PJ_\-W<_P#RSH_X55^TW_T6'X5?
M^&[N?_EG1_P\@\.?]$W^/?\ X;?5?_C5'_#R#PY_T3?X]_\ AM]5_P#C5 !_
MPJK]IO\ Z+#\*O\ PW=S_P#+.C_A57[3?_18?A5_X;NY_P#EG1_P\@\.?]$W
M^/?_ (;?5?\ XU1_P\@\.?\ 1-_CW_X;?5?_ (U0 ?\ "JOVF_\ HL/PJ_\
M#=W/_P LZ/\ A57[3?\ T6'X5?\ AN[G_P"6='_#R#PY_P!$W^/?_AM]5_\
MC5'_  \@\.?]$W^/?_AM]5_^-4 '_"JOVF_^BP_"K_PW=S_\LZ/^%5?M-_\
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M%7_AN[G_ .6='_#R#PY_T3?X]_\ AM]5_P#C5'_#R#PY_P!$W^/?_AM]5_\
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MX3?M'>)_#-EJ#?'[PI$UU'O*+\-HR%Y/&3>UI?\ "B/VC/\ HX+PK_X;6/\
M^3: /H:BOGG_ (41^T9_T<%X5_\ #:Q__)M'_"B/VC/^C@O"O_AM8_\ Y-H
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M"?2O /@)_P %'?A[^TU^UAXW^%/@JZDUVZ\ :7;7^IZQ;D'3VEFFEB-O$_\
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M_P#T9<T 5_#_ /Q]>,?^O\_^D=O5_P"'/_)/M"_[!\'_ *+6J'A__CZ\8_\
M7^?_ $CMZO\ PY_Y)]H7_8/@_P#1:T ;-%%% !1110!SOAG_ )'[Q-_O6O\
MZ*KHJYWPS_R/WB;_ 'K7_P!%5T5 !7/0?\E8NO\ L$P_^CI:Z&N>@_Y*Q=?]
M@F'_ -'2T =#7.^-_P#D-^&O^PE_[0EKHJYWQO\ \AOPU_V$O_:$M '15SW@
MS_D9?%'_ &$$_P#2:&NAKGO!G_(R^*/^P@G_ *30T 'B_P#Y&KPS_P!?DO\
MZ(DI?BI_R3O5O^N!_F*3Q?\ \C5X9_Z_)?\ T1)2_%3_ ))WJW_7 _S% $?Q
M7_Y)GJO_ %[_ -13OB-_Q[:/_P!A>U_]&4WXK_\ ),]5_P"O?^HIWQ&_X]M'
M_P"PO:_^C* #Q/\ \CYX8_W[G_T2:Z*N=\3_ /(^>&/]^Y_]$FNBH **** "
MN>^)_P#R*H_Z_;3_ -*(ZZ&N>^)__(JC_K]M/_2B.@#H:*** ,#XK?\ ),?$
M/_8.G_\ 1;5NP?ZA/]T5A?%;_DF/B'_L'3_^BVK=@_U"?[HH =7._"S_ )%
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M0USTO_)6(/\ L$R?^CDKH: .>\1_\C]X;_[>O_18KH:Y[Q'_ ,C]X;_[>O\
MT6*Z&@#GO"__ "/'B?\ Z[6__HA:;X__ .0AX:_["Z?^B)J=X7_Y'CQ/_P!=
MK?\ ]$+3?'__ "$/#7_873_T1-0!9^)/_).M>_[!UQ_Z+:H/&W_)*M5_[!<O
M_HHU/\2?^2=:]_V#KC_T6U0>-O\ DE6J_P#8+E_]%&@"OX\_Y$:R_P"OJQ_]
M'QU8\:?\C%X8_P"P@W_I/+5?QY_R(UE_U]6/_H^.K'C3_D8O#'_80;_TGEH
MZ&BBB@ HHHH YWXL_P#)/-2_W4_]#6NBKG?BS_R3S4O]U/\ T-:Z*@ KR_\
M;>_Y,P^+?_8FZO\ ^D4U>H5Y?^V]_P F8?%O_L3=7_\ 2*:@#9_9E_Y-N^'W
M_8M:=_Z2QUV]<1^S+_R;=\/O^Q:T[_TECKMZ "BBB@ HHHH **** "N-_:,_
MY-[\=_\ 8NZA_P"DTE=E7&_M&?\ )O?CO_L7=0_])I* .>_89_Y,F^#O_8D:
M+_Z005ZG7EG[#/\ R9-\'?\ L2-%_P#2""O4Z "BBB@ HHHH **** "BBB@
MHHHH **** /GW_@I5_R07PM_V4WP/_ZE&F5]!5\^_P#!2K_D@OA;_LIO@?\
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M/6'"/$__  LJYYT'[1_9D6>)MFWS9,>^<Y_2N_KGH/\ DK%U_P!@F'_T=+0
MW'BWU\._E/6'XN'B;^UO#_FG0-_]H?NMHFQN\F7K[8S^E=_7.^-_^0WX:_["
M7_M"6@!,>+?7P[^4]8?A7_A)_P"WO$7E'0=_VY/-W";&[[/#T]L8_'-=_7/>
M#/\ D9?%'_803_TFAH P?$X\3_\ "1^'O,.@>9]JD\O FQGR7SG\,_C2_$<>
M)_\ A!=4\\Z#Y/D'=L$V[''3/%;OB_\ Y&KPS_U^2_\ HB2E^*G_ "3O5O\
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MS6X!XLP.?#OY3T[XL_\ ).M5_P"N0_\ 0A70I]P?2@#S_P ##Q-NUKR3H/\
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M]]>F:WB/%N>OAW\IZ7XL_P#)/-2_W4_]#6NBH YS'BWU\._E/7F7[:8\4_\
M#'/Q8\T^'_*_X0[5]VT39Q]BFSCWKW"O+_VWO^3,/BW_ -B;J_\ Z134 ;/[
M,O\ R;=\/O\ L6M._P#26.NWKB/V9?\ DV[X??\ 8M:=_P"DL==O0 4444 %
M%%% !1110 5QO[1G_)O?CO\ [%W4/_2:2NRKC?VC/^3>_'?_ &+NH?\ I-)0
M!SW[#/\ R9-\'?\ L2-%_P#2""O4Z\L_89_Y,F^#O_8D:+_Z005ZG0 4444
M%%%% !1110 4444 %%%% !1110!\^_\ !2K_ )(+X6_[*;X'_P#4HTROH*OG
MW_@I5_R07PM_V4WP/_ZE&F5]!4 %%%% !1110 4444 !KEM.^-?A35OBWJ/@
M.UUW3KCQCI&GPZK?:3%+NN;2UF=TBDD ^Z&9&P#R<9QCFNH<94]N*^"_V2_V
M;_"G[.G_  6/^+NE>&+6]A37?AQI&J:E=7=]+=W=_=2ZA?!I9)I&+%L  <X
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M4/C&X'Q,N9?[ UO<=+B7R]L.\?O9.?\ 68QSZ]J .]KG?&__ "&_#7_82_\
M:$M._P"$YN?^A;\0?]\0?_':P?&'C"XGUCP\QT#7(_+U#< RPY?]S(,#$G7O
MSCH: .^KGO!G_(R^*/\ L()_Z30TO_"<W/\ T+?B#_OB#_X[6%X3\8W$.O\
MB-AH&N2&6^1BJK#F/_1XA@YDZ\9XSP10!N>+_P#D:O#/_7Y+_P"B)*7XJ?\
M).]6_P"N!_F*PO%'C"XF\2>'7.@:XACNI"%98<O^Y<8'[SKWYQTI?B3XQN+K
MP)JD9T#7(0T!&]UAVKR.3B0F@#8^*_\ R3/5?^O?^HIWQ&_X]M'_ .PO:_\
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MZGKOAJ-O#VLW)$+"6_LF-M<D,9!N7S8WPV!D<UZ9_P )S<_]"WX@_P"^(/\
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M44 <_P#%7_DG6L?]>S5OQ_ZM?I6!\5?^2=:Q_P!>S5OQ_P"K7Z4 +7._%?\
MY$#4/I'_ .C%KHJYWXK_ /)/]0^D?_HQ: .BHHHH YWX3?\ )/--_P!U_P#T
M-J/BG_R)<W_7>W_]'I1\)O\ DGFF_P"Z_P#Z&U+\4_\ D2YO^N]O_P"CTH Z
M&N=^&?\ R!K[_L*7G_H]ZZ*N=^&?_(&OO^PI>?\ H]Z %\'_ /(U>*/^OZ+_
M -)HJ73?^2GZO_V#K/\ ]&7%)X/_ .1J\4?]?T7_ *314NF_\E/U?_L'6?\
MZ,N: *_A_P#X^O&/_7^?_2.WJ_\ #G_DGVA?]@^#_P!%K5#P_P#\?7C'_K_/
M_I';U?\ AS_R3[0O^P?!_P"BUH V:*** "BBB@#G?#/_ "/WB;_>M?\ T571
M5SOAG_D?O$W^]:_^BJZ*@ KGH/\ DK%U_P!@F'_T=+70UST'_)6+K_L$P_\
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MN[_]*)*Z*N=^%G_(H#_K[N__ $HDH /BS_R3K5?^N0_]"%="GW!]*Y[XL_\
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MR4W7O^O*R_\ 0KBOE7]@72OBAH/C36_'WQQ^,V@WU]X@M!!;>$;/58#8:/\
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MOJF];KFLM-=-&DNMKG4H*=;V4M;632TM[M]^^J;?38_0S_@J9_P4&\9^%O\
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M_ ^E_#G08/%OQL^,FJP>&?!6FW"Y@^UR!-]Q(H(W*A= %R 6D7)"@U\J0?\
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MTE=E7&_M&?\ )O?CO_L7=0_])I* .>_89_Y,F^#O_8D:+_Z005ZG7EG[#/\
MR9-\'?\ L2-%_P#2""O4Z "BBB@ HHHH **** "BBB@ HHHH **** /GW_@I
M5_R07PM_V4WP/_ZE&F5ZQ\<?'=_\+_@_XE\1:7HUQXAU'1=.FO+?38,^9>NB
M$B,8!/)'85Y/_P %*O\ D@OA;_LIO@?_ -2C3*]Q\6V^J77AJ^CT2XL[35G@
M<6DUW$98(Y<?*74$$KGJ 145$W!I%TVE-.2NKGYX? 75+OX__M#6TGAKQ_\
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M^O\ C6M_9UO_ ,\(?^^!1_9UO_SPA_[X%069/_"S/#W_ $&M-_[_ *_XT?\
M"S/#W_0:TW_O^O\ C6M_9UO_ ,\(?^^!1_9UO_SPA_[X% '&_$OX@Z'>^ =6
MBAU?3Y)'MV"JLZDL?:MM/B7X>" ?VUIO3_GX7_&J_P 4K&"/X>:N5AB!%LW(
M05O1Z?;F-?W$/3^X* ,K_A9GA[_H-:;_ -_U_P :P?B;\0=#OO U_%#JVGR2
M,$PJSJ2?WBUVG]G6_P#SPA_[X%<]\5+*&/P#J!6&)3B/D(/^>BT 6_\ A9GA
M[_H-:;_X$+_C1_PLOP]_T&M-_P# A?\ &M;^S[<_\L(?^^!1_9UO_P \(?\
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M+.]\(MXGB@UKR;TQ/'#<6]Q;1X,;"3FXF@'RY R"PV@D?G?^UI_P1SN?V?\
MQ%_PD_@"[L?BKX*M)C-=>'Y+W[/J\<.>4!B(,H Z/'AL@?NV&:_4_P#;:T6)
M/V:?$>K)%'N\)+#XG$0C'^EG3IDO?(S_  ^9Y&S=SC=G!QBO3]+%OJ6GP70@
MA'GQK*,*#C(!Z]^M>YPSQ=F.2XFI#"SO3E9N#^%Z.+VLXO1:II^IS\7\(9;G
MN3X2MBH?O*<JL%-6YEK"K&][J2]Z6C3C;31WO^4G[%/[*O[&'[95C=V<.D>+
MO"7B_2HO-U+0M5UN59( &"LT<F LB!B ?NL"1E1D9]HL?^",O[+TOBK4+:1=
M4%G!;P/"W_"0OR[&7?SWX5..U?<&G_";PMI/C2]\26OAS0K;Q#J,0@N]2BL8
MDN[F,'(1Y0NY@/0FH='LH6^)6NJ88BHLK+ V#CYKBO6S+C7,JE=SP6(JP@[>
MZZG-9]4G975]KZVW/E\NX,RVG04,;AZ4YJ_O*FHW71M7=G;>VE]CXX_X<K_L
MJ>NJ?^%$]'_#E?\ 94]=4_\ "B>ON?\ LZW_ .>$/_? H_LZW_YX0_\ ? KA
M_P!<<\_Z"ZG_ ($SM_U0R/\ Z!*?_@"/@5_^",G[+P\81VH75/L+63RLW_"0
MO_K!(H S]">*T_\ ARO^RIZZI_X43U]CRV4/_"U8%\F+;_9,AQL&/]<E=!_9
MUO\ \\(?^^!1_KCGO_074_\  F/_ %0R/_H$I_\ @"/@75/^",O[+\'B/2X(
M5U1K6X\[[0?^$A<XVH"O/;FM&;_@BM^RP]M)''/K%NSJ5$D?B-MR'U&<C(]P
M1[5]D^(K*%?'GAP"&( _:LC8.?W8KH/[.M_^>$/_ 'P*/]<<]_Z"ZG_@3%_J
MAD?_ $!T_P#P!'Y#_$#_ (-V_"?C7QCJUKX>_:1\1>$O#R/%&H72[635-C .
M_E7L<L05B,ID1<<Y#9Q7TS^P%_P2P_9Y_P""6&EZ<OPS/]H>)-6U&-=9\3ZU
M?1W>JWL0BE.PNJJD46[!V1HH)P6W'FOK_P ,64+>-?$RF&(A9K? V#C]PM-\
M>V4*:AX;Q#$,ZN@.$'/[F:O,Q^;XW&S53&593DE:\G=VO>U[+2_0]+ 91@L#
M!TL'2C3BW>T597VO:[UMU/@'_@JU_P $2?@Y_P % ?B:_P 7M%^)&O\ PH^+
M=AI_V=]=\-W2'^U(XT*J)HMR,9!'F,/'(A*D!MX  \EMO^#9?X$S_!?Q?-\1
M/C#X]^,7Q%U+P[<Z?I/B'Q)JGGIX>E:-O+GM;3S"2ZG;\LLSCCC:>:_6#XCV
M,"?#W7B(8@1IUP00@X_=M4/C6RA7X6ZJPAB#?V7+SL&?]4:\Q02BXK;7\=[=
MOE8]-S;?,]_\MK]_F?$?QC_X)I>'OB)_P1BTG]D[4/BX)[>PM=,TI/$T>EQ"
MX\BWOXIH\VOG;<K&BH?WG1<^U?2/P3\*^'OV=O@A\(/A_:^)[/6;?X?Z;9Z%
M]O<I$UREK8- )F0,0A;8#C) +8R:]$\=6<*>"+,B&($W5ED[!_SWCJ?QE90K
MXA\,@0Q#=J#9^0<_Z/+6TJLY.3;^)IOS:5K_ '&:BDHQ6T;I>5W=_B?*?[(?
M_!//PA^R;_P4"^.?QZM_B?#KEW\;71YM&DM(H(])VR"3"S"1C)TQRJUH?\%<
M?V$?"/\ P5>_9MTCX=7_ ,2H?!,&D^([7Q"+ZVMH[YY6@CFC$6QI$ !\XG=G
MC:.#FOKS^SK?_GA#_P!\"C^SK?\ YX0_]\"HN[07\G+;RY7S+[GJ:<\N>4^L
MKW^:L_PT/&?VHO@/\'OVT/V?-2^&7Q+CT7Q+X5U6%(Y89+@1RPR(/DGAD4[H
MI5/*LIR.1R"0?S)D_P"#5WP!;7,GA[3_ -KGXPV/PGE)1_"*W\1!B89:/S X
M@P6YYMCQP03S7[.?V=;_ //"'_O@4?V=;_\ /"'_ +X%3RKF<NKW\_5;$K2*
M@MEMY>A\S_ +]D[X-_L)_L:7/PI^%:V.D:"D3F1WNA<7E_<2E1)<SR'!DE(
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M_P"3>_'?_8NZA_Z324 <]^PS_P F3?!W_L2-%_\ 2""O4Z\L_89_Y,F^#O\
MV)&B_P#I!!7J= !1110 4444 %%%% !1110 4444 %%%% 'S[_P4J_Y(+X6_
M[*;X'_\ 4HTROH(G KY]_P""E7_)!?"W_93? _\ ZE&F5]!'I0!\\?&7_@HS
MX7^$WQTTOP);Z#XC\2W<^LV.@:K?Z<D0L]!N[W_CUBF>1UW,X#$K&&*@ L!N
M&?0_V:OVDM%_:<\$WVK:3:ZEIESHNJ7&B:MINH1>5=Z9>P;?,AD4$C.&1@02
M"K@@X-?%_P"W[\(OAIX2_:9EUBQ_:)\)?"/Q9J>K:5XMUK1-=T^/5H;N[L R
MV5RL0FA>'*EU<%B) %P%VDGZ0_X)N^$? 7ACX):M<^!O'<7Q+F\0:_<ZMXC\
M1H4QJ.K2I%YS!$ 6-0HB"H,[5"@ECDE4/>I<TM_UNOE:UU]W6X5DXS2CL[?=
M9_CMMY]#Z$HHHI@%%%% !112.<*<<FDW;4!:^?/C-_RDL^ W_8F^-/\ T=H%
M?&-S^WE\4[?QBNIGXB:G_P +C_X64OAUO@VME9OHXT4W)A$VX0_:-QM<7/VC
M[5Y>_C9SMK[,^,1+?\%*/@*2,'_A#?&>1G./WV@4X>]2C56S_P HR]'I)7ML
M[IZH)>[4=-[J_P"#<?EJM+[JS6C/H6BBB@ HHHH Y_XJ_P#).M8_Z]FK?C_U
M:_2L#XJ_\DZUC_KV:M^/_5K]* %KG?BO_P D_P!0^D?_ *,6NBKG?BO_ ,B!
MJ'TC_P#1BT =%1110!SOPF_Y)YIO^Z__ *&U+\4_^1+F_P"N]O\ ^CTI/A,,
M?#W3?]U__0VI?BG_ ,B7-_UWM_\ T>E '0USOPS_ .0-??\ 84O/_1[UT5<[
M\,QC1K[_ +"EY_Z/>@!?!_\ R-7BC_K^B_\ 2:*ETW_DI^K_ /8.L_\ T9<T
MGA#_ )&KQ1_U_1?^DT5+IO\ R4_5_P#L'6?_ *,N: *_A_\ X^O&/_7^?_2.
MWJ_\.?\ DGVA?]@^#_T6M4/#X_TKQC_U_G_TCMZO_#G_ ))]H7_8/@_]%K0!
MLT444 %%%% '.^&?^1^\3?[UK_Z*KHJYWPR/^*^\3?[UK_Z*KHJ "N>@_P"2
ML77_ &"8?_1TM=#7/0?\E7NO^P3#_P"CI: .AKG?&_\ R&_#7_82_P#:$M=%
M7.^-Q_Q._#7_ &$O_:$M '15SW@S_D9?%'_803_TFAKH:Y[P:/\ BI/%'_80
M3_TFAH /%_\ R-7AG_K\E_\ 1$E+\5/^2=ZM_P!<#_,4GBX9\5>&?^OR7_T1
M)2_%3_DGFK?]<#_,4 1_%?\ Y)GJO_7O_44[XC?\>VC_ /87M?\ T93?BO\
M\DSU7_KW_J*=\1O^/;1_^PO:_P#HR@!/$YQX\\,?[]S_ .B37\^?Q[_X*&?$
MCXN?\' 'B_XX?#3]GGQW^TEX9^ 44O@7P_::!!>-::7<JLL<EV\L%K.-S2/=
ME05&05(/RBOV?_X*C?$KQU\)?V6?$6L_#'PQKOB_XAC2KVS\/:=I%L;BZ-Y/
M#Y,<P0?PQ%_,/LE>4?\ !N_^P1J7[ 7_  34\,Z-XHTNYTGQ]XQNIO$WB>"Z
MCVW4%S.0J0R=3NCA2($'HV[U-*BFZKJWMR+3SE*Z_"/-JMFUU*J-*DH6OSO7
MRC&S_&7*K=4F?D/_ ,%D/V_?VE?VQ=+^&_Q-U3]BOXM?!#7/@-K'_"16WC&[
MM=2GM;6 ,C-'.9+"!4C\R.)MYDP,,,?,37[O_"O]J31/VUO^";%O\4_#[+_9
MOC;P1<:CY0;)M9C:R+- W^U'*'0^Z&O7?B_\+M'^-_PJ\2>#?$-L+S0O%6FW
M&DW\) _>03QM&X&<X.&.#V.*_+#_ (()_ ?X[?L?_L_?M%_LW?$?P'XM@T'P
MM<:G<>!=?FLF%AK<,RRPR16\G1M[K',@[^>_3&*SJ-/#5\/;[,IKS=G&2]6N
M5I=;/J5%-5J5:^TE%^ETXOT3NGVOV/A__@A3^P?^VM^T-^P9:^(O@3^TWIGP
MK\!-KM];IH,\4K.ERA3S9<K X^?*_P 7:OJWX@_\&_?[57[4F@6VD?M.?MD:
MQXL\ 0:E:/<:!H5O+C45,H4[RXBC5@6!5GCE QG&0*^D_P#@U\_9O\>_LK_\
M$M[3PI\1_"6N>"O$B>*=3NSINK6S6]P(9#%LDV'G:V#@^U?>/Q/&?"H_Z_;3
M_P!*(Z[<0HJIIKMOKTC^3^[Y''A7)TM='>6VGVI?FO\ /J>*?M'? [PQ^S3_
M ,$J_B+X"\&:9#HWA;PG\-]6T[3K./D11)83 $GJS$Y9F/+,Q)Y-?,W_  :;
M_P#*%7P'_P!AG6?_ $NEK[5_;<\+:EXY_8U^+&BZ-8W.IZOJ_@_5K*RL[==T
MMU-)9RI'&@[LS$ #U-?+7_!M9^S]XV_9C_X)-^#?"'Q"\+ZSX.\3V6JZK-/I
MFJ6YM[F))+R1T8H>0&4@CV-849-U<1*;U<8?-\\FS>K%*E1C'I*7R7(D?:WQ
M6_Y)CXA_[!T__HMJW8/]0G^Z*POBL,_#+Q#_ -@Z?_T6U;L'$*?[HI#'5SOP
ML_Y% ?\ 7W=_^E$E=%7._"T8\(C_ *^[O_THDH /BS_R3K5?^N0_]"%="GW!
M]*Y[XL_\DZU7_KD/_0A70I]T?2@#G?AW][7O^PO/_)*\@_;"3^U_A_XHT& J
MVJ>)]9T33=-B8X$]QY\4NTMT7Y(I#DX'R_2O7_AW][7O^PO/_)*\B^,Z_P#"
M4_M.^"/#(R@DUZ/Q!),@W-%]ALV94*]ED,I7=VV\9KDQVM"4?YK+[VE^K/H.
M%7RYK1K_ //OFJ?^"X3G]UXQNMVFTM3UWPK_ ,CUXH_ZZ6W_ *(6E\+?\COX
MF_ZZV_\ Z)%)X5_Y'KQ1_P!=+;_T0M+X7_Y'?Q-_UUM__1(KK/GP^$O_ "3C
M2/\ K@/YFNBKG?A,,?#C2/\ K@/YFNBH CN[<75M)&>-ZE<^F1BO)_V()S9_
MLZZ1H3 E_!T]SX:,A/S7/V*9[<3%?X#(L8?;DXW=2.:]</0UY!^SYG2?CE\:
M+"Y'V>\O/$EKJT$#\/+9R:590)<*.\;36UP@;INA<=C7)5]VO3EWNOPO^:/H
M,O\ WF58NB_LNG47JI.F_P#R6:N]E9=[GK]<]HW_ "4W7O\ KRLO_0KBNAKG
MM&'_ !<S7O\ KRLO_0KBNL^?.AHHHH YZ7_DK$'_ &"9/_1R5T-<]+_R5>#_
M +!,G_HY*Z&@#GO$?_(_>&_^WK_T6*Z&N>\1_P#(_>&_^WK_ -%BNAH Y[PO
M_P CQXG_ .NUO_Z(6F^/_P#D(>&O^PNG_HB:G>%_^1W\3_\ 7:W_ /1"TWQ_
M_P A#PU_V%T_]$34 6?B3_R3K7O^P=<?^BVJ#QM_R2K5?^P7+_Z*-3_$D9^'
M>O?]@ZX_]%M4'C4?\6JU7_L%R_\ HHT 5_'G_(C67_7U8_\ H^.K'C3_ )&+
MPQ_V$&_])Y:K^/ 3X'LN/^7JQ_\ 1\=6/&8_XJ'PQ_V$&_\ 2>6@#H:*** "
MBBB@#G?BS_R3S4O]U/\ T-:Z*N=^+(S\/=2_W4_]#6NBH *\O_;>_P"3,/BW
M_P!B;J__ *135ZA7E_[;PS^QC\6_^Q-U?_TBFH V?V9?^3;OA]_V+6G?^DL=
M=O7$?LR_\FW?#[_L6M._])8Z[>@ HHHH **** "BBB@ KC?VC/\ DWOQW_V+
MNH?^DTE=E7&_M&?\F]^._P#L7=0_])I* .>_89_Y,F^#O_8D:+_Z005ZG7EG
M[#/_ "9-\'?^Q(T7_P!((*]3H **** "BBB@ HHHH **** "BBB@ HHHH ^?
M?^"E7_)!?"W_ &4WP/\ ^I1IE?01Z&OGW_@I5_R07PM_V4WP/_ZE&F5]!'D4
M ?!G@+_A9EK_ ,%%OVBW^$7A?X?WMK(^B?VY)XWU2[L9YKW[+)A[0V]O.6MO
M+VCYPF'#8SDU]?? N7Q[+X1D/Q$TSP7I.N_:6"0^&+^XO;,PX7:Q>>"%]^=V
M1LQ@#D\X^7OVF?\ @GIK_P 4/VD?$/CC1?AQ\+=1NM9A@MWUB_\ B%XET;4[
MN*- %CECLHS$JJ2VU58CG/4FNP_X),^+&\0? WQ9I]UX9TSP?K7A;QA?Z'JV
MD67B?4/$*6MQ"D/)N;X"3YXVC<*ORA6'<M1A]:*@]XQ7_I36GWKO;TLQXC^(
MYK9O_P!M6_\ X"^U_70^IJ***!!1110 5!J5H;_3KB!97A::-HQ(GWHR1C</
M<=:GHJ914DXOJ--IW1^:5A^PE\8;']C\_LUM\/-&FW>*/[4_X6@VKVOV1(?[
M1^W_ &T0Y^V_;PH\K_5A=YSOV5]+_&KPQ#?_ /!0W]GVQO)+FX%OX*\8J9!.
M\4DC+)H"[BR$'GG//>OI:OGSXS?\I+/@-_V)OC3_ -':!5J3Y>7T^=HJ*\MD
MEHEW]):O+F]?QDY/\7U]#V+_ (5;HW]S4?\ P9W/_P <H_X5;HW]S4?_  9W
M/_QRNAHI#.>_X5;HW]S4?_!G<_\ QRC_ (5;HW]S4?\ P9W/_P <KH:* ."^
M)/PXTJQ\!ZK-&E]OCMV(W:A<,/R+X-;2?"W1B@.S4.G_ $$[G_XY3_BK_P D
MZUC_ *]FK?C_ -6OTH Y_P#X5;HW]S4?_!G<_P#QRL'XE_#G2K#P1?2QI?!U
M"8W:A<,/]8HZ%R*[^N=^*_\ R3_4/I'_ .C%H 7_ (5;HQ_@U'_P9W/_ ,<H
M_P"%6Z-_<U#_ ,&=S_\ '*Z&B@#@/AE\.=*U#P-I\TB7Q=U;.W4+A1]]NP<
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M=&_N:C_X,[G_ ..4GAG_ )'[Q-_O6O\ Z*KHJ .>_P"%6Z-_<U'_ ,&=S_\
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MX8=1V+D&G>//ASI5G!I1C6_!DU2V1LZA<-P7YZOP?<<UM?%?_DF>J_\ 7O\
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M=3V#@"M[_A5NC?W-1_\ !G<__'*3X2_\DXTC_K@/YFNBH YW_A5NC?W-1_\
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M/[,IS^S=\/O^Q:T[_P!)8Z[>N(_9E_Y-N^'W_8M:=_Z2QUV] !1110 4444
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M<_\ HDUT5<!XAT'7$\:>'E?Q 'D=[C8_V",>7^Z.>,\YK=_X1OQ!_P!#*O\
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M_1TM '0USOC?_D-^&O\ L)?^T):Z*N=\;_\ (;\-?]A+_P!H2T =%7/>#/\
MD9?%'_803_TFAKH:Y[P9_P C+XH_[""?^DT- !XO_P"1J\,_]?DO_HB2E^*G
M_).]6_ZX'^8I/%__ "-7AG_K\E_]$24OQ4_Y)WJW_7 _S% $?Q7_ .29ZK_U
M[_U%.^(W_'MH_P#V%[7_ -&4WXK_ /),]5_Z]_ZBG?$;_CVT?_L+VO\ Z,H
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M>7_MO?\ )F'Q;_[$W5__ $BFKU"O+_VWO^3,/BW_ -B;J_\ Z134 ;/[,O\
MR;=\/O\ L6M._P#26.NWKB/V9?\ DV[X??\ 8M:=_P"DL==O0 4444 %%%%
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M !(U"]OM:MO&HF%^G]FW,<5M&C6BF&&WM@-JY.YD(/+;J^V?CZM^_P#P4?\
M@+]@:T2Y_P"$/\9Y^T*S)CS= _ND'.<?K7T1<Z9;7L\,LT$,LMLQ>)W0,T1(
MP2I/0X)'%>!?&7_E)9\!O^Q-\:?^CM IQTIJGV;^YJ*M_P"2_CZWF2O4=3NE
M^#D_ULNR5NUO8O+\6?\ /;P]_P!^IO\ XJCR_%G_ #V\/?\ ?J;_ .*KHJ*!
MG.^7XL_Y[>'O^_4W_P 51Y?BS_GMX>_[]3?_ !5=%10!P7Q)C\3#P'JOVB70
MC#]G;=Y<4N['MEJVDC\6;!B;P]C'_/*;_P"*I_Q5_P"2=:Q_U[-6_'_JU^E
M'/>7XL_Y[>'O^_4W_P 56%\2H_$P\$7WVB70C%A,^7%*&^^N.K5W]<[\5_\
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MN_,4NW;YD^,?-UZY_"MSP?\ \C5XH_Z_HO\ TFBI=-_Y*?J__8.L_P#T9<T
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M$7QX^#GAKQG96VFZ9:>)M/BU"*TO;>99X%D7(5ANQG'<<'J.*O\ Q$B\3?\
M"-#SYM"V?:[;[D4N<^?'CJW3./PKN;*RATVTBM[>*.""!!'''&H5(U P% '
M '&*P_B?_P BJ/\ K]M/_2B.OR*M*$JDI4U:+;LKWLKNROULK:GZY2C-0BJC
MO*RN[6N[:NW2[OIT$,?BS/\ KO#W_?J;_P"*H\OQ9_SV\/?]^IO_ (JNBHK,
MT.#^),?B8?#W7/M$N@F#[!/YFR*7=MV'.,MC.*V8XO%?EKB;P]C Q^ZF_P#B
MJD^*W_),?$/_ &#I_P#T6U;L'^H3_=% '/B/Q9G_ %WA[_OU-_\ %5A_#J/Q
M,?# ^SRZ$(_M5S]^*7.?/DST;IG./:N^KG?A9_R* _Z^[O\ ]*)* ,+XF1^)
MAX$U/[1+H1A\H;O+BE#?>'3+5N;/%84?OO#V/^N4W_Q5+\6?^2=:K_UR'_H0
MIGQ=\6MX$^%7B'64N;>TFTW39YX99B BRK&?+SG@Y?:,=R0.]3.2C%R?0VP]
M"=:K&C3WDTEZMI+\6>*?L9QZMXZG^(/Q#T]](,GC/Q+<0K)/'*K-;63&VA!C
M#80@B7U)!!)[#U+0(_$W_"9^(-DNA>;FW\S,4NW_ %?&/F]*P?V(O":^"OV?
M-)L1;3V<[ 7EW#,&62.ZN(TGN RMRI\Z63Y3]WIVKN_#?_(^>)?K;?\ HJL,
M'!QHQYMVKOU>K_%GJ<1UX5<SKNG\$9.,?\,/W<5_X##YWOU,#PY'XE_X33Q'
MY<NA^;YEOYNZ*7;GR1C'S>E+X<C\2_\ "8>(?+ET+S?,@\W,4NW_ %0QCYO2
MMSPM_P CWXH_ZZVW_HA:7PM_R._B;_KK;_\ HD5TGBF%\,H_$Q\ Z5]GET(0
M^0-OF12EL9/7#5N^7XL_Y[>'O^_4W_Q5'PE_Y)QI'_7 ?S-=%0!SOE^+/^>W
MA[_OU-_\51Y?BS_GMX>_[]3?_%5T5% '@GQ_C\1_#[XE^ /'C3:&GV34?^$9
MOV2*9V>TU%D1$5"V"?MJ61+ AE17QD$J>]TF/Q+_ ,+!UD)+H7GBSM-^8I=I
M&9]N/FSGKG\*T/CUX#MOB?\ !GQ-H%W--;0:GI\T+30X\R$[20ZYXW @$'U%
M<W^S!X[N/BEX-T3Q/>0PV]WXC\):)J<\41)CB>:&21E7/. 6(&>:Y*?N5Y0Z
M22E\_A?Z,]_%_O\ *:&(?Q4I2I/_  M>UA]UZB\E8[#R_%G_ #V\/?\ ?J;_
M .*H\OQ9_P ]O#W_ 'ZF_P#BJZ*BNL\ X&6/Q-_PLJ'][H7VC^S),?NI=FWS
M4_VLYSBMSR_%G_/;P]_WZF_^*I9?^2L0?]@F3_T<E=#0!P&O1^)O^$VT#?+H
M7F_Z3Y>(I=O^K&<_-6[Y?BS_ )[>'O\ OU-_\52^(_\ D?O#?_;U_P"BQ70T
M <#X=C\3?\)?XA\N70O-\V#S=T4NW/DKC'S>E)XUC\2B^\/>=+H9/]JKY>R*
M7 ;R9NOS=,9_2M[PO_R/'B?_ *[6_P#Z(6F^/_\ D(>&O^PNG_HB:@#)\?Q^
M)QX%UKSY=!,/V&?S D4NXKY;9QEL9Q47BZ/Q*/AOJ?FRZ%]G_LV3=MBEW[?*
M.<?-C.*Z3XD_\DZU[_L'7'_HMJ@\;?\ )*M5_P"P7+_Z*- '.>,X_$G_  A]
MIYLNA^5]IL]NV*7=GSH]O?IG&?;-3>+(_$O]N^'O-FT+?]O;RML4N,^1+U^;
MIC/XXK5\>?\ (C67_7U8_P#H^.K'C3_D8O#'_80;_P!)Y: $\OQ9_P ]O#W_
M 'ZF_P#BJ/+\6?\ /;P]_P!^IO\ XJNBHH YWR_%G_/;P]_WZF_^*H\OQ9_S
MV\/?]^IO_BJZ*B@#@/B9'XF'@;4/M$NA&':N[RXI0WWUZ9:MTQ^+,_Z[P]_W
MZF_^*H^+/_)/-2_W4_\ 0UKHJ .=\OQ9_P ]O#W_ 'ZF_P#BJ\S_ &U(_%'_
M  QS\6/.FT#RO^$.U?=MBESC[%+G'S=:]NKR_P#;>_Y,P^+?_8FZO_Z134 ;
M/[,O_)MWP^_[%K3O_26.NWKB/V9?^3;OA]_V+6G?^DL==O0 4444 %%%% !1
M110 5QO[1G_)O?CO_L7=0_\ 2:2NRKC?VC/^3>_'?_8NZA_Z324 <]^PS_R9
M-\'?^Q(T7_T@@KU.O+/V&?\ DR;X._\ 8D:+_P"D$%>IT %%%% !1110 444
M4 %%%% !1110 4444 ?/O_!2K_D@OA;_ +*;X'_]2C3*^@J^??\ @I5_R07P
MM_V4WP/_ .I1IE?05 !1110 4444 %%%% !113+B(3P.C9VN"IP<'!]^U*3=
MG8#PJ#_@IG\#[GXSKX!C\=0-XADU0Z(C_P!F7HTQ[\(7^R#4/)^QF? /[L3;
MLC;C/%4_C+_RDL^ W_8F^-/_ $=H%?-GB?X0^'/VH+W1/V<_@/H@TKX4?#3Q
MC#X@\;>+I6DEACO;>Z^V&QL9G+/<7;W!'FN2%C7<-Q/RU]#_ !\U"31_^"CW
MP%DBLKO4#_PA_C-?+M]F_'FZ <_.RC''KGD54+.DI]7^*LO>2Z)OF2[I*6SU
M4KJJXK9?@[O1OJ^6S?\ *VX]-/I"BN>_X3J[_P"A8\1?E;?_ !ZC_A.KO_H6
M/$7Y6W_QZD,Z&BN>_P"$ZN_^A8\1?E;?_'J/^$ZN_P#H6/$7Y6W_ ,>H 7XJ
M_P#).M8_Z]FK?C_U:_2N#^)/C*ZNO >JQMX=UV%7MR"\@M]J^YQ*3^0K:3QS
M=A /^$8\0]/2V_\ CU '1USOQ7_Y)_J'TC_]&+2_\)U=_P#0L>(ORMO_ (]6
M#\2_&-U=^"+Z-O#NNP A,O(+?:/G7KB4G]* ._HKGO\ A.;O_H6/$/Y6W_QZ
MC_A.KO\ Z%CQ#^5M_P#'J $^$W_)/--_W7_]#:E^*?\ R)<W_7>W_P#1Z5@_
M#/QC=6G@;3XU\.Z[.JJV'C%OM;YV]90?TI?B1XRNKKPE,C>'==A!F@.^06^T
M8F0XXE)YZ?C0!WU<[\,_^0-??]A2\_\ 1[TI\<W8/_(L>(?RMO\ X]6%\/O&
M%U:Z3>!?#NNS!M1NFR@M\*3,QVG,HY'0]OK0!N^#_P#D:O%'_7]%_P"DT5+I
MO_)3]7_[!UG_ .C+FL'PMXQNH?$GB-QX=UV0R7D;%5%OF/\ T>(8.9>O&>,\
M$4MAXRNE^(NJ2_\ ".ZZ6>PM5,8%OO7#S\G][C!SQSV/X@&KX?\ ^/KQC_U_
MG_TCMZO_  Y_Y)]H7_8/@_\ 1:URNB>+[F.Y\5X\/:XWFWI9L"W_ '1^RP##
M?O>N!GC/!'?BKG@+QG=6W@?1HQX<UZ4)8PJ'06^U_P!VO(S*#@^X% ';T5SW
M_"=7?_0L>(ORMO\ X]1_PG5W_P!"QXB_*V_^/4 =#17/?\)U=_\ 0L>(ORMO
M_CU'_"=7?_0L>(ORMO\ X]0 GAG_ )'[Q-_O6O\ Z*KHJX#P_P",;J+QMXAD
M'AW77,AM\HHM]T>(N_[W'/L36]_PG5W_ -"QXB_*V_\ CU '0UST'_)6+K_L
M$P_^CI:/^$ZN_P#H6/$7Y6W_ ,>K"A\8W0^)ES+_ ,([KNXZ7$OEXM]X'FR'
M=_K<8YQUSP>* .^KG?&__(;\-?\ 82_]H2TO_"=7?_0L>(ORMO\ X]6%XO\
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M=>\8W4OC;0)#X=UU#']IPC"WW29C'3][CCW(K=_X3J[_ .A8\1?E;?\ QZ@
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M$N;_ *[V_P#Z/2D^$W_)/--_W7_]#:E^*?\ R)<W_7>W_P#1Z4 =#7._#/\
MY U]_P!A2\_]'O715SOPS_Y U]_V%+S_ -'O0 O@_P#Y&KQ1_P!?T7_I-%2Z
M;_R4_5_^P=9_^C+BD\'_ /(U>*/^OZ+_ -)HJ73?^2GZO_V#K/\ ]&7- %?P
M_P#\?/C'_K_/_I';U?\ AS_R3[0O^P?!_P"BUJAX?_X^O&/_ %_G_P!([>K_
M ,.?^2?:%_V#X/\ T6M &S1110 4444 <YX9_P"1^\3?[UK_ .BJZ.N=\,_\
MC]XF_P!ZU_\ 15=%0 5ST'_)6+K_ +!,/_HZ6NAKGH/^2L77_8)A_P#1TM '
M0USOC?\ Y#?AK_L)?^T):Z*N=\;_ /(;\-?]A+_VA+0!T5<]X,_Y&7Q1_P!A
M!/\ TFAKH3TKS?5OC)X9^$FI>)+G7]7MK(SZK'!!;C,MU=RFTB98HH4!DDD8
M*=J(I9L< U,YQ@N:3LC?#X:MB*BHT(.4GLDFV_DD_P"NJ.F\7_\ (U>&/^OR
M7_T1)67^T+X\T7X??"+6=0US5+'2;)8@GG74RQJSLP547)^9F8@!1R20!R:\
M[\3?$;Q]\7_$GA^7P;I5CX8T&>YD6WUCQ+9W*7S,(9-[+IS"*15(RJF5T8$9
MV%<;M;5?V8?"_@30-2UUTU#Q!XBBMGV:KK5X]]<0LXQ(8MYV0!\G<L2HI]
M*YO;SJ?P8Z=W=+Y=7^"\SV/[*PV%US*K:7_/NGRRGZ2E?DIOU<Y;^ZNN-\2-
M4\>_'+X?ZG<V$UY\-O"\<'R/<6,4VMZIR"LB!V:.VBZ962-Y&#$$1%>>ML_@
MGX?^$MC8S:;9QR:OJFL6<NJ:M.BO?:M*'_UL\N,LW)P.B@[5 4 5UGQ6'_%M
M-6/?[/\ U%.^(W_'MH__ &%[7_T95PP\4^>7O2[O]%LOE][.?%9S5J4GAJ"5
M*D_LQZ_XY?%/77WVTGJHQLA/$XQX\\,?[]S_ .B371USOB?_ )'SPQ_OW/\
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MHVFA:0_@WQ7#->WC>5!'<3-H3I$6Z!F$<A [[&]*^7_VQ/V-?&_P]\:?#/\
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MYE_B<OF?-7B7_@J)^SK=>(?#\B?&?X?LEO=2-(1JJ$*#"XR?3D@<^M+\1O\
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MZW7(!*I,X&?+_@SM))&:B4XI3D]HQ<GZ*WW[[+_A[C3E*UNK45ZO8[?X:_\
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MK_Q(UW5T\+:S8:3)+H$UAK#@>?<WHS#;F#?,721E;"*0#N&=_P"&OP_\5_\
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M6%MH>GZS;-::BUA8645J)YK=OGA,DJ2,JN VTJ2!FOJVBBDW[L8K:*27HO\
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MO^*GB#Q3XQL-$U#PEJFOV>MQ:G83Y6ZD"01J\1@C+3>9DJ/+P>M?0W_!5O\
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M]?Y8-^4G'WE_Z2_5L****984444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6?XL\,VOC7PKJ>C7RNUEJUI+97 1BK&.1
M"C $=#@GFM"B@#%^&_@'3OA3\.] \+Z0DL>D^&].M]*LEED,CK!!$L489CRQ
3VJ,D]:VJ** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>formdrs_009.jpg
<TEXT>
begin 644 formdrs_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &. X0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** $W TH.:^4O^"H'_!7[X9_\$F=/\"W'Q&T?QCK$
M?C^2_BT]?#]M!.839BW,IE\R5,9^TIC&>C5\D#_@\;_9?!.?!_QD'_<,LO\
MY*HL]!V/UDHK\F_^(QS]E\]/"'QD)_[!EE_\E4O_ !&-_LP?]"=\9?\ P667
M_P E4"/UCHK\FQ_P>._LOD_\BA\9/_!99?\ R52G_@\;_9?_ .A0^,G_ (++
M+_Y*H _6.BOR;_XC'/V8/^A/^,G_ (+++_Y*H_XC'/V8#T\'_&0GT_LRR_\
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M&/PCTF\\B3X??%QW]4L;(C_TIIFH_P#!QQ\(M+LQ/+\._B_Y9YXL;(D?^3-
M'Z"T5^<=E_P<]_ &[NQ _A;XI6TI;;B:PM!C\KBN]M/^"^/P=O[/SX/#_P 0
M)8\9RMI;?_'J /M^BOSAUS_@YT^!^B>(&TW_ (03XO75PIQF'3[+:?SN16TW
M_!QS\'(-,-W<^!OBO9Q8R!-960)_\F: /T$HK\Y8/^#FWX'W+LL?@;XN2;>Z
MV%D1_P"E-07O_!SS\$+'[WP_^,9Y_ATZS/\ [<T ?I#17YO#_@Y\^!HA:1O
M?Q@1$ZEM.LQ_[<U/I_\ P<X_ K5(@\'@SXL./3[!9Y_]** /T:HK\^[#_@X^
M^"=^!CPG\3XV/17LK0$_^3%.U/\ X.,O@_IVGRW \!_%FZ$0RR0V%F6_6XH
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M>?P9\);2S827%X8-I^7DYKQ_X?>"6\.^)#K%Y R)&I;:S;22?2N_^&ESX_\
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ML<,L;X$JM<1@J0/8T ?UE7Q_T^?_ *Z-_,U%4E\<ZA/_ -=&'ZFHZ "BBB@
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MM6650TL@)*%CD 4_2K)=1U!;UL/;D;=N<%:B\8^(X_ UA<7]RNRVLAG;'RS
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M110 4444 %%%% !1110 4444 %%%% !1110 C_</TK\X/^#K3/\ PYZ\1_\
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M444 %%%% !1110 4444 %%%% !1110 C_</TK\X/^#K/_E#UXD/_ %,>F?\
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M[LMNI:<90PPRL_4U\KI^WW+?_M#&RAL99-(DE"+?!SAO?TK[J\*:Q#=V%OJ
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB@G H _"_\
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M*%.!W-3^85B8D8X[]Z(+F-Y.AW#H.U2N)+]U208#D*F.IYK*U[L&M;&I\,O
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MN?VK/ >DZ8XDM[/Q%8H%'+'-S%F@#^Q*^.;^?_KHW_H1_P *CJ2]_P"/^?\
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ME ##<Q% 'RW?>']4LH)5M='D:R3YUDQDJ#SUJ+6OBI:^$_#BZE=+(R0?*R,
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M>)__ $#2J_&+]CG5U\/_ !=BOF@$_D)E0>S=C16JPI4G4ET1I3AS>[YGW?\
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MB?VW860\FV8--$5.2HZXJ*PM[WQ)I!@NY1)';_,"BYR*\C_:[UR/PGX.>**
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M/@<)R?\ A)+%B1W_ -)BH _N2O?^/^?_ *Z-_,U'4E[_ ,?\_P#UT;^9J.@
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MY:]_X_Y_^NC?S-1U)>_\?\__ %T;^9J.@ HHHH **** "BBB@ HHHH ****
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MUKK/V>IXI/VA? _R\_\ "0Z>>/\ KYCH _N3O?\ C_G_ .NC?S-1U)>_\?\
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MIFH);2;0-Y4YRQK5BU"74\X$;!1GKT]Z)73ON!;M;AY)UM3DQL>2W.?QKO\
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M?0E>*I_L[1-/\1])7 *%"1QR*\'&4^7,(M'B8S_?XH^R/'\G_"R]=AD"A+>
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M:!ING27"Y)D)ZUE>'/@MXNT6![6WTAXY[K.X=SFNU\,_$.'X>_:;MXF<@?*
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MU[?^SO,T'Q*TH*6*&'EQT7ZUY,GP=72X U[&R2*&V'MCM7L'[,UY!X5NI()
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M\I^\*^%_%GC#4O%FM333QR2K$V"IR0E9U(>Z["G!*+9ZQ\)/]+U/1E+!"'!
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MHH **** "BBB@ HHHH **** "BBB@ HHHH _"_\ X/9FV^%/V8S_ -/7B?\
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M#I[W,= ']Q-[_P ?\_\ UT;^9J.I+W_C_G_ZZ-_,U'0 4444 %%%% !1110
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M22YQ&V!QM Q7R;X(\!:E\4]7DO;L,^QM^YCC-?17PW8>$].%H+<B,8R#PPH
M]6N-;5;9@C@>O'-066O""0.S%@IZ5S,WBB/>V1C<1A1S6AI8^W0N2KD=0.E
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M 7[-Y,  R0J]:[/]FUPWQ^\"-L_YF.PX_P"WF*N4\Y# H7G*BNP_9V")\>_
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M#M0M?(FG\FZ'^LF5^2/:OB&X^(>KW"EH[Z903DKFDT_QUJT),PNI9"W!#=Z
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MHBY-K/%+&2"<VDZLIY&!ZBN<_P""E?Q'\0_#;0_@K)X?UG4-%EUKXK^'])U
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MM;3PCX=UGQ-I?VK3M;A2YCM[24HED!&=V]5X\[OUH ^W!Q2U\D?"W]LQ-/\
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M$&N1J3F2&"2TV;XF4D*SER.X':OLL+@_YYH*Y'04 ?$WPO\ V4OB]^R1XO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>formdrs_010.jpg
<TEXT>
begin 644 formdrs_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %- X0# 2(  A$! Q$!_\0
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M50 <' !UX^*/[41.!\'OV?21UQ\9=7X_\MB@_%#]J,8_XL[^S_S_ -5DU?\
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M_P +&_:G_P"B-_L__P#AY-7_ /F8H_X6-^U/_P!$;_9__P##R:O_ /,Q7O\
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M_:(^*7Q)\-2PZ-"W@^]7^SI+2\\Y[VR$DEM)+*IY1A=6URH7^[Y9_BH M?\
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M_P#YF*/^%C?M3_\ 1&_V?_\ P\FK_P#S,5[_ $4 > ?\+&_:G_Z(W^S_ /\
MAY-7_P#F8I#\2/VIAU^#?[/X_P"ZR:O_ /,Q7T!2,F[OB@#P#_A9/[4O_1'/
MV?O_  \FK_\ S,4G_"ROVI1_S1S]G[_P\FK_ /S,5[_Y?N:39QU]J /G]?BC
M^U&P&/@[^S_@\@_\+CU?!_\ +7HC^)_[4<N-OP=_9^.<X_XO)J_/_EL5X3XZ
M_P""H7CKPW/XZ;3/!V@>)+;PMKK:6B6TEW UGY>HM;-:SNPV-=RP1R3Q[#A
MHW## U[G^S3^V*_[1G[0?Q%T'3+"S/A'PYI^F7FB:O'(WFZN9WNH[@LAX5$D
MM]J$'D;CWH >_P 4?VHT<*WP=^  )Z _&/6/_F7I3\3?VI 3_P 6<_9_XX/_
M !>35_\ YF*S?C!^V=??#WX0?$W7(-/T9=5\,>(E\+Z!%>W#Q6M]=2K (6G?
M:2BAIBS;0<+&>]>:V'_!5Y]4\6ZI#:^'["32-0\"Z=KWA:5+H^9J>KW**?[.
MD.-JX:11D$G"2'' H ]<'Q-_:D) _P"%.? #)YP?C'J^?_48I/\ A:/[418#
M_A3W[/V6SC_B\FK\XZ_\RQ5;6/VL_$%O_P $WX/C%:Z%IDWB>\\)VNM0Z.\[
MI9_:IE3;&9" XCWN!NQG SCM7#>!/^"K6BZEI-]JGB#1)+#3H-:L="=+>\@-
MQ87,D$!N8IXY)$>62&X=XRD".Q\L_*#@$ ]";XH_M1KU^#O[/_7'_)9-7Y/_
M (3%/7XD?M3,,CX-_L_D'_JLFK__ #,5Y1/_ ,%5%?2[\2: UG<Z7X<U_4;A
MM0M+FRLY;NRU&*RM88KB1!%+'(T@+O$S;.]?1G[*7QV/[0_[/GA;Q<T%I;7F
MJVQ2_M[>82PVMY$[17,,;C[RI-'*H/HHH XO_A8W[4__ $1O]G__ ,/)J_\
M\S%'_"QOVI_^B-_L_P#_ (>35_\ YF*]^4Y4'UH=MHH \!_X6-^U/_T1O]G_
M /\ #R:O_P#,Q1_PL;]J?_HC?[/_ /X>35__ )F*]]1BQ.:=0!X!_P +&_:G
M_P"B-_L__P#AY-7_ /F8H_X6-^U/_P!$;_9__P##R:O_ /,Q7O\ 10!X!_PL
M;]J?_HC?[/\ _P"'DU?_ .9BC_A8W[4__1&_V?\ _P /)J__ ,S%>_YYQ2,V
MW'N<4 > _P#"QOVI_P#HC?[/_P#X>35__F8H_P"%C?M3_P#1&_V?_P#P\FK_
M /S,5[X9#D\"A9"6 XH \#_X6-^U/_T1O]G_ /\ #R:O_P#,Q1_PL;]J?_HC
M?[/_ /X>35__ )F*]_HH ^=]7^*O[56EZ7<7,7P.^!6HRP1LZ6MK\9=3$UP0
M.$0R>&T3<>@W.H]2*Y-?VG_VOV8 _LG>  ">I^-4>!_Y2:^M** /A/\ 9Q_X
M*2_M-?M5_!30?B!X/_92\'3^'/$<<LEF]W\8XX)R(YI(6W)_91Q\\;=SQBJO
MQD_X*R_%3]FRY^R?$OX5_!;P%J;6OV]=/U#XJZO>3O;;R@GS8^&KB,*7##!<
M-\IRH!4GT'_@A9_RBD^$7_7I?_\ IRNZ^,_^#AOQ39>&?VJ/!;W4D<3GPVJQ
M[26FDS<S;@%'88!S0!Z-;?\ !Q/%<Z5<WW]F_L^0V5FI:>>;XD>)XDBQU!+>
M$1S_ (BJ,W_!R5IEM/IL<UM^SU =6<);M+\1O%*(21GYF/A#"C'.37XJ_ML?
M$/POXA^#HL/#7B+3+VXU2^1[ZV#":ZFY.4(!RN" S9Z_=K@/A]^PSXD^-'P>
MM=6D\5BP4 M'I][!*5MBQVQ$$@@9QW]L4 ?T0:9_P6]\0ZSHD.HVWAKX 2V5
MQ&)8I1\2_$P$BGH1GPER".GK7-Z]_P '#2^&897O=-_9\A$)Q(/^%C^*&9.G
M4#PCGOSZ5^;GPR\">//"&FZ!+9:]HMU%I6C+#KTQO?-L[.8H$CA7:=TC[<MC
MY<#O7SC^U'^SIX;?X6W<%M?:G=_$;5':[41S3"UN61\N((\X"@+@Y4#.,L30
M!^W6H_\ !P!=Z9I!OWT+X!R6:V:WSR1?$?Q/((HF4,"P'A'(."#CK[5R>C?\
M'-^B>(- EU.SL?@1/90G:\@\>^+!CUP#X0R0/6OSE^.7QST/PG^S/H,VJ7FR
MTUO0A]EM9(V@N;H",+A$(#$D_P!T''7I7P[\ /BUIWAY%\/>(A]@T"=V8W)C
M8R6@;)8/CE@1@<<Y/O0!_2=\./\ @M%XH^+F@Z'JGASPU^SUJMAXC57L9H?B
MAXC*MN)4!_\ BD_W9R,'?C&:V=<_X*Q^/_#MY!!=^#OV?(Y;KF(#XI>(G#C<
M5R"/"9'45^ __!//]K'1OV-_'6IP6_C)=4\(^*I_L9TYK>2.XT]G?:D@5NXW
M88#T!K[HU_QK;Z!9MJ"(-0VYGBG;+"6,M\I4#H!G.!0!^B&E?\%8_'NM:HUC
M;^$OV=VNU8)Y3?%7Q"A).< 9\)\]/PJW=?\ !4KXBV=W<0-X0_9T9[12TY3X
ML^('2$9QEF'A0@<^]?EG_P +ZCOYK]X0@NH9P&P-A"[<M&I]3QSP><5YE\;/
MVF-0TGQS)IUU+;64)CA@A1%V0P/O&99 "1D#J>_/<4 ?KQXK_P""SWB3P1IH
MN]4T7]FRVA8$C'Q8\0NQQ_LKX3)_2N2/_!P9,8GD31/@'-'&N]WB^(OBB14'
MJ2/")Q7XH_&34-3@\37>BZ@J:AJ%G.;M[VQN3)%<0O&I50. !D@\<UG>&+[6
M/A]X?UBU2\6WM=113?"&)9R$91C:QX&,GG/M0!^UJ_\ !QU9M9/<?V?\ !%&
M<$GXB>*1^7_%(<U'_P 1(EB-V=/^ (V@'GXA^*N<_P#<H5^.GQ#^'?AO_A$-
M%3POK=_?ZG(-U]!?0>08BR#"J%!'+ \EB:Y#1;E?AIXV@B\1:9#J,-L<W-G+
M(V7!!Q@@C&#COT[4 ?N!+_P<;VD4ZQ?8/V?7=@& 3XB^*6ZCCIX0Z]L4WXJ?
M\''-M\$[&PN?$^E_ /3(M3>2.W+?$/Q3(79 I((7PB2.&!&:_%"2\_X2_P 9
MW&HV2Z9IBWFZ]-I';F.WM&)(V*&R67 []S4W[8?@";X@_LQ0:O"8V_X1JX22
M5B2V]&C*'&.!MX/XB@#]E='_ .#F[0==M4FMX/V?C&Z;P7^(7BN/CCU\(#UJ
MUXI_X.4]*\%Z3:7VHVG[/T%K>G;"X^(?BI]QQG''A X/UK^?/X/^'#?^$T?4
M;>\^PW,D:":$!6C!4#Y0?<&M7X_^(],\'^"+?PQ9W$UP;A(YY%N&YA?)Y4]<
M=,\]Z /Z ]"_X.-(/$WA/^W+'2/@-<:4,[IU^(/BK" '!)'_  B&<"M ?\'!
MQ.,Z=^SR,MMP?B5XG!'N1_PB.0*_'+X ?#!F_9MT_29Y4TK4=3MY/*19#<6[
MAMQ^;'.[:<D'@9&*\L\87L_@SQC!X;O[NV?7+B-6"0;V$OR@@#('/?'O0!^Y
M7C;_ (.1++X>6!NM6TWX"06P /F)\0O%4B]?]GP@:PK3_@Z-\+WVG_:HHO@$
MUN%#%_\ A/O%F%!.T9_XH_J3QBOQKT_QJL^GW=MK$<%S#$H!M9#F7 &05R.,
M>M>:^,?'OA3P_P"*A9:5J*RFY?S;F$.)(]XY!Z'!&?I0!^_NG_\ !R#8ZG?Q
M6T6G_ 'SIONJWQ"\5+CC//\ Q2%>S_#[_@IO\4?B?X)T_P 1:3X!^ G]DZI&
MDMM+>?%#Q%9NZNVU"4E\)JZ[B.-P&1STYK\)_P#@F;^SUJOQ6^+3_$_5T%IX
M(\&3BY:9U#QZI<KQ#:Q+T?YB"Q&<#%?J?^T%\1];;X>P:9IVH16+6]M->.9-
MLY@15'S.C88NS$!57H7 H ]\\:_\%7O'WP[9UUCPG^SI:/'-]G9!\5_$$C!^
M>,+X4)QP>>E>>:[_ ,' D_AS4GL[K1_V?A<1_>2/XD>*),?BOA$BOS _:Q_:
M,N/"5[':/=2W6LQH(I9B0<C.<\?=SG]!7SC+XLNM2U>[U:VW6SW'RA$;S%+,
M1Q\W)_"@#]N(_P#@XZM99_+72_@(7!QC_A8/BK^?_"(5/>?\'%,=A*B2Z3\
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M9P67&2"?7- 'ZM_$W_@LYXK^#GA&WU[Q'X8_9\T[2+NX2V@N3\3_ !(ZS2.
M5"[?"1)R&'-<G)_P<&21&,'2?V?29250#XD>)SN([#'A'KW^@-? ?[87QF\)
M_$OX.Q7.GP:7X@T?PQ:S+!816CW,DEQ=JL85$'RJ47G><$8 KYNUS41H.F3^
M'_#&M:5?6D*Q7@N#IWDOISIG$".O+,%<Y]?6@#]F=!_X+XWGB6^^SVFD?L]-
M*2<"3XE^)HPP'<%O"(!KU+XB_P#!1WXK_"KX$W?Q,UOP+^SQ#X(LK<W4VIP?
M%O7;E43&<[(_"K/GCH1FOY^_"'@KQ1XFT_<)W2%+P8D#A2@QRX4]C7:?M#?M
MSZE\*?V,_$/P=T[Q#9ZEKWBR:.VU*UC?SCI]J-S2$XRH=@ H'^U0!^JVA_\
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M\0O^"GOPG^%NEZ)J&N:_?6>DZY:_;8]233);BTAMPV#-(T88QQ@YRQ&!SD@
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MV$L%NKW!*,0@;'.T#[W7DU\D_MD>-_&&OZQ-X8@U[6;GPGI^K,UMIUS!) T
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MJ?PU6>>^?5M1U5M,N=4EN I**)#&K^0%4(1NB!W$$YS0!T?[4&G0>.H]3TJ
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MNA6%%:1(U,D:^8#^\^9RBG:,LR_F-XTTK4OAQ\3=?\*:[::C9WNC7LUO&M_
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MOP6Y^Z,8K\_/V@/&6I_'/XU7E_80WM[92SC3]/2WA=TN G0* ,%CR?7&#3?
M.BZ)8:;KNF^*KC^Q[J62*V,%S:2?:HQABSC(P " ,<B@#Z#\8>%M&\6?"RZ\
M.Z9XCL;J76)HX+F:"[286<:R*S  ,V,G(' [UY'\2/$?B/X6_":Z\&PQ17?A
M[3[@6L5R3&3>EAN_U:?-P< Y.21TQ7FEMJ%WX)U'4K?1-3GBMYI-C30'R_M*
M(V58]P>_YU[#^S]J=KK?QAT"7QU;0PV/V5Y=)%_O6&]NB5'F$]]PRN3PN<T
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MKH".,ENO/!P*]G^(WAF/X=Z!97.N26NGIIFGE[BZ0!8+BX:7Y45SC<Q!X7J
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M\Y8\ UX%^UZVD?"+XR0>$_!6JZ7J'A]=$ACAM2B36]G;&26TNK0KDB:1$#'
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M@&!9E1E*##$5K?ME?M+_  \_8F^)I\)>-?$ND37T]D)+RPGBD%\UI=,Q2:W
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M6&  <9H ^ZOV59?[2_9QTF:Q06DEW#/)'&(5B2*1F<\(.%7?T'3';-?*F@>
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M24T29.,8IU 'R5_P0L_Y12?"+_KTO_\ TY7=?E-_P=7>.?'?PP_X*9?#K6/
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M[V&UWH?]>K'!)'3(&3Z\5Z=<_"L:KINHVS[8-)L['RD#XSM  &PG@$8%>+_
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M_!0?_E-G_P $]?\ KY^(?_J.+7W=< F!P,9VG&3B@#^;[_@K-^Q7\7?VFO\
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M 8Y(^?\ X*_L^:[\;-5=W:;2=&2,W,FK7%O(T-QN9@%A/'FN[JR\2#&&).<
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MH6.%RWS;LYR0?SEUCXW^,_V3/C+XD\+:!J^KZ=XT\'7MQIUK?WVG1^;]CD3
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MAX!^)7[."?$GQ3X(TCQC?ZC/<QB6]#7::9%"S+O\LY0#Y9,80G<KCT4>8_\
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M:9)X?\;:#<1W2W]G=Q_8KYX$=A<FWE(A0^9LW NPW8/"G)^C_CQ\?;?]E_\
M9F\6?%/4M0L]6M(-.EDM;FP4K#=S,_EVWDR$L61I6B Y. GL:^/] ^+WA'3_
M (M6L_BKPQJ/AV<:8-4UFTFTV0:;;V-QN#1NTH##)<,TF'2/)7/RBO&?VNOV
MT=%_;M_M[X<?#Z&\TKX;P7]OJ-[="-A)JSH91&BQDE(H@S!@=F22#A G(!\=
M?!_1YM>@GUN]\^[O]8N);BXG=V;=EF#9))+,6).<U[A\.O#$=E>P7$,<D2PL
M'@DB8I+;NO*LK Y!![@YKLOV5?V18/C1\3;WP]IT[Z-X<\/Z:^KWJ1XN+J!
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M(::/YME!?"VT[6HM8$KWKQZ9*C2&%FR8L[E+*GWB#SS7]$%IB9&.".<>F?\
M"OP._P""8AT;X+?MX?!'0[6Z?^SM<U>[MM%_LJ,QV#(MM<RF)PZJ4CC4/C(+
ML73D@9K]\K'BW'0'VH D$8!SS3J** /DK_@A9_RBD^$7_7I?_P#IRNZ_,_\
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M?QM"S! S2J008\#G)&.>V* /G+0/A#HGBA9UCT&R6Y8@.DBJI?G!R1T/)Q7
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M.6!,"'DUY9^VK_R<S^R1_P!E3O\ _P!0KQ/0!]%4444 ?!W_  4'_P"4V?\
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M:>TTV=;K5!;PMJ,NR&WE>.1EE/8LK#<H_C8A<<BOT#^(MC?^)[)[>:XAT5=
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M@6&C:1%I5GIWPSO9].L]*U+$<FJ#>//GSDF/)50L9 X'J:L_$G_@J;\+M?\
M@?XH30O$GBCPY=:E=,L.E6EF8KN1?+\M9$?C:2 "?GX)KP/P/^VE\18O'F@:
M#\'?#.LZMXANH9+JYM=4L<,S*%=W1RXR3R68MR2,4 >B0Z=!8^!?$4/BF.T%
MI80O;7$#L(S!&,K(I7IP.BD$]*^3/@-\:?&?PC\2:D? \ZOH&]S;VFN0L]OY
M9)P5&<@[?[I ]J^D/@'^Q5J'C#PY+JOCKQEJ]MJ6J2RQW.E/'+'::+=H^?)F
M!)WR$$DGMZ=Z]F^#G[.?@OX-2W\VLZGX?UN2Y 6*.)9)9(,$CY=P5%SD=<T
M?T2?L[3O=? /P5+)L\R30[-FV$E<F!,X)[5Y/^VK_P G,_LD?]E3O_\ U"O$
M]>P? RR73?@QX4@1V=(=)M45CU($2C->/_MJ_P#)S/[)'_94[_\ ]0KQ/0!]
M%4444 ?!W_!0?_E-G_P3U_Z^?B'_ .HXM?>#ML0D] ,U\'_\%!_^4V?_  3U
M_P"OGXA_^HXM?>#C*'DCZ4 ?E-^W[K%OXE_:;\;00RI,+#4([.53G]S)]GB)
M4CO\KH???6?X_P#!^H>-_@UH%MH^FW.HZ=X3T>[U"\2UV+)<2M*",*YP9&1
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M&<X':OI[]BKXM>"_@S_PF%OXKO=0MAXG^SVEN\>G?:;6VB,4R.\A#!U7=+R
M&Q@.H+#%<M:?LC>%O#?[*\WB[2/$&JZKXET6YV:D[ &SU&"1EVS)GYHRA*CD
ME7W-G&*]D\)_\$\H_$/AW1+Y/B'X?4ZKHXU."46TCVP=ANCMN[L67/S*H7)7
M@XS0!Z3XJ^%/A7X::DLGAZUTC[1J6@6MP\.F7!N)([)9<1R!PQ=]XD67?)S\
MF 0#572+(^'6BC:W@U.779K:RD87+VJAY#$^R,GY5)##=M&"2!DDY'A_P9\4
MI\#/BG>6.OK)HFGO'-I6L8A;=;JZ-AVCP3L63RGR 25'0EJ^BIK&+1;2[O\
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MM;Z#XFB\)ZYH6JIX4NX;^1A;S>0RNP\H@L 3*"&W!<%#Y;J54N#XS^U/\#_
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M _A=^T-X;T4>(O#X\36]W/-J>G#4XTO(%@F12X0-\T9'F*.5);"[CE>/D/\
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M?PTC\/>*[WXA^*/$,'BBZMO["TX7ZO>6']DJJ-)%"#$Q6X1QL3YD0<#:,%@
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M'59U%BTEU?216UO\T7DQ[8R!$4(E&$54\LLQ8,=PZW_A34OQ:\!>*/#.K_\
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M_A/0O#'@FPC\'^)=(6RTK7GU*.)=+N1<>9):NDP&(MNX;SG:9B2=V  #S?\
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MBJST'5[/3/$FF/)%+<6+26E]:K((SO&#M"R!0"Y!#%=N,KGZG\$?M?ZSXO\
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M-RRRJJ0?-NPP&[;DX !^CO\ P2XT^\TW_@DEI4-W:W5C.-*U8^7<1E9 N^8
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M<6X/+Q2J22KC=M.?[O'6@#H/!=_X-_9V^'.L:&FH:CK6MW4,16XAE6"WMY\
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M(^"OB^ZT*Y\6:79ZO;RR:;.TEFS74L\D>UV0-P)5!)3.0W%?EUX+_P"#>/\
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M@>QKLOV=/V])O@=^T#8Z]I&E76K:?>Z7#8ZK<6=VZQZ<M[&@9781D!HB5'.
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M! .W<,@<] /6G^S)X7\*?$OXE^+_ !9#;6%_&\@MXQ>VXE^T,N"9E##C=N(
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M6QEM+6RB'DY;F96!&2YY?(.?K@U\[^.?@JW@;QIKS6#MKN@Z#/"\MYO =HI
M&5CV;DX++D9%>[Z1^UGX+\;_  \T_P#M][G1-1T5TM?LEO TIOHPJHK(<XS@
M?,">IR.* /$/VD_@%J^C^%E\2ZE?SQZ>Z"/33,6VW# @-%D#!(V\ \5Y+X'&
MHQZ_8RZ7:RW=[:2).B1KNZ,.37VQX^^(=O\ M3M/\*?$.I:9H5EX3$$]@T*J
MLVKQ(C$1GJJ.F 6(.3FLL?LWV/[.'AT7GAZ]NI9;F54O&O=DT9..IP <#@8!
MH X7]F']HB?_ (:/LM%_LK4-+MO$+FUD6489+A!E3@< 9&.O\5?='Q>\ V=]
MX0TU[I_L0A/V>61TW'+X8D@]<9;GH*_/B_TF]UC]IC1HK.ZM[==.CDU0F!?W
M@;E3G)P=Q/2O4/BC^UYX_P#".C&:6?39=-L+/FRNU++=$# ^888&@#V67X7N
M,S^'38ZO K[96A8NZ'.-Q4#@>]:_C#P-;^'_  KIL+QW#:TC"9+?.^%(SD99
MLX#$CH>:\2^&WQ6\>ZSX.M_$EDUOH=M=1_OGM8!&""IPFYR6/UKY\\-_$GQK
M\1OBEI\=IXUU,7NL70MS)?S?Z-;;GZLI.W8!_%C.%QF@#[!\=?$#P[\'[F+5
MO$&JZ=;*H7871KDAV!^4)CD^^*X/4O\ @I[IFC6\D?ABQO\ 5IFP8FOXH[>V
MC;& Q4+N;!YP<"OH[X5?LSZ;X5M+74_%=S:>++K38R3--;HB@DCYEA7NH+ 9
M//7VK@_B7^Q5X4_:!\9VS^)+J?PSKR1F""YT^*&..[B+$Q.X$>'( &1D'J#Z
MT ?#GB'Q;J7BGQ#>:A=7DEU?7\SW%S*Y^^[,2Q_E6>)Y-.U"VO7WRM:RI+A6
MVDE6##G\#7J'[1_['WBS]DSQ;#;ZR(M2T;4F8:?K-LC?9KP#G:<_<D SE2>G
M()K@I=/$L1.,X% 'W'\+O%^L:W^SS?>/?#MB-*O;Z.,0PQW#[MD:L[D@  .2
M%.1V(R:@_9D_;&\3:Y+JO]J62-+#$UQ(E]*521U^\Q8$8!4GKW7WKQK]D_\
M:Z\6>'O#S?#.RT^RO'UJ6*RLM2GB#G2X7;YV.0P)QA0,#(&#Q7T_\-/A1X=\
M>WNJ:9>7/]H7%M!'!<Z6UFEG]K3G>\H0!I 6P"%X&/0F@#Y7UW]J[1],_:"'
MB7P_X=CLKC7;VW&MR^:S0RS"52X&<D9Y&>@R*^[?VG_%6DW_ ,,8-/\ #&E)
M;R7H^S7"6T.Z2XGR4 =QSUX&,5\FVW[.'AA?VN=)\.:+IS1Z5IUTIU*!2UQ$
M77]Z0,G  PH../>OHWP7IU\VMZ[>6<6][)7NFG4,)+95P2Q_A(0C/3.XCZ4
M<QJNM+X?\!6UM<?.\:^6D.P !2?NYZDD\?A7+2^)-/34]2:".1;75(8U>T!!
M$+(S DGG('. #WYJU\3]1EU'5DMEBE<!/,&U S;<GY@/Y9_*N0M[1['3H$$X
M0RN9'9N<*-W3TZT ?U"_ =@WP3\)%6#J=(M=I'<>4N*\A_;5_P"3F?V2/^RI
MW_\ ZA7B>O6_V?G$GP+\',N-K:-:$8Z8\E:\D_;5_P"3F?V2/^RIW_\ ZA7B
M>@#Z*HHHH ^#O^"@_P#RFS_X)Z_]?/Q#_P#4<6OO!N%-?!__  4'_P"4V?\
MP3U_Z^?B'_ZCBU]X2?ZMOI0)[%6_O+>PM7EN)8H8HQEWD8*JCU)/ IMGJ5KJ
M,"3V\\$\,@RDD3AT<<\@C@]#^5>/?\%#-!OO$_[&OC_3],AGN+^^T\10QPQ-
M*[LTB# 1?F;OD#G&:Y?_ ()U>&[OX??";Q+X=U>$V6KZ7XBO!<1I"UO8L'5'
MC>SC<DK T;J0H)VOYG.36:7O2#[*/HIM3MEM_-,\'E$9W[QMZXZ_7 ^M*+^
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MOMUE]HB :2(S+OC!X!9<Y /J:^0_^"<NFZYJ7QK^+?CKQ!IVLZ3=?$:VT7Q
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M2OF1XD*$HK$CG@$X[9)["OJ7]B+P?X7T[X6'Q&EMIU_XAEO)8KA[@!Y;.-2
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M^4\?6O4_ 6H1Z]K%PRNMAK?*Q_Z0 F\,0R(W;YB?KG Z50K=3]8_BO\ &;X
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M"?@/]K"/3-035KWP+K7A]M;TR$RH+CYYC$R^9_=C(^]U.[VH \>\2_M@^/\
MQFUS&NLRZ/I5T#$=.TYC'%LR=ZEC\Q+9PQS\P'I7#&Z,\YE"(@;D*@PJ^U?>
M'P\_X)N?"FT^+]U/K-QK=YX7UZ,6F@Z<+A_M$5R=Y8-(HSP@0AF^7KSGBOE'
MXV_LT>)_@!X\_L'7-/:">[N)4L1YR2-<(KX4Y''0KU[F@#@)5##(8#/)J/Y5
M1EVCYU(SG&3C-='XH^'VJ> M<33=>LY-*NFB6;9+\W[ML_,,=< '/?BK>J_
M[7;BQN+W1HX]2M[7<Q0.$E9 ,[U!X8$=LT 7_P!D7X6I\3?'%U)<-*VF>'[-
M[F]C0MFX#C"0Y7IEN3_N50^*'PD\-B[O)X=$L[56<L&C9U?&>F=W6OJC_@DM
M\$AJ/P0^(_C]XIXTNV_L\!QM1A".5'.,[V8D]B!SBN*\6>!K#^TY[B;2[=O.
M8JD18NW7AP1T(.#T- 'R3<_#Z+0[=[FS&IZ<^=@ECN9(WC'7BNZ\&_M@^,?
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MES/K+W/V6.*)/-EVN%VH .2Q?&"!D=.E '-/\2;75-&2Y,RI+.OE>6QR$QU
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M-%M[U?LD$,\A22[<?O9)UCX^7)VYQCZUGS?$V^31WTR*Z>06NH1SN 3B4@
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M_P %!_\ E-G_ ,$]?^OGXA_^HXM?>#L$0DG  R30!_.G_P %>/'@TW_@I_\
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MXFENY!$3+>WBY=&:4#IQRH Z$\9XKZ._X+,6-TW[4OAE[= ^=#6$97*QEI'
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M/Y*Q1SE<C!&WG$9CY'?->/?MY>+=6T7X;V6D1S:C+K/B.\%C9$3.\DEN !L
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M\$9;MS0!^=OC_P"$WB+X0Z\FD^)=.?3+N6%98<.)(KE" =Z.N0P]^Q!KZ/\
MV-OVM_"_@CP;#X=\3W%UH4^CP/'8W$=N9+:X!R3NVC(;KP1\Y/)[&C^V[J<E
MWX&\&Z?J7E2ZG!<3SQR*,-]G*JJD^@8C."<\5\W:OJ9\/:1)^ZA^8[@Y7+<]
MO2@#]/?@)^V_\-?B/^SE\5K:_P!5GL#X9MEU.VDNFBLS<G!81QHQ!#M)'L*G
M@E^O-?ES\3OCL?B3XZU?7(;3[$^MW;W1A+[_ "BYSC/4\8_'-<?X9L+[XO\
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MH/>@#^Q3]F!UE_9P\!,C!U;P_8D,!@-_HZ<UY?\ MJ_\G,_LD?\ 94[_ /\
M4*\3UZ5^R>0?V8/AY@Y'_".6 SG.?]'2O-?VU?\ DYG]DC_LJ=__ .H5XGH
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MY/I7RHOC-_/B^?YF49=1P@SP3Z9KHM(\;QR,D<[%(P_#(HW'GZX/3I0!]K?
MWXBS:TM[I*30L]S;RF%7;$<C@$E3D<9 /;KUQUK\R/VWO@=_PJS]K7Q'I<\=
ME86'C4#4M)F1/*M[0.^=G<*Z,K*P&1\V>F*^O_!_BL>$=)U"]$UO)LCRDEM,
M76$' W#Y0W0G/4#UK2^)?[.Z_P#!1?P3)X:B@GN]4T4&>RUB.,;M// 8,?NL
MCX48- 'X\_M:>#?'OP[\NTM]/:_T99H]MWII>X>4$!EP4&6#,<8 [9K]KO\
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M;:??G- 'TU_P2G\4W=W_ ,%!_AC;F>8Q2ZA(708(SY35^_2YR?<^G2OY_?\
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M+;%)"D$@IQUXZU]?6'[1TEG^REJ^N0":Y\1:?I26]K'%E_M4IQY7;G:0&/7
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M$%N&(VGY&.$4 #..W-<9XW^"OBOX82I'J6C7GD2)NBNK>%YK>0=\.!CUZXH
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M*W=-T,Q)'IDUI-'>V]VO]I3"$FXL\G8T#+NVD E<@C(R* -7PO\ LS^/]?\
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M!D@Y:L32I],\5V/BWQ5K_P */%,7@+2])EOM.N=1TQX?)9"1D1,V9 #@AMI
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M3L9S'#'?J2#'O/WU4@9! ;+\4 >=_MA>"M;\0>"[76-*T_6)BN9K"\M-.Q'
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MIMI([0,\MUL"$NQ;A.!C ]Z\]^&W[*\GBN!(9-5N(=49"Z)Y(,:^F[/)SZT
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M9+N=C)&6+KS%\V#CIS^&<U]G_P#!1:SDN?VR_&4<8M]U[<QE1*Q&PB"/<?\
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MF6VE;:))-A&8]C%=KDD#H<5Y1XYL(-$\>SV&E&?2+#3;B5%N9XQYUVR.5WG
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M20R30Q2RRGY9I&?#*WH0<"L'PW-I/B6^M/[0MD>ZC1I+O486V3/$1PC ?+U
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M"MU(\ESJ\61%I4I"B0PH2&9,J-R$;CG-9,^MZ=KT.H6]A:[89IY&-Q#"P=9
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MQXVF1^)M-L]&BCQ?;!*SJ0R0(/O,3_(?G4M[^SY>.D=S93+-!&X4^<F%+=2
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M)\6AMTCNGYDMMK')C0@XDQS@5;^(OAE]._L6Z7RRE]H5O-&5(!^4NA8'N1M
M/N:E^%?A&T\9>.;6RO(9[ZPN3^]ACE:%BFW  /)!!Z=O6@#]9/V)95NOV1_
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M2#C'I0!]2_\ !.I/+_;3\$BZ5&1KQY;=@VXAS$V]?4 $5^Q*G/\ GI7XH_\
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MJ^'^F>%-7T2/38IQ?:7&A6ZCW&1YE&7QP2PZ[B0<CVKD;GPU?^*[6YO5O/[
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M9DAMTC2W*#<TN,?-[').175_$]K7X4?#6SUW4@E[KNMSS6>GZ=#CS;U@"5(
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MO3YO+C()9A@A5+/Z<\UC?'OQ;IWB#XF:DVFO<&WL;^>W>4KM@F!D/F;1_O\
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M;8!"FU"YP[ ?+\I[<]:\RN?$"?#^RO-0U/4(6CSODCC93++*WS!-H^[G!^E
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M[;U 5<EB0!S0!Z1^QO\ M'7UC\/-7\(-+,9=,ADN]/*;CNC8YD0CI@-@_P#
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MU_3?AQ-IMGX-\*:/INEQR6>IRZ5XGM]9N+6YB9%DCG$1_=S;G&%( .#@G:2
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MP'RQDGD@\5^7OB#]M'5_A]=:!J>H^"X(9=;TZ/4[%1JO)MGEDC5L*OREC$2
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MI1FELCJFNVT$SOGY8E60DC') VKDD=Z^9O%GPTM/"VG07MIJEE-?1RB14GE
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MQLR0I##!]>:U/&O[6'AOQOK>E:IJ?Q.\*7^E01"WC<:E!!%&%V_NTR<*PX)
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M-J=3A'EC;R9,'( Z]P2:^9OC9_P4,:?Q;:2> _$-OI=II\>);K>CM>O@C)#
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MAYX'8*, '0K4C_T"I!^S3\.50*/ 7@P*$$>!HML!M'1?N=/:O//^'77[.O\
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MW\G[,'PUE^]\/?!#?70[8_\ LE-D_9?^&K;0?AYX)*H,*/[#ML#_ ,<K@O\
MAUU^SK_T1?X=_P#@FA_PH_X==?LZ_P#1%_AW_P"":'_"@#O#^S#\-2,?\*\\
M$D=,?V%;8_+93F_9=^&GWO\ A7O@DL >?[#MLG\=F:X'_AUU^SK_ -$7^'?_
M ()H?\*/^'77[.O_ $1?X=_^":'_  H [P?LP_#4* /AWX( 7IC0K8;?I\G%
M36_[-?PZ@ V> ?!<85MX"Z);#!]1\G6O/?\ AUU^SK_T1?X=_P#@FA_PH_X=
M=?LZ_P#1%_AW_P"":'_"@#T)?V9_APB@#P!X+ '  T2VX_\ '*:/V:_AT<?\
M4!X,_P#!);?_ !%>?_\ #KK]G7_HB_P[_P#!-#_A1_PZZ_9U_P"B+_#O_P $
MT/\ A0!Z'_PS5\.O^A"\&?\ @EMO_B*:W[-7PZ!X\ ^##_W!+;_XBO/O^'77
M[.O_ $1?X=_^":'_  H_X==?LZ_]$7^'?_@FA_PH ]"3]FKX=$9_X0'P8#_V
M!+;_ .(H;]FKX=8/_% ^#/\ P2VW_P 17GO_  ZZ_9U_Z(O\._\ P30_X4?\
M.NOV=?\ HB_P[_\ !-#_ (4 >@?\,U_#K'_(@>#,?]@2W_\ B*5/V:?AT22?
M /@S_P $MM_\17GW_#KK]G7_ *(O\.__  30_P"%'_#KK]G7_HB_P[_\$T/^
M% '?R?LS_#@L<_#[P2V002=#MCD'J#\GL*3_ (9?^&KY)^'O@C<PP3_8=MD]
M^NRN!_X==?LZ_P#1%_AW_P"":'_"C_AUU^SK_P!$7^'?_@FA_P * /0$_9A^
M&L;;E^'W@@$YY&AVO<Y_N>M++^S3\.64J? '@LJ00?\ B26W0]?X.^37GW_#
MKK]G7_HB_P ._P#P30_X4?\ #KK]G7_HB_P[_P#!-#_A0![9H^@6.@Z5%8V-
MG;V-G NR*"WC$4<0]%5<!1SVKE+W]G#X>:A=2S7'@'P;/-,[22/)HMLS2,<Y
M8DIR3D\FO/O^'77[.O\ T1?X=_\ @FA_PH_X==?LZ_\ 1%_AW_X)H?\ "@#T
M!?V8OAJN,?#WP0,'</\ B16O!]ODI/\ AE_X:;<?\*]\$8XX_L.UP,=/X*X#
M_AUU^SK_ -$7^'?_ ()H?\*/^'77[.O_ $1?X=_^":'_  H [Y/V7?AG&%V_
M#SP.NS[N-"M1M^GR4X_LQ?#8Y_XM]X)YY(_L.VP?K\G->?\ _#KK]G7_ *(O
M\.__  30_P"%'_#KK]G7_HB_P[_\$T/^% '>S?LN?#.4[F^'?@9R!@9T*U/?
M/]SUI#^R]\-)EVO\._ [+@<'0K8@X((_@]0#^%<'_P .NOV=?^B+_#O_ ,$T
M/^%'_#KK]G7_ *(O\.__  30_P"% 'H9_9I^')5P? /@O$ARP_L6VPQYY/R=
M>3SUYH'[-/PY'3P#X,'_ '!;;_XBO//^'77[.O\ T1?X=_\ @FA_PH_X==?L
MZ_\ 1%_AW_X)H?\ "@#T/_AFKX=?]"%X,_\ !+;?_$4?\,U?#K_H0O!G_@EM
MO_B*\\_X==?LZ_\ 1%_AW_X)H?\ "C_AUU^SK_T1?X=_^":'_"@#T/\ X9J^
M'7_0A>#/_!+;?_$4UOV:OAT#QX \&?\ @DMO_B*\^_X==?LZ_P#1%_AW_P""
M:'_"C_AUU^SK_P!$7^'?_@FA_P * /0E_9J^'6T?\4#X,'_<%MO_ (BE_P"&
M:OAU_P!"%X,_\$MM_P#$5YY_PZZ_9U_Z(O\ #O\ \$T/^%'_  ZZ_9U_Z(O\
M._\ P30_X4 >A']FCX<-U\ >"SCUT2V_^(I#^S'\-F.3\/O!)/\ V [7_P"(
MKS[_ (==?LZ_]$7^'?\ X)H?\*/^'77[.O\ T1?X=_\ @FA_PH [Q_V8/AJ6
M)_X5WX'R>XT*UY[?W/<_F:E7]F;X;@8_X5_X*P#D9T.VXS_P"O/O^'77[.O_
M $1?X=_^":'_  H_X==?LZ_]$7^'?_@FA_PH ],T3X!>!?#.JPW^F^#/"NG7
MUL28;FUTJ"&:(^JNJAE/T-=8JA <#'>O!_\ AUU^SK_T1?X=_P#@FA_PH_X=
M=?LZ_P#1%_AW_P"":'_"@#W7D3DX./I4F?:O ;[_ ()6?LW:I:26]U\$/AI=
M6\HVR0S:%!)'(/1E92"/J*R?^'-W[)O_ $;?\%/_  C['_XW0!S_ /P0O1H_
M^"4_PB5E((M+_@\?\Q*[KV+XX_L1?!W]IGQ+:ZS\1/A=X$\<:M96XM+>\US1
M+>^F@A#%A&K2*2%W,3@<9)KSW_AS=^R:/^;;_@I_X1]C_P#&Z7_AS=^R=_T;
M?\$__"/L?_C= %P?\$D_V71T_9Z^#@Q_U*5C_P#&ZF@_X)1_LRVMG<6\7P ^
M$,=O=JJ3QKX5L@DP4Y4,/+P<$ \]Q6;_ ,.;OV3O^C;_ ()_^$?8_P#QNC_A
MS=^R=_T;?\$__"/L?_C= %M?^"2'[+BC _9X^#8 _P"I1L?_ (W2_P##I+]E
MT8_XQZ^#GR]/^*2L>/\ R'5/_AS=^R=_T;?\$_\ PC['_P"-T?\ #F[]D[_H
MV_X)_P#A'V/_ ,;H NM_P24_9>=<-^SU\'6'3!\)6)_]IU/IW_!*?]F;2-02
M[M?@%\(K:ZC)*31^%;)74D;3@B/(R./I67_PYN_9._Z-O^"?_A'V/_QNC_AS
M=^R=_P!&W_!/_P (^Q_^-T 7?^'2G[+V3_QCU\'<GJ?^$2L<G_R'[4G_  Z1
M_9<QC_AGGX.8 Q_R*5CT_P"_=4_^'-W[)W_1M_P3_P#"/L?_ (W1_P .;OV3
MO^C;_@G_ .$?8_\ QN@#3M_^"4O[,MI;W,,7P ^$,<5X@CG1?"ED%F4,& 8>
M7R RJ>>X!JNW_!([]EMR2?V>/@V2W)_XI&QY_P#(=5/^'-W[)W_1M_P3_P#"
M/L?_ (W1_P .;OV3O^C;_@G_ .$?8_\ QN@#2L?^"4?[,NF1W"6WP ^$,"W<
M9AF$?A2R42H2&*MB/D953@]P/2HA_P $E/V7E.1^SW\'0?\ L4['_P"-^U4O
M^'-W[)W_ $;?\$__  C['_XW1_PYN_9._P"C;_@G_P"$?8__ !N@"X/^"2/[
M+JK@?L]?!P =O^$2L?\ XW["AO\ @DG^RZY!;]GKX.DCU\)6/_QNJ?\ PYN_
M9._Z-O\ @G_X1]C_ /&Z/^'-W[)W_1M_P3_\(^Q_^-T 7/\ ATE^R[C'_#/7
MP=Q_V*=E_P#&_:I_^'4G[,HT[[)_PH'X1?9?-\_R?^$5LMGF8QNQY>,XXS69
M_P .;OV3O^C;_@G_ .$?8_\ QNC_ (<W?LG?]&W_  3_ /"/L?\ XW0!<_X=
M(_LNY'_&/7P<XY'_ !25CQR3_P \_4G\Z'_X))?LNR*5;]GKX.LI&"#X3LB"
M/^_?O5/_ (<W?LG?]&W_  3_ /"/L?\ XW1_PYN_9._Z-O\ @G_X1]C_ /&Z
M +@_X))?LN@Y_P"&>O@[G_L4[+_XW1_PZ1_9=SG_ (9Z^#H/3(\)V7_QNJ?_
M  YN_9._Z-O^"?\ X1]C_P#&Z/\ AS=^R=_T;?\ !/\ \(^Q_P#C= &E<?\
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MLN_]&]?!W_PD[+_XW5/_ (<W?LG?]&W_  3_ /"/L?\ XW1_PYN_9._Z-O\
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M_&Z +2_\$C?V6T! _9Y^#H!.3CPG9#)_[]TO_#I#]EW_ *-[^#W_ (2EE_\
M&ZJ?\.;OV3O^C;_@G_X1]C_\;H_X<W?LG?\ 1M_P3_\ "/L?_C= %O\ X=(?
MLN_]&]_![_PE++_XW1_PZ0_9=_Z-[^#W_A*67_QNJG_#F[]D[_HV_P""?_A'
MV/\ \;H_X<W?LG?]&W_!/_PC['_XW0!;_P"'2'[+O_1O?P>_\)2R_P#C='_#
MI#]EW_HWOX/?^$I9?_&ZJ?\ #F[]D[_HV_X)_P#A'V/_ ,;H_P"'-W[)W_1M
M_P $_P#PC['_ .-T 6_^'2'[+O\ T;W\'O\ PE++_P"-T'_@D?\ LN''_&/7
MP>X_ZE2R_P#C=5/^'-W[)W_1M_P3_P#"/L?_ (W1_P .;OV3O^C;_@G_ .$?
M8_\ QN@#Z)T71;3PWI%KI^GVL-E8V42P6\$*!(X8U "HJC@    #TKP#]M12
M?VEOV2&P=H^*=^">P_XHKQ1_A57_ (<W?LG?]&W_  3_ /"/L?\ XW71?"3_
M ()G_L\_ 'XAZ=XN\#_!+X7>$?%.D&0V.K:3X;M+2\M/,B>*39(B!EW1R.AP
/>0Q'>@#W&BD7H** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>formdrs_012.jpg
<TEXT>
begin 644 formdrs_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" #5 & # 2(  A$! Q$!_\0
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M<NS$;>" 2#]?6=K'9Q&.&-(4+%RJC R>3^9->9_!.V$HG?!VFX@.>G AD/\
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MPY\3M&BT03ZS:Z]X4D<1O<?VA"RV\>0I($R;HV"EMN>.>V*M_$A=)-C=>)-
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7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>formdrs_028.jpg
<TEXT>
begin 644 formdrs_028.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'J ZP# 2(  A$! Q$!_\0
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MK6K10!E?\(KI/_/C%^M'_"*Z3_SXQ?K6K10!E?\ "*Z3_P ^,7ZT?\(KI/\
MSXQ?K6K10!E?\(KI/_/C%^M'_"*Z3_SXQ?K6K10!E?\ "*Z3_P ^,7ZT?\(K
MI/\ SXQ?K6K10!E?\(KI/_/C%^M'_"*Z3_SXQ?K6K10!E?\ "*Z3_P ^,7ZT
M?\(KI/\ SXQ?K6K10!E?\(KI/_/C%^M'_"*Z3_SXQ?K6K10!E?\ "*Z3_P ^
M,7ZT?\(KI/\ SXQ?K6K10!E?\(KI/_/C%^M'_"*Z3_SXQ?K6K10!E?\ "*Z3
M_P ^,7ZT?\(KI/\ SXQ?K6K10!E?\(KI/_/C%^M'_"*Z3_SXQ?K6K10!E?\
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MK6K10!E?\(KI/_/C%^M'_"*Z3_SXQ?K6K10!E?\ "*Z3_P ^,7ZT?\(KI/\
MSXQ?K6K10!E?\(KI/_/C%^M'_"*Z3_SXQ?K6K10!E?\ "*Z3_P ^,7ZT?\(K
MI/\ SXQ?K6K10!E?\(KI/_/C%^M'_"*Z3_SXQ?K6K10!E?\ "*Z3_P ^,7ZT
M?\(KI/\ SXQ?K6K10!E?\(KI/_/C%^M'_"*Z3_SXQ?K6K10!E?\ "*Z3_P ^
M,7ZT?\(KI/\ SXQ?K6K10!E?\(KI/_/C%^M'_"*Z3_SXQ?K6K10!E?\ "*Z3
M_P ^,7ZT?\(KI/\ SXQ?K6K10!E?\(KI/_/C%^M'_"*Z3_SXQ?K6K10!E?\
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MT/1VNX$1Y!+%'MDSC#2*IZ>QK7KFOB%_R++_ /7Q;_\ HY* .EHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\S\>?\C!)_US7^5>F5YGX\_Y&"3_ *YK
M_*@#M_"O_(OV/_7/^IK5K*\*_P#(OV/_ %S_ *FM6@ HHHH **** "BBB@ H
MHHH *YKXA?\ (LO_ -?%O_Z.2NEKFOB%_P BR_\ U\6__HY* .EHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *\S\>?\ (P2?]<U_E7IE>9^//^1@D_ZY
MK_*@#M_"O_(OV/\ US_J:U:RO"O_ "+]C_US_J:U: "BBB@ HHHH **** "B
MBB@ KFOB%_R++_\ 7Q;_ /HY*Z6N:^(7_(LO_P!?%O\ ^CDH Z6BBB@ HHHH
M *S/$VIWNC:#>WNG:5-KE]#'OATZWE2)YV_NAG(4'ZG%:=% 'DOPS^-VM?$/
MQ=J6BS?#[5-"BTN9K74+ZZOK:1+:<1K(L95'+,65UY4$<\FO6J\?^!__ "/W
MQF_[&A/_ $AMJ]@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM:7&IZW8V<%VN^WDDF7;*N =RGNN".>G-.U_QWX>\+1VTFK:S9V$=T-T+33
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(;:O8*\?^!__ "/WQF_[&A/_ $AMJ]@H **** "BBB@ HHHH **** "BBB@
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M$X@:>=O,R#R2CKQUP<5['0 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !124M #9(TFC*2(KHW56&0:
M=110 4444 %%%% !1129H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@N@\CW-KJ]FUU;7#NB)YI0.I#JL:J#G&">,\T =!\,;K7K[P'H]UXF)_MR>
M2W*F$0[&/.W8"<8&..OK74USOP_\)'P/X3LM&-XU\T&]C*R[5!9RVU%R=J+N
MVJN3@ #-=%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD\A3AE(&!BO<O!?A^'PIX3TK2+> VT-G;K$L)G:?9@=/,(!;ZX%;/3@<"EH
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MYK^&7QYU;X9:YI_PU^,%G#H6J(JV^D>(H1MT[4XU 5!NZ1OC P<#Z=_I,,&
M(.0>AKP,1AYX>5I;/9]&O)GGU*;INSVZ'D'QF_Y*I\%?^P]=?^F^XKV"O'_C
M-_R53X*_]AZZ_P#3?<5[!7*9!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 445Q?Q@^(EQ\*?A_J7B6U\
M+:WXSN+38$T;P];^?=SEG"_*GH,Y)[ &@#M**^,_^'A7B;_HV#XO?^"5O\*_
M/;]MS]NSXN?$#XM365D_BKX4:-IJ1?9_#D[R6-XKE0QEG"[2Q8G(SP%QCN2
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M<(:S_@MIVE^*O$/C+3/$<%OJ&AZ3;RP:+'?8DCCL3<W :2/=V&Q5WCD!5&:
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M?OC-_P!C0G_I#;5[!7C_ ,#_ /D?OC-_V-"?^D-M7L%>8<H5Y''_ ,G:3_\
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M>7=71UXC"*C3C4C*Z9['1117SAYH4444 %%%% !1110 4444 %%%% !1110
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M?\3&I3H*349Z>G_!/7_$WCB32M<M="TG3&UO79X&NS:B=84A@#!?,=R#C+'
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M(:;I-E9KOQ;P)$/,?>WRJ!RW<\=>] %NBBB@ HHHH **** "O,_'G_(P2?\
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MT-\-/%6KV6E:1XWT;4=1O7\NVMK>Z5GE;!.%'<X!H ]$HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN_9_\*D]2+H_^34U<7K_ /Q4O[=WABW7YE\.>%KBZ=>P:9R@/U^85V?[)O\
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M %%%% !1110 5YGX\_Y&"3_KFO\ *O3*\S\>?\C!)_US7^5 ';^%?^1?L?\
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MX4^EU_Z535QG[&9.N+\4_%A.]=;\6W;1M_L1X4#Z#-=G^R;_ ,F^^%/I=?\
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M$;2/33YI"QSQNS28_P!6,*<;L$GM4O+\5S**IMWVMJG\UH3]7JWLHW_$^B?
MFD^)=&TF6'Q3XAM_$FH-,72ZMM/%DJQX "; [9((8[L]^G%=)7'_  M^*_AO
MXR>%8_$'AB]-W8LYBD61"DL,@ZHZGH<$'\:["N&<)4Y.$U9HQE%Q=FM0HHHJ
M"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"">1UH \@\$:3H%W8^&?%WB.[\:ZDMMKO]F6NE>)=0CG33;Q9&A1Y%CPKD.
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M?@SX<^$,-U#X=.I);W 53!>:C-<QQ[2Q_=I(Q"9+$G:!GO6F,J>UQ%2?=O\
M,JM+FJ2EW9W5%%%<AB>/_ __ )'[XS?]C0G_ *0VU>P5X_\  _\ Y'[XS?\
M8T)_Z0VU>P4 -9BJL0"Q S@=Z^9-'^)FO:A^U%#<S?#GQ#8RW'AN&QDM9Y+4
MO!$;UB;IMLI'E@DC );@_+7T[7D<?_)VD_\ V)$?_I>] 'KE%%% 'C_QF_Y*
MI\%?^P]=?^F^XKV"OF7XW_$+7H/B]\.HD^'NN7":5KER;2:.:U"ZH393+B',
MN1@,6^?;PA[XKZ(\.ZI<ZUH=C?7FF7&C75Q$LDFGW;(TL#'JC%"5)'L2* -*
MBBB@ HHHH Q/&_\ R)>O_P#8/N/_ $6U<K^SG_R0/X=_]@"R_P#1*UU7C?\
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MU>;*,H/EDK,YFG%V:"BBBI$%%%% !1110 4444 %%%% !1110 4444 %%%%
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M[7H<N*_FC]S_ ,SY'VV1?\^*O_@R'_RL\,_X>#_!/_H8KS_P63__ !-1R_\
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M8RHXH ][HK)\*Z#)X9\/V>F2ZK?ZW);J5-_JDBR7$V6)R[*J@D9QP!P!6M0
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MBZ3,FG"229Y/+#Q+(ADBW>KKE<=\X[U]%5\0_MFWUQ^TA\=OA_\ LUZ-,_\
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M;X9F;"[L';GKC!IG[+?[5WP6^&&K7FI_%.\\2^'OBYK#,=5U;QCH\T81B?\
M4PLH;8@XZA<X[  #U+X!WD/[.FGW&L^)_ >M75[KVV[N?&D+?;FN(W =%/>-
M0"/ESGN:^B=/\8?"_P".FFBT,VA^)X6&#8ZC"CNN>H\J09'Y4Z4HUI*=6W,M
MEV^_=^9]JN(L#&,LNR^JX\R7.IKDG)K=6:4E"_2[O:[[+Y&_:,_X*0?!;0_B
M]\-4T_5[GQ3::#J$FH:A?Z'&L]ND<MI+$JHY8;V!D4D#IR,YXK[E\#^-M%^)
M'A'2?$_AV^CU/1-4MUN;2ZCSB1&''!Y![$'D$$5^*?[8'_!/KQ!X)_:#N[3P
M=-H1\,^(;UKBPA-]';?V4CDMY<Z,?W<:G(5AD$8[\5]E_"_]F?\ :D_9>\ Z
M+I_PS^)'A?QWHEO LK^%]>M#'"CN2\BVTX.[868X)90<YQ7H*2;LF<4*]*I*
M4(33<=TFKKU['W]17Q;#_P %"];^%\Z67QX^#'BGX=MDJVM:;%_:6F'!ZB1.
MV.>"Q%?1'PK_ &DOAA\;+=9/!7C?1]>D8 FUAN ERN>FZ%\2+^*TS8]*HHHH
M XKXM>-O#_@_P=J*Z[K>GZ,U]:7$-J+ZY2'SW\L_*FXC<>1P/6N6_9=\::!K
MWP;\&Z3IFMZ?J&J:9H=E'?6=M<I)-:MY07$B Y4Y5ASW!K1^/5MKUQX1D.B>
M&=#\1JD%P;EM:N#$;9/+/SQ?NWW-UX^7H.:Y?]DFWUV/X9>'I-1\-:'I.FOH
MEE]BU+3KC?=7R^6/FG7RUVMC!^\W+&@#W6BBB@ HHHH *\@\#_\ )R_Q2_[!
M6B_RN:]?KR#P/_R<O\4O^P5HO\KF@#U^BBB@ HHHH *\B_:R_P"3?O%?TM?_
M $JAKUVO(OVLO^3?O%?TM?\ TJAH ]=HHHH **** "BBB@ K-UKPWI/B2W^S
MZOI=GJD&,>7>6Z2K^3 UI44FD]&5&4H/FB[,\+\6_L2_!GQ@S/-X,MM-G))\
M[29'M&!/?"$*3]17F,O_  3PM?"NI?VG\/OB/XA\+W\?S1F8K+SV!=-AQ]0:
M^PJ*J@WA9<]!\K>]M+^JV?S/8_MK,)0]G4K.<>TO>^[FO;Y'R%K6O_M2?!>W
M#S6>B_%'2( ,W%O;LMSM [JA5L^^'K!\-_\ !3&QCN_L7BWX?:MIEVC;9?[-
ME6XV8ZDHX1A7VW7!_$CX%^!OBQ;LGB;P[:7T^/EO%7R[E/=95PP_.NR=2AB/
MXB<)=XV_&+T^YQ-,-C\*O=Q>&C->5XO\';[TS@?"O[<GP;\3R)"_BM="NVQ_
MH^MV\EHPSZLPV#_OJO8] \7Z%XJMUGT76=/U:%AD26-RDP/XJ37ROXJ_8[\3
M^%5=O!NK:5XUT<'=_P (UX\LTNE(_NI<8W#]/K7D=[X-^$>BZRMK\1OAYXF^
M!NO/\JZSH%[,VGN?[R.-RJ,^BGZUA]1Q;UPTHU5Y7C+_ ,!=_P +H]+ZODF*
MUI2J4W_V[47_ +9+[DS]&Z\@_:<!/@_PO@9_XJW1?_2V.O)?"_P2^(<>FV^I
M?"C]HRYUS2@/W4.MQQZC"%[*7RV/^^0:^.?VKOBQ\9]-^)EWX8\;^)6BN=-:
MVN$M]&=X;)G50\5PB_WLD'/8CC%>+B,;+"1O6I-/Y'H97PDLYQ/L,%C(2LKO
M2:DE_A<5Y;-GZ_T5\&?LP_M9_$]?A3;MJ?PV\6?$I([J91XALI/->4;L[""I
M)*YV_0>QKU/_ (;D737VZY\(/B'H^/O,VE%P,=>X[XK2&.H3BI-VOW3//Q/"
MF:8>O.@H*;BVO=E%_A>_R:N?4%%?,L?_  4(^&$9Q?V/BK22/O?;-%<8_P"^
M2?I6SIO[>GP.U# ;QHMF_P#<NK"Y0]/7R\?K6JQF'?\ R\7WG#+AW.(*[PDV
MO*+?Y)GT#17DFG_M:?!S4L>3\1_#Z9_Y^+L0]L_QXKJM-^,G@+6,&Q\:>'[K
M/3RM3A;MG^]Z5K&M3EM)/YGG5,MQM'^)0FO6+7Z'8T5GVWB#2[S!M]2LYP?^
M><Z-_(U?5@PR#D>U:WOL<$HRC\2L+1113)"BBB@ HHHH *\I\;?M%:/X!\2?
MV-J/ACQ=-/)<K:6UQ9Z,\L%W*4WA(7SB0X#<#^ZWI7JU>0?'O_D9OA!_V.$/
M_I)<T >E>%_$"^*- L]52PO],6Z3>+34[<V]S'R1AXSRIXZ>A%:M%% !1110
M 4444 %%%-DD6-2SL$4=2QP* '45E7GBO1-/!-UK&GVP'4S72)_,UR^J?'SX
M:Z+G[=X^\-VN/^>FJ0C_ -F]C4.I".[.JGA<16_ATV_1-G>T5XQJ/[97P5TL
M$S?$327Q_P ^Y>;_ - 4US%[_P % O@O Y2TUZ_U9AVL=*N&S_WT@K"6*H1W
MJ+[T>G3R'-JOP86H_P#MR7^1]'45\Q2?M]^#[H$:/X,\<ZTW;[/HA /XEO3V
MIT7[8'BS5!G2?@#X^NE/1[BV$"_F0:CZY0Z2OZ79T_ZMYJE>='E_Q2C'_P!*
M:/INO'_VJR!\(^2 /[;TCJ<?\Q""N"_X7]\>]4;&E_L^S0H?X]2UR&+';D'!
MKXE_;<^)'Q9U_P ?6.G?$#3V\*PPVB36>C6-R9+7D\R[P<.^X<G^' ''?FQ&
M8PHPYU%OY-?BT>UD_!N)S3%+#3K4X:-Z3A-Z?W8R;_(_7>BOS[_9+^,W[0$?
MP?M_[(\ #XA:'!<216FH7^K+;7&T8S&#(?G53G!^H[5[3'^TY\6=-'_$X_9X
M\1<=?[-O8[CUZ;5YXK6GCJ=2"FTU?R?YV.'&\+8S"XBI0A.G/E;6E2FG_P"
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M.:[^JNGZ;9:7 8[&U@M(6._9;QJBDGO@#KTJU0 4444 %%%% !1110 4444
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M0?I[5?E.WX''-^VEJVFL!K/P.^(>FCNRZ=Y@Z_A[U\:_M*?MM^-?'7Q,M)=
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MX=:&Y'>>W\[_ -#)KU^BM%A:$=H+[D<M3/,UK?Q,54?_ &_+_,XO2_@K\/\
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M^>,\  U]/44?5YK:K+\/\@_M?#2_B8&D_3VB_*=OP/F*7]LKQ!I/_(:^!'Q
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M@C/%=6?V.[S3P1HGQA\>:3C[O_$P\W'IU ]_SKYK_9;_ &Q/VA?^%%^%)6^
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MVY;FL^7]K7Q]IZO+??"JV2%.&V>)K,,#G'=J/[/K=''_ ,#C_F'U>?=?>O\
M,^J**^0[[]O:^T9E34/AI(DC\HL'B*S?CWP>*QIO^"GGA>QB9K[PA=VKH<.O
M]JVS!><=0:/[.Q'1+_P*/^8?5ZGE]Z_S/M6BOBG_ (>K?#".2-;C3;Z$MC.+
MF!L>N/GYK2M?^"I7P?FFV21ZJBXZK]G8_EYHI_V;BND/Q7^8?5JO\I]B45\G
M6O\ P4U^"]QNS<ZM#M_OPP'/_?,QJ_#_ ,%'_@O<0[DU+4G?./*6T5F_1\?K
M2_LW&?\ /I_<'U:M_*SZBKY$^-/B+PQ/^TCX1TBW\+:/;>*(O%&ER3Z_%>6S
M7TT>P'8\(_?!<%1EN,*/45N2?\%%OA$I79)K<RD9+1V P/8Y<5\P_M ?MFWW
MQ(\8Z9=^#K*+1]'TB]@U&TN;JTC-Y<7$0.UY#EL(,D! >1U/8;T,GQN(GR>S
M<?-W2-*>#KU';EMZGZ>T5Y'^RY\:+KX[?":T\1:A:QVFJ0W$EC>+""(GECVD
MN@)) (93CL<BO7*\NK2E1J2I36J=CEG%PDXRW04445D0%%%% !1110 5YGX\
M_P"1@D_ZYK_*O3*\S\>?\C!)_P!<U_E0!V_A7_D7['_KG_4UJUE>%?\ D7['
M_KG_ %-:M !7G?QVT&]\0^ Q!:V$NL6T-];7-_I,!^>_M$E#2P*,@,64?=)^
M;&.]>B5Y]\=O$&M>&?AY<WNB7JZ5+]H@BN=4:$3?8+9I LMP$/#%%)// Z]J
M /#/A[>-KFBZ+X-\->$]8TR2U\7OJWG3:8]G:Z;9BZ>4?,P W-&=@1<_>(-?
M6E>'^'=%V:QILO\ POJ\UG$T;?8FFT_;=<C]WA$SANGR\\\5[A0 4444 %%%
M% !7-?$+_D67_P"OBW_]')72US7Q"_Y%E_\ KXM__1R4 >)_M)?\5!\=O@3X
M;7YE_MB?59H_[R0H"/US7T=+*D$3R2,$C0%F9C@ #J37SEJW_%2?MX:%#C<O
MAOPG-<D]E:>0I^>#77?M->+KS3O!]IX5T5F/B+Q7<#3+54/*1MCS7^@4X_X%
M[5WX^:HT:,>T;_-MO_(SS/%1P.$]M+7EC>W=MZ+U;LD?!G[>/QF\=Z9X+U/X
MH>$KJZTFRUG5SX8LM6M<K-:V4<;,QC<?ZLRL,;ASPP!YKRW_ ((Y>//$%O\
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MO/X$T@^-GQ+LU_TSX-ZC+QD_9+]&^G\)H]O'JG]S_P @_MO#1TG"I'UIU/\
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M<?9_!SP#IT;1VO@CP[;HQR5BTJ!03Z\)6S%X/T&  1:)IT8' VVD8Q^E:]%
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M_5JS/$GAO3?&&@WNC:Q:K>Z9>Q^5<6[,RAU],J01^!K/_P"%B>&_^@M!^O\
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M<Y_PL3PW_P!!:#]?\*/^%B>&_P#H+0?K_A0!T=%<Y_PL3PW_ -!:#]?\*/\
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M/^%B>&_^@M!^O^%8U,[Q]6;FZK5^G3Y&]+(\OI4XTU23MUZ_,\9/[%^DP_\
M'IX_\;V>?O>7JY^;T[4?\,<11_-#\4?'L,H^[(NK'*_I7LW_  L3PW_T%H/U
M_P */^%B>&_^@M!^O^%9_P!KX[_GY^"_R-/['P/_ #[_ !?^9XS_ ,,B7W_1
M9/B'_P"#7_ZU.'[*OB&,;8_C9XX"#A0UR&./<]Z]D_X6)X;_ .@M!^O^%'_"
MQ/#?_06@_7_"C^UL9UFO_ 8_Y#_LC!?R?^32_P SQS_AF'QA;\6OQP\7HI^]
MYQ60Y]N>*/\ AFWX@P_/!\=/$HE'W3+ CK^(W<U['_PL3PW_ -!:#]?\*/\
MA8GAO_H+0?K_ (4O[6Q?5K_P"'_R(?V3A.B?_@4O_DCQS_AGOXI?]%XUK_P7
M1_\ Q5,_X43\9EX7X]W>T=-VA0D_B=U>S?\ "Q/#?_06@_7_  H_X6)X;_Z"
MT'Z_X4_[5Q/:/_@$/_D0_LG#='+_ ,#G_P#)'C/_  I7XXV_RP_'$3J>2T^A
MQ CZ8)H'PD^/5O\ /%\9+*=Q_!-HJ!3^5>S?\+$\-_\ 06@_7_"C_A8GAO\
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MC_A8GAO_ *"T'Z_X4?VE+_GU#_P!!_9L?^?L_P#P-GC7_"-?M-_]#?X#_P#
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MYGX\_P"1@D_ZYK_*O3*\S\>?\C!)_P!<U_E0!V_A7_D7['_KG_4UJUE>%?\
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M HHHH **** "BBB@ HHHH *\S\>?\C!)_P!<U_E7IE>9^//^1@D_ZYK_ "H
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MQ_SWE_[[-'VZX_Y[R_\ ?9H ]GHKQC[=<?\ />7_ +[-'VZX_P">\O\ WV:
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M&/MUQ_SWE_[[-'VZX_Y[R_\ ?9H ]GHKQC[=<?\ />7_ +[-'VZX_P">\O\
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MO&/MUQ_SWE_[[-'VZX_Y[R_]]F@#V>BO&/MUQ_SWE_[[-'VZX_Y[R_\ ?9H
M]GHKQC[=<?\ />7_ +[-'VZX_P">\O\ WV: /9Z*\8^W7'_/>7_OLT?;KC_G
MO+_WV: /9Z*\8^W7'_/>7_OLT?;KC_GO+_WV: /9Z*\8^W7'_/>7_OLT?;KC
M_GO+_P!]F@#V>O,_'G_(P/\ ]<U_E6)]NN/^>\O_ 'V:LV[&:/=(2[9^\W)H
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>formdrs_029.jpg
<TEXT>
begin 644 formdrs_029.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *'!,4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ4UGPE<65LEM9><8YT+;R$95&03CO6QXFU:YN9FTW3T#,K#S"?N]?7ZBO-/
M'S_M(>*F'15N@?\ OZE>T:EHR7@+P.89B<MCA9/9A_6DU<J,N5WL97AOPZ]M
M<MJ-]+'-<'[A3H,CK]:ZFN*M-1DT[4EL@Y\]7'GQ$<!#P#]3V^E=K0M@DW)W
M84444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZVBJFF37L]BCZA;+;7.2&C5PPZ\'(KGQXFU'5M2EM= LX9(H3B2YN"=GZ?\
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M_+M_.M)5(Q2?<YZ>&J5).*5N7>^B7J=517)7/B/6=#N8O[;L;8VDC;?/M"V
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M5%+:X5L-.C\35UI9--_<7****T.8**** "BBB@ HHHH **** "BBB@ HHHH
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M@)';02SR"=3MB0L<8;G K'5PJ.VYV>["OA8N2=EK9Z;LV=&4+H=@%  ^SQ\
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M');QEPP'0$]/Q'MQ6OP5+O9K\CC5\1A%"+7,I-M72WZJ[1V=<-#_ ,E8N/\
MKF/_ $4M;FASZ[>7<]UJ42VMHRXAML#<#GJ3U_/\JQM5M+_2_&Z:W#93W=M*
MH#BW0NP^7:>/R-%67,HRMU#"4_9U*E)R5W!K?2^FE]KFQXS=D\)7Y4X.$'X%
MU!_2L?PPOB-?#UK_ &>-(%L0Q7SO,WGYCG...M;D4C^)-)O+>[T^XL8Y 47S
MAACZ-CM@XK!T:?6/"Z/IUWI5S>6JN3'+:KOP#[>G?G%*?\13UM;^NAI0NL-*
M@DG-2O9VU5NFJ5UZDFK^'_$>MS6KW<FE1_9V)5H3(#SC/4'TJ+XB?,^D1-_J
MWD?=_P".C^IK9@\0WUW>Q0P^'[Y(6<!Y;C]WL7/)P1SCTS1XNT*37-,46^/M
M4#;XP3C=ZC/;_P"M2G!2A+DNV_Z\AT:\Z>(I*O:*5[6MI?T;ZF^ %4*H  &
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ****  G )QGVKD_#6B7Z:W?:QJT CGE)$2[U; /7H3T  KK**B4%)IOH
M;TZ\J<)PC]K1][?\$****LP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HI"<*3Z"HD:=T5@(^1GJ: )J*B_?^D?YFC]_P"D?YF@"6BH
MOW_I'^9H_?\ I'^9H EHJ+]_Z1_F:/W_ *1_F: ):*B_?^D?YFC]_P"D?YF@
M"6BHOW_I'^9H_?\ I'^9H EHJ+]_Z1_F:/W_ *1_F: ):*B_?^D?YFC]_P"D
M?YF@"6BHOW_I'^9H_?\ I'^9H EHJ+]_Z1_F:/W_ *1_F: ):*B_?^D?YFC]
M_P"D?YF@"6BHOW_I'^9H_?\ I'^9H EHJ+]_Z1_F:/W_ *1_F: ):*B_?^D?
MYFC]_P"D?YF@"6BHOW_I'^9H_?\ I'^9H EHJ+]_Z1_F:/W_ *1_F: ):*B_
M?^D?YFC]_P"D?YF@"6BHOW_I'^9H_?\ I'^9H EHJ+]_Z1_F:/W_ *1_F: )
M:*B_?^D?YFC]_P"D?YF@"6BHOW_I'^9H_?\ I'^9H EHJ+]_Z1_F:/W_ *1_
MF: ):*B_?^D?YFC]_P"D?YF@"6BHOW_I'^9H_?\ I'^9H EHJ+]_Z1_F:/W_
M *1_F: ):*B_?^D?YFC]_P"D?YF@"6BHOW_I'^9H_?\ I'^9H EHJ+]_Z1_F
M:/W_ *1_F: ):*B_?^D?YFC]_P"D?YF@"6BHOW_I'^9H_?\ I'^9H EHJ+]_
MZ1_F:/W_ *1_F: ):*B_?^D?YFC]_P"D?YF@"6BHOW_I'^9H_?\ I'^9H EH
MJ+]_Z1_F:/W_ *1_F: ):*B_?^D?YFC]_P"D?YF@"6BHOW_I'^9H_?\ I'^9
MH EHJ+]_Z1_F:/W_ *1_F: ):*B_?^D?YFD=YHUW,(R!UP30!-141>0RLJ!<
M+C[QH_?^D?YF@"6BHOW_ *1_F:/W_I'^9H EHJ+]_P"D?YFC]_Z1_F: ):*B
M_?\ I'^9H_?^D?YF@"6BHOW_ *1_F:/W_I'^9H EHJ+]_P"D?YFC]_Z1_F:
M):*B_?\ I'^9H_?^D?YF@"6BHOW_ *1_F:/W_I'^9H EHJ+]_P"D?YFC]_Z1
M_F: ):*B_?\ I'^9H_?^D?YF@"6BHOW_ *1_F:/W_I'^9H EHJ+]_P"D?YFC
M]_Z1_F: ):*B_?\ I'^9H_?^D?YF@"6BHOW_ *1_F:/W_I'^9H EHJ+]_P"D
M?YFC]_Z1_F: ):*B_?\ I'^9H_?^D?YF@"6BHOW_ *1_F:/W_I'^9H EHJ+]
M_P"D?YFC]_Z1_F: ):*B_?\ I'^9H_?^D?YF@"6BHOW_ *1_F:/W_I'^9H E
MHJ+]_P"D?YFC]_Z1_F: ):*B_?\ I'^9H_?^D?YF@"6BHOW_ *1_F:/W_I'^
M9H EHJ+]_P"D?YFC]_Z1_F: ):*B_?\ I'^9H_?^D?YF@"6BHOW_ *1_F:/W
M_I'^9H EHJ+]_P"D?YFC]_Z1_F: ):*B_?\ I'^9H_?^D?YF@"6BHOW_ *1_
MF:/W_I'^9H EHJ+]_P"D?YFC]_Z1_F: ):*B_?\ I'^9H_?^D?YF@"6BHOW_
M *1_F:/W_I'^9H EHJ+]_P"D?YFC]_Z1_F: ):*B_?\ I'^9H_?^D?YF@"6B
MHOW_ *1_F:/W_I'^9H EHJ.)V8N' !5L<?0'^M24 %%%% !1110 4444 (_W
M&^E-A_U$?^Z/Y4Y_N-]*;#_J(_\ ='\J 'T444 %%%% !1110 4444 %%%%
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MP7,5I)(Z1_:$"L^TX+  GC(/OQ6W0 456U'4+72M.N=0O91#:VT;2RR$$[5
MR3@<G\*CTC5K'7=*M]3TV<3V=PNZ*4*5W#..A (Y!ZB@"[1110 455NM3L+*
MYMK:[OK:WGNF*V\4LJHTS#&0@)RQY'3U%6J "BBH;J?[+9SW'E22^5&S^7$
M6? SA<D#)[<T 345C>%O$VG^+_#]OK.F>8+:;<-DJ@.A!((8 D \>M;- !11
M10 445G:]K5MX=T&]UB\25[>TC,LBQ %R!Z D#/XT :-%<W:>.] NO["1KIX
M+C7(1-96\L3;V7&<$KE5/U/TS724 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 11?ZR;_ 'Q_Z"*EJ*+_ %DW^^/_ $$5+0 4444 %%%%
M !1110 C_<;Z4V'_ %$?^Z/Y4Y_N-]*;#_J(_P#='\J 'T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>^L+/4[.2SO[2"[
MM9,;X9XQ(C8((RIX." ?PJQ10!X-;^'-";]I&ZTHZ+IQTY; .+0VJ>4&\M3G
M9C&<^U;[>,]?LOB/J7@#PKH6B)!:0H]J7#01P!D1W9PG49<C"J#DY]:OP^$]
M:3X^7'B9K,?V.]B(EN/-3[^Q1C;G=U![8I-,\):W;_'S6O$\MF%T>XLUBBN/
M-0[F$<2XV@[ARC=1VH S="^(?CSQ#?ZKH%GH.C)K>ER,MS<RSR+;#!( "C+$
MD@XYQQSBM+PM\2-:\3^!+W4[;2++^V+*Z^S31270B@7H3(68G"C)XR3QP:F\
M">%M9T;XA^--5O[3R;+4KA7M)/-1O,&YSG )(ZCJ!7GT/PH\82_#S6]+-M';
MW<VKI>1V[W"$7,2JPVY5L#E@>2/N]N* .HTSXIZW;^-M)T+6)/#&HPZE)Y2S
M:%=-(8&Z /DGOCT[^E6=7^*U]X.\9:OI/BJSMULEMFN=*GMHV4S@9*HV6(R?
MNY&.5Z8(Q@Q^!O$E[XT\+:O%X'TOP]9:?<KY\-I<1-(0""7<KC<.. ,GKFKO
MB7X<:_\ $7Q-KE]KL1T^SM;8V^B1^<C;WSD2-M8X!(Y!P<,/[M 'H7@/5==U
MSPE::KX@M[6VN[O,L<-LC*$B/W-VYB<D<_0CCK7,^,/B!K^B?$K3/"NCZ997
MOV^R$J"=V1A(6D&2V<! $R1M)/.#70?#I?$D/@^UL_%-F;?4;3]QN,R2>=&
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MW_X3C_A:4>WR/^$.^SG?_J]WF;3_ ,#W;L?[./>@#CWD72?VH8DAR!J^F8F
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M/;P,RIP-SLH;\][_ )FO4_$_P_FUS5=+UVPUV72_$&GQ>2+]+99!(I!R&C)
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MNQS][Y.G^U6M9^"Q:?$R_P#&(ORQN[$6GV3R<;<%#NWYY^YTQWZT =71110
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M%95SK]O;:@;0P7#JCQQS3H%\N)Y/NALG/.1T! W#-:M !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% $47^LF_WQ_Z"*EJ*+_63?[X_]!%2T %%%% !
M1110 4444 (_W&^E-A_U$?\ NC^5.?[C?2FP_P"HC_W1_*@!]%%% !1110 5
M%<F);68SR>5"$8R2>84VKCD[@1MP.^>*EHH \U>YT^70=,M[>XTIECO;K OF
M#6BC=(5#@'[Q!!7VR>>^O+<V4GA318IGQ9QR6RWL=PX;;&5.WS?]DL%/( /I
M79T4 >9-]A,5^DVTI]FD_L$'^^9I,>3WW9\K&/X=O:O3%W;1NQNQSCIFEHH
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M5'D_]-)/^^JEHH B\G_II)_WU1Y/_323_OJI:* (O)_Z:2?]]4>3_P!-)/\
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MDW_/5?\ OC_Z]&R;_GJO_?'_ ->@"6BHMDW_ #U7_OC_ .O1LF_YZK_WQ_\
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MY+_U[M_Z$M=6#_WB'J<F._W:?I_D>A4445]>?&!1110 4444 %%%% !1110
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M_P#/*/\ [^'_  J6B@"+=/\ \\H_^_A_PHW3_P#/*/\ [^'_  J6B@"+=/\
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M_/*/_OX?\*-T_P#SRC_[^'_"I:* (MT__/*/_OX?\*-T_P#SRC_[^'_"I:*
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M^^&_PH^T)_M_]\-_A0!+147VA/\ ;_[X;_"C[0G^W_WPW^% $M%1?:$_V_\
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M EHJ+[0G^W_WPW^%'VA/]O\ [X;_  H EHJ+[0G^W_WPW^%'VA/]O_OAO\*
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M5^?(_P!:&=F.SYOD.'91G=P1W%=,      .@% "T4UD#C#9Q['%,^SQ^C?\
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MIWGSS_8+7SIU*32>2NZ13U#''(.!P:MT4 5%TO3EO%O%L+472C:LXA7>!C&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML;L<XZ9I:* &N6"Y5=Q],XIGF2_\\?\ Q\5+10!%YDO_ #Q_\?%'F2_\\?\
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M2_\ /'_Q\5+10!%YDO\ SQ_\?%'F2_\ /'_Q\5+10!%YDO\ SQ_\?%'F2_\
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M_P#KNG_H0KZ$KY[TS_D*V?\ UW3_ -"%?0E=>'V9X.;?%#YA11172>*%%%%
M!1110 5QOC#QA>>'-0@M[>W@E62+>3)G(.2.Q]J[*O*_BC_R'+/_ *]O_9C6
M55M1NCMP-.-2LHS5UJ'_  M'5/\ GQL__'O\:/\ A:.J?\^-G_X]_C7"T5R>
MUGW/H/J6'_D7]?,[K_A:.J?\^-G_ ./?XUZ+HE_)J>BVE[*BH\T8=E7H#[5X
M!7NOA+_D4],_ZX"MZ,Y2;NSS,QP]*E33A&VILT445TGBA1110 4444 %%%%
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MGC]&_P"^C_C7E_AW_D8;'_KJ*]5KZ+*?X4O7]#YK./XL?3]2+[/'Z-_WT?\
M&C[/'Z-_WT?\:EHKUSQB+[/'Z-_WT?\ &C[/'Z-_WT?\:EHH B^SQ^C?]]'_
M !H^SQ^C?]]'_&I:* (OL\?HW_?1_P :/L\?HW_?1_QJ6B@"+[/'Z-_WT?\
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MH?XT 2UX-XF_Y&C5/^OJ3_T(U[IYDG_/!O\ OH?XUX5XE)/B?4R1@_:9./\
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M^2QW^\3]?\C[' ?[M#T_S"BBBN,[3U_3?^07:?\ 7!/_ $$5:JKIO_(+M/\
MK@G_ *"*M5]M#X5Z+\CX2I\;]7^;"BBBK("BBB@ J*Y_X]9O]QOY5+45S_QZ
MS?[C?RI2V8X[H\;HHHKX<^]"NG\"_P#(<E_Z]V_]"6N8KI_ O_(<E_Z]V_\
M0EKJP?\ O$/4Y,=_NT_3_(]"HHHKZ\^,"BBB@ HHHH *Y3QY_P @NV_Z[_\
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M^04445S'LG7?#C_D;%_ZX/\ TKV"O'_AQ_R-B_\ 7!_Z5[!7;0^ ^:S3^/\
M)!1116YY@4444 %%%% !7@WB;_D:-4_Z^I/_ $(U[S7@WB;_ )&C5/\ KZD_
M]"-<V(V1[&4_Q)>GZF51117(?0%K3/\ D*V?_7=/_0A7T)7SWIG_ "%;/_KN
MG_H0KZ$KKP^S/!S;XH?,****Z3Q0HHHH **** "O*_BC_P ARS_Z]O\ V8UZ
MI7E?Q1_Y#EG_ ->W_LQK&M\!Z.6_[PO1G"T445PGTX5[KX2_Y%/3/^N KPJO
M=?"7_(IZ9_UP%=&'^)GD9K_#CZ_H;-%%%=A\\%%%% !1110 5QWQ+_Y%9?\
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MR/)S?^ O7_,V-T__ #R3_OO_ .M1NG_YY)_WW_\ 6J6BOI#Y<BW3_P#/)/\
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MIV+WEN;2)T\AD*;XV+.V_B5<, OW3\O(P =+NG_YY)_WW_\ 6HW3_P#/)/\
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M[VRU&VO=4U2._DLK,V=IY=KY.U&*EV?YVW.WEIR-HX.!S3O^$UTCUG_[]_\
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MQKU2O*_BC_R'+/\ Z]O_ &8UC6^ ]'+?]X7HSA:***X3Z<*]U\)?\BGIG_7
M5X57NOA+_D4],_ZX"NC#_$SR,U_AQ]?T-FBBBNP^>"BBB@ HHHH *X[XE_\
M(K+_ -?*?R:NQKCOB7_R*R_]?*?R:HJ? SJP?\>'J>14445YQ]<%>H?"S_D&
M:A_UV7^5>7UZA\+/^09J'_79?Y5M1^,\_,?]W?R.^HHHKN/EPHHHH **** "
MBBF33);P232'"1J78X[ 9- &7KVE7FK000V][#!"LF^:*:W,JS@=%8!U.W/)
M&>>AXR#.\.L&W*QWUBL_RX=K-RO3YOE\T'D\CG@<<]:R/^%@>'/^?U_^_+_X
M4?\ "P/#G_/Z_P#WY?\ PJ.>/<Z/JU;^1_<1#P;)'!+!#J2I#>0>3?K]GSYH
M,CNQC^8"//FN,88 $>F:ZRN8_P"%@>'/^?U_^_+_ .%7-,\6:/K%X+2RN6DF
M*E@IC9>![D4U.+ZDO#U8J[B[>AMT4451B%%%% !45Q_J&_#^=2U%<?ZAOP_G
M0 1_\?$W_ ?Y5+44?_'Q-_P'^52T %%%% !1110 51;1=*>Y>Y?3+-KAP0\I
M@4LP(P<G&3D$@^U7J* *ITVQ:ZBNFLK8W$*[(I3$N]%YX!QD#D]/6K5%% !1
M110 4444 <%X\_Y"=K_UQ_\ 9C7)UUGCS_D)VO\ UQ_]F-<G7R6._P!XGZ_Y
M'V. _P!VAZ?YA1117&=IZ_IO_(+M/^N"?^@BK55=-_Y!=I_UP3_T$5:K[:'P
MKT7Y'PE3XWZO\V%%%%60%%%% !45S_QZS?[C?RJ6HKG_ (]9O]QOY4I;,<=T
M>-T445\.?>A73^!?^0Y+_P!>[?\ H2US%=/X%_Y#DO\ U[M_Z$M=6#_WB'J<
MF._W:?I_D>A4445]>?&!1110 4444 %<IX\_Y!=M_P!=_P#V4UU=<IX\_P"0
M7;?]=_\ V4UQX[_=Y^G^1VX#_>8>O^9P-%%%?)'V(5Z9X0_Y%JW_ -Y__0C7
MF=>F>$/^1:M_]Y__ $(UZN5?QGZ?Y'DYO_ 7K_F;M%%%?2'RX4444 %%%% !
M7DFL_P#(<O\ _KXD_P#0C7K=>2:S_P AR_\ ^OB3_P!"->-FWP1]?T/;R?\
MB3]/U*-%%%?/GT9J>'?^1AL?^NHKU6O*O#O_ ",-C_UU%>JU]%E/\*7K^A\U
MG'\6/I^H4445ZYXP4444 %%%% &/XI_Y%J]_W5_]"%>75ZCXI_Y%J]_W5_\
M0A7EU?.9K_&7I^I]-E'\%^OZ(****\D]@[KP#_QZWO\ OK_(UU]<AX!_X];W
M_?7^1KKZ^LP'^[Q_KJ?'YA_O,_ZZ(****[3A"BBB@"*+_63?[X_]!%2U%%_K
M)O\ ?'_H(J6@ HHHH **** "BBB@!'^XWTIL/^HC_P!T?RIS_<;Z4V'_ %$?
M^Z/Y4 /HHHH **** "BBB@#&\376E6FFH^JQ031F4"*&=@$DD(( .[Y<<DY/
M QGJ!61<O:0^#K*S_M"WO((3;B[>*4.IA\P!B>2=G!'T!]#7844 >9O_ &9]
MHU)9_)_LOR+C^R0<>7O^7=Y/;=N^[MY]*]%L_-^PV_GY\[RU\S/]['/ZU/10
M UBP'RJ&/H3BF;YO^>2_]]__ %JEHH BWS?\\E_[[_\ K4;YO^>2_P#??_UJ
MEHH S-::7^PM0S$H'V:3^/\ V3[5X)7T!K?_ " =1_Z]9?\ T$U\_P!<F(W1
M[^4_!+U7Y!1117,>R=9\.BP\5+M4,?)?@G'I7KN^;_GDO_??_P!:O)/AQ_R-
MB_\ 7!_Z5[!7;0^ ^:S3^/\ )$6^;_GDO_??_P!:C?-_SR7_ +[_ /K5+16Y
MYA%OF_YY+_WW_P#6HWS?\\E_[[_^M4M% $6^;_GDO_??_P!:C?-_SR7_ +[_
M /K5+10!%OF_YY+_ -]__6KPKQ+D^)]3R,'[3)Q_P(U[U7@WB;_D:-4_Z^I/
M_0C7-B-D>QE/\27I^IE4445R'T!:TW_D*6F.OG)_Z$*]_P!\W_/)?^^__K5X
M!IG_ "%;/_KNG_H0KZ$KKP^S/!S;XH?,BWS?\\E_[[_^M1OF_P">2_\ ??\
M]:I:*Z3Q2+?-_P \E_[[_P#K4;YO^>2_]]__ %JEHH BWS?\\E_[[_\ K4;Y
MO^>2_P#??_UJEHH BWS?\\E_[[_^M7EWQ.+'6[/>H4_9NQS_ !&O5J\K^*/_
M "'+/_KV_P#9C6-;X#T<M_WA>C.%HHHKA/IPKW'PHTH\*Z;B-2/)'.[_ .M7
MAU>Z^$O^13TS_K@*Z,/\3/(S7^''U_0U-\W_ #R7_OO_ .M1OF_YY+_WW_\
M6J6BNP^>(M\W_/)?^^__ *U&^;_GDO\ WW_]:I:* (M\W_/)?^^__K4;YO\
MGDO_ 'W_ /6J6B@"+?-_SR7_ +[_ /K5R'Q(:0^%UW(%'VE.0V>S5VE<=\2_
M^167_KY3^35%3X&=6#_CP]3R*BBBO./K@KTWX7EQIM_L0-^^7JV.U>95ZA\+
M/^09J'_79?Y5M1^,\_,?]W?R.YWS?\\E_P"^_P#ZU&^;_GDO_??_ -:I:*[C
MY<BWS?\ /)?^^_\ ZU&^;_GDO_??_P!:I:* (M\W_/)?^^__ *U&^;_GDO\
MWW_]:I:* (M\W_/)?^^__K54U9I?[&OLQ+C[/)_'_LGVK0JGJW_(&OO^O>3_
M -!-)[%0^)>I\^T445YA]L%=7\.RP\5Q[5!/DOP3CM7*5UGPY_Y&V/\ ZXO_
M "JZ?Q(YL7_ GZ'KN^;_ )Y+_P!]_P#UJ-\W_/)?^^__ *U2T5Z)\@1;YO\
MGDO_ 'W_ /6I0TV>8E_[[_\ K5)10 5%<?ZAOP_G4M17'^H;\/YT $?_ !\3
M?\!_E4M11_\ 'Q-_P'^52T %%%% !1110 5ST6M7SZC&[K;BPEOI+)4"'S59
M WSEMV""R$8P, CFNAK''AZ!;U[E+NZ0&5YXX04*12NI4R*"N<\L<$D9)XH
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M45VG"%%%% $47^LF_P!\?^@BI:BB_P!9-_OC_P!!%2T %%%% !1110 4444
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M^^11]F@_YXQ_]\BI:* (OLT'_/&/_OD4?9H/^>,?_?(J6B@"+[-!_P \8_\
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M &:#_GC'_P!\BC[-!_SQC_[Y%1V.H6VHPM+;,Y5'*,'C9&5AU!5@"#TZBK-
M$7V:#_GC'_WR*/LT'_/&/_OD5+10!%]F@_YXQ_\ ?(H^S0?\\8_^^14M1SR^
M3;R2XSL0MC/7 H 3[-!_SQC_ .^11]F@_P">,?\ WR*Q-*\4IJ<5@QM&BDN?
M,$L>_<8BJA@.!\V5*D>Q%6_^$BTWRW<O<*4=4,36DHD+,"1A"NXYP>@['TH
MT/LT'_/&/_OD4?9H/^>,?_?(JO\ VM9#?F5E,;Q1N&C8%6D(" @CN6'TSSBG
M6>HVVH-*+9I'$3;2YB=48Y(^5B &Y!Y4F@";[-!_SQC_ .^11]F@_P">,?\
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MV:21HQ&+64R!EQG*;=PQD<D <CUJP-5LBRCSP-T[VXRI \Q59F'3L%8YZ<4
M3_9H/^>,?_?(H^S0?\\8_P#OD5%8:A;ZE!Y]MYIB[-)"\>X8SD;@,CW'%6J
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M0 4444 %%17!G%N_V98VFQ\@D8A<^Y )K,M-9<^$AK-U&I=+5KB1(P0#M!)
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MB&^-7=T0+&)"!&S?-T8GZC'(%/B\4V4ET8Y(I8( LCBZG:-(BJ/L)Y?<!N(
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MO7)PHYIUWX=ADM)$@ED$V;EXRY^7?,&SG S@%N,<U:U'4+BVNK6SL[:.>YN
M[ 2S&-%1,9)(5CG+*,8[GTK*T_7[X7;PWL$7DO=W$,<YF VF/<V"-OW<*1NS
MGCD4 2:%H,]GI][87R6XL[A=H@A*]P0Y+)%'U&T=,\=>>+E[X;TS4KBYGOK=
M+F2:,1 S(K>4H!^YD?+R2?K63!XHN-0:%$A%NPNX$8KO*R1R!CQYD:'^'J!]
M#0GBBYM["V7[+)?7<IN'(5'X1)2H_P!7&W/0#( XY([@&LOA^V#AS-<._FPR
MEF89+1* N>.^.?Z4L&A);Q3VZ7UW]CE61?LQ\LJF\DG!V[NI.,L:J7'B2:&Z
MD5=.)MH?(,TDDNQU$I &$VG)&>02.G?I57_A,Q]HO!]DA:&U29I-EP6E3RWV
M ,@3"EB>!NZ GVH 35/#5[+J5I<:>UL!;6\<,<D^PM&4+'=AHFSP1]UD/'7I
MC4?P]#N62"[NK>=)Y9EFC*%AYG++AE*E>G49X'-2:-JDVIQ3&>QDM7C8+\R2
M!7!&<J9$0GT/RUIT (H*H 6+$#!8XR??BEHHH **** "BBB@ HHHH **** "
MBBB@ HHHH RH=$\F<SG4KZ698_*BDE9"8DR"0/EP<[5R6R>!S44GAQ9+F_E;
M4[[;?*4FC_=%=I4J%!*;@!DD#/4D]SG:JCJE^VGV\;1PB:::9(8D9]BEF/=L
M'  R>AZ4 0/H%JXF!DF_>F M@CCRB"N..^.?Z5F^'] O])U6>>1K402^87,8
M4O(2V5)(C5ACG[SOU_&D;7=4M-4NQ=6D+6T/V<2!)\^49&V_)\@+]03G;C'&
M:AU3Q7/$-2MH(E1XH)VAN8R[#?'@$'=&%R,\A6;!&#0!LR^'=,G^RI-;)-;V
MJ,D5O* \8+8^8A@22,8'/<U$GA>QC@E@1YEB>WFM@BE0(XY6W$+QQCMZ#UJM
M=:_-I\^IAXVN"EY%;VT2J>-T2N<[%9L?>/0FEE\1WOV>V:'229Y8)YGCGE:'
M8(F4'&Y-Q#;AC*CMD#G !H)HXAU!KNWO;J /L\Z%-A24J, G<I(.  =I'05E
M:SX8>YL;2VLQ%*D-Q+,RW++R7+$_>C=>"QZKG'?U</%GG:Q;V-K:PN)C%GS+
MC;*%=-Y81A3E0O4Y'/'O5G0O$+ZU,W_$OGAMVC$L$S)(%=2>,ED4!L$'"EAU
MYXY "/PZ);(B\N9/MDBP&2:#:NR2+[K(,8Z^HP?0=*U[>)X(%CDN)+AUZRRA
M0S<]]H _(5+10 4444 11?ZR;_?'_H(J6HHO]9-_OC_T$5+0 4444 %%%% !
M1110 C_<;Z4V'_41_P"Z/Y4YN4(]JABF58D4K)D* ?W;?X4 3T5%]H3^[)_W
M[;_"C[0G]V3_ +]M_A0!+147VA/[LG_?MO\ "C[0G]V3_OVW^% $M%1?:$_N
MR?\ ?MO\*/M"?W9/^_;?X4 2T5%]H3^[)_W[;_"C[0G]V3_OVW^% $M%1?:$
M_NR?]^V_PH^T)_=D_P"_;?X4 2T5%]H3^[)_W[;_  H^T)_=D_[]M_A0!+14
M7VA/[LG_ '[;_"C[0G]V3_OVW^% $M%1?:$_NR?]^V_PH^T)_=D_[]M_A0!+
M147VA/[LG_?MO\*/M"?W9/\ OVW^% $M%1?:$_NR?]^V_P */M"?W9/^_;?X
M4 2T5%]H3^[)_P!^V_PH^T)_=D_[]M_A0!+147VA/[LG_?MO\*/M"?W9/^_;
M?X4 2T5%]H3^[)_W[;_"C[0G]V3_ +]M_A0!+147VA/[LG_?MO\ "C[0G]V3
M_OVW^% $M%1?:$_NR?\ ?MO\*/M"?W9/^_;?X4 2T5%]H3^[)_W[;_"C[0G]
MV3_OVW^% $M%1?:$_NR?]^V_PH^T)_=D_P"_;?X4 2T5%]H3^[)_W[;_  H^
MT)_=D_[]M_A0!+147VA/[LG_ '[;_"C[0G]V3_OVW^% %>ZTJTO+J*ZE659X
MAM62*9XB5R#@[2-PR.AR/SJ-M"TUK=(&M@8HXY(E4NW"N06'7N0.>HQQ5S[0
MG]V3_OVW^%'VA/[LG_?MO\* *=IH6GV3K)#%)YBRM,'DF>1B[+L))8DGY0!S
M33H&G?Z-LCFB-M"L$9AN9(SY:]%)5@6 ]\]_6KWVA/[LG_?MO\*/M"?W9/\
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M]P<9(]JV_M"?W9/^_;?X4?:$_NR?]^V_PH I0Z):Q7*76^X-R%022"X=1*5
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4A( ))P!U)H)P">>/2N%\2_$#1_P"QM1L[&YE.HF-H5B:WD0JQ^4YW
M*,$9)Y]*N%.4W:*)E)15V=V"",CD45P7ACQ_HZ:'IMC?74PU%(Q T8MY'9BO
MRC!53DD '\:[Q6W*& (R,\C!IU*<H.TD$9*2NA:**X_XD^)[WPKX:@N=/\E)
M[J]BLQ<SKF.V#YS(P]!C\R*S*.PHKE=#T_Q3IUZ)]3\46VM:6\19BUBL,B-@
M$%#'PRGG@\^YK'\+_%&QUWQ%JFFSLRJEXL&GF.QN 9%*CF0E<*<_WMO% 'H5
M%<OJ7Q$\*:3>S6EYJZ++ VR<QPR2I"WH[HI5#[$BLSQS\1+?PN= %H\<XU&]
M@$K_ &>65?LC[MSHR<%N!@9).?NF@#NZ*X*\\>:1JNJ:-9Z7XDN=.EDOD5XI
M=&F(O%[P[I$ 3/\ >!R*W=9\;>'M OA8ZAJ&RZV>88889)G1?[S"-6VCW.*
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MNY\0P[9U#*1%(=H)P-_R_)_P+%=E'(DL:R1NKQN RLIR&!Z$&@!U%>;:S?\
MB?5/BU)X9TKQ&VD6<6CB])2SBG+/YH0_?&>C#OVKJ+%;WPOHM_>^)?$CZG#"
MIF:X>S2+R8U'/RQCYO7IF@#H:*Y%OBAX*2\AM6U^W$DVT*=C[ 6&0&?;M4X[
M,015G5;]8?''AZS_ .$@-H;A+@C3!:[Q>X3.?,_@V?>]^E '2T5Y=;W7B_Q-
M\0?%NEV'BQM)M-(>W6"-=/AF!\R,DY+#/5?7OVK9\$^+[N\T[7H_$D]HDV@W
MDEK<7J?NXI%7^,@_=/J* .XHKF])\?>&-;U".PL=4#7,H+11RPR1>:!U*%U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[_\ ?1&: /._%NOKJ6@?#OQ->0FRMY-7M9Y_,/RPAD;DD_P^Y[5J>,[RUO\
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>formdrs_030.jpg
<TEXT>
begin 644 formdrs_030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +0!0 # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT(Z@^QYJ(5Z51\L)IOR:-J^7XS"P53$490B^KBTOO:-2BFLRQJ68A549+$X
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M&LK=%^2/,S#$5H\,8&:F[N4];ONSIK:VAL[>*WMXD@@B01QQ1J%5% P% '
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M#-?0OP9^,FF_%[09+B"/[%JEKM6\L2<["<X93W4X/N,$'U/A/[;W_(P>%_\
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M]_U_M_Z+-?1U?./[;/\ R)OA[_K_ &_]%FNG,_\ <ZGI^IY7"/\ R/,-ZO\
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MKY?\;^&],\)_M4:+IVD6<=A8IJNFNL$6=JEFB8XSTY)K[=KXU^+'_)W>D?\
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M4OB$VY*]VH]%*W7;3R-*BBBOH3\P"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH X3XZZ@VF?!_Q;,IVEK"2'MTD_=GK_ +U>3?L1V+1^%_$M
MYM(6:\CA#8."40G&?^V@_.OHK4M+L]:L9;+4+2"^LY0!);W,2R1O@@C*L"#R
M ?PJ'1?#^E>&[5[72-,L]*MG<R-#90)"A<@ L0H S@ 9]A7GSPSGBH8B^D4U
M8^FP^;0H9-6RSD?-4DG?I96T^]'G/[37@P^,/A-J9BB\R\TPB_AP.<)GS!_W
MP6X]0*\6_8^\.S>(_'&I^)[W,HTRT2UB=O\ GHRA ??$:$'_ 'A7UY-"EQ"\
M4J+)$ZE61QE6!X(([BJ.B>&])\,V\D&D:79:5!(V]X[&W2%6;&,D*!DX Y]J
MSJX%5,5#$7VW7>VQUX/B&>$R>OE:C=S>C[)VYE\[?B9'Q2T]=5^&OBJU9=WF
M:9<[?]X1L5/X$"OG[]A_4UW>+=.8_,1;W"#V'F*W\UKZFFA2XA>*5%DB=2K(
MXRK \$$=Q63HG@WP_P"&9I)M'T+3=*FD78\EC:1PLRYS@E0,C-:5<-*>)IXA
M/X;_ (G+@\VIX?*<3ELXMNHXM/LTT_QL?-/[2WP_UKP?X^M/B3X?A:6%9(I[
MEHTW?9YH]H#N/[C +D^H.>HSZ+X3_:R\#:UI*3ZM>2:%?*H\VVF@DD&>^QD4
M[A]<'VKVEE#*01D'@@US5Q\,?!UW,99_">AS2MR9)--A9C^)6L?JE6C5E4P\
MDE+5IK2_<[?[:P>.P=+"YI1E*5)6C.#2?+V:::=OZZWX;PO^TOX?\;>.K'P[
MH>G:C>QW!8/?F+;''A20=O+8. ,G&,UQ'[9_@O4-6TG1/$%G#+<6^G^;#=J@
MW")7VE7QV&5()]UKZ*TS1M/T6$PZ=8VUA"3DQVL*QK^2@5;90RD$9!X(-:5,
M+/$4)4:\[M]E:QRX;.,/EN94L;E]%QC#1J4KN5[IMNRM=/HK*USPCX:_M.>!
MX_ >E0ZOJ+:1J%E;1VTUJUO(^XHH7<A12"#CIU'0^I\(_:0^*NG_ !5US2KK
M2;.[AT^SBDA2YNDV^>Q(+;1V X[YYZ"OLI_AEX/DN#._A/0VG8Y,C:="6)]<
M[:LZEX%\-:Q';I?^'M*ODME*0+<V44@B4G)"@J=H]A7)7P>*Q%'V,YJVG3>W
M?7\CW,OSW)\MQ_U^AAYN3OO-65[WLK:_-[>8O@C_ )$O0/\ L'V__HM:^/?V
M:_\ DX9O^WS^35]LP01VL,<,,:Q0QJ$2.-0JJH&  !T %8^F^!?#>BZC_:&G
M^']*L;_YO]*MK**.7GK\RJ#SWKJQ&$E6G1DG\#_R_P CQ\MSJG@:&.I2@W[>
M-EY?%O\ >;E?$7_-WW_<P?UK[=K#_P"$%\-_VQ_:W_"/Z5_:OF>;]N^Q1>?O
M_O;]N[/OG-5C,++%<EG;E=S+(LXIY3]8YX.7M(.*MTOU-RO(OVHO&W_"'_"J
M^MXI-E[JS"QBPV"%;F0_38"O_ A7KM96N>%=%\3K"-9T>PU80Y,0OK5)MF<9
MV[@<9P.GH*Z<1"=2E*$'9M6/)RW$4<)C*6(Q$>:,6FTNMM5^.YXQ^QWX-.A_
M#VYUR9-MQK,^Y#CGR8\JO_CWF'Z8KWRJ]AI]KI5G#:65M#9VD*[8X+>,)&@]
M%4< ?2K%+#45AZ,:2Z%YMCY9ICJN,EISN_HMDODK(^</VT?!_P#:'A72?$<*
M9ET^<VTS <^5)T)]@R@?\#KO?@+XFA^)7P9L([W_ $AXX7TN]4_Q;5V\_6,H
M?QKTC4]+LM:L9;+4+."_LY<"2WNHEDC?!!&58$'D _A5;0_#.C^&8I8M'TFQ
MTF.5MTB6-LD(<C@$A0,FN>.%<<5*O%Z25FCU*F<0K9/3RZI%\].7-&79/==]
MW?[CXZTAM;_92^*=P][93WOAVZ)@\]5 %S!G*LIZ"1?[I/J.AS7OO_#5'PX_
MLO[7_;4OF;<_9/LDOG9_N_=VY]\X]Z]5O+.WU"V>WNH([FWD&'BF0.C?4'@U
MSR_"_P &QS><OA+0EESGS!IL(;/KG;6%+"5\+>&'FN5]&MOQ/0Q>=9=G#A6S
M.A+VR23E"27-;NG%V?I_PWRU=V&N?M7?%"&^AL;C3O"=GB$7$RX$<(;+#/0R
ML2>!G''89K[&M+6&QM8;:WC$4$*+''&O15 P /P%.M[>*TA2&")(84&%CC4*
MJCT '2I*Z<+A?J_-.3YI2W9Y&;YP\R5*C2A[.C25HQO>W=M]6_ZZGR;\9/A!
MX@^&7CH?$#P1%)+;>>;J6"W3<ULYSO!0=8F!.<= 2#@8->A^"OVM?!FNZ9&=
M;N)/#^I*O[V&6%Y(RW<HR \?[P!^O6O;ZP-2^'_A?6KEKC4/#>D7UPQ+-+<V
M$4CDGJ264FL%@ZE"I*>&DDGNFKJ_==CTI9YA<QPU.AFU%RE35HSBTI6[.Z:?
MK^MV_,?$G[77@72(V737O->N.BI:V[1H3Z%I OZ UZ]X?U0ZYH.G:BT#6S7E
MM'<&!CDQ[U#;2<#IG'3M5/2?!'AS09EFTS0-+TZ5>DEI91Q,/Q516W791C73
M;K23\DK'AXZMETH1A@:4HM;RE*[?E9))'/?$+P]+XL\#:]H\#E)[VREAB;./
MG*G;GVSC/MFOE+]F[XG:=\'=:U_0?%T4VD&Y=,SR0L3#)'N!1U +8.[@@<8]
M\U]G5CZUX.T#Q)(DFKZ'INJ2(,*U[:1S$#V+ USXG"SJ585Z4K2CWV9Z659Q
M1PN#KY=C*;G2JV?NNTDUU5TUT6YX/\9OVD/">O>"]9\/^'S=:Y=WMLT9E@@9
M(H5QEF8L 3@#L,>XJM^Q#_R ?%/_ %\P_P#H#5[]:^"/#MC9W%G;:!I=O:7"
M>7-;Q6<:QR+_ '64+@CV-6-#\+Z-X9CE31])L=)24AI%L;9(0Y'0D*!FLHX2
MM+$QQ%6:=DU9*QVU<ZP%/*:V5X.C*/.T[RDGLUO9*VW0^?OVVM)NKGPWX;U"
M.)GM;6XFCF=1D(75-N?3.PUI?#G]ICP1H/POT&WU/4)(M3L+**TDL8K:1Y"8
MU" @XV\@ \L.OX5[Y=6D%_;R6]S#'<6\@VO%*@96'H0>#6#:_#;PC8W GMO"
MVBV\X.1)%IT*L/Q"TY86M'$RQ%&27,K.Z_X)G1SG U<KI9;CJ4G[.3:<9)7O
M=V=T^_0L^#/%EIXY\,V.N6$5Q#:7BLT:72!)!ABO(!/<'OTK;HHKU(W22D[L
M^/J2A*<G35HMZ*][+HKZ7]3XU_;"_P"2P:#_ -@N#_THFK[)K'UCP7X>\17D
M=WJN@Z9J=W&H1)[RSCE=5!)"AF4D#))Q[FMFN'#X9T:U6HW\;1]#F>;0QV!P
M>$C%IT4TWWO;;[CY&_;>_P"1@\+_ /7K-_Z&M?3W@?\ Y$O0/^P?;_\ HM:D
MUSP?H/B:2*36-$T[5GB!6-KZTCF* ]0"P.*TX(([6&.&&-8H8U")'&H554#
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M*G]NK.9T_+EOTMR[][:W[GB'AG]J+P%H_@+1?M6H3G4(;.*&6PAM7:175 K
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M -'25SW[7_\ R1]O^O\ @_DU>R:;I=EHMC%9:?:06%G$"([>VB6.-,G)PJ@
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M*_-\[W/C']F_XG:=\&]<U_0?%T4VD&Y=,S20L3#(FX%'4 M@YX('&/?-=_\
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M^3FX_P#KYL/_ $&.OMNL/4/ _AO5M4_M*]\/Z7>:CE6^V7%E&\V5QM.\KGC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M -\"C[)!_P \8_\ O@4 >:_\-3?!?_HKW@/_ ,*:R_\ CM'_  U-\%_^BO>
M_P#PIK+_ ..UZ5]D@_YXQ_\ ? H^R0?\\8_^^!0!YK_PU-\%_P#HKW@/_P *
M:R_^.T?\-3?!?_HKW@/_ ,*:R_\ CM>E?9(/^>,?_? H^R0?\\8_^^!0!YK_
M ,-3?!?_ **]X#_\*:R_^.T?\-3?!?\ Z*]X#_\ "FLO_CM>E?9(/^>,?_?
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M3?!?_HKW@/\ \*:R_P#CM>E?9(/^>,?_ 'P*/LD'_/&/_O@4 >:_\-3?!?\
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MKW@/_P *:R_^.UZ5]D@_YXQ_]\"C[)!_SQC_ .^!0!YK_P -3?!?_HKW@/\
M\*:R_P#CM'_#4WP7_P"BO> __"FLO_CM>E?9(/\ GC'_ -\"C[)!_P \8_\
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M5]D@_P">,?\ WP*/LD'_ #QC_P"^!0!YK_PU-\%_^BO> _\ PIK+_P".T?\
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M?9(/^>,?_? H^R0?\\8_^^!0!YK_ ,-3?!?_ **]X#_\*:R_^.T?\-3?!?\
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M_"FLO_CM'_#4WP7_ .BO> __  IK+_X[7I7V2#_GC'_WP*/LD'_/&/\ [X%
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M_? H^R0?\\8_^^!0!YK_ ,-3?!?_ **]X#_\*:R_^.T?\-3?!?\ Z*]X#_\
M"FLO_CM>E?9(/^>,?_? H^R0?\\8_P#O@4 >:_\ #4WP7_Z*]X#_ /"FLO\
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M:3:ZKH^H6NK:7=QB6WO;&99H9D/1D=258'U!J]7E/[+:A?@=X> & &NL ?\
M7S+7JU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %>5?LR_P#)+KC_ +&;Q)_Z
M>[ZO5:\J_9E_Y)=<?]C-XD_]/=]0!ZK1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !67>>*-&T[6K/1[O5[&UU:]!:UL)KE$GG SDI&3N8#
M!Z#L:U*^9OC]X4OO%'QJM9=&#'Q#HWA&;6=)VKN)NK>_MW5,8.=XW)COOH ^
MAO$'B;1_"=BMYK>K6.C6;2");C4+E((RYR0H9R!DX/'L:TZ^./CMXNL_CUX+
MU77=/+-X=\,Z);WJKZZE>-'A&[$PP%ATX:;VKU?QEXY\6ZU\4M<\+:#'KUM:
M:+I]M.9/#L>F/-+-/O(:4W[@>6HC "QKDDL68?*" >X45X/)XS\<W]OX=T'4
M6US3O&ITI[[4=+\+VFFO(@$QB2:2>[D: (V,B*,E\[N<"LKP_P#$[QCX]TOX
M+QPZ[_85QXF@U#^U;BVLH9'<VZ [D$@948E6YP5!;E2 !0!]&UG:EXBTK1;N
MPM=0U.SL+F_D\FTAN;A(WN'X^6-6(+MR.!D\UQ'P8\5:MK9\8Z/K-\VJW7A[
M79M.BU"2*..2X@V)+&9!&JIO D*DJJ@A0<9)KQKXR:@OQ$\9>-WM+?6+B_\
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M^%/B1XT:Q^$OB;4O$*WT'C*[6TO-&CL88K6!6MW97B;!EWAH\DM(RL6.%48
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MXYL_!7C_ ,:KXLD\OPUXENK*VT<:?;?9YK6*\$9CE<H9"=C;0R,A&T9W')H
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MP0;%#OOD5BJX4ACD\ YJ7PWXOT+QC:RW.@:UIVN6T3^7)-IMW'<(C8!VDH2
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MH8A06*9Y( )["N4\'_$3Q%>?&3QA:3^$O$QM/L^F!;.6[L633]WG;I67[65
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M?^(/_(@^)?\ L&7/_HIJZ"N?^(/_ "(/B7_L&7/_ **:@#.^#?\ R2'P1_V
M[+_T0E<WX!_Y+Y\5_P#KAH__ *(EKI/@W_R2'P1_V [+_P!$)7-^ ?\ DOGQ
M7_ZX:/\ ^B): /5:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *XJZ^#/@R]\(:;X7N-$2;0=.NA>VMG)/*1','9PV[=N/S.W!)!#$8QQ7:
MT4 8TG@_1YO$TGB"2R635I+'^S'G9V(:VWE_+*9VXW,3G&><9Q6)X?\ @_X4
M\+7EM<:;8W,*VLCS6MG)J-S+:6KMNRT-L\ABB.'< H@P&8# )KM** //M-^
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MV/3;<L8H?,>3;N8NWS,23EF)Y/>KD.EV=O?W-]%:017MRJ)/<I$HDE5,[ S
M98+N;&>F3CK5JB@#A]*^"WA#1M2L;VVTV=FT^1I;*VN-0N9[6S8YY@MY)&BB
M(R0-BC:.!BHK[X'>#]2O-5GFM-1"ZM.US?VL.M7L5K=2, &,D"S"-LA5!!7!
M  (Q7>T4 06-C;:99P6=G;Q6MI;QK%#!"@1(T48554<     5/110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y3^R[_ ,D/\/\ ^_=?
M^E,M>K5Y3^R[_P D/\/_ ._=?^E,M>K4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Y5^S+_R2ZX_[&;Q)_Z>[ZO5:\J_9E_Y)=<?]C-XD_\ 3W?4 >JT444
M%8_BNUDNM$G*:[>>'%A'G27]DL#.B*"6SYT4B8QU^7/'45L5G^(-!L?%&B7V
MD:G"UQIU[$T%Q"LC1^9&PPRDJ0<$9!YY!(H ^>+/QMX]D\+ZUJDGBZYMSHWA
MO_A++>*YM+0RWL,TMRT$%SB!0%$-HNXQB-@UPV3\H%?2D,GG0QR;&CWJ&VN,
M,,CH1ZUS'B3X7^&?%NI6E_JFG--<6T2P 1W,T,<L2N'$4T:.J31A@#LD#+R>
M.3GJJ (C<Q"X%N94$[(9!%N&XJ" 6QUQDCGW%2UQUQ_R6"Q_[ 5Q_P"E$-=C
M6LX<JCYJY$9<U_(****R+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ IAAC:992BF55*J^/F ."0#Z' _(4^B@ HHHH **** "BBB@ HHHH *Y_X
M@_\ (@^)?^P9<_\ HIJZ"N?^(/\ R(/B7_L&7/\ Z*:@#.^#?_)(?!'_ & [
M+_T0E<WX!_Y+Y\5_^N&C_P#HB6ND^#?_ "2'P1_V [+_ -$)7-^ ?^2^?%?_
M *X:/_Z(EH ]5HHHH *CF$C0R"%E24J0C.I90V."0",C/;(^M25'<0+=6\L+
MEU212A,;LC $8X92"#[@@B@#YXU_XS:MX1\!ZK9:IXKLX/$\VL:C8V>K7D<%
MM'%%;#>[*C#83]V-$.YBTJ9W ,:F\*_%#Q%XFL(/%=OXFCN-,M-9TG0WTN"*
MW>WO!<1VJS3-($WB0/=E@$=540X(.37K7A[X7^'_  OINKV%C#?-::MN-Y'>
M:I=7?F%@P=@996*LVXY*X)XSG Q#;_"'PG:Z[:ZO%ICK>6PAV+]LG,!:&/RX
MG>'?Y;NB8"NREA@8/ H [&HUN(FG>%9$,R*KM&&&Y5.0"1V!VG'T/I4E<CI/
M_)4O$W_8+T[_ -&7=:1CS*3[+]4OU)E*S2[G74445F4%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E/[
M+O\ R0_P_P#[]U_Z4RUZM7E/[+O_ "0_P_\ []U_Z4RUZM0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7E7[,O_)+KC_L9O$G_I[OJ]5KRK]F7_DEUQ_V,WB3
M_P!/=]0!ZK1110 445C>+?%5GX-T.74KQ)IPK)%#:VJ;YKF9V"1Q1KD9=F(4
M9( SDD $@ V:*\WUKXV6WAW*ZEX7UZVFM[0ZCJ,(%I(VF6GF%!<3E+@J4.V0
M@1EVQ$Y*C'/I% ''7'_)8+'_ + 5Q_Z40UV-<=<?\E@L?^P%<?\ I1#78UT5
MMH>GZLRI[R]0HHHKG-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E7[,O\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 5P]Y_P ELTG_ +%^\_\
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M<1\9?^1%;_L)Z9_Z7V]=O7$?&7_D16_[">F?^E]O0!VU+24M !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KA[S_ )+9I/\ V+]Y_P"E-M7<5P]Y_P E
MLTG_ +%^\_\ 2FVH [BBBB@ HHHH **** "BBB@ KG_B#_R(/B7_ +!ES_Z*
M:N@KG_B#_P B#XE_[!ES_P"BFH SO@W_ ,DA\$?]@.R_]$)7-^ ?^2^?%?\
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M:-(9XO*+ Y<;0=U 'U57(Z3_ ,E2\3?]@O3O_1EW775R.D_\E2\3?]@O3O\
MT9=UT4_AJ>GZHSEO'U_1G74445SF@4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% '$?&K_DEGB+_KW_\ 9EKM4^ZOTKBOC5_R
M2SQ%_P!>_P#[,M=JGW5^E #J*** "BBB@ HHHH **** "BBB@ HHHH ****
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M7%?&K_DEGB+_ *]__9EKM4^ZOTH =1110 4444 %%%% !1110 4444 %%%%
M!1110 5Q'QE_Y$5O^PGIG_I?;UV]<1\9?^1%;_L)Z9_Z7V] ';4M)2T %%%%
M !1110 4444 %%%% 'E/[+O_ "0_P_\ []U_Z4RUZM7E/[+O_)#_  __ +]U
M_P"E,M>K4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y5^S+_ ,DNN/\ L9O$
MG_I[OJ]5KRK]F7_DEUQ_V,WB3_T]WU 'JM</\8/AM!\4/"9TJXU>YT6-)4G:
MZMW(VA&#$D!@,X'#'[IP<<5W%87B[19M:TT1Q^(;[P[&A)EFLDM6\Q2,%7^T
M0RKMY[ 'WH XWX4_$;PE<:?HWA;1M5U#5YX[?;%=RZ7>1P3!5+%EFDC\L)C.
MT;R ,*">*WOBMX^MOASX1DU&:ZM;2YN)H[&SDOI5B@$\APK2.Q 5%&YVR1PA
M Y(%5O _P\E\"?V=IT7CC7M4L+* QPZ5J7V%E,8&T99+9)2%R,?/@8 Z<5W5
M 'R[X?\ B[XG\5>"M8U/3_&\,T_A/P])K%S+;0VD@U.<7-V!'.!&0B"*S7_5
M;&_T@-D_+7T_#)YT,<FQH]ZAMKC##(Z$>M<3<?!/P9=&Q\S2'VV:M&D:7MPB
M2QM,9C',HD GC\PEMDH9>2,8)%=S0!QUQ_R6"Q_[ 5Q_Z40UV-<=<?\ )8+'
M_L!7'_I1#78UT5MH>GZLRI[R]0HHHKG-0HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *X>\_Y+9I/_8OWG_I3;5W%</>?\ELTG_L7[S_TIMJ .XHH
MHH **** "BBB@ HHHH *Y_X@_P#(@^)?^P9<_P#HIJZ"N?\ B#_R(/B7_L&7
M/_HIJ ,[X-_\DA\$?]@.R_\ 1"5S?@'_ )+Y\5_^N&C_ /HB6ND^#?\ R2'P
M1_V [+_T0E<WX!_Y+Y\5_P#KAH__ *(EH ]5K#\<>%U\:>$=6T)KJ2R%_;M#
MY\>?ESZ@$;E[,N1N4D$\UN51UK3Y]5TR:UM=3NM'GDV[;VR6)I8\,"=HE1TY
M (.5/!.,'! !Y-\+O%'@[X8V\?@:W\0ZMKVH)J4MN;A]-O)T$[2E2C3+&T:D
M-]\[@-^]CMW$#V>O.?#'PUE\+3136OQ%\13V=W?-?-:SC33!<R2,9)%&+0$*
MYW,1&R_>9A@DFO1J /._C=XCU?PYX?TAM%GOX[J\U6&U>+1[>&>_FC*2,RVZ
M3*T>\;=S%Q@1I(<C&:\G\,_%;QAK'A?5-??Q,[GPZUA%)8K90)]M:2?$R70:
M(.DP1A$5B,862-CAAQ7T!XJ\%Z1XTMK6'58)G^R3"XMYK6ZEM9X)-I7<DL3*
MZG:S X89!(-8%I\#_!=C<6DMOI,D1M_*_=K?7'ESM'*TL;SIYFVX=9&9PTH=
M@QSG- '="N2TG_DJ7B;_ +!>G?\ HR[KKJY'2?\ DJ7B;_L%Z=_Z,NZZ*?PU
M/3]49RWCZ_HSKJ***YS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#B/C5_R2SQ%_U[_P#LRUVJ?=7Z5Q7QJ_Y)9XB_Z]__
M &9:[5/NK]* '4444 %%%% !1110 4444 %%%% !1110 4444 %<1\9?^1%;
M_L)Z9_Z7V]<?J'QJOG^*]_X>@NK32=,T^^@TL&^T*_N%U"ZD@2;8+Z,K;VW^
MM1 '$C$@G;@J#SA^(FO^,/"OBBQUPV<\NEZIHAC:VTNYTJ5O,O(696M;IS+M
M!7"S$*LGS8'RF@#Z)I:^4K/]KK5/LMM#]J\.:UJ^L6<,]I8Z-:W,\^BS-.D;
MP7MO'))-*Z+*&PBQ,S1.H49W+]!?#+Q0_B[PI%?2ZK;:O<K-+!/-;:5/IFR1
M'*M&UM.[RQ,N,$.<GK@ B@#JZ*** "BBB@ HHHH **** /*?V7?^2'^'_P#?
MNO\ TIEKU:O*?V7?^2'^'_\ ?NO_ $IEKU:@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "O*OV9?\ DEUQ_P!C-XD_]/=]7JM>5?LR_P#)+KC_ +&;Q)_Z>[Z@
M#U6N(^,FEMJW@>18[VQLYK:\M;V)=4F$5I<-#.DHAE8_POLV^Q(.#C![>N?\
M=>?_ ,(]+]G\-1^+)=ZXTR:2*-7Y^]F7Y>.M 'G_ (8U;5_B=X_T+5[FQTK1
M[70([AG6SUF*_GN&F01[,1C"1C&[).253@8KV"O$O#NCWEU\4/#-_<>"]*^'
MIM([H%4OK9[G4E>/'DJD(^95(\PYZ%!@=Z]/\<>)'\(^&;K58X[)S"4!;4K]
M;&VC#.%+RS,#L4 Y.%8G& "30!O45XM'^T)J%YX?_M:S\*1W,%CI;ZUJY_M(
MJL-F+B:))+9O)_TCS%MIY5!\K**G.7P/9TD61%=&#HPR&4Y!'K0!R%Q_R6"Q
M_P"P%<?^E$-=C7'7'_)8+'_L!7'_ *40UV-=%;:'I^K,J>\O4****YS4****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBD(R,$9%
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M<6\QU@22W#0_8>08PB!LCRXO.?YM^P?8\)D:%#*JI+M&Y48L <<@' R/? H
M?1110 4444 %%%% !7/_ !!_Y$'Q+_V#+G_T4U=!7/\ Q!_Y$'Q+_P!@RY_]
M%-0!G?!O_DD/@C_L!V7_ *(2N;\ _P#)?/BO_P!<-'_]$2UTGP;_ .20^"/^
MP'9?^B$KF_ /_)?/BO\ ]<-'_P#1$M 'JM8?CK25U[P1XATQ[X:8E[IUQ;&]
M9MHMP\3+YF>VW.?PK<JEKF_^Q;_R[!=5D^SR;;!F51<G:<1$M\H#?=R>.>:
M/%-/UK7/B"WAGPP=-\-Z;%I=]:7DU]INN17(*6KJ^VWA1=X#[-IW8VH[#FO>
M*\#U+1]0U;5/#BS_  VT?P$8=9LYUUJ;4+0.NR56:&(1?,SRJIBV]")#7OE
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M\E@L?^P%<?\ I1#78UT5MH>GZLRI[R]0HHHKG-0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .'^''_(<^(/_8PG_P!(K2NX
MKA_AQ_R'/B#_ -C"?_2*TKN* "BBB@ HHHH **** "BBB@ HHHH **** "BN
M0^+TCP_#'Q.\;,CK82D,IP1Q7P?_ &Q?_P#/]<_]_6_QKP<QS59?.,'#FNK[
MV_0\_$XSZO)1Y;W/T?KB+P'_ (77I!QQ_P (_>?^E-M7PO\ VQ?_ //]<_\
M?UO\:/[8O_\ G^N?^_K?XUY/^LL?^?7X_P# ./\ M1?R?C_P#]'Z*_.#^V+_
M /Y_KG_OZW^-']L7_P#S_7/_ '];_&C_ %EC_P ^OQ_X ?VHOY/Q_P" ?H_1
M7GOP!F>?X0^'9)':1VCERS')/[Y^]>A5]=1J>VI1J6MS)/[SV82YX*7<****
MV+"BBB@ KG_B#_R(/B7_ +!ES_Z*:N@KG_B#_P B#XE_[!ES_P"BFH SO@W_
M ,DA\$?]@.R_]$)7-^ ?^2^?%?\ ZX:/_P"B):Z3X-_\DA\$?]@.R_\ 1"5S
M?@'_ )+Y\5_^N&C_ /HB6@#U6J6MV=SJ6BW]I9WKZ9>7%O)%#>QH':W=E(60
M*>"5)!P>#BKM% 'SWH/PEU_PE\3O#^MZWHD/C988I[2;7EO7FN5DEEMS%<M;
MW+D0B(1R?ZES@2-A>,'Z$KPG2_BSJ.N^/[BPG\>>']!6UUV33!X=;2));FXC
MCN"B_OS.!OE7'*IA2V,$J:]VH YCQWX3N_%-OI,NFZE'I.JZ3?K?VES/;&XB
MW>7)$RO&'0LK1S2#AU/(.>Q\]TS]G>XTJ&]LX?$R'2]9F@N];MVT[#W%PEPT
M[FW82A8(W9MI0K)A  &!^:O::* $KDM)_P"2I>)O^P7IW_HR[KKJY'2?^2I>
M)O\ L%Z=_P"C+NNBG\-3T_5&<MX^OZ,ZZBBBN<T"BBB@ HHHH *P_%7C;0O!
M%K'<Z[J4.F6[[MLL^0ORC)YQQ@5N5QGQJ_Y(WX\_[ -__P"D\E '2Z+K5CXA
MTV'4-.N$N[*;)CFCSAL$@]?<&KU-3[J_2G4 %%%% !1110 4444 %%%% !11
M10 4444 %><_$3X7ZI\3KV&PU;6[!/!\=S%=_P!GV^F.M^7C&5'VLSE0-_)Q
M"#M^7/))Y'QQ^V%X,\ >+-2\/ZAIFNS7MA)Y4LEK;PM&3@'Y2TP..>X%87_#
M>?@#_H#^)/\ P&M__C]>M'*<=.*G&DVF<4L;AXMQ<U=%OQ=\)]=\)?#_ %*_
MO_%%GK%QI^C6^BV[#26@_P!"C<%MW[]LSN1'F083Y.(QG-:R?LW0R:EK.L2V
MW@5M6O[=K5%3P:JV3QR3)+*UU#]IWW,C&-,,9%"D$A<LV?._B)^VCX)\6>"]
M6TBSTKQ!'<W<6Q&FMX @.X'DB8GMZ5T2_MY>  H']C^).G_/M;__ !^J_L?'
M_P#/ED_7\-_.CV'X4_#6Q^%?A,:/9+:AY+B6\N7L;-+.!II&+-Y<*$B- ,*J
MY)"J,LQRQ[&OF[_AO/P!_P! ?Q)_X#6__P ?KTKX._'?0/C8FJMH=GJ5H--,
M0E_M"*--V_=C;L=L_<.<X[5C6RW&8>#J5:;45U-*>+H59*$)IL]'HHHKS3K"
MBBB@ HHHH **** "BBB@ K\M/CE_R67QO_V&+K_T:U?J77Y:?'+_ )++XW_[
M#%U_Z-:ON.%?]XJ>GZGSN=?PX>IP]%%%?I9\B%%%% 'UG_P3_P#^0YXR_P"O
M>V_]"DK[0KXO_P""?_\ R'/&7_7O;?\ H4E?:%?C_$/_ ",:GR_)'W>5_P"Z
M1^?YL****^</5"BBB@ HHHH \I_9=_Y(?X?_ -^Z_P#2F6O5J\I_9=_Y(?X?
M_P!^Z_\ 2F6O5J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\J_9E_P"277'_
M &,WB3_T]WU>JUY5^S+_ ,DNN/\ L9O$G_I[OJ /5:KZ@]Q'8W+VD:RW2QL8
M8VZ,^#M!Y'&<=ZL5E>)];TGP_HMQ=:UJ]MH=@1Y37UU<I;K&6X&'8@!LGCWH
M \'^$EQ\09/B!I*:UK6JZI:?O'OWDGM&L/FLXV\I?+PWGQW!E!3H% /3FOH'
M5]8L/#^FSZAJE];:;80#=+=7DJQ11C.,LS$ <D#D]Z^;_@1X9TG2?%FDZ=;_
M !"\%ZY;:;<3WEC8Z%=H]W<R-9I;%G0.0H"(SD*&^9B<X%>Z_$;7HO#'A6XU
M.30;OQ)-;O&]OI]C9O<R/,&'EL%1&*A6PQ< E0,@$X! )9?B+X4@ATF:3Q/H
MT<6KDKITC:A$%O2"%(A.[]X<LH^7/+#UKHJ^4QX>DL]'\4V4.A:UK5YXH\./
M8VEVN@W=M$NJ2W=Y+,"DD:_9H]]U RR2;5VPYW$H:^J85>.&-9'\V15 9\8W
M'')QVH Y&X_Y+!8_]@*X_P#2B&NQKCKC_DL%C_V KC_THAKL:Z*VT/3]694]
MY>H4445SFH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%4-=M;^^TFYM]+OTTR^D4+'>26XG\KD98(6 +8SC.0#@D, 5/S'XI_:6
MN]*^&WPV1_%^FZ-XGO-%T;7M8N[Y[:-[F*=HHWBCB<;<N6FD9D7]VD)^[O4@
M ]S^''_(<^(/_8PG_P!(K2NXKP'7M>UO2;'Q9K/AW6X;&W'C73DG,=LDYNX9
MQIL)578E54I*Q)"DGC!7&3U&H?\ "06_QMT+2;#QIK%U9RQW&K:II5Q;V/V:
M"S ,<,2,MJ)06F=2"92=L$@.200 >K4444 %%%% !1110 4444 %%%% !111
M0!QWQB_Y);XH_P"O"7^5? M??7QB_P"26^*/^O"7^5? M? <1_QZ?I^I\[F?
M\2/H%%%%?(GC!1110!]S_L]_\D=\.?\ 7.7_ -'/7HE>=_L]_P#)'?#G_7.7
M_P!'/7HE?L&"_P!UI?X5^1]I0_A0]%^04445VFX4444 %<_\0?\ D0?$O_8,
MN?\ T4U=!7/_ !!_Y$'Q+_V#+G_T4U &=\&_^20^"/\ L!V7_HA*YOP#_P E
M\^*__7#1_P#T1+72?!O_ ))#X(_[ =E_Z(2N;\ _\E\^*_\ UPT?_P!$2T >
MJT45!?7UMI=C<7EY<16EG;QM--<3N$CB102S,QX  !))X % 'SO>77Q%?XGJ
MW]KZK+:OK,(:RLY[3['9VRZC,A2X7[Z"2S%NZ<Y9RX[X'T?7RYI.F^'[CXF7
M_P#9WQ.\#7.D:[J]C>O#!?Q/J4\L.H37L4*@289C+.L0;D[(T %?4= $-W=P
M:?:S75U-';6T*-)+-,P5(T R68G@  $DFL=O'WAA;O2[5O$>DBZU6-9M/A-]
M%OO(V^Z\*[LR*>Q7(-9'Q1T/Q#XBT_3+/1;?3;VS%XDVI6>I7CVJW,*?,L0=
M89?E,@3<"OS*&7HQKP'PCX=\26?@1]!U3PQJ-MKFKZ9X<CT]H;6>:&);;RP?
M.F,:K;O$4:5HY"N"Q"ESR0#ZSKD=)_Y*EXF_[!>G?^C+NNM'2N2TG_DJ7B;_
M +!>G?\ HR[KHI_#4]/U1G+>/K^C.NHHHKG- HHHH **** "N,^-7_)&_'G_
M & ;_P#])Y*I>//B)KO@S7=+CC\-6]YH-Y>VNG?VA)J@BG-Q.Y1?+@$3;T4[
M2S%U8 L0K!>>+\<^/?$VK>&?B=X9UWP[I.G&Q\(W5[)>:3K$M\B-)%,L<3A[
M6'#$1NW!. %R/F!H ]R3[J_2G5X=J'[1]UI=]XMMCX>TZ\70;<SN]CKJW'V8
M_:5@5;\K$5LR06E(W2D1Q2DC*8/>_"?X@3?$CPW/JDUC:6@CNY+:.;3;[[=9
M7:IC$UO/Y<?F1G)&=H^96'.,T =I1110 4444 %%%% !1110 4444 %%%% '
MYD_M+?\ )=/&'_7Y_P"R+7F5>F_M+?\ )=/&'_7Y_P"R+7F5?NV!_P!UI?X8
M_DC\WQ'\:?J_S"BBBNTYPK[%_P""??\ Q[^./]ZS_E-7QU7V+_P3[_X]_''^
M]9_RFKYWB#_D6U/E_P"E(]3+/][A\_R9]?4445^/'W@4444 %%%% !1110 4
M444 %?EI\<O^2R^-_P#L,77_ *-:OU+K\M/CE_R67QO_ -ABZ_\ 1K5]QPK_
M +Q4]/U/G<Z_AP]3AZ***_2SY$**** /K/\ X)__ /(<\9?]>]M_Z%)7VA7Q
M?_P3_P#^0YXR_P"O>V_]"DK[0K\?XA_Y&-3Y?DC[O*_]TC\_S84445\X>J%%
M%% !1110!Y3^R[_R0_P__OW7_I3+7JU>4_LN_P#)#_#_ /OW7_I3+7JU !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>5?LR_\DNN/^QF\2?\ I[OJ]5KRK]F7
M_DEUQ_V,WB3_ -/=]0!ZK7$_&3Q!X3\,?#_4+_QK;K=Z K1K)"T7F%G+@)M'
M9MV,-D8/.1UKMJ* /F_X&_$Y?$GCR*QTGQ=9IX>F24P^&M3U9=4U(D+N#)(H
MS&J@<JTLW /W>M?2%%% !1110!QUQ_R6"Q_[ 5Q_Z40UV-<=<?\ )8+'_L!7
M'_I1#78UT5MH>GZLRI[R]0HHHKG-0HHHH **** "BJ6LZ?+JNFS6L&H76E2R
M;<7=GY?FQX8'Y?,1UYQ@Y4\$]#S7(_!F34[WP9%?ZKK=[K5U<3S+OO%A78(Y
MGC 41QIU"@G.>>F.E '=T444 %%%% !1110 4444 %%%% !1110 445YU\;/
MB?=?"S0+'4+2RAOGN+GR"DS%0!L9L\?2L:U:&'INK4>B(G.-.+E+9';:[HMO
MXBTF?3KJ2[BMY@ SV-Y-:3## C;+"ZR+R/X6&1D'@D5@:7\*?#6C^"8/",%G
M<OX>MVA:&TNM0N;@Q")T>)5DDD9U13&F$#;0%QC'%>"?\-AZS_T+UC_W^>C_
M (;#UG_H7K'_ +_/7C?VY@?Y_P &<7U_#]_P/0]%^%>@>.;SQW8:Q_:T]I%X
MJ:[6.#6[VWS(;:SE!8Q3*6"NJLBG(CVC8%P*]-T;PCI6@ZE>ZC9P2"_O8H(+
MFYFN))I)4A4K$"SL3P&;ZEF)R237RUH?[4&HZ#=ZS<0:%:N^J7OVZ823L0K^
M5'%A< <8B4\YY)K5_P"&P]9_Z%ZQ_P"_ST?VY@?Y_P &'U_#]_P/JFBOENV_
M:^UB:XBC/A^Q =PI(F?N:^I*]#"XZAC>;V+O;?0Z*.(IU[\CV"BBBN\Z HHH
MH **** "BBB@ HHHH X[XQ?\DM\4?]>$O\J^!:^^OC%_R2WQ1_UX2_RKX%KX
M#B/^/3]/U/G<S_B1] HHHKY$\8**** /N?\ 9[_Y([X<_P"N<O\ Z.>O1*\[
M_9[_ .2.^'/^N<O_ *.>O1*_8,%_NM+_  K\C[2A_"AZ+\@HHHKM-PHHHH *
MY_X@_P#(@^)?^P9<_P#HIJZ"N?\ B#_R(/B7_L&7/_HIJ ,[X-_\DA\$?]@.
MR_\ 1"5S?@'_ )+Y\5_^N&C_ /HB6ND^#?\ R2'P1_V [+_T0E<WX!_Y+Y\5
M_P#KAH__ *(EH ]5K+\57VF:7X7UB]UI$DT>WLYIKU)(O-5H%0F0%,'<-H/R
MX.>E:E% 'R?X!^+VC:EX\T6V\#^*;;PSX;GNXH6T?7=56[:\5F"B.VMAO:W9
MB<#]\H!/,9Z5]8444 %%%% !7(Z3_P E2\3?]@O3O_1EW775R.D_\E2\3?\
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M\ABN=)N'1[Y5M]1B>6$/>L)'<-OR8XT^5=OS?HG7#_!?_DG5A_U\7G_I5+0
M[X*ZFVL?"OPW=MI-EH@>U"I9Z; 8+4(K%5DAC/*1.H$B*<D*X&3U/;444 %%
M%% !1110 4444 %%%% !1110 5X-^U__ ,B1HW_81_\ :;U[S7@W[7__ ")&
MC?\ 81_]IO7DYM_N57T./&?P)'R;1117Y0?(!1110!/I_P#Q_6W_ %T7^8K]
M(Z_-S3_^/ZV_ZZ+_ #%?I'7W'#6U7Y?J>]E>T_E^HM%%%?:GNA1110 4444
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M+$R!7!X(^6O<?&7@?2/'NGVUEK,5Q+!;74=Y#]EO9[5TF3.QP\+HV03D<XR
M>H!&.OP;\*?;K:\DM+ZYN(?*RUUJMW,+CRI&DB,X>4B<H[$J9=Q7 Q@ 8 .U
M%<EI/_)4O$W_ &"]._\ 1EW775R.D_\ )4O$W_8+T[_T9=UT4_AJ>GZHSEO'
MU_1G74445SF@4444 %?FW^UM_P G!>*_K;?^DL5?I)7YM_M;?\G!>*_K;?\
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MWP;_ .20^"/^P'9?^B$KF_ /_)?/BO\ ]<-'_P#1$M=)\&_^20^"/^P'9?\
MHA*YOP#_ ,E\^*__ %PT?_T1+0!ZK1110 4444 %%%><>//BQ=^$=6U."RT)
M=5L-#L(M4UJZ>\,#VUN[N 84\MA,X2&9RI9!A0-V6X /1ZY'2?\ DJ7B;_L%
MZ=_Z,NZZT'(S7):3_P E2\3?]@O3O_1EW713^&IZ?JC.6\?7]&==1117.:!1
M110 5^;?[6W_ "<%XK^MM_Z2Q5^DE?FW^UM_R<%XK^MM_P"DL5?8\+?[[/\
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M\*Q$\';I<0S^E3_\,I_!S_HF7A?_ ,%D7^%>J4M+?<9Y5_PRG\'/^B9>%_\
MP61?X4?\,I_!S_HF7A?_ ,%D7^%>JT4@/*O^&4_@Y_T3+PO_ ."R+_"C_AE/
MX.?]$R\+_P#@LB_PKU6B@#RK_AE/X.?]$R\+_P#@LB_PH_X93^#G_1,O"_\
MX+(O\*]5HH \J_X93^#G_1,O"_\ X+(O\*/^&4_@Y_T3+PO_ ."R+_"O5:*
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M@#JZ*Y3_ (6SX'_Z'+P__P"#2#_XNC_A;/@?_H<O#_\ X-(/_BZ .KHKE/\
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MPMGP/_T.7A__ ,&D'_Q= &)HWP)\.Z#;""TGU )]NLM0.^96+36Q!4DE.=[
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MY>'_ /P:0?\ Q='_  MGP/\ ]#EX?_\ !I!_\70!U=%<I_PMGP/_ -#EX?\
M_!I!_P#%T?\ "V? _P#T.7A__P &D'_Q= '5U7O[--1L;FTD++'/&T3%>H#
M@X]^:YS_ (6SX'_Z'+P__P"#2#_XNC_A;/@?_H<O#_\ X-(/_BZ .0OO@EJ<
M>D^%M+L/&FL2VFC:A!/%+>"T6:SABMIX5$!CM0'8F6/(F# A3[AM$? ?0?[+
MN;-[[5)?M5BUC<7#S1F67=<M<R3,=F/,>5W8D#;SPHK>_P"%L^!_^AR\/_\
M@T@_^+H_X6SX'_Z'+P__ .#2#_XN@";Q=X'A\63:7=)J=_HNIZ9*\EKJ&G&(
MR)O0HZE98Y(V5@?XD." 1@BL_5?A78:[:ZM'J.IZE>3ZIIMIIEU=,84D=+>2
M:1' 6,*'+3ONPNW &%'>U_PMGP/_ -#EX?\ _!I!_P#%T?\ "V? _P#T.7A_
M_P &D'_Q= '5#CBEKE/^%L^!_P#H<O#_ /X-(/\ XNC_ (6SX'_Z'+P__P"#
M2#_XN@#JZ*Y3_A;/@?\ Z'+P_P#^#2#_ .+H_P"%L^!_^AR\/_\ @T@_^+H
MZNBN4_X6SX'_ .AR\/\ _@T@_P#BZ/\ A;/@?_H<O#__ (-(/_BZ .KHKE/^
M%L^!_P#H<O#_ /X-(/\ XNC_ (6SX'_Z'+P__P"#2#_XN@#JZ*Y3_A;/@?\
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M':29<AI6>*SMCTVC#^:QZ[Q@[O8JY3_A;/@?_H<O#_\ X-(/_BZ/^%L^!_\
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ME#X*?]$C\#_^$]:?_&Z/^&4/@I_T2/P/_P"$]:?_ !N@#K_^%8^#O^A3T/\
M\%L/_P 31_PK'P=_T*>A_P#@MA_^)KD/^&4/@I_T2/P/_P"$]:?_ !NC_AE#
MX*?]$C\#_P#A/6G_ ,;H Z__ (5CX._Z%/0__!;#_P#$T?\ "L?!W_0IZ'_X
M+8?_ (FN0_X90^"G_1(_ _\ X3UI_P#&Z/\ AE#X*?\ 1(_ _P#X3UI_\;H
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M (FN0_X90^"G_1(_ _\ X3UI_P#&Z/\ AE#X*?\ 1(_ _P#X3UI_\;H Z_\
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M_!;#_P#$T?\ "L?!W_0IZ'_X+8?_ (FN0_X90^"G_1(_ _\ X3UI_P#&Z/\
MAE#X*?\ 1(_ _P#X3UI_\;H Z_\ X5CX._Z%/0__  6P_P#Q-'_"L?!W_0IZ
M'_X+8?\ XFN0_P"&4/@I_P!$C\#_ /A/6G_QNC_AE#X*?]$C\#_^$]:?_&Z
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M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
MT!M/_P# 6/\ PH \U_X2SX!?]!GX;_\ @5I_^-'_  EGP"_Z#/PW_P# K3_\
M:]*_X1/0_P#H#:?_ . L?^%'_")Z'_T!M/\ _ 6/_"@#S7_A+/@%_P!!GX;_
M /@5I_\ C1_PEGP"_P"@S\-__ K3_P#&O2O^$3T/_H#:?_X"Q_X4?\(GH?\
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M59 KMEL,".0IH ^HJ*\,N-<G^$7Q8U/2[:^U75M"G\*7.N+8:IJ4MXT=Q;2
M$)+,SR*KHW(R0",@=:LV/QX\2W?_  AA;P'$O_"96[2:.B:VC.KB-9?])S$!
M''Y1=]T9E?" >7N;: #VJBO"==^*&G>*]-TZ+Q'X51]4T?QU8:-)9PZDYBM[
MLRH8;J.4(AE4"16V,JY.01W-S5OV@-8T_3_&FL0^#8I] \):G)87]T^K!)I5
M0IO>"(0G<55]Q5V0= &;G ![516;J7B72=%T,ZSJ.IVFG:2JH[7UY,L,*JY
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M?17R?XRNF\<_'GPEXM$N_2M/\51^'=+"MPXCMYGNI>."&E(0'/2'WKK-:_:
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MU[510!7T^QM]+L;:RM(E@M;>-88HEZ(B@!0/H *L444 %%%% !1110 4444
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M?:4$A8E@P0+N!<X.W' X-1S_  IT&X^%I^'YBE70/[.&FC:P$H0+M#[L8WY
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M,:&*%8EV *" 54$Y)Y].E7M0\-Z;JFM:7JUU;>;J&E^:;2;>P\KS%VOP#@Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*?V7?^
M2'^'_P#?NO\ TIEKU:O*?V7?^2'^'_\ ?NO_ $IEKU:@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O*OV9?\ DEUQ_P!C-XD_]/=]7JM>5?LR_P#)+KC_ +&;
MQ)_Z>[Z@#U6BBB@ HHHH **** "N1^&7_($U3_L-ZI_Z6S5UU<C\,O\ D":I
M_P!AO5/_ $MFK>/\*7JOU,G\:^?Z'74445@:A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%<)XT\;>)O#?B+1].T_PWINI
M6VK7)M+6XGUA[=O,6WEG;>@MWVC;"X!#')QP,\=O;M*]O$TT:Q3%07C5MP5L
M<@' SSWP* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Y_X@_P#(@^)?^P9<_P#HIJZ"N?\ B#_R(/B7_L&7/_HI
MJ ,[X-_\DA\$?]@.R_\ 1"5S?@'_ )+Y\5_^N&C_ /HB6ND^#?\ R2'P1_V
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M, ?TH OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;-6\?X4O5?J9/XU\_P!#KJ***P-0HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .'\?\ _(X?#7_L.S_^FN^KN*X?Q_\ \CA\
M-?\ L.S_ /IKOJ[B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?Q;
M_P E,\!?]O\ _P"B17<5P_BW_DIG@+_M_P#_ $2* .XHHHH **** "BBB@ H
MHHH *Y_X@_\ (@^)?^P9<_\ HIJZ"N?^(/\ R(/B7_L&7/\ Z*:@#.^#?_)(
M?!'_ & [+_T0E<WX!_Y+Y\5_^N&C_P#HB6ND^#?_ "2'P1_V [+_ -$)7-^
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MBB@ HHHH **** "BBB@ HHHH **** .'\?\ _(X?#7_L.S_^FN^KN*X?Q_\
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M9VRQ;DG).8](^ >@:#?6C6-]JD&E036MTVBB:,VD]Q;QK'#.^8_,+@1QL<.
MS1J6!YSZ510 5R.D_P#)4O$W_8+T[_T9=UUU<CI/_)4O$W_8+T[_ -&7==%/
MX:GI^J,Y;Q]?T9UU%%%<YH%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!Q'QJ_Y)9XB_Z]__ &9:[5/NK]*XKXU?\DL\1?\
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M002HSEL$8 )R.M=36%XR\*Z/XNT.6SUS31JMBA$YM><NR'<  ",\@<=#T/%
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRK]F7_ ))=<?\
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M"Z. >X#<C(.0<4 >5+XO\5S:%\&-8&N(EOKCV4.J6RV4>^[>6SDE9BYX1=R
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M?^(/_(@^)?\ L&7/_HIJZ"N?^(/_ "(/B7_L&7/_ **:@#.^#?\ R2'P1_V
M[+_T0E<WX!_Y+Y\5_P#KAH__ *(EKI/@W_R2'P1_V [+_P!$)7-^ ?\ DOGQ
M7_ZX:/\ ^B): /5:\0\?#5M"\<:S=^&IO%VERWPB:_;3]"BU"TN)%B55EC+D
M%7"!4..#L&0<<^WUXY\6?%5UX-U2ZO;KXLZ;X4T]D$D6E2Z/'=W"*J#>P ?S
M'&0S9"\ ^U '9_".'1X?A[I0T.[N;^P?S9#=7BE9Y)VE=IVE4@;9#*9-RX&&
MR,<5V%<?\)+&+3_ .G1Q)JBF22XN)6UJ 07<LTD\DDLCQ_P;W=G"]@PZ5V%
M!1110 5R.D_\E2\3?]@O3O\ T9=UUU<CI/\ R5+Q-_V"]._]&7==%/X:GI^J
M,Y;Q]?T9UU%%%<YH%%%% !1110 5POQRL;:\^#_C9Y[>*=X=#OWC:1 Q1OL[
M\KGH>.U=U7&?&K_DC?CS_L W_P#Z3R4 =;9VL-E:QPV\,<$*CY8XU"J._ %3
M4U/NK]*=0 4444 %%%% !1110 4444 %%%% !1110 45'//':PR332+##&I=
MY)&"JJ@9))/0 5Q"?&[P=/X<37;;4KF_TZ2[DL8VL=-NKF665 S.$BCB:1U"
MJ6WJI7:,YQS0!)\:O^26>(O^O?\ ]F6NU3[J_2O%?B[\9?".I> [O3K34Y;F
M75K.&2TN(K&X:U?S4$T:M<"/RD=HQN".X8@K@?,,]WXD^+7A?P?K$.DZK?SP
MWC+ TAAL+B>*V6:0QQ-/+'&T<"LZL TK*#M;G - '8T5R/A7XK^%_&VM76E:
M/J,ES>VZ/+B2SGACGC20QM)!)(BI/&'&TO$67E>?F&>NH **** "BBB@ HHH
MH **** "BBB@ J.X:5;>5K=$EG"DQI(Y16;' + $@9[X./0U)45U"]Q:S11S
MR6LDB,JSQ!2\9(P&7<"N1U&01QR#0!X->?&#QY'X;M+AK?3[:Y3Q!J&E:E>Z
M?X>O]9@M88/,".(()%E.615+D@<YVCH,+XK?%C6[Q?"5K;:AI6J^'=<U+2 E
MQ;Z+>0I-&S1S?:([R23R QDCVBU7S) AW%N&V^G:-\%[[P_IM_:6'Q)\6V_V
MV\EOYIA%I9D,DK%I,9LL ,S$\#C Q@<5R'Q*^"MGX>\&Z:ECXDU^+1]+U+23
M9Z*\\$EM%(MQ! LFYHC*3@EMID*%R6*DT 6?BA\;];\%_%33_#%I)I,/VK^S
M_LEA>6<TDVI^?<-'*%N5E6*U**C%1*K>8PPN2<4?!#X]7OQ&\46^E7VI^'-0
MEOM';5OL6B[UN='=941[2[5I7)D'FI\VV+E'&STZ?6O@58^(-4EN[OQ)KIAO
M8[--5LE:U$.J-;,&C>7]QN0G #"!HE('0<YW_"_P^'A_7+C6;[7M5\2ZK) +
M2.ZU7[.IMX-Q;RXT@AB0 MR6*ECA06(4  '6T444 %%%% !1110 4444 >4_
MLN_\D/\ #_\ OW7_ *4RUZM7E/[+O_)#_#_^_=?^E,M>K4 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5Y5^S+_P DNN/^QF\2?^GN^KU6O*OV9?\ DEUQ_P!C
M-XD_]/=]0!ZK6%XV2^;P[<-I^OP>&9HRKG4KJW2:.-0><J[*.>F2>*W:P_&7
M@K1OB!H,NC:[:?;=/D=9#&)'C8.IRK!D(8$$ @@T >0_#_7+?QA\3M.\_P ;
MW7Q GT=)I(IM*T9;;3K-I$9/,EG4E9"RJZJ%8CD\=Q[U7G?A'X7:EX)\97.J
MVGB>XU33+Z"*VNK/5H%DG58ED\KRYTV_=+D'>K$@_>R!6_\ $B31H_ ^L'Q#
M>0V&C^3B>:XNS;1\D!59]R\,VU2I.&W;2"&((!TM%?',VL>%M>\#:4E[>V>H
MZE#\/M/@\)A)4E=-87S5E2UP21="06(*K\PP >,UV7P?;3Y/&GA1[+R#XRWZ
MR/%9A ^U ><=HN\?,!Y@C\KS/X1\GRT ?2E<C\,O^0)JG_8;U3_TMFKKJY'X
M9?\ ($U3_L-ZI_Z6S5O'^%+U7ZF3^-?/]#KJ***P-0HHHH **** "N+^(_\
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M8J*^S_L'+?\ GU^,O\SY_P#M+%_S_@O\CZX_X>!WG_0DP?\ @R;_ .-4?\/
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M_?NO_2F6O5J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME_Y(A%_V$+C_ -EKWVOQ'-O]^K?XF?H>"_W:GZ(****\H[0HHHH *Y_X@_\
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M_P"C+NNNKD=)_P"2I>)O^P7IW_HR[KHI_#4]/U1G+>/K^C.NHHHKG- HHHH
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M]-_:6_Y+IXP_Z_/_ &1:\RK]VP/^ZTO\,?R1^;XC^-/U?YA1117:<X5]B_\
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MG_(O?JCV<I_WE>C/I*BBBOR4^W"BBB@ HHHH **** "BBB@ K\B-:_Y#%_\
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M=A4HTMM&0QD!5688; KWBB@ KD=)_P"2I>)O^P7IW_HR[KKJY'2?^2I>)O\
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M]EW_ )(?X?\ ]^Z_]*9:]6KRG]EW_DA_A_\ W[K_ -*9:]6H **** "BBB@
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M_>L_Y35\[Q!_R+:GR_\ 2D>IEG^]P^?Y,^OJ***_'C[P**** "BBB@ HHHH
M**** "ORT^.7_)9?&_\ V&+K_P!&M7ZEU^6GQR_Y++XW_P"PQ=?^C6K[CA7_
M 'BIZ?J?.YU_#AZG#T445^EGR(4444 ?6?\ P3__ .0YXR_Z][;_ -"DK[0K
MXO\ ^"?_ /R'/&7_ %[VW_H4E?:%?C_$/_(QJ?+\D?=Y7_ND?G^;"BBBOG#U
M0HHHH **** /*?V7?^2'^'_]^Z_]*9:]6KRG]EW_ )(?X?\ ]^Z_]*9:]6H
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M_F%%%%=ISA7V+_P3[_X]_''^]9_RFKXZK[%_X)]_\>_CC_>L_P"4U?.\0?\
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M]#=XS_\  NS_ /D6C_AWEX&_Z&[QG_X%V?\ \BU]3_K5A/Y)?A_F>-_8M?\
MF7X_Y'Q#17V]_P .\O W_0W>,_\ P+L__D6C_AWEX&_Z&[QG_P"!=G_\BT?Z
MU83^27X?YA_8M?\ F7X_Y"_L"_\ (B>)O^PDO_HI:^I*\(\%_LF6GP[L[BU\
M.?$KQWI5O<2>;+'%<V!#,!C/S6A[5T7_  H[5_\ HKWQ _[_ .G?_(=? YAB
M8XS%3KP5E+OZ'TV%I.A1C3ENCU6BO*O^%':O_P!%>^('_?\ T[_Y#H_X4=J_
M_17OB!_W_P!._P#D.O..H]5HKRK_ (4=J_\ T5[X@?\ ?_3O_D.C_A1VK_\
M17OB!_W_ -._^0Z /5:*\J_X4=J__17OB!_W_P!._P#D.C_A1VK_ /17OB!_
MW_T[_P"0Z /5:*\J_P"%':O_ -%>^('_ '_T[_Y#H_X4=J__ $5[X@?]_P#3
MO_D.@#U6H+W_ (\Y_P#KFW\J\Q_X4=J__17OB!_W_P!._P#D.D;X&:LZE6^+
MOQ *D8(\_3O_ )#I@?FE17V]_P .\O W_0W>,_\ P+L__D6C_AWEX&_Z&[QG
M_P"!=G_\BU^G?ZU83^27X?YGQ_\ 8M?^9?C_ )'Q#17V]_P[R\#?]#=XS_\
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M2+_A1VK_ /17OB!_W_T[_P"0Z\QF_P"">_@BXF>63QAXT9W8LS?:[/DGD_\
M+K7TV2YI2RQU'5BWS6V\K_YGD9A@YXQ1Y&E:^Y\/T5]O?\.\O W_ $-WC/\
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M%EBJ2A!VUN?!U%?;W_#O+P-_T-WC/_P+L_\ Y%H_X=Y>!O\ H;O&?_@79_\
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M'_?_ $[_ .0Z/^%':O\ ]%>^('_?_3O_ )#H ]5HKRK_ (4=J_\ T5[X@?\
M?_3O_D.C_A1VK_\ 17OB!_W_ -._^0Z /A[]I;_DNGC#_K\_]D6O,J^[M?\
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MH1J&HB6-2L:.BVZQR65IC8!G*K)G?S(2!0![I1110 4444 %%%% 'E/[+O\
MR0_P_P#[]U_Z4RUZM7E/[+O_ "0_P_\ []U_Z4RUZM0 4444 %%%% !1110
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MBC_AF#X3_P#0@:'_ . HH ]0HKR__AF#X3_]"!H?_@**/^&8/A/_ -"!H?\
MX"B@#U"BO+_^&8/A/_T(&A_^ HH_X9@^$_\ T(&A_P#@** /4**\O_X9@^$_
M_0@:'_X"BC_AF#X3_P#0@:'_ . HH ]0HKR__AF#X3_]"!H?_@**/^&8/A/_
M -"!H?\ X"B@#U"BO+_^&8/A/_T(&A_^ HH_X9@^$_\ T(&A_P#@** /4**\
MO_X9@^$__0@:'_X"BC_AF#X3_P#0@:'_ . HH ]0HKR__AF#X3_]"!H?_@**
M/^&8/A/_ -"!H?\ X"B@#U"BO+_^&8/A/_T(&A_^ HH_X9@^$_\ T(&A_P#@
M** /4**\O_X9@^$__0@:'_X"BC_AF#X3_P#0@:'_ . HH ]0HKR__AF#X3_]
M"!H?_@**/^&8/A/_ -"!H?\ X"B@#U"BO+_^&8/A/_T(&A_^ HH_X9@^$_\
MT(&A_P#@** /4**\O_X9@^$__0@:'_X"BC_AF#X3_P#0@:'_ . HH ]0HKR_
M_AF#X3_]"!H?_@**/^&8/A/_ -"!H?\ X"B@#U"BO+_^&8/A/_T(&A_^ HH_
MX9@^$_\ T(&A_P#@** /4**\O_X9@^$__0@:'_X"BC_AF#X3_P#0@:'_ . H
MH ]0HKR__AF#X3_]"!H?_@**/^&8/A/_ -"!H?\ X"B@#U"BO+_^&8/A/_T(
M&A_^ HH_X9@^$_\ T(&A_P#@** /4**\O_X9@^$__0@:'_X"BC_AF#X3_P#0
M@:'_ . HH ]0HKR__AF#X3_]"!H?_@**/^&8/A/_ -"!H?\ X"B@#U"BO+_^
M&8/A/_T(&A_^ HH_X9@^$_\ T(&A_P#@** /4**\O_X9@^$__0@:'_X"BC_A
MF#X3_P#0@:'_ . HH ]0HKR__AF#X3_]"!H?_@**/^&8/A/_ -"!H?\ X"B@
M#U"BO+_^&8/A/_T(&A_^ HH_X9@^$_\ T(&A_P#@** /4**\O_X9@^$__0@:
M'_X"BC_AF#X3_P#0@:'_ . HH ]0HKR__AF#X3_]"!H?_@**/^&8/A/_ -"!
MH?\ X"B@#U"N?^(/_(@^)?\ L&7/_HIJX_\ X9@^$_\ T(&A_P#@**1OV7?A
M+(K*WP_T)E88*FU!!'I0!T'P;_Y)#X(_[ =E_P"B$KF_ /\ R7SXK_\ 7#1_
M_1$M>G6-C;Z796]G9P1VMI;QK%#!"H5(T4855 X    %<;XL^!W@#QUK;ZQK
M_A#2=5U5XUA>\N+93*Z+G:&;J<9.,^M '<T5Y?\ \,P?"?\ Z$#0_P#P%%'_
M  S!\)_^A T/_P !10!ZA17E_P#PS!\)_P#H0-#_ / 44?\ #,'PG_Z$#0__
M  %% 'J%%>7_ /#,'PG_ .A T/\ \!11_P ,P?"?_H0-#_\  44 >H45Y?\
M\,P?"?\ Z$#0_P#P%%'_  S!\)_^A T/_P !10!ZA17E_P#PS!\)_P#H0-#_
M / 44?\ #,'PG_Z$#0__  %% 'J%%>7_ /#,'PG_ .A T/\ \!11_P ,P?"?
M_H0-#_\  44 >H45Y?\ \,P?"?\ Z$#0_P#P%%'_  S!\)_^A T/_P !10!Z
MA17E_P#PS!\)_P#H0-#_ / 44?\ #,'PG_Z$#0__  %% 'J%%>7_ /#,'PG_
M .A T/\ \!11_P ,P?"?_H0-#_\  44 >H45Y?\ \,P?"?\ Z$#0_P#P%%'_
M  S!\)_^A T/_P !10!ZA17E_P#PS!\)_P#H0-#_ / 44?\ #,'PG_Z$#0__
M  %% 'J%%>7_ /#,'PG_ .A T/\ \!11_P ,P?"?_H0-#_\  44 >H45Y?\
M\,P?"?\ Z$#0_P#P%%'_  S!\)_^A T/_P !10!ZA17E_P#PS!\)_P#H0-#_
M / 44?\ #,'PG_Z$#0__  %% 'J%%>7_ /#,'PG_ .A T/\ \!11_P ,P?"?
M_H0-#_\  44 >H45Y?\ \,P?"?\ Z$#0_P#P%%'_  S!\)_^A T/_P !10!Z
MA17E_P#PS!\)_P#H0-#_ / 44?\ #,'PG_Z$#0__  %% 'J%%>7_ /#,'PG_
M .A T/\ \!11_P ,P?"?_H0-#_\  44 >H45Y?\ \,P?"?\ Z$#0_P#P%%'_
M  S!\)_^A T/_P !10!ZA17E_P#PS!\)_P#H0-#_ / 44?\ #,'PG_Z$#0__
M  %% 'J%%>7_ /#,'PG_ .A T/\ \!11_P ,P?"?_H0-#_\  44 >H45Y?\
M\,P?"?\ Z$#0_P#P%%'_  S!\)_^A T/_P !10!ZA17E_P#PS!\)_P#H0-#_
M / 44?\ #,'PG_Z$#0__  %% 'J%%>7_ /#,'PG_ .A T/\ \!11_P ,P?"?
M_H0-#_\  44 >H45Y?\ \,P?"?\ Z$#0_P#P%%'_  S!\)_^A T/_P !10!Z
MA17E_P#PS!\)_P#H0-#_ / 44?\ #,'PG_Z$#0__  %% 'J%%>7_ /#,'PG_
M .A T/\ \!11_P ,P?"?_H0-#_\  44 >H45Y?\ \,P?"?\ Z$#0_P#P%%'_
M  S!\)_^A T/_P !10!ZA17E_P#PS!\)_P#H0-#_ / 44?\ #,'PG_Z$#0__
M  %% 'J%%>7_ /#,'PG_ .A T/\ \!11_P ,P?"?_H0-#_\  44 0_LN_P#)
M#_#_ /OW7_I3+7JU9OASPWI7A#0[/1M$T^WTK2K-/*M[.UC$<42^BJ.E:5 !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
C 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>formdrs_038.jpg
<TEXT>
begin 644 formdrs_038.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *J!%4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW%S_ ,\H^WU-9S^,[J!1)<Z#<PPGH[,>?S4#]:3P5IRO;2:O<#S+F=VV.W)
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M=V#CICBMNN'\'?\ (R:K_P "_P#0Z[BL,/.4X7EYF=.3E&["BBBN@T"BBB@
MHHHH **** "BBB@#A_ __(7U3_/\1KL+N_M+"(R75Q'$H&?F/)^@ZFO/- T.
MVUO4K]+F29!$<CRR!U)]0:Z6'P+I$3AG-S*!_"\@P?R KS\/*K[.T4NO7S.:
MDY<NB,S11)K_ (OFUCRRMK"?DSW.,*/KWKHO$_\ R+5]_P!<_P"HK3M[>&UA
M6&")8XU& JC %9GB?_D6K[_KG_45M[/DI2OJW=LTY>6#.6\+Z VKVL<]_*S6
M4+$10 X#'N3Z?SKIK_POI=W9-#':102;<))&NT@]LXZ_C4'@G_D6HO\ KH_\
MZZ&E0HP=)76Z%3A'D6AR?@6\FEL;JRF)/V5P%SV!SQ^8/YUO:MI[ZG8-:I<O
M;AF&YD&25[C\:Y;P.Q_M755SP2"1_P "/^-=1K&K0:-8-<S MSM1!U9O2E0:
M=#W]M0IM>SU*]IX8T>SC"K912G'+3*')_/C\JYSQ;H]OI*6VIZ<GV>190I"'
M SR00.W2K4%WXLU=1/;+;V4#\H7 Y'KR"?TK,\2VOB&'2U;5+ZWGM_- "QJ
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M5T.G_P#(-M?^N*?R%5#^/+T0U_$?R(M:_P"0%J'_ %[2?^@FLCP-_P BZ/\
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MY-6&)_A2]#.K\#*WA_PTMY;0ZCJY-P[QKY,3'Y53'RY_#M2^+/#UG'I;W]G
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M[W_=;^0J<12C>%M-;:=A5(JZL;MIX7TBUM?(-G',2,-)*NYC^/;\*YW3X_\
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MB\V+<&V[B.1[BJE3G*G*,G=O[AN,G%IO5D6B_P#("T__ *]H_P#T$56\3_\
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M5232;&/4GU%+<"Z<8,FX\\8Z9Q15IN;BUT=PG%RMY":S8G4M(N;0'#2)\O\
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M0 4C ,I!S@C'!Q2T4 5K'3[738#!:0B*,MN(R3D^N3S5FBBDDDK($K!1113
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JV
MH68O]/GM"Y02H5W 9Q5FBDTFK,&KF;H>DC1=.%H)O.^<L7V[>OMDUI444HQ4
M5RK8222L@JEJ>E6FKVWD7<>Y0<JP.&4^QJ[13:4E9@TGHSDD\%W%L2++7;JW
M3T4'^C"GQ^"DEF$FHZG<WF.S$C/XDDUU5%8?5J7;\_\ ,CV4.Q4ETNRFT[[
M\"_9< >6I*C@Y[<]:FMK:&TMTMX$"11C"J.PJ6BMU%)WL79!1113&%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M4U74(])TB]U*9&>*T@DG=4^\0BEB!GOQ6.NO:ZRAAX1O"",C_3+?_P"+J?QI
M_P B+XA_[!ES_P"BFK8@_P"/>+_<'\J ,'^W=>_Z%"\_\#+?_P"+H_MW7O\
MH4+S_P #+?\ ^+KHJ* .=_MW7O\ H4+S_P #+?\ ^+H_MW7O^A0O/_ RW_\
MBZZ*B@#G?[=U[_H4+S_P,M__ (NC^W=>_P"A0O/_  ,M_P#XNNBHH YW^W=>
M_P"A0O/_  ,M_P#XNC^W=>_Z%"\_\#+?_P"+KHJ* .=_MW7O^A0O/_ RW_\
MBZ/[=U[_ *%"\_\  RW_ /BZZ*B@#G?[=U[_ *%"\_\  RW_ /BZ/[=U[_H4
M+S_P,M__ (NNBHH YW^W=>_Z%"\_\#+?_P"+H_MW7O\ H4+S_P #+?\ ^+KH
MJ* .=_MW7O\ H4+S_P #+?\ ^+H_MW7O^A0O/_ RW_\ BZZ*B@#G?[=U[_H4
M+S_P,M__ (NC^W=>_P"A0O/_  ,M_P#XNNBHH YW^W=>_P"A0O/_  ,M_P#X
MNC^W=>_Z%"\_\#+?_P"+KHJ* .=_MW7O^A0O/_ RW_\ BZ/[=U[_ *%"\_\
M RW_ /BZZ*B@#G?[=U[_ *%"\_\  RW_ /BZ/[=U[_H4+S_P,M__ (NNBHH
MYW^W=>_Z%"\_\#+?_P"+H_MW7O\ H4+S_P #+?\ ^+KHJ* .=_MW7O\ H4+S
M_P #+?\ ^+H_MW7O^A0O/_ RW_\ BZZ*B@#G?[=U[_H4+S_P,M__ (NC^W=>
M_P"A0O/_  ,M_P#XNNBHH YW^W=>_P"A0O/_  ,M_P#XNC^W=>_Z%"\_\#+?
M_P"+KHJ* .=_MW7O^A0O/_ RW_\ BZ/[=U[_ *%"\_\  RW_ /BZZ*B@#G?[
M=U[_ *%"\_\  RW_ /BZ/[=U[_H4+S_P,M__ (NNBHH YW^W=>_Z%"\_\#+?
M_P"+H_MW7O\ H4+S_P #+?\ ^+KHJ* .=_MW7O\ H4+S_P #+?\ ^+H_MW7O
M^A0O/_ RW_\ BZZ*B@#G?[=U[_H4+S_P,M__ (NC^W=>_P"A0O/_  ,M_P#X
MNNBHH YW^W=>_P"A0O/_  ,M_P#XNC^W=>_Z%"\_\#+?_P"+KHJ* .=_MW7O
M^A0O/_ RW_\ BZ/[=U[_ *%"\_\  RW_ /BZZ*B@#G?[=U[_ *%"\_\  RW_
M /BZ/[=U[_H4+S_P,M__ (NNBHH YW^W=>_Z%"\_\#+?_P"+H_MW7O\ H4+S
M_P #+?\ ^+KHJ* .=_MW7O\ H4+S_P #+?\ ^+H_MW7O^A0O/_ RW_\ BZZ*
MB@#G?[=U[_H4+S_P,M__ (NC^W=>_P"A0O/_  ,M_P#XNNBHH YW^W=>_P"A
M0O/_  ,M_P#XNC^W=>_Z%"\_\#+?_P"+KHJ* .=_MW7O^A0O/_ RW_\ BZ/[
M=U[_ *%"\_\  RW_ /BZZ*B@#G?[=U[_ *%"\_\  RW_ /BZ/[=U[_H4+S_P
M,M__ (NNBHH YW^W=>_Z%"\_\#+?_P"+H_MW7O\ H4+S_P #+?\ ^+KHJ* .
M=_MW7O\ H4+S_P #+?\ ^+J_H6L?VU92S-:2VDL,\EO+#*RL5=#@\J2"*TZY
MWPC_ *K6?^PO<_\ H5 '15S,?B?4;N2X-AX:O+J"&XEM_.%S @9HW*,0&<'&
M5/6NFKG_  ?_ ,@J]_["M_\ ^E4E #?[=U[_ *%"\_\  RW_ /BZ/[=U[_H4
M+S_P,M__ (NNBHH YW^W=>_Z%"\_\#+?_P"+H_MW7O\ H4+S_P #+?\ ^+KH
MJ* .=_MW7O\ H4+S_P #+?\ ^+H_MW7O^A0O/_ RW_\ BZZ*B@#G?[=U[_H4
M+S_P,M__ (NC^W=>_P"A0O/_  ,M_P#XNNBHH YW^W=>_P"A0O/_  ,M_P#X
MNC^W=>_Z%"\_\#+?_P"+KHJ* .=_MW7O^A0O/_ RW_\ BZ/[=U[_ *%"\_\
M RW_ /BZZ*B@#G?[=U[_ *%"\_\  RW_ /BZ/[=U[_H4+S_P,M__ (NNBHH
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M"_DN1+9-I_-U'<*-T8(R#\I(((Z8)S1:^((I[^"RN+&]L9KF,R0"Y51Y@')
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MEZ=?I&MY86MPL7$8FA5PGTR..@_*K=% %:YTZQO+9+>ZL[>>!""D4L2LJD#
MP",#@XIO]EZ?Y31?8;;RV<.R>2N"PQ@D8ZC Y]JMT4 4I]'TNZN&N+C3;.:=
MEVF22!68C&,9(SC'%6%M;=)_/6")9A&(O," -L!R%SUQGM4M% &3J.@V]];V
M]K&([>U2Z6XEBCB $I!W8.,8RV"3SG%:U%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5SJ_\ )1Y?^P0G_HYJZ*N=7_DH\O\
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M* "BBB@ KG5_Y*/+_P!@A/\ T<U=%7.K_P E'E_[!"?^CFH Z*BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SJ_\E'E_[!"?^CFK
MHJYU?^2CR_\ 8(3_ -'-0!T5%%% !1110 4444 %%%% &'XT_P"1%\0_]@RY
M_P#135L0?\>\7^X/Y5C^-/\ D1?$/_8,N?\ T4U;$'_'O%_N#^5 $E5;Z6\A
M16LK..Y<G#!YO+P/K@YJU69XB&?#>I#$I_T9^(C\WW3TH HQW&I7^LV!EAMK
M>*!W:18[T2%\H0!M"CN<UT(&!@=*Y/0++RKZWE_LOPU!\A_>V#YE^[V^0?CS
MT]:ZB=96@=8)%CE(PKNFX*?4C(S^= $E%<C:7^IZE;Z=:KJ;V\TEK//)<B.,
MLQ1U1005*@?-DX';M5.#Q+J4VE+KIGVQ^?'$;$(NPAHE).<;L[FSUP ,8/6@
M#NJ*Y[1+N^-[!!=WC70N+!+K+(B^6Y."%V@?*<C&<GCJ:Z&@#,T?_6ZG_P!?
MK?\ H*UIUF:/_K=3_P"OUO\ T%:TZNI\7]=D3'8****@H**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#)3_D;I_^O"/_ -&/6M62G_(W3_\
M7A'_ .C'K6H **** "BBB@ HHHH **** "N=\(_ZK6?^PO<_^A5T5<[X1_U6
ML_\ 87N?_0J .BKG_!__ ""KW_L*W_\ Z525T%<_X/\ ^05>_P#85O\ _P!*
MI* .@HHJ"\LX;ZW-O.',3$%@DC)GVRI!Q[4 .-Q LOE&:,29QL+#/Y5+7$6U
MQX/,4EM>:19P3)*\;)]A+YPQ 8.$YR,'/O776-A;Z=;^1;*ZQ9)"L[,%]ADG
M ]NE &/I&M7UY<V372VXM]0@DGMUC0AXPI7"L2Q#95@<@#D'BK8OK_\ MZXL
M3';>6+7SH/F;).['S'L/8 XQU.<!EIX<AL7#07MV/+1H[<,4(MT9@Q5,KT.
M,MDX'6I)-%:35)+_ /M.]1WB:$(HB"JI]/DSP>0<]1W'% !H][>W%Q?VUXUO
M*UK(J">WC9$8E02N"S<K]>XX%:M9^D:5_9%M]F6]N;B( !!.(_EZDG*JI)).
M23DD\^N="@#,\._\B_9?]<_ZFM.LSP[_ ,B_9?\ 7/\ J:TZNI\;]28_"@HH
MHJ"@HHHH Y'7/^0M-]%_D*SJT=<_Y"TWT7^0K.KP:O\ $EZGT%'^''T"BBBL
MS4*LZ=_R$K;_ *Z+_.JU6=._Y"5M_P!=%_G50^)$3^%^AVU%%%?0'SH4444
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M@#D=<_Y"TWT7^0K.K1US_D+3?1?Y"LZO!J_Q)>I]!1_AQ] HHHK,U"K.G?\
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M?^2CR_\ 8(3_ -'-715SJ_\ )1Y?^P0G_HYJ .BHHHH **** "BBB@ HHHH
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M% !1110!DI_R-T__ %X1_P#HQZUJR4_Y&Z?_ *\(_P#T8]:U !1110 4444
M%%%% !1110 5SOA'_5:S_P!A>Y_]"KHJYWPC_JM9_P"PO<_^A4 =%7/^#_\
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M_'O%_N#^58_C3_D1?$/_ &#+G_T4U;$'_'O%_N#^5 $E9FNB*XT\Z;(V'O\
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M^%[6*#3973S"SW$RDO(S\+*ZJ.2>@&* -NBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH R=?_ -38?]?\'_H8K6K)U_\ U-A_U_P?^ABM:@ HHHH
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MHG_?0IP(89!!'J*\]KM=&_Y!%O\ [I_F:RJT>17N:4ZO.[6+U%%%<YN%%%%
M!1110 5SOA'_ %6L_P#87N?_ $*NBKG?"/\ JM9_["]S_P"A4 =%7/\ @_\
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MNEL&FC!^U7)P6'_/=ZY6BJ^JKN3]9?8[[[5;_P#/>+_OL4"Y@) $T9)[;Q7
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M25T%<_X/_P"05>_]A6__ /2J2@#H*K:A=066GW%S= F".,M( N[(],=ZLT4
M><P:G;37Z3:3>0:# 7RRM-O,H_ZXC*+GUSFO1J** ,32]?DU"Y@62S$,%W$\
MUI()=Q=5('S+M&TD,#C)[\\4B>(6-^%DM4CL&N9+5;EIOF\Q 2<IMP%RK#.[
MMT&:98>'[FP>$KJ$<BVD;0V:O;G]VC,"=^'^<[5"@C;ZX--E\++<S2PW5UYN
MF//+<?9=A5M\BD,#(&Y7YG(  /(Y.* +FBZS_;'VL_9C"D,H5"6R9$*JRMC
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MH *VO#/_ "$)/^N1_F*Q:VO#/_(0D_ZY'^8K*K\#-*7QHZFBBBO,/2"BBB@
MHHHH **** "BBB@ K-U[_D$2_5?YBM*LW7O^01+]5_F*NG\:(J?"SCJ***]4
M\P**** "NUT;_D$6_P#NG^9KBJ[71O\ D$6_^Z?YFN;$_"CIP_Q,O4445P':
M%%%% !1110 5SOA'_5:S_P!A>Y_]"KHJYWPC_JM9_P"PO<_^A4 =%7/^#_\
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M?$CB****^?/HPHHHH *Z+PU_JKC_ 'E_K7.UT7AK_57'^\O]:Z<+_%1RXO\
MA,W:***]D\0**** "BBB@ KG5_Y*/+_V"$_]'-715SJ_\E'E_P"P0G_HYJ .
MBHHHH **** "BBB@ HHHH P_&G_(B^(?^P9<_P#HIJV(/^/>+_<'\JQ_&G_(
MB^(?^P9<_P#HIJV(/^/>+_<'\J )**** "BBB@"M>:=8ZBJK?6=O=*ARHGB5
MPI]LBF)I&FQS0S)I]HLL"[(76%0T:\\*<<#D\#U-7** *]M86=G)-):VD$#S
M'=*T484R'GEB!SU/7UJQ110!F:/_ *W4_P#K];_T%:TZS-'_ -;J?_7ZW_H*
MUIU=3XOZ[(F.P4445!04444 <EXB_P"0I_P 5DUK>(O^0I_P 5DUZE+X$>;4
M^-A1116AF%36G_'Y!_UT7^=0U-:?\?D'_71?YTGL-;G>T445Y!ZH4444 %%%
M% !1110 4444 %%%% 'GS_?;ZTVG/]]OK3:]@\D**** "MKPS_R$)/\ KD?Y
MBL6MKPS_ ,A"3_KD?YBLJOP,TI?&CJ:***\P](**** "BBB@ HHHH **** "
MLW7O^01+]5_F*TJS=>_Y!$OU7^8JZ?QHBI\+..HHHKU3S HHHH *[71O^01;
M_P"Z?YFN*KM=&_Y!%O\ [I_F:YL3\*.G#_$R]1117 =H4444 %%%% !7.^$?
M]5K/_87N?_0JZ*N=\(_ZK6?^PO<_^A4 =%7/^#_^05>_]A6__P#2J2N@KG_!
M_P#R"KW_ +"M_P#^E4E '04444 %%%% &!8>'[FP>$KJ$<BVD;0V:O;G]VC,
M"=^'^<[5"@C;ZX-'_"/7"W;O'J"BW6XDNX(F@RR3.I&2V[YE!9B%P.HYXK?H
MH R]$TVZTRV>&YNH+DL=YDC@:-W<_>9R7;<3QTP!C XP!J444 9GAW_D7[+_
M *Y_U-:=9GAW_D7[+_KG_4UIU=3XWZDQ^%!1114%!1110!R.N?\ (6F^B_R%
M9U:.N?\ (6F^B_R%9U>#5_B2]3Z"C_#CZ!11169J%6=._P"0E;?]=%_G5:K.
MG?\ (2MO^NB_SJH?$B)_"_0[:BBBOH#YT**** "BBB@ HHHH **** "BBB@#
MA+C_ (^9?]\_SJ.I+C_CYE_WS_.HZ^>>[/I([(****0PK6\/?\A(_P#7,_S%
M9-:WA[_D)'_KF?YBMJ'\2)CB/X4O0ZFBBBO</ "BBB@ HHHH **** "BBB@
MJO?_ /(/N?\ KDW\C5BJ]_\ \@^Y_P"N3?R-3/X65#XD<11117SY]&%%%% !
M71>&O]5<?[R_UKG:Z+PU_JKC_>7^M=.%_BHY<7_"9NT445[)X@4444 %%%%
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M$)TC_GOK?_@\O?\ X[1_PA.D?\]];_\ !Y>__':YS<Z*BN=_X0G2/^>^M_\
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M_P#P>7O_ ,=H_P"$)TC_ )[ZW_X/+W_X[0!T5%<[_P (3I'_ #WUO_P>7O\
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M_@\O?_CM(W@C1V4JTVM%2,$'7+W!_P#(M)JZ:'%V:9AT5K?\*\\._P!S5/\
MP<WG_P =H_X5YX=_N:I_X.;S_P".UYOU*7<]3Z_'^4R:*UO^%>>'?[FJ?^#F
M\_\ CM'_  KSP[_<U3_P<WG_ ,=H^I2[A]?C_*9-=%X:_P!5<?[R_P!:I_\
M"O/#O]S5/_!S>?\ QVI(_ >AP@B)]83/7;K=X,_^1:UHX5TYJ39C6Q:J0<4C
MI:*YW_A"=(_Y[ZW_ .#R]_\ CM'_  A.D?\ /?6__!Y>_P#QVNXX#HJ*YW_A
M"=(_Y[ZW_P"#R]_^.T?\(3I'_/?6_P#P>7O_ ,=H Z*BN=_X0G2/^>^M_P#@
M\O?_ ([6AI>AV>CM*;62^<R@!OM5_/<=,]/-=L=>V,T :5<ZO_)1Y?\ L$)_
MZ.:NBKG5_P"2CR_]@A/_ $<U '14444 %%%% !1110 4444 8?C3_D1?$/\
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M007<$LT)Q+''(&:,^C =.AZU6L]82[U"2R-I=6\BIYJ&95 D3<5W  DCD=&
M//2H-(L+VRO+LR"*&RD.Z*WCF:4!RQ+,"54J#D?*,CKC'>O8Z9J%MJ4U_P#9
M-.@=X]KQVTC*MRY8$R/\GRD -CAC\YRU %]-8CDO9X$MIS!;DK-=DHL4;!<D
M$E@QQQR 0,]>#A\>MZ5+(D<>IV3R.YC55N%)9QU4#/)Y''O7.WGA*>:\NWAB
ML8S+-+,MX"1,0\;+Y;87[NYNNX\#IZ67\,S>5<*GV96>*SC0C(V^2VYNW X&
M/IVH W%U33FOC8K?VIO!P;<3+YG3/W<YZ<U;KC=$BNH_%$HFL[OR_.NF1F#*
MD0=]V?\ 5 -NPO\ RT?U '..RH **** "BBB@ HHHH **** *&L:M!HFG/?7
M$<LD:LJE8E#-EB ,#(]:1=;L"UR7G2*&W2-WGD8+&0_W2&)_SD4NJV4E];P1
MQ,@,=U#,=Q/W4D#'\<"L2'PU?V,>I16=S&L4LD/V91*\;")6RT9< E>"5!7)
MQB@#>_M;3=MLW]H6FVZ.VW/G+B4YQA>?FY('%2B]M2%(N82&+!?W@YV_>Q],
M'/I7-67A_5+-;1HOL\=RD\CR3B[D<B-Y=[1D,G[S([L0<\@BGIH&H"=(Y8[.
M6RA:[* S.&E$Q8A6^7Y<;L$@GU]B =#;7]G>6YN+6[@G@!(,D4@91CKR.*KZ
M7K-MJUI-=0B2.**1D)F 7. #NZ]""#S5.VT>[GT&XTW4;AHUE8K'Y$OF-%%Q
MA-[*-W0C+#.#@YZTW3=%O+&*^MY;K[3%>3.Q=V56C0I@$!4 +$XR. !T]" 2
MV?B6RN1NF66R0Q+/&]V419(V. P(8X[<'!Y'%7;;5M.O)5BM=0M9Y&3>$BF5
MB5SC. >F>]<ZOAK4;E;(7QLO]#2"%51F82HDBNS'*C!(087GZU)<^'[F*&66
M-8F83WEP53)9Q*C!0.!D\KGGMUH W[/5-.U!W6RO[6Y9.7$,RN5^N#Q5NN6\
M&I<1QW*W%M<J^R(>?-N&X!2H0*T4>-H'8'[WWC74T %%%% !1110 5SJ_P#)
M1Y?^P0G_ *.:NBKG5_Y*/+_V"$_]'-0!T5%%% !1110 4444 %%%% &'XT_Y
M$7Q#_P!@RY_]%-6Q!_Q[Q?[@_E3+ZS@U'3[FQNDWV]S$T,J@D;E8$$9'(X-8
MH\(6BJ -4UP # _XFL__ ,50!T-%<_\ \(C:_P#04US_ ,&L_P#\51_PB-K_
M -!37/\ P:S_ /Q5 '045S__  B-K_T%-<_\&L__ ,51_P (C:_]!37/_!K/
M_P#%4 =!17/_ /"(VO\ T%-<_P#!K/\ _%4?\(C:_P#04US_ ,&L_P#\50!T
M%%<__P (C:_]!37/_!K/_P#%4?\ "(VO_04US_P:S_\ Q5 '045S_P#PB-K_
M -!37/\ P:S_ /Q5'_"(VO\ T%-<_P#!K/\ _%4 =!17/_\ "(VO_04US_P:
MS_\ Q5'_  B-K_T%-<_\&L__ ,50!T%%<_\ \(C:_P#04US_ ,&L_P#\51_P
MB-K_ -!37/\ P:S_ /Q5 '045S__  B-K_T%-<_\&L__ ,51_P (C:_]!37/
M_!K/_P#%4 =!17/_ /"(VO\ T%-<_P#!K/\ _%4?\(C:_P#04US_ ,&L_P#\
M50!T%%<__P (C:_]!37/_!K/_P#%4?\ "(VO_04US_P:S_\ Q5 '045S_P#P
MB-K_ -!37/\ P:S_ /Q5'_"(VO\ T%-<_P#!K/\ _%4 =!17/_\ "(VO_04U
MS_P:S_\ Q5'_  B-K_T%-<_\&L__ ,50!T%%<_\ \(C:_P#04US_ ,&L_P#\
M51_PB-K_ -!37/\ P:S_ /Q5 '045S__  B-K_T%-<_\&L__ ,51_P (C:_]
M!37/_!K/_P#%4 =!17/_ /"(VO\ T%-<_P#!K/\ _%4?\(C:_P#04US_ ,&L
M_P#\50!T%%<__P (C:_]!37/_!K/_P#%4?\ "(VO_04US_P:S_\ Q5 '045S
M_P#PB-K_ -!37/\ P:S_ /Q5'_"(VO\ T%-<_P#!K/\ _%4 =!17/_\ "(VO
M_04US_P:S_\ Q5'_  B-K_T%-<_\&L__ ,50!T%%<_\ \(C:_P#04US_ ,&L
M_P#\51_PB-K_ -!37/\ P:S_ /Q5 '045S__  B-K_T%-<_\&L__ ,51_P (
MC:_]!37/_!K/_P#%4 =!17/_ /"(VO\ T%-<_P#!K/\ _%4?\(C:_P#04US_
M ,&L_P#\50!T%%<__P (C:_]!37/_!K/_P#%4?\ "(VO_04US_P:S_\ Q5 '
M045S_P#PB-K_ -!37/\ P:S_ /Q5'_"(VO\ T%-<_P#!K/\ _%4 =!17/_\
M"(VO_04US_P:S_\ Q5'_  B-K_T%-<_\&L__ ,50!T%%<_\ \(C:_P#04US_
M ,&L_P#\51_PB-K_ -!37/\ P:S_ /Q5 '045S__  B-K_T%-<_\&L__ ,51
M_P (C:_]!37/_!K/_P#%4 =!17/_ /"(VO\ T%-<_P#!K/\ _%4?\(C:_P#0
M4US_ ,&L_P#\50!T%%<__P (C:_]!37/_!K/_P#%4?\ "(VO_04US_P:S_\
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M045S_P#PB-K_ -!37/\ P:S_ /Q5'_"(VO\ T%-<_P#!K/\ _%4 =!17/_\
M"(VO_04US_P:S_\ Q5'_  B-K_T%-<_\&L__ ,50!T%%<_\ \(C:_P#04US_
M ,&L_P#\51_PB-K_ -!37/\ P:S_ /Q5 '045S__  B-K_T%-<_\&L__ ,51
M_P (C:_]!37/_!K/_P#%4 =!17/_ /"(VO\ T%-<_P#!K/\ _%4?\(C:_P#0
M4US_ ,&L_P#\50!T%%<__P (C:_]!37/_!K/_P#%4?\ "(VO_04US_P:S_\
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M_@8/_B:/^$3/_0PZ]_X&#_XFNBHH YW_ (1,_P#0PZ]_X&#_ .)H_P"$3/\
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MKW_@8/\ XFNBHH YW_A$S_T,.O?^!@_^)H_X1,_]##KW_@8/_B:Z*B@#G?\
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M_P#B:Z*B@#G?^$3/_0PZ]_X&#_XFC_A$S_T,.O?^!@_^)KHJ* .=_P"$3/\
MT,.O?^!@_P#B:/\ A$S_ -##KW_@8/\ XFNBHH YW_A$S_T,.O?^!@_^)H_X
M1,_]##KW_@8/_B:Z*B@#G?\ A$S_ -##KW_@8/\ XFC_ (1,_P#0PZ]_X&#_
M .)KHJ* .=_X1,_]##KW_@8/_B:/^$3/_0PZ]_X&#_XFNBHH YW_ (1,_P#0
MPZ]_X&#_ .)H_P"$3/\ T,.O?^!@_P#B:Z*B@#G?^$3/_0PZ]_X&#_XFC_A$
MS_T,.O?^!@_^)KHJ* .=_P"$3/\ T,.O?^!@_P#B:/\ A$S_ -##KW_@8/\
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MBBB@ HHHH *YWPC_ *K6?^PO<_\ H5=%7.^$?]5K/_87N?\ T*@#HJY_P?\
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MHHH **** "BBB@ HHHH *YU?^2CR_P#8(3_T<U=%7.K_ ,E'E_[!"?\ HYJ
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MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG5_Y*/+_P!@A/\
MT<U=%7.K_P E'E_[!"?^CFH Z*BBB@ HHHH **** "BBB@##\:?\B+XA_P"P
M9<_^BFK8@_X]XO\ <'\JQ_&G_(B^(?\ L&7/_HIJV(/^/>+_ '!_*@"2BBLC
M7XE%C+>37-\D%M&SM#:2^69,<\L,-^1'XT :]5M0L8M2L);2<N$D ^9#AE(.
M0P]P0"/I6!:Z=X=NGC72]7E2=ERAM]3=F(Z_=9B#Z\CM731JR1(K.9&50"[
M L?4XX_*@"E8Z6+%V<7ES+)(YDF>79F9B HW848P%  7 ]<U+I]A%IUH+>)G
M<;F=GD(+.S$DDD=22:M44 %9N@?\@6#_ 'G_ /0VK2K-T#_D"P?[S_\ H;5:
M^!_+]2?M(TJ***@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH R="ZZG_U_P O]*UJR="ZZG_U_P O]*UJ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH RM%_UFJ?]?S_ /H*UJUE:+_K
M-4_Z_G_]!6M6@ HHHH **** "BBB@ HHHH *YWPC_JM9_P"PO<_^A5T5<[X1
M_P!5K/\ V%[G_P!"H Z*N?\ !_\ R"KW_L*W_P#Z525T%<_X/_Y!5[_V%;__
M -*I* .@J"\GFM[<O!:O<RY 6-&5<_BQ  J>B@#$^T^)''F)I^E[<_ZLWKEN
M.HSY>,YK2L9[BXM]]S9O:R@D&-G5Q]01U'Y'VKD+>2XMIIXM.U;4FM1<2$"'
M2_,C#%B6"L1R-V?;K7<4 %%%% !1110!F>'?^1?LO^N?]36G69X=_P"1?LO^
MN?\ 4UIU=3XWZDQ^%!1114%!1110!XQX_P#^1RO?]V/_ - 6N9KIO'__ ".5
M[_NQ_P#H"US-?'XG^-/U9]GA?X$/1!1116!T!6KX9_Y&C2_^OJ/_ -"%95:O
MAG_D:-+_ .OJ/_T(5I2_B1]5^:,ZO\.7H_R9[Q1117V9\0%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5SJ_P#)1Y?^P0G_ *.:NBKG5_Y*
M/+_V"$_]'-0!T5%%% !1110 4444 %%%% &'XT_Y$7Q#_P!@RY_]%-6Q!_Q[
MQ?[@_E6/XT_Y$7Q#_P!@RY_]%-6Q!_Q[Q?[@_E0!)6)XEURRT?3)Q/+:_:'A
M9H8+AN)2!TQW&:VZHW]G=W#))9ZC):2*,$>6KHWU4\_D10!SOA^[TZ?4X!!K
M6DW,I4D16]DL3GY><'=D5M>)+B2VT&=XI6A):.,R*<%%:158@]B 3SVJ,Z?K
MTF%EUV%$Q@FWL0KGWRSL ?PK5^SQM:?9IAY\93RW$H#;QC!W=CGO0!@VUQ-8
MV?B"."669+)F-NTTC2D'R5<KN8DG#'N>^*/#$\H>2VN%=K@VT-PTWVZ2X5PV
MX X8 (3M)PHQSQTXVH-.L;58EM[*WA$.[RA'$J[-WWL8'&>^.M+::?9:>C)9
M6EO;*YW,L,80$^IP* +%9N@?\@6#_>?_ -#:M*LW0/\ D"P?[S_^AM5KX'\O
MU)^TC2HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#)T+KJ?\ U_R_TK6K)T+KJ?\ U_R_TK6H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#*T7_ %FJ?]?S_P#H*UJUE:+_ *S5
M/^OY_P#T%:U: "BBB@ HHHH **** "BBB@ KG?"/^JUG_L+W/_H5=%7.^$?]
M5K/_ &%[G_T*@#HJY_P?_P @J]_["M__ .E4E=!7/^#_ /D%7O\ V%;_ /\
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M%% !1110 5SJ_P#)1Y?^P0G_ *.:NBKG5_Y*/+_V"$_]'-0!T5%%% !1110
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M0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*T7_6:I_P!?S_\
MH*UJUE:+_K-4_P"OY_\ T%:U: "BBB@ HHHH **** "BBB@ KG?"/^JUG_L+
MW/\ Z%715SOA'_5:S_V%[G_T*@#HJY_P?_R"KW_L*W__ *525T%<_P"#_P#D
M%7O_ &%;_P#]*I* .@K,\0W<]CX?OKJV;;/%$60X!Y_'BM.FR1I+&T<B*Z,,
M%6&0?PH XO\ LO?<O,?"FJJ\DAD=AJP +$\G FKMJQD\1+.S_9M,U&XB61HQ
M-'$NQBIP<98'&0>U;- '(^'KB9[K2IC=SSR7]I--=))*S*K!EP54G"8+%<#
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MU>34!-.9VMTD6W^SLBOQL,8W@A"OWSSSUQQTM !1110 4444 %%%% !1110
M4444 %9OB'_D6M5_Z\YO_0#6E6;XA_Y%K5?^O.;_ - -14^"7H_R9I2^./JO
MS1X)1117Q9]N%%%% !7IGPL_X\]2_P"NB?R->9UZ9\+/^//4O^NB?R-=^7_[
MQ'Y_D>?F7^[2^7YGH-%%%?4'R@4444 %%%% !7.K_P E'E_[!"?^CFKHJYU?
M^2CR_P#8(3_T<U '14444 %%%% !1110 4444 8?C3_D1?$/_8,N?_135L0?
M\>\7^X/Y5C^-/^1%\0_]@RY_]%-6Q!_Q[Q?[@_E0!)5+5[Q].T>\O(D1Y((6
M=5<X!('>KM4M7:X31[Q[2$37 B8QQE=P9L<<=_IWH S-(UDWUU"A\0:+=EUS
MY%K&5D/&>,RL>/\ =_*M35;#^T]-EM/-,3-M9) ,['5@RG'<9 X[UR^D'4X?
M%"6T\S2Q!G)_XEZQ#RS&"K[PO'S$KMSG(KM* ,>'19#'=I>W$5P+XM]KVQ-'
MO&P(JIA\J !SR2<GD4_2M"ATF]O+B&:=Q<%<)+-(^P*H'5F.>G7\.E:M% !6
M;H'_ "!8/]Y__0VK2K-T#_D"P?[S_P#H;5:^!_+]2?M(TJ***@H**** "BBB
M@ HHHH R?#7_ " 8/]^3_P!&-6M63X:_Y ,'^_)_Z,:M:@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** ,G0NNI_]?\ +_2M:LG0NNI_]?\ +_2M
M:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,K1?]9JG_7\_P#Z
M"M:M96B_ZS5/^OY__05K5H **** "BBB@ HHHH **** "N=\(_ZK6?\ L+W/
M_H5=%7.^$?\ 5:S_ -A>Y_\ 0J .BKG_  ?_ ,@J]_["M_\ ^E4E=!7/^#_^
M05>_]A6__P#2J2@#H***IZI>"PT^2<S00D8"O/G8"3WQS0!PD]U';7D\EK%K
M0MFDEG,B:@(T($NQWV=0-Q^O>O1Z\]NKZSN[D%[OPTZ+.SH&67=N8@G.#C)P
M"?4UZ%0 4444 %%%% &9X=_Y%^R_ZY_U-:=9GAW_ )%^R_ZY_P!36G5U/C?J
M3'X4%%%%04%%%% 'C'C_ /Y'*]_W8_\ T!:YFNF\?_\ (Y7O^['_ .@+7,U\
M?B?XT_5GV>%_@0]$%%%%8'0%:OAG_D:-+_Z^H_\ T(5E5J^&?^1HTO\ Z^H_
M_0A6E+^)'U7YHSJ_PY>C_)GO%%%%?9GQ 4444 %%%% !1110 4444 %%%% $
M%[96^HV<MI=1^9!*,,N2/?@CD'/((Y%5[71[.RC"6XG0 N23<R%G+=68ELL>
M!@MDCMBN"NOB9?V]Y/"+"V(CD9 26YP<>M1?\+1U#_H'VOYM_C7 \QPZ=K_@
M>@LMQ#5[?B=POA;2DL[FT O?)NFW3*;^<ESR#R7SSGGUXSG IS>&=*=H"\,S
MF%%0;[F5MZJQ95?+?O "20&SC-<+_P +1U#_ *!]K^;?XT?\+1U#_H'VOYM_
MC2_M'#]_P'_9F([?B>A6VC6=K>M>()WN"&4//<R2[ Q!(4.Q"@X'3'0>E7Z\
MN_X6CJ'_ $#[7\V_QK;\*>-;OQ!K!LIK6&)!$TFY"<Y!'K]:N&.H3DHQ>K\B
M)X"O3BYR6B\SMJ***[3A"BBB@ HHHH **** "BBB@ K-\0_\BUJO_7G-_P"@
M&M*LWQ#_ ,BUJO\ UYS?^@&HJ?!+T?Y,TI?''U7YH\$HHHKXL^W"BBB@ KTS
MX6?\>>I?]=$_D:\SKTSX6?\ 'GJ7_71/Y&N_+_\ >(_/\CS\R_W:7R_,]!HH
MHKZ@^4"BBB@ HHHH *YU?^2CR_\ 8(3_ -'-715SJ_\ )1Y?^P0G_HYJ .BH
MHHH **** "BBB@ HHHH P_&G_(B^(?\ L&7/_HIJV(/^/>+_ '!_*L?QI_R(
MOB'_ +!ES_Z*:MB#_CWB_P!P?RH DJIJD%Q=:3=P6DWDW$D3+')G&UB..>WU
M[5;K%\2Z?IE]IZ-JET+6*%]Z2EU4!L'J&R#]"* ,K0M)U*WU)/,L!8V45Q).
M%^T"3.Z,(%&.O.3DUL^)+B2VT&=XI6A):.,R*<%%:158@]B 3SVK \,0*NJJ
M8-(BEME4[-42%K?/!XV-][/3*\5V4L4<\3Q2HLD;J5='&0P/!!'<4 8VE/Y#
M:S;-=R_9;6;"3S2EVC!C5F&]\YVDD\YQGVJ+PXMQ;7^I65U)(7C$4@C:Z>Y"
M*P(R)'PV25)*X '&.M:T6EZ?!'''%8VT:1A@BI"H"AOO8&.,]_6GV=C9Z?$8
MK*U@MHRVXI#&$!/3.!WX'Y4 6*S= _Y L'^\_P#Z&U:59N@?\@6#_>?_ -#:
MK7P/Y?J3]I&E1114%!1110 4444 <9X=N9WO=)N#>7$\NH6UQ+=1R3,R*5=<
M%4)PFTDI@ #GGFK6H2/;>(3=64NH73VJ23WL$<K.FSRB(X5C'R[V;:PP,X!R
M?F&=L:-I:M<L--LPUT<W!$"YE.<_-Q\W//-(-#TD7_V\:79?;-V_[1]G3S-W
MKNQG- 'GGAG6KM=(O[4G4VDFNPC21VD[BU1E+.4 4D="  .K*3W-7[*XO3H^
MDZ_.]W<V,=G;QRJU_<6\@D#D,^S&)<[E^\?FQWS75>%X8H]%21(T5Y'D+LJ@
M%B'8#)[\ "K7]B:3]H@N/[+LO.MU"PR?9TW1@= IQD >U %^BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH R="ZZG_P!?\O\ 2M:LG0NNI_\ 7_+_
M $K6H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*T7_6:I_P!?
MS_\ H*UJUE:+_K-4_P"OY_\ T%:U: "BBB@ HHHH **** "BBB@ KG?"/^JU
MG_L+W/\ Z%715SOA'_5:S_V%[G_T*@#HJY_P?_R"KW_L*W__ *525T%<_P"#
M_P#D%7O_ &%;_P#]*I* .@HHJ"]NUL;&:Z>.218D+E8EW,0/04 <-/<L4U'3
M$O0-,#27+SM:$R$"7YPC;\,0YP&Q^>*] K@8(M*U6X^UVMEK<MNS'=#%)&8O
MF;>RD!L@%ADKFN^H RO$MS+:>'KN:&4Q.%"^8O5 6 )'I@$G-1Z-NAU+5;)9
MII;>"2/R_.E:1D+1@E=S$D]CR?XJUY(TEC:.1%>-P596&0P/4$57@TVPM5B6
MWLK:$1$M&(XE783P2,#C/>@"AH'FK)JT,MS/<>5>E5>9LG'EQGZ 9).  .>!
M6S5.STK3M.=GL=/M;9G&&,$*H2/? JY0!F>'?^1?LO\ KG_4UIUF>'?^1?LO
M^N?]36G5U/C?J3'X4%%%%04%%%% 'C'C_P#Y'*]_W8__ $!:YFNF\?\ _(Y7
MO^['_P"@+7,U\?B?XT_5GV>%_@0]$%%%%8'0%:OAG_D:-+_Z^H__ $(5E5J^
M&?\ D:-+_P"OJ/\ ]"%:4OXD?5?FC.K_  Y>C_)GO%%%%?9GQ 4444 %%%%
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M?*!1110 4444 %<ZO_)1Y?\ L$)_Z.:NBKG5_P"2CR_]@A/_ $<U '14444
M%%%% !1110 4444 8?C3_D1?$/\ V#+G_P!%-6Q!_P >\7^X/Y5C^-/^1%\0
M_P#8,N?_ $4U;$'_ ![Q?[@_E0!)5+4=)L=66);V$R")M\>'92IQC(*D5=HH
M SK30K"RN%G@CF$BYP6N)''/'0L15^21(8GEE=4C12S.QP% ZDGL*=63XEAE
MGT&=8H7F*M'(T:#)=5D5F '<E0>._2@#0M;NVOH!/:7$5Q"20)(G#J?Q%-L[
M^SU"-I+*[@N44[6:&0. ?3(-8^FRIYVJW$EK<BVO)2\<3VK@N%B56)4KQN((
M ."V.,TOAR1;J:]OGM[BVGN-F8);5XA%&H(1<LH#-U)QD#..@!(!OUFZ!_R!
M8/\ >?\ ]#:M*LW0/^0+!_O/_P"AM5KX'\OU)^TC2HHHJ"@HHHH *\[\6^,M
M6T;Q!-96C0B%54C?'D\C->B5XW\0O^1ON/\ KG'_ .@BO/S&I*%*\'9W/2RV
MG"I6:FKJQ)_PL;7_ ._;?]^O_KT?\+&U_P#OVW_?K_Z]<E17@_6Z_P#.SZ#Z
MI0_D1T]KX]UJSMU@@^SK&I) \O/4DGJ?4U-_PL;7_P"_;?\ ?K_Z]<E11];K
M_P [#ZI0_D1UZ?$77V=07ML$X_U7_P!>O7J^=(_]:G^\*^BZ]?+:LZG-SN^Q
MXN:4:=/EY%;?] HHHKUSQPHHHH **** "BBB@ HHHH **** ,>T\16UWJ(M$
MM[E4D>2.&Y8+Y4SQG#JN&+<8;D@ [3@FK+ZM"FMQ:68;CS98VD67R\1_+C(R
M>IY'3/OBL:TT/5;6Y@4_8WMK&:YN+4^:P>5I-^U7^3" "1@6&[/'%6K^QU:Z
MUZRN(XK5+6&*2)I!=,)1Y@7)4>61E=O&3S[4 4-*\1V=O-X@C*3N]K?=$4$S
M,[%%1.>3N0CG 'KC)&I>^(HM-L8+F^LKN!YI1$MN?+:0<_>.URNWWSW ZD"N
M/TSP5,S:JL=REW;QW,*1VUX$V2^4Y8B3;'W5L C/WB2#@5HOX%N7L)3#?&QN
M'8A+2V*&VA0RB0JNZ,L.F> H) XQ0!W%%-12J*I<N0 "S8R?<XXIU !1110
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MJ^&?^1HTO_KZC_\ 0A6E+^)'U7YHSJ_PY>C_ "9[Q1117V9\0%%%% !1110
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MPU_T%X/R;_"N@HH Y_\ X3CPU_T%X/R;_"C_ (3CPU_T%X/R;_"N@HH Y_\
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MHH Y_P#X3CPU_P!!>#\F_P *U[&_M=3M$NK*99H')"NO0X.#5FB@ KG?"/\
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M]!>#\F_PKH**]0\DY_\ X3CPU_T%X/R;_"C_ (3CPU_T%X/R;_"N@HH Y_\
MX3CPU_T%X/R;_"C_ (3CPU_T%X/R;_"N@HH Y_\ X3CPU_T%X/R;_"C_ (3C
MPU_T%X/R;_"N@HH Y_\ X3CPU_T%X/R;_"C_ (3CPU_T%X/R;_"N@HH Y_\
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M_P B+XA_[!ES_P"BFK8@_P"/>+_<'\J )**** "BBB@ HHHH **** "BBB@
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MP:S>_O&ADF::<'RR9F+!N3LXY&1MVXS], !XCUN;2K<+9I')<[?,82 E4C!
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M_IS6O7,Z3H.H:?XAN+TM:K!-)*\C(%+R!F+*/]4&&,CK(PXQCICIJ "BBB@
MHHHH **** "BBB@#*\0W]YIVE^=I\<4MT\T<4:2YVDNX7G!&.O6J=KXG2>&^
MN_+!M8(H9%&Y48;\[@Q=@H(([D=#6Q>V4=]%''*S@1S1S#:1]Y&##\,BLYO#
M-D7OGCDGB>[GCN"493Y<B-N#*""/O<D'(R30 VT\4V=^]E':P3RO=%\!6CP@
M1MK$G?A@#S\A;CFICXALQ#%*4G"R&?'R@D>22&[_ .R<?TJ%?#,(@@@:_O)(
MH[C[2ROY>9)-^_<3LR#G^Z5I\?AR&&\^TQWUXNQIGACRFR%I<EBHV\\G(W9
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M=%7.K_R4>7_L$)_Z.:@#HJ*** "BBB@ HHHH **** ,3QDK/X'\0*H)8Z;<
M #DGRVJK#X]\(B",'Q-I (49!O$]/K72T4 <[_PGWA#_ *&?2/\ P,C_ ,:/
M^$^\(?\ 0SZ1_P"!D?\ C7144 <[_P )]X0_Z&?2/_ R/_&C_A/O"'_0SZ1_
MX&1_XUT5% '._P#"?>$/^AGTC_P,C_QH_P"$^\(?]#/I'_@9'_C7144 <[_P
MGWA#_H9](_\  R/_ !H_X3[PA_T,^D?^!D?^-=%10!SO_"?>$/\ H9](_P#
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M#/I'_@9'_C7144 <[_PGWA#_ *&?2/\ P,C_ ,:/^$^\(?\ 0SZ1_P"!D?\
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MGWA#_H9](_\  R/_ !H_X3[PA_T,^D?^!D?^-=%10!SO_"?>$/\ H9](_P#
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M#/I'_@9'_C7144 <[_PGWA#_ *&?2/\ P,C_ ,:/^$^\(?\ 0SZ1_P"!D?\
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>formdrs_032.jpg
<TEXT>
begin 644 formdrs_032.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2%") # 2(  A$! Q$!_\0
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5S/Q _Y T/_7PO_H+5TU<S\0/^0-#_ -?"_P#H+4 'P_\ ^0--_P!?
M#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %<S\0/^0-#_U\+_Z"U=-7,_$#_D#0
M_P#7PO\ Z"U !\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %<[XT^(?AKX=Z>M[XEUNRT:W<D(;J4*TA'4(O5C[ &KOBKQ!!X2\+
MZQKETK/;:99S7LJKU*QH7('OA:_-#X:^#/$G[9'QFOI]=UAX4$9N[VZQN\B
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M/:\UTE@;&:XS9R"-]RE<<D'CD]J^P)O^">OPQFB9%O/$4+'HZ7L1(_.(C]*
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M)X*[?]MW_DVOQ1_UTL__ $JBKB/^"<W_ "2'Q!_V'9/_ $G@H ^K&8*I9B
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MTR[9OP!F/\J /H']N[4K&S_9ZU.WNF3[3=WEK':*S $R"4.Q [_(K_G7#_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9^('_
M "!H?^OA?_06KIJYGX@?\@:'_KX7_P!!:@ ^'_\ R!IO^OAO_05KIJYGX?\
M_(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHU><_M&?\D'\>_\ 8&N?_19H ^4O^";?_(T^-O\ KRM__0WK[SKX,_X)M_\
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M(C(ZAT88*L,@CTIU% & GP_\+QW7VE?#>D+<XQYRV,0?'7&=N:WE4*H & .
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M,=Q"XPT<JAE;Z@]:EHH YZ'X=^%;6Z-S#X9T>*X)R9DL(E<\YZA<UT &!@#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$EU+%%-V*R73L@_[YC!K[%KR_P#9W^"-K\"/A_'H:7"WVI7$INK^\5=JR2D
M84'G8H  SUY/&<5ZA0 4444 %>?>*C+J7Q)T?2))Y$L9;5I&C0@?,!*<\C_9
M'Y5Z#7G^L_\ )9=!_P"O)OY34 ;7_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[
M77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_
M  K_ $__ )[77_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[7
M7_?2_P#Q-=-10!S/_"O]/_Y[77_?2_\ Q-'_  K_ $__ )[77_?2_P#Q-=-1
M0!S/_"O]/_Y[77_?2_\ Q-:NC:'!H<<B0/(XD.X^80?Y 5HT4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7,_$#_D#0_\ 7PO_ *"U=-7,_$#_ ) T/_7PO_H+
M4 'P_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW_H*UTU !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_K/\
MR670?^O)OY35Z!7G^L_\EET'_KR;^4U 'H%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7,_$#_D#0_\ 7PO_ *"U=-7,_$#_ ) T/_7PO_H+
M4 'P_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW_H*UTU !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_K/\
MR670?^O)OY35Z!7G^L_\EET'_KR;^4U 'H%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7,_$#_D#0_\ 7PO_ *"U=-7,_$#_ ) T/_7PO_H+
M4 'P_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW_H*UTU !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_K/\
MR670?^O)OY35Z!7G^L_\EET'_KR;^4U 'H%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7,_$#_D#0_\ 7PO_ *"U=-7,_$#_ ) T/_7PO_H+
M4 'P_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW_H*UTU !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\S_%[]LO2]+FN_#'P[M+CQ3XR+R6PV6[B"U=<A
MV;< 7*X)X^7@DM@<_3%<7<> ?#?@_P /^)+G1-"L-+NKRUN)+FXMK=4EF9E9
MB7?&YN>>30!Y7^Q'\2O$OQ0^&NLZEXHU635[V#5WMXYI$1"L8AB8+A0!U9C^
M->K_ !>^)5E\(_AYK'BF^B-PEC&/+MU.#-*S!8TSVRQ&3V&3VKP/_@G-_P D
MA\0?]AV3_P!)X*^F/$WA71_&6E/IFNZ;;:MI[LKM;7<8DC+ Y!(/H: /EGP7
M#^T;\:=&A\7V_C'2_!>F7RF;3]-%HK9CS\K$&-CM/8LQ)'.,$5TWP/\ CEXW
MM_BU??"KXGPVDWB&.%I[/5+%0J7 "[\$* I!3+ @*1M((ST[;XR?'GPU^S;I
M.A65UH6HW%K/ T5G#I4,8@@CBV*$8LR[!AU"@ ].U>2?LXQR?'?XX:I\8M1O
M-.L_LMO]DL-!M;M9[FW4H8P\V/N@J7[#)8] ,$ [O]L#XF>+/AWX;\*Q>#-3
M72M8U?5UL_.:"*8,A1AM(D1@!N*'(&>*YC_A7O[5_P#T4WPK_P" T?\ \@UG
M?MT>((M#\7?!QY[>>\@@U>2]EM;5-\LJQR6WRH,\L0Q '<UK:I\=/C[;V\FL
M0?!F&+1$^<V\EUYEYLZ_<5P^<?\ 3/K^5 'L7P7T?XA:'X7NH/B3KNG^(-=:
M\9X;K3D"1K;[$"H0(HOF#B0_=/##GL._KS'X"_'O1?CUX9GU'3H)-/U&S=8K
M_39F#- S E2& &Y3AL-@?=/ Q7IU !1110 5Y_K/_)9=!_Z\F_E-7H%>>:]*
MD/QBT)Y'6-!9-EF. .)J /0Z*J_VI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"-
M %JBJO\ :EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^- %JBJO]J6?_/W!_P!_%_QH
M_M2S_P"?N#_OXO\ C0!:HJK_ &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C0!:HJ
MK_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (T 6J*J_P!J6?\ S]P?]_%_QH_M
M2S_Y^X/^_B_XT 6J*J_VI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"- %JBJO\
M:EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^- %JBJO]J6?_/W!_P!_%_QH_M2S_P"?
MN#_OXO\ C0!:HJK_ &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]
MP?\ ?Q?\:/[4L_\ G[@_[^+_ (T 6J*J_P!J6?\ S]P?]_%_QH_M2S_Y^X/^
M_B_XT 6J*J_VI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"- %JBJO\ :EG_ ,_<
M'_?Q?\:/[4L_^?N#_OXO^- %JBJO]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\
MC0!:HJK_ &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\ ?Q?\
M:/[4L_\ G[@_[^+_ (T 6J*J_P!J6?\ S]P?]_%_QH_M2S_Y^X/^_B_XT 6J
M*J_VI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"- %JBJO\ :EG_ ,_<'_?Q?\:/
M[4L_^?N#_OXO^- %JBJO]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\ C0!:HJK_
M &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\ ?Q?\:/[4L_\
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M@_[^+_C0!:HJK_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (T 6J*J_P!J6?\
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MXO\ C0!:HJK_ &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\
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M\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (T
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M_KX7_P!!:NFKF?B!_P @:'_KX7_T%J #X?\ _(&F_P"OAO\ T%:Z:N9^'_\
MR!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*\6?\
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MTW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\
M? _QH Z.BN<_X3S3?[L__? _QH_X3S3?[L__ 'P/\: .CHKG/^$\TW^[/_WP
M/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\ ? _QH Z.
MBN<_X3S3?[L__? _QH_X3S3?[L__ 'P/\: .CHKG/^$\TW^[/_WP/\:/^$\T
MW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\ ? _QH Z.BN<_X3S3
M?[L__? _QH_X3S3?[L__ 'P/\: .CHKG/^$\TW^[/_WP/\:/^$\TW^[/_P!\
M#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\ ? _QH Z.BN<_X3S3?[L__? _
MQH_X3S3?[L__ 'P/\: .CHKG/^$\TW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*
MYS_A/--_NS_]\#_&C_A/--_NS_\ ? _QH Z.BN<_X3S3?[L__? _QH_X3S3?
M[L__ 'P/\: .CHKG/^$\TW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_
MNS_]\#_&C_A/--_NS_\ ? _QH Z.BN<_X3S3?[L__? _QH_X3S3?[L__ 'P/
M\: .CHKG/^$\TW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&
MC_A/--_NS_\ ? _QH Z.BN<_X3S3?[L__? _QH_X3S3?[L__ 'P/\: .CHKG
M/^$\TW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_N
MS_\ ? _QH Z.BN<_X3S3?[L__? _QH_X3S3?[L__ 'P/\: .CHKG/^$\TW^[
M/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\ ? _Q
MH Z.BN<_X3S3?[L__? _QH_X3S3?[L__ 'P/\: .CHKG/^$\TW^[/_WP/\:/
M^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\ ? _QH Z.BN<_
MX3S3?[L__? _QH_X3S3?[L__ 'P/\: .CHKG/^$\TW^[/_WP/\:/^$\TW^[/
M_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\ ? _QH Z.BN<_X3S3?[L_
M_? _QH_X3S3?[L__ 'P/\: .CHKG/^$\TW^[/_WP/\:/^$\TW^[/_P!\#_&@
M#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\ ? _QH Z.BN<_X3S3?[L__? _QH_X
M3S3?[L__ 'P/\: .CHKG/^$\TW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A
M/--_NS_]\#_&C_A/--_NS_\ ? _QH Z.BN<_X3S3?[L__? _QH_X3S3?[L__
M 'P/\: .CHKG/^$\TW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]
M\#_&C_A/--_NS_\ ? _QH Z.BN<_X3S3?[L__? _QH_X3S3?[L__ 'P/\: .
MCHKG/^$\TW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/
M--_NS_\ ? _QH Z.BN<_X3S3?[L__? _QH_X3S3?[L__ 'P/\: .CHKG/^$\
MTW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\
M? _QH Z.BN<_X3S3?[L__? _QH_X3S3?[L__ 'P/\: .CHKG/^$\TW^[/_WP
M/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\ ? _QH Z.
MBN<_X3S3?[L__? _QH_X3S3?[L__ 'P/\: .CHKG/^$\TW^[/_WP/\:/^$\T
MW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\ ? _QH Z.BN<_X3S3
M?[L__? _QH_X3S3?[L__ 'P/\: .CHKG/^$\TW^[/_WP/\:/^$\TW^[/_P!\
M#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_NS_\ ? _QH Z.BN<_X3S3?[L__? _
MQH_X3S3?[L__ 'P/\: .CHKG/^$\TW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*
MYS_A/--_NS_]\#_&C_A/--_NS_\ ? _QH Z.BN<_X3S3?[L__? _QH_X3S3?
M[L__ 'P/\: .CHKG/^$\TW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_
MNS_]\#_&C_A/--_NS_\ ? _QH Z.BN<_X3S3?[L__? _QH_X3S3?[L__ 'P/
M\: .CHKG/^$\TW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&
MC_A/--_NS_\ ? _QH Z.BN<_X3S3?[L__? _QH_X3S3?[L__ 'P/\: .CHKG
M/^$\TW^[/_WP/\:/^$\TW^[/_P!\#_&@#HZ*YS_A/--_NS_]\#_&C_A/--_N
MS_\ ? _QH Z.BN<_X3S3?[L__? _QK3TG6K?6HY'MPX5#@[QB@#0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%S!I]WMB!/HKJV![#CFO1?A3\"/!GP7MYD\,:4(+JX4+/?7#F6XE YP7/09
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M:$",C[$W!^DU>@UY_K/_ "670?\ KR;^4U '>>1'_P \U_[Y%'D1_P#/-?\
MOD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_
M +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U
M_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/
M-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\
MSS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_
M ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1
M_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y
M$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4
M>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y
M%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^
M^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7
M_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \
MU_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\
M/-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_
M #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'
M_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D
M1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'
MY$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244
M1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E%
M $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)
M10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%
M244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^
M14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\
MOD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_
M +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U
M_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/
M-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\
MSS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_
M ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1
M_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y
M$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4
M>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y
M%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^
M^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7
M_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \
MU_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\
M/-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_
M #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'
M_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D
M1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'
MY$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244
M1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E%
M $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)
M10!'Y$?_ #S7_OD4>1'_ ,\U_P"^14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%
M244 1^1'_P \U_[Y%'D1_P#/-?\ OD5)10!'Y$?_ #S7_OD4>1'_ ,\U_P"^
M14E% $?D1_\ /-?^^11Y$?\ SS7_ +Y%244 1^1'_P \U_[Y%'D1_P#/-?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N9^('_ "!H?^OA?_06KIJYGX@?\@:'_KX7_P!!:@ ^'_\
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M:^S^?<^C****_-S[$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *YGX@?\ (&A_Z^%_]!:NFKF?B!_R!H?^OA?_
M $%J #X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH
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M8OV/_BIXHU/6/%WPX\:7;ZEK?AB4I%?2-O>2-9#&ZLYY;#!2K'DA^>@KZ=H
M**** "O/]9_Y++H/_7DW\IJ] KS7Q9>-I_Q8T:=(6N&2R.(TZG/G#^M 'I5%
M<S_PF%Q_T![K]?\ XFC_ (3"X_Z ]U^O_P 30!TU%<S_ ,)A<?\ 0'NOU_\
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M_P#B: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\
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MC_H#W7Z__$T?\)A<?] >Z_7_ .)H Z:BN9_X3"X_Z ]U^O\ \31_PF%Q_P!
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MC_H#W7Z__$T?\)A<?] >Z_7_ .)H Z:BN9_X3"X_Z ]U^O\ \31_PF%Q_P!
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MC_H#W7Z__$T?\)A<?] >Z_7_ .)H Z:BN9_X3"X_Z ]U^O\ \31_PF%Q_P!
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M_P#B: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)H Z:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B: .FHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B: .FHKF?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)H Z:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/
M=?K_ /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T!
M[K]?_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z
M ]U^O_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NO
MU_\ B: .FHKF?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B: .FHKF?\ A,+C
M_H#W7Z__ !-'_"87'_0'NOU_^)H Z:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU
M_P#B: .FHKF?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B: .FHKF?^$PN/\
MH#W7Z_\ Q-'_  F%Q_T![K]?_B: .FHKF?\ A,+C_H#W7Z__ !-'_"87'_0'
MNOU_^)H Z:BN9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B: .FHKF?^$PN/^@/
M=?K_ /$UJZ-JLFJQR.]I):%#@+)W_2@#1HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHJ!;ZV:Y:V6XB-PHR80XWC\.M TF]B>BBB@044
M44 %%%% !17#?%CXR>'/@MHMGJGB66XBM+JX^S1FVA,IW[2W('084UY;_P -
M[?"C_G[U7_P ;_&@#Z+HKQ?X>_M<?#[XG>,-/\,Z'<ZA)JE]YGDK/9F-#LC:
M1LMGCY4:O:* "BBB@ HKA)OC9X2M_BI#\.WU!QXHEB\U;?R6V?ZLR;2^,!M@
M+8]/?BG?%CXR>'/@MHMGJGB66XBM+JX^S1FVA,IW[2W('084T =S17SJ/V]?
MA/G_ (_-4'_;@W^->I_#7XU>#/B[!,_A77(=2D@&Z:V*M%/&,XR8W ;&?XL8
M]Z .WHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y
MGX@?\@:'_KX7_P!!:NFKF?B!_P @:'_KX7_T%J #X?\ _(&F_P"OAO\ T%:Z
M:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@#Q7]J#X?_$+XD>&K
M#1_ VIV=C:S>='JL-ZP5;B)@NQ>4;N&Z8ZUX)X8_9U_:2\&:+!I&B^-;+3]-
M@SY5M'J3E(\G)"YB.!DDX]Z^LOBS\5]"^#7@^?Q#K\KBW5A%#;PKNEN)2"5C
M0=,D G)P  2:^6;W_@HAK!5;JT^&<BZ?(XBBFFOW(D8Y( (A R1_",_C0!9_
MX4[^U/\ ]%!M?_!@W_QFOIGX+Z+XL\/_  YTRQ\<:BFK>)8VF-S=QR>8'!E8
MI\VT9PA4=.U?+EY_P4#\4Z?-;Q77PO>VEN&V0I-=2HTK9 PH,7)Y' ]17U)\
M&_'FH_$OX=Z7XBU71)/#U[>&7=I\I8M&%D95/S*I^8*&Z=Z .VHHHH *RO%G
M_(K:S_UY3?\ H!K5IDT*7$3Q2HLD;J59'&0P/!!'<4 ?*O\ P3F_Y)#X@_[#
MLG_I/!7LOQY^-FF? GP.^NW]O)?7,TGV:RLX^/.F*E@&;^%0%))]!P">*[+P
MYX2T/P?9R6F@:-I^AVLDGFO!IMK';HSX W%4 !. !GV%)XD\(Z%XQM8K;7]$
MT[7+:)_,CAU*TCN$1L$;@'! ."1GWH ^$?A7\3/AQXL\:-\1_C+XTCU#Q('_
M .)?H(TZ[DM=/52=O"Q%21U502!G<2S'CZG\.?M:?"GQ;KUAHND^*OM6I7\R
MV]O!_9UVF^1CA1N:( <]R0*Z;_A1GPW_ .B?>%?_  2VW_Q%6=-^#W@+1[^W
MOK#P1X<L;VW<20W-MI-O')&PY#*P0$$>HH \7_:8^)'CKX,_$CPEXKM9KR[^
M'!"P:M86T2,%D#-EF8KD;E==O(!:/&1FNGN_VT/A':Z$VI)XG^T-LW+8Q6DW
MVAFQ]S:5 ![9) ]Z]LN+>*[@D@GB2:&12CQR*&5E/!!!ZBN(A^ _PWM[_P"V
MQ^!/#RW.[>'_ +-AX;U VX!H \'_ &,?#^L^*/&WC[XL:I92:;:>(IW6PAD!
MRZ-*9&()ZJN(U#=#AO2OK.FQQI#&L<:JB* JJHP !T %.H **** "O/]9_Y+
M+H/_ %Y-_*:O0*\_UG_DLN@_]>3?RFH ] HHHH **** "BBL'Q[XFC\%^"-?
MUZ0J%TVPGN_FZ$HA8#\2 /QK2G3E6G&G!7;=EZLB<U3BYRV1^6W[3_BX^.?C
MWXOOHV,L,=Z;&#;R"L($0V^Q*$_\"K]/_A?X37P)\.?#7A\*%;3M/AMY,=Y
M@WM^+;C^-?EK^S[X7D^(GQT\):=/NN!/J2W5SNYWQQDS29^JHWYU^N5?M/B+
M4C@Z.!RBF]*<;_<E&/Y2/SGA&,L14Q./GO.5OU?YH****_$C])"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "OD+]K+]CR]^(&LW/C/P4(
M3J\J WVDL1']J8#'F1L> Y& 5. <9SG.?KVBO;RC.,7D>*6+P<K2V:>S79^1
MYN89?0S*@Z&(6GXI]T?CM<?!CQ_:WS6<O@GQ"MRK;/+&ES$DGIC"\Y]J^E/V
M:/V)M:N/$&G^)_']HNFZ99RB>'19P&FN77E?-'1$!P=IR6Q@@ YK[UHK[_,O
M$?,L=AGAZ-.-+F5FU=OY7V]=7V/E,'P?@\-656I-SMLGHOGW"BBBOR4^]"BB
MB@ KF/'GPS\+_$[3%T_Q1HEKK%LA+1^<"'C)ZE'4AE)_V2*Z>BM:5:I0FJM&
M3C);-.S7S1G4IPJQ<*B33Z/5'AVE?L6?"'2;Y+I?"YNF3E8[J]GECSZE2^#]
M#D5I?&K]F/PA\9/#L5F]G#HFJ6</E6&I6,*H8% ^6-D& T?^SVYP17K]%>Q_
M;V:^WAB7B9N<-FY-V^_OU77J>?\ V7@?92HJC%1ENDDK_<?D9X]^'/CC]F_Q
MS;B[-QI5_!(9;#5[%V$4P'\4;_0\J>1G!'-?9/[-O[:VG?$#[)X<\;20Z1XD
M;$<-_P );7S= #VCD/I]TGIC(6OHOQQX#T+XD>';G0_$6G1:EITXYCD'*-V=
M&'*L.S @U^<G[1G[(^N_!B:?5]*\W7/"!;(NU7,UH">%G [=MXX/?:2!7[!A
M,VRKCBA' YLE3Q*TC-:7?E^L'H^FNWY_7P&.X9JO%8!\]%[Q?3U_^27S\_TZ
MHK\\?V;?VV-0\!_9?#GCF2;5O#JXC@U'!>YLEZ -WDC'I]X#ID +7Z :'KFG
M^)=)M=4TJ\AU#3KI!)#<V[AT=3W!%?E6?<.X[A^O[/$QO%_#);/_ "?=/\M3
M[G*\WPV;4^>B[26\7NO^!YEZBBBOESVPHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N'^,WQ6TSX,^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX'!Y"#TK'^%W@S1O%_[<_P 17UFPBU#^RUEOK5)AN1)@\**Y7H2 [8ST.#U
M- '?Q_M[>!HM4MX=0T'Q-I.G7# 0ZE=V*"(K_?P'+;>_RAC[5]':??V^J6-M
M>V<R7-I<QK-#-&<K(C %6![@@@UY/^UQH]KK'[//C%;J)9#;6RW43,,E)$=2
M&'H>H^A-2?LEW4EW^SKX(>5B["T>,$_W5E=5'X  4 >N4444 %%%% !1110
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MV[0?2LGX3_LH_$'XNF*[M=-.D:-)\W]JZKF*-@><HN-TF?51CU(K];P7 -#
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M&L1+%?V5O?1JVY4N8ED /3(!!YH K>$_^16T;_KRA_\ 0!6K3558U554*JC
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MK,*\Q^!?_!,?XB_&+PSHWB>^UG1_"_A[5;>.[MI)F>YNGA=0R.(D 7!!SAI
M?:OKOX<?\$G/A/X7\J;Q1J.L^-+E<;XI9OL5JWT2+]X/^_AKYIT\IP;M-N<E
M\_\ )'J\V,KZQ7*OZ^9^=_Q!_;-^-GQ8D>WU7Q[JR6\YV#3]'8643 \!"D 7
M>/9MU/\ A[^Q7\;?BJZ3Z7X"U6&VF.\WVL*+&(@_QAIBI<?[H:OVO^'WP/\
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M_KX7_P!!:NFKF?B!_P @:'_KX7_T%J #X?\ _(&F_P"OAO\ T%:Z:N9^'_\
MR!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@#S;X^?!:P^.G@&;0;J?[%>12
M"YL;T+GR9@" 2.ZD$@CWSU KY%^*'PU_:1U#PWI_A77+#_A+](TN]CO;2_MI
M(II&>-71<ME9&&)#]]<].>*^S_BQ\6_#WP9\*OKWB*>1+?S!##;VZAIIY#DA
M$4D G )Y(  ZU\RR_P#!1M;J9QI7PWO+^)3RS:GL8>F0L+8S]: *EQ\,?VB/
MVB#'I?CN^B\)>$VD62X@41(9 ,' CC)9ST($C!01GJ*^O_!OA'3? ?A72_#V
MD1&'3M.@6"%6.6('5F/<DY)/J37R3_P\0U+_ *)1=?\ @V;_ .1J^F?@O\2)
M?BU\.M,\43:0^A27C3*;&28RF/9*R?>*+G.W/W1UH [>BBB@ HHK#\:>-=%^
M'OAR[UW7[^+3M-M5W/+(>2>RJ.K,>RCDT ;E%<'\'_C-H'QN\/W>L^'4O$M+
M6Z-I(+V(1OO"*_ #'C#C]:[>ZNX+"UFN;F:.WMH4:26:5@J(H&2S$\  #.30
M!+17S;XB_;\^%^AZE):6ZZUK:(Q4W6G6B>4<>ADD0D>X%>K?"?XW>$?C1IL]
MUX8U+[1);X^T6<Z&.>#/3<A['^\,C@\\4 =Y16/XM\7:/X%\/W>MZ]?Q:;I=
MJNZ6XF/ [  #DDG@  DDX%> 1_\ !0+X8MJ0MVMO$$=J7V#4&L4\GZX$F_'/
M]W/M0!]+T5F^'/$FF>+M#L]8T:^AU'3+M/,@N8&RKCI^!!!!!Y!!!YK2H **
M** "O/\ 6?\ DLN@_P#7DW\IJ] KS_6?^2RZ#_UY-_*:@#T"BBB@ HHHH ^?
M_P!N3QA_PB_[/^IVR/LN-9N8=.3!YP6\Q_P*1L/^!5\1_ 7Q7'\)] ^)7Q/D
MVB;PSH#Q:?N'_,0NG$-N/?G?D>F3VKV[_@I!XM,VO>$/#,;_ "V]M+J,R ]3
M(PC3/T$<G_?5?$7QT\7_ -A?!?P[X/MWVSZ[J,FO7VTXS!"&MK53Z_O/MC$>
MR&OZ RK#_4>#;/26(E^#=G]\(O[S\JQM3ZWQ%Y4E^*5__2G^!D_L5_"=_CE^
MTQX4TF]C:[TZWN3J^J-)\P:"$^8P?V=]D9_ZZ5^\-?GS_P $BOA#_8O@/Q1\
M1KR#%SK5P-,L'8<BWA.96!]&E(4^\-?H-7X]G6(]MB7!;1T^?7_+Y'Z)@*?)
M2YGNSS7]H3X#^'OVB_AIJ'A'Q!'L\P>;97Z(#+97 !V2I],X(_B4L.]?B1K6
MC_$#]CGX[")G?1?%GAZY$MO<QY,-S&<[77.-\,BY!!Z@E2 00/Z :^<?VUOV
M2-._:?\ A^39K#9^.=)1I-(U!OE$G<VTI_YYN>A_A;!'&X,LKQZP\O8U=:<O
MP_X'<,7AO:KGA\2.O_9?_:0T']IKX9VWB/2BEKJD&V#5M*+Y>SN,<CU*-R4;
MN/<,!Z_7X&? ?XU>,/V0OC.VHI:3V]Q9S-8:YH-T3']HC5L21./X74C*MV8#
MJ"0?W)^%_P 3?#_QA\"Z3XM\,7JWVCZE%YD;<!XVZ-&X_A=3E2.Q%9YE@'@Y
M\\-82V_R_P BL+B?;1M+XD=51117BG>%%%% !1110 4444 %?B/_ ,%++Z^O
M/VQ/&<=V6\JVAL(;56.0(OL<+\>Q=W/U)K]=?CA\>/"'[/?@F?Q+XOU 6MN,
MI;6<6&N;V7&1%"F1N;WX ')('-?B)^T9\<M9_:D^,5QXHFT>*RN+I8["PTVP
M0R2")6(B1B!F60[N6QSD    #ZK(:-3VLJUO=M:_W'CYC4CR*%];GDM%/N+>
M6UGDAFC>&:-BCQR*596!P00>A!KJ_A?\)_%GQF\5V_AWP=HMQK6J3$$K"N$A
M3.#)(Y^6-!_>8@?C7V\I1BN:3LCP$G)V1]$?L8_L%R?M3^&]1\3W_BEO#NAV
M&H'3S#!9^=/<.L:2-M8L%0 2+SAOI7Z!?#7_ ()O? WX="*6?PW+XMODQ_I7
MB*X-P#Z_N5"Q$?5#7J?[-_P/T[]GCX0:'X*L)?M4MJAEO;S&/M-T_,LF.PSP
MH[*JCG&:]-K\YQN9UZU22IS:ATMIH?44,)3IQ7-'4S]#\/Z7X7TV+3M&TVST
MG3XO]7:V,"0Q)]$4 #\JT***\5MO5G>%%%%( HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH X;XV?!_0_CM\--:\%^((S]BU"+$=PB@R6TPYCF3/\ $K8/
MN,@\$U^-?QO_ &"_BY\%]<G@3PW>^+M$W9M]8\/VLES&ZD\>9&H+Q-TR&&,G
MAFZU^YM%>K@LRJX&ZCK%]#CQ&%AB-7HS\$?AG^QK\8OBIKD.G:;X%U?38FD"
M2ZCK5I)96L ZEF>11G YPH9NF <BOV"_9-_9CTC]ESX9KX?M)TU/6[R3[5JV
MK+'L-S+C"JH))$:#Y5&>[-P6->V45IC<TK8V/(U:/9$X?"0H/F6K"N0\9?"'
MP5\0E;_A(O#&F:I*PQ]HFMU$X^DHPX_ UU]%>;1KU</-5*,W&2ZIM/[T=52G
M"M'DJ1379JY\L>-/^">?@/6_,D\/ZGJ?AJ9ONQEA=P+_ ,!?#G_ONO!?&G_!
M/_XC>'_,DT6;3?$]N/NK;S?9YR/=),+^3FOTAHK[G <=Y[@;)UO:+M-7_'27
MXGS&*X7RO$Z^SY'_ '7;\-OP/Q[OO#_Q#^"^I>?/9^(/!]T#@72"6V#_ .[(
MN P^A(KTKP7^W)\4O">R.[U&U\26J\>7JMN"V/\ KI'M8GW8FOTVFACN87BF
MC66)QM9'4%6'H0>M>5>-/V5OA=XZ\Q[[PE9V=R_/VG2\VCY]2(R%8_[P-?81
MX\RK,UR9U@%+^\K2^Z]FOE(^??"^.P3YLMQ37D[K\KI_<>,>"_\ @HUX=OO+
MB\4>&;_29#P;C3Y%N8\^I5MC ?3=7O/@O]HKX;^/_+71_%^FR7#\+:W4GV:8
MGT"2A6/X U\Z>,_^";]C-YDOA3Q=/;'JMKJ\ E!]O-CVX'_ #7@OC3]C+XK>
M#?,?_A'O[=ME_P"6^BRBXS](^)/_ !RJ_L7@S.M<#BG1F^C=E]T]_E(7]I<1
M9=_O5#VD>Z7ZQV^:/U+!# $<BEK\@O#_ ,4?B/\ ".\^Q:?KNM^'I(>NGSLZ
MQK]8) 5_-:]N\%_\%#O&^C;(O$6CZ;XCA7K)&#:3M]67*?D@KR<;X:YI17/@
MZD:L>FO*W]^G_DQW8;C+!5'RXB$J;^]?AK^!^A]%?-7@O]OOX;>(O+BU<:CX
M8N&X8W<'G0Y]GBW''N5%>Z>%/B%X8\=6XF\/:_IVLIC)%G<I(R_[R@Y7\0*_
M/<=DN99:_P#:Z$H+NUI]^WXGUN&S'!XS_=ZJEY7U^[<Z&BO)?CQ^TEX8^ ^G
MHFHE]1UZXC,EII%N<.XR0'=NB)D$9.2<' .#CY0NO^"C?CEK\O;^&_#T5EG_
M %,J3O)CTWB4#_QVO8RKA'.,XH_6,-2]SHVTK^E]_7;S/.QV?Y?E]3V-:?O=
MDKV]?ZN?H317SC\&_P!M[P7\1+.6'Q'+#X-U>!&D>.\G!MI5 R3'*0.?]@@'
MTW5Q/Q:_X*%:/I/G6/@'3#K5R/E&J:@K16P]UCX=_P =GXU-+A'.ZN+>#6&:
MDMV_A7GS;?<V5//\MIT%B'65GMW^[?[SZXU;6+'0=/FO]2O+?3[&%=TMS=2K
M'&@]2S$ 5\N_%K]O_P +^%_.L?!=FWBC45ROVR;=#9H?4?QR<]@%![-7QCXH
M\??$'X^>(X8=1O-2\37\C?Z/IUK&61/^N<*#:..X&?4U[U\)?^"?/B#7_)OO
M'6H+X=LC\W]G6966[8>C-RD?_CQ]0*_1*/"&2\/06(XAQ"E+I!7L_DO>EZZ+
MN?(U.(,RS:3I931:7\S_ *Y5^+['AWQ ^,_Q!^.NK1VNK:C>:GYTF+?1[",B
M'=V"0I]X^YRWO7K?PE_8'\8>,/)OO%MPOA+3&PWV=@);UQZ; =J9_P!HY']V
MON'X:_!;P;\([+R/#&AV]C*R[9+QAYES+_O2MEB,]LX'8"NWKS\Q\0I4Z?U3
M(J*HTUL[*_RBO=7SYCKP?":G/V^9U'4F^EW;YO=_@>;_  K_ &>? OP>A0^'
M]&C.H!=K:I>8FNG]?G(^7/H@4>U>D445^2XG%5\95=;$S<Y/JW=GWE&A2P\%
M3HQ48KHE8****Y3<**** "N=^(7@'1/BEX)UCPIXCM!?:+JMNUO<0G@X/(93
MV92 RMV(![5T5%.,G%J2W0FDU9GX^_&__@EG\3?!.N3R> 8X_'7AYVW0D3Q6
M]["I/W9$=E5B./F0G/7:O2N>^&?_  3'^-7C;7(8->TBW\%:1Y@$^H:E=12L
MJ]3LBB=F<XZ9V@G^(<X_:.BOH%GF+4.72_>VO^7X'FO+Z/-?7T/-_P!G_P"
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M65M'_<BC0(@_!5%:5%%?%-MN[/?V"BBBD 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'G/Q6_9V^&_QNMFC\:>$--UF;;M6]:/RKM!Z+.A60#@<!L<=*^(?C!_P
M2#MIO.O?AEXO:W;JND^(UW)]%N(UR!Z QGW;O7Z245WX?'8C#?PYZ=NASU,/
M2J_$C\!OB+^SO\8/V;=634M;\.ZQX>-J^8=>TUV>!#V*W,)(0GL"0WM7KGP=
M_P""GGQ?^&OD6FO7-MX^TF/"F+6!LN@O'W;A/F)X^]('ZU^S<D:31M'(JNC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?R'_ ,31Y'BC_GXM?R'_ ,30!TU%<SY'BC_GXM?R'_Q-'D>*/^?BU_(?_$T
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MQ:_D/_B:/(\4?\_%K^0_^)K$T.FHKF?(\4?\_%K^0_\ B:/(\4?\_%K^0_\
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M_P#$T =-17,^1XH_Y^+7\A_\31Y'BC_GXM?R'_Q- '345S/D>*/^?BU_(?\
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MO+1IB]_(&!DWRLXX9F/ 8#KVH [>BBB@ K,\41O-X9U:.-6=VM)E55&224.
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MID(M].TVUBL[:$=$BC0(B_@ *]KC#,GBZTFOMN__ &ZM%_7D<60X-8:E&/\
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M51DL3@ >M> ZY^V]\.=,UB?3].36O$[0'$MQHMB)8E SN;<S+E1C[P!![9H
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M2Q<;.=[<]>] '9US/Q _Y T/_7PO_H+5TU<S\0/^0-#_ -?"_P#H+4 'P_\
M^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %>2?'
M+2?BF+K2==^&>I6;2Z?'(MYH5^!Y=^"5*X)X##!_B0\_>[5ZW10!\I:;^W9%
MX9OCI7Q)\":SX5U1,JS6Z>8C8_BVR;&"_0OVYYKO=-_;4^#VH)'GQ6;21ADQ
MW.GW*E?8L(ROZU[#K6@Z9XDL7LM6TZTU2S?[UO>0+-&?JK BO--2_9/^$FK9
M,_@?3TS_ ,^S20?^BW7TH P]:_;;^$&DP2-%XDEU.9/^6%EI\Y9N.S.BI_X]
M7"+^UIXY^,%T^F?"+X?W+HQ*G7-:P(8?4L%.Q2.N"[9_NGI7LFC?LS_"S09H
MY;3P-I!DC.5:YA^T8.<Y_>%J])M[>*UA2&&-(8D&U8XU"JH] !TH Y;X5Z'X
MF\.^!["R\8:S'KWB,-))=WT0PC,\C,%48'"@A1P.G05UM%% !1110 4444 %
M%%% !1110 4444 %%%% !7G^L_\ )9=!_P"O)OY35Z!7G^L_\EET'_KR;^4U
M 'H%%%% !7X[_P#!1KXD?\)!\8/$\$,NY(YTTF(9^ZD"@2_^1-__ 'U7Z\>(
MM:@\-^']3U>Z.+:PM9;J4YQA$0LWZ U_/?\ &7Q9/XO\>:E=W$GFR>:YD;^]
M(S%I#_WT2/PK](X17U>CB\9UY537_;SO+[E'\3Y+//WU6AA^B;F_^W=%^+_
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MPV&CS&.0#U>88=F^A ] *\=\1:;XI\.VT6F:]:ZQIEONW1V>HQRPIN4 9".
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7_E+LO\ XS7Z*?\ "C/AO_T3[PK_ ."6V_\ B*/^%&?#?_HGWA7_ ,$MM_\
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M#D9  ;)&* /7/C-XM@\>?LC:[XCMHS##JFA)=B)CDQE]I*$]R#D?A6-^P_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M $%J #X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH
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M1]0LM%77KS4M06R2U:8Q=49L@A3DY"C&.]>:_P##3GQB_P"B#:I_W\F_^-4
M?4U%<!\%_'7B7X@^%[K4?%/A*X\&ZA%>-;QV%P6+21!$82_,JG!+,O3^"N_H
M **** "O/]9_Y++H/_7DW\IJ] KS_6?^2RZ#_P!>3?RFH ] HHKQ#]M#XO\
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MKHM(4M;1QU5F R[@\%5X'(+ C%>$Z1_P4R\<PZ@'U3PKX?N['/,-GY\$N/\
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MF;MS.[4;Z+R271:!11172>&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M?^2GQ^*X.P51\V&DZ;^]?CK^)^8'@7]MKXI>"_+BN-6A\26:<>3K,7F-CO\
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M@ K]$OV0?^"9=OXX\$W_ (@^,%EJVB2WVU=*TN"86]S#'C+32@AL%B0%1@"
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MW/3[$8KF3_OU&Y<?BM?(XOAO#X"LHXMN/ES1O\GK^I[^'S>IBZ;EA[/SL_\
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M'=6-U#>6T@RDUO('1A[,#@U\CCO$//IZ1C&EZ1U_\FO^1[N&X1RN.LFY_/\
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M?&/,WYZY&<?=[8QQ7A'[#7@M[SXK>,;O77_M2_\ "$$>CV<DP#"#,DJY3/3
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MG_DLN@_]>3?RFKT"O-?%EM->?%C1HH)S;2M9';*O4?ZXT >E5^67_!7;XO\
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M_P#CE'U#@'_H)E_Y/_\ (!]:XI_Y\Q_\E_\ DCU;_AX-\+_^??7_ /P"C_\
MCE'_  \&^%__ #[Z_P#^ 4?_ ,<KRG_AVSJO_0]6?_@N?_XY1_P[9U7_ *'J
MS_\ !<__ ,<H^H< _P#03+_R?_Y /K7%/_/F/_DO_P D>K?\/!OA?_S[Z_\
M^ 4?_P <H_X>#?"__GWU_P#\ H__ (Y7E/\ P[9U7_H>K/\ \%S_ /QRC_AV
MSJO_ $/5G_X+G_\ CE'U#@'_ *"9?^3_ /R ?6N*?^?,?_)?_DCU;_AX-\+_
M /GWU_\ \ H__CE'_#P;X7_\^^O_ /@%'_\ '*\I_P"';.J_]#U9_P#@N?\
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MZUQ3_P ^8_\ DO\ \D>K?\/!OA?_ ,^^O_\ @%'_ /'*/^'@WPO_ .??7_\
MP"C_ /CE>4_\.V=5_P"AZL__  7/_P#'*/\ AVSJO_0]6?\ X+G_ /CE'U#@
M'_H)E_Y/_P#(!]:XI_Y\Q_\ )?\ Y(]6_P"'@WPO_P"??7__  "C_P#CE'_#
MP;X7_P#/OK__ (!1_P#QRO*?^';.J_\ 0]6?_@N?_P".4?\ #MG5?^AZL_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWI7?EI?IKH?I?134=9$5T8,K#(93D$>M.KZX_G<**** "BBB@ HHHH ****
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M3+ZDL)5AR2I^ZXVM:VEK>04445)B%%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_A1_86)_Z"7^/_R0?\16R;_H20^^'_RH_'O_ (:6^*W_ $4+Q%_X,)/\:/\
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M:6DLD5O*%/\ X!\%+_P4*^+RL";O2& /0Z>N#^M7O^'C7Q6_Y]_#O_@#)_\
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M6BV>KJG_ . A[3PHG]B:_P#!W^;);7_@IMX09F^T^$-;B7'!BEA<G\V%6?\
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MW_AZ)_U3/_RO?_<U=U'_ ,$T_AF$4/KWBQGQR5NK8 GV'V?BG?\ #M/X8_\
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M* "BBB@ HHHH **** "BBB@ HHHH *;)((XV=N%49/&:=2,P52S$!0,DGH*
M/YR_B/XZU+XG>/-?\5ZO.\^HZO>27<K2,6*[FRJ#_95<*!V"@=JYRNC^(6FP
MZ=XNU0VD!@TV>YDFM$_NPLY*K]0,#\*YROUC"UZ.)H0K4'>$DFO0^7S# XK+
M,75P>-@XU8-J2?1K^M'LUJA59HV#*2K*<A@<$&OMS]EG]F[Q%^TM=6=\WF:7
MX9B2/^T-79>K;03%"#]Z0_DH.3V!^+-+TV?5[Z*UMUW22'\ .Y/L!7] _P"S
M?9Z98? 'X>0:/:I96"Z%9[(44+AC"I<G'5BVXD]222>M?'<61ABZ-+ U)>ZY
M<[CWY4TO_2F?H7!.;8SAE8K.,'27/*/L8S?V')J;LNKM!>2T;OL^D^'_ ,/=
M!^%_A:S\/>&]/CT_3;8<(O+2,>KNW5F/<G^5='117RT8Q@E&*LD>76K5<14E
M6K2<I2=VV[MM]6PHHHJC$**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#G_%OP]\,>/8(X?$GA[3-=2/_ %?]H6B3
M%/\ =+ E?PJIX3^$_@OP'<-<>'?"FCZ+<MUN+*RCCD(QC&\#./;.*ZNBLO94
MW+G<5?O8[8X[%QH_5HU9*G_+S/E^Z]@HHHK4X@HHHH **** "BBB@ HHHH *
M*** "FR1K-&R.JNC#:RL,@@]013J* //;K]GGX87E\UY-\/_  W)<,V]F.F0
MX9O4C;@_ES7=:?I]KI-G%:6-M#9VD(VQP6\8CC0>@4# 'TJQ16<:<*;O"*7R
M.VOCL5BHJ.(JRFEM>3=O2["BBBM#B"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** .+^+7PB\-_&KPE+X>\36C3VI?S89H6V36\H! DC;L0"
M>H((.""*^%/%G_!-?QS8ZK(OAW7=&U73"Q\N2\DDMY@.P90C+GW#=N@K]'Z*
M\O&9;AL:U*K'7NM&?><.\;YWPQ"5' 5?W;UY9+FC?NNJ?HU?J?#GP7_X)PQ:
M7JD.I_$?5;;4XHB'71]+9_*<]<2RL%8C_94#/]['7[@AACMH8X88UBBC4(D:
M !54#   Z"GT5MA<%0P4>6C&U_O9YF?\39IQ-75?,JO-R[):1CWLEWZO=]6%
M%%%=Q\L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/_Q8
M_8A^&WQ6U:75VMKKPYJLQW33Z,Z1I,V>6>-E9<GG) !)Y.:Q/ 7_  3Y^&/@
MW5HM1OSJ7BB2%]\=OJDJ?9\CINC1%W\]F)!]*^FZ*\Z67824_:.FK^A]E3XR
MXAHX7ZE#&S5.UK<VMNR>Z7S([>"*U@CAAC6&&-0B1QJ%55 P  .@ J.^L+;4
M[62VO+:&[MI!AX9T#HP]"#P:L45Z'D?'J4D^9/4\5\;?L<?"/QQYCW'A*WTJ
MZ;G[1H[&T(/KL3Y#^*FO O&W_!,BVD\R7PAXSEA_N6FM6X<'ZS1XQ_W[-?<]
M%>96RO!XCXZ:OY:?D?=99QUQ)E-EAL9)Q723YU]TKV^5C\FO&W[$/Q=\%^8_
M_".#7K9/^6^B3"XS](^)#_WQ7#:#\3/B7\&K[[%8:YK_ (8FAZZ?,\D:#_>@
M?Y3^*U^SU9FO>&='\56)LM:TJQUBS;K;W]ND\9_X"P(KQ*G#L(OFPU5Q?]=K
M'ZAA/&/$5J?L,[P-.M![VT^^,N9/\#\Y?!/_  4>^(F@^7'X@T[2O%$ ^](T
M9M)V_P"!1_(/^_=>^^"?^"COPZU[RX_$&GZKX7F/WI&C%W O_ H_G/\ WQ76
M^-OV$_A'XP\R2#1;CPY=/UFT:Y:,?]^WW1C\%%> ^-O^"96K6_F2^$O&%I?+
MU6VUB!H&'MYD>\$_\!6LO9YU@_ADJB^_\[,[OK7ACQ%_&I2PE1]DXK_R7FIK
MYI'V=X+^,W@7XB*G_".>*]*U65^1;PW*B?\ &(X<?B*[.OR \:?LE_%GP"SR
M7O@Z_N[>/D76E8O$P/XOW1+*/]X"J'A']HSXI_#.;[-IGB_5[58#M-C?/]HC
M3'5?*F#!?P JHY_.B^7%T7%_UT?^9C6\(\+F,'6X>S*%6/9V?WR@W_Z2C]CJ
M*_.KP3_P4N\6:;LB\4>&--UR(<&:QD>SF/N<[U)]@%KW[P3_ ,%!/A5XH\N/
M4KG4/"]RW!&I6I>//L\6_CW8+7L4<XP5?15+/ST_X!^;YGX;\3Y7=SPCJ176
MG[_X+WOOBCZ7HK \*>/_  SXZMO/\.Z_INMQ8R38723%?]X*21^-;]>Q&2DK
MQ=T?G%6C4H3=.K%QDMTU9_<PHHHJC(**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKY]_:,_;&\,? >
M:31K> ^(?%NU6.FQ/LCMPPR&FDP=N0<A0"3QG (-?,</_!3#Q\NHAYO#'AM[
M#=_J$2X67'IYAE(S[[?PKQL1F^#PT_9SEKY:V/TK)_#OB/.\*L;A:%J;V<FH
M\WFD];=GHGT9^CU%>+_L\_M3^%OV@K-[>R5](\26\7FW6CW#;F"Y +QO@"1,
MD#. 1GD#(S[17IT:U/$052D[IGQ&8Y;C,HQ,L'CJ;IU([I_U9I]&M'T"BBBM
MCS HHHH **** "BBB@ HHHH *R?$_A+0_&VDR:5XBT73]?TN1E9[+5+6.YA9
M@<@E'!4D'IQ6M133:=T&^YYI_P ,Q_!W_HD_@?\ \)RS_P#C='_#,?P=_P"B
M3^!__"<L_P#XW7I=%:^VJ_S/[R/9P['FG_#,?P=_Z)/X'_\ "<L__C='_#,?
MP=_Z)/X'_P#"<L__ (W7I=%'MJO\S^\/9P['X?\ [;W[)&L?LZ_$C4K_ $[3
M9Y?A[J=P9M,U"--T5OOR3:R$?=9#D+G[R@$<[@/F>OZ3-6T>P\0:;<:=JEC;
MZEI]RGESVEW$LL4J_P!UD8$,/8BO)[7]C?X(6>J+J$?PO\-_:%?S KV2O%G_
M *YG*8]L8KZK#9\H4U&M%MKJNIX]7+N:5Z;LC\V/^">G['%]\8O'=CXV\6Z*
MW_"O=*;SXUOH 8=6G4X6(*PQ)$""7."IV[.YQ^H'_#,?P=_Z)/X'_P#"<L__
M (W7HUK:PV-K%;6T,=O;PH(XX8E"HB@8"@#@ #L*EKP\9F%7%5>>]ET29Z%'
M#0HPY=SS3_AF/X._]$G\#_\ A.6?_P ;H_X9C^#O_1)_ _\ X3EG_P#&Z]+H
MKA]M5_F?WG1[.'8\T_X9C^#O_1)_ _\ X3EG_P#&Z[W1=#TWPUI-MI>D:?:Z
M5IEJGEP6=E"L,,2_W410 H]@*O45,JDYZ2;8U&,=D?)?_!1S_DEWAG_L,C_T
M1)7U;8_\>-O_ -<U_D*RO%G@;P_X\LX;3Q%HUGK5K#)YL<-[")%1\$;@#WP2
M/QK;50BA5&% P *S*/B#]K;X:ZK\&?%MW\3_  :GDZ7KD$VG:[:J/W:M.A1F
M8#^&3.<]I%!_B KT_P#8"_Y("O\ V%;G^25]":QHUAXATNYTW4[.&_T^Y0QS
M6UP@>.13V(/6JOA?PCHO@G2_[-T'2[72+#>9/LUG$(TW'&3@=S@4 ?%?P'U+
MP?H_[0'Q,F^+,MC:^*A?'[#/X@*B%5\R3>4:3Y0=OE;23]S&TXS6]^V/\=/#
MGCCX8:AX8\(%O$D4$MO<:AJFGC=96""0"-6DQM9G8@ *?7GC%?3_ (R^$G@S
MXA7"7'B/PSINKW**$6XN+=3*%!R%WCYL<GC..:EC^%O@^+PM-X:C\,:5'H$S
M!Y=-CM$6"1@00S*!@G*@Y// H X_P?J6N:/^RWX:O_#5I#J&O6OA.RFL[2=&
M=)I%M8R$VJRDDX( !')%<E\+/VEO /Q<^'<0\?ZAX;TS6XR\>HZ3JVR&$,&8
M HD['<"N.Y(.0:]]TW3;71].M;"QMX[2RM8E@@MXEVI'&H"JJCL   ![5QOB
MCX$_#[QGJ3ZAK/@_2;Z^D.9+EK<+)(?5F7!8_6@#Y=^%-KX<E_;42;X4@?\
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MBQ':@#V*N9^('_(&A_Z^%_\ 06KIJYGX@?\ (&A_Z^%_]!:@ ^'_ /R!IO\
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M/[D?A7#V83EPSA\!;><ZLF]7*<K07R4(*WFV%%%%?#'>%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:(CW\J3=G_OL5[[X)_;E^$7C/RT?7Y/#UT__ "[ZU;M#CZR+NC'XO7#>-O\
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M%4]0UBPTE-]]>V]FN,[KB58QCUY-<QJ7QJ^'VC[OMWCKPW:,N<K-JT"MD=0
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M )^X/^_B_P"-9G_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C0!I_VI9_\
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MVI9_\_<'_?Q?\:/[4L_^?N#_ +^+_C69_P (7I/_ #P;_OXW^-'_  A>D_\
M/!O^_C?XT :?]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\ C69_PA>D_P#/!O\
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M_OXW^-'_  A>D_\ /!O^_C?XT :?]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\
MC69_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XT :?]J6?_ #]P?]_%_P :
M/[4L_P#G[@_[^+_C69_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I_P!J6?\
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MI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"-9G_"%Z3_ ,\&_P"_C?XT?\(7I/\
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M (UF?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^- &G_:EG_P _<'_?Q?\
M&C^U+/\ Y^X/^_B_XUF?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XT :?\ :EG_
M ,_<'_?Q?\:/[4L_^?N#_OXO^-9G_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-
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MP]&'PP2^2/"K9MF.(_C8B<O64G^;+]O=:;:Q".":UAC'1(V50/P%2?VI9_\
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MU]%% !1110!\X?M/?LB6GQJN6\1Z'=QZ5XK2(1N)A_H]ZJCY0Y RK@<!^>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH **** "O/]9_Y++H/_7DW\IJ] KS_6?^2RZ#_P!>3?RFH ]
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\!_)?DKW+(Q]E[4 ?9M%4](U:RU[2[34M.N8[RPNXEF@N(6RDB,,A@?I5R@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:4-\9-"!&1]B;@_2:@#>_P"$\TW^[/\ ]\#_ !H_X3S3?[L__? _QK?\B/\
MYYK_ -\BCR(_^>:_]\B@# _X3S3?[L__ 'P/\:/^$\TW^[/_ -\#_&M_R(_^
M>:_]\BCR(_\ GFO_ 'R* ,#_ (3S3?[L_P#WP/\ &C_A/--_NS_]\#_&M_R(
M_P#GFO\ WR*/(C_YYK_WR* ,#_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\:W_(
MC_YYK_WR*/(C_P">:_\ ?(H P/\ A/--_NS_ /? _P :/^$\TW^[/_WP/\:W
M_(C_ .>:_P#?(H\B/_GFO_?(H P/^$\TW^[/_P!\#_&C_A/--_NS_P#? _QK
M?\B/_GFO_?(H\B/_ )YK_P!\B@# _P"$\TW^[/\ ]\#_ !H_X3S3?[L__? _
MQK?\B/\ YYK_ -\BCR(_^>:_]\B@# _X3S3?[L__ 'P/\:/^$\TW^[/_ -\#
M_&M_R(_^>:_]\BCR(_\ GFO_ 'R* ,#_ (3S3?[L_P#WP/\ &C_A/--_NS_]
M\#_&M_R(_P#GFO\ WR*/(C_YYK_WR* ,#_A/--_NS_\ ? _QH_X3S3?[L_\
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MP/\ &C_A/--_NS_]\#_&M_R(_P#GFO\ WR*/(C_YYK_WR* ,#_A/--_NS_\
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M--_NS_\ ? _QH_X3S3?[L_\ WP/\:W_(C_YYK_WR*/(C_P">:_\ ?(H P/\
MA/--_NS_ /? _P :/^$\TW^[/_WP/\:W_(C_ .>:_P#?(H\B/_GFO_?(H P/
M^$\TW^[/_P!\#_&C_A/--_NS_P#? _QK?\B/_GFO_?(H\B/_ )YK_P!\B@#
M_P"$\TW^[/\ ]\#_ !H_X3S3?[L__? _QK?\B/\ YYK_ -\BCR(_^>:_]\B@
M# _X3S3?[L__ 'P/\:/^$\TW^[/_ -\#_&M_R(_^>:_]\BCR(_\ GFO_ 'R*
M ,#_ (3S3?[L_P#WP/\ &C_A/--_NS_]\#_&M_R(_P#GFO\ WR*/(C_YYK_W
MR* ,#_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\:W_(C_YYK_WR*/(C_P">:_\
M?(H P/\ A/--_NS_ /? _P :/^$\TW^[/_WP/\:W_(C_ .>:_P#?(H\B/_GF
MO_?(H P/^$\TW^[/_P!\#_&C_A/--_NS_P#? _QK?\B/_GFO_?(H\B/_ )YK
M_P!\B@# _P"$\TW^[/\ ]\#_ !H_X3S3?[L__? _QK?\B/\ YYK_ -\BCR(_
M^>:_]\B@# _X3S3?[L__ 'P/\:/^$\TW^[/_ -\#_&M_R(_^>:_]\BCR(_\
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M$\TW^[/_ -\#_&M_R(_^>:_]\BCR(_\ GFO_ 'R* ,#_ (3S3?[L_P#WP/\
M&C_A/--_NS_]\#_&M_R(_P#GFO\ WR*/(C_YYK_WR* ,#_A/--_NS_\ ? _Q
MH_X3S3?[L_\ WP/\:W_(C_YYK_WR*/(C_P">:_\ ?(H P/\ A/--_NS_ /?
M_P :/^$\TW^[/_WP/\:W_(C_ .>:_P#?(H\B/_GFO_?(H P/^$\TW^[/_P!\
M#_&C_A/--_NS_P#? _QK?\B/_GFO_?(H\B/_ )YK_P!\B@# _P"$\TW^[/\
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M#_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\:W_(C_YYK_WR*/(C_P">:_\ ?(H
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M(_\ GFO_ 'R* ,#_ (3S3?[L_P#WP/\ &C_A/--_NS_]\#_&M_R(_P#GFO\
MWR*/(C_YYK_WR* ,#_A/--_NS_\ ? _QH_X3S3?[L_\ WP/\:W_(C_YYK_WR
M*/(C_P">:_\ ?(H P/\ A/--_NS_ /? _P :/^$\TW^[/_WP/\:W_(C_ .>:
M_P#?(H\B/_GFO_?(H P/^$\TW^[/_P!\#_&C_A/--_NS_P#? _QK?\B/_GFO
M_?(H\B/_ )YK_P!\B@# _P"$\TW^[/\ ]\#_ !H_X3S3?[L__? _QK?\B/\
MYYK_ -\BCR(_^>:_]\B@# _X3S3?[L__ 'P/\:/^$\TW^[/_ -\#_&M_R(_^
M>:_]\BCR(_\ GFO_ 'R* ,#_ (3S3?[L_P#WP/\ &M/2=:M]:CD>W#A4.#O&
M*N>1'_SS7_OD4Y45/NJ%^@H =1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,_$#_D#0_P#7
MPO\ Z"U=-7,_$#_D#0_]?"_^@M0 ?#__ ) TW_7PW_H*UTU<S\/_ /D#3?\
M7PW_ *"M=-0 4444 %%%% !1110 4444 %%%% "*H7@  9SQ2T44 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7G^L_\EET'_KR;^4U>@5Y_K/_ "67
M0?\ KR;^4U 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M,_$#_D#0_P#7PO\ Z"U=-7,_$#_D#0_]?"_^@M0 ?#__ ) TW_7PW_H*UTU<
MS\/_ /D#3?\ 7PW_ *"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %>?ZS_R670?^O)OY35Z!7G^L_\
M)9=!_P"O)OY34 >@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<S\0/^0-#_ -?"_P#H+5TU<S\0/^0-#_U\+_Z"U !\/_\ D#3?]?#?^@K7
M35S/P_\ ^0--_P!?#?\ H*UTU !1110 4444 %%%% !1110 4444 %%%% !1
M110 5'/<1VL$DTTBPPQJ7>21@JJH&223T %25\A?$3PO\<OCE<:YI^NFV\#?
M#ZT>=F6W8">_AC+;00&9FW  _-L3G.#@"@#ZG\.>+=#\86<EWH&LZ?KEK')Y
M3SZ;=1W"*^ =I9"0#@@X]Q6M7RE_P3F_Y)#X@_[#LG_I/!7JG[4GQ.N/A1\%
M]:U>PF-OJT^VQL9!U260XW#W5 [#W44 =1XD^,G@7PAJ3:?K7B[1M,OT&7MK
MB]C61?JN<C\:Z;2=7L=>T^&_TV]M]0L9ANBN;6598W'JK*2#^%?+W[/O[(?@
MS4OACIVN>-M+/B'Q!KT*W\TUU/*IB24!U4;6'S8(+,><D\XKG?@VMQ^S?^U5
MJ/PR6]GF\)>((OM&G13,2(W*EXV^OR21$C[V%)Z< 'V8\BQHSNP1%&2S'  ]
M:X>/X[?#F;4QIZ>.- :\+^4(AJ,7+?W<[L9[5X9^VYXPU;5=0\&?"O0+M[6[
M\47*B\9"1F%I!'&K$?P%BY8>D?I74WG[#OPRF\"MHD&EO#JPMRD>N&:0S^=M
M_P!:R[MI&>=F,8R!CK0!]!@Y&1R*6OEW]ACXA:IJ'A[Q'X"U^>2?5?"MUY,1
ME)9A 693'D\D(Z,.>@90.!7U%0 4444 %>?ZS_R670?^O)OY35Z!7G^L_P#)
M9=!_Z\F_E-0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MS/Q _P"0-#_U\+_Z"U=-7,_$#_D#0_\ 7PO_ *"U !\/_P#D#3?]?#?^@K73
M5S/P_P#^0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444
M%97BS_D5M9_Z\IO_ $ UJUE>+/\ D5M9_P"O*;_T T ?,_\ P3F_Y)#X@_[#
MLG_I/!4O_!18R_\ "E]$V_ZK^WH=^/\ KWN,?AU_2HO^"<W_ "2'Q!_V'9/_
M $G@KU#]JKX9W'Q4^"NM:580-<:M:E+^RB7J\L9R5 [ED+J/=A0!Z'X)V?\
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ME5Y_K/\ R670?^O)OY34 ;7_  F%Q_T![K]?_B:/^$PN/^@/=?K_ /$UTU%
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MTU% ',_\)A<?] >Z_7_XFC_A,+C_ * ]U^O_ ,37344 <S_PF%Q_T![K]?\
MXFC_ (3"X_Z ]U^O_P 37344 <S_ ,)A<?\ 0'NOU_\ B:/^$PN/^@/=?K_\
M37344 <S_P )A<?] >Z_7_XFC_A,+C_H#W7Z_P#Q-=-10!S/_"87'_0'NOU_
M^)H_X3"X_P"@/=?K_P#$UTU% ',_\)A<?] >Z_7_ .)H_P"$PN/^@/=?K_\
M$UTU% ',_P#"87'_ $![K]?_ (FC_A,+C_H#W7Z__$UTU% ',_\ "87'_0'N
MOU_^)H_X3"X_Z ]U^O\ \37344 <S_PF%Q_T![K]?_B:/^$PN/\ H#W7Z_\
MQ-=-10!S/_"87'_0'NOU_P#B:/\ A,+C_H#W7Z__ !-=-10!S/\ PF%Q_P!
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M@/=?K_\ $UTU% ',_P#"87'_ $![K]?_ (FC_A,+C_H#W7Z__$UTU% ',_\
M"87'_0'NOU_^)H_X3"X_Z ]U^O\ \37344 <S_PF%Q_T![K]?_B:/^$PN/\
MH#W7Z_\ Q-=-10!S/_"87'_0'NOU_P#B:/\ A,+C_H#W7Z__ !-=-10!S/\
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M^$PN/^@/=?K_ /$UTU% ',_\)A<?] >Z_7_XFC_A,+C_ * ]U^O_ ,37344
M<S_PF%Q_T![K]?\ XFC_ (3"X_Z ]U^O_P 37344 <S_ ,)A<?\ 0'NOU_\
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M ,37344 <S_PF%Q_T![K]?\ XFC_ (3"X_Z ]U^O_P 37344 <S_ ,)A<?\
M0'NOU_\ B:/^$PN/^@/=?K_\37344 <S_P )A<?] >Z_7_XFC_A,+C_H#W7Z
M_P#Q-=-10!S/_"87'_0'NOU_^)H_X3"X_P"@/=?K_P#$UTU% ',_\)A<?] >
MZ_7_ .)H_P"$PN/^@/=?K_\ $UTU% ',_P#"87'_ $![K]?_ (FC_A,+C_H#
MW7Z__$UTU% ',_\ "87'_0'NOU_^)K5T;59-5CD=[22T*' 63O\ I6C10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<S\0/^0-#_U\+_Z"U=-7,_$#_D#0_P#7
MPO\ Z"U !\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU !1110 44
M44 %%%% !1110 4444 %%%% !1110 4R:%+B)XI462-U*LCC(8'@@CN*?10!
MD^'/"6A^#[.2TT#1M/T.UDD\UX--M8[=&? &XJ@ )P ,^PK6HHH XCQ-\$/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<S\0/\ D#0_]?"_^@M735S/Q _Y T/_ %\+_P"@M0 ?
M#_\ Y TW_7PW_H*UTU<S\/\ _D#3?]?#?^@K734 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G^L_\EET'
M_KR;^4U>@5Y_K/\ R670?^O)OY34 >@4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<S\0/\ D#0_]?"_^@M735S/Q _Y T/_ %\+_P"@M0 ?
M#_\ Y TW_7PW_H*UTU<S\/\ _D#3?]?#?^@K734 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G^L_\EET'
M_KR;^4U>@5Y_K/\ R670?^O)OY34 >@4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD!=W./F+'U[8'0 5\Z:OHMK^S[^VEX8;P_&-/\/^,H/(NM/APL2RNS)A5_A
MD$3CTW,!@<4 ?2/Q8^,'AWX+Z#:ZQXEEN(K.YN1:1_9X3*Q<HS=!VPAY^E>5
M?\-[?"C_ )^]5_\  !O\:Q_VWE75+SX3Z&P#C4/$: HW1@"B?^U?UKTZZ\>?
M!:QU1].N-8\%PWD;^6\3R6P*M_=)Z _6@#H?A1\7/#WQF\.W&M^&I+B6QM[I
MK-VN83$WF*B.>#VQ(O-=I5#1;+3+.Q0Z3!:06<W[Y?L2*L;Y ^8;>#D <^PJ
M_0 4444 %>?ZS_R670?^O)OY35Z!7G^L_P#)9=!_Z\F_E-0!Z!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MYGX@?\@:'_KX7_T%JZ:N9^('_(&A_P"OA?\ T%J #X?_ /(&F_Z^&_\ 05KI
MJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6^N?]#IJ'Y2?_':] HH \_\ ^%;ZY_T.FH?E)_\ ':/^%;ZY_P!#IJ'Y2?\
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M^4G_ ,=KT"B@#S__ (5OKG_0Z:A^4G_QVC_A6^N?]#IJ'Y2?_':] HH \_\
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M?E)_\=H_X5OKG_0Z:A^4G_QVO0** //_ /A6^N?]#IJ'Y2?_ !VC_A6^N?\
M0Z:A^4G_ ,=KT"B@#S__ (5OKG_0Z:A^4G_QVC_A6^N?]#IJ'Y2?_':] HH
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M_':] HH \_\ ^%;ZY_T.FH?E)_\ ':/^%;ZY_P!#IJ'Y2?\ QVO0** //_\
MA6^N?]#IJ'Y2?_':/^%;ZY_T.FH?E)_\=KT"B@#S_P#X5OKG_0Z:A^4G_P =
MH_X5OKG_ $.FH?E)_P#':] HH \__P"%;ZY_T.FH?E)_\=H_X5OKG_0Z:A^4
MG_QVO0** //_ /A6^N?]#IJ'Y2?_ !VC_A6^N?\ 0Z:A^4G_ ,=KT"B@#S__
M (5OKG_0Z:A^4G_QVC_A6^N?]#IJ'Y2?_':] HH \_\ ^%;ZY_T.FH?E)_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M##[P<'MD_25 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT#N+B*SMY9YY%BAB4N\C' 50,DGVQ0!)17Q3X1U/XE?MC^*-?U+3?&&H> ?
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MOS/Q+^'OQ;_9JT-/'&A_$[5O&=E9RH=2T_5O,>/:S8+E'E<%22 <889SGJ0
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M-S2O_P!\9]*^LM%TU-%T>PT^,[H[2WC@5L8R%4*/Y4 7:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^;/VG/'^K>+
MM>T_X+^")?\ BH-= .K7:'*V%D1E@Q'0LN2>^W ZN*^C;QIEM)S;J'N C&-6
MZ%L<#\Z^&OAGX-_:0^&'B#Q!KUI\/='UC7M<E\R\U/5KZ"2;&<[%*7:!5SS@
M#L.R@  U/VM/ .E?#'P;\'?#>BP^58V.JL@8@;I7_=EI&]68Y)^OI7TI^T-?
M/I_P+\>31DA_[&NHP5ZC=&5S_P"/5\6?M.>)_C1K'_"'?\+!\(Z-H7DZ@6TS
M^SY5;SYODRKXN),#[O\ =Z]:^K="L_B7\4?@WXUT7XB:#IOAS7=0MKBRL8M/
MD5XV1X,([8FEYWD]QP.G>@#'_85T^*S_ &=-&FC15>[N[N:4KU9A,R9/OM11
M] *X[_@HU81/\*_#5\0OGP:T(4;^(*\$K-C\8U_(5=_8 \;6]]\,M0\(7#B#
M6="OI2UHXP_DR'<&QWQ)YBGTPN>HKGOV[M8'CCQ#X!^&&D2K/K-[?K<31+SY
M)?$4);Z[Y#[!<]#0!]9^&;U]2\-Z3=R9WW%I%*V>N60$_P ZTZ@L;1-/L;>U
MC_U<,:QK]  !_*IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@!]W$L?NV*]S_:F\?67P_P#@?XHFN9UCNM1M)--LXR?FDEF0I\H_V5+-]%H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7,_$#_D#0_]?"_^@M735S/Q _Y T/\ U\+_ .@M0 ?#_P#Y TW_ %\-_P"@
MK735S/P__P"0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 4-=T.P\3:->Z3JMK'?:=>1-#/
M;RC*NC#!!_Q'(KYINOV!M BDO+?2/&OB31]%NFW2:9',K(0>"">-PQQ\P)QU
MS7U+10!Q?PI^$/AKX,^&O[%\-VC10L_FSW$[;Y[A\8W.V!GCH  !V KM***
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M7M]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ;AGC#<-L '!(ZL<GJ,@$BO9Z** "BBB@ HHHH **** "BBB@ HHHH ****
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MG!&1S@C)KU*B@#YK\._L->&+;Q!::IXH\1ZWXT%IM,%GJDH\GCLXY++P/E!
MXYR.*^DU4(H50%4#  & *6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9^('_(&A_Z^%_\
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MY]\>/BE#\'OA=K7B1RIO(X_)L8F_Y:7+\1C'< _,?936+^RYH>OZ7\'](O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,_$#_D#0_]?"_^@M73
M5S/Q _Y T/\ U\+_ .@M0 ?#_P#Y TW_ %\-_P"@K735S/P__P"0--_U\-_Z
M"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'7?^0'J'_7
MO)_Z":O51UW_ ) >H?\ 7O)_Z": /CW_ ()L?\@/QW_U\6?_ *#+7VA7Q?\
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MNO*)'32I)"?.\QG+%6B0*/G;@>M?1U 'R!^V]>2^,?B!\+?AQ'N\C4M02XN
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,_$#
M_D#0_P#7PO\ Z"U=-7,_$#_D#0_]?"_^@M0 ?#__ ) TW_7PW_H*UTU<S\/_
M /D#3?\ 7PW_ *"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !5+6E:31K]54LS6\@"J,DG:>*NT4 ?(?\ P3S\+ZSX9T;QLNL:1?:2TUQ:
MF-;ZV>$N LN2NX#.,CIZU]>444 ?(?[#/A?6?#WC+XHRZKI%]ID=S<6Y@>\M
MGB$H$EP25+ ;NHZ>HH_:H\+ZSK'[2?PDOK#2+Z^LK6XM#/<VUL\D<0%X"2[
M$+@<\]J^O** "OD+X<^%]9M?V[O&&KS:1?0Z5+!.([Z2V=8')2+&'(VGH>_:
MOKVB@""]4M9S@#),;  ?2OE#_@GMX8UCPSX9\8QZQI-]I3RW=NT:WUL\)<!&
MR0& S7UM10!\F?M!?"7QEX&^,5C\8_AU8R:O<KM&JZ3""TDFU-C$(.65XP%(
M4%@PW#.>)[K]NJ2XLS::7\,?$L_B1HQLL98CY8<CU4%V /\ L@GVKZLHH ^;
M_P!D'X2>+/"4?B+QAXW>:#7?$4GF+I\K9:!"S.S.O\+,S#Y>P49Y.!](444
M?(7[9EM)X)^+GPG^(W_+E97L=I=-CA0DHE )_P!I6F_[YKZ\5@RAE(((R".]
M>=?M _"N+XQ?"O6?#V%^WE/M-A(W&RY3)3GL#RA/HYK*_9=\6:OXG^$.DP>(
M--OM+US2%_LVYCO[=XGD\L )(-P&X,FW)_O!J /'OV&?"^L^'O&7Q1EU72+[
M3([FXMS ]Y;/$)0)+@DJ6 W=1T]17NW[15C<ZI\#?&UI9V\MW=3:9*D<$"%W
M=B.BJ.2?I7HU% '@_P"Q/HNH:!\ ],L]3L+G3KM;NY9K>[A:*0 R$@E6 /-<
MU^W]X=U7Q)\*="M](TR\U6X36DD:*RMWF=5\B8;B%!(&2!GW%?3M% ' ?8;C
M_A0OV/[/+]K_ .$:\K[/L/F;_LN-NWKG/&*\A_8!\.ZKX;^%.NV^KZ9>:5</
MK3R+%>V[PNR^1"-P# $C((S[&OIVB@#Y#\1>%]9E_P""@6AZRFD7SZ0EN VH
M+;.;=3]BD7!DQM') Z]37UY110!\A_LS>%]9TG]JSXNZA?:1?6=A=7%^;>ZN
M+9XXI@U\&4HY&&R.1@].:ZC]L+XF_%'X>GPT/ %K.MG=-)]JO+:P6[;S 1LB
M(96"@@D],G'!X-?2E% &'X&U#5M5\%Z%>Z]:"PUNXL89;VU4$"*9D!=<'IAB
M>.U?*WQ!M3\4?V]?"VE1-YEIX6M(;FYV\A&CW7 /U+20K7UMKVKQZ!HM_J<T
M4T\5G \[16\9DE<*I.U%'+,<8 '4FOG[]D?X=ZK]K\5_%#Q5936'B/Q5=RF*
MSN$9'M;;S"=N& (W,!@$?=C0]Z /I"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *YGX@?\ (&A_Z^%_]!:NFKF?B!_R
M!H?^OA?_ $%J #X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9
M^('_ "!H?^OA?_06KIJYGX@?\@:'_KX7_P!!:@ ^'_\ R!IO^OAO_05KIJYG
MX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KF?B!_P @:'_KX7_T%JZ:N9^('_(&A_Z^%_\
M06H /A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW_Y"3_"BB@ _X3#5_P#G[_\ (2?X4?\ "8:O_P _?_D)/\*** #_ (3#5_\
MG[_\A)_A1_PF&K_\_?\ Y"3_  HHH /^$PU?_G[_ /(2?X4?\)AJ_P#S]_\
MD)/\*** #_A,-7_Y^_\ R$G^%'_"8:O_ ,_?_D)/\*** #_A,-7_ .?O_P A
M)_A1_P )AJ__ #]_^0D_PHHH /\ A,-7_P"?O_R$G^%'_"8:O_S]_P#D)/\
M"BB@ _X3#5_^?O\ \A)_A1_PF&K_ //W_P"0D_PHHH /^$PU?_G[_P#(2?X4
M?\)AJ_\ S]_^0D_PHHH /^$PU?\ Y^__ "$G^%'_  F&K_\ /W_Y"3_"BB@
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M^0D_PHHH /\ A,-7_P"?O_R$G^%'_"8:O_S]_P#D)/\ "BB@ _X3#5_^?O\
M\A)_A1_PF&K_ //W_P"0D_PHHH /^$PU?_G[_P#(2?X4?\)AJ_\ S]_^0D_P
MHHH /^$PU?\ Y^__ "$G^%'_  F&K_\ /W_Y"3_"BB@ _P"$PU?_ )^__(2?
MX4?\)AJ__/W_ .0D_P *** #_A,-7_Y^_P#R$G^%'_"8:O\ \_?_ )"3_"BB
M@ _X3#5_^?O_ ,A)_A1_PF&K_P#/W_Y"3_"BB@ _X3#5_P#G[_\ (2?X4?\
M"8:O_P _?_D)/\*** #_ (3#5_\ G[_\A)_A1_PF&K_\_?\ Y"3_  HHH /^
M$PU?_G[_ /(2?X4?\)AJ_P#S]_\ D)/\*** #_A,-7_Y^_\ R$G^%'_"8:O_
M ,_?_D)/\*** #_A,-7_ .?O_P A)_A1_P )AJ__ #]_^0D_PHHH /\ A,-7
M_P"?O_R$G^%'_"8:O_S]_P#D)/\ "BB@ _X3#5_^?O\ \A)_A1_PF&K_ //W
M_P"0D_PHHH /^$PU?_G[_P#(2?X4?\)AJ_\ S]_^0D_PHHH /^$PU?\ Y^__
M "$G^%'_  F&K_\ /W_Y"3_"BB@ _P"$PU?_ )^__(2?X4?\)AJ__/W_ .0D
M_P *** #_A,-7_Y^_P#R$G^%'_"8:O\ \_?_ )"3_"BB@ _X3#5_^?O_ ,A)
M_A1_PF&K_P#/W_Y"3_"BB@ _X3#5_P#G[_\ (2?X4?\ "8:O_P _?_D)/\**
M* #_ (3#5_\ G[_\A)_A1_PF&K_\_?\ Y"3_  HHH /^$PU?_G[_ /(2?X4?
M\)AJ_P#S]_\ D)/\*** #_A,-7_Y^_\ R$G^%'_"8:O_ ,_?_D)/\*** #_A
M,-7_ .?O_P A)_A1_P )AJ__ #]_^0D_PHHH /\ A,-7_P"?O_R$G^%'_"8:
MO_S]_P#D)/\ "BB@ _X3#5_^?O\ \A)_A1_PF&K_ //W_P"0D_PHHH /^$PU
M?_G[_P#(2?X4?\)AJ_\ S]_^0D_PHHH /^$PU?\ Y^__ "$G^%'_  F&K_\
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MPU?_ )^__(2?X4?\)AJ__/W_ .0D_P *** #_A,-7_Y^_P#R$G^%'_"8:O\
M\_?_ )"3_"BB@ _X3#5_^?O_ ,A)_A1_PF&K_P#/W_Y"3_"BB@ _X3#5_P#G
M[_\ (2?X4?\ "8:O_P _?_D)/\*** #_ (3#5_\ G[_\A)_A1_PF&K_\_?\
MY"3_  HHH /^$PU?_G[_ /(2?X4?\)AJ_P#S]_\ D)/\*** #_A,-7_Y^_\
MR$G^%'_"8:O_ ,_?_D)/\*** #_A,-7_ .?O_P A)_A1_P )AJ__ #]_^0D_
MPHHH /\ A,-7_P"?O_R$G^%'_"8:O_S]_P#D)/\ "BB@ _X3#5_^?O\ \A)_
MA1_PF&K_ //W_P"0D_PHHH /^$PU?_G[_P#(2?X4?\)AJ_\ S]_^0D_PHHH
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M1_PF&K_\_?\ Y"3_  HHH /^$PU?_G[_ /(2?X4?\)AJ_P#S]_\ D)/\***
M#_A,-7_Y^_\ R$G^%'_"8:O_ ,_?_D)/\*** #_A,-7_ .?O_P A)_A1_P )
MAJ__ #]_^0D_PHHH /\ A,-7_P"?O_R$G^%'_"8:O_S]_P#D)/\ "BB@ _X3
M#5_^?O\ \A)_A1_PF&K_ //W_P"0D_PHHH /^$PU?_G[_P#(2?X4?\)AJ_\
MS]_^0D_PHHH /^$PU?\ Y^__ "$G^%'_  F&K_\ /W_Y"3_"BB@ _P"$PU?_
M )^__(2?X4?\)AJ__/W_ .0D_P *** #_A,-7_Y^_P#R$G^%'_"8:O\ \_?_
M )"3_"BB@ _X3#5_^?O_ ,A)_A1_PF&K_P#/W_Y"3_"BB@ _X3#5_P#G[_\
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*],\ >IHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>formdrs_033.jpg
<TEXT>
begin 644 formdrs_033.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 2W"*,# 2(  A$! Q$!_\0
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q
MFBBB@#T#X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH \9HHHH ] ^'_\ R!IO^OAO_05KIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /*?B+^T]\/OA7XE?0?$>JSVFII$DQCCLY91M89!W*I%>J1R"6-7
M7E6 (^AK\T/V]O\ DX.[_P"P=:_^@FOTJL?^/&W_ .N:_P A0!/5'7-9M?#N
MBZAJU\YBLK"WDNIW52Q6-%+,<#D\ \"KU<=\9/\ DD/CG_L!7W_I.] &1\+_
M -H3P1\8]3O+#PMJ4U[=6D(GF62UDB 0L%SE@,\FO2*_/_\ X)P_\E$\5_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_P#R!IO^
MOAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUZ?Q1\)_!VK73F2ZO-(M9IG))+2&)=Q_%LUV% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >,T444
M>@?#_P#Y TW_ %\-_P"@K735S/P__P"0--_U\-_Z"M=-0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*C9A7 8#&.HS6_5#0=$M/#6AZ=I%A'Y5CI]M':V\><[8T4*H_("K] !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >,T444 >@?#_P#Y TW_ %\-_P"@K735S/P__P"0--_U\-_Z"M=-
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@#T#X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\9HHHH ] ^'_ /R!IO\ KX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /&:*** /0/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0101C+.?<X'ZD5@1_$/39$5UBN65AD':O(_[ZIGQ2_Y$34_^V7_HU*U?"?\
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MG_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\
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MG_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\
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MG_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\
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MG_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\
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MG_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\
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MG_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\
MXJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/
M&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@
M#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QN
MO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%
M@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_
M^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&
MG_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\
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MG_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\
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MG_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\
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MG_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\
MXJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/
M&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@
M#F?^%@:?_P \;K_OE?\ XJMK2M4BUBT%Q"KJA)7$@ /'T-7** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#QFBBB@#T#X?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#E/BE_P B)J?_ &R_]&I6KX3_ .15T;_KRA_]%K65\4O^
M1$U/_ME_Z-2M7PG_ ,BKHW_7E#_Z+6@#6HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /&:*** /0/A__ ,@:;_KX;_T%:Z:N9^'_ /R!
MIO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#E/BE_R(FI_P#;+_T:E:OA/_D5=&_Z
M\H?_ $6M97Q2_P"1$U/_ +9?^C4K5\)_\BKHW_7E#_Z+6@#6HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /&:*** /0/A_\ \@:;_KX;
M_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .4^*7_(B:G_VR_\
M1J5J^$_^15T;_KRA_P#1:UE?%+_D1-3_ .V7_HU*U?"?_(JZ-_UY0_\ HM:
M-:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH \9HHHH ] ^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KI
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH Y3XI?\ (B:G_P!LO_1J5J^$_P#D5=&_Z\H?_1:UE?%+
M_D1-3_[9?^C4K5\)_P#(JZ-_UY0_^BUH UJ*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_P#(&F_Z^&_]!6NFKF?A_P#\
M@:;_ *^&_P#05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH Y3XI?\B)J?\ VR_]&I6KX3_Y%71O
M^O*'_P!%K65\4O\ D1-3_P"V7_HU*U?"?_(JZ-_UY0_^BUH UJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKQ]M&=P4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#?+?X4?\)7I/\ S^+_ -\M_A0!K45D_P#"5Z3_ ,_B_P#?+?X4?\)7I/\
MS^+_ -\M_A0!K45D_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A0!K45D
M_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A0!K45D_P#"5Z3_ ,_B_P#?
M+?X4?\)7I/\ S^+_ -\M_A0!K45D_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_
M -\M_A0!K45D_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A0!K45D_P#"
M5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A0!K45D_P#"5Z3_ ,_B_P#?+?X4
M?\)7I/\ S^+_ -\M_A0!K45D_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M
M_A0!K45D_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A0!K45D_P#"5Z3_
M ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A0!K45D_P#"5Z3_ ,_B_P#?+?X4?\)7
MI/\ S^+_ -\M_A0!K45D_P#"5Z3_ ,_B_P#?+?X4?\)7I/\ S^+_ -\M_A0!
MK45D_P#"5Z3_ ,_B_P#?+?X5S7Q(^,WAKX8^ ]=\5ZG=&2RTFT>Z>*)3OE*C
MY8USQN9L*,\9(JHQ<FHQW8FTE=FG\0OBAX3^%&A_VOXP\06'AW3BVQ)KZ8)Y
MC8SM0=7;&3A03Q7DNA?M^? #Q%JBZ?:?$FPBN&;:&OK6YM(<_P#76:)4Q[[J
M_&?XV_&WQ1\?/'E_XH\47\MS-/(QMK,R$P64).5AA4\*H&/<GDY))K@:^THY
M!3Y/WLWS>6QX4\RES>XM#^E.VNH;RWBN+>5)[>9!)'+&P974C(8$<$$=ZEK\
M8OV)?V\;S]FUM0T'Q:NJ^(O!,T)>TLK5EDEL;@'(\H2.H$;Y.Y<\'# 9R&]P
M\7_\%C#^\C\+?#4#^Y=:QJ?\XHX__:E>/5R;%1J.$%S+OL=L,=1E#FD[/L?I
M;17XR^+_ /@J=\<_$GF+IUYH?A9&/']EZ8LC ?6X,O/OC\J\7\2?M,_&3XD7
M'V?4OB#XHU(S,<65M?2QQN?:&(A3W[5T4\AQ$M9R2_$REF--?"FS]X_%'Q!\
M+>!XO-\1^)=(T"/&[?JE_%;#'KEV%?EU_P %/OVH])^*6H>&?!?@CQ-:ZWX6
MM8CJ&H3:;*'AFNB[)&C,.NQ5+8''[T'J!CY9\._LW_%CQU-YUAX&UZX\[YOM
M-Y;- CY[^9+M4_G6O\4/V1_B5\'?!,7BGQ/I-O:Z<9T@E6WNX[B2W9L[3)Y9
M*A2?ER"1D@=Q7IX/+\+A*\92JJ4NBT_*[.6OB:U:FTH61XU1117U1XY^JW_!
M(KXKZGXD\ ^+O VHW#W%KX=F@NM.\PY\N*X,N^,?[(>/<!ZR&OT"K\U/^"0E
MWX8T71_B%<W&M6Z^);R>VC.F-N\V.UB5R)1Q@JSS,IP3@H,XR,_HK_PE>D_\
M_B_]\M_A7YEFT5'&U.56_P"&/J\&VZ$;FM163_PE>D_\_B_]\M_A1_PE>D_\
M_B_]\M_A7DG::U%9/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^% &M163_PE>D_
M\_B_]\M_A1_PE>D_\_B_]\M_A0!K45D_\)7I/_/XO_?+?X4?\)7I/_/XO_?+
M?X4 :U%9/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^% &M163_PE>D_\_B_]\M_
MA1_PE>D_\_B_]\M_A0!K45D_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X4 :U%9
M/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^% &M163_PE>D_\_B_]\M_A1_PE>D_
M\_B_]\M_A0!K45D_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X4 :U%9/_"5Z3_S
M^+_WRW^%'_"5Z3_S^+_WRW^% &M163_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_
MA0!K45D_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X4 :U%9/_"5Z3_S^+_WRW^%
M'_"5Z3_S^+_WRW^% &M163_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A0!K45D_
M\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X4 :U%9/_"5Z3_S^+_WRW^%'_"5Z3_S
M^+_WRW^% &M163_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A0!K45D_\)7I/_/X
MO_?+?X4?\)7I/_/XO_?+?X4 :U%9/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^%
M &M163_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A0!K45D_\)7I/_/XO_?+?X4?
M\)7I/_/XO_?+?X4 :U%9/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^% &M163_P
ME>D_\_B_]\M_A1_PE>D_\_B_]\M_A0!K45D_\)7I/_/XO_?+?X4?\)7I/_/X
MO_?+?X4 :U%9/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^% &M163_PE>D_\_B_
M]\M_A1_PE>D_\_B_]\M_A0!K45D_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X4
M:U%9/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^% &M163_PE>D_\_B_]\M_A1_P
ME>D_\_B_]\M_A0!K45D_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X4 :U%9/_"5
MZ3_S^+_WRW^%'_"5Z3_S^+_WRW^% &M163_PE>D_\_B_]\M_A1_PE>D_\_B_
M]\M_A0!K45D_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X4 :U%9/_"5Z3_S^+_W
MRW^%'_"5Z3_S^+_WRW^% &M163_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A0!K
M45D_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X4 :U%9/_"5Z3_S^+_WRW^%'_"5
MZ3_S^+_WRW^% &M163_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A0!K45D_\)7I
M/_/XO_?+?X4?\)7I/_/XO_?+?X4 :U%9/_"5Z3_S^+_WRW^%'_"5Z3_S^+_W
MRW^% &M163_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A0!K45D_\)7I/_/XO_?+
M?X4?\)7I/_/XO_?+?X4 :U%9/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^% &M1
M63_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A0!K45D_\)7I/_/XO_?+?X4?\)7I
M/_/XO_?+?X4 :U%9/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^% &M163_PE>D_
M\_B_]\M_A1_PE>D_\_B_]\M_A0!K45D_\)7I/_/XO_?+?X4?\)7I/_/XO_?+
M?X4 :U%9/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^% &M163_PE>D_\_B_]\M_
MA1_PE>D_\_B_]\M_A0!K45D_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X4 :U%9
M/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^% &M163_PE>D_\_B_]\M_A1_PE>D_
M\_B_]\M_A0!K45D_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X4 :U%9/_"5Z3_S
M^+_WRW^%'_"5Z3_S^+_WRW^% &M163_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_
MA0!K45D_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X4 :U%9/_"5Z3_S^+_WRW^%
M'_"5Z3_S^+_WRW^% &M163_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A0!K45D_
M\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X4 :U%9/_"5Z3_S^+_WRW^%'_"5Z3_S
M^+_WRW^% &M163_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A0!K45D_\)7I/_/X
MO_?+?X4?\)7I/_/XO_?+?X4 :U%9/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^%
M &M163_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A0!K45D_\)7I/_/XO_?+?X4?
M\)7I/_/XO_?+?X4 :U%9/_"5Z3_S^+_WRW^%7[.^@U"$36\@ECSC< : )Z**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^'_P#R!IO^OAO_
M $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH *SM<\1:5X8T][[6-2M-*L
MD^]<7LZPQC_@3$"O,/CAX@^*G]J:;X<^&FC6OF7T+277B&_/[FQ&[  !&TMW
MZ.<?P]Z\QTO]A-/%%Y_:OQ,\=:QXIU9SN9;:39&N3RH>0,Q7_="?2@#UJ_\
MVI?A/IIQ-XYTM^0/]'=INO\ N*:U-%_: ^&WB*YCM[#QOHDUQ(=J1->)&S'T
M 8@DUQ=K^Q)\'+>$))X5DN6'_+274[L,?^^90/TK-US]@_X2ZLC+:Z=J6C$]
M&L=0D8CCMYWF?Y- 'T*K!U#*0RD9!'(-+7R9#^S+\4/@C(]]\*?'CZI91_-_
MPCNMC$<H_NCGRRQ]<1G_ &J^B?A?XBUWQ5X%TS4_$VB'PYKLOFI=Z:23Y3)*
MZ @G^%@H<=>&')ZD ZJBBB@ HHHH **** "BBB@#G?B,VHK\/?$[:.S)JPTN
MZ-FR$AA-Y3>61CONQ7SM_P $\Y-!D^%>J_9%@_X2$:B_]H-P9RA5?*)/79C=
MCMD/WS7U77SYXZ_8Q\+>(_%%QXC\.ZQJW@C6+AF>:31Y=L;LQRS!>"N3U"L!
M[4 <A_P4/DT-/AUH#2R0IXG34U:PV$?:/*V/YA'\03.S)'\02O4?B-\9K_X*
M?!?P]XIU;0[C6[MX[2WOX5F\IX9'A)9V)5OXQM^K"L#X?_L9^$_"?BB'Q)KF
MJ:IXUUNW=9()M8EW)&ZG(?;U8@\C<2 ><9YKV_Q%X=TWQ9HEYH^L646H:9>1
MF*>VF&5=3_(YP01R" 1S0!6\&^++#QUX5TO7M,F2>ROX$G1HW#;<C)4D=P<@
MCL0:^3?CC?6WB_\ ;<^&.FZ*ZW>H:4;<WQA.[RPDSS,C>ZQ@L?\ >KK+C]A/
M2M-O+@^%O'GB;PQI]PY:2QMY]RX/5005)'0?-N.!R37I7P6_9M\)?!$W%WI2
M7&I:W=*5GU;4'#SLI.2JX "J3SP,GC).!0!ZM1110 4444 <I\4O^1$U/_ME
M_P"C4J?POH>GS>&=(D>SA9VLX69B@R24'-0?%+_D1-3_ .V7_HU*U?"?_(JZ
M-_UY0_\ HM: )O\ A']-_P"?&#_O@4?\(_IO_/C!_P!\"M"B@#/_ .$?TW_G
MQ@_[X%'_  C^F_\ /C!_WP*T** ,_P#X1_3?^?&#_O@4?\(_IO\ SXP?]\"M
M"B@#/_X1_3?^?&#_ +X%'_"/Z;_SXP?]\"M"B@#/_P"$?TW_ )\8/^^!1_PC
M^F_\^,'_ 'P*T** ,_\ X1_3?^?&#_O@4?\ "/Z;_P ^,'_? K0HH S_ /A'
M]-_Y\8/^^!1_PC^F_P#/C!_WP*T** ,__A']-_Y\8/\ O@4?\(_IO_/C!_WP
M*T** ,__ (1_3?\ GQ@_[X%'_"/Z;_SXP?\ ? K0HH S_P#A']-_Y\8/^^!1
M_P (_IO_ #XP?]\"M"B@#/\ ^$?TW_GQ@_[X%'_"/Z;_ ,^,'_? K0HH S_^
M$?TW_GQ@_P"^!1_PC^F_\^,'_? K0HH S_\ A']-_P"?&#_O@4?\(_IO_/C!
M_P!\"M"B@#/_ .$?TW_GQ@_[X%'_  C^F_\ /C!_WP*T** ,_P#X1_3?^?&#
M_O@4?\(_IO\ SXP?]\"M"B@#/_X1_3?^?&#_ +X%'_"/Z;_SXP?]\"M"B@#/
M_P"$?TW_ )\8/^^!1_PC^F_\^,'_ 'P*T** ,_\ X1_3?^?&#_O@5\]_M_>"
M_P"UOV0_B)'I5FBW4-M;W;>6@SY4-U#+*?H$1C^%?2E>9_M&?&;PY\"/A)KG
MBCQ,D=W:+$;:#37P3J$[J0EN >H;G=P<*&)&!73AG*->#@KM-:?,RJV=.2D[
M*Q_/G16_H/A?6_B1XHDT_P +^'KK4]2NFEGBTK1[>2=U0 N0B#<Q55'?)P*Z
MG0OV:_BQXDU./3]/^&_BF:Y?H'TF>-5]V=U"J/<D#FOU652$?B:1\<HRELC%
M^$/PYN_B]\4/"_@RQE-O/K>H169N!'YGD(S#?*5R-P1-SD9&0O45^GWA'_@D
M3\,M+V2>(/%'B37I5(RD#0VD+>N5".WY.*VOV#?V#YOV>+B;QIXUDM;SQM=6
M_D6UI;_O(]+C;_6#S.C2L,*67A0& +!B:^TJ^*S+-IRJ\F&G:*ZKJSW\+@XJ
M'-5CJ?/_ (2_8'^ O@W8UK\.M/OY5.3)JTDM]N/NLSLOX 8]J]<T'X:^$O"]
MOY&C>&=)TB#&/+L+*.!?R4"NDHKYRI6JU?XDF_5GIQIPA\*L9_\ PC^F_P#/
MC!_WP*HZYX#\.>)M(N]*U;1+'4=-NXS%/:W,*O'(IZ@@]:WJ*R3:=T:'Y[_%
M/_@D/X;U[7IK_P "^,I_"UC,^[^RK^T-['%GM')YBMM'8-N/^U5#P_\ \$=]
M%@T'4EUOXB7MYK,D++926-@L%O;RY^5I%9G:5>.0"G7KQFOT7HKU5FV-45'V
MGY'%]3H7ORG\_/BKPI\0_P!D7XQBVNQ-H'BC1YA-;7</S0W,>>)$)&)(G&00
M1SRK $$#]:OV._VJ/!O[4?A<PR6%GH_CC3X@=2T? PXX'GP9Y:,GMR4) .<J
MS=]^TM^S-X5_:<\"OH6OQ_9-1M]TFF:S"@,]E*1U']Y#@;D)PP Z$*P_%[QU
MX#^(W['GQDA@N7N- \2Z3-]IT[5;0GRKF/) EB8C#QL,@J1W96'45[T94<ZI
M<LO=JK^ON_(\]JI@)W6L&?O?_P (_IO_ #XP?]\"C_A']-_Y\8/^^!7SK^QE
M^VIHG[3WAT:?J'D:-X_L(@;W2PV$N5'!GM\\E">J\E"<'(PQ^FJ^1K49X>;I
MU%9H]FG4C4BI1>AG_P#"/Z;_ ,^,'_? H_X1_3?^?&#_ +X%:%%8FAG_ /"/
MZ;_SXP?]\"C_ (1_3?\ GQ@_[X%:%% &?_PC^F_\^,'_ 'P*/^$?TW_GQ@_[
MX%:%% &?_P (_IO_ #XP?]\"C_A']-_Y\8/^^!6A10!G_P#"/Z;_ ,^,'_?
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M10!G_P#"/Z;_ ,^,'_? H_X1_3?^?&#_ +X%:%% &?\ \(_IO_/C!_WP*/\
MA']-_P"?&#_O@5H44 9__"/Z;_SXP?\ ? H_X1_3?^?&#_O@5H44 9__  C^
MF_\ /C!_WP*/^$?TW_GQ@_[X%:%% &?_ ,(_IO\ SXP?]\"C_A']-_Y\8/\
MO@5H44 9_P#PC^F_\^,'_? H_P"$?TW_ )\8/^^!6A10!G_\(_IO_/C!_P!\
M"C_A']-_Y\8/^^!6A10!G_\ "/Z;_P ^,'_? H_X1_3?^?&#_O@5H44 9_\
MPC^F_P#/C!_WP*/^$?TW_GQ@_P"^!6A10!G_ /"/Z;_SXP?]\"C_ (1_3?\
MGQ@_[X%:%% &?_PC^F_\^,'_ 'P*/^$?TW_GQ@_[X%:%% &?_P (_IO_ #XP
M?]\"C_A']-_Y\8/^^!6A10!G_P#"/Z;_ ,^,'_? H_X1_3?^?&#_ +X%:%%
M&?\ \(_IO_/C!_WP*/\ A']-_P"?&#_O@5H44 9__"/Z;_SXP?\ ? H_X1_3
M?^?&#_O@5H44 9__  C^F_\ /C!_WP*/^$?TW_GQ@_[X%:%% &?_ ,(_IO\
MSXP?]\"C_A']-_Y\8/\ O@5H44 9_P#PC^F_\^,'_? H_P"$?TW_ )\8/^^!
M6A10!G_\(_IO_/C!_P!\"C_A']-_Y\8/^^!6A10!G_\ "/Z;_P ^,'_? H_X
M1_3?^?&#_O@5H44 9_\ PC^F_P#/C!_WP*/^$?TW_GQ@_P"^!6A10!G_ /"/
MZ;_SXP?]\"C_ (1_3?\ GQ@_[X%:%% &?_PC^F_\^,'_ 'P*/^$?TW_GQ@_[
MX%:%% &?_P (_IO_ #XP?]\"C_A']-_Y\8/^^!6A10!G_P#"/Z;_ ,^,'_?
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M10!G_P#"/Z;_ ,^,'_? H_X1_3?^?&#_ +X%:%% &?\ \(_IO_/C!_WP*/\
MA']-_P"?&#_O@5H44 9__"/Z;_SXP?\ ? H_X1_3?^?&#_O@5H44 9__  C^
MF_\ /C!_WP*/^$?TW_GQ@_[X%:%% &?_ ,(_IO\ SXP?]\"C_A']-_Y\8/\
MO@5H44 9_P#PC^F_\^,'_? H_P"$?TW_ )\8/^^!6A10!G_\(_IO_/C!_P!\
M"C_A']-_Y\8/^^!6A10!G_\ "/Z;_P ^,'_? H_X1_3?^?&#_O@5H44 9_\
MPC^F_P#/C!_WP*/^$?TW_GQ@_P"^!6A10!G_ /"/Z;_SXP?]\"C_ (1_3?\
MGQ@_[X%:%% &?_PC^F_\^,'_ 'P*/^$?TW_GQ@_[X%:%% &?_P (_IO_ #XP
M?]\"C_A']-_Y\8/^^!6A10!G_P#"/Z;_ ,^,'_? H_X1_3?^?&#_ +X%:%%
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MXAV46;BQ4[8[] .9X 3_ -])R5Z\CD>P?'SX ^$_VC/ =QX9\56F]>9+._A
M%Q8S8P)(V_FIX8<$5^*7QF^"OC_]C_XL6UM>S3Z??6LWVO1?$%@2D=RJM\LL
M3?PL.-R'E2<'(()^PA4HYU2]G4]VJMOZ[=T>)*,\#/FCK!G[[45\D?L0_MT:
M9^T9I,7AKQ/);Z5\1K6/YH5PD6J(HR981V< $O&.G++\N0OUO7RE>A4P]1TZ
MBLT>S3J1JQYHO0****YS0**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?_
M /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ KP']KKPS\1
MO&WAC3O#_@CP_9:_IE\LZZM'=O AC(,1@9#)(A# ^8<KG&!GW]^KFOB'\1M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#"[/'!\#^&+W?X(\/SD230ME-1O%RK2Y[QIDJG8_,W(*X^C?\ @F/^R/\
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M*#[5])0S+"5%RPFE;OI^9Y53"UXZRC>_8^:J^YOV,O\ @HMIW[/_ (#T_P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(FI_]LO_ $:E:OA/_D5=&_Z\H?\ T6M &M1110 4444 %%%% !1110 4444
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MGOA>U?=7PK^/'P_^-FGB[\%>*M.UT!0\EM#+MN8@?^>D+8D3_@2BOC#XS?\
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MBB@#T#X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH
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MQR%-;4J-2M+DIQNR)SC35Y.R/HBOGOX_?MS_  K_ &?OM%EJ6L?V]XDCRO\
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MZ_US+\?IB8<LN_\ P5^J.+V&)P_\*5UV/O#X;_&#P5\7])_M'P9XGTWQ#;
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 >,T444 >@?#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0
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MF=6U&WL/M)3>(O-E5-^W(SC=G&1G%=E?+,'55Y0M;MH84\77@[*5[]SZ)_:
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M; ,2=L:RKAU(&-S;6!.<#&"?EWXK?L8?&;X&3O>ZKX4O;BPMF\Q=9T(F[@4
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M)&)^RW4:&21%]%=%8D=F0$?>.?U7KY#&X26#K.E+7MZ'MX>LJ\.=!1117"=
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!XS1110!Z!\/_ /D#3?\ 7PW_ *"M
M=-7,_#__ ) TW_7PW_H*UTU !1110 4444 %?*W[;.BFU\1?"CQA?0-<^&M$
MUI5U12NY$C>6!LL/0B)U)/<J.]?5->(_M/?"SX@_%;2=*TSP7K^GZ1IYCN8M
M6MM1D=4NE?R_+&%B?.W;)UQC<,>P![3;7,-Y;Q7%O*D\$J"2.6-@RNI&0P(X
M(([U+7Q!H7[*_P"T/X8TFWTS2?B9I^GZ?;C;#:P:O>+'&,YPH\C@9)J__P ,
MZ_M,?]%8M?\ P<WO_P 8H ^T**X[X0^'_$GA7X=:/I7B[55UOQ%;K(+N_29Y
M1*3*[+\[JK'"E1R!TKL: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** .4^*7_(B:G_ -LO_1J5J^$_^15T;_KRA_\ 1:UE?%+_ )$34_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM7BXC+<5A]9PNNZU.ZGBJ57X7J>]T4G7D4M>8=84444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[2\SX++LPQ'#^(_LW,?X?V9=%_P/R/TWHJII.K6>NZ;:ZCIUU%>V-U&LL%Q
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M.Y5  36W117E-N3NSKVT04444AA1110 5@^-? GAWXC^'[C0_%&BV6O:3/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(+#DA656!/0]/O5J_M>:7J7CK]D_3-7FAS?6?V#5[J/;AE+1E),#'&#,2?0
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MP;_OXW^-'_"%Z3_SP;_OXW^-24:?]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\
MC69_PA>D_P#/!O\ OXW^-'_"%Z3_ ,\&_P"_C?XT :?]J6?_ #]P?]_%_P :
M/[4L_P#G[@_[^+_C69_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C0!I_P!J6?\
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MGKZ(_<_#;@*AQ4ZF.S!OV%-\MD[.4K7:OT235[:N^C1][:1_P4^TJ;4 FJ>
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M2?\ G@W_ '\;_&C_ (0O2?\ G@W_ '\;_&@#3_M2S_Y^X/\ OXO^-']J6?\
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M_OXO^-']J6?_ #]P?]_%_P :S/\ A"])_P">#?\ ?QO\:/\ A"])_P">#?\
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MX/\ OXO^-']J6?\ S]P?]_%_QK,_X0O2?^>#?]_&_P :/^$+TG_G@W_?QO\
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M[^+_ (T?VI9_\_<'_?Q?\:S/^$+TG_G@W_?QO\:/^$+TG_G@W_?QO\: -/\
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M@6,J<="<@>AZ5^D?P1_:A^#_ ,9/AK+XMFU2T\'_ &.00:C8Z[J,<#6LNW(
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M_"%Z3_SP;_OXW^- &G_:EG_S]P?]_%_QH_M2S_Y^X/\ OXO^-9G_  A>D_\
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M_&LS_A"])_YX-_W\;_&C_A"])_YX-_W\;_&@#3_M2S_Y^X/^_B_XT?VI9_\
M/W!_W\7_ !K,_P"$+TG_ )X-_P!_&_QH_P"$+TG_ )X-_P!_&_QH T_[4L_^
M?N#_ +^+_C1_:EG_ ,_<'_?Q?\:S/^$+TG_G@W_?QO\ &C_A"])_YX-_W\;_
M !H T_[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?\:S/^$+TG_G@W_?QO\:/^$+T
MG_G@W_?QO\: -/\ M2S_ .?N#_OXO^-']J6?_/W!_P!_%_QK,_X0O2?^>#?]
M_&_QH_X0O2?^>#?]_&_QH T_[4L_^?N#_OXO^-']J6?_ #]P?]_%_P :S/\
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M<A ,GW-;]%%>2VY.[.Q)+1!1112&%%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4^O!/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_P#^0--_U\-_Z"M=-7,_#_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8RQ%&.\D?:M%?G%KW_!8_2H0ZZ)\,+RZ/19+_5T@QUY*I$^>W&1]:\X\0?\
M!8#XCW1<:+X,\,::C9P;S[1=,HY[K)&,].W8\<\=<<GQLOL6^:,)8Z@OM'ZR
M45^*FO\ _!3SX^ZSN^R^(M-T0-VT_28&Q[ RK(:\XU[]LSXX^(MWVOXH^)(M
MW7[!>M9^G_/'9CI_/U-=D<@Q#^*27W_Y&,LRI+9,_?*N6U_XK>"?"F[^V_&&
M@:/M^]_:&IP08^N]AZ&OP871?B]\5, 6'C;Q?YG&!#>7N[H/1L]!^5=3X?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5?S1?Q1^:V[.SZ'YX_\ !/7X]_\ "+^)I?AWK-SMTO6)/-TQY&XAN\<Q^PD
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M@9#+;7MW_;'B(+F/1;!PTH/;S6Z1#Z\XY"FOSM^-G[47COX^7IL[ZZ:PT1Y
M(-!TTL(B<_+O_BE;I][C/0"N''9QA\%>"]Z?9?J^GYGU7"OASF_$O+7DO8X?
M^>2W7]V.CEZZ1\SZ[^/7_!0;P_X/^T:1\/XH?$VL+E&U.3/V& _[.,&8_3"]
M/F/2OB*ZOOB+^TIXZ4.VI>,/$$^=D2C*PIGG X2*,'_=49YKW/X#_P#!/_Q-
MXZ^SZMXY>;PIH;8=;+:/M\Z^FT\0CW8%O]GG-??_ ,.OA;X6^$^A+I'A71[?
M2;3@R-&,R3,/XI'/S.?<DXZ#BO$C@\?F[4\6^2GV_P"!^K/U&MQ%PIX=TY87
M(*:Q.+V=1NZ3\Y+_ -)A9=VF?+7P&_X)XZ3X?^SZQ\2)X]<U 8==%MF(M(CU
M_>/P93[#"]?O"OL>PT^UTNSAL[*VAL[2%0D5O;QA(XU'154< >PJQ17U>%P=
M#!QY*,;?F_F?S]GO$F:<25_;YE6<NRVC'_#'9>N[ZMA1117:?,A1110 4444
M %>:_%S]GGP3\:H8V\0Z:R:A&-L>IV+"*Y5?[N[!##V8$#M7I5%=6%Q5?!55
M7PTW":ZIV9A6H4L3!TJT5*+Z,^5]*_X)V_#ZSODFO-8U[4(%Y-NTT4:M]2L>
M<?0CZU](>%/".B^!M#M]'T#3;?2M-@'R6]NFT9[DGJS'NQR3W-;%%>CF&=YE
MFJ4<;7E-+9-Z?<M+G)A,MP>!;>&IJ+?W_>,FACN(GBE198W&UD<9!'H17E'C
M;]E3X7>/-[WOA2TL;IN?M6EYM'SZD1X5C_O UZU17#A<=BL#/VF%JR@_[K:_
M(Z:^&H8F/+7@I+S5SXH\;?\ !-^W??+X1\6R1'^&UUJ$.#_VUC Q_P!\&O ?
M&W[(/Q4\#^8\OAF76+5?^7G1F%T#[[%_>#\5%?JK17Z%@/$3.L':-:2JQ_O+
M7[U;\;GR>*X1RW$:TTX/R>GW._X6/R*\*_'+XE_"NY^R:9XFU;3?LYVG3[QC
M+$GMY,H*K^0->\^"?^"C'B33_+A\4^&['6(QP;C3Y&M9<>I4[E8_3:*^W?%7
M@'PUXYM_(\0Z#IVLQXPOVVV20K_NDC*_@17@_C;]@/X<>(_,ET9]1\+W#<A;
M6;SX,^Z29/X!A7T?^M7#&=:9M@>23^TM?_)H\LOP9X_]AYUEVN Q/,ET>GX.
M\?Q1L>"OVXOA9XN\N.ZU.Z\-W3<>5JUN57/_ %T0L@'NQ%>W:'XBTKQ-8K>:
M/J=GJMHW2XLITFC/_ E)%?GYXV_X)Z^.]#\R3P]J6F^)H%^[&6^R7#?\!<E!
M_P!]UXEK'@GXB?!G4/M5YIFO>%+E#A;Z(20KG/\ #,GRG\&H_P!3>'\X][)L
M=:3^R[/\'RR7SN/_ %AS;+],QPMUW6GXZQ_(_8&O/OBK\!O _P 9[$P^*-#A
MNKE5VQ:A#^ZNH?3;*.<?[)ROJ#7P'X)_;@^*?A'RX[G5+?Q':KQY.KP!VQW_
M 'B;7)]R37OW@G_@HQX;U#RX?%/AN^T>0\&XT^1;J+/J5.UE'TW&OD<S\.\Y
MP\6O9*M#^Z[_ (.S^Y,^GRKC;"T:T:^'K2HU%L]4U\U_F>+_ !F_X)Y>+?!_
MGZAX(N?^$NTI<M]C8".^C7TV_=E_X#@GLM>+_#?XY?$;]G_6)+72-2O--$,A
M%SH>I1LT!;/(>%\;&]2NUO>OU-\$_M!?#OXA>6FA^+=.GN9/NVL\GV><GT$<
M@5C^ -2?%/X%^"/C+8&W\4Z%!>3JNV*_C'EW4/\ NRK\V.^TY4]P:_%\PX7K
M8*K>DI4:BZ237YZK\3^I<A\7HXW#_4N(J,<50>CDE%OYQ^&7RY7UU9\D:C_P
M4TFF\!LMEX16V\9,?+\R2;?8(,<R@<.3G^ \<_>.,'YDUK]IOXKZ]J#7EQ\0
M/$$,I.[997SVL0_[9Q%5Q^%<M\2/#$'@_P"(_BCP]9&>6VTO5;JQA:XP962*
M5D4M@ ;B%&<#%8RZ7,PR=J^Q->/@\MXBXB<HX&C.JH:/E6B?FU97_$_9Y+P]
MX'IQK8N5&A[?WH^T:<FG_*I7DHKRT[GUA^SW^WQXF\+ZU::1\0;IO$.@7$BQ
MG4I0!=60)QO) _>J.I#?-Z'L?T>M[B*\MXIX)%F@E4/')&P964C(((Z@BOPK
MFM9+?[Z\>HZ5[3X0_;,^*_@?PSIV@:5K\*:;I\(@MTFL8966,=%W,I) ' SV
M K6CCL7DM6>"S:G.,X])*TEZWMIV/C^)?#_+N,*='..$*E+EG?F<9?NY>:Y%
M)*2>C5EYZIW_ %OHK\J/^&]_C-_T,-I_X++?_P"(H_X;W^,W_0PVG_@LM_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNSCHTI5IJ,3XPL?@%\9/']P+J'P#XRUEY.?M<VEW+J<\\R,N.<YZ]Z[[0?\
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MJ[:+NSI?B]^U!\/O@G<)9^(=6:7567>-,T^/S[@+V+ $!,]MQ&>V:\^\*_\
M!0KX3^)-2CM+E]9\/"1@JW&JV:"+)]6BDDVCW( '>OS"U#4+G5;ZXO;VXDN[
MNXD:6:>9R[R.QR68GDDGO5>O@JG$>*=2\(I1[?\ !/ZVPG@SD=/"JGBJLYU;
M:R325_*-GIZW/W7L;ZVU2SAN[.XBN[2=!)%/ X>.12,AE8<$'U%3U^=W_!.W
MXWWND^,)/AOJ$S3Z5JBR7.G!VS]GN$0NZK_LNBL<>J\?>-?HC7VV QD<=05:
M*MT:[,_E[BSAJOPKFD\NK2YE92C+;FB]G;H[II^:[!1117HGQH4444 %%%%
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M% !1110 4444 %%%% !1110 4444 %%%% 'C-%%% 'H'P_\ ^0--_P!?#?\
MH*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!RGQ2_Y$34_^V7_ *-2
MM7PG_P BKHW_ %Y0_P#HM:ROBE_R(FI_]LO_ $:E:OA/_D5=&_Z\H?\ T6M
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M>GQ2G\V4^@_*N UK]D'X1:Z6:;P;;6SGHUE/-;X^@1POZ5['17IX?-,?A?\
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MBS4_./ED_8[F7?VV_=.?3%6;7]G7XI7@8Q_#OQ.NWKYNDSQ_EN49K]FJ*/\
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MDGRAANDR4QT4<Y!-?,^L^)_B'^T%XGBBN[C5?%NJ.28K2%"Z1#N4B0;8QZD
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M ./UYO\ :^8_] K^Z7^1]O\ \0\X-_Z'L/\ P.E_\D?I5_POSX8_]%&\)?\
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MAC_T4;PE_P"#RU_^.5^:O_##/QN_Z$G_ ,JUC_\ 'Z/^&&?C=_T)/_E6L?\
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MFN^\'?!/P-\/]6.J>'?#-CI&H-$T)N+=2&V$@E>3T) _*NH\$\D_:P^/6O\
MP4\7?#L:==^1HM_<2OJL*VR2R2PQR0;@FX<':[@8(Y(J*^_X:2\>VK>(-$O?
M#_@BPE'G6>@7D8ENFCQE1,[1.%<C' *X/!"\U@_MCJ&^-7P&5@"#K!!![_Z3
M:5]:T >"?LQ_M":I\5+C7?"WB[3H])\;:"Q6ZAA4JLR!MC-MR=K*V P!P=P(
MX.!!XR^+OB?1_P!KSP;X#M;R-/#6I::;FYMC A9GV7)R'(W#F).A[>]<!X!
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M<HEF13U"8557/0D*"1QG%>)_M[_;F\9_"-8+A+2$WL_EW$R;XHI?,ML.Z]"
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M1DC[KRN#D'Z1./SKZN_X*#>,/[#^#-IHL;XFUO4(XV3/6&(&1C^#B+\ZY/\
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M%T?R;[Q[J9URZ&&.F:>S16JGT:3AW_#9^-?I2R'AGA5>TSBM[>LOL+_Y%/\
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M9M[+NP S,V"V!@;0!P,F#QE\(O$^L?M>>#?'EK9QOX:TW33;7-R9T#*^RY&
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MGD=?F4D'Y6%>JT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH.A1'[RS7;RRCCTC0K_X\*_2:U/A3@Q?[3?%XE?92ND_3X(_]O-RZI'YIEN
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\
M"C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5
MTU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7
M_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;
MK_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_
M //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_
M .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% '
M,_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_P
MH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=
M-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=
M?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_
M +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO
M_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06
MW_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S
M/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\
M"C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5
MTU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7
M_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;
MK_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_
M //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_
M .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% '
M,_\ ""V__/[=?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_P
MH_X06W_Y_;K_ +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=
M-10!S/\ P@MO_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=
M?]]#_"C_ (06W_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_
M +Z'^%=-10!S/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO
M_P _MU_WT/\ "C_A!;?_ )_;K_OH?X5TU% ',_\ ""V__/[=?]]#_"C_ (06
MW_Y_;K_OH?X5TU% ',_\(+;_ //[=?\ ?0_PH_X06W_Y_;K_ +Z'^%=-10!S
M/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\
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M +)X8T.VTP,H62X5=T\O^_(V6;Z$X'8"OHGG7#'"BY,JI>WK+[;U_P#)K?\
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M/_""V_\ S^W7_?0_PH_X06W_ .?VZ_[Z'^%=-10!S/\ P@MO_P _MU_WT/\
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M)/Y"OC/P+9_$W]L2YUCQ*_CF^\">#8+MK6RL-++!GV@-AMCINP&4EF)R<@
M< 'VK17QGKFO?$/]D7Q_X5AUCQE=>/O!>O3?99%U3>T]OM9 Q4LS$$!P1\V&
M ((& :^S* "BBOC[Q)X_^('[3'Q>UGP7\/O$$WA'P?H+F*_URUR)9'!*Y#*5
M;EE8*JLH(4L3T  /L&BOCGQ?\-_B_P#LVV]CXH\+>.=9^(>G1SI'?Z'?123%
MD+=50O)P>A9<,N0>1G'UEX?UU-=\-Z=K#P26"7=K'=-!=*4>'<H8JX(&"N<'
M/I0!J455EU2RAL6O9+N".S7EKAI5$8YQRV<=>*-/U6RU:$RV-Y;WL0."]O*L
MB_F#0!:HJA?:]IFFW$=O>:C:6D\GW(IYU1F[< G)J\#D9'(H 6BFR2)#&SNR
MHBC+,QP /4FN:\2?$SPOX3\,W_B#4M;LX])L0//N(I!+@DX"@+DEB> !R: .
MGHKA_A'\8- ^-GAV[UOPZ+L6-M>/8L;R(1L9%1') !/&)%_7BNXH **** "B
MBB@#QFBBB@#T#X?_ /(&F_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#E/BE_R(FI_]LO_ $:E:OA/_D5=&_Z\H?\ T6M97Q2_Y$34_P#M
ME_Z-2M7PG_R*NC?]>4/_ *+6@#6K\JO^"OWQ$_M3XD^"_!4,H:'2-.DU&=5/
M_+6X?:H;W"0 CVD]Z_56OP-_;$^(7_"TOVG/B!KD4AFMCJ;V-JPZ-#;@0(1[
M,(PW_ J^BR.ESXEU'M%?GI_F>9F$K4E!;MEW]G'P4WBSQ%X:T;:2VMZM!;'
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MS7VM;6_R/CZ$:E2K&-'XFU:W?H?5O_#RW_JG/_E<_P#N:C_AY;_U3G_RN?\
MW-7<?\.Z?AO_ -!OQ5_X%VW_ ,CT?\.Z?AO_ -!OQ5_X%VW_ ,CU_/GUGP__
M .?$OOJ?_)GZQ['BO_G['_R3_P"1.'_X>6_]4Y_\KG_W-1_P\M_ZIS_Y7/\
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MJX)P%X1O2@#S'QY^ROX=?P[I_BGX"SK:>)K&XC>";3M9,T$Z9^;+R2, 1P<
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MZAIUO=FW086/S(E?:!Z#./PK=J*UM8;&UAMK>-88(46..-!A54#  'H *EH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO;V[;H[+5+]C%QT!ZMCK]TCK7T-:6D&GVL-K;0QV]M"BQQ0Q*%1% P% '0
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M!\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU !1110 4444 %%%%
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MPTX7_P#;8_A%_>?QOP?3E5^L8Z>\Y6_5_F@HHHK\4/T@**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#QFBBB@#T#X?\ _(&F_P"OAO\ T%:Z:N9^'_\ R!IO
M^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH Y3XI?\B)J?_;+_ -&I7Y"_\%)OB(/%WQNT
M;0H9=UKX9\/V5D5!ROGR1B>1A[[9(U/^Y7Z[_%B5(/A_JTDC!(T6-F9C@ "5
M"2:_!+5)M1^.WQO<6Q9]0\4:VMO;!A]WSI@D2_105'T%?39#33K2K/:*_/\
MX%SR<QE[B@NK/8=5T?\ X1'X8?#70L%9I=(;7;H?]-;R5G0X][:.U_SBOIC5
MY?\ A7O[!/A;2E_=7OC'5Y+V>/H6A1R0??B*W_.O"_VA;ZWU+XU>)[?35)L-
M/NETBS1>?W-JBVT8&/\ 9B'YU[/^V9<+H.J> ? $+ P^$_#MO;R*#TG=5#_F
ML<9S[UY/ASAGGG&D\9)7C!RE]S]W\4C^@/%ZM_JUX9Y9DL=)5%&__@-YK[YW
M^1WO_!.'PA]I\3>+?$\B?+9VL>GPL1U:5M[X]P(E_P"^J^\J^>_V%_"'_",?
M '3[MTV7&M74VH/D<[<^4GX;8@P_WJ^A*^EXRQWU[/<3-/2+Y5_V[I^:;/YQ
MX=PWU7+*,7NUS??K^5@HHHKXH^D"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHK\IOV^/V^?$.N>,=8^'7PZUA])\-Z<YM-0U:P8I<7TZDB1$E!RL2G
MY?EP6(;DJ0*[L'@ZF-J>SI_-]CGKUXT(\TC]4/[2M/MGV3[5#]KQGR/,'F=,
M_=SGI5FOYK&NYWNC<M-(UR7\PS%B7W9SNSUSGO7W7^PC^WUXC\(>,M'\!?$/
M69-8\(ZC*+6UU/4',EQITS'$8,I.6A+84AL[,@@@ @^UB<BJ4:;G3GS6Z6M]
MVYP4LPC.7+)6/UHHHHKY<]<**** "N-^*GQ8T#X-^&XM<\1R7$5A+<K:*UO"
M9&\QE9AP.V$:NRKY@_X*'?\ )#=._P"P[;_^B9Z /H'P/XVT?XB^%K#Q#H-T
M+S3+U-\<F,$$'#*P[,"""/45KWUY'I]E<74Q(B@C:5\#)VJ,G]!7P[\#?%&I
M?LI_$ZS\'>);EG\$>+(8;W3[^3B.&615PY/0<D1O]$;@=?M3Q9_R*VL_]>4W
M_H!H P/A1\7/#WQF\.W&M^&I+B6QM[IK-VN83$WF*B.>#VQ(O-=I7RS_ ,$Z
M?^2)ZW_V,,__ *36U>J_%O\ :.\&?!F\M=/UJXNKW6;I0\6E:7#YUPRDD D$
MA1DC R03VZ&@#U&BOGC3_P!MKPC'K=KIWB3P_P")?!BW1Q!=ZU8".$C.,MAB
MP'3D @=R*^A%F22)95=6C9=P<'((ZYSZ4 /HKY[US]M;P?;Z]=:3X=T7Q#XT
MFM6*RSZ'9"6'C(.UBP+#(Z@8/4$UW/PA_:%\(?&IKRWT.:ZM-5LN;G2M3A$-
MS&N=N[:"01G@[2<9&<9% 'I=%><_$+X[:#\-?''A+PKJ=IJ4^H>);A+:SDM(
MHVBC9I5C!D+.I RXZ \9KT:@ HKSGX;?';0?BEXN\6>'=*M-2M[WPW<&VNY+
MR*-8W82/'F,J[$C,;=0."*K?&#]HGPA\%)+.UUN6ZO=6O%WP:7ID(FN'7.-V
M"0%&<@9(S@XS@T >GT5\_>'_ -M+P?>ZY9:7XAT;Q!X*FO2!;W&NV0BMWR0!
M\X8D D]2-HZDBOH '(R.10 M%%>0_M*?&L_"'P;'%I2?;/%^M/\ 8]'LD7>[
M2G ,FWN%W#CNQ4=S0!UMK\8/!U]X]E\%V^O6\_B>+<'T^-7+*53>P+;=N0O4
M9XZ=:[&OS^^ _P .]1^&/[8VA:/K-XU_K4FFRWM_,S;OW\UL[N-W\6"<;NY!
M/>OT!H *Y7QY\4_"7PQMH9_%&O6>C+,?W23OF23'4J@!9@,C) P,\UU).!D\
M"OB/]G_PCIW[47QH\<_$/Q;!_;&C6%PMOI>GW:[H2K%_+#*>"$C53MQ@M(2?
M< ^H? /QT\!?%"Z:U\,>)K/4[Q5W_9?FBF*]R(Y K$#N0..]=Y7QI^V-\&=)
M^&>CZ-\2_ EC!X8U;2+Z))DTR)882K'Y)-BX4$. IP/F#G.<5],6_P 4-/;X
M0Q_$":&8Z;_8XUB2" !I0GE>8R*"0"PY') R.M '9T5X%<?MK?#N'PCI&M(N
MK7%UJGF&WT.WMDDO]J2-&6=5<HH)0XR^2.@ZU?\ A5^UYX$^*FK3Z3&]YX>U
M6&-Y6MM:C2$,J M(5<,5^4 DAB#@$XP#0![=17S?XB_;Q^'FAZA+%:V.O:Y8
M0R>5)JFGV:?9L\C"L[J6Y'H 1R":]L^'OQ"T/XH>%;3Q#X>N_MFG7&0"RE71
MQPR.IZ,#_B,@@T =)17GGQ:^/'A+X,Q6BZ_=32ZA>?\ 'KI=A%YUU/SC*ID
M#/ +$ G@5Y/XN_;<T[3].^QZ9X.\0Z?XGO&2'3+7Q/:)8V\SLP7<S^8<*N<G
MD=AD=0 ?3=%<+\'V\?R>&;J3XC)ID6MO>.T,6E?ZJ.WV)M4\GYMWF=SP1S7=
M4 %%%% !1110!XS1110!Z!\/_P#D#3?]?#?^@K735S/P_P#^0--_U\-_Z"M=
M-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>5?M*?M"Z%^S3\,;SQ;K49O9]XMM/TR.0))>W#9*Q@D':
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'LOM']H^8GVH'R#)C.W&,C'3I7VIXBUBV_9W^!\EVD-YK]MX;L(XDC=P)K@
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MN"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M )_;K_OH?X4?\(+;_P#/[=?]]#_"@#IJ*YG_ (06W_Y_;K_OH?X4?\(+;_\
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M )_;K_OH?X4?\(+;_P#/[=?]]#_"@#IJ*YG_ (06W_Y_;K_OH?X4?\(+;_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >,T444 >@?#_P#Y TW_ %\-_P"@K735S/P_
M_P"0--_U\-_Z"M=-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5\X_'[X-^+OCC\6O"&G7-HD'PUTEQ<7LYN4W7$AY<>6#N^ZJQ@XXWN
M>E?1U% #8XTAC2.-%CC0!551@ #H *Q?''@[3OB!X1U7PYJR,^GZE T$NPX9
M<]&4]F4@$>X%;E% 'Q[X4\'?M$_L_P!G=^%?"&DZ-XV\-)*\EA=WLZ(T*L<X
M"M/&5SU*_, 2<&NY_9U_9\U_POXOU?XC_$._2_\ '&JAD\F%P\=JC8SDC@MA
M0H"_*JC SGCZ)HH **** "OG']M/]G.X^.'@FUU+081+XLT3<UM#N"_:H6QY
MD.2<;N RD]P1_%D?1U5]0U"UTFQN+V^N8K.SMT,DUQ.X2.-0,EF8\  =S6%?
M#1Q=-T)JZE_6A[&3YOB<AQU+,L)*TZ;OKLUU3\FKI^1^&FJZ3>Z%J5QI^I6D
M]A?6[F.:VN8S')&PZAE/(/UK8TVSEN#;6L$;2SR%42-!DLQ.  /4DU]E_M*?
MM2?"_P ;1ZCI>F^"[7Q7J2KY4'B&\MXT$; CF,LAD9>HP=H/TP:^=?V?WT2'
MXT>#Y_$5]#IND6^H1W$US<G$:F/+H&/8%U5<G@9YP,U^T^&?!V-X46-S;&TW
M=PM!6]YK64M-6FVHZ;G)XO\ BIAO$+"Y?E&$CR<DW*IK>/-91C9V6B3GZ7/T
M4_95^!7_  HKX:QV-[M?Q%J<GVW5'5@P60C"Q*1P0@XR.I+$<$5[-3(9DN(D
MEB=9(W4,KH<A@>00>XI]?CMK7OOU]7J_O9.*Q53&UI5ZKU?W))627DDDDNB0
M4444'(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >,T444 >@?#_\
MY TW_7PW_H*UTU<S\/\ _D#3?]?#?^@K734 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q3_P40^*E]I\>
MB^ ;*4PVU[ -2O\ ;UE02,L2?[NY'8CU5?2OM:O@W_@HUX%O8_%'AOQA'"SZ
M=-9_V9-*HXCE1WD0-_O*[8_W#7Z!P'3P]3/J*Q'2[C?^9+3_ #7G8^4XHE5C
ME=1TO*_I?7_@^1\;4445_79^!'Z)?L _%2^\8^ -3\+ZE*9YO#CQ+:RL<L;:
M0/M3/?848#T!4=J^J:^.O^"<_@>]TOPOXG\4W43Q6NJRPVMF6&/,6'?YCCU&
MYPN?5&K[%K^..,J>'IY]BHX;X;K;^:RYO_)KW\S^A>'959Y71=;>WX7=OPL%
M%%%?%GT84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#E/BE_R(FI_P#;+_T:E:OA/_D5=&_Z\H?_ $6M97Q2_P"1$U/_
M +9?^C4K5\)_\BKHW_7E#_Z+6@#6HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /&:*** /0/A_\ \@:;_KX;_P!!6NFKF?A__P @:;_K
MX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** .4^*7_(B:G_VR_\ 1J5J^$_^15T;_KRA_P#1
M:UE?%+_D1-3_ .V7_HU*U?"?_(JZ-_UY0_\ HM: -:BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ]
M^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y3X
MI?\ (B:G_P!LO_1J5J^$_P#D5=&_Z\H?_1:UE?%+_D1-3_[9?^C4K5\)_P#(
MJZ-_UY0_^BUH UJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#QFBBB@#T#X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH Y3XI?\B)J?\ VR_]&I6KX3_Y%71O^O*'_P!%K65\4O\ D1-3
M_P"V7_HU*U?"?_(JZ-_UY0_^BUH UJ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^O*'_P!%K0!K4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'C-%%% 'H'P_\ ^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%%
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M_':] HH \_\ ^%;ZY_T.FH?E)_\ ':/^%;ZY_P!#IJ'Y2?\ QVO0** //_\
MA6^N?]#IJ'Y2?_':/^%;ZY_T.FH?E)_\=KT"B@#S_P#X5OKG_0Z:A^4G_P =
MH_X5OKG_ $.FH?E)_P#':] HH \__P"%;ZY_T.FH?E)_\=H_X5OKG_0Z:A^4
MG_QVO0** //_ /A6^N?]#IJ'Y2?_ !VC_A6^N?\ 0Z:A^4G_ ,=KT"B@#S__
M (5OKG_0Z:A^4G_QVC_A6^N?]#IJ'Y2?_':] HH \_\ ^%;ZY_T.FH?E)_\
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M6^N?]#IJ'Y2?_':] HH \_\ ^%;ZY_T.FH?E)_\ ':/^%;ZY_P!#IJ'Y2?\
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M^4G_ ,=KT"B@#S__ (5OKG_0Z:A^4G_QVC_A6^N?]#IJ'Y2?_':] HH \_\
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M?E)_\=H_X5OKG_0Z:A^4G_QVO0** //_ /A6^N?]#IJ'Y2?_ !VC_A6^N?\
M0Z:A^4G_ ,=KT"B@#S__ (5OKG_0Z:A^4G_QVC_A6^N?]#IJ'Y2?_':] HH
M\_\ ^%;ZY_T.FH?E)_\ ':/^%;ZY_P!#IJ'Y2?\ QVO0** //_\ A6^N?]#I
MJ'Y2?_':/^%;ZY_T.FH?E)_\=KT"B@#S_P#X5OKG_0Z:A^4G_P =H_X5OKG_
M $.FH?E)_P#':] HH \__P"%;ZY_T.FH?E)_\=H_X5OKG_0Z:A^4G_QVO0**
M //_ /A6^N?]#IJ'Y2?_ !VC_A6^N?\ 0Z:A^4G_ ,=KT"B@#S__ (5OKG_0
MZ:A^4G_QVC_A6^N?]#IJ'Y2?_':] HH \_\ ^%;ZY_T.FH?E)_\ ':/^%;ZY
M_P!#IJ'Y2?\ QVO0** //_\ A6^N?]#IJ'Y2?_':/^%;ZY_T.FH?E)_\=KT"
MB@#S_P#X5OKG_0Z:A^4G_P =H_X5OKG_ $.FH?E)_P#':] HH \__P"%;ZY_
MT.FH?E)_\=KK/#>DW.BZ8MM=:A+J<H8M]HFSN(/;DGI]:U** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF6Z9AY:QA=Q?/ICFODO]A&UN?%'BOXH^/I(O+M=6U$I"2#DNTCS2#\!)'^=
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M=127S+C'RS2-(F??8R5[)0 4444 %%%% !1110 4444 %%%% !1110 4444
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M;CP_\"?MURFPZSJ4U[%GKY05(AG\8G(]B*^DJ "BBB@ HHHH **** "BBB@
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M\?;-6NP!)( <[5 ^ZN><9))ZDX&/5Z** "BBB@ HHHH **** "BBB@ HHHH
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MF$7+Q[#)EBV=N3CKZU/\0OA_HGQ/\)WOAWQ!:_:M.N@,[3M>-ARKHW9@>A_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'C-%%% 'H'P__P"0--_U\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!XS1110!Z!\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\4?\ !2K_ (\?
MA]_UTOOY6]?9.A?\@/3_ /KWC_\ 017QM_P4J_X\?A]_UTOOY6]?9.A?\@/3
M_P#KWC_]!% '@W[:OQ6\5?"3P%H>H^$]4_LJ\N=3^SRR?9XIMT?E.V,2*P'*
MCD#/%>SZ3JEU<^ K/49)=U[)IB7#2;0,R&(,3C&.O;&*^:_^"CG_ "2[PS_V
M&1_Z(DKZ*T/_ ));I_\ V!H__1 H ^._@C^U#\8OB-INH>'=(MX_%7BZ></'
MJ5Y;PP6FFVH7#._EJ@)+=-WIP&Z5I_$;Q=^TG^S_ &]MXI\2>(M(\2Z&UQ''
M<06L$;1*3G"OB&-T!QC<IQDC)R:V/^";JC_A"_&+8Y.H0@G_ +9FO4_VUE#?
MLS^,"0"5-F1['[9 /ZT <+!\</BK^T,@7X1:5:^&=%AC07/B'70&S.5!>*,%
M7!"DE20C= ?ER >7C^-7Q@_9Y^*/A[0OBGJ5CXC\/:PRH+ZVB4*BEPK.CK'&
MQ9"P+*RG@C'4&O:_V-V+?LV>"\\_NKC_ -*IJ\6_X*3 #1_ 4@X=;B\ ;N/E
MA_P'Y4 ?7GBCQ+I_@WP[J6N:K-]GT[3X'N)Y.I"J,\#N3T [DBOE+PGX\^._
M[3#WFM^$-2T[X?\ @U)V@MI)X5EEGVD9Y*.S$=R-BYR!D@UZ-^W%=7%O^SCX
M@$!95EGM8Y2IQ\GGH?RR /QKR?X&W'[05K\)O#4?@_3_  G)X;^S%K-KICYI
M4NQ8O\X^;<6S0!MR?&OXJ_LZ^--&TWXM3:?XE\+:M((8]>L8UB,!R-Q.U%SM
M# E67) RK'!KZVCD66-71@Z,,JRG((/<5\8_%[X7_M$?&SPS!H7B+3/"HLX;
MI;Q&LYS'()%5E')8\8=NU?67@'3[_2? OARQU4*-4M=-MH+ORVW+YRQ*KX/<
M;@>: -JXN([2WEGE;;%&I=V] !DFOD7]AUG\?>.OBA\2+R,_:M2O%MX&;_EF
MCLTKQ_0 0#_@-?3?Q)N)+3X=>*9XO];%I5TZ?40L17S]_P $[843X)ZNX.7?
M7IMWMBWMP!_GUH W?VU?BMXJ^$G@+0]1\)ZI_95Y<ZG]GED^SQ3;H_*=L8D5
M@.5'(&>*Y33?''Q\^/6CV^H>!?[-\%>'?*6./5-81?M&HL%P\BKY<FU2V2-J
M >C'LW_@HY_R2[PS_P!AD?\ HB2OI?P&H7P/X=51@#3K< #_ *Y+0!\@:#^U
M9\1/@?X[U/PC\6[;_A(9DM]]I-8PQK*\A7,01D55='/RY*[@?H177W5G^U+\
M0+;^W+'4]!\#6SCSK?0I IG"]5#EH9/F(QD,RC/55Z#E?VE%$?[<'PG*C!:/
M3"2._P#I\X_E7VO0!\Y?LE_M":]\4IO$'A;QG D/BO0F_>2+$(C*H<HX=!PK
MHX ., [AQP:H?M9?&3QA\,_'OPZT[PUJ_P#9MEJTS)>Q_9H9?- EB4#+HQ7A
MF^Z1UKB_V<P(_P!N+XLJORJ8-08@=,_;;?G]3^='[=W_ "5+X1_]?#_^CX*
M/ISXT^(M0\)?"7Q=K6DW'V34K#3)[BWGV*^R14)4[6!!Y[$$5\L_"3]H3XT_
M&+P?'H?A2V@O_$<4LC:EXIU2"**VM48_NHT5%"E\<_=8X_A/4?2G[1G_ "0?
MQ[_V!KG_ -%FO.OV"5"_L^VI P3J-T3[_,* /+/&WQ,_:"_9IU+2M7\;:OIO
MB[PY>7)CE6UBC\LMC)3>(8WC8J&*\%?E/!K[1T/6+;Q#HMAJMDYDL[ZWCNH'
M(P6C=0RG'T(KYX_X* 1K)\ PS*"4U:V93Z';(,_D3^=>K? %BWP.\ $G)_L&
MR'Y0(* .^KAOCAX/3QY\(O%NAO&)9+G3I3 I_P">R+OB/X.JG\*[FFR;3&X?
M&S!W;NF.] 'SU^PIXVD\6? >TLIR6GT.[ET[<QY:/B1#] LFW_@%?0]?'O\
MP3@DD/@_QH@!^RC4(3&6/.XQG.?P"U]A4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 >,T444 >@?#_\ Y TW
M_7PW_H*UTU<S\/\ _D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA)')&S%B 20'7+%@RDD;L$#%?;-,FACN(VCEC66-NJ. 0?PH ^)_BI\?-?\
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M7VA10!YS^T9_R0?Q[_V!KG_T6:\Z_8)_Y-\M/^PC=?\ H0KZ+HH ^;OV_?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFBBB@#T#X?\
M_(&F_P"OAO\ T%:Z:N9^'_\ R!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \9HHHH ] ^
M'_\ R!IO^OAO_05KIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&:***
M/0/A_P#\@:;_ *^&_P#05KIJYGX?_P#(&F_Z^&_]!6NFH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QFB
MBB@#T#X?_P#(&F_Z^&_]!6NFKF?A_P#\@:;_ *^&_P#05KIJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\9HHHH ] ^'_ /R!IO\ KX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /&:*** /0/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\+$_ZA__ )&_^QH_X6)_U#__ "-_]C110 ?\+$_ZA_\ Y&_^QH_X6)_U#_\
MR-_]C110 ?\ "Q/^H?\ ^1O_ +&C_A8G_4/_ /(W_P!C110 ?\+$_P"H?_Y&
M_P#L:/\ A8G_ %#_ /R-_P#8T44 '_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T
M44 '_"Q/^H?_ .1O_L:/^%B?]0__ ,C?_8T44 '_  L3_J'_ /D;_P"QH_X6
M)_U#_P#R-_\ 8T44 '_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\ V-%% !_P
ML3_J'_\ D;_[&C_A8G_4/_\ (W_V-%% !_PL3_J'_P#D;_[&C_A8G_4/_P#(
MW_V-%% !_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &-%% !_PL3_ *A__D;_
M .QH_P"%B?\ 4/\ _(W_ -C110 ?\+$_ZA__ )&_^QH_X6)_U#__ "-_]C11
M0 ?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C110 ?\ "Q/^H?\ ^1O_ +&C_A8G
M_4/_ /(W_P!C110 ?\+$_P"H?_Y&_P#L:/\ A8G_ %#_ /R-_P#8T44 '_"Q
M/^H?_P"1O_L:/^%B?]0__P C?_8T44 '_"Q/^H?_ .1O_L:/^%B?]0__ ,C?
M_8T44 '_  L3_J'_ /D;_P"QH_X6)_U#_P#R-_\ 8T44 '_"Q/\ J'_^1O\
M[&C_ (6)_P!0_P#\C?\ V-%% !_PL3_J'_\ D;_[&C_A8G_4/_\ (W_V-%%
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M3_J'_P#D;_[&C_A8G_4/_P#(W_V-%% !_P +$_ZA_P#Y&_\ L:/^%B?]0_\
M\C?_ &-%% !_PL3_ *A__D;_ .QH_P"%B?\ 4/\ _(W_ -C110 ?\+$_ZA__
M )&_^QH_X6)_U#__ "-_]C110 ?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C110
M ?\ "Q/^H?\ ^1O_ +&C_A8G_4/_ /(W_P!C110 ?\+$_P"H?_Y&_P#L:/\
MA8G_ %#_ /R-_P#8T44 '_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T44 '_"Q/
M^H?_ .1O_L:/^%B?]0__ ,C?_8T44 '_  L3_J'_ /D;_P"QH_X6)_U#_P#R
M-_\ 8T44 '_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\ V-%% !_PL3_J'_\
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M^QH_X6)_U#__ "-_]C110 ?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C110 ?\
M"Q/^H?\ ^1O_ +&C_A8G_4/_ /(W_P!C110 ?\+$_P"H?_Y&_P#L:/\ A8G_
M %#_ /R-_P#8T44 '_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T44 '_"Q/^H?_
M .1O_L:/^%B?]0__ ,C?_8T44 '_  L3_J'_ /D;_P"QH_X6)_U#_P#R-_\
M8T44 '_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\ V-%% !_PL3_J'_\ D;_[
M&C_A8G_4/_\ (W_V-%% !_PL3_J'_P#D;_[&C_A8G_4/_P#(W_V-%% !_P +
M$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &-%% !_PL3_ *A__D;_ .QH_P"%B?\
M4/\ _(W_ -C110 ?\+$_ZA__ )&_^QH_X6)_U#__ "-_]C110 ?\+$_ZA_\
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M_P#Y&_\ L:/^%B?]0_\ \C?_ &-%% !_PL3_ *A__D;_ .QH_P"%B?\ 4/\
M_(W_ -C110 ?\+$_ZA__ )&_^QH_X6)_U#__ "-_]C110 ?\+$_ZA_\ Y&_^
MQH_X6)_U#_\ R-_]C110 ?\ "Q/^H?\ ^1O_ +&C_A8G_4/_ /(W_P!C110
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MU#__ "-_]C110 ?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C110 ?\ "Q/^H?\
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>6)_U#_\ R-_]C110!RD6GSS1ATCW*>AR**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>formdrs_034.jpg
<TEXT>
begin 644 formdrs_034.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &: I0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?D!*\C!PM)^/5[I&G>#-$O+J/7]5\364TEGXA5[<(TICGEB)M8V#&+;$/G&
M<C!/./9;CP7HUUXFA\02V9?5H;1K%)C*^T0,<LACW;#DXY*YXKE+[]GCX=W]
MYI]T_AF"*;3X(K6U^RSS0+%'&KK&H6-P/E6211QD!R!P:SL^3E_JVO\ P/\
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M(\;<;0!BN@M?ASX<M?!TWA7^RX[KP_/&T4UE>N]RLJ-U#F0LS?B>,#'04O\
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M.6..5Z5>NO@#X!O;>]@E\/)Y-Y<I>2HES,@$ZDD2IAQY;DDEF3!8DELDUJ>
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M:PO''PA\*?$;4+.^\0:=+>7=G%)!!+%>W%N41\;U'E2+][ SGKBD[VTW_P"
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MQCACD#D]3QWKTJO./V<_,'P-\%B8JTW]G1^88P0I;G) )) SGJ:]'H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,#Q#X^\.^$]7T72]9UBUTV_UJ?[+IT%P
M^QKJ;&?+3/5L<XZ\'TJ&U\?>&=?US6O#ECJUGJ>M:;'F]TNWF5ID!'0KGW /
M/!(!QFO,_P!I;P=XG\7ZY\(YO#N@7&M0>'_&%OKNHM%<V\(BMXX)XS@2R*68
MF8$ 9X5N1QG@?AE^SOXQ\*_%Z75M1OI-+T?29O$UQ#K,4\4AO!JEQ#-$5C.X
M@PB-MWF+MW*N PR00]Z5I:+7\$K??=KY!/W5>.NWXMW^ZR^\]E_9L54^ W@9
M4A:W1=+B"PO]Z,8X4\GD#CJ>G4UZ57FW[-KK)\!_ [I-]I1M,B*S''[P$</Q
MQSUX]:])H **** ./^(WQ"B\!644C1122/%/<O)<2F*&""%-\LKL%8X48X4$
MDD8KQ_1?V]OA5<6LHU76C9744A3%O:W$T<JX!#HWE X.2,, 1C\:?^VM&NO^
M$_"G@ZT,BZYXFUJ+3[:2%RK1PG_7L>>5VD @\<U[!X+^%^@>!]+^QV=JMR6*
MM)<7:J\CE45%YP  %10   ,5Y$IXJIB)0HR2C&U[J^_3=?TS]$P^'R/!Y-1Q
M694ISJU7+E4)J&D7;FNXS5G>RTWB_5>1W/[?'P>AAD>'6KZZ=5)$<>FS@L0.
MF2H _&KOP>_:ITWXK:[;V,#6&;AQ&UK"TR75LQC+KN21%\Q/E92Z< XR,$&O
M<)=&L)X9(9+*W>*12C(8EP5(P0>*\*^)_P"RU%J'V3Q)X&U:\T3QWHJJ=)N[
MBX,D7EJ#BV<'_EF02.<XSCD<4JD<=3:FI*26Z2LW][9I@ZO"F*C/#3HU*,Y:
M1G.HIQB^EU&G!I7M=J]M]5H_H&BO)/@3\=XOBA!>:)K=F?#WC[1SY6JZ)-PP
M8<>;'G[T9]LXR.H()];KTZ56%:"G!W3/A\?@,1EF(EA<5'EE'[FNC3V::U36
MC6J"BBBM3SPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBLUO$VCIK TEM5L5U5N18FY3SSQG[F=W3GITH TJ*** "BBB@ IDV_P I
M_+VF3:=N_IGMGVI]<W:^/O#.N:UK'AZQURQU#6M-CS?:9:7*M<P@CNBG<#R!
M[$B@#G/V<_,_X4;X*\X*)O[.CWB/.T-SG&>V<XKT>O-?V; B_ ;P,(TDCC&E
MQ!4ESO48X#9YSCKGG->E4 %%%<G\1/'0\#Z0LT=O'=7LJRM%%-+Y486.-I9)
M';!PJHI)P"3P .:B4E"+E+8Z,/0J8JK&C25Y,\>A(^*'[:$C\3:5\/=(V#NH
MOKGK^/E_^@5]&U\V?L22S:EX5\2^(=6@DA\0^)]1;7)V?[LEO(66$ISG:"D@
MP>1]"*^DZX<![]+VW6;;_P OPL?5\6+ZOF"RY?#AX1IKU2O-_.;D_F%%%%>B
M?&'C?QV^!,OCR>R\6^$KT>'OB-HXWZ?JD?RK<*/^6$_]Y#R.<XSW!(K/^%O[
M4FD^)+.XTGQ=:W'AGQOI):/5]*:UED$.T?-."JG$1X^8GC(YQ@GW2OD[]J?X
M3^(=#NKWXH>$K:WEUK29QJ#7:R,+@VHB"36\D>-LL6%W#D$ N,$&O'Q49X5O
M$T%_B7?SMW_/J?HV05L-GD89+FLK6THSNDXMOX&W?W&WLT^5ZQW:?U?'(DT:
MR1LKHP#*RG((/0@TZN4^%.N:9XD^&OAC4=&G:YTR;3H?(D<_-@(%PW^T""#[
M@UU=>K"2G%274^!Q%&6'K3HR33BVM='H[:H****LYPHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M37P[XLT>Z\8?M47\6L^"EGT6YUJVM);L?"K[5#>6R*FQI=::8  $GYO+(7:
M,X!HC_$2_K=%?8;9]M:9?#4M.M;M5V">)9-N0<9&<9'6K55["&VMK&WALTC2
MTCC5(5AQL"  *%QVQC%6*;W(04444AA5&;4;*=KRT%VC3PQYFA@DS-&I'7:O
MS XZ?I5ZOBCX,_#7Q3X<_:D\4ZM;:%JEAI=\-=N#J&MV17^R;F6XB\L_:1M6
M_AG6)9$CW$P*"NX9-$=9\K[-_<$M(\R[I?>?1O[-I0_ ;P,8VD:/^RXMK39\
MPC'!;/.['7/.<YKTJO./V<2S? OP26D69CIL9:1!A7/.6'L>OXUZ/0 5\]3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU.F[-'R[K7P=\2_LTZI<>-OA<)]?TFX/F>(?"<VT?:1DDSVP50$=<GY%'3@
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MFH]=\Z _H#7M&A:>-(T33[ <"UMXX!_P%0O]*\*_;(?[?H/P\T$#<=8\8Z?
MR^J LS']!7T'7GT_>Q51]E%?F_U/K\;^ZR#!4_YIUI_A3BO_ $EA1117H'R
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@M@9P.IKX33QUX=\4?M26,5UIOQ)\/WLGB*%9/#EY9VEKI<]Q$3Y5U+.!YK
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MCQA&,<H8!AE9(65L@@U7UG]EGPMXXT/5+'QQ<7WB^74X&AN);R8JL;$A]\*
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M[LDGVNM3I:***ZSYT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *_.;XR>(I/"_P"T5XA\3P>%O MMK6B^)-.%
MAJ=Z+>74=0BDFAA=96#M/;,KSKMD,80Q A>0IK]&:^,/%7A3QGXF_:E?=X=U
M[4?#LVL6Z7DU_P""-$_LJ2RC4$@Z@[F[<*-V#LSDE1@<TX?Q8O\ K=#?P2N?
M8FD:@-6TJSO54*+B%)0JMN W '@]QSUJW4<$$=K!'##&L,,:A$CC4*JJ!@
M= !4E!(4444AA7R3\,[[Q'>?M/>-M176+'Q]9W,=_!!#I/B6\6WT66!E1+2\
MT^1FBC9P HF10=P?Y3DFOK:JUQ;V\4-S(T8C#H?->-2'( /<<D]?>A:2YO)_
MB#UC;T.!_9Q#+\"_!(>-87&FQAHT.50\Y4>PZ?A76>+O$$GAO1Q<06ZW5W-/
M%:V\+OL5I9'"+N;!PH)R3CH*Y#]FSR_^%"^!O)WF'^RXO+\S.[;CC=GG.,9S
MSZUU_C:WLKCPCK U&%;BSCM9)I$8D?<4N"".005!!'((J)WY7;<ZL*H.O!5%
M>-U==]?E^:]4?/G[%^MW%Q_PFOVZWB\_7->U#58KN!R5D"2K$Z[2,@ XP3U#
M'TKZ>KYZ_8=\(VNC_ ?0-9:)FU75%GEEN)'9B4-Q(549/RCG/'4DDU]"UP9<
MI+"T^;JK_?J?5<95*53/\6J.T9./_@/NZ;Z:?\-LBO./CYXDFT/X>W5E9,%U
M36G72K,$(<R2_+_'A"=N?E9EW= P)%>CUY+"5^('QVF?[VG^#X/+&"5/VN8<
MY&48#:.XDC; (*LIKZG+(1]O]8J*\:2YGYVV7SDTO1GP\]K+J=_X*\,Q>#?"
M>E:+"[2)96ZQ&1F=BS <G+LS<G/5B<<9-;=%%>94J2JS=2;NV[OU9:T5D%%%
M%9C"BBB@ HHHH *R?$GA71_&&FS:?K6FV^I6DR/&T=P@;Y61D;!ZJ2KLN00<
M,?6M:BKA.5.2G!V:ZH-]SR.Z^#.K^$9IKWX?^(YM+=F>7^R=29I[*1SYK8_O
M("[P@D9Q'"$7;G--;XW:AX)EEA^(/ARYT6VCWD:S9CS[1HU\YM[;<E/W4 =A
MS@S1H-S&O7J9+"D\;1R(LB-U5AD'\*]C^TE7TQM-5//:?_@2W_[>3,^2WPNQ
M1T3Q%IGB2U-QIE]#>Q!F1FA<':RL592.Q# @@]"".U:->8^(/@'HEY<3W_AV
M\O/!NL2*5%[I#[1G$H!,9^5L&>9P.F]]Q!(%9LGBKXE?#UI/[;T./QGI:EF6
M\T4;+H F1E7R3][EK>(<\XD=B!Q1]1HXG7!54W_+*T9?)_"_O3?8.9Q^)'L%
M%<AX/^+7A7QTQCTK5HGN0<&UGS%-UD .QL$AA$[#'51NZ$&NICO();F6W2>-
M[B$*TD2N"Z!L[21U&<'&>N#7EUL/6P\W3JP<6NC5BTT]434445@,1@&!!&0>
M"#7@_C[]EVW.O2^+OAGJS_#[QE]YWLQ_H-[SG;/#]W!]0/<@U[S16%:A3KJU
M1?YKT?0];+LTQ>55'4PD[7T:WC)=I1=U)>33/GKPG^T[>>$]:M_"GQDT7_A"
MM>D(2WUA,MI5^?[R2]$)QT)P,\D=*^@H9H[B%)8I%EBD4,DB$%6!Y!!'45E>
M+/!^B^.M#GT?Q!IEMJVFSC#V]T@9?J/0CL1R*^>[CX5_$3]F]WU#X8:@_B[P
M7&3)/X-UB8F6!.I^RS'IC^Z?R8UQ\U?"_'[\._VEZKKZK7R/HO895GNN&:PV
M(?V&_P!U-_W9/6FW_+-N/]Z.Q].45\]> ?VT/"'C6_MX;E8_#ZRS1VK6^IW:
M17<,K 8+1$ &(E@ ZL3W*J.:^@89X[B-9(I%EC;D.A!!_$5UT<12Q"YJ4KGS
M^99/C\GJ*ECZ3@WW_P UH24445T'CA1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJG7I5E>G)/T9X..RK'Y;+EQM"5-_WHM?==:ENBBBMSRPHHHH **** "BBB@
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M%I/T>S^3-BBBBND\4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLH_^E(^TX4E*EBZ]>+LX4*[^^E**_%H^B$18U554*JC 51@ >E>4?M*7B2^
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M/&.K 5]K4UD612K*&4\$$9%<W+@7_P N'#_!.2_"7/'\#W'Q)C*W^^TZ=?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX)Y'6N&_8*\4:_XN_9F\/ZAXF36/[9-[J*SW&NX^TW'^F3$.<$X&#MQP!L(
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M\+4\%?\ 0X:#_P"#.#_XJC_A:G@K_H<-!_\ !G!_\57$?$KQKX=^%=MX<O\
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MM@9M5CE!$=N8B=H,94$CHOEKM^\*^[J\*Y-#$8V@LRIN-!-P?++WVFM-K/\
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MNY[LS%F/N:Z6BA>ZK+R_#1 ]7=_U<\\_9_\ ^21Z#_VW_P#2B2O0Z\\_9_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>formdrs_020.jpg
<TEXT>
begin 644 formdrs_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (A X0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_***YWXM
M_%;0?@9\,M=\8^*+R33_  [X:LI-0U&YCM9KIX((UW.PBA5Y'( ^ZBLQ[ T
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M:/X%NM36'Q7X@TV[U?3[ PR;KJUM9(([B57V[/W;W, (+9_>KQS72T %%%%
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MEP+/ _RAO++(&"$?HSBH;^T^WV,T'FRP^=&R>9$VV2/(QN4]B.H/K4)V\_\
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M^\83I@9937Z++$JNS!0&; )QR<=*=BD]5;R:^]6'Y^C^X_)7XE_M5ZY\%/\
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MSLC!'+<S1P/(I:.,R;4C0R3R;&V)(RL!35KWZ"3NE;K^G_#G9?\ "J_VNO\
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M5 6IM6W!._Y%+_A5?[77_1;?@#_X:'5/_FAH_P"%5_M=?]%M^ /_ (:'5/\
MYH:VO%/_  48\">%/B1J?AR:P\67 T/Q#H7AG5=5@TT'3M.N=:$']FN\A<,T
M4TES;Q%HU?RWE&\(N6'O8I6'<^:O^%5_M=?]%M^ /_AH=4_^:&C_ (57^UU_
MT6WX _\ AH=4_P#FAJ?XR_M(>)?%'[>7A?\ 9_\ !NH6_AN=_!UQX^\4:]):
M)=7-MIZWB6-K:V229B$\TYF9I94D6..V($;-*K1])IWQ)\1_ 7Q]-H'CCQ!%
MXTD\9:H+;P%:6&GPVNK7:163W%U%<?.D#-$(99#/^YCVO$FWS"/,%_7]?ULP
M9RG_  JO]KK_ *+;\ ?_  T.J?\ S0T?\*K_ &NO^BV_ '_PT.J?_-#6BO\
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MK^.E^'=MX&O)(].:/1M0N;5)8K;5Y+(3%S<Q07%U O[\D17,B;\8-<O\%/\
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MV/X3_P""97B+PCXH36++QIX-L)K/XK6?Q0LK&P\'R6FGVKKX<&@W=D(EO/\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>(_\
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MI>FWEU=W]YK-YJJVT=Q#$C_9X;<:Y*)) 75C"DC-#&'6O2?^"8/PSUSX.?\
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MNV?,;._HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***YCXS_ !G\+?L\?"[6O&OC76K/P[X5\.P?:M2U*Z)\FTCW!=S8!/5@. >M
M '3T5\=?\1 W[&?_ $<'X%_[ZN/_ (W1_P 1 W[&?_1P?@7_ +ZN/_C= 'V+
M17QU_P 1 W[&?_1P?@7_ +ZN/_C='_$0-^QG_P!'!^!?^^KC_P"-T ?8M%?'
M7_$0-^QG_P!'!^!?^^KC_P"-T?\ $0-^QG_T<'X%_P"^KC_XW0!]BT5\=?\
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M7_$0-^QG_P!'!^!?^^KC_P"-T?\ $0-^QG_T<'X%_P"^KC_XW0!]BT5\=?\
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M7_$0-^QG_P!'!^!?^^KC_P"-T?\ $0-^QG_T<'X%_P"^KC_XW0!]BT5\=?\
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M^52#3:_K\!)WV&?\,K_##_HG'@+_ ,)^T_\ C='_  RO\,/^B<> O_"?M/\
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M_P!$X\!?^$_:?_&Z[RB@#@_^&5_AA_T3CP%_X3]I_P#&Z/\ AE?X8?\ 1./
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M_##_ *)QX"_\)^T_^-UQ_P"WS\9_$OP"^!^D^(?"]U86MY+XV\*Z)="ZM/M
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M%R@*D1 -]8T54G>]^M_QW)BK6MTM^&QY#X=^ GB_X/\ @.U\*?#GQ9X8\/\
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M3M3NWM8-.>.,Q&+S3-'JHVA1"PM'.W[HK[4TSPA8:9X<@TOR%NK6"R73S]I
MF::%5V[9"WWP1USUR?6KEGIMOIR*MO!# J1K"HC0*%1<[5&/X1DX'09-:N2N
M_5O\_P#@?<0DTEWM_E_P?O/F3X]_LVZ!\'_%WBCXUZYKL%GX9\(PW?CC4XET
M:P:2.XM8(V+C= 4.(+=_W[*;P.5"W B415XGX _:T^.W@;P;XGE\5>+-&O/&
MOP\_9RA\=^(-(UJUM+:PA\2W?VN:V,AMXDF5(5T^Y2X56\LK-#M"L-S?H7<6
M\=W \4J))'("K(P!5@>Q!ZUROQ1^#FF_%"PC66>[TJ_@O;&_2_L"B7#/9W N
M($D+*PDB#@YC<$?.Q&UL,(Z6_KK_ %\BE:]_ZZ?Y?B?(NG_M"_$WQ_X1O])\
M._$"R\0I\:+NQ\-_#+6+673;BZL[6.R$FO>(G:R_=*D&9O)C9F N(K:)MOVA
M .9^%7QB\;^$_'7A?P1\/O$L6@_#I/BM>^#_  IISV-G+#:>$O#NAM;ZM)*Y
MB,LD:ZO:RPK)O$N^6+=(5.#]I_"']G7PQ\%M4\0ZEH^GVR:OXKU:;6]5O1;Q
M127-W-#;0RN!&JJ@=+.VW!0-[1!WW.2Q[---MXRI6"%2FX+A -H8Y8#ZGD^M
M4Y:W0DNC/S6L/V@[O]J[P]^P]X:\<>+K/49_'NOWOQCU2[NKBTLY'T?2EFO-
M)MYDB6.(RK<7NCAMB+N:RF;'RL!]'?M-_M Z5\6!\&8?AUJ]EXAN-:^+=CI4
M-]I\RS6YCL$N;G562525=([:VNX'920)28S\V17T7)X T*:T@MWT72'@M8E@
M@C-G&4AC7A448PJC)P!P,U6M?A?H=EXRM=>CL(5U'3[%].LF"@)8P2.LDJQ*
M.$\QDC+D#+>5'GA1237XW_+_ "_,'=_UZ_Y_D= .E%%%(84444 %%%% !111
M0 5\.?M5^,Y_#G_!83X>KI?CGP5X'U2/X*>*C]N\1VOVVTA#:QH17="+NU;D
MQLX/F#*PR#'!9?N.LW4/!VD:O=&>[TK3;J=B"9)K9'<D=.2,\=JF4;V\O^#_
M )C3T:_K=?Y'S%_P1)EL8_\ @FQX$LM,TNXT^PTFZU:QAN&N?M%OK?EZI=AM
M3M7\N+_1+MMUQ"@C54BF1%W(JLWU?115MB.*_:%\3^*?"'PFU.]\&>'-4\4^
M(LQ0VUCITME'=!9)422=/MDT%NS11L\H2250YC"YYKXM_8K_ &AO!OP#'[2.
MO_$CPM>_"K0/#7Q:CGL;OQ?K&BKC4KCP[I%L+;SHKZ53>R!F=Y'<1D7FXREA
M,(_T'JG>^'K#4XFCN;*TN4=_-9985<,^-NX@CKCC/I4K1_UY!TL>'?\ !.JS
M\"0?!KQ!>>!/&'A/QM%XB\7:QXBUJ^\-:E%J&EV^IZA=->S6L,L1*,(A/&A(
MPS$;V56<@>^G!!SC'>H-.TRVTBU$%I;P6L*DD1PQA%!/4X'%3.@D0JP#*PP0
M1D$4V)'R3_P35\;^&='_ &([V^U'7/#-A9/\4_'$%E>:A<1?9!=S>--7%JH)
M=0SN\D>Q58,Q=0IR15[]@W5F^#FE_$;PS\0]6\$KJ>K?%34M.TS7K2/^RK?Q
M_=W=G!J#F&WFFDS<Q;KFU:*)W'_$LD(P5<+](ZA\/= U;P_<:3=:'H]SI5V0
M9[*6RC>WF(((W1D;6P57J.P]*NG0;$Q6D9L[0QZ>X>U7R5Q;,%*@H,?*0K,,
MC'#$=Z4596\DOR_R&]?OO^?^9X#'?:+KG[67C'5[N]L/#O@OX%>#AH1O3)'9
MVFDWE^D=]?,SMA(A;:?;:6X<X")=R=!FOD']H3P/K_P>^!7B[P!X>^(6O?%[
MX%Z);^ O%J7^I30:E>>']+B\3VCW]H]]!&GVNR?2X)+@>;OD2*&7<[I*E?I]
M%HMG"MV%M;91?N9+K$2C[2Q4(6?CYCM55R<\*!T%5_#?A#2O!NBIINCZ9IVE
M:='G;:V=LD$*YZX10%&?I3B[-/M_G<35TU_6UCY2\"Z]9VG_  4J^/>HVNM^
M']$L-3T/P?X?TJ_U0)):7'BH0:U,\4*&2/SKE=.N+$O'&ZR-$T8R%''6?\$V
M;+Q-X2_8\OM)U.RT2YU[P_XC\26L>IZ9;R6ECXMF&JW<IU5(7DD,)NYI'E=!
M(R+(\GEGR]E>[7/PR\-WOAR'1YO#VARZ1;3+<16+V$36T4BMN#K&5VA@W((&
M0>:VHX5AA6.-5C1%VJJC 4#H *5O=<5VM^;_ %'?6_G?]/T/E']CCQ&^K_\
M!-/X+Q6_C;PUX0^*WCWP#!J-KJ^MVT=]=/J]S:1W>J70M7FB:XD%S)++*@<
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M:AY5&_ 8M]^Z19/INE6UM)<37DEO$D;3RX\R<@ %VP ,G&3@ 9-*'PZ[_P#
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M>1_"?_@IEK_[0-]JOA[PQX4TK3_&OA/PEJWB#6K'4[MWM;B]T_6[_16L;:5
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MWD;*.FW3OM,I!Z*H/I0D_P ?\O\ ,&U^'^?^1[[1112&%%%% !1110 4444
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MF-SR.%5<G R3TYHN;Z&RV>=-%#YKB--[!=['HHSU)]*^3?@7\-C^UC_P2_\
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MX4:6/"7V3P5I=E)X#T@Z!X>EMGEAETBP(4-;PNCAE1@B;AGYMB;L[1BWX/\
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MEGIT ACDG<*&D8#JQ"*,GG"J.@%=C(@DC93D!AC@D'\QTKS']DG]IVT_:O\
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M*D$:J%^<OV%<;X5^.6A^+?%VFZ/;R2I-K^BKXAT65U*IJUC^Z$DD>?F#1-/
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M^H?LK^#;OQ*GP^\2^,/#N@VO]I:_=Z7/;1R:?9AB':&*616NIE +^3'\Q5<
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M/&%EXH\-^()/#C>']1U;2@99H[:&=YC=V]S/;K"OG",D.SB5'39E3@::;3Z
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M.B2W\T$$$GV265;FXA22Y@$SQ1GRPYP)#'*J-*^P-V/?:***0!1110 4444
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MS2 **** "BBB@ HHHH **** "BBB@ KP_P"-'PP\1?'WX^Z;H\L_BGPIX/\
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MLN4'J[A7&?M&Z5?Z]^S]XXL-*T^YU74]0T&^M;.SMVC66ZFD@=$C4R,J EF
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M@ HHHH ***H^)O$-MX2\.W^JWIF6STVWDNIS# \\FQ%+-MC0,[M@'"J"Q.
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MT[3/[*BDT6QL=8MGU!K/)-HMU9R6Y>$_ZJ;4$B.&P*$DQ2T/N2BBBD,****
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MHW(T;X@Q6#>'+=+2234-:EO81-;6\%LH,CS-'ERH'R)'([E4C=ES?VA?VR]
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M72%,+[<7!O9KZWDA2,LTD1D;'R, 1VN_+\M?N$[]//\ /3[S[=\??'_P_P"
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M:!^W'XP^"^O:M-XDM[#P3I'C72=4N;:&&Z N+N^L;JWE$*)&562SAE0A ?\
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MY'NU9/CGQYHOPR\*W>N>(M5T_1-&L%5KF^OIU@M[<,P4%G8@#+,!SW(I6O\
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MN?(D:6R=5\@B/9OCD21_J4QJ23@9(P:@T[2+72(G2TMK>V21S(ZQ1A S'JQ
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MM"^-?[&GBO5;NVC\&R? K5M'L]0DD LX-6DB\.W*H93\@DDL[.]9><E+:;'
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M3LO"6LZE8ZK8P>(-0M='BDU"WMY+=(H;&UMI&$LJEP]L22A</I*-IN/9V_\
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M5GDWM!*TXMK> LJJI115_P"OZ[K\>PY:?U_7]6[GZ,T4 YHH **** "BBB@
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M'OB-X5CU.#1?$*S".WU& 0W=I+!/);3P2JK,N^.:&5"49D)3*LRD,?0Z=K:
M%>>?$?\ 9*^%_P 8/#6KZ+XK^'O@WQ'I'B#5DU[5++4=(@N+?4=02*.%+N9&
M4K),L442!V!8+&@S\HQZ$[B-"S$* ,DGH*\%\%_MNS?%_P ->/KCP+X$UWQ'
MJ?@_Q<?"-C:2W,5G'J\G]G6FH"]:9LK;VABN@0[ LP5=J%I$0H9Z7\$OV??
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M[.ETR_=:X6#]R)B/,$?R!MO%<+^RW^U?J/QU\;>//!WBCP/J/@#QQ\.Y[/\
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MI/X9@GPRR2V,TZWDBB%DE+10LI$B $L2%JS3MU)NFKGOE%%%(84444 %%%%
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M7C/4]5E\4:<GQ(LK.R\5V.DZQ+8VNO\ V-E-I/*$^9)XE54$L31L\:HCEU1
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M87M1'/?,;=()')N (U5MK1\7IWQM\<3?&7XF>!O"OBOXE:=\2];_ &B+O0/
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MS@A\J=:^V?B9\&[+XL_!K4?!&JZMXDBT_5K(6%W?:?J<EAJ<D? 8K<P['1F
M(9DVG#-TS7GOAK]@#P9X>\/_ &*?6_B+XAN;?5K+7-.U'Q!XLOM9O=$O+/?Y
M$MH]S)((0!+*KHJ[)4E=)%=&*U4='<AZH\V_95_;(\-_##X@_%7X=?$#Q_I-
M@^@_%6[\*^"5UK4E6[U&VET_2=06TC:1MTQ@FU8P+R2J"%3TKPZ__:L\<^$?
MV4_!GQY6^UK4?&.K_'35_#E]HK74AM[O2?[<U318M*$&=BK!#;VTP*J&\ZW>
M0DF67?\ H!\(/@QH/P0\/W]AH5O(AU?4[K6M3NIW\RYU.^N9#)/<3/W=F(
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MKHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#<R2V:QVYF6:$H964$2IS\PS[C7Q=^RI>V,W[<G[<,MY+)!87VMZ#=V]R3)
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M7=I(\+C($L9( ="?$_\ @E)I6KZ+<?'>.ZL]7U31+_XC3ZGI7CC5M/ETZ_\
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MF%MI44"JB:E9QW-ZTEMO:>:1H9XV,<BI"_XRVOA_XA_ S3M;\/\ Q%\5>/\
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M&9WH6H/0^MJ*!THH *X*_P#VF_ ^D_M#V'PIO-=CL?'VKZ5+K>G:7<VTT/\
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M:Y#::IJVCP&SM]0272DE*RB5$2TD5K9GD+"+ 1RH(H<;7\O^#_E^(1=[/O\
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M%O(E&'02+53C9Z?UM_7R)B[[_P!:O_(][\+_ !FT#QC\1_$7A.PEU)M<\*+
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M?$VG:!J37MUX*U1M#UB*2":)[.Z2*.0H3*J^8-DB$2)N1LG#$AL7*-FUVO\
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MVM>&?&3VN-+BM[V=3<Z5J<,P^SW",8[1WM)BDNZ)7A8-%(1-X.UWQ=_P4?\
M@!\/O WC7P;X4\+ZOJ?@@^(?B%X5U2RNX;-Y-1BGLXX8X\K(F4>ZN6AD)EMV
MDLR^'*L2VCM_7]:^GFA+=7_K^M/7U/N#Q#XLT_PI]B.HW*VB:A=1V4$D@(C,
MTAVQQENBEVPB[B-SLJC+,H.CFOSS\+?&;Q-\2/\ @B%\9?"OBFYO;_XK_";P
MWK_@"XOUAFCD\0:M8Q2VVE:I9LX#3&]9;.>*1,@SR,JDLAQ^@'A\7@T*R_M#
MRS?^0GVGR_N>;M&_'MNSBAJU[?UI<$WU+E%%%(84444 %%%% !1110 4444
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MH ,4F!BEHH ,<T8_6BB@!-HQC'%&T4M% !C% &*** $VC%!4'K2T4 %&***
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MMKU_7_)'Z=9HS7P%\<8OB;XAO/CC:69\20?%ZQ^)6@7_ ,++FV$ZP2:$T>D
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MH&][=/RLM?Q_JS/HGQ%_P4V^$/A#X9_$#QEJVLZYIOACX5^(1X6\6:A/X=U
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M1/PL^/GA'XTW^MV7AS6(KS4_#,\=MK.FS0RVFHZ3))&)(EN+694FAWQD.F]
M'7E<CFM?2OB#I>M>.]8\-V\ET=7T&VM;N\1[*:.%8[DRB(I,R"*4DP296-F9
M,+N"[ES\G?L*M>R?\%#/C]?VMY>_$;P[KNC>'Y5^(TMK]FA:>%KY!H,31*EG
M=):HYG\ZV0,IOF29G<(1YY_P4!^-_BWPKX[_ &FM-T;QMXJTJ'1?#?PZO=&C
MT_4986TR[GUS4(M0-L4P5+VZVGG*,C8R%QM8926R[E=[=#]#L5SWC#XJ^'/
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M*VL+:5?&P6XECPT-M)J M49\JI=H48[)&5D^GW"74^@LTV2184+,P50,DDX
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MRT2^M[OPAK-F-,O;U8VM(+EY;54MWF66(H)63<)$(^\,X?\ P2O\9:M\6/\
M@GE\,M1\5:C?^(=7?36MKN[U5VGN[DP7$L2-.TGSO+LC0L[Y9F^8DDDUXK\'
M?'NE^&_VH_\ @H-K$UQK,MOI]UI&L1'0;9+S5)4L_"EDDDMA$ZLD]Q%/"R*,
M,!/&$89XIM)7OT5_R_S!:V2ZNWXM?H?2.DZ+\/\ ]@_P]J5[<:EK%EI_Q&\=
M1S2R7*SWZMK>LWD<$:CRXV,,<US+$@W;8D+CE0>>Y^(GQH\-?"C7?">FZ_J)
ML+SQQJXT+1%-M-*M[>F":X$.Y%*H3%;S,"Y4'RR,YXK\P=3^--Y\:? ?BS29
MO%]_JGA&WU[X,>*["6'7I]1;3;*;Q!;+J%^+]@N[;]D#W$\2QQ12I*Q5'$C'
MO=2M=;\(_'OP+I4FO^(?$?PRT_\ :/L)? NHZYJUSK%R;)_!]Y]M5+RX>26>
MSBU*>6*.21V"N[1!L(@IQBW+E?\ 70ARM&Z_KJ?I5Q^=<'KW[2?@_P -_&./
MX?W5]?GQA-I,NNQ:;!I%Y</+8Q.B23JT<3(RJ\D:'#$[G5<;F /RG_P3E^*V
ML_&WXF:#K?B'XEZN/B-I6FZKI'Q!^'@T^[5=,OS=(ZRW:2W$D5L(&C=+62**
M(7$-SD>8@!3NO&OB_2]#_P""Q_A>>]U&SL[>S^#FM6]Q-/*(XH)7U?2YEC=S
M\JN8HI9 I.2D;-C )KW>'\KIXZ=>-5-\E&K42CU<%!Q6ST?,]E?MJ35FXKYI
M?C8^@/@9\=?"O[2GPRT[QEX*U,ZUX9U<,UE?BUFMTNE5BI9!*B,RY!&X#!P<
M'BEUSXW^&/#GQ;\-^!KO4'C\3^+;*^O]*M1:S.EU#9&%;EO."&)2AN(?E9PQ
MW\ X./!?^"+[1WW_  2W^$UF[2QSVFCO9W<)+PSVL@FEW(PX>-P"#V(R".H-
M?)/[(?AS0O''@?\ 8DT;5]>\26T=M\,/%]GXCFA\27]G?V%_'#I"W%O+=)*M
MQ:R))#/F,21D- XQA7%3Q/EE++LXQF7T6W"C4G!7LVU&4XIMI)7:BGHK:Z:6
M%1J.=*,WN_\ @?YGZNTAK\KOAI^T;XR^,7PH^%?AKQ[\8O$GPRUOQ/\ !GP;
MK?A;7UTZ]N-0UWQ&K7/]L)#Y<L<5UJ"R1V22V4\<S.DQQ$5DF!^_?VN/BY<?
M#'X,O#IE]::7XL\874'AOP\]V^Q(;^\81),Q4-\L 9IFQGY82!DD9\-JQK%W
M-N']I3P1>_"'7/'MIKUOJ/A+PW+J$.I:A8PRW:VSV%Q+;W@V1*SMY4L$JMM4
M_<)&5YJA!^UKX#O/A'X0\>0:IJ%SX4\>2V46@WT&BWTOV\WA46K"-83(B2ET
MV.ZJIWJ<X89^,/!/@S7OV;_CU\<?@ =,\.:;I/QX\"W/BGP5I^C73R66G:S%
M8C3+ZS9Y41D:Y2.RNDW !G6];).ZNY_8S^)^@?$;]@?]FKX?:/JMM<^._#.G
M>$+77O#V2NJ>'I=,CMFODOK8XDM3$UM*A\Y5!?8HR74$23_#]4_NM^(/17]?
MR37YGTGXI_:_\ ^$_&7B#P_)JFI:GJWA*))M>AT;1+[5QH8>+SD6Z>UAD6"1
MHBL@C<AS&ZOMV,&/9_#OX@:-\6/A_H7BKP[?PZIX?\2Z?;ZKIE[$"([RUGC6
M6&5=P!PR.K#(!YZ5\=_\$[?B;H/[*%S\8OAW\4=2L?!7CV7XH^(_$J2:S(MH
M?&5CJ-X]W9:A9.^%NU^S/%;LL1=X7M3$RJ54'7L/B)K'@[]O/0=-TMI/$'P]
MUV^M-+L=*L+FZTG5?A_.NA23^5<Z:P6*YTF6+RY-Y5);>[D"LKA%\@2O;SM^
M7]+Y W:_]?UW^9]C=Z0L%4GT].:^2OVT_C18^%/VH-#\%?$+Q/XF\ _#?QKX
M)U*UT37M'NY[%G\0F>-/)6XA!*WJ6Q$EI&P(D?SBJ2/&H'E>L?M/SZ1^W;X0
MT73_ !EXNAATCXMV?A7Q+!XCU I<SVMSX)GDA06<<<<,.GRWJVCI-(&>:_>X
M"%%159)7MY_U_7J$M$WV/N+X/?&7PW\?/ D/B;PGJ)U719[N\L%G-M+;L)[2
MZEM+F,QRJKJT=Q!+&<J.4.,C!/3\'TK\R/V=?V@-*^&WP_\ ASHWCKQ#JWA+
MX2^+_$'Q5@N-;L[FYL88]=D\6SRZ5#-=PX,!EL9[^:WWLJRN(F7<XAS)\>/C
M3XE^#>O?%3PF/B'\3)-3TZ[^%.I>&/[2OKN+5]0TYM0L[35;P0QJF4D1)A>+
M'$L0=V\Q$+C+@N:WG_P/\_N'/W;^7_!_R/T,\!?&7PW\3O$_B[1M$U!KS4_
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MXNU[6OB3^S7\3-9O5.M9EEU+29[)-.NK5(=IAG1+B[0M"%,@7Y][1@J6TO\
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M+C%?FU\-/VF_$/QL\%?'7PMHGQ>.E:S;67A+4?A[=V7B2'6[DZAJ%J!#$TV
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M9Z;=);_\(C8Z[!9^9%9O;?:&GNYDC8VV7BMMIS(=Y+:+S&]#[M-I$3_JX_\
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MXG*I:6\=H);<3E+=FF+0XC ,N=WQ5^V5X]TG4/V?_%FH^-TTCP!\6?"^@_\
M"7R6>EVKQ>!=0OGMY+*^\QXI"MMJ,WG::!.Q6)Y8Y5SLD*BCM\OQ!Z;_ -6/
MN2+1[2W8&.UMXR"Y!6-1@NP9^W\3 $^I&34=NNG^(=)WQ?8[ZPO8L97;+#<1
MGZ9#*03[<UXC_P %(/$VI>'OV:;>VL))X;?Q+XS\*>&=6EB8JT>F:CXAT^QO
MAN'*[K:XFC+#!42;@1C->4_M5?M#_$'X0_'?XUIX:\1W=OX:^"OP@TKXD:=X
M7L=)LI%UFYW^(HY+&21H7F%O*NFVW$)212@V.H+*TW_KT5Q/I_76Q]C:CJ5C
MX8T>>[N[BUT_3[&)I9IIG6&&WC499F8X55 !))X%87PO^(/@OXFV6IZCX+US
MPSX@MXKUK74+G1;R"Z5+M%4M%,T1.)55D)5CN 9<CD5\)_M9^*?'WC']F34[
MS4OBGX9\1^$/$?B7X8ZIX<DT&\M;Z^CBNO%6G0W,CR"RBA:RG5X)( 49MZ3J
M7>+]VJ^!OC#JW[./Q\^*OA32]7M89/B9^T>GANYUW4YK73C%(_P]TF_11)':
MM EQ/<6R1*3;DN9&'^M=7JG&VC!.ZNC]#8-.M[6YFFB@BCFN2#,ZH TI P"Q
M')P..:?)!'*<LB,2,9*Y]?\ $_G7Q5X.^/GQ*UWQ)+\(?%?QA\&^&?'NF?#R
M\\06GC#2[.WN;#6;Q-5O;+SFCG2..5;"*VM#>11"$-+>L 85" <OXB_:S\9_
M"G]H#XL6TGC.:ZT_6/C+X;\!V4NJ3PVFF>&;6\\*:=J :)C;RM#Y]XYMT\P2
M+YEZF07.XBC?8&[;GWMJ,UEI%A/>7;VMK:VJ----,52.%%!9G9CP  "23TQF
ML_1/&/AWQ)X(M?$NFZKHU_X;O;)=1MM5MKF*6QGM602+.DRDHT13#!P=I7!S
MBOE#P'\>/B*/CAX;^#?C7QWHC:E=>'/%OB"3Q'H@MY7U/[#J5G!9V3/);I ;
MBWM;T-=".!-TB(5")YB'?_X)V:C+:?\ !%CX+7-C/:I<6_P<TAX99(EGA61=
M'BP60G:RAARI.#R*B3M%R[*_Y_Y#2O)1[_\  _S/I?PS>:/XBTVVUS1YM-O[
M/6+:*XM]0LV26*^@9=\4B2ID.A5@5()!#9'6H?'6M^'_  ?X=N]=\2WFCZ7I
M&E02276H:G+%!;6<)&'9Y9"%1".I) QUK\YO%G[:GQ5G_9TT#5]#\<1>$I(O
MV37^+@ATO1=.^SC6K6&UE4A)H9 MHXD9&A7'R8V-&1NKZ9_X*4^('\7?\$=?
MCQJMPD22:G\']>NY$3[BL^C3N0,]@3Q5SCRIM=/\VOT%!\S2[V_1_J?2EM%#
MY2O"L6QU&TH!@KU&,=J+*P@TVU2"VABMX(QA(XT"(@] !P*^'OV@/VQO'_A?
MPO\ M/7OAW6(M"U3]G30M'UGP]HTEC%/#XJBDTL7_P"_WJ97CO)UN-/3R60J
M]JY4E\@<[\3/V[_B-^SK\;-7TSQCXBU231OAU\0[;5_%&-)LT1O &LVJP:?<
MEE@+ V>K3>0YC/F21:=>R$GC:W'WN5$QE>*E_70^I/#/[&ECH/CO4=3O/&?C
M#Q#HE]K,^OQ>'M7CTVZLK&ZEN3=$Q7!M!?"-)L-&C7++&%5% C547UZXTZWN
M[66"6"&6"8%9(W0,D@(Q@@\$?6OB#4?VA_C/X@^(_BKP78^-/"WA#Q1\-;#P
MWXCO?^$HF@@BU&TOKF6>\26**S8RP"))+".2"2%EFM][%BVT^H_L.>//'/QF
M^(OQ7UGQ'XZO-2T?P?X[U_P?I^@QZ;906D<$$UL]O,\J1>>T\2F6/_6!&64%
MD+J'I6T*;/HRYTBTO,>=;6\NV-H1OC5L(V R\C[IP,CH<"DFT>TN!<"2VMW%
MV@CG#1J?.4 @*W'S#!/!]37P9^U)^TO\8O"/C']I35?"?CVXA/P1U;PQ/X<\
M+?V/82VOB);VUM7GTNX=H3<L;F25HX6ADBD261/FD V5O7G[8?Q"UOP_'XLT
M[7$AOK+X^2_"O4?"26,+(-+;63I22J60S+=+9M#JX<L4,98%#$05$KJ_]:A=
M7M_6A]M):1(5Q&@V !<*/E SC'YG\Z66!)Q\Z*^/[PS7YS_#G]O'XL^'_%OA
M3P[XK\0W^I:O:?V]\)_$DB:59VUO)X[29YM#NEQ!N2.]T^"2X*?ZJ-;NQW E
MVSZC\&OC_P#$[XO?&"X^S>.?"VF:3X!^(]YX%\2Z1JD\27VI6L5JT4$B6Z68
M:.]GD-M?1LLXA,$K+Y>W!42OJOZ_JZ^\'IO_ %_5F?89TRW-\UR8(3<O'Y+2
M[!O*9SMW==N23CIS7/3?&7P7IOQ'@\&2>*_#%OXNNT\Z'0FU.!-2F7:S[EM]
MWF,-B,V0O12>@->*_P#!+'Q_XX^.7[(W@[XD^.O'%WXKU+QUH=I>/:?V;96=
MGIDR&59&@\B)7/FCRRPE=P&C)38K%1PS_"._^!W[?WA+QIHOB_3/B'X7^,^N
MZMI^LV6K:3IDNI>%7BTV[G^U:?J=M#%<?98C916,D%R\NP3Q 2*PVNNM@OI<
M^HO 'QB\$_%#7-<L/"WBKPMXBU+PQ<_8M9MM*U*"[GTF<DGRKA8V+0N2K?*X
M!.T\<5G^./VC/AK\)/$R:/XE\>>!_#.LSQK,MCJ>MVME=21LS!7$<CJQ4L&
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M&I_%KPYK]W;Z2?&6F:?>6ND7)9!>BRF,!N8X_P")H2T=NS#E=R1D\XKY6^.
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M",9L,SV/V3_VT/&WQRU7P%X \2^+7L;V_P! \=7MQXD2SLX;GQ#+H7B0Z-
MIB-NK+!_I%PL<:@NT94)&'1HD[1O_6URXJ[M_6]C[:\':OH/C+PQ8:WX?NM)
MU71M9MHKRRO]/DCGM;Z!D4Q2QR)E9$9-I5E)!7&#C%6?M6G7UY=Z5YEE-/'
MDES9[E9UBDWJC.G4*_ER $C!V,!T-?/_ /P2CUBTTG_@DS^SK?7-U;6]E9_"
MOP]+/<22!8H432K<NS,3@!0#DGI@U\\V'Q3\0_!/]N#X<?'?6?#'B#P]X-^/
MMPW@/Q-?WM_;269CN)3-X2N%@CE>2!D EMI-Z*/,U9BQR *N4;2Y?Z\B(N\>
M8^U_^$O^''Q'\#^(]!M/$7A>]T/2;>2RUN#3=7B1-,B*L'25H7!@&T-G)4@
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MO[*UN8FNX]NT%I8U.\8WH,L.-Z^HJG\-?!/A'PAK'BZX\+6NE6MUKNN-J7B
M6)3][J1MK>)WE"\+,88H-V<$\,>6R?SM_9GO=;TW]FK]@RYM[>\O?B5'X_\
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M:9HCW$4LOE>>7CEU*66)TD1@44.9$^6JY?>Y7_6MA7TO_7<^CO&'['MKXO\
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M (3'XFZ[I:7UC%L-FUUH>E*\@"%3DEV+%65CN8A@WS5*_K_R7_,;W:??_/\
MR/ISX>^%? /PW\0:[XAT2X\/VMW\2]:6>[NH)+>,:O?) (0BF,*)91';MG.Z
M0['R2%PM_4?V=_A_J^M7VI7G@;P==:CJ6H0ZM>74VBVSS75Y#&(X;F1RFYYH
MT5560DLJJ " *^8O _C?PMI7[9,*V'A#2[N^T?2;R^M)-,MHK:RTVVMVM],N
M+A9"FYVW*MA:1A4WBUU%R4CDC!^S(IDF!*.KA25)4YP0<$?4&J:V8O)G%?\
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M=LQUV_K9_J5)6_KS:_0^@)_A3H]YX\M/$5S +F^TVPDTW3TD"F#3X92AF$2
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MW]EP6<<=EY3YWQ^2 $VMN;(Q@[CGK7Y[>/?V\?BIX-^!GB+7/#-[X2\.Z?\
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M^)&@>,)/AWX,?Q3X6LH=-TG53I$'VO3[:$Y@ACDVY"1$DQCI&68KMR<^C44
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MP  [ [K?!?PC)XLT'7F\-:&^N>%K*73='U!K.-KK2[64*)8()"-T<;A$#*I
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M+,<LD2J@/7  [5U-% '%S_L\>#KKXZP?$Q]%1O'=MI;:)%K'VB83)8LXD:U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>formdrs_035.jpg
<TEXT>
begin 644 formdrs_035.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '= =,# 2(  A$! Q$!_\0
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M90N>NX8ZTO\ PFOA[^T;33_[>TS[?>-(EM:_;(_-G:,E9 B[LL5((('0@YH
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M]>G'QU,%)_X1S6.!G_4#_&O$_AK^U9K'C3XCW&AW/AH&R?S?)CL@S7,.S/\
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MEGF8N[MG+,>IZU#_ ,*J\)?] .V_\>_QKK** .3_ .%5>$O^@';?^/?XT?\
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M%%% '#_ O_DB/P]_[%W3_P#TFCKN*X?X%_\ )$?A[_V+NG_^DT==Q0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !114<\\=K#)-*ZQQ1J6=V.
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M/_Q^C^Q/&/\ T-.G_P#@F/\ \?H ZRBN3_L3QC_T-.G_ /@F/_Q^C^Q/&/\
MT-.G_P#@F/\ \?H ZRBN3_L3QC_T-.G_ /@F/_Q^C^Q/&/\ T-.G_P#@F/\
M\?H ZRBN3_L3QC_T-.G_ /@F/_Q^C^Q/&/\ T-.G_P#@F/\ \?H ZRO.=0FE
M^*6L2:9:2LGA:RDQ>W$9Q]LD!_U2G^Z.YKS;]HK4/B'H]EI6F:;KC:@;TR--
M#I%D8)PJ@ 9P[DH<GICD"NZ^%_AKQU9^ =%AO-7L='N5@&^SDTKS'CY.-["5
M06(P3P.37GNK[:L\/9V6[[^1]3#!_P!GY?#,^=.<VU%7UC:]Y6^6G:Z>]CU&
M&&.VA2*)%CBC4*J*,!0.@%25R?\ 8GC'_H:=/_\ !,?_ (_1_8GC'_H:=/\
M_!,?_C]>@?+WOJSJ+?=Y*;RI?'.WI^%25QUKH?B_[/'M\36$2[1A&T8Y'M_K
MZE_L3QC_ -#3I_\ X)C_ /'Z!'645R?]B>,?^AIT_P#\$Q_^/T?V)XQ_Z&G3
M_P#P3'_X_0!UE%<G_8GC'_H:=/\ _!,?_C]']B>,?^AIT_\ \$Q_^/T =93)
M?]4^5WC!^7U]JY;^Q/&/_0TZ?_X)C_\ 'Z;)HOC!8W+>*]/5<')&C'C_ ,CT
M =7#Q#& NP;1\OIQTI]<A#HOB]HD*^*[!E*C!.C')'_?^G_V)XQ_Z&G3_P#P
M3'_X_0!UE%<G_8GC'_H:=/\ _!,?_C]']B>,?^AIT_\ \$Q_^/T =917)_V)
MXQ_Z&G3_ /P3'_X_1_8GC'_H:=/_ /!,?_C] '65%=';;R'S/*^4_O/[OO7,
M?V)XQ_Z&G3__  3'_P"/TR;0_&)B?_BI]-?C[K:,<'V_U] '7UD^(/"NE>*+
M?R=3LH[D#[KL,.A]58<C\*R?[$\8_P#0TZ?_ ."8_P#Q^C^Q/&/_ $-.G_\
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MFMQUXQWH W:*** .'^!?_)$?A[_V+NG_ /I-'7<5P_P+_P"2(_#W_L7=/_\
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MF#IUHWBSA=!\$ZK\-='M=.\-SKJ.D6J;5L+T@2#G)*R#N22>?6MS2O'5A?7
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M$FDWEY^T;XB@L=$OETO2-3L5CDTBPT:"VC\RWBFD,K3K]HD8L[,73LP"\J:
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M#VF?^!D?_P 50!M45B_\)KX>_P"@]IG_ (&1_P#Q5'_":^'O^@]IG_@9'_\
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M1AE# $ C=P>:L?\ ":^'O^@]IG_@9'_\569Z2::NC:HK%_X37P]_T'M,_P#
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M7$SRRZ38RRN=S.]LA9CZDD<TS_A$="_Z NG_ /@+'_A6M10!D_\ "(Z%_P!
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M:@#._P"$1T+_ * NG_\ @+'_ (4?\(CH7_0%T_\ \!8_\*UJ* ,G_A$="_Z
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M5(\LTFO,SO\ A$="_P"@+I__ ("Q_P"%'_"(Z%_T!=/_ / 6/_"M:B@LR?\
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MM<;<^#=26W<OXPUIDQR%2WR?_(=2_P#"%ZK_ -#EK'_?%O\ _&J .MHKDO\
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M9,^6VT G!QGI0 D.##&0V\;1\Q[\=:?3(\^6FX -@9"]/PI] !1110 4444
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M% !1110 5PUQ_P 3KXMVT7WH=%L&E/IYLIP/_'1^M=S7#?#'_B9R>(=>//\
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M0!Q__"3>+/\ H3/_ "JQ?X4?\)-XL_Z$S_RJQ?X5V%% ''_\)-XL_P"A,_\
M*K%_A39/$GBPK_R)B]OO:K%CK]*[*H+P*UN0R,XRORKUZB@#EO\ A)O%G_0F
M?^56+_"C_A)O%G_0F?\ E5B_PKL** ./_P"$F\6?]"9_Y58O\*/^$F\6?]"9
M_P"56+_"NPHH X__ (2;Q9_T)G_E5B_PH_X2;Q9_T)G_ )58O\*["B@#C_\
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M]%N[O^T;';K3:/=W.HZ#&8X6>S1X[5XL2@%\M,FP3N6'W<@'T_1110 4444
M%%%% !1139)%BC9W.U%&2Q[ 4 <18_\ $[^+5_/]Z'1K%+93V$LIW-^.T 5W
M-<1\*(VNM%O]:D7$NKWLMT">OE[MJ#\E_6NWKGH:PYN^O^7X'J9E[M?V*^PE
M'YI:_P#DUSEOB)>-:^'9XHI"L]V!:QIZEV S^ S70Z?9II]A;6L8PD,:QCZ
M8KY<\<77Q1O?VD+2RM5NY]'@O(9[:!5S9K:\;G?'&?O9)YSC':OJNNV6D4CY
M3!XGZU6JRY6N5\NO6U]5_78*BN#A%_>>7\Z\^O(X_'I^-2U'-NVKM56.Y<[O
M3(R?K61ZY)1110!%<,RPN4=8VQPS=!4M0W2[K>0>7YO'W,XS4U !1110!#9D
M-:Q%9#*-HPYZM[U-4=OO\E-X4/CG;T_"I* "BBB@ HHHH *9+GRWPVPX/S>G
MO3Z;)GRVPNXX/RGO[4 )#DPIEMYVCYAWXZT^F0Y\I,J$.T?*.WM3Z "BBB@
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MX191M\4:6AW D_:4/&>1U[U)L=;17+?\+3\'_P#0S:7_ .!2?XT?\+3\'_\
M0S:7_P"!2?XT =%>;1:R;F9%QRR]14]<E-\4O"1B81^)M)#XX+728_G4G_"T
M_!__ $,NE_\ @4G^- '4T5RW_"T_!_\ T,VE_P#@4G^-'_"T_!__ $,VE_\
M@4G^- '1V>T6L05&C7:,*W4>QJ:N2M_BCX16% WBC3)& Y8W*#/OUJ3_ (6G
MX/\ ^AFTO_P*3_&@#J:*Y;_A:?@__H9M+_\  I/\:/\ A:?@_P#Z&;2__ I/
M\: .IHKEO^%I^#_^AFTO_P "D_QH_P"%I^#_ /H9M+_\"D_QH ZFF38\E]V=
MNTYV]>E<S_PM/P?_ -#-I?\ X%)_C37^*7A HP7Q-I8;'!^U)U_.@#I[?'D1
M[<[=HQNZ].]25RD?Q2\(B-0WB?2V;')%TG)_.G?\+3\'_P#0S:7_ .!2?XT
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M'B&\-KIFLV5_<A#(8K>97;:" 3@'IR/SH VZ*** .'^!?_)$?A[_ -B[I_\
MZ31U\Y>++/2_^&M-9EUFST=[HZEIC:?+JNC:K>W&S[/",P3PXMX5#[L!LX?<
MS<$"OHWX%_\ )$?A[_V+NG_^DT=?//Q:\564?[0$FGW^I^+6L[;5K)[/[/+;
MV]E8WQ2S$C*6F62<>3)"/+VE5-Q,P#'. #Z^J.XB:>WEC61H6=2HD3&Y"1U&
M1C(]ZDHH Y/X>_#NU^'MIJ2Q:A?:M>:E=?;+R\OV3=))Y:1C:B*J(H5% 55'
M<G))-=9110 SRT_N+^5'E)_<7\J?10 SRT')50/I7C?@7XH>&/''QGUB&SO/
M-GAM!:V.Z(A951BTI0_7\P,U[+(5$;%\;,'=GICO7AGP(^"^AZ/J3^-(?/-Q
M.\_V*W=P4MXV=ER.Y)7C)/<UPXCVKJTXT[6O=^B_X<^DRQ8..#Q=7$N2ERJ,
M+=W=Z_\ @/W7ZV/<O*3^XOY5R;*NO?$!4"@VFCP[CQP9Y.GY+73ZA?1Z;8W%
MW,<10HTC'V S6#\/[*2'0S?7 Q=ZE(UY+GK\WW1^"XKTHZ)R/D*OOU(4_F_E
MM^/Y&^T*^>A\E"NTY? R.G%2>4G]Q?RIC;/M4>=V_:<>F.*FK,ZQGE)_<7\J
MCGA7:N(4D.]>"!QR.?PZU/4-ULV)OW8WKC;Z[AC\,T /\I/[B_E1Y2?W%_*G
MT4 5[J&-K>0& 2C'W .M2^6G]Q?RIEXP6VD+2&(8Y=>HJ:@!GE)_<7\J/*3^
MXOY4^B@""WA @0/%&C8Y50,#V%2>4G]Q?RIEGM^RQ; P3:,;^OXU-0 SRD_N
M+^5'E)_<7\J?10 SRD_N+^5'E)_<7\J?10 SRD_N+^5-DB3RW_=*_!^7 Y]J
MEIDV/)?)(&TY*]>E #884\E/W2I\H^7 XXZ4[RD_N+^5);X\B/:2PVC!;J>*
MDH 9Y2?W%_*CRD_N+^5/HH 9Y2?W%_*CRD_N+^5/HH 9Y2?W%_*HKJ*/[/+F
M'S!M.54<GV%6*BNFVV\A,GE#:?GQG;[T .\I/[B_E1Y2?W%_*GT4 ,\I/[B_
ME1Y2?W%_*GT4 ,\I/[B_E1Y2?W%_*GT4 ,\I/[B_E4=Q"IA.($E.1\I ]14]
M07A46YWE@N5^YUZB@"3RD_N+^5'E)_<7\J?10 SRD_N+^5'E)_<7\J?10 SR
MD_N+^5'E)_<7\J?10 SRD_N+^513Q1YBS#O^<8P.G7FK%17! ,69/+^<?\"Z
M\4 .\I/[B_E1Y2?W%_*GT4 ,\I/[B_E2JBKR% /L*=10 4444 <+\#5+? _X
M?J&*D^'=/&X=1_HT?-?+/PQ\9V'CSXG:38^)OBM<86]DU#1K;4-1T.YEN)(+
MCR?+FB6T62WG8$856+;21N!7%?5'P+_Y(C\/?^Q=T_\ ])HZV$^'GA6.^%ZG
MAG1UO!)YPN%L(A)OSG=NVYW9YSUH Z"BBB@ HHHH **** .>^(.J'1O!.LW8
M.'2V=4_WF&T?J14O@W2AHGA_3K$1%&@M(49_4X.1^9/YUA_%1OMMKH>C@\ZE
MJ<*,/5$.]O\ T$5V4>/M$H#DD*OR=EZ\CZ_TKGC[U63[)+]?\CU*G[O TX_S
M2;^2LE^/,<SX\D;4%T[0HC\^I3@2X[0I\SG] *ZJ-%C144;548 '85R>@_\
M$\\8ZMJI^:"S'V"W/;(YD(_' KKJ[):)1/ H>_*57OHO1?\ !NR-B?/0;U"[
M3E.YZ<U)439^T(?+R-I_>>G3C_/I4M9G6%1SLRJNUU0[EY;OR./QJ2HK@91?
MW?F?.O'IR.?PZ_A0!+1110!'<;O)?9MW8XW]/QJ2H;M0UM(&C,HQ]Q>IJ:@
MHHHH BM26MXRT@E.T9=>A]ZEJ*U!%O&#'Y1VCY!_#[5+0 4444 %%%% !39,
M^6VT@'!P3TIU,EYC?Y=_!^7U]J "+/EIN(+8&2O0T^F0\0IA=@VCY?3CI3Z
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MX>_]B[I__I-'7<4 %%%% !1110 5%=7"6=M-/(<1Q(78^P&34M<I\4M0;3?
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M#@'I3J9-CR7R"1M.0.IH (L^4FX -@9"]!3ZC@QY,>T%5VC ;J.*DH ****
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M&/#A/G&<]_:@"6BBB@ HHHH **** .'^!?\ R1'X>_\ 8NZ?_P"DT==Q7#_
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M./N'H:EKYYD_;B^&-Q&T9B\8+NXR/"6I#]?(IW_#='PQ_P">/B__ ,)#4O\
MXQ0!]"45\]_\-T?#'_GCXO\ _"0U+_XQ1_PW1\,?^>/B_P#\)#4O_C% 'O\
M:J5MXP8Q$0H^1>@]JEKYYC_;B^&-O&L0B\8-M&,GPEJ1)_'R*?\ \-T?#'_G
MAXO_ /"0U+_XQ0!]!T5\]_\ #='PQ_YX^+__  D-2_\ C%'_  W1\,?^>/B_
M_P )#4O_ (Q0!]"45\]_\-T?#'_GCXO_ /"0U+_XQ1_PW1\,?^>/B_\ \)#4
MO_C% 'T)3)?]6^%W'!^7U]J^?O\ ANCX8_\ /'Q?_P"$AJ7_ ,8I&_;E^&,B
ME/)\8#<,9_X1'4A_[0H ^@H<B%,KL.T?*.W'2GU\]+^W)\,8U">3XP.T8R?"
M.I'I_P!L*7_ANCX8_P#/'Q?_ .$AJ7_QB@#Z$HKY[_X;H^&/_/'Q?_X2&I?_
M !BC_ANCX8_\\?%__A(:E_\ &* /H2BOGO\ X;H^&/\ SQ\7_P#A(:E_\8H_
MX;H^&/\ SQ\7_P#A(:E_\8H ^A*BN1NMY!Y?F_*?D/\ %[5X!_PW1\,?^>/B
M_P#\)#4O_C%-D_;B^&-Q&T9B\8*&&,CPCJ0(_'R* /H:BOGO_ANCX8_\\?%_
M_A(:E_\ &*/^&Z/AC_SQ\7_^$AJ7_P 8H ^A**^>_P#ANCX8_P#/'Q?_ .$A
MJ7_QBC_ANCX8_P#/'Q?_ .$AJ7_QB@#Z$HKY[_X;H^&/_/'Q?_X2&I?_ !BC
M_ANCX8_\\?%__A(:E_\ &* /H2HKH%H2!&)3D?*?J*\ _P"&Z/AC_P \?%__
M (2&I?\ QBFR?MQ?#&X788O&"Y(.1X2U(=#G_GA[4 ?0U%?/?_#='PQ_YX>+
M_P#PD-2_^,4?\-T?#'_GCXO_ /"0U+_XQ0!]"45\]_\ #='PQ_YX^+__  D-
M2_\ C%'_  W1\,?^>/B__P )#4O_ (Q0!]"45\]_\-T?#'_GCXO_ /"0U+_X
MQ1_PW1\,?^>/B_\ \)#4O_C% 'T)44P)\O\ =B3YQU_A]Z\ _P"&Z/AC_P \
M?%__ (2&I?\ QBFO^W%\,9MO[KQ@-AW<>$=2&?\ R!0!]#45\]_\-T?#'_GC
MXO\ _"0U+_XQ1_PW1\,?^>/B_P#\)#4O_C% 'T)17SW_ ,-T?#'_ )X^+_\
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MO!3>T>[AAGI/@]J?B+5/"4DGB.WOH9H[R:*SEU6&.&]N+4']W)/''A4<\C
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M( !)% $'Q"^(D'@1M)ADM+JYFU6:2V@-I 9V618F< (.78[>%!&0"<C%<O\
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M;J".YMIE*20S(&1U/4$'@BHM+TFST.PBLM/M8K.TA&$AA0*J_@*MT4 %%%%
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MU'_#S#_JG'_E=_\ N:BS ^X**^'_ /AYA_U3C_RN_P#W-1_P\P_ZIQ_Y7?\
M[FHLP/N"BOA__AYA_P!4X_\ *[_]S4?\/,/^J<?^5W_[FHLP/N"BOA__ (>8
M?]4X_P#*[_\ <U'_  \P_P"J<?\ E=_^YJ+,#[@HKX?_ .'F'_5./_*[_P#<
MU'_#S#_JG'_E=_\ N:BS ^X**^'_ /AYA_U3C_RN_P#W-1_P\P_ZIQ_Y7?\
M[FHLP/N"BOA__AYA_P!4X_\ *[_]S4?\/,/^J<?^5W_[FHLP/N"BOA__ (>8
M?]4X_P#*[_\ <U'_  \P_P"J<?\ E=_^YJ+,#[@HKX?_ .'F'_5./_*[_P#<
MU'_#S#_JG'_E=_\ N:BS ^X**^'_ /AYA_U3C_RN_P#W-1_P\P_ZIQ_Y7?\
M[FHLP/N"BOA__AYA_P!4X_\ *[_]S4?\/,/^J<?^5W_[FHLP/N"BOA__ (>8
M?]4X_P#*[_\ <U'_  \P_P"J<?\ E=_^YJ+,#[@HKX?_ .'F'_5./_*[_P#<
&U%%F!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>formdrs_036.jpg
<TEXT>
begin 644 formdrs_036.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &+ I0# 2(  A$! Q$!_\0
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M$,-Y).\Y .X\^] 'IM%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'GNH_ GPCJWQ*UCQU=V<T^O:MH
M/_"-W3/.QB:R+,Q0)T!)9N>O-<AH'[&OPT\,^"_ /A;3[&_@TOP1K/\ ;^CD
M7K^:EV7=RSOU<9<\'C&!VKW&B@#PW1_V-?AUX<^)$OC31?[=T2\FU%=6FTS3
M=:N(--FN@=WF/;*VPY/)&,'N*P->_P""?_PEU_Q!J>J26^N6@U#64\03:?::
MQ-'9"^5MWG+!G:&))SQWXQ7TC10!Y+J'[+_@/4M7^)NI3VEZ;KXBVL5GK[+>
M.!+''%Y2B,?\LSM[BNIT?X5Z'H/PIMOAYI_VRU\.V^E_V/%Y=RPN$MQ'Y?$O
MWMVW^+K78T4 >.-^R3\,'^!__"ISX=C/A+[*+7;G_2MH?S WG8W;]P!W9K!\
M?_L._#/XB76B7UZ->TW5]*TN+1DU;2-8FM+NYM(U"I'/(A_>X ZMSR:^@:*
M/*1^RW\,O^%(Q_"1_"]M+X%CCV+I\C,6W[BWF^9G=YNXEM^<Y-5_@M^R_P"$
M?@1JEWJ'AZ_\1WT\]L+-5UO6[B^C@A#!@D:2,0HR!R!GC&:]>HH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%U^'_P#GQ\2_^$SJ/_QBN^HH X'_ (77X?\ ^?'Q+_X3.H__ !BC_A=?A_\
MY\?$O_A,ZC_\8KOJ* .!_P"%U^'_ /GQ\2_^$SJ/_P 8H_X77X?_ .?'Q+_X
M3.H__&*[ZB@#@?\ A=?A_P#Y\?$O_A,ZC_\ &*/^%U^'_P#GQ\2_^$SJ/_QB
MN^HH X'_ (77X?\ ^?'Q+_X3.H__ !BC_A=?A_\ Y\?$O_A,ZC_\8KOJ* .!
M_P"%U^'_ /GQ\2_^$SJ/_P 8H_X77X?_ .?'Q+_X3.H__&*[ZB@#@?\ A=?A
M_P#Y\?$O_A,ZC_\ &*/^%U^'_P#GQ\2_^$SJ/_QBN^HH X'_ (77X?\ ^?'Q
M+_X3.H__ !BC_A=?A_\ Y\?$O_A,ZC_\8KOJ* .!_P"%U^'_ /GQ\2_^$SJ/
M_P 8H_X77X?_ .?'Q+_X3.H__&*[ZB@#@?\ A=?A_P#Y\?$O_A,ZC_\ &*/^
M%U^'_P#GQ\2_^$SJ/_QBN^HH X'_ (77X?\ ^?'Q+_X3.H__ !BC_A=?A_\
MY\?$O_A,ZC_\8KOJ* .!_P"%U^'_ /GQ\2_^$SJ/_P 8H_X77X?_ .?'Q+_X
M3.H__&*[ZB@#@?\ A=?A_P#Y\?$O_A,ZC_\ &*/^%U^'_P#GQ\2_^$SJ/_QB
MN^HH X'_ (77X?\ ^?'Q+_X3.H__ !BC_A=?A_\ Y\?$O_A,ZC_\8KOJ* .!
M_P"%U^'_ /GQ\2_^$SJ/_P 8H_X77X?_ .?'Q+_X3.H__&*[ZB@#@?\ A=?A
M_P#Y\?$O_A,ZC_\ &*/^%U^'_P#GQ\2_^$SJ/_QBN^HH X'_ (77X?\ ^?'Q
M+_X3.H__ !BC_A=?A_\ Y\?$O_A,ZC_\8KOJ* .!_P"%U^'_ /GQ\2_^$SJ/
M_P 8H_X77X?_ .?'Q+_X3.H__&*[ZB@#@?\ A=?A_P#Y\?$O_A,ZC_\ &*/^
M%U^'_P#GQ\2_^$SJ/_QBN^HH X'_ (77X?\ ^?'Q+_X3.H__ !BC_A=?A_\
MY\?$O_A,ZC_\8KOJ* .!_P"%U^'_ /GQ\2_^$SJ/_P 8H_X77X?_ .?'Q+_X
M3.H__&*[ZB@#@?\ A=?A_P#Y\?$O_A,ZC_\ &*/^%U^'_P#GQ\2_^$SJ/_QB
MN^HH X'_ (77X?\ ^?'Q+_X3.H__ !BC_A=?A_\ Y\?$O_A,ZC_\8KOJ* .!
M_P"%U^'_ /GQ\2_^$SJ/_P 8H_X77X?_ .?'Q+_X3.H__&*[ZB@#@?\ A=?A
M_P#Y\?$O_A,ZC_\ &*/^%U^'_P#GQ\2_^$SJ/_QBN^HH X'_ (77X?\ ^?'Q
M+_X3.H__ !BC_A=?A_\ Y\?$O_A,ZC_\8KOJ* .!_P"%U^'_ /GQ\2_^$SJ/
M_P 8H_X77X?_ .?'Q+_X3.H__&*[ZB@#@?\ A=?A_P#Y\?$O_A,ZC_\ &*/^
M%U^'_P#GQ\2_^$SJ/_QBN^HH X'_ (77X?\ ^?'Q+_X3.H__ !BC_A=?A_\
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MGQ%_T4WQ+_X"Z;_\B4?\*Y\1?]%-\2_^ NF__(E=[10!P7_"N?$7_13?$O\
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MTW_Y$KO:* ."_P"%<^(O^BF^)?\ P%TW_P"1*/\ A7/B+_HIOB7_ ,!=-_\
MD2N]HH X+_A7/B+_ **;XE_\!=-_^1*/^%<^(O\ HIOB7_P%TW_Y$KO:* ."
M_P"%<^(O^BF^)?\ P%TW_P"1*/\ A7/B+_HIOB7_ ,!=-_\ D2N]HH X+_A7
M/B+_ **;XE_\!=-_^1*/^%<^(O\ HIOB7_P%TW_Y$KO:* ."_P"%<^(O^BF^
M)?\ P%TW_P"1*/\ A7/B+_HIOB7_ ,!=-_\ D2N]HH X+_A7/B+_ **;XE_\
M!=-_^1*/^%<^(O\ HIOB7_P%TW_Y$KO:* ."_P"%<^(O^BF^)?\ P%TW_P"1
M*/\ A7/B+_HIOB7_ ,!=-_\ D2N]HH X+_A7/B+_ **;XE_\!=-_^1*/^%<^
M(O\ HIOB7_P%TW_Y$KO:* ."_P"%<^(O^BF^)?\ P%TW_P"1*/\ A7/B+_HI
MOB7_ ,!=-_\ D2N]HH X+_A7/B+_ **;XE_\!=-_^1*/^%<^(O\ HIOB7_P%
MTW_Y$KO:* ."_P"%<^(O^BF^)?\ P%TW_P"1*/\ A7/B+_HIOB7_ ,!=-_\
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M$/\ G^O/_!9=?_&Z/^%X>$/^?Z\_\%EU_P#&Z]@^".\HK@_^%X>$/^?Z\_\
M!9=?_&Z/^%X>$/\ G^O/_!9=?_&Z .\HK@_^%X>$/^?Z\_\ !9=?_&Z/^%X>
M$/\ G^O/_!9=?_&Z .\HK@_^%X>$/^?Z\_\ !9=?_&Z/^%X>$/\ G^O/_!9=
M?_&Z .\HK@_^%X>$/^?Z\_\ !9=?_&Z/^%X>$/\ G^O/_!9=?_&Z .\HK@_^
M%X>$/^?Z\_\ !9=?_&Z/^%X>$/\ G^O/_!9=?_&Z .\HK@_^%X>$/^?Z\_\
M!9=?_&Z/^%X>$/\ G^O/_!9=?_&Z .\HK@_^%X>$/^?Z\_\ !9=?_&Z/^%X>
M$/\ G^O/_!9=?_&Z .\HK@_^%X>$/^?Z\_\ !9=?_&Z/^%X>$/\ G^O/_!9=
M?_&Z .\HK@_^%X>$/^?Z\_\ !9=?_&Z/^%X>$/\ G^O/_!9=?_&Z .\HK@_^
M%X>$/^?Z\_\ !9=?_&Z/^%X>$/\ G^O/_!9=?_&Z .\HK@_^%X>$/^?Z\_\
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M+P\(?\_UY_X++K_XW7Z)A_X,/1?D?RIF?^_5_P#'+\V=Y17!_P#"\/"'_/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH RO%G_(JZS_UY3?\
MH#5\& ?+7WGXL_Y%;6?^O*;_ - -?!RCY17S.<?%#YG[#P'_  <1ZQ_)C:3%
M/HP*^>L?J=R/;25)MI,4AGJ_[,?_ "4A_P#KRD_FM?6-?*'[,O\ R4A_^O*3
M^:U]7U]AE7^[_-GX-QI_R-?^W5^H4445[!\&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\U_M9?\AC
MP_\ ]<)/_0A7@M>]_M8C_B;^'_\ KC)_Z$*\%Q7P^8?[S/\ KH?T;PN_^$>A
MZ/\ ]*8W;2;33J*\\^JN,H*T^D*C%(9]M?!?_DEOAS_KU'\S7:UQ7P7_ .27
M>'/^O4?S-=K7Z%0_A0]%^1_+.9?[]7_QR_-A1116YYH4444 %%%% !1110 5
M\Y?';QM\4OAKJ&HZROQ"^%_A'P=G=:_\)1!<"XVA1N!*R .V<\*/2OHVOF3X
MM?L7Q^*O'7B#Q[X1\2KI/B[6+9K:>/Q!I\>JV)4QE,1*^)+?@]8G _V30!T'
M[']S::YX1\3>)H];N?$VH:]K+WU[K+:1+IEI<OY4:K]DBD^9H%154.?O$$U[
MW7FG[/>D^-/#'PWT[PYXWT[2[/4-"BBTVVNM(NVG@O;>*)%2;#JK1DX(*'.,
M=>:]+H HZWKFG>&M)NM4U:_MM,TVU0R3WEY*L442CNS,0 /K52W\8:+=>$T\
M30ZE;R>'WM?MRZ@&_=&#;N\S/]W;SFJ'Q1TW^V?AIXKL1:B]:XTJZC2W*!_,
M8Q-M7:>I)Q7C?P[CMA^S5X4^'7BC2O$&FF;P+')?W%K9-_HRI&D;Q;MK 3Y;
MA-I) /% 'LO@3XF>&/B;8W%YX7UB'6+6!E226 ,%4D;@.0,Y'/%=/7B/[,Z^
M*UC\4C4CJY\&+<P1^&3XCM([;4C L*B4R(B)B/S =F\;MO7C%>W4 %%<[XHT
MGQ'J4UNVA^(+?18U4B5)].%T9#D8(/F+MQSZ]:Q/^$7^('_0]6'_ ((!_P#'
MZ .]HK@O^$7^('_0]6'_ ((!_P#'Z/\ A%_B!_T/5A_X(!_\?H [VBN"_P"$
M7^('_0]6'_@@'_Q^C_A%_B!_T/5A_P"" ?\ Q^@#O:*X+_A%_B!_T/5A_P""
M ?\ Q^C_ (1?X@?]#U8?^" ?_'Z .]HK@O\ A%_B!_T/5A_X(!_\?H_X1?X@
M?]#U8?\ @@'_ ,?H [VBN"_X1?X@?]#U8?\ @@'_ ,?H_P"$7^('_0]6'_@@
M'_Q^@#O:*X+_ (1?X@?]#U8?^" ?_'Z/^$7^('_0]6'_ ((!_P#'Z .]HK@O
M^$7^('_0]6'_ ((!_P#'Z/\ A%_B!_T/5A_X(!_\?H [VBN"_P"$7^('_0]6
M'_@@'_Q^C_A%_B!_T/5A_P"" ?\ Q^@#O:*X+_A%_B!_T/5A_P"" ?\ Q^C_
M (1?X@?]#U8?^" ?_'Z .]HK@O\ A%_B!_T/5A_X(!_\?H_X1?X@?]#U8?\
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M_P"" ?\ Q^@#O:*X+_A%_B!_T/5A_P"" ?\ Q^C_ (1?X@?]#U8?^" ?_'Z
M.]HK@O\ A%_B!_T/5A_X(!_\?H_X1?X@?]#U8?\ @@'_ ,?H [VBN"_X1?X@
M?]#U8?\ @@'_ ,?H_P"$7^('_0]6'_@@'_Q^@#O:*X+_ (1?X@?]#U8?^" ?
M_'Z/^$7^('_0]6'_ ((!_P#'Z .]HK@O^$7^('_0]6'_ ((!_P#'Z/\ A%_B
M!_T/5A_X(!_\?H [VBN"_P"$7^('_0]6'_@@'_Q^C_A%_B!_T/5A_P"" ?\
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M'QKJ$=PR/J'@R%8[1>!\C;3AG'4D*G!'RBO8* "BBB@ HHHH **** "BBB@
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MRKC?@[_R3+P]_P!>P_F:[*OOJ'\*'HOR/Y@S+_?:_P#BE^;"BBBMSS@HHHH
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M?X2_!6W^&-YK&JW>O:GXL\3:NL$5[K6K%/.>*%2L,85 %55!8],EF8GK7I%
M'.^*/B)X8\$S6\7B#Q!IVBR7"LT*7URD1D P"5W'G&1^=8G_  OSX;_]#UX?
M_P#!A%_C7>8!ZC-&T>@H X/_ (7Y\-_^AZ\/_P#@PB_QH_X7Y\-_^AZ\/_\
M@PB_QKO-H]!1M'H* .#_ .%^?#?_ *'KP_\ ^#"+_&C_ (7Y\-_^AZ\/_P#@
MPB_QKO-H]!1M'H* .#_X7Y\-_P#H>O#_ /X,(O\ &C_A?GPW_P"AZ\/_ /@P
MB_QKO-H]!1M'H* .#_X7Y\-_^AZ\/_\ @PB_QH_X7Y\-_P#H>O#_ /X,(O\
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M_P#0]>'_ /P81?XUWFT>@HVCT% '!_\ "_/AO_T/7A__ ,&$7^-'_"_/AO\
M]#UX?_\ !A%_C7>;1Z"C:/04 <'_ ,+\^&__ $/7A_\ \&$7^-'_  OSX;_]
M#UX?_P#!A%_C7>;1Z"C:/04 <'_POSX;_P#0]>'_ /P81?XT?\+\^&__ $/7
MA_\ \&$7^-=YM'H*-H]!0!P?_"_/AO\ ]#UX?_\ !A%_C1_POSX;_P#0]>'_
M /P81?XUWFT>@HVCT% '!_\ "_/AO_T/7A__ ,&$7^-'_"_/AO\ ]#UX?_\
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M3AE8$ JP/56 (]* .AHK@_ /QS\#?%'5KW3?"VOQZQ=V8<S+#!*J*%<HV'9
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M?DQFVBG[:3%> ?IMQE&VG;:-M 'I_P"SGQ\0G_Z\Y/YBOJ"OF#]G/_DH+_\
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MS:G9J6GM4E!>,#J2/;OZ=Z5T!S?]C_$O_H:/#G_@CF_^2:/['^)?_0T>'/\
MP1S?_)-;-O\ $KPM>:5>ZE!K]A+863B.XN$F!6)CT!^O;UK9TG5K/7-/BOK"
MX2ZM)1E)HSE6[<470'&_V/\ $O\ Z&CPY_X(YO\ Y)KQ[XN6.MP>)(EUZ^L]
M1O/LZ[9;&U:W0)EL JSN<YSSG\*^GZ\!^.T>[QA"?^G5?_0FKJP_QG@YTKX3
MYH\ADA]JJR0>U;<D-5I(/:O1/SQQ,22&JTD-;<D%59+?K2L8N)B2P<'CBOJ7
MP#I/C^3P7HK:?XBT&WLC:H88I]'ED=%QP&87 !/O@5\URP<'BOLOX9C;\/\
M0!_TYQ_RKDQ&R/J.'(VKU/3]3F=<TCXBKHFH-<>)?#\EN+>0R)'HLJLR[3D
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M-']C_$O_ *&CPY_X(YO_ ))KOJ* .!_L?XE_]#1X<_\ !'-_\DT?V/\ $O\
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MU;Q3ZI9W$$+HT^Y6<<$[I"N/HH]J[G^W],_Z"-I_W_7_ !I/^$@TO_H)6?\
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M1'\UYA_OE;_%+\V%%%%;'GA1110 4444 %%%% !1110 4444 %%%% !1110
M45YQ\5OVBOAM\#KK3K;QYXOT_P ,SZ@CR6J7K,#*J$!B, ]"P_.N$_X> ?L\
M?]%7T'_OX_\ \30!]!45\^_\/ /V>/\ HJ^@_P#?Q_\ XFC_ (> ?L\?]%7T
M'_OX_P#\30!]!45\^_\ #P#]GC_HJ^@_]_'_ /B:/^'@'[/'_15]!_[^/_\
M$T ?058GC:/S/!>OI_>T^X'_ )#:O&/^'@'[/'_15]!_[^/_ /$UG^(?V^/V
M?+OP_J<$7Q4T&226UE14#ODDH0!]VE+9B>Q\Z?\ "-/Y:\OT_O&J\GAM_5_^
M^C5<?M3_  :*@'QUI73^\W^%,;]J'X,M_P SWI?_ 'TW^%?/<M3^5GEVEV%D
M\-R<_,__ 'T:JR>&Y/5_^^C4C?M-?!EO^9]TK\V_PJ%_VE/@VW_,^Z3^;?X4
M[3[,?O=BO)X;D]7_ .^C7N7[&>DM8?%+4I"6P=*D7YB3_P M8Z\.;]I#X.M_
MS/ND_P#?3?X5Z'\!?VMO@AX0\97=[J'Q&T:TA>R:(/(S8+%T./N^QK>BI>T5
MT:4^;F6A]_UXG\9?^1JA_P"O9?\ T)JR?^'@'[/'_15]!_[^/_\ $UY1\4OV
MUO@;K7B**>R^)6C7$0@52Z.^,Y/'W:^CP[2GJ89K&4\/:*N[H[&BO'O^&P/@
MS_T4+2?^^F_^)H_X; ^#/_10M)_[Z;_XFO2YX]SX[ZO6_D?W,]>:,-4$D%>4
M?\-@?!G_ **%I/\ WTW_ ,31_P -?_!C_HH6D?\ ?3?_ !-'/'N3]6K?R/[F
M>F2P<'BOI_P&-O@W1A_T[)_*OA"3]KKX,,#_ ,7!TG_OIO\ XFO=?"?[>G[/
MMAX9TVWG^*FA1S1P*K(SOD$#I]VN/$--*S/=R:C.G5FYQ:T/H7Q-_P BWJW_
M %Z2_P#H!KXOQ7J6O?M\?L^76AZC#%\5=">22VD15#ODDJ0!]VOEG_AJKX2?
M]#WI?_?3?X5\CF=.<Y1Y5?<_>^#\31H4JRJS4;M;M+N>J45Y7_PU5\)/^A[T
MO_OIO\*3_AJKX2?]#UI?_?3?X5XGL:O\K^X_0_[0P?\ S^C_ .!+_,]4Q2;:
M\L_X:J^$G_0]Z7_WTW^%)_PU5\)?^AZTO_OIO\*/8U?Y7]P?VA@_^?T?_ E_
MF?4/[//_ "/S_P#7I)_,5],5\"?!3]L;X+>'O&376H_$32+2W^S.GF2.V,DC
MC[M>\_\ #P#]GC_HJ^@_]_'_ /B:^GRZ,HT+25M3\>XJK4ZV8\].2DN5;._<
M^@J*^??^'@'[/'_15]!_[^/_ /$T?\/ /V>/^BKZ#_W\?_XFO3/CSZ"HKY]_
MX> ?L\?]%7T'_OX__P 31_P\ _9X_P"BKZ#_ -_'_P#B: /H*BOGW_AX!^SQ
M_P!%7T'_ +^/_P#$T?\ #P#]GC_HJ^@_]_'_ /B: /H*BOGW_AX!^SQ_T5?0
M?^_C_P#Q-'_#P#]GC_HJ^@_]_'_^)H ^@J*^??\ AX!^SQ_T5?0?^_C_ /Q-
M'_#P#]GC_HJ^@_\ ?Q__ (F@#Z"HKY]_X> ?L\?]%7T'_OX__P 31_P\ _9X
M_P"BKZ#_ -_'_P#B: /H*BOGW_AX!^SQ_P!%7T'_ +^/_P#$T?\ #P#]GC_H
MJ^@_]_'_ /B: /H*O+?B]\<!\*M4T^S.BR:I]JA:;>DP3;AL8Y!KC_\ AX!^
MSQ_T5?0?^_C_ /Q->,?';]L3X%>+M:TR:R^(^CWB0V[(S1LY"DMG'W:PK2E&
M%X;F=1N,;Q/5F_;(5?\ F4+C_P "U_\ B:C;]LY%_P"9/N/_  ,7_P")KY=;
M]I3X+-_S/FE_FW^%1-^T;\%V_P"9]TK\V_PKSO;U^S^XY/:5.Q]0M^VJB_\
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MPIGX?_\ 0B^&O_!1;_\ Q%=E10!QO_"F?A]_T(OAK_P46_\ \11_PICX??\
M0B^&O_!1;_\ Q%=E10!QO_"F/A]_T(OAK_P46_\ \11_PICX??\ 0B^&O_!1
M;_\ Q%=E10!QO_"F/A]_T(OAK_P46_\ \11_PICX??\ 0B^&O_!1;_\ Q%=E
M10!QO_"F/A]_T(OAK_P46_\ \11_PICX??\ 0B^&O_!1;_\ Q%=E10!QO_"F
M/A]_T(OAK_P46_\ \11_PICX??\ 0B^&O_!1;_\ Q%=E10!QO_"F/A]_T(OA
MK_P46_\ \11_PICX??\ 0B^&O_!1;_\ Q%=E10!QO_"F/A]_T(OAK_P46_\
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M_P %%O\ _$5V5% '&_\ "F?A_P#]"+X:_P#!1;__ !%'_"F?A_\ ]"+X:_\
M!1;_ /Q%=E10!QO_  ICX??]"+X:_P#!1;__ !%'_"E_A]_T(GAK_P %%O\
M_$5V5% '&_\ "F/A]_T(OAK_ ,%%O_\ $4?\*8^'W_0B^&O_  46_P#\1794
M4 <;_P *8^'W_0B^&O\ P46__P 11_PI?X??]")X:_\ !1;_ /Q%=E10!QO_
M  ICX??]"+X:_P#!1;__ !%7M%^&OA#PWJ"7^D>%=$TN^0%5NK+3H895!&"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJGJ ,"A842/8J*J?W0,"GT4 (JA5  P!P *,>U+10 FT>@]>E)L7^Z/RIU%
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DXQM&.G2G44 1K;Q+MQ$@V_=PHX^E/V@= /RI:* "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>formdrs_037.jpg
<TEXT>
begin 644 formdrs_037.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &E NP# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***2@!:*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKP&^_;$\,:'^U0/@EK-J^
MF:C<V,=S8:I),/)N97!/D;<?*V!P<G)XJE^U)^V':?LT^*_ >@2^&9M?NO%=
MV+:.1+H0);C>JECE6+?>Z<?6@#Z+HKY0\5?MQ7^H_'+6?A+\+_AY/XY\6:*A
M?49+W4X]-M8L %@K,K%R-P["K?PO_;>_MOXW)\(?B-X$OOASX]FC\VTA:\2]
MM+I<9&R90O4 XX[=: /J,G:"37)V/C:SNO%(TLM+%),I:WWQ_+,!PVTY['U
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3;AE<.Q .1TYYKX6\$M?>/&\6:E??#^[\=ZGJ$A!OH[MXS8NP;&%"G/48SC
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M\3>%M?EUC5K[5I8[U422^N7F9%V X!8G KG?@+$?!?[17C7PEI9D;0A'+(L
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MD[G5_O[SN^[C[HZUZ711=DRPM&7)>/P:KRZ?U<\U^'?P;_X0'QYXN\2?VO\
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MI>-[_6)-32"*.[O(2Z6B1.&"I&9#UZ'YNP].6ZW^SO\ VQ\&=&\!?\)!Y/\
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M 4444 %%%% !1110 4444 %%%% !1110 44E+0 4444 %%%% !1110 4444
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MDUF>%_&NA^--/:^T34X-1M5<QM)$>C#L0<$5GZ]\+O#'B1;W[?I4<KW@82R
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M)+[1G/?K0!ZC2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO^?C_P# 7_D'_$-N)/\ GRO_  ./^9]P45\/_P##P3Q#_P!"GIG_ ($24?\
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M^:+T]$SZ0HHHKZ4_/@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!*6DI: "BBB@ HHHH **** "BBB@ HHHH ****
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M\=/^% %JBJO]IVW_ #T_\=/^%']IVW_/3_QT_P"% %JBJO\ :=M_ST_\=/\
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M44?V/EW_ #XC]R#_ %LS[_H-J?\ @;_S/!?^&)OA?_SXZA_X'/1_PQ-\+_\
MGQU#_P #GKWJBC^Q\N_Y\1^Y!_K9GW_0;4_\#?\ F>"_\,3?"_\ Y\=0_P#
MYZ/^&)OA?_SXZA_X'/7O59^O:]9>&=)N=2U&;R+2W7<[XS^ '<TO['R[_GQ'
M[D'^MF??]!M3_P #?^9XK_PQ-\+_ /GQU#_P.>NL^&O[.?@SX3^()-9\/VUU
M#?26[6S-/<M(NQF5B,'OE171^#_B=X?\;V4EQI]X(_+;8\5UB-P?H3R/I72Q
MWEO)]R>-_P#=<&KI9;@*4E4I48IK9I(YJ_$N<8NE*C7Q<Y0EHTY-IHEHH#!N
M0<BEKUCYT2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2EH
MHH **** "BBB@ HHHH 2EI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** *VI6YO-/NK=6=&EB9 T;E&&01D,.0?<=*\'T7X=_$&UU#PNM
MU<7SO9QV7^G?VJQC@6,,+F.9-W[YI"1AB&Z\E=HKZ!HH :^[:=A ;MN&15?;
M>?\ /2#_ +]M_P#%5:HH J[;S_GI!_W[;_XJC;>?\](/^_;?_%5:HH J[;S_
M )Z0?]^V_P#BJ-MY_P ](/\ OVW_ ,55JB@"KMO/^>D'_?MO_BJ-MY_ST@_[
M]M_\55JB@"KMO/\ GI!_W[;_ .*HVWG_ #T@_P"_;?\ Q56J* *NV\_YZ0?]
M^V_^*HVWG_/2#_OVW_Q56J* *NV\_P">D'_?MO\ XJC;>?\ /2#_ +]M_P#%
M5:HH J[;S_GI!_W[;_XJD5KIF8+-;DKP0$/'_CU5?$FKQZ3IK_,WVJ<&*WCB
M&9'D(XVCVZY[5XW\+?@UXGT7Q/?7NN7TD%E*A#+:W;;YV)R,D= *SE-IV2N0
MY:V2/:KFZELTWW%W:0+_ 'I 5'ZM6/-XVL(V*)J5O=2#C9:P23'_ ,=)JU;^
M!]#MY/,.GQSR?W[C,I/_ 'UFMF&WBMT"11)$@Z*B@"CWWV7X_P"0>\<P?$VL
M7/%CHEQ-Z/<((%^OS/G]*FC/BRZ7YQI=@#Z;YF'Z@5TM%'*^K#E?5G+2>%]8
MO#_I7B.X9?[EO&L(_3G]:I:I\+=+UC3KBTNXUN/.7:9I7D>1?<,6.#7;44>S
MCU0<L>QY_P"#?@[H_@NQFMH(8+]I7WO-?1"1_8#H /I6V_@;39.NG:</]V C
M^35TM%/V<.P^6/8Y5OA[I9Y%C:*?55<?R>D_X0"T'W"T7_7.:9?_ &>NKHI>
MSA_*A<D>QRG_  @H7[FH7D?^[>3?_%T?\(;>+_J]>U"/_MLS?S)KJZ*/9P[!
MR1['*?\ "(ZJOW?$U^OU"-_-:>OAS7X_N>)I3_OVL;5U%%'LX_TV'*CFAHOB
M1>GB.-O]ZQ3_ !IPT_Q/'TU:QD_W[0C^35T=%'LUY_>PY4<[Y/BI>EUI+_[T
M$@_D](S^+%Z1Z1)^,J_XUT=%')YL.7S.8:Z\7K_S#]*?Z7$@_P#9:8=4\6)]
M[1;1_P#KG<_XXKJJ*.5_S/\ #_(.5]SE?[<\2K][P[G_ '+B,_S:C_A)M83_
M %F@W2_[BH_\GKJJ*.67\WY!RON<K_PEUZOW]&U%?I9[OY24?\)FR_ZRUO8O
M][3I/Z,:ZJBCEEW"TNYRO_"<VP^])-'_ +VG3_X4H\=:=_%J4,?_ %TM95_G
M744%0>H!_"BT^Z^[_@A[W<Y<^/-*4$MK>GJ ,G<&'\S65X)^,N@^-];GTFSD
MF^UQAF1I(MB2J#@E>3^M=S):PS1LCQ(RL"I!4<@]JY#PC\(O#G@K6KG5=-MY
M%NI@5'F2%EC4G)"CM2_>76U@]^Z-.Y\9VT.H7]E'"\US9+OF4$#:IQM/XY_2
MIF\9:2F=]R4Y R8WP<Y P<8.2"!CJ1BI[CPWI]S<23/!^]D)+.K$$Y !'T^4
M<>U5I/!>D2[@]NSJ2&"-(VU<$D8&>,$DCT)S3]\/>))?%VEPQ7$C3OMMV"3?
MN7_=D]FXXJ"7QOIL-Z\#-(8UCWB98G8,<G(7 ^;&"21P*=<>"=*N!)OADW2O
MYDC"5@7;!&2<\G!Q0W@G268MY4@/1=LS#8#G(7G@')SCUH]\/>%D\66R:_::
M6J&1[F/S$D##D$$Y [CCD^XITWC+2H+I[=YI%=6VLQ@DV#!P?FVXQGC.:L?\
M([8?;H;L0E98@NT!B%X!"G'3(!(IL_ANQG63,15GW?,&/!+;L_\ ?7-/WA^\
M3:7KEIK2RFT=W$3!6W1LG.,\9 SQ5^L3PKX;/AFRDMA<^?&S[E79M"<<XY/4
M\GGO6W5*]M1J]M0HHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .,\;
M?%33/!.HP::^G:UK>J31>>++1-.DNI%CR1O8@;5&00-S G'&:T_!?CC3?'FE
MO>Z<MY!Y4K03VNH6DEK<02#JCQR*"#^A[$UYE^U1XT\0_#OPEIFNZ'XE_L$&
M]6R>-H+/RYFD!*&2:Y(2%5V-SW) K;_9GCG'P>T>:ZU!=5NKEYKF:[2Z@N5D
M=Y69B)("8R,G^'@=* /4JXC7?BYHWA_Q;#H$\%[+*TL$$]Y#&I@MI)@QA23+
M!LMM."JL!QDC-=O7&>(OA7HWBCQQHWB6_B1[G2OFAC6% 7D&=K/)C>P4,=JY
MV@DG!- '9,P526( '4FHOMD'_/:/_OH5*RA@01D>AJ/[+#_SR3_OD4 )]K@_
MY[1_]]"C[7!_SVC_ .^A2_98?^>2?]\BC[+#_P \D_[Y% "?:X/^>T?_ 'T*
M/M<'_/:/_OH4OV6'_GDG_?(H^RP_\\D_[Y% "?:X/^>T?_?0H^UP?\]H_P#O
MH4OV6'_GDG_?(H^RP_\ /)/^^10 GVN#_GM'_P!]"C[7!_SVC_[Z%+]EA_YY
M)_WR*/LL/_/)/^^10 GVN#_GM'_WT*/M<'_/:/\ [Z%+]EA_YY)_WR*/LL/_
M #R3_OD4 )]K@_Y[1_\ ?0JAK/B.ST6S\YY!-(QV10QL"\CGHH_Q[4:UJ%CH
M=H)IH5DD<[(H8U!>5ST515'0_#KF[;5=42-M0D7:D*C*6Z?W%]_4]ZSE)WY8
M[D-ZV0FA:?BZ?5=5N(9=3E&%0."ELG]Q/ZGO6]]K@_Y[1_\ ?0KB?BIX]M/A
M_P"'9[BW@M[K5.!#:L,]?XF YP*YWX??&"X\1^'4OM2\,W)?>R>?I]N6A?'<
M G/ZFL_:4X2]G?4]FCE.+J87ZW"/N7MNKMGK'VN#_GM'_P!]"C[7!_SVC_[Z
M%<:OQ,\/+Q<6MY9'_IXLF'\LU;M_B)X2N!\NHVR>TD93^8K3VD.YSRP.*CJZ
M4ON9T_VN#_GM'_WT*/M<'_/:/_OH5E6WB+P]>#,.H6#_ /;1!6A"UC<@&$V\
MH/0H5/\ *KNGL<LJ<X?%%HE^UP?\]H_^^A1]K@_Y[1_]]"E^RP_\\D_[Y%'V
M6'_GDG_?(IF8GVN#_GM'_P!]"C[7!_SVC_[Z%+]EA_YY)_WR*/LL/_/)/^^1
M0 GVN#_GM'_WT*/M<'_/:/\ [Z%+]EA_YY)_WR*/LL/_ #R3_OD4 )]K@_Y[
M1_\ ?0H^UP?\]H_^^A2_98?^>2?]\BC[+#_SR3_OD4 )]K@_Y[1_]]"C[7!_
MSVC_ .^A2_98?^>2?]\BC[+#_P \D_[Y% "?:X/^>T?_ 'T*/M<'_/:/_OH4
MOV6'_GDG_?(H^RP_\\D_[Y% "?:X/^>T?_?0H^UP?\]H_P#OH4OV6'_GDG_?
M(H^RP_\ /)/^^10 GVN#_GM'_P!]"C[7!_SVC_[Z%+]EA_YY)_WR*/LL/_/)
M/^^10 GVN#_GM'_WT*/M<'_/:/\ [Z%+]EA_YY)_WR*/LL/_ #R3_OD4 )]K
M@_Y[1_\ ?0H^UP?\]H_^^A2_98?^>2?]\BC[+#_SR3_OD4 )]K@_Y[1_]]"C
M[7!_SVC_ .^A2_98?^>2?]\BC[+#_P \D_[Y% "?:X/^>T?_ 'T*D219%W(P
M9?53FF?98?\ GDG_ 'R*>J+&N%4*/0#% #J*** "BBB@ HHHH 2EI*6@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \;_:2T/4O$>CZ+:06ADLXK
M^.YCN+'6(+"_CNE#!! +B)XI"59_E8J:Z'X(^(+;5?"LNG))K<E[I$[6=X/$
M(@^V++]XAS!^[/!'W:X7]M5-*F^$-K%JVU(I-7MTBN)IX88()"L@$DKRQ2J%
M W8.PD,5(Y&:=^R+\-;/P?X,N]>MM>&O-K\GGM-'<0W,8VD@_OXX8O.8G.79
M0>@[4 >]T45X/\5[/Q=<?&SPI<Z5#J3:-;M;B5;83;),O)YA#H?*3 *[Q,#N
M 4+@]0#WBBFN6"DJ S=@3BJ_G7?_ #[1_P#?[_[&@"U157SKO_GVC_[_ '_V
M-'G7?_/M'_W^_P#L: +5%5?.N_\ GVC_ ._W_P!C1YUW_P ^T?\ W^_^QH M
M455\Z[_Y]H_^_P!_]C1YUW_S[1_]_O\ [&@"U157SKO_ )]H_P#O]_\ 8T>=
M=_\ /M'_ -_O_L: +5<)\7/B6WPST6VNX[+[;/<2^4BLVU%P,DDUV/G7?_/M
M'_W^_P#L:\N^-&L/=VJ:0+2&YN@AFCM3^]\R4_*@QCMR?RK*K+D@VC2G2G7G
M&E3WD[+^NRW?D;'P]UZV\5Z''XTU9EMY'#I&LIQ';*#@A<]2<=>IJQ)XHU?Q
ME(UOX:B^R6&=KZM<K@>_EKW^M<)\(/!_B/6;%V\86=PUI9L$LK&Z(A0>I* <
M@=LU[5&;B&-4CM(D11@*LN !_P!\UE3O.*>R_$]:O0HY74=&ZJ375:Q_X+]=
M%V9E>'?!&G^']\N&O;^4?OKRY^>1\]>O0>U;T<20QA(T5$'15& *@\Z[_P"?
M:/\ [_?_ &-'G7?_ #[1_P#?[_[&NE)1T1Y=2M4K2YJCNRPRJW50?J*JW&CV
M%U_K[*WF_P"ND2M_,4[SKO\ Y]H_^_W_ -C56]UQ--&;M[.U'_3:Z"?S%!DI
MN&J=BK<> _#UT<R:/:$_[,07^59\WPI\-2_=L##_ -<I77^1IDWQ2T2%BB7D
M%W(./+LV>=OR1#3%^(5Y=L!8>%M6NP>DC((4/XO@_I4<L'T-8YE6AI"L_DV'
M_"K;"'_CUU/5K,=A#=G _,&LWQ)\/?$,F@WL.D>+-0%TT9$27###'T+#D9]:
MV&U;QC>#-OH%A8C_ *?KXN?R12/UKG_&7A7X@>*_#&I:>NMZ=ITUQ"406<3*
M#[%R2P!Z9%+V<'IL:_VOBJ?[R*YVM;-+6W^(R/A?\/\ Q[H>ARQ:AX@^Q,TI
M:.W;%SM'KN)XR>PKL?\ A'_&*]/$\)^MFM>>_!GX.^,O!/AVXL]4\0S6QDF\
MR.VL;A71!CDY=#R3SQQ7H'_"&ZRW7Q+K'_ 9X1_[2H]C&G[L6W;S'+.\7CG]
M8JT(QE+5KECI]^OWCO[$\:KT\1VA^MD*/['\<#IX@L&^MG3?^$+U7OXCUH_]
MO47_ ,:I?^$)U/OXAUH_]OL?_P :HY/7[Q?VA6_Y]1_\!C_D+_9WCI?^8OI;
M_6V(H^S^/%_Y>]'?ZQN*3_A"=0[Z_K1_[?U'_M.E_P"$'O.^N:V?^XB/_B*.
M3S?WA]?J=:,?N10\0-\1;?0[Y[0Z1)<K$Q01!]^?]G/&?K7(?"'QSXVDT.ZN
M-7T^;7[59BJ31RQF9"/O*0.HS78:[\,[C6-%OK$:UK$;W,+1"1M29@I(ZD;1
MD>U</\'_ -GG5_AS;ZB+K7[CS;IU(72[@PH .[!E.31[&_O\[370K^V*L8_5
M7@X2C+5RV:MT5NYZ9:?%#0Y9!%=R3Z5/_P \[Z%H_P!>E=-9ZA;:A'YEK<17
M"?WHG##]*XN[^'MY>QF.;6]6E0_PRW,3C_QZ(UAK\$FMYO.M-8U"UESG<DJ
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MXD7,NI7-A:VUK=RQ[%65)&$>XE@<\9Q\O!Q@@TWQ!XWU&!/#DUL@@%[M>>/
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MW_?;?XT?V;;_ -UO^^V_QJU10!5_LVW_ +K?]]M_C1_9MO\ W6_[[;_&K5%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK]N/_/M/_P!\C_&C[<?^?:?_ +Y'^-6J* *OVX_\^T__ 'R/\:/MQ_Y]I_\
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M]UZBJ_V$_P#/S/\ ]]#_  H M455^PG_ )^9_P#OH?X4?83_ ,_,_P#WT/\
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MW8\T /HHHH **** "BBB@!*6DI: "BBB@ HHHH **** "BBB@ HHHH ****
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MC:>^C:6::23:(%Z1#&/F:1@X _V&/I0!V-%-D<1J6;A1R>*K_P!I6_\ ?/\
MWPW^% %JBJO]I6_]\_\ ?#?X4?VE;_WS_P!\-_A0!:KA_'DS:]JFG>&(&.+E
MO/O"O\,*GH?J:ZFZUNSL[>6>64K'&I=FV'@#\*Y+X?R+>2W_ (BO=RW.HO\
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MI6_]\_\ ?#?X4?VE;_WS_P!\-_A0!:HJK_:5O_?/_?#?X4?VE;_WS_WPW^%
M%JBJO]I6_P#?/_?#?X4?VE;_ -\_]\-_A0!:HJK_ &E;_P!\_P#?#?X4?VE;
M_P!\_P#?#?X4 6J*J_VE;_WS_P!\-_A1_:5O_?/_ 'PW^% %JBJO]I6_]\_]
M\-_A1_:5O_?/_?#?X4 6J*J_VE;_ -\_]\-_A1_:5O\ WS_WPW^% %JBJO\
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M?3?^*I\;W%]][3M&S:VWHTY_UC#Z#"_G79TXQY58PIJ[<ODBKY-W_P _$?\
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MY-W_ ,_$?_?K_P"O1Y-W_P _$?\ WZ_^O5JB@"KY-W_S\1_]^O\ Z]'DW?\
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M>?Y1_5_,;-?VUO"\KSQJB*68[AP!7!R:X^F>';_6U*G5M8E$5G$3RN?EB'T
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M_P!]"D^R0?\ /&/_ +Y%'V2#_GC'_P!\B@!?M4/_ #UC_P"^A1]JA_YZQ_\
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MB@!?M4/_ #UC_P"^A1]JA_YZQ_\ ?0I/LD'_ #QC_P"^11]D@_YXQ_\ ?(H
M7[5#_P ]8_\ OH4?:H?^>L?_ 'T*3[)!_P \8_\ OD4?9(/^>,?_ 'R* %^U
M0_\ /6/_ +Z%/5UD7*L&'J#FH_LD'_/&/_OD5(D:QKA%"CT Q0 ZBBB@ HHH
MH **** $I:2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHKC_'UOKLFI>$Y=%N+J.&/55_M"&WV;)+<QOGS,C. VW[I')[T =A4=Q.E
MK!)-(=L<:EV;T &33GW;3L +=@3@5Q?Q(U"\_L>'2HEC6YU246R;')(4_>/3
MTJ92Y5<Z,/2]O5C3[_EU?W"_#6W>^AU'7YQB;4YRR9[1*<**[0D*"2< 5G:=
M:3Z98V]I##"L4*!%'F'L/I63XRU*ZM]-6S!AMY;YO)$OF$"-,9=R2. %S^=3
M_#AJ&*K*K5E46W3TV2^XQKK7'M;'5?$:+YEU=N+'2XS_ !<[5Q]6RWT%=5X4
MT%/#>@VMB#OD5=TLAZO(>68_4DUX#\/?C0WQ"^+MCX?31TBTS2TF%F$D)PR@
M+YDG'IT^M?1>^\_YY0_]_#_A5JFZ:M+<\;"5Z>*3JTW=+3_,M455WWG_ #RA
M_P"_A_PHWWG_ #RA_P"_A_PIGHEJBJN^\_YY0_\ ?P_X4;[S_GE#_P!_#_A0
M!:HJKOO/^>4/_?P_X4;[S_GE#_W\/^% %JBJN^\_YY0_]_#_ (4;[S_GE#_W
M\/\ A0!:HJKOO/\ GE#_ -_#_A1OO/\ GE#_ -_#_A0!:HJKOO/^>4/_ '\/
M^%&^\_YY0_\ ?P_X4 6J*J[[S_GE#_W\/^%&^\_YY0_]_#_A0!:HJKOO/^>4
M/_?P_P"%&^\_YY0_]_#_ (4 6J*J[[S_ )Y0_P#?P_X4;[S_ )Y0_P#?P_X4
M 6J*J[[S_GE#_P!_#_A1OO/^>4/_ '\/^% %JBJN^\_YY0_]_#_A1OO/^>4/
M_?P_X4 6J*J[[S_GE#_W\/\ A1OO/^>4/_?P_P"% %JBJN^\_P">4/\ W\/^
M%&^\_P">4/\ W\/^% %JBJN^\_YY0_\ ?P_X4;[S_GE#_P!_#_A0!:HJKOO/
M^>4/_?P_X4;[S_GE#_W\/^% %JBJN^\_YY0_]_#_ (4;[S_GE#_W\/\ A0!:
MHJKOO/\ GE#_ -_#_A1OO/\ GE#_ -_#_A0!:HJKOO/^>4/_ '\/^%&^\_YY
M0_\ ?P_X4 6J*J[[S_GE#_W\/^%3Q&0K^\55;T4Y% #Z*** "BBB@ HHHH 2
MEI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN>U?X
M@>']!UNVTB_U*.WU"X**D11B 7)"!F VH6((&XC..* .AKA[/_BI?B1<W/WK
M31HO(C]#,W+'\!6YXP\7:?X-T6:]O[J.W^4B%9#@R/C@ =ZXKP'>:A=>'XX-
M$C#W%VS7%UJLP)A1F.2$'\9 X]*PJ27,D=U&I&C1J5+^\_=2ZZ[O[M/F=SX@
M\567AV-!,6FNI>(;2$;I9#[#T]Z\-T7PMXW\4?%2.;Q+8W$FC+(TCQW+9MUC
MQE54 X/../;FO;]!\)VFAR/<%GO-1E_UM[<'=(WT]!["MNGRN=G+0\MQ<_C^
MXI6NBZ?8W4ES;6-M;W,@"O-%$JNP'0$@9-7:**V-4DM@HHHH&%%%% !1110
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M #XR_P#@7-_\71_PJWPU_P ^,O\ X%S?_%UUE% ')_\ "K?#7_/C+_X%S?\
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MP3XFC^#FE>'IK>YU'Q%8?9Q9WUJ7N'DD#*S*7RODC@)YK$X&2!VKWJS\P6<
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M&_5=PS@_0T ;M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 )2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
)HHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>chart_003.jpg
<TEXT>
begin 644 chart_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'T WX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0Z'>PZGI.M:=9ZAIU_:+*+6]L[J-&BN;;ST64V[*P9?-2*9$*B9%8[4ZHN,
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MC?:AX.\11Z>E_->:?,NLP"Z@$UMIUX+4LT6HKJ%G-!+9&%XV,_[3O[?OQ/\
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MU'4+3QSI<FJZUH.I>%HM"\-B&.PO+._@FT]+Q;Z\-Y;R'5PT,?DVX3WKQ?\
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MMA:_^RC\*? GQ2\,V/AWQ!I/B;XH>&/"VM3ZPFHW-K;>$]3T;Q%K>J:CH_\
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M406%CJ$&OVDEE+)>PK%IEI+;+%<6S0.9P))=^:[-?C]^S_O+CXZ_",Y(R/\
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M%+G/K^((_G7AO_#2'P&_Z+E\'?\ PXWA#_Y=4?\ #2'P&_Z+E\'?_#C>$/\
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M;1/U1[EG/K^1'\Q2DX]?R)_E7AO_  TA\!3G'QS^#N,D<_$;PAG@D'_F-?S
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M_#2'P&_Z+E\'?_#C>$/_ )=4_J6._P"@''?^$.-_^81?VCEW_0?@O_"JC_\
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MUMHB-:O.DJGUVM4FYRC*G1KU9RA9*[E>VG-=+XMGLR#[);#_ )=K?_OS%_\
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M/L=M_P ^UO\ ]^HO_C56J*/81_G_ /*&#_\ F,/K.(_Z",3_ .#YE7[';?\
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M 'ZB_P#C56J*]OV$?Y__ "A@_P#YC.'ZSB/^@C$_^#YE7[';?\^UO_WZB_\
MC5'V.V_Y]K?_ +]1?_&JM44>PC_/_P"4,'_\QA]9Q'_01B?_  ?,J_8[;_GV
MM_\ OU%_\:H^QVW_ #[6_P#WZB_^-5:HH]A'^?\ \H8/_P"8P^LXC_H(Q/\
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MCQ#@_=E!-V^%1<[^ZX_F3#XX^.^H:/X\\3P^,_C;>^&_$^JZ5!\6?$%IXO\
MB+>:/XI\0ZE+>R^&1\0]=@OVT_4?$-S%9-#H,_B2^^U+!HGG:9&19A;7!G^)
M'CK6I[W_ (2#QKXM\566L^*=)\7^+M'UOQKXKN].\6>*M,LIH+;6O%D3:Q<&
M_P!8MM,O'L;76M5F;5(M-EEM+'488YX[F/\ 8K]KGX,_#?X(_LE_'KPC\,_A
MS'X'\+7_ ,<OV?7\'^,Y?CCIGQ?U#XR^%]-TGQRL/Q2;PU9"\O/AY"UQJ,B3
M:=)$]E=)<PZA9Z=81V9$DT/P@_9N^.GAC_@GN]U\(/#G@CP/XC^&7C;3-=\6
M>&_CSHVFW_BGQ_X2L?'.HZ;\#=7N[V+[59ZMXO\ $NDV5[>_$34XK#5-%BUB
M+PEIFHJ]I#792\3^'7E%3/7P/4CE.8<09UD=/$8+*,KCB:&&P/#N49AA*=J>
M#]I#%4W#,E3^I5H8C#+E_>4WA94\/G5X4S2.)IX.GQ!AEBH8*GF-*^,JN,*R
MQ<**TE5E&46JJ;]JN63GK#6$I?G3\5_VP?B;\7I?CE/K6F^&=%NOV@/%'PVU
MGQQ<Z&FMJ\7AGX3Z5J=CX1^'NE+J6M:A%#X5MK^\MO$EP;A;G49==LVG2[2U
MN5M;;Q.V^+GQ@L_"4/@*S^+OQ4L_ MM$8;;P-:_$;QI:>"[5/M9O4:S\,6>N
MVVEV4Z76V]%U;P+=C48K:_$PEMU0_4_[;7P<^%OPDNO@U_PAO@]?A#\0O%W@
M/6M;^+GP$B^,&G_'7_A5>LVOB**T\-K/XUT^ZU&[%SXET-GOWM;Z\N;&.,H;
M8PS0RM)\-?C_ )_S[FOTG@C"\&9SPSEN:9#PY'!Y1C<15Q^&P6;X+#8F=+%8
M>"RNI5HRQ=+,)3I*GA53HSA7E24'*5!J-6I*K\MGN(SK!9KB\-B\P<J\*5+#
MRGA*TZ4)4I15:49QI.FE/VLYR?NQFK\LM$DNH\8^._'OQ%U>/Q!\1_'7C3XB
MZ[#91:;!J_C[Q7KOC#4X=,AEGN8=*BU'Q%>ZGJ$.DI=7$DR:?:W=M'EG8LTT
MLT\G+!>5Y+'Y<ECN+,,@ECU.23@') P,GJ5I5ZCZC^=?<T,-A\+AXX7"T*&&
MPU.'+3H8:A1P]*G!-R4*=.A2H4Z<$Y2M"G3IP3;Y8IMW^?J5JM6<JE:I.K.;
MYIU*DI3J3;48\TYS<I2?+"/O2;;45=Z)'MOB)L_LZ_"M< 8^+?Q@[GI_8'PW
M' P,$?4Y&!@=:XCP/\4/B=\,Y=2F^&GQ,^(WPXEUHZ<NNM\/O'OBSP0-=@TQ
MKMK&VUS_ (1;6=(_MB&R&H:@+ :B;E-/.H7[6T8^VW2R]IXA_P"3>/A9_P!E
M:^,'_IA^''_UJ\13J?HO\J\#*\)A<5ALPP^*PN&Q>'J9QBU4P^+P]#%X>HH/
MGC[3#XJCB:%3DG&-2'M*-11J1C.-IPA*/I8N=2E/#5J52I2J/+:#]I2G.$[J
M=.W+*$HRC>[ORRC>+<97BY)]#?\ BWQAJFE:CH6H^,?%M]HFK:]-XLU/2;WQ
M+K%WINH^+[RQFTO4/%FH6%S=R65[XAO]--G93:O<6[:D([)6-Y(\@,7L'Q._
M:4^)?Q*\2?#?Q/#J$OP_O_A-\+?#OPB\#'X?ZWXLT>XT3PQH%I?VDUQ;:O=Z
M]?ZW#J_B*+4KN'Q%>6^HPIJ%C(=/\B.%=]> T5V5<@R.>)P6-ED^6SQ& ^MK
M"MX'">R@L;2H4L6JF&CAH8;$^VI8:C2G]:HXA*%/ECRJ4^;E_M''*%:"Q=91
MKJDJWORO/V$I3I>]?FCR2J3DN5J[D[W22CN2>*O%<T7AFVE\5>*9+;P0\I\$
M6[^)-:^S^"4N-8.O7">"H8KZ&/P<UQJ\MQJ=U+X832'N]1D2\NC-+#F2Y'XY
M\<0^+G^(,/C;QC%X_DU-]<D\<IXHUQ?&$NN2^>)=7E\4"^'B";4;A;F6*ZNY
MM2EN[B%A!).84"5R^0>AS17=2P&!ASRA@<'%5,'C,OG&.$PWLW@\?B%BL905
M+ZO[)+$XE>WJR4%.I6<ZDW.<YRGC+$5YQG&=6I/VM6%6;E*4I2J0^&3FY.7N
MI)))I*.B26AW>A?%/XH^%IM#F\,_$_XE^&Y/#+:V?#<WAWXA>+] O/#H\3W<
M=[XG'A^[T;5[!M(;Q)/#$_B!K2-1KCQB35EO6"[*VM_$GXE^)XM:A\3_ !)^
M(/B>#Q-<Z'J'BA/$GCCQ3KQ\4ZAX;TN+1] OO$YU;5KQ/$5QH.G(]CH5QJ\=
MY>:78.EG#=-#&0_&T5SK(LB558A9'DWUB*26(_LG+O;KDMRR5;ZG[12BXJ:F
MII^TO4TJ-S>\LQS&2<'C\;RM.+I_6\3&GRM)<J@JRCRVM&RBDE:*TT.SO?B5
M\2]2^W&_^)/Q"OFU6^\-ZGK$M]XW\3WTNK:KX,MH;'P?JNHF\U2XBO-5\*6<
M$,/AK4[F&;4/#IMK(Z'<Z=';&&7=MOCA\;[2RUG2[?XU_&6#2_$VI:CK/BG2
MK7XL>/[;3?%.L:V##KVK>)+"/Q +3Q!JNMVCO!JFI:W#J=_>,[237$B'R!Y?
M2$@=2!]:RJ<.</UG%U,AR:3C*-2+_LO )JI"7-"HN7!*TX2CS1:::EJK22DI
M6.QT7>.-QD'R.'NXK$03@[7A)1JKFBTE=23325STGP=\:/C3\/-&;P]\/_C-
M\7O .AR7+7LVB>!/B;XU\&Z)-=O"L#W,FC>'=:T_3C,RJ 6%N(RH4O%)-F8^
M<RR27$\MS/)+/<3R22S37$K3S///(9KB5II09"]S,QFN'+^9/,6EG>9F!5M%
M=V'R[+\)B<9C,+@,'AL5F$(4\;7PV%P]&IBHTXJ$/;RI4:<JLXQ2BIU)5*B2
M^+5WRJXG$UE&-:O6K1C\,:M6=2%/K:G&<I1A%[M1C%-ZM.]R/ ! Z],GM]Y0
M,#MTY[GK[#W#]GW_ )*)>?\ 9+?CA_ZJ+QA7B!^]^"_^ABO;_P!GW_DHEY_V
M2WXX?^JB\85XO%*4<@SN*5DLI:5KMI*I2VZNR3];V>AWY;)RQM&4K7<97LDE
MM)*RBDMEVN9'[/GAGP?XU^.WP/\ !OQ NDM/ WBSXL?#CPWXNEEG@M8)?#VM
M^+-'TW4[&ZO+ADBLK+4[>YDTR^O?,CDL[6[GNH)([B&*1?UC^)OPRU3Q=\/?
MVO=,^-_[+'PX_9]\'_#/Q/X'T']G?QWX<^#>G?#+Q)=^()?B;IOAC3= \.^+
M+RPAU#XM0^(?!$LNLWU]<+KFG_:[I'2YED!,'X@)S&%^8AX3$PZAHY8O+E0X
M(;9)&[1N,X=&93D&NRUWXA?$#Q19:=IWBGQ_XY\4:=HKA]&L/$GC#Q'KUEI!
M^S_9E_LJUU74[NWTP10[8X/L,=MY!AA,91H4*_ \;>'^<\59WE>:8'B##Y=A
M:664'1E6KXFAF&#JT\32KSQ678;"8K#86MB:]-0P-:.,H8JDL&IRA3]I>_NY
M'Q!@LHP=;"XK+(8CVJDIPFW)5(R4[1GSJ4DE/]Y!PJ1:GO[JU_6W0O\ @GK^
MS3XC^+G[1'@30/&W[2^KZ)^S?=>'O#OB[2= \*^"=1\<^+?%/BOQ0UC;ZMX.
ML]!T'59;CP3X'\/K-9^)WU;PI=:IXAF@N+^TDT=&LQ/Y3=_L&?#:#X.?'OXH
MZ9XS^*NJ7/P*\7_&'P-#HM_H6G^$F^)\7@[Q/X3T30?&EC;:WX=LO$GA'PIX
M$N?%,R_M!Z;K&BZS?>'O$-HFC6E[I<MM+)8?G/IOQ \?Z-XAU'Q=H_CSQOI'
MBW5X[B#6/%>D^+O$.E^*-9@NY;:>XAU7Q#8:C;ZQJ$,TUI:2O#=7DL3-:0GR
MSLXEN/B1\1[V>2XO?B)\0+VXFM_$EG-+>>-O$]S)-8^,[V/4O&=C,\VJ.SV?
MC#4!]M\5VK9A\171>?5DNG9C7@U/#OQ-HU:E:CXF^TPWL,JH4I8J"YO;TIU/
MKO+>DH2AB7-.',Y584HTXS4ITH5)=D.)>%X480?#-)8F5:JYRA6KPO3GRNE=
M0J1@W!\U[**E*4G:TK+](_VF_P!@'P'\$OA7\:/%F@Z]\?T\4? ;Q#\-- UK
MQ3\6O /AKPA\(OCU<>/+>47VI_ 2^TJ\N]2O;71YX4O-4CN[_P 02V]W-::5
M-<"2=KV/\J@Q(<XRJR,D;8"K+&(H)1.AW,6C?SF120,M$^">B]+K7C7QKXFT
MS1]$\3>-/%_B31?#HMQX?T;Q!XHU[6]'\/\ V58X8/[#TK4]0N[#2#Y421O_
M &9;6OF0HL4F8P%KFB,8.%7) PB[ 0!A5PN-J+@[5SA"[G&68C],X'R7B;(<
MOQ>7<49]#B'&?7L75H8^G&+4:-6%%TJ5^2G*]*?/.5.[A2]HJ-&^'A!OYS.\
M9@,PQT:V P:P%#ZO1I^Q4ZD_WE-U'.=ZDYR]].*WVBI-*3D/_P _X44B]!T]
M>.F3]"?\\<=*6OM(QE&,8SES3249/17DE9NT4DKO6R279);^*[7=G=)Z?U_7
MW!1113$%%%%#V?\ 76(#2,E?;)_(BO;O%/\ R;]\!?\ LH_[1?\ Z3?L_P">
MQ[>WUQUKQ+N/H?YK7MOBG_DW[X#?]E&_:+_])OV?Z^<SW_><C_[&J\_^769=
M[_D]+]+GIX/W<'F,HZ/E3OOM3['D<FO:[-X;;P=)KFO2^$QJ4GB>7PG%J&J2
M^&5UJZ2/2T\0OH%O*='_ +2,0;3;/49;**[N=.N+BPO)[JV))]2\)_M#_'+P
M7XIT[QEIOQ@^)TNI6]WX7.HP7?Q1\?P:1XHT?P;=6\VA>$_$?V+Q;!-KGA.T
M@M8;9-&AOI;.PM)VM-)6""&=9?TK_P""8NH>/#X%^)7AOPN)_"GA_P 5_$3P
MI=>*?C;X"^)'PB\,?$SX1MX9T%9?MWQ \#_%G;IOCWX#7-K&\NMV>D_:+O6;
M9M0M--M++4D&H19G@;]BGX5^.="\"?$>W?PWX_\ AM%X&_;"C^-'CO1/B1#X
M9L=;^*/@/Q#\64^#EQ:>#9?$NE>(-#@UK2]%\->)+7POX7TFVT*?39OM>H1R
MZ-<R3ZI^.<2>)?#6"XBXNX8XGX5P.*PN#Q_)A\32PM#$XG,IUZ,\16P^)FJ%
M*>&J8J_L*-..)EB*U2GA)5)-4<#5P_V> X>S:I@,GQV!S6=+$UZ/M:^$J5ZE
M&EA>6M&$*\I1FI2A&,^:5_W24_=2<91?P9XY^./[1VG>,_&WBR+Q/\;/@O/\
M9?&>N?')O!OA7Q'\4/AYH6I77CC5]1\066N^'O#4&J:;)KVDS&Z%EHNL11ZG
M=7&GVUO90WL<UM(U<?J/COX__#ZPU#X/:MX^^.O@/1-)U;R]1^%.H^,OB7X3
MT>PU-=3L-26TO_ UWJ>GVL%TUVEGXA9KW28[P7]Z-;!MK=VO)OUS^.WP?^$'
MCS]ECP=\3/&_@^WTG6/!/["_[/EWX,^.EM\;])D&H_$^UT/PW!9_!)_@E!>W
MES<W$VF7MYJD_B&;3);LQOY&GW.U+:<>N?%KX8_##XR?';Q%X6^(&HZIJ?@+
MQM_P4G^)&B^*/#MIX[U+0_#M[X:TW]C/P9J4&LVL5EJEA!::B/$L$6EOK4,D
MDMV1)X8N&FTZXDL1\UE/BED$9990P?AWE4,+A*N9O'RJ992Q$HU<IKXJC@%@
MZN)P6)EC*^%RS#4U-XNHL1#$3C];E&K+V\O6Q7"N9*.+JRX@IU*E3$*A"C/'
MXBT*4Z2J3;4<0G'FJN2]V+4HIV;5XK\(Y_C;\;+KQ3)XYN_C1\8+KQO-HTGA
MQ_&4_P 4O'<WBIO#,LCR/X9_X2:77Y/$ \/2O-=SW&A_VF-(N;R\FN9+$D)$
MN=8?%7XHZ3JFGZYI'Q-^)&D:UI7AA? VF:QI?CWQ98:QI_@B)O*M_!5GJ]MJ
MR7]IX.M+9;<6OA6UN(= M[^RLKVWTZ**UCLA^N?PG_99_9"^+5S\+OB99_#+
MQEX?\&ZU\$OCMXK\1_"/_A9GQ-\:S2>*_AA\;=.^#WAK5-8U3P%X1\1?%[[-
MXCL=2D\67&G>#O#=F+6ZLH)(]+N_#-OK%R>0F_9'^!_Q9\1?%W2_@A\-]4\)
MS_#7]K+X*^&+WPI\2/B+X@\&>)]-_9GO?!LJ_$KQ5J&B?%[Q%X*\064.N^)C
M;^)=,OKNQU'Q98Z5<:?8Z/90L^H:;#])3\6?#B6)K4L1P7F.&P^6X;"1Q[ED
M614J>%ISQ=?+</A9JCA(>TIT9X=6E&.(I2YHN<Y7I\WF_P"IF?PH2E_;6&=)
M2FX1^O5VVU&,[P;J.=Y)V3:CS232;<6X_EWX>^+/Q5\%Z-J?AGP=\3_B9X4\
M,Z^;G_A(O#GA?XB>,O#7A_Q%'>*UOJ2:_HVA:SIVG:NNHV'E:??->6LLLUC"
MELT@MVEC?E]7\-^(O"TUG9>)?#^M^'+NZTS2-6L;7Q!HM[X?N]0T75[&"^TG
M6;*SU"ST\W&D:M93P7FFWVGPR:?=VLT<]G(;>1*_;72?V'/V<-0\ _M3:M)X
M/TV6'P;XQ_:YTSX9_$/2OV@[Z\U7P</A-JGB&'X7>%=7^&TMW&FN-J\.E6D,
M$ER_BS7M>LFN[^^O-/GFL:^!?VZ[BSN/BS\-I-/DCG@E_98_9>4W$,MO<H94
M^$>@K<6_VFU$0D>(V\2SJ;B1$*L5M"KLC^WP?X@Y#Q'Q,LEX<R+$8&=:.)CG
M^98_ 8;+O;U<)D'#V8X6*6!HTJ-:5.IF&(C)XB3Q,&Z5-)4N6*XLTX8QV5Y;
M_:&89A@\2O<CA83Q=2JHTYNO%QA"=1I-."E3E&$HSY]6G9OXS_+Z<\=^I[=A
M]/I11_\ K_/I17[9>]W;?K\[^?Y[GP7]?UV\_/<****/^!^:!'NW[,1Q^T!\
M*CC('B.\./4CPSX@(!X/!QR<8 R2#7S_ &?_ !Z6H!SMMXL9!'/EJ,?Q#')Y
M'/?'!KZ _9B./V@/A6?3Q%>\YQT\,>(20!C)) P!T[D&OGVQ4O:V42+\\L-N
MB'"EG=XP(XH&:6WA29VP%69KF2;Y5M[?()/S^'='_6/-)UZOL:-'#\-NK+^9
M2>?PWEHFZ<I0T[WMS)->O)1J9=@H0C^\5:NW*[O9U+PNFW%6;MLMM;K4M @8
M'8+UQCU[<],=\'CI@4I(ZC/3/U'?'X8/;G\:MWVFZEIH(U'3-1TQG-PMNM]I
MM]ICSW%O' T\22ZK'!'<NC-*/]#1_LQR;M'",M01VUS(MP\%K<WJVT=Q+>26
MUK?"UL;47*Q17E]-%9WZV.E%"88]4U*>PM+JY!C1\@X[L+F>%JX:EBZ6*P&*
MR_EA;&T\1[]::C:6&C&G/V7M.?\ =6C:7/%Q3N<4L-*-^:VB;=]-5=M-:;N[
MM9-)I[:N+.2./8]>HYR0><+[C'(/H2H.1G&,]J9Q\X^<-NP2Z-#($8J526W<
MNT<R<[W$C0S*T;PJ@5\N7_/.1@]QWP>>3SG/;%=M.;D]7=2C[2&EK0;VV5]6
MM[M=6<[LNB4M.O36UE?9]QU%%%:DA1110 4444:==O\ AP$)P"?0$_E2,/X/
M4]?^!C_&E;H?H?Y4/][\3_Z&M<N(2DE!J\94*W,M>E7+;;:]6_ZN7'5/UC^#
MN>V_$#CX-_L[9Z#2OBH/R^($I'?'4 ?B/H?$-Q+B-!YDYBFECMHRKW,X@V;E
M@AR&D;]XI&0BD*V&;!%>X_$  _!O]GG(R!I7Q4/X_P#"PI /IUY/85]N_LJ:
M9\&]1_8X\>^&?B[H7AFTL?C1^U#H/P0L?BOJ6E63ZS\)M7\0?!RY\0^"?$]O
MKLL'VRR\/6OCS0]#C\30)>0VD7AZ^URYF$<DL<U?"9QQ73X-X=Q&;2P,\QC'
MBK%T)82G)QJ.AB>-<]H8F4+6E4E.A07+",E4ER25&4:M^?Z7!Y4\ZS&6$=6.
M'Y<#A)1JV3]]TI66]E=M1O)-+=IWL?E@9(^2K$QLQ*3F.1+=X]Q _P!)8"!;
MGR(YKA[8RC9$L3><PG#(/)%'%'+)+#$&>6-FDF@CA\R&:9)?)D>9/M2I#''=
M.+>.2Y6)YB;8_9V:3^@?1/@-X<^%G[0WQ3^)'Q!\-? /PG:_!3X'?LE?#B'2
M_CMJ_@KP!\&M1^*?C;P/X$@^)5E=:]XDTD>%M7\06G@;PGXNO(GTV*]NFU+5
M='N8Y8OM[31L^#?[.<OPQ^,7[17PH\.?""Z\3:;XM^,7@BX^$W[1<?P8\(_M
M%?##2O _B+1+/QCX?\"?$+P]=3QZIX6^%'B3P]XG%[<_%#PC/X=M]$O[;4+.
MU\9/-HL6F3?FDOI%Y;.CCJE'(DJT,)EV,P]*6/A&,5B:RIXFC[6<'%_5:-7#
MUY-.O6K1JNG2PRE3G4G]%#PYQ+FHO%N4?:3@Y^QDVXQ3E%J%X2_><LEJH1A9
MN4TFDOY^C+&#)OEAB$<:NYGD$/E>8J/ +A9=KVYECDB;:5>6,SVZ-&3*"LF5
M\TP,=LA"E4.W?M>(3(IC+F1YGA>*8);K<Q+%(7GGA"X;]VOA/^SE=ZWKO_!/
M/7M'^'G@OQEX*^'/Q0_:/T?]HGQ[X#T72M6^&NEKX+^-OCN],OCW7[R.\%KX
M5?PS9Z=J'A6X\8/)<7EC#HMC97N)GKCIOAS<^+OV&]>L?#WP@T'X61^$_A%X
MR\=:KXR\?_ K0M6^%_QDL+CQU:ZIX>\<_#W]I/0)(?%'A'XL26VI2>']+^&F
MI:[>K<16TEM_8.C168:XZX?2 P=?'952I\/*GAJV883 X^<LPH)47C<RQ&6T
M9RC44ZSJ25*CCH4*5+VKHXBES0A13Q<\:_A]B:>'QU=8MIX7!UL73@J,I*M*
MA##3=-22:49.M.DZCFHJI2EJY/D7XH^?$'1'DCB,D<;Q*[KYDCREMB+$K-(5
MD1&DCF4/$ZF/!"RA@IE4!R'BS'(D,J^;&6ADF,20+,J,[IYLDC*?D94BC>4L
M0&1?VY_9]^(_[/GP/_8F^!OQ!^,?AK1=5L/&WQ%_:+TO7/"X^ W@3QSKOQ<T
M_3G&F6/A_5OB%XAO+77OABNC7EQ:/9:[H5S-)-,RV9L6$,;2^@?!?X:?L[:O
MXM_89U#6 ^C_ !!U;]B_XDZOI?P@B^#>F>)O WBF*/PK\7K@:[XJ\?S:I9(N
MN:%NF_LL/X6UF^U.;1=*ACU6W.J"Y'1F_CEB,BQ><T,?P5CZF$RW.\TR7"YG
M0JN-+'5<I3^M2LZ*C%T:DH*N^1T\-3E3G7ES.5-3#@BEB?JDL/G&#I5\5A:5
M:OE^)O">$J2?*J:?,YU/;*U2*E)2E)^SIJ*:;_ G+"40;&,Y7 MD DN_.*Q$
M1+:H2[1R+<6SP7"DK+'.&V1E0C1?:%^;&WY1N.^1(@$8D1R[I"L;Q2$<&!YY
M/2)C@']R/ ?[+_A;4?V)=/\ @9(GP+MOC=\0O@%J'[3VFZ5<^*O""?M/)\0;
M#Q#H7C7X>^#])\"R0IXSE\!ZO\&-(NAK,MM9VRVVLH\$=O"WG71Z;XI:'\-G
M_8@O]#T'PWX&\1>/-&_X)W_L_?%5O %E\(/!'@[Q!X6BUW1M'M-<_:&TSXQV
M-S;^,/%%SX6M;66W\1>%UO2=+FU32=5NQ=179A3B_P")@\JE['V&38RO[;.*
MF68B4JL*/U+*8X7 3CQ"HU,-!5(/%U\10]C.HL/%4U_M56=2G$V7AW74ZL:N
M8PI3CEJQ,:=.FITE7]MRN*FW*<OW=I+24=7^[NFU^"D<J.KDL(]C%7WK(HCD
M"PF.*<LBB*6228QQ@DJ6C<[P,D+O&R)G*Q^:&""8F(,Z%@T<;LFR? V[I(#+
M&N\@G"$M_2[^TG\*/V?XOBSXA_::LO OPZT72_V+/^$O\ >/_A+IWAK0-(T+
MXB^/-3\.Z#XA_9M-YX<L-/BL-0@UWQ7\1FTGQ#=W%JT4EQI!$&VTTB58N8\*
M?!3X/^$/V@OVLO&GCRS_ &<_"?@OXD?M0C]G3PQI/Q<U_P #?#>PMOAS:>%K
MJ[^(^J_![3_$U@;?4O'NE^(?&OA"+1[+PU#:&_FLK_33=VSA<I?2+RB&#E7K
M\-XVGB8Y=3QLL+7K3A&.95<QHX"624:L:7^U+#Y75H<1RQ-*$JG^VQPLDH<J
MI[U/#>JO:>SS'VE-8Z5!5?917LZ*P\JB;7NI+VD53O*[YM>?7E/YS&^4\*^"
M!@R*8B<@\A6)R"<A&'RN #Z@?=G_  3'Q_PW;^SIC_H<M2S]?^$2\0<'Z5\H
M?%CX;:U\'?B=X_\ A7XAAEAU?P!XMUSPG<E[>>V6Z31]1GM(-1MQ<1Q--8:I
M:1PZEIMU&K076G75M-!)-$ZRO]7_ /!,?_D^W]G3_L<M3_\ 43\0U^@\?X[#
MYGX6<19CA*T:^'QW#6(Q=.I&S25?!RK1IIQ;B[4ZD)7=Y6T<FTVOFN'\+/!\
M499AIR4Y4<UPL)3T3?+7A&W*DDK-:Z)WTV1_<I']]?\ @?\ .K%5X_OK_P #
M_G5BO\M*/\.'^%_^E,_LWK+U_1!5.;_6M_UQ'_M6KE4YO]:W_7$?^U:5;X8?
M]?:7_IR 2^"I_P!>JO\ Z;F?YU_CS_D??'W_ &/'C'_U)M2KDZZSQY_R/OC[
M_L>/&/\ ZDVI5R=?[ 9%_P B7)?^Q+D__JOPQ_"F8_[_ (W_ +#<9_ZDU0HH
MHKUCC"BBB@ HHHH **** "D;H?H?Y4M(W0_0_P J4OAE_A?Z#C\4?5?J+7MU
MW_R;!H?_ &<=XT_]5+\/#T')Z5XC7MUW_P FP:%_V<=XT/Y_"7X?#_V6O%S1
MM++FG9_VUEFM[?\ +S&=>_8]G!J\L0M/]TQ6ZO\ 9I]/(\*F@AD&R2&*5%F9
MU22-&0.VTNZJRE0[E5+, "Q523P"%^SV^T+Y$.T&(A?+7:#;Y\@A<8!@RWDD
M &+<VS;DU(_WF]G+?@ ,_CSQ_,4;@<C&?KTYX&<9QG/<\8.0:])TXU,1B5R0
MG.5:3DW&G*<E&Z7,Y0;DXIR47*3LI22:4I*7EP=26'PZ@ZCY?;JRG)63JMV7
MOQ232U2TM:Z6A"+2T#,XM;<.P4,X@C#,%5%7+; S;5CC5<D[5C0#&Q<(+2T7
M<5MH 6)9BL**2<1@DD*"6(BC#$\D1H"2$4"?<",X./? Y]!SC'/)./YT,<\#
M!XYP<]R/3'?/7WSZ)8:E/2-"A+>Z]EA7\3DY)WA9WE*3DM5*4I-MRE)R?)B6
MI2O5?):\E4;Y$TI*[59M)I*R3TLK6T2@2W@CV".&V@*))'&3;AHXXW9RT?EQ
MQLQA<RR;HT4AC+(=C,[Y^F_!'[87[27P[^&=C\(/!GQ)FT'X=Z5IFOZ1H^G-
MX3^'6H:YH>B>+GE?7M*\/^,K[PMJ_P 0-#6_:>YBN$T[6K"..VO;K='')LEB
M^:\-S@XY.,>XP/PZD\ ^Q/-&"?3/7..,Y) _7J,Y!(R#7EYCPYP]GE'#T,]R
M:EF,L'7IXG#*I2I2HQQ%&<I4:FT>5TW9J44VK/25T=6%S'&X*,JN%Q3HO$1E
M1KTW.:J^RDFI)W;]V25FDWI:^^E_PMJU]X)\2>&_&?AS[!I_B/PAK&CZ[X>U
M*;2].U:*QU'P]J5E?:5<RZ9>PZE;ZE-8W%K:R1PZ[;Z]9WBI/,MO%(9571\6
M>*?$'CKQ3XE\:>+=3?6?%'B[7M7\1^(=6DAM[9M2U?6;V6\U"[^S6D-O:6Z3
MS2?N[:VMX;>&%888HHXHD1>>()/.,8'N3SD[CCD<]./3C'#A_G\">.@SCZ5T
MT<KPE+%/'++\'1S!4'@HXK"Q2<L$ZOMG0G:$-95TJU25G.<[N=2I)77+*K65
M%T)UO:P=9U[<S;4Y)KKY/;[.PM%%%>G!-)WTU_1& 4C=#]#_ "I:1NA^A_E1
M/X)_X9?D./Q1_P 4?S1Z?\#_ /DL_P (/^RF>!O_ %(].KB_%S*OBCQ6SG"1
M^)->=RV-JA-2N59N>@7>%)XP'(/#5VGP/_Y+/\(/^RF>!O\ U(].KA/&XW^(
M?&D:$&0ZUXE.W(+;1J,SF38 6$:&-8WD8;%EN+=<_,[1^#.M/#9Y7Q,*-.N\
M-E-'$.G5_AM4GB)N4UKS*+4?=Y97<E[LFTCU8<KP6#4YSIP>8UHRJ4TG.$9:
M.45+2R3O+JEJM4>VW7[&_P"U!IL^AZ=>_LU?&"QG\5WL]CX?LI_ASKL+^(=0
MMM(U'6KBTTZ$V"B^NXM"T[5M3DCC#NNG6=[.P,4<AKSCQ9\$_B=X%\6:'\._
M&WPK\8^$_&VNRZ9#X<\'>(O"6H:9KNLW&M:FFFZ1'HFE7=I'/J$NH:U-'96:
MV*2--J4L<*DSR ']IO%G[57[/?B[]NN\UC2-3^&OA3PI:_#7QKI+_M)7?Q)^
M(MSH>O:SJ_[/ESX*T[2-5T6YU;5? _A2'2O$NLKITNL>%?"MIX@DDT=ML\TL
M]T+SA?AW\5_V??A?;?LL^$OBY\?_  [\9]>_92T_X]?&C4_'_@34M<\96K^(
M/%NEVEK\+?@[\,-7^*5GX?F^(>NVVOR7'C%8-=E\.Z)H6H:!X>ANGBBN+Q]/
M_ ,%XG\=82K@*.;<%8.O[++OK-+)L+E&8O'8F.,6?2PF(C*CA:M"-+#R>#AB
M:6(Q&'QM\91E"A1E&<(??OA?(JRHRH9Y4J4K>_B,5B:<*=&<H4I2IQC'EJN4
MY2J6G&E.C&-.TI2?O/\ +"T_9^^+UYXN\<?#]_AIJUIXX^'?@S6?'7C?P3XA
MEL?"7B?3O"'AS2K+6]7N6TG7]4T:]U62WT2]L=930K""^O\ 4M+426\ @VRG
MR$PVYVS;+>5Q(SB98(XV,L$TL*S*0G$A,0EC=7D,*%(?-+0MC]TO WC?X,?%
MG]JS]E3X[?#7QCX@U5M,^ 'QR\'?M):5\3[/PMX>^)=CI?P>^#/Q#\/P>/\
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M7_V5KXP_^F'X;UX<?ND\X Z\X!V @G'?C@=2,GH#7N/B'_DW?X5_]E:^,/\
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M[/O_ "42\_[);\</_51>,*^?XJ_Y$6=_]BJ7_IVD>EEG^^8?TG_[=_PYX?&
M8X\_W%_]!'3TI^!Z=.Q.1^73Z>G2HU8+$A. !&&)/0!4!))[ =3UZ="<5[CX
M*_9V^+_Q#TKP%K'A+PJNI6GQ1^)=_P#"/P#'+J^DZ??>)/'&DZ=8:MK%I::?
M?W=O>0:1H]AJ"SZKXDOH;70;!;:],^H*MN2_;CLQRW*Z%+$YGC,)@:$VZ5.M
MBIPIP<Z6'>(JQC)TYM2A0PU>JTE%>SI5)7DXJ,N2AAL5BJDJ>&HU,144?:N-
M-<TO9N;BI6<E>+E**5F[R:T3N>)8'^?;FEZ5T?C'PKK'@/Q=KW@?Q"-,.O\
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M^"8__)]O[.G_ &.6I_\ J)>(:^$Z^[/^"8__ "?;^SI_V.6I_P#J)^(:^/\
M$R"AX=\7QC!0C'(\:HQC&,8I?5ZME&,8QC%):)*,;+1::'J<*MOB+*&VVWF.
M#U;;;?MX;OK\S^Y2/[Z_\#_G5BJ\?WU_X'_.K%?Y5T?X</\ "_\ TIG]K=9>
MOZ(*IS?ZUO\ KB/_ &K5RJ<_^L;_ *Y*/PQ.?Y@?E3JJ\8^52F_NJ0%/X)_X
M)_\ INH?YU_CS_D??'W_ &/'C'_U)M2KDZZOQZ<>/?'OI_PG/C'/X>)=3/\
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MFU']L#5/B#X3T=/#,&JZ/X1LKC1[5?#!CMA%I5U9^"K>S2>:[UZSFF!;IO\
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MP\4\_L_? 4?]5&_:,_\ 2;]G_N>!]3Q7B!Z@ XX)/TX&![\#W[C/->W^*O\
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MS\#-<TG1Y/VAO$%Q)+X*T_4YYX+F+7+.6^UZ"'5=/DBFDT/2H8O[.C7U;6?
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MH_X=\_MO?]&L_&#_ ,)I/_DNOZP/^%K?$;_H:[S_ , ="_\ E-1_PM;XC?\
M0UWG_@#H7_RFH_XCKXF_]$_PG_X*SO\ ^?0?\0MX:_Z#,[_\*LM_^8#^3_\
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MWED'"3;NY/V.=)W;;OIG>[W:MU>B1FO"OAM?\QF>:6_YB<MZ)+5_4/0_D_\
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M-)_\ET?\.^?VWO\ HUGXP?\ A-)_\EU_6!_PM;XC?]#7>?\ @#H7_P IJ/\
MA:WQ&_Z&N\_\ ="_^4U'_$=?$W_HG^$__!6=_P#SZ#_B%O#7_09G?_A5EO\
M\P'\G_\ P[Y_;>_Z-9^,'_A-)_\ )='_  [Y_;>_Z-9^,'_A-)_\EU_6!_PM
M;XC?]#7>?^ .A?\ RFH_X6M\1O\ H:[S_P  ="_^4U'_ !'7Q-_Z)_A/_P %
M9W_\^@_XA;PU_P!!F=_^%66__,!_)_\ \.^?VWO^C6?C!_X32?\ R72C_@GU
M^V\",?LL_%\'(Z^&XP.H[F[PO^\< =20.:_J_P#^%K?$;_H:[S_P!T+_ .4U
M*/BM\1LC/BJ\(R 1]AT,@@\$$#1P2"#@X.<=.:/^(Z^)O_1/\)_^"LZ>FE]\
MZMMW$_"SAMII8S.UH_\ F*RWL^V7M]>Q_,OK?["_[9%S\#/AYX>@_9J^*\NM
MZ7\2OB=JVH:4OA]1>6>G:UHO@>#3+V:,W2CR+R;2[^.)HV8J]NWFB,20F7R0
M_P#!/O\ ;?)!'[+7QA/N/#D8P#G_ *?,Y^OOT/-?UJR_$SQU'H.F7L?B>]%[
M-JNJPSS_ &+0R98(K+2VCA8/HY4)&2738%D)"AW90166/BS\1F_YFJ\X_P"G
M#01G\M&_SZ=:Y\/XW>(U&%:$,@X2JPJXZ6+J0J4LX]^I[2,YTOW><4G[%V2E
M%-R<6TYNY<_"KAVK[.53&YPXT</'#J,<5@8\U-6Y;OZCS<UTN9J44[:1W/Y/
M?^'?/[</'_&+7QAQCD#PVG4YSC-[Q[=>.#WRO_#OS]MX_P#-K/Q?[_\ ,MQC
M@=!Q>]<=^?H.@_K"_P"%K?$;_H:[S_P!T+_Y34?\+6^(W_0UWG_@#H7_ ,IJ
MZUX\>)ZE6?\ J_PDX5Y^TJTG#/U3<[<JDN3B&E).,%&FFI-J$8QOI=PO"GA5
M2C/ZQGGNW7*\;A;--):_[-L[;*UKOT/Y/#_P3Z_;?//_  RU\7^#D@>'$YR%
MXS]L]0>2HSGGG .]H?[$?_!0?PR;EO#/[/\ ^T-X9:_C6*_D\.1ZGHGVV*W#
MM;QWR:?K%O%=B!Y)'M/M$4RQR/)YI6(K7]4O_"UOB-_T-=Y_X Z%_P#*:C_A
M:WQ&_P"AKO/_  !T+_Y35SU?&[Q'Q$'0Q'#/!N(PC4G+!XG#9MBL,YS=W-K%
MYSBJLI*24H)UI4Z;25.G!*QI0\,.&\-4=7#XW/*,G&M%<F,P.GM_C:;P;DF^
MFMO)G\GR_P#!/K]MX@D_LM?&)BS,[L_AR-G>20^9+)(PN@&E>5G:5@,-*789
M!!*_\.^?VWO^C6?C!_X32?\ R77]8'_"UOB-_P!#7>?^ .A?_*:C_A:WQ&_Z
M&N\_\ ="_P#E-6D?'/Q,A&,(\/<)1A",8Q2HYTDE&*C&*2SJR22LDE:R6B,U
MX6<-Q2B\=GDFEK*6*RV\NCE)_P!GV;;U;T3;;21_)_\ \.^?VWO^C6?C!_X3
M2?\ R71_P[Y_;>_Z-9^,'_A-)_\ )=?U@?\ "UOB-_T-=Y_X Z%_\IJ/^%K?
M$;_H:[S_ , ="_\ E-3_ .(Z^)O_ $3_  G_ ."L[_\ GT/_ (A;PU_T&9W_
M .%66_\ S ?R?_\ #OG]M[_HUGXP?^$TG_R71_P[Y_;>_P"C6?C!_P"$TG_R
M77]8'_"UOB-_T-=Y_P" .A?_ "FH_P"%K?$;_H:[S_P!T+_Y34?\1U\3>G#_
M  G_ ."LZ_\ GT'_ !"WAOIC,[_\*LM_^8$?R?G_ ()]?MO@$?\ #+/QAP1R
M%\-IGVZ7@]3SU&>*]:^"?["_[9&@>.9=1UO]FGXL:78'X>?%W2S=WGAY4B.H
M:U\,?$VD:3:Y^ULWFW^J7EK96XV[6FF0N50,Z_TRGXL?$9?^9LO1SVL="Z<]
MO['&>2#P?YY&KH?Q/\>W>H/#<>)KN6-M.U:4@V.A*1-%I6H7-O,KKI&X2VUQ
M:I+$02@0R*ZL'KAS+QO\1\7@\5A<1D?"T*6)P[P]5TJ6;QJ1I<T9N<'4S>I%
M2345K&:LU>.B;JEX7\.T:T*T,7G;G%I14L3@.23UT?)@$]F^J7J]#^2=/^"?
M7[< 1 ?V6?C'D(N<^'$!SCG(^W<<]NW-2?\ #OK]M[O^RS\8OQ\.(?R_TPU_
M6 /BO\1L#_BJ[S)&3_H.@X_31OY<8(QWH_X6M\1O^AKO/_ '0O\ Y35W_P#$
M=O%%I)Y'PK)62LZ6<6TY;)\N<K^5.^FO3LGX6<-_]!F=_P#A5ERWOLG@/-KK
MMTZ_R?\ _#OG]M[_ *-9^,'_ (32?_)='_#OG]M[_HUGXP?^$TG_ ,EU_6!_
MPM;XC?\ 0UWG_@#H7_RFH_X6M\1O^AKO/_ '0O\ Y34O^(Z^)W_1/\)_^"<Z
M_P#GV+_B%O#7_09G?_A5EO\ \P'\G_\ P[Y_;>_Z-9^,'_A-)_\ )='_  [Y
M_;>_Z-9^,'_A-)_\EU_6!_PM;XC?]#7>?^ .A?\ RFH_X6M\1O\ H:[S_P
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M?C!_X32?_)='_#OG]M[_ *-9^,'_ (3:?_)=?U@?\+6^(W_0UWG_ ( Z%_\
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M^?VWO^C6?C!_X32?_)=?U@?\+6^(W_0UWG_@#H7_ ,IJ/^%K?$;_ *&N\_\
M '0O_E-4_P#$=?$W_HG^$_\ P5G?_P ^@_XA;PU_T&9W_P"%66__ # ?R?\
M_#OG]M[_ *-9^,'_ (32?_)='_#OG]M[_HUGXP?^$TG_ ,EU_6!_PM;XC?\
M0UWG_@#H7_RFH_X6M\1O^AKO/_ '0O\ Y34?\1U\3?\ HG^$_P#P5G?_ ,^@
M_P"(6\-?]!F=_P#A5EO_ ,P'\G__  [Y_;>_Z-9^,'_A-)_\ET?\.^?VWO\
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MK/Q@_P#":3_Y+H_X=\_MO?\ 1K/Q@_\ ":3_ .2Z_K _X6M\1O\ H:[S_P
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MBU,WDBV&@YN'BU!C [?\2<E?*AD$(5-JD#<RL0A7+_X6M\1O^AJO/_ '0O\
MY3US8/QQ\2*5&<*.0<+2A/%XW$2<Z6<<RJXO'5\;72Y,XA'DC7KSC37+S*FD
MIRE-.;VJ^%_#TY<U3&YPVH0BG#$Y>HN,5:+][ MM\MN9WM?9+5'\G_\ P[Y_
M;>_Z-9^,'_A-)_\ )='_  [Y_;>_Z-9^,'_A-)_\EU_6!_PM;XC?]#7>?^ .
MA?\ RFH_X6M\1O\ H:[S_P  ="_^4U=7_$=?$W_HG^$__!6=_P#SZ,_^(6\-
M?]!F=_\ A5EO_P P'\G_ /P[Y_;>_P"C6?C!_P"$TG_R71_P[Y_;>_Z-9^,'
M_A-)_P#)=?U@?\+6^(W_ $-=Y_X Z%_\IJ/^%K?$;_H:[S_P!T+_ .4U'_$=
M?$W_ *)_A/\ \%9W_P#/H/\ B%O#7_09G?\ X59;_P#,!_)__P .^?VWO^C6
M?C!_X32?_)='_#OG]M[_ *-9^,'_ (32?_)=?U@?\+6^(W_0UWG_ ( Z%_\
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MYZ9J:OY>II*$4G=*Z_'_ #^[8_7^K?G?\%_7XA43?ZQ?JG_M2I:B;[Z_5/\
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M5Z4UJTTXS23BHNSNH[QE=7OL]=C*=/V;:NFM':T973;2:<6^UW?9-6OJS]+
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M;!ZG]/\ "C8/4_I_A3Z*++M^+_S"R[+[D,V#U/Z?X4;!ZG]/\*?119=OQ?\
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M)9>$M!DUOQ5<^++J^^#NCZU;>$](ACU0:CXM@^&6IZ\_A[0H-,U'7=2GGO\
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MXK^)?A[XEW?A:>\U;6[.!/IG]@W]GS2/V=OV=M$TB+X<>#OA5XS^*?B7Q/\
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M+Q!X8M/%6AK,3;6^O6GA[Q7XET>SO;F&Y2TMM<OI885O1:W$'M'_  J[6_\
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M+?\ ?WQ5_P#,=1_:F!_Y^R_\$XG_ .9P]A5_E7_@4?\ ,\XHKT?_ (5=K?\
MT'?"W_?WQ5_\QU'_  J[6_\ H.^%O^_OBK_YCJ/[4P/_ #]E_P""<3_\SA["
MK_*O_ H_YGG%%>C_ /"KM;_Z#OA;_O[XJ_\ F.H_X5=K?_0=\+?]_?%7_P Q
MU']IX'_G[+_P3B?_ )G#V%3^5?\ @4?\SS8_>7_@7\JW[[_D6?#W_85\2_\
MI+I%=6/A;K1()UWPKQ_TV\5#K_W)U:US\-]7DT31[1M9\.1M;ZAK,HG,^O-%
M(;L:3"4VMX;BG4QJ0S;X44LR['8!BN4\RP;JT9*<VH2]Z]"NM+S;Y>:DKNSV
M773H2Z%2^RZ+XH])>MOQ/(:*]'_X5=K1Y&N^%L?]=?%1_'CP>1@]0 6QTR>I
M/^%7:W_T'?"W_?WQ5_\ ,=6O]I8)+^+*W_7C$V6_7V'IML[E>PJ?RK_P*/\
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M2+V_WQ_Z'7I'_"KM;_Z#OA;_ +^^*O\ YCJ=_P *NUA?F;7?"P1#N9A/XGX
M);I)X1C7'4Y,B@<Y]D\SP=G%59-M)6]AB//O02Z]6D#H5+/W5M_-'_,Y&_\
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M"<3_ /,X>PJ_RK_P*/\ F><45Z/_ ,*NUO\ Z#OA;_O[XJ_^8ZC_ (5=K?\
MT'?"W_?WQ5_\QU']J8'_ )^R_P#!.)_^9P]A5_E7_@4?\SSBBO1_^%7:W_T'
M?"W_ ']\5?\ S'4?\*NUO_H.^%O^_OBK_P"8ZC^U,#_S]E_X)Q/_ ,SA["K_
M "K_ ,"C_F><45Z/_P *NUO_ *#OA;_O[XJ_^8ZC_A5VM_\ 0=\+?]_?%7_S
M'4?VI@O^?LO_  3B?_E _85?Y5_X%'_,\XKT+X4G'Q#\+'TNE/\ Y+752_\
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MO?L:Z-J'@^.\O?$]EK?[5'P%TF\\.6^D^)&\(WMUXALM1\?V]UHMO9>+X_\
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M#@J?F PV?EP<X.[CGGBDU1Z4I7Z>]'_Y "T?FTJR=F<G[9<C)=CGS%R^%9L
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M;HQ6ME&AI^[ET^U'LNO)_P .K,@;Q_M?^/T<?[7_ (_3J*=J'_/J7_@4?_D
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MQ_M?^/TZBBU#_GU+_P "C_\ ( -X_P!K_P ?HX_VO_'Z=11:A_SZE_X%'_Y
M!O'^U_X_1Q_M?^/TZBBU#_GU+_P*/_R #>/]K_Q^CC_:_P#'Z=12M0_Y]O\
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MU_X_3J*+4/\ GU+_ ,"C_P#( -X_VO\ Q^CC_:_\?IU%%J'_ #ZE_P"!1_\
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M_P ^I?\ @4?_ ) !O'^U_P"/T<?[7_C].HHM0_Y]2_\  H__ " #>/\ :_\
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MA[H_[.[_  K7Q'H7BVWM)Q!K5UXL'P[OX](;3;2YL;)-8BFOU:9;@54\3?\
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M,ZIX\\2>+?!VBW%OK6KZ7X5T?0]-TV+2M$73]!\/Z)9Z?'I.C:#9V5EI4U[
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M4E9Q?-;1RD[;LWS_ #YK?\,?\A_3?]]O_1)K _P_7_Z_6M_PQ_R']-_WV_\
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MTZ#7;B&WM,2T_P""HGA>UUSQ/\4+<?%;X@_"SQA\%?\ @FGX]^%7P=TWX7^
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MBIPUNTK)W6SUES6LUW7H>F_\+1U7_H#Z+_WZO_\ Y+H_X6CJO_0'T7_OU?\
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M ?1?^_5__P#)=>8[6_V?R'_Q-&UO]G\A_P#$T?V?@?\ GW4_'_,/K&,[P_\
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M_P ^JGX_YC^L8S^:-O\ #"S_  /3O^%HZK_T!]%_[]7_ /\ )='_  M'5?\
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MG)Z#T'4;?K^5)8# /:G-V[._Y,I8C%])0=NT8==>W8]/_P"%HZK_ - ?1?\
MOU?_ /R71_PM'5?^@/HO_?J__P#DNO,=K?[/Y#_XFC:W^S^0_P#B:?\ 9V"_
MY]5/N8?6,9WA_P" T_\ Y$]._P"%HZK_ - ?1?\ OU?_ /R71_PM'5?^@/HO
M_?J__P#DNO,=K?[/Y#_XFC:W^S^0_P#B:/[.P/\ SZJ?C_F'UC&=X_\ @,/_
M )$]./Q3U4#']C:+R&&?)U \=_\ E\ SVSCC//!K7T7XDZC<WQ$FDZ2BM8:B
M0(UU'>/LVCZM,XQ]J*KYNV-6Z%PH^\53'C>", ]B1E> <E1U&.I'MT[UO^&L
M#4I<9;9I^LR,$(./^)%JZA!DCYP23@<[<'^(@16R[!+#5GRU$W9P3YDVEI*S
M332NE>W703Q%64U&2<IR5[1CK)]TET6B>G<ZX?%+52 ?['T4''_/*_\ _DO_
M #QWS1_PM'5?^@/HO_?J_P#_ )+KS(Q2*"779LB\QS(AC 427$(5#(J"9S):
M7000>;O%K<%21#(5B$B,&V20R$*C*$E@993)M6-()0_V>9Y99(((/+F9+F>Y
M@CMGFW,4K^S\%_SZJ;>O:_5^?IMOLEBL2_=]I3;6EN6'1O3X;Z>IZE_PM'5?
M^@/HO_?J_P#_ )+H_P"%HZK_ - ?1?\ OU?_ /R77F,J^4-TCP)&'1#,\D,<
M $L4\L<GGRE(GCE6!E1XV?=)+!$!OF12T#.X%HE*[=ZR/#&T?F%EC\X2.A@$
MC*%C,PC60R1M&SQL76HY;@I?#2J/O9_+K)#>)Q,6DZD(W[QC9_\ DK_(]0_X
M6CJO_0'T7_OU?_\ R71_PM'5?^@/HO\ WZO_ /Y+KR]2&57#1^6P0K)NB*8:
M)YGW8;<K01H#/&RB5-Z@(Q63RVHWF<H59?F <&-T+([QR('CW*)898Y(KB(D
M202H4D4$KD>68-:NC5MWU_--H(XG$RORS@^_NQ_6)ZE_PM'5?^@/HO\ WZO_
M /Y+H_X6CJO_ $!]%_[]7_\ \EUYCL;_ &?R'^'O_G%&UO\ 9_(?_$TO[/P/
M_/NI^/\ F5]8Q?\ -#_P&'_R)Z=_PM'5?^@/HO\ WZO_ /Y+H_X6CJO_ $!]
M%_[]7_\ \EUYCM;_ &?R'_Q-&UO]G\A_\31_9^!_Y]U/Q_S%]8QG>'_@-/\
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MM;_9_(?_ !-#R[ IV=.HG\_\RO;XO^:#_P"W8?Y'IW_"T=5_Z ^B_P#?J_\
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M^S^0_P#B:-K?[/Y#_P")H_L[ _\ /NI^/^8_K&+[Q_\  8?HCT[_ (6CJO\
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MCFP3X,_%CX4?M+:QJ/@J#X?Z;9W&G:_\*'^!<&D^(O$WQ&U.YUG4=3NK6_\
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M=D$U&*G;VB;NULU9::V=T[OX;M6N^ABO-IZNWI?3YI:,****H84444 %%%%
M!1110!O>%PS>(=+5%5I?.?RE<R+%+++!-:QQ7/V>WNM0:T,EPLLZ:2D.HJ(5
MNFNH-+M-4$GX$ZM^UK^WM\+-1U_X9_$/0_&@^-WC?PI^SQ&8_&?A[]ES3_"7
MPO\ B3\>OVH;3]GV\U#X#^(OA.?&UU;_  5?P;JFOWOPP'[9VC^)_'5_XO\
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MR#\.M2\+7WBN/_A-?!WV.)?^$LO?"GC73K#Q#X0M;W4UNU\-V5XUY-JWA?\
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M_,M>(O\ P1ZI_P#(M?2A)/S9#;MO,H>60D]Y)/,4NYZNQ W'G&32[6_Z9?\
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M_P (UXB_\$>I]N1@_9<C\*^E<-_TR_[]M_\ ':,-_P!,O^_;?_':T_MC%?\
M/K#_ /@-3_Y,?L(_S2_ ^:O^$;\1C'_%->(LC./^)'JGRAOO #[+@;B 3C@G
MGJ30?#OB3_H6_$7MG0]4Z?\ @+7TKAO^F7_?MO\ X[1AO^F7_?MO_CM']L8K
M_GUA_P#P&I_\F'L(_P TOP/FH>&_$@_YEKQ#WZ:'JF>A!R?LO.02,Y.02*/^
M$<\2?]"UXB_\$>J?_(M?2N&_Z9?]^V_^.T8;_IE_W[;_ ..T?VQBO^?6'_\
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M]"UXB_\ !'JG_P BT?\ ".>)/^A:\1?^"/5/_D6OI7#?],O^_;?_ !VC#?\
M3+_OVW_QVC^V,5_SZP__ (#4_P#DP]A'^:7X'S5_PCGB3_H6O$7_ ((]4_\
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M5FP,G)HPW_3+_OVW_P =J_[7Q*;M3P_7I5[^<Q^PC_-+\/\ (^:O^$<\2?\
M0M>(O_!'JG_R+1_PCGB3_H6O$7_@CU3_ .1:^E<-_P!,O^_;?_':,-_TR_[]
MM_\ ':?]L8K_ )]8?_P&I_\ )B]A'^:7X'S5_P (YXD_Z%KQ%_X(]4_^1:/^
M$<\2?]"UXB_\$>J?_(M?2N&_Z9?]^V_^.T8;_IE_W[;_ ..T?VQBO^?6'_\
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MPW_3+_OVW_QVC^V,5_SZP_\ X#4_^3#V$?YI?@?-7_".>)/^A:\1?^"/5/\
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MNJ^&O$6XDDD:'JHY)W%B1:DDLP4DDC)4,<D !1X:\3#_ )EOQ"!_"HT/5!@
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M  STRT^*/[0]S^RW\:5T3]JKXT^*?V:=%^&WQ-U+Q/\ M1Z-\)YOA':?LQ^
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M_LF?&_X'Z=K/@3X<?$/Q9>/\9?B/\2-7^#_ASX,>.OBM\2/$WB2;Q+X(\)>
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MT[]E37?#/@C]N?\ ;@_:7\(?!SQ)\6?BO\$-(L_AE^U?^RY\*O@;IFC6FL^
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M_G_"3_0W4Z+_ +B?R-/KBA\0?"@X%SJIPJ@DZ-(">."0+M\,><C<1C&":/\
MA8?A3_GYU/\ \%$G_P DUT5,-B)3YE2J.+4;/E:N[:Z/7KV0>WI?SK[FG]UC
MM:*XK_A8?A3_ )^=3_\ !1)_\DT?\+#\*?\ /SJ?_@HD_P#DFH^J8G_GS/[A
M>WI?SK[I?Y':T5Q7_"P_"G_/SJ?_ (*)/_DFC_A8?A3_ )^=3_\ !1)_\DT?
M5,3_ ,^9_<'MZ7\Z^Z7^1VM%<5_PL/PI_P _.I_^"B3_ .2:/^%A^%/^?G4_
M_!1)_P#)-'U3$_\ /F?W![>E_.ONE_D=K17%?\+#\*?\_.I_^"B3_P"2:/\
MA8?A3_GYU/\ \%$G_P DT?5,3_SYG]P>WI?SK[I?Y':T5Q7_  L/PI_S\ZG_
M ."B3_Y)H_X6'X4_Y^=3_P#!1)_\DT?5,3_SYG]P_;TOYU]TO\CO;/\ X_+/
M_KZ@_P#1@J!OO'ZR?^CYJYC3/'GA>YU"QBCN=3,CWME&BG2F4,TUW#!]YKH
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M_=[![>E_.ONE_D=K17%?\+#\*?\ /SJ?_@HD_P#DFC_A8?A3_GYU/_P42?\
MR33^J8G_ )\S^X/;TOYU]TO\CM:*XK_A8?A3_GYU/_P42?\ R31_PL/PI_S\
MZG_X*)/_ ))H^J8G_GS/[@]O2_G7W2_R.UJW8?\ 'X/^O+5/_3=<5P'_  L+
MPIMS]IU3)X _L>0^G_3SD<D9P.!G-:FD>./#%U>[8;G4V?[#J1VMI6P ?V7J
M$LA.;PME$@R%VC?O7E!\QBIAL1&G.;I348Z2?+>U[=GY@Z])II36SZ2_R-\
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M['PE\2O">N_#S5&U[PY;:MX8_M#QAX=\2Q>$[K6H-6L]"U!=.RGA_A+X!?\
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M_C5BBCVL_P"6'_D__P D'+'LOZ^97V#_ )Y_^A_XT;!_SS_]#_QJQ11[6?\
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M=EKTW:W5F[Z<[NKI)76FVCW6_FCZ+V#_ )Y_^A_XT%%'5 /J6_\ BJ^=+?\
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M!XF?\L/7W_\ ,<;._NI6(-@_YY_^A_XT;!_SS_\ 0_\ &K%%:>UGVA_Y/_\
M)#Y8]E_7S*^P?\\__0_\:-@_YY_^A_XU8HH]K/\ EA_Y/_\ )#Y8]D0!%S@K
M@'.2=W3&#_%G(SP0"1R>,5OWD8/AOPZ#G!U3Q,I4LV&!MM&)7&1@LR)CN-I
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MG^/!_2IE4FXRT@M-?=D]-?YGY=+@XQL]%L_R-C5 3HWAHL,@0:HBKN; 5+X
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M\/E1K^@E@S*FKZ4659'BW*U[ DBETPZ[HW= \317$3.L]K<6MU%#<P_D7/\
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MG^RMXG\,>%?BI\3M+^"_[2GB3XD>-/AQ\#OC7+^SM\8O&FA:S\"?B'\+;$^
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M\1CX/_8W^)GP'^'6O:9^S;_9'['6A^*_V,_BWIGC3XW?">\^+-Y\2OC/\6_
M7Q"_:=TS]F'XE_"WQ_H'C/X=?#OQ%KGB/XHQ?'KXG^(?@[IWQ)\7^!_#^O\
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MX$^!N@VW@(^+M/C_ &F?'OB[QMK>L^);'PGIW@7P!INE37NN?JL<L[2C]V[
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M4!8LP154L0JU)75&'LXQ@VI<JMS*]I>:OT_R"_-[W?7ON%%%%4 4B]O]\?\
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M6,:L"R.L>U6A=[=@8',1]^NC_I-P1G'VF?D9R?WLG3/3@\ ^N1C)J+ _O/\
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M_A_Q-:]^H/0]O?TH_M3'_P U#[O_ +?7TZA]7PO252_2\I6OTOIM??R/ ?\
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M?72__!_H7_RUKWZBC^U,?_-0_K_M\/J^$_FJ_?+_ .1/ ?\ A7'BS_GUTO\
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M+_[</J^$_FJ_?+_Y$\!_X5QXL_Y]=+_\'^A?_+6C_A7'BS_GUTO_ ,'^A?\
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MN/%G_/KI?_@_T+_Y:U[]10LRS&+]V5*-]^6Z_*:_,/J^$_FJ_?+_ .1/ ?\
MA7'BS_GUTO\ \'^A?_+6C_A7'BS_ )]=+_\ !_H7_P M:]^HH>99@]Y47ZZ_
M^W_J'U?"?S5?OE_\B> _\*X\6?\ /KI?_@_T+_Y:T?\ "N/%G_/KI?\ X/\
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MS^ZX_J^$TNZM^K3FU?K9VVO>UCP+_A77B[_GVTS_ ,*#0O\ Y:T?\*Z\7?\
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M-KE4&L%A:/+[3V>*Y91YU+EJ.+@[>\FOBC>R4MGHKVLCP;_A7'BW_GUTL_\
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M:=_R$;+_ *[_ /MO=537H/H/Y4">Z]?T8M%%% PHHHH **** "BBB@ HHHH
M*C?[A_X'_)ZDICJ2I"AF8@A0,L2Q! PN1DCJ!D9(P#S5PDDIWW:T]=?\P+T_
M_'IIOUU3_P!+$JI7S-^V'^UM\.OV-/@]I7Q5^(.A^,O&*:CXBET#PYX%^'MM
MX?N/''B669+S7->U+3++Q7XB\+Z3!X=\ >#]+U?QWX]U_4]9L['1= TJ:&+[
M9J=YIFGWGTLA+#=\VQA\K&,QEMI*/O1Y6DAN%=66YLY(8GT^8-9-+?- U_<8
M0TNNO-/;57O>S?31]?ST0/HHHK0 HHHH **** &GJ..F3GTQ^([X['\.:\7^
M._QE?X'> Y?'I^&7Q"^)UA::UIVE:Q8_#^3P!;2^%M-O]QD\;>*[WQYXZ\%6
M6F>!-(*[?$&LZ>^LZGHV^*YNM"_LDRZG;^TD ]?_ -6>,_D2/QJ*65;='N'L
MKO4XX(6G_LVR6*6?4#!!-=/96=K.1:7&H7HA%GB\0Q7$<T=I.\MJ[VK<^+I5
M:N$K1P]><,2^?V-_@A>G447>^B51TVXZ*:YH.454<X"MUVZ^FB?X-GYJ76D_
M&WQ1\8-/_:X7P$--\6>"H]'^'W@3X(W'Q5\,WDFI?L^:YI&N7_Q,O+OQ3I4F
MI?#VT^(7CSQ[K'AWQ=%:_P!IWWAJT\._"+P9H=GXEM[FZO;F+ZX^ ?QQG^.V
MB>)M</PH^(?PRM/#?B:3PQ;7WC>_^&6K:+XWN+2R@GU74OAWKOPU^(7CVS\3
M>'M#OIFT/5M?NUT.QDUV*?3="?7&T[6I-)^$?A;\,/VLS^R%HOAS5OAUX(\.
MSZG\'-3\,>)_@;:^,VL?C5_;?Q$\*W.I>*M3\$?$?PYK,7PG^'^NZ#XC\33Z
M5\(_A&--U&+7M"TG2M9OOBO\-]9O6\.Z)^A_P*DU]_@O\(T\5^%X?!/BV'X9
M^!;;Q7X0M;/1=/MO#?B*U\+Z7;ZQHD&G>'I6T;3H=/U-+];33M($NCP6L\-Y
MISVAU*ZL(_XR^BQ1^EC#BKQ:G](S%9,\@K\03S'@"A@,FHX3%3P=7&XO+U4E
MBJ.8XF&68:. P&!7^KOL\;*"K?6GF<O:NC'Z#.89#&E@%E-"I"M0PJH8B=6N
M[)IQ=J<?^7JNW=V@[>[R)1YI>L'KUSCWS[X_SZ\9K?\ #'_(?TW_ 'V_]$FL
M#TXQV_+_ "*W_#'_ "']-_WV_P#1)K^TJW^[8G7_ )=_YGSWVH^K_0]YHHHK
MYH]!;+T7Y(*@8!I5W)]S.UBN?O -A6([,BL1G!95)Y1<3U#(Q5@2 % 9@>IR
M%/&!VY/I_6I>\?\ %^C&?SK?##_@I!\0Y6U+5_$OPU\5_&G7OVCO^"CG[7'[
M)7[*/PL^'9^%_P /X_!?A3]F32?$&@WLOCGQCXLU2T:>WU_4/@Y\3?'&I^*-
M6N-8O["7Q'I^EV&A6MM_8R"QHW_!9SX3^-KWX!6'PM^!OQ2\;W7QV'[.&FWE
MA/XP^#W@G6OA_KO[3WQ@^(GP-\$^'V\.>(/%NH:U\1H?"'B[X4>/9OBCJ?PZ
MM]<T;P-X>\,RZQ?:[-:M='3Z6J_\$GM2UGQ=X&TG6OBT(O@O\,_^"C'[2'[;
M/AC0_!6O_%/X9?%&R\*?M&?"[QQINO\ PZTSXB?#[Q%X=UGPWXE\/_&OQ[XA
M\9:7XH\+:UH4-UX.U"?0YC:ZM->7EYRNM_\ !(C7?!O[3/@SXN?LO?$;P9\"
M?!WPZ\%_LI?#/X27]A/\3)OB1\#OAK\ ?&OC+Q!\3_!^EZ!_:][X$^/D_P"T
M'H'CCQ9X=UOQ=\;]6;6O#=KXSU]+F+Q7/8V6H:C]#"#=./Q*4HNTDY.UFFGO
M;6Z5M+VLY:6.+F49322UEK?R5E^"74]/^-?_  61^ ?PRMM3USX:?#OXI_M$
M>"M*_9D^./[6GB'QMX&DT3P1ING?"+]GKX]0?L\_&EO[(^,1\$^*]<\3>!_B
M01;V^AZ7IL5GXO@M[C4M(UKR8Y;N:#4O^"BM]X]^*_P6^'.C:/\ $_\ 9[\9
MV7_!1#X+_LR?%_P3XE\'?"#XJIX_\,?&?]EWX@_'SX?0GQ7:_$&*'X=:%XA\
M._V'J6H>,_"I\4>/_!?B;P]<^!K_ ,':Q;Z@WB*;[>^.7[&G[-O[1_BOQMXR
M^,7P^OO%OB#XA?LY^._V2?%NH?\ "<^.] _M?]GSXC^*O#WC'Q5X&^Q>%->T
M&QL;G4=<\)^'+L^*]/MK/Q59?V=)IVF:K:Z)<G3ES&_8>_9@?XBV7Q9;X;7A
M\?V?QI^%O[1,.L-X^^(\EO;_ !B^"OPEO/@9\-?%,>DS>+WTV2VT+X6:E?>%
MI_#$L4WA#599O^$FU30K[Q8L&N0W[.HXO5\\HZ6O%*6J5UJE;2[5[M/=.P_:
M;>ZM_,^+O@Q_P62^#GQ2^'&N_%GQ+\'OBC\'/!L?[!_C7_@HAX%UKQKJGP\\
M0V_CCX+_  OUG7_#?CJQBT[P;K6MW7AWQCX?\5V^FVFF>%-?B1_%L6N:9%8Z
MC?>1>6%MXAX(_P""G?C/]C_X$^#O"/[6/PU^.GQN^.7@G]F3]G_]K[]I[QMH
M6M?#NW'P\\.?ME_'_P 4_#[PSX/T+2M?USP]K.J3?"7Q'?V'@VU\-6^C?;T\
M 6^F7[WE_J-A>P7OU;\2/^"2G[*7BSX7_##X2>!-%U?X5^$_AMX&^'?P+-O9
M^*/B'XV/B+]E+PC^T!X/_:,\6?LUW4/BOXA20)HWQ(\:>"=*T_6OB1KH\4^.
MM+T"XU'1]*N(M*OCIUM]*?&?]AW]EW]H;Q%\3O%/Q=^&\_B;6?C+\+OAC\%_
MB5>V?CCXA^&X]<^&OPA^+=W\;? 'A^QT_P .>*])L] ;0OB5=W'B3[=H\-I>
MZQ;71\/>()M6TJ&2&X%2Q<5[RI_94IIR:25[\JT3>V]N6UDWJE'NW>FG3>^Z
M2O\ *_H?)GA7_@I1XB^(G[4_[,W[/^@?"D?#J?QA^T3^W!^S=^TUX:^)MS;>
M)_B!X$\7_LJ? #PU\:?#%S\,O%WPV\3)X#O-&\3Z7XK\.WE]=ZQI?B=;SP[=
MOI%K9Z-X@MS+-[W^R!\<_B7\2?BO^WS\&/BCJEIKFL_LP?M;7G@?P/X@LM$T
M/PZE[\'/B;\*?!?QJ^&&@ZE9:+;QVUYKG@#1/%]WX,NM9:==0\41Z2=>U":^
MNFN&6WXE_P""=O[*7BKQW)\4I_"?Q&\+?$F3XT?$O]H1?''PW_:"_:!^&OBB
MP^+GQK^'_@?X6?%CQ5H^M^ OB;X7OM(A\4> / 6C^&1X8M)'\'P6AN[@>'_M
M>HZC+=[O[*O[,>J_ 'Q1^UEX^\6^*=.\9>-?VHOVD=5^+]U?::GB!H/#_P /
M_#?@7PI\)?@WX+O]2\47^JZ_X@\5:'\./!6B#QGXFN+U+;5_$UQK%]:Q/%>*
MP<8R4E?6R5W>]WRI-]U%-*,;N]K<_-)<PGNG=]=/+IK?7[M]C["]/H,?3M11
MSWY]\ ?R^O\ *BM0"BBB@ JX?^0:G_82F_\ 2.WJG5P_\@U/^PE-_P"D=O6=
M7X8_]?:7YS H)T7_ '$_D:?3$Z+_ +B?R-/KHJ_&_P###_TD HHHK, HHHH
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M_P#MO=537H/H/Y5<T[_D(V7_ %W_ /;>ZJFO0?0?RH$]UZ_HQ:***!A1110
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M:-KO9C^LQMNON?Y'NNYO0?\ ?4?_ ,=HW-Z#_OJ/_P".UX%_PL3QG_T&;?\
M\$GAW_Y44?\ "Q/&?_09M_\ P2>'?_E15_V+F?\ SYA_X'+_ .0%]9CW_P#)
M6>^[F]!_WU'_ /':-S>@_P"^H_\ X[7@7_"Q/&?_ $&;?_P2>'?_ )44?\+$
M\9_]!FW_ /!)X=_^5%']BYG_ ,^8?^!R_P#D ^LQ[_\ DK/?=S>@_P"^H_\
MX[1N;T'_ 'U'_P#':\"_X6)XS_Z#-O\ ^"3P[_\ *BC_ (6)XS_Z#-O_ ."3
MP[_\J*/[%S/_ )\P_P# Y?\ R ?68]__ "5GONYO0?\ ?4?_ ,=HW-Z#_OJ/
M_P".UX%_PL3QG_T&;?\ \$GAW_Y44?\ "Q/&?_09M_\ P2>'?_E11_8N9_\
M/F'_ ('+_P"0#ZS'O_Y*SWW<WH/^^H__ ([1N;T'_?4?_P =KP+_ (6)XS_Z
M#-O_ ."3P[_\J*/^%B>,_P#H,V__ ()/#O\ \J*/[%S/_GS#_P #E_\ (!]9
MCW_\E9[[N;T'_?4?_P =I58Y7. -Z$G*<8;KQ(3CUP,XKP'_ (6)XS_Z#-O_
M ."3P[_\J*4?$/QF67_B<P$$@$#1/#F>2!WTCTS[^GH4\ES-*_L(/_M^7_R
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MY51<EF. HR20*C_X6+XR"L7UF!0&C7/]A^'VP7GBC&Y(])!8$OM(9T&"<NA
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M>/I1N;T'_?4?_P =KP$?$3QF0/\ B<V_0==$\.9Z>VD8_*E_X6)XS_Z#-O\
M^"3P[_\ *BMUDV9Z?[.E?6[J2?;=>S7]=1?68]_P;_4]]W-Z#_OJ/_X[1N;T
M'_?4?_QVO O^%B>,_P#H,V__ ()/#O\ \J*/^%B>,_\ H,V__@D\._\ RHI_
MV+F?_/F'_@<O_D ^LQ[_ /DK/?=S>@_[ZC_^.T;F]!_WU'_\=KP+_A8GC/\
MZ#-O_P""3P[_ /*BC_A8GC/_ *#-O_X)/#O_ ,J*/[%S/_GS#_P.7_R ?68]
M_P#R5GONYO0?]]1__':-S>@_[ZC_ /CM>!?\+$\9_P#09M__  2>'?\ Y44?
M\+$\9_\ 09M__!)X=_\ E11_8N9_\^8?^!R_^0#ZS'O_ .2L]]W-Z#_OJ/\
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MS<DG_#Z\K7;0?UF/])_D?0&YO0?]]1__ !VC<WH/^^H__CM>!?\ "Q/&>?\
MD,V_0'_D">'>_P#W".H[T?\ "Q/&?_09M_\ P2>'?_E13639I_T#Q7_;\O\
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M+_A8GC/_ *#-O_X)/#O_ ,J*/^%B>,_^@S;_ /@D\.__ "HK3^Q<S_Y\P_\
M Y?_ " OK,>__DK/?=S>@_[ZC_\ CM&YO0?]]1__ !VO O\ A8GC/_H,V_\
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M3\'?AK>?"?P[\2-;_:0_:/U/]H_Q=\+;'X#:;?WUDVJSVGQ(\,Z9IVFQ^$/
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M[>)MS<CO%*%](NUEI&VCU;>KZ)<\KN3:22;6BU3:T;WZO7;7\WUMO_R*T?\
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M>^I'M:_,FZ3E&]Y*UN97UV?5:=]3\\/'7Q3_ &Y?!D'[9?B7Q!XM^+W@34/
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MV>IV%%%%64%%%% !1110 4444 %(O;_?'_H=+37) R&9>O*!2V<9&T,KJ6+
M!05;YB,*6Q45)*,7I>^G9[/K\P9NW_\ R!/#7_7+6/\ TXK6)7C?[0/[2WPN
M_9_TKP-I_P 0'\67&L7WA+XJ?$2^TGP#X'\7>.]5\.?#3X9:OI<7Q%^*?B6Q
M\/:3K#Z+\.? 5QXD\+67B'7M8N+:U%YJ:6\%K>38LW\X\;_MA_!/P)=_&BQU
M"Z\;7^J_ GX%7W[17C'3]/\  _B&VL-9^'&GG4K9?^$#\3^)(O#_ (5\6ZE>
M76GPV<KV&OPVMBVI#4-9O-!ELKNUL,*%6"@U?:<]$U_,_/Y$Q55J\*,I16EU
M**NXZ-:KI==>I]5T5\Z?#+]I#P[\4/$&C>"].\$^/]%\=&S\77?Q \)ZW_P@
M%W=?!Q/"WCG5_AA:6_Q!U7PAXY\3^&]2;QA\1O#VM^&OA[-X+UK7O^$XDT[6
M[FUU>+1_"WB:_P!+^B>,I@YX/OV^@_S^0WA-3O9-)<SOI]E-_H--W::::M=.
MSLWJUIVV'44458PHHHH **:<Y.#Z]#[<#Z@\^@Y]:XGXA_$3P9\*?"6J>._B
M#KB>&O".BR:?::CK;Z?JNIQV5UK,SV^EPW-AHFF:MJ#B_N%>&ROHK;RX9UV7
M[)$8LYU*M*C2J5:]14H4TW>2;32C.3=UHDHPE*3>D8QE)Z1DTF[*_P#7]-V7
MJT=Q17Q5XN\=_%/QGXP\.?$[X56/Q3LOA/\  Y]$NOB'X3U'P#XI\)ZC\=)/
MB1KT?ASQ)IGAGPYXNTG2_$/B;_A1OP]M=0^)MO9KH>GW.KZ[K?AO1]/_ +6U
M6&^9/?\ P%\:OAU\2]<U[PQX4U+7/^$E\-:;I6NZ[X<\3>"/'/@C7=*T37KS
M5;'1M8N+3Q?X7T*.>PU[4=(UJRTIM/O+V#_BGKYK93$LTB?G?!OB]X;^(.>\
M5<-<'<791GN=\%XW"Y?GV"PF+P=24:V(R^CF52KETZ>8XB6:8'"4,30AB,QP
M>&>!CB*CH?68UJ<Z3Z:^$Q>&CAYXK"XC#QQ5#V]&56E.,'[RC*GS-)*<=[NR
MDM8IIJ3]6KT+X4?\E$\+?]?2_P#I-=5Y[7H7PH_Y*)X6_P"OI?\ TFNJ^[S-
M_P#";CO^O$OQO_D84_\ ><+_ -?)=?[G;^NY^@O<?0_S6EI.X^A_FM+7Y3#X
M?FSWEN_7]$%1/]\8ZY3'_D2I:B;[Z_5/_:E$]E_B0S\R;MY(]6O9(I&AE34K
MEXYD61GAD6]E9)46%DE9HV =5B99&( C97P1^=_@S_@G/\+O!/BSX<>(-*^)
M?QAN="^#'QG_ &G_ (W?#7P!?2?#-_"GAGQ/^USX;^(/AGXJ^%KK6-)^%\'B
M?7_#.FZE\4-:\4>$Y/$^NZIJ_AG7$TK3OMCZ1;7$#?H=?*7U+4$54=GO[M56
M1G6-F:[G"K(T>9%C8D"1HP9%3)C!8 '^<+P'^V/^WOXQN_V&?$NLZ]\.-=\5
M>//VMO\ @I_\.[OPS8>+M3\#>"OB5X._9P\&_M&6_A7P=\39_#/PL2SLM%\#
M7WP\L#X)OM"TWQ/KOB2/2['7/$-W93SZQ!IWZ@J^&IX; PKTI5'*A.4''ELH
MQFE)/1O>2:WTOZG@J-:4ZKI2<4II.SZM-[>B^YKM9?9GA7_@CM^S#X+UCX3Z
M_I%_=^)-2^&/PB^$?P;DO/B]\&/V5?CW/XOT#X&ZOJ=UX,U^X/QH^ GC*]^'
M/BVZLM:UOPUXAU7X/ZCX&.M:9;:'J%S<S:MI45ZW9?$O_@EC\"OBK\,1\)O%
M7CCXEW_AL?M,?M%_M27*ZOI?P?\ &]AJ'C3]IP_$"7QYHNH>$/B/\+?&'@#5
M=/\ #E]\2-2U'X5:]>>#;?QY\.];T6P\:>'O'>G>(I!:Q?-.D?\ !87Q-K'P
MT^(GQQ3]G31+3X7_  G_ &#_ (%?MD^-(KKXIWUY\0+_ ,0?'W2O'5IX1^#W
MA+2=.\#3Z5?6UAXX\&7BW?C35=0T['@JXN+^/P__ ,)!!::)?=_XX_X*2_M
M_#OX6ZY\1/&'['/C;P[H/@[XB6-EXV^*GBCX7_ME^"/A+X;^!TGP?U3XE>(/
MCH_A/QK^RMH'[3>J^$O WB333\-_'6O:)\"M1\%>%KV^L/%FJ^*;?P[-(\,?
M\)<US2@X.=WRWM+114OLIN_+%R:O=)-NR;=J&*O\<OOC_>:V?3F?WK=[<O\
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M>2WERO)PY]=HRUTT5KQ6NKUT35VD[JRY<3_._OLNG6R6F_5^3V/NRU_X)=>
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M^EEIZ?U=D)6ZM^KOZ;6]?5M]0HHHK085MO\ \BM'_P!C#J?_ *CL%8E;;_\
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MS1^]?Y@+2-T/T/\ *C(]1^8H)&" 02>  >N<C]/ZT*4;KWH[KJNZ\P-/0?\
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M -N3_OK_ .M5?ZW8O_H7X?\ \&1_^5D_V93_ .?M7\#\P/[.OO\ GQO_ /P
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M']G7W_/C?_\ @!=?_&J/[.OO^?&__P# "Z_^-5^G_E_[<G_?7_UJ/+_VY/\
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M -"_#_\ @R/_ ,K#^S*?_/VK^!^8']G7W_/C?_\ @!=?_&J/[.OO^?&__P#
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M7Y?ZKM1_9U]_SXW_ /X 77_QJOT_\O.?GD'_  +^7%'E_P"W)_WU_P#6JO\
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M<&IZ?>C1O#L8M+QF1-9615L[HM&5OXPH9?)X#@[EP>@.X FL#^SK[_GQO_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>formdrs_025.jpg
<TEXT>
begin 644 formdrs_025.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" 'Z X0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<\$=#VIX.10 4444 %%1R3%2P'89SC-.1]XSZG H =1110 4444 %%%(3@4
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M\,O)^\6U"/\ --Y9(5LGJ" 2,,0#]+A<Y( &<C- N=PX YZ9[U\"_P#!(O\
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M8^ Q]DTO6'5=#\/SF0M+J]P OF2>5&"0H;YCM&#G%'[7?["_[5_[#W[.^O\
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M_MW?\$N["#X@_';P]\(_C!\%[*XCC\0WW@B&YL]8T"!W"_:627*M&N1P >2
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M!'Q/X@TF6W\2:U EMK_@^[@G1D@E*#;/#,?E5NH(Z#H?UI_X+%_%GQ+\!_\
M@F'\;O&/A#6;O0/$WA[PQ/=Z;J-J0)K.4% '4D$9Y/- 'TKYN>@X]Z:+GD9!
MY]J\A_X)]>.-8^*'["'P8\2^(=1N-7U[7O!&D:CJ-]/CS;RXELH7DD?  RS,
M2< =:^9=6_:8\>Q?\''^G_"9/%.IK\-Y?@M)K[: "OV0WXOVC^TD8W;]F%SG
M&!TH ^^OM"CU]/I2&0XSM(]:^!_^"KW[;?Q,L?VBOA?^R[^S_?:;HOQ8^+<<
M^H:EXEO8#<)X-T>($/>", [I6(<(6&W*8_BR.0\6_P#!*C]J_P""ND2>+/A5
M^V?XX\7>/+#%T=%\<:;!)H.OR*<F&019:!&P0-N2,CD<F@#["_X*!?MF:5^P
M!^R-XS^+NM:1?:[IW@V"&:6PLW59KCS9XX5 9N!\T@.3V%>B?"SXB6_Q4^&W
MA[Q/:036UKXATZWU&*&;B2)9HPX5NV1D#\*_+W_@Y:_9M^)/C'_@F]XS^)%W
M\8_$GAO2=#\-Z;%X@^'NG6\4FAZQ=&[@#L9&Q* )'R.N?+6O8O\ @F3_ ,$^
M/B]\+]-^%'CO7?VL?B;XV\*0Z!;SOX+O]-M8]/ECEM-L<)D7+[8BRD'J3&.0
M,T ?H!'<9(7:0?0]J#*<XP21R?05^97[0?Q#^+G_  42_P""LGCG]F_PE\7=
M?^!7@/X1^%[36M5NO#]M'_;7BB>Z*<+)+GRX(]X&5!SQ_>&/I#]A7]BWXN_L
MB_$OQ!#XJ_:#\3?&;X=ZAI<<>E6'B:QB75-'O5E^9A<1\2Q-'Q@@$'\Z /B;
M_@M]\9_BQ\(/^"T?[*,WPANFE\3WND7<1T6XNVBLO$$'GNTUG( =I:2-2JG&
M0VW!%>5_M/?MF1_'O_@JY=?$;P%KNL:=:7/[+NM7L5L9VANM U".:Y2X@EBS
MB.Z@E5HG&,AXSC. :^^_VU_^"9?BK]IG_@J#^SM\<=*U_0+#P[\&A)_:.GW7
MF_:[XM([?N=JE> P^\PKSK]I'_@A';>,_P!O7QS\:_AUJFB^'5^)7P\UGPOK
MVDW:R*CZI=@!+Z+8"%5\9D7&=P+#)=L 'YE:-\2/V<[O_@W\M_$LVM:U:_M4
M:5IDNKV_B" ZVFIMJ(U)]K/>J/);,+ $,^WIW%?KYX(TGQ?^UG_P3E^"OB#5
M-1U#58[_ ,(:=>:Y;6W%SJDY@CS,S=2#ABP'.6..M<7X>_X)#>+M#_X(&7'[
M*,FN^$G\>SZ!/I2ZUME&G"234#= EO+\W;M(7.S.1TXKT;2];\5_L4?LD?##
MX/:!-IFL>/=&\.6^EM<62-<K')"B1AUB(#%7^;!;:!BL:[7)J;X:-1U%[/?N
M;/AKQ7X7\,_LH_$/PQX:T>/PM?P>%M5U#RK25B79;5U\TO\ >5\X(!.1@XZ'
M'C'_  :Z^-]<^(G_  2:\.:AXBUS5O$&I+XAU6$W>I7DEW/L68!4,DC%B!V!
M/'I7T?\ L[_LKW%IHGB#5/&ADGUKQM826NJ+O!E(F3;(7*C:'() "@@#\:^;
M/V,O^"=_[2__  3*^$NN?##X0^+/@[XM\#76KW>JZ+>^*(+ZRU+2&N6#,LD<
M*R1SJI QADSSTZ"J;;B9U+\[N]3RS_@W<\4>.?C%\"_VI;$^+=6O-2M_B3>V
M>D76JWDUXEBF7^2/S&)1., # 'I7U3^SKH7A7]FCQ_>R:WX;N+?77F\FXUB\
MD\RZ!E?:&V]"K,<93/!%9'_!/C]B.P_X(U_L@>*XM4\4P>,O%OBG6I_$&K7S
M1C3X+[4+A@$MX4+,0NYL YR<]!TK:^$'PM\:_M3^-X/&'C]3;Z387#R:1$T7
MD>7 XQMC3[P8\ LY]P*RJ2CS6MJ=%.-147).T>OF?7ZG(&,8/-.IL:@(/:G5
MT(Y HHHI@%%%% !1110 4444 %%%% !1110!#J&?L$V,9\MOY&ORX_X-?O#F
MFZU^RY\99+O3]/NI!\6-;7?-;H[?ZQ3C)&<5^I-U%Y\#)G&\%?ID8K\FO@1_
MP1N_;-_8MNO&FD?!C]H[X:^'_!OB?Q/>>(8[/4_#,EU<HUP^X[WV]0,# XXZ
MT ?JIIOA[3M 9Y+#3K*R+C#M;P)&67/0[0,^M?G-_P %K9-W_!2;_@GECI_P
MLN].0?\ IG:\5Z)^R_\ LQ?MT^!?CIH&I_$_]HCX9^+_  ):S$ZMI%AX5:WN
M;V(C[J2%0$/OGBNY_;W_ ."?VO?M<_M5?LQ>/M*UW2M*T_X%^++CQ#J=K=I(
M9M2BD2(!(2H(#AHN=Q PW6@#ZMSA@ ._KZU^;G_!LZH'[.O[0H^4?\7^\4KC
M_@-I7Z0Y9&SM//4#OZ5\K_\ !*+]@C7O^">WPQ^*&A:_KFD:]/XY^)>L^-[6
M33TD"6]O>^2(X7WJ"9%$7S;05R0 3UH ^5?A#\=?VE_^"U/Q?^)]W\-?BG'^
MSG\#_AOXCN/"EC=Z9HT>I>(?$-Y;G$TK&1@D<?*X Y&Y>"<UY!\?/V1O'7[*
M?_!:K]B2+QO\??'OQNEUS5M9DMO^$FB@A_LG9;*',*Q=GW*#G^XHKZ'D_P""
M2W[1O[&OQ\^('B+]DKXQ>!O#O@OXG:E)KFK>$_'>ESWMKIM_(299+1HE8@-G
M)SCL#D 5!X,_X(;_ !.O_P!N+X.?M#_$?XWO\0?B-X0U:>\\1">V:UTR"R>W
MD2*PTJV4%8HUD?<6?#-UZT /_P"#C1C_ ,))^Q=MZ_\ #06@@<>TE?I@&P^<
M #..G-?*'_!4'_@GSKW[>VJ_ :?1->TK04^$GQ,TWQQ?B^21C?VUMNW0Q; <
M2-D8+8%?5X.9<XXQ0!^:W_! ?(_:-_;Q!(./CGJ7W>F?GJ#]FQA%_P '0?[2
M8;@R?#OP^5_VL6\72OH7_@G!_P $_P#7OV)_BI^T7K^LZYI6M6_QI^(EWXRT
MZ.R217T^WF!Q%-O !D!8YVY''6O./VYO^"87Q7\5?MQZ5^TA^SE\1?"_@+XF
M#0_^$<UVR\3Z?+>:1K=JN?+=Q&"PD4$ <?P+@CG(![Q_P5&<?\.Z/C2.I'A*
M^_\ 11KXT_9<\+:OXW_X-1](TS05F?5;KX77@@$60YVRS,V,<_=5J^LD_9G^
M+GQ8_P""=?B?X:_%?QQX;\1?$_Q;I-_87FNZ7I[V>F1-.[^2$BQNV)&44G;D
ME2<<UO?\$[?V2;S]C;]@KX=?![Q!>Z;XCN_!^BG2K^XMXF^RWVYY&;:K@$J0
M^,,* /(_^#>GQ1I7BK_@C5\!YM(^S+!;:)+:2QQ.#Y,\=W.LBMW#;P2<_P!X
M'N*\5_X.N;J'5O\ @G)X;\*V_P"\\3>,_'^C:9H,2G]\UT92V4 YR%!'_ AZ
MBIM"_P"".W[0/[!GQ)\477['7QH\*^%/ 'C&];4KKP/X[TV;4--T:Y;EFLFC
M#%%)SV' 4$D*#78_L^?\$BOB-\0/VK/#OQQ_:Q^*.G?%GQAX(W_\(IX;T2Q:
MT\,:!,RA/M*0N SRX .2HPP#$DJ, '$_\',EA-I'_!*+PG:7.5N;;Q=X;AF&
M?XUGC#<_4&OTI\)*?^$:TP<?\>D/;_8%?,__  5[_8 US_@I#^RE:?#[0=>T
MOP]?VWB+3M:-UJ"2/"R6TZR.F$!;)4''O[5]0:-9OIFF6MN<,;>)(B?[VU0,
MC\N] 'YQ_P#!"P!OVT/^"@ Y_P"2R2G_ ,=FK*_X.8VV>"/V:). T?Q@TD@@
MX9?F'2OH_P#X)Y_L!:]^QQ\>/VE/%NKZYI6L6GQN\>/XLTR"S619=.@97_=S
M;E WY?\ A)&!UJK_ ,%7_P#@G9KG_!0OP]\*K+0]?TGP_)\//&]GXIN3?QR.
MEY#"<M&FP$[SVS@4 ?,'_!V?X7U+5?V)_AIJ%O>W6EZ5I?Q$TPZC?V[ /8"1
MML<P!X+*V2,\9Q7I]O\ \$;OBOJ%O'<6_P"WK^TM-%<()8Y([NS=)%/(92$P
M00>,<8KZ]_:Q_9:\'?MH_L_^)?AKX]TP:GX:\46AM;E!\LL#=4FB;!V2HWS*
MPZ$"OA;X:_\ !/W]OG]D;PU;^!?A5^TA\+?%?P]T5!;Z)-\0=!N;G6K"W4!8
MX3)$K*RHH 7+8 XP!B@#U[]A+_@CC8_L;_M5^)OC/K7Q<^(7Q9\?>)M'71+C
M4/$IBW^0&1@"8P-Q&Q0,]!7C'[,.5_X.?_V@R-Q_XM?IW)[?Z1%^E?4O[ _[
M,'QM^">I>*_$/QP^-]S\5_$/BK[.L6FV6G+I^A>'UAWY^R1#Y@TF_P"<G^XM
M87PF_P"">&M_#G_@K;\2OVBY]?TJYT+QQX2M/#MOI,<<GVRWEBE5VD=B-FTA
M>,$F@#ZOA;]YDGD_E7YL_P#!K\K/^P+\3U0[7;XN>)@I]#FWK]*%8]2, >HQ
M7RK_ ,$B?V!-?_X)R?LZ^*_!?B#7-)\0WNO^.-6\4Q7&G+(L44-VT?EQMO .
M]1'\W&,G@F@#YQ_X-6=;L[;]@KQ[X;:5$\0^&_B=KD.L6C,#-:R2,A3S!U&X
M*<9ZX-?IG&P;RV&U@.01T^H_"OSS^./_  2+^+WP;_:X\5?&C]DCXL:)\-M9
M^(TPN/%WA7Q1927OAW4[CDM=HB!BDQ)[*,9;!&<5UW[*W_!//]H+4_VG?#_Q
M<_:3^.\'C'4_!ZS)H/A'P=9R:9X;MGEB,;7$R-M::7:S ;EQTH ^Z <BOSR_
MX.B@3_P1R^(:YX>]TY&SZ&X4''X&OT- Q7S'_P %;_V&M8_X*,?L-^*/A5H6
MMZ;X=U379[:>*^OXG>W3R90Y#! 6Y Z@4 ?.?[,7_!N+^RAJ?P@\#^(-5\":
MKX@GU+1-/U"YMM3UZZN+2:5H$D.Z/< 1N8\5^@?PP^%'AOX(>!=-\+^$-"TK
MPWX=TB)8;/3M/MU@M[= , *JC'X]3ZTOP>\&S?#GX2^%_#MQ-'<3Z!I%IILL
ML8(25H84C+#/."5)&:Z"1>3@9^7I0!^:7_!+"^AL/^"Z7_!0BPFE1+NYOO"]
MS%$3\\D8L)=S =P-Z_F*ZK_@Z%URRTS_ ((E_%V&YO+:VFOWTN"UCFE5&NI/
M[3M7*(#RS;%9L#G"D]JO_MM_\$J?B/XC_;/LOVD?V:_B-HWPT^+4^E#1/$%E
MKUB]SH7B6T7[IN$C!;S%PN#@D[$.1CGQ3]KW_@@]\=/^"D'P&\4-\>_C=X?\
M2?$P6T4'@K3-&L[C3O!WA63[1$\UT8@#+//)"DD>YE^4/QGL ?8?[6[@?\$;
M_B/_ -D=O_\ TS/7/?\ !!'_ )0Z?L\,?^A3A''0?O).:]@^-'[.M_\ $_\
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MQF\2W=]JWB+XNW\=O87]X[-<2:)I:FSLE8')4 I-A02-NROU>AX3H!0 I;!
M]:_-+_@UK!3]@CXA^O\ PMKQ%_Z'!7Z62'!'4XKY1_X)"_\ !/[7O^"<7[./
MB;P3XAUW2O$%YKOC75?$\5QIR2+%'#=O&4C.\ [P$^;C&3P30!X/_P $3_\
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ME_P4U_9.U;]N7]@KXE_"70]4L-%U?QOI2V%K>WZN;:W<31R9?8"V#LQP#UH
MW/V!R3^PG\%2<9;P%H1/_@O@KXV\+'/_  =>^)1G_FW2+_T]05]V?LZ_#*Y^
M"7[//@'P;=S1W]WX/\.Z?HDUQ""(YWMK:.%I%SS@E"1GG!YKPW2/V ==L?\
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M^#$%Q+_8;>+= FO/$'ARWF8N\<)1?*8J[.5W-MR<X7.*[']BK_@AC<?L6?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR7Q'ERWJ+[G_ )'Z#>:*/-%?GU_P_P"?"@_YI_XAS_U^Q_X4A_X+^^%0<?\
M"OO$/_@9%_A1_J5G=K_5W]\?\P_UAR__ )^+[F?H.'#4N1ZBOSX'_!?WPM_T
M3[Q#_P"!D7^%+_P_\\+=_A]X@_\  N+_  I?ZEYW_P! [^^/^97^L&7_ //U
M'Z#9'J*3=[&OSY'_  7[\*D?\D^\0_\ @9%_A1_P_P"_"O\ T3[Q#_X&1?X4
M+@O.V[+#O[X_YA_K!E__ #]1^@V[\*"P K\^?^'_ )X5Q_R3_P 0_P#@9%_A
M1_P_[\*G_FGWB'_P,B_PIK@O.WI]7?WQ_P P_P!8,O\ ^?J/T%\P4X'(K\^#
M_P %^_"O_1/_ !#_ .!D7^%'_#_SPJ/^:?>(?_ N+_"C_4K/'MAW]\?\P7$&
M _Y^+\3]!R<4FZOSY_X?_>%O^B?>(/QO(O\ "C_A_P">%2/^2?\ B#_P,B_P
MI+@O._\ H'?WQ_S#_6#+_P#GZC]!\CU%)O%?GS_P_P"_"IZ?#_Q#_P"!<7^%
M;FE_\%OO#>K?#?6_$B^!M=2'0[ZSLI(#=Q[I3<B8A@<=%\DY^HJ*O"&<TTG.
M@]6EO'K\RHY]@)7M56A]TF0#L:#( >]?GU_P_P"?"V>? &OD#N+Z+G]*0_\
M!?KPJ!_R3_Q#_P"!D6?Y5K_J5G?_ $#O[X_YD?ZPY?\ \_5]S/T&\P?6E#@U
M^?/_  _[\*CI\/\ Q#_X&1?X4?\ #_OPJ/\ FG_B'_P,B_PI?ZE9YTP[^^/^
M8GQ%E][>T7W/_(_08N!0'!K\^?\ A_WX5)_Y)_XA'_;Y%_A1_P /^_"H./\
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M!7V/Q[9W+>%[BZM?$.E7&JE;K40TT?E$0$YF0?>&> .G3BO\(/'6D:;^Q/\
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M[6UU>E]U;;<P^I4O:\JEHD>-:5X U[7M9ETZQT/6;S4+>40S6T5G(\L#GLZ
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M/-(B,SW#>8R!8U QC.2Q QC)KC->^ "^$?VKK3X>/J":C;R:W!8+>)P98Y'
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M:RLGKVT:T&LMJ.*DWM;]3Y93YEXP?EW8R,X]_2GRP206@N7C=;9F*+*01&Q
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MR1_Q;BX]>;I^?_'JUEQKECKO$/"S<G9]+72M>U[7&N&<7R6C./\ P/N/S/\
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M9:K5'DUL\P5*HZ=2=FC]."J_WL4W'^]7YE+_ ,'!&JJ/^25Q_P#@V7_"@_\
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MB=\(M2^%]_\ ##P;\3= ^*\/A;PYX?U^Y6U@N?".N6<44?VFVU)Y6)MY(2&
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MP>^.'P"TKX<>(/$/_"S?$]S>>'O&5J\0T*'3[Z2!IVNI&.Z&6+9. F#O)3!
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M:>V6R"Q]U[MI)8YR<X')!_'I[FF7%Q'9R6J3S0P-<N8($DD"F=AGY5[L0.2
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M0I_>F2?=;Z'^0J7U] 6YI^+AG7",<""#\?W:UG8.0>./6M/Q;_R'3_U[P?\
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M I ,''I7MUS\$_!?Q&\&>&/%OA :[I.FW/BFR\,:[I&HWB7<]H]R_P"[EAN
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MWMBG4R'[OXT^O$>ATA1115 %,/3\J?3#T_*I8'XA?\%;/^4DWQ+_ .O;1_\
MTW15\\D<U]#?\%:_^4D_Q+_Z]M&_]-\5?/)()K^H^$O^1-AW_<7YGXYG?^_5
M?5_H&,_C7JOP*^(WAL?##Q=\/_%]Y?:5I'B>>TU&TU2TMOM+:;=VQDVL\>5+
M1LLK D'(P.*\K YZT@((Y!(_E]/?UKVL=@XXJFH3TLTU;>Z/.H5W2ES+7?\
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M)O!-S\&9+Z&S\0W_ (6U"?3S';64,LES<!XE17$DK;( Q,L:*ZY5P3W7B/\
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MWP%^+/Q.\=>([EO"FA_$BY\,^'?*T:<:C-"+>S,-DEFJ&>2X\V68%-F]0K9
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M^"?[2'Q4\#?M=>#_ (7_ !5U3P5XHA^*GA&?Q1H&I^'[8V;:?+;F-I;1X_\
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M(,1JQ[MSP>.#7<>//'VB?##P/J/B3Q#J=OI&A:7#]HN[Z8'RXH\C:2 ">20
M .=WM0L-%IM,/:/JCVG^WM,R1_:=CQ_MT#7M,Z_VG8X_WZ^6/A/^W%\*OCEX
M5\2:SX>\86$]EX/B%QK@N(WMI]+B969998V&[8RJ6#8(('X58^ G[9/PT_:?
MU?5-.\%>)K?5=5T6-+B[L7B>WN8X''R3B-QEH6_A<<9]*/J\.X>T?8^G_P"W
M],'_ #$[+_ONC_A(-,_Z"EC_ -_!7EY4'M0(P:KZI&^X>U/4/^$@TS_H*6/_
M '\%'_"0:9_T%+'_ +^"O+_*%'E"G]37</:GJ'_"0:9_T%+'_OX*/^$@TS_H
M*6/_ '\%>7^4*/*%'U-=P]J>H?\ "0:9_P!!2Q_[^"C_ (2#3/\ H*6/_?P5
MY?Y0H\H4?4UW#VIZA_PD&F?]!2Q_[^"C_A(-,_Z"EC_W\%>7^4*/*%'U-=P]
MJ>H?\)!IG_04L?\ OX*/[?TP_P#,4L?^_@KR_P H4&,"E]37</:GJ']NZ;_T
M%++_ +^"K5OK>G'2K@C4;-DWQ@G>.#\U>2;%![?E6E9?\BCJ0'_/>W_]GJ)X
M5*VHU5\COAKVF <ZG9=>F\4O]NZ7_P!!.Q_[[%?.WQW_ &D/!7[->@VNH^,]
M872HM2E-O9Q1P///>2!2Q2-$!)( )/TK5^#_ ,7_  O\?OA_I_BOP;K-EX@T
M#5D9K>[M7W(Y4D,I'564@@J>ASZU7U:/-9L7M?(]S&OZ9G_D)V/_ 'W2_P!N
MZ8?^8G8_]]BOB_XD?\%0?@A\(O$NJZ3XC\63:5=Z-=?8[QIM-G6*&7(4+YF-
MI!) # \DU-\5O^"F?P5^"7B+5=+\3^*;G3;G1.;UCILS6\ *A\F4+M(P0<Y]
M*7U>">X>TEV/LH:]IG_03LN/]L4'7],!_P"0I8_]_!7DNB:O;>(='M-0LI$G
MLM0A6XAD0$"2-AE>O(]:M>6#5+")ZW#VOD>H?\)!IG_04L?^_@H_X2#3/^@I
M8_\ ?P5Y?Y0H\H4_J:[A[4]0_P"$@TS_ *"EC_W\%'_"0:9_T%+'_OX*\O\
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M']IJL7ANY-R;6.Q,;397;C-?H0T8(Z4H0#M6-?C#-Z]-TJM9N+WVZ_(NED&
MIR4X4TFG<:BY'M3Z ,#BBOFCV0HHHH **** "BBB@ HHHH **** $/2OFWQ6
MN[QAJ@(R//?C./6OI)SA>U?-/C)D_P"$MU,$X_TA@<MUYKT\K?[QG/B$VM#\
MO/@]<ZUK7[*7[.GAO1_&&O>$;?QC\6M=TG5;O1;H07%U:'S6>#=S@$]"!N4X
M8$&MGQG\3/%OP?\ V>OVB?">E^-?%MU:?#7XL:)I.@ZA>ZI)<:E:6%Y%%<2V
MS7#'S74%R 78MMX.:^^=/^$WA/2K;3(+7P]H,$.BWCZAI\<5E&JV5R^=\T8
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MO_&CXW^*_P!E(?M,:'\*?'&N>-?#OACPEI6KV&H7^LG69/#E_<R*EP8[M_-
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M[+]I/QS^PIXV^(WBWQ%%J_B'0_%=C=ZBOBB?3H[B6SN;5+8"2.2-!(X!$A4
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M^V"_X5<-RH8#@$\ $4HFSGCH?SI*4FMV%D5)/"VG3$%[&R=@ ,F!2<#I2?\
M"(Z9_P! ZP_[\+5LW!* X&3T -*+@XSC(]AS3YI=W]X613_X1'2_^@=8?]^%
M_P */^$1TS_H'V'_ 'X6KT4OF ]...#FB63RQTHYI=W]X611_P"$1TS_ *!U
MC_WX7_"D_P"$1TS_ *!UC_WX6F:QXUTGP[?6=KJ6J:;I]UJ3^5:0W%TD4ET_
M]V-6(+GV&:T@[9/R]/UHYI=W]X611_X1'3/^@?8?]^%H_P"$1TS_ *!]A_WX
M6I_[5M_[2%F9X/M9C\[R!(#(8\[=^WKMSQGIFJR^+M,;6#IXU&P-^LGEFV%P
MGG!M@DV[,[L["'QC[ISTYHYI=W]X60[_ (1'3/\ H'V'_?A:/^$1TS_H'V'_
M 'X6KOF-C.#]*/-.>A]![T<TN[^\+(I?\(CIG_0/L/\ OPM'_"(Z9_T#[#_O
MPM8_Q(^+FD_"MM"_M=Y(H_$&IKI4$B[=D4AAEFWR$D;4"0N2>V*YVV_:Z^&U
M_I*:M:^.?!UWX;\B:>778?$%B^FV_E-&K*\HFP#^^3ID#<,D9&4I2_F861W7
M_"(Z9_T#[#_OPM'_  B.F?\ 0/L/^_"UPWC_ /:\^&'PQTVXNM<^(/@VP6WT
MQ=9:)M8MS,UDQVK<K'OW-$6. X&TGO3]#_:M^'VL2:7!-XQ\+:9J.MV[W=AI
M]YK=FEU>P(N]IHT$I+H$RQ9<@ '.,4W*7=_>%D=K_P (CIG_ $#K#_OPM!\)
M:8!_R#K#_OPM<LG[2'@K4/AM?^+=&\2Z)XGT.PD:V:XT6_AOTEN P7[.C1L5
M,Q<A0F<[F KAO 7[=^@>.?%FO6LWA[Q+X>\.^')[NWO?%&LS:?::/"UL<.68
MW1F0$]"\2CUQ2O/^9A9'L0\)Z8?^8=8?]^%I?^$2TS_H'6'_ 'X6N!O?VPOA
MGIEM;WUSX\\&6WA^\MEN;77)?$-BFG71,IBV)*9OF;<.PV\XSGBMB^_:1^'V
ME76KV]WX[\&6L_AZW6[U6.77+5&TR%AE99P7S&A'1FP#ZTU*7=_>%D=-_P (
MCIG_ $#[#_OPM*/#&G)&5^PV01N2OD+@FO.]/_;0^&.I_$"V\.0^./"KW6H:
M1'K>GW']LVOV;5+9Y)HRUN_F?O=A@DW;<A0!D\U/H/[7_P -=>O885\=^#(O
M[1OAI^E,_B"Q8:W)Y4<G^BA929.) -N W&<8().:7=_>%D=V/">F-_S#[ _]
ML%I?^$1TS_H'V'_?A:YI/VA/!5UX1\2Z[8^*M!U?3?!Z3MK+Z7?17S:>T(8R
M1R+$6*R#:PV$;LC&,UQ_@[]M7P]XS^"6O>-H=$\86R>')Q;WFC7&FA=5#LL;
M18C#E=DB31L)"X0*279 K[3FEW?WA9'JO_"(Z9_T#[#_ +\+1_PB.F?] ^P_
M[\+7EW@/]O'X5^-/AUH7B2Z\;>&?#%OX@LC?VUKKNKVEC=")=X9BK2891Y;Y
M="R84D,0,UM^(/VL?AWH$MQ:?\)IX7O]9@TIM:32+'5K:XU*ZLUB:4S16ZOY
MDB&-68,H((!(-'-+N_O"R.V'A'3/^@?8_P#?A?\ "D_X1'3/^@=8_P#?A:YG
MQ;^T/X0\!VUK>:[X@T;0]&NK(7XU74=3MK2S2-F55#/)(IR2P (&,\9SQ6!\
M;OVNO#WP3\":5XE&G^(?%^AZK$]XM[X:M5U"W@LT0.]V\H<1B$*000Q9OX0Q
MHYI=W]X61Z-_PB.F?] ^P_[\+1_PB.F8_P"0?8_]^%_PKBY/VM?AA#JW]GGX
MB^!O[3,@A%@VNVJW?FMG;%Y1D#^82"-N,Y'2NB^&_P 1[#XI^!M.\0:8+A;#
M4T,D(F39)@,5.5&>ZFCFEW?WA9&E_P (CIG_ $#[#_OPM'_"(Z9_T#[#_OPM
M>2_$_P#;Q\"?"2\^(MMJCZRT_P +M.L=4UP1V12,1WDC1P+%+(4CD8LOS8;:
MF>6'-9MO_P %"?"D5]X:AU'1O%&DKKEI%>W]Q/':S6GAJ*>26.U>]N(9WA59
MV@E"-$\@^7YBN:7-+^9A9'MG_"(Z9_T#[#_OPM'_  B.F?\ 0/L/^_"US>L?
M';P[H_B[P_H8U&WO=1\27(M[:.TF2?RLP33H\F#E4=;>7:W\14XZ&KEW\5]-
MM/BSIW@QA<?VQJ>DW&M0X4>5Y$$L,3Y.<AMTZ8&.1FGS2[O[PLC8_P"$1TS_
M *!]A_WX6D_X1'3,?\@ZQ_[\+_A7G^M?MG?"O0-8M;"X^(?@PWEUJRZ%Y46L
MV\K07K(TBV\NU_W<A5&.UL'CBN.\9?\ !1[P-X*U7Q3#-8^)[NS\,I=(FHVU
MK$;+6;NUC,MS96DC2KOFB126WA$X/ST.4N[^\+(]Q_X1+3?^@=8?]^%_PH/A
M/3!_S#K'_OPM>+^&?^"@/A;4O%&EZ)KNB>*?!6K:UI%]KMI;ZU':X>SM,^=(
MTEO/+&N,9 +9Y%-^&/\ P41\#_%?Q[X-T'3K/Q/;-XZT7^V]+O;ZQ6V@DB\A
M9RA#/YA98G4LRHT:$[6<,"M2IRWYF-Q/:AX2TP_\PZP_[\+2_P#"(Z9_T#[#
M_OPM?/VJ_P#!4SX76%CH=S:R:[JT7B#5;C2[;[':*7Q!-Y+W6UW4O 7^X8P[
MR+ED5@"1](!CCH,_6JO/>[%9%#_A$=,_Z!]A_P!^%H_X1'3/^@?8?]^%J_OV
M]1S[4+*&;&#S1S2[O[PLBA_PB.F?] ^P_P"_"T?\(CIG_0/L/^_"UH,VT4F[
M'?./2CFEW?WA9%#_ (1'3/\ H'V'_?A:/^$1TS_H'V'_ 'X6KQER>^.]/HYI
M=W]X61FGPCIG;3[#_OPO^%6;'2;?34*V\,4",<D1H%!/X59SBHGN0C 8/-',
M]FPLMR15VC%+47GDGH!]:#< YQ@D=@:D9+140GR6 ZK2&[!4]1Z#'(^M,":B
MH1= DX(/XT)= ]>N?RH FHJ'[2!G/3GF@78.,9QW]J+@345#]HX!&#D<8-*U
MQ@>^3Q0!+140GQQP#[F@3D*21T/UH ?+]PUSWQ%^&&A_%GP+J'AOQ%I=GJVA
MZM UO=6EQ'NCD4C]"#R",$$ @@UN23;D.,]<?2EW@ 9 P1G&:<92BU*+LT*4
M4TT]F?A]^WY_P3_US]ACQJ)K?[7J_P -]8F\O2=5<%I-/9B2MK='  D X1S@
M.!@X/%8?[$_[$WB7]MOXE'2M+,^E^%=*DQKVO;2$MD+#,$#8(:Y8'IT4=:_;
MWXD?#30/BSX&U/PUXCTRTUC0]9@:"[M+I \<R,,'KT([$<CK5#X+?!'PO^SS
M\.=-\)^$=+M](T338]L4$:#<[=Y)& R[MW8\DU^B4O$7&QR[ZK;]YMS^7^9\
MG/A6B\7[6_N;\OG_ )!\$O@9X9_9Y^&>F>$O"6FPZ5HVFQ!(XT4;Y6P-TLC?
MQR,1DL>I]J[.,Y7UJ)'&Q2#P!QD8I6N/*V@@\]?:OSN<Y3DYS=V][GU<(J,5
M&.B1,.E%1M-M0YQD=:0SD#G P:11+14/VD98>@!SGBA+@L"2-N.V>10!-147
MGY/'(!QZ8I&N2&P!D]?J* )J*1>12T %%%% !1110 4444 %%%% !1110 57
MU*]33[&>=RJI!&TC%C@  9R?RJQ576M*MM<TFYLKR&.XM+R)H9HI!E)$88*G
MV(- 'PWX4_X+ 2>#/!;W/CWP7K4WB$W\Z2:?H,,5U (8B5>6VN$E:&Y@#_QA
MP^W.Y588K=US_@L3I/A?5);+4?AGXVMK];G4K:"W+6IDOFL06ECA'F_O))$&
MZ)%R7!XYXKNM6^#OA:]^(^N^'O"_P?\ !-Y%X66V2>2[5(%9KB/S=L2@$!0O
M7IDGO45Q^RU;WNL6U_+\$OAI+>V886UP]QND@W##8)3(8CN.: ,SX*_\%&;G
MXH7OC+2[KP7K%CJGAG2[G6H+J2,)8W5JP,MC@D^8?,B>-68+CS!(N<"O,?A%
M_P %FK^+PI"WQ#^'>M:?XF?4H],DTO2;9F,+"*&*>?=*5#0B]^T(&'/EA&QR
M:]J?]GS9)EO@]\.X_,0H";W!90/N?=&5]NGM2#]G=IF$C_!CX<N6 +,;D%L=
M^=OX^],#C-/_ ."MEA)KUCIEY\+?'UA>7EW=6@WI;>0CV\\D,L;2^;L63,9D
M4$X:/+ \$5]8>%=?_P"$E\-V6H")8A?0+.$659 %89!#*2I!!!!!(.:\!E_9
MXWQ,C_!KX=."22IN@<]<YROWL'D^Y]:[W1]8^(?A_2K:PLO!GA>UM+6)8;:&
M+5"J1HH 55&WA0,8 Z4K:(#RK_@H+\./%_Q=^)GPZT7PWHLNNV1CO[F\@EUN
M[T2R1U6,1O)<V\<C!@6.U2O.2>U> :5X<\7_  ^_;M\/Z#X]O(_$LNCV/AR,
M:G=ZAKZF:7S)S(ULMM9O;3XS&C-/)%N* N "2/KGQSX0\4_$NXMY=>^''A#4
MYK-3' \^IL2@;J!Q]*P'^ ;2$HWPE^'[_,2 VI$GMGJ.H]*F*LDO,&CYG^%'
MP1^,V@? ?5/'C+K6ASWFA7;7$<6NWU]K&OW+W#>49+*2 +;,B_-E&9L*%P0<
MCUO]O#Q7:I\:_AAHMOJGQ+TCQ3=V\5S;ZAIT5V^@Z-$DR>;/.L,3B6[<;HDC
M;@JQW;%^:N]?X$SL.?A3X"!QG_D*../7IT/'-(_P!EE"A_A+X =@<8.HLQ!]
M!D<&J@[)(5CY>F\8GQ5JGQ%N_#NL?'"#P4VK:=8^)+2_L]1DU6_M!J)^W:G
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MNO& U;PQXED>\L;/5ET1M(NYT .RXCM6>0(R] 0[@E<^U:H^ -XC@K\)/!
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M@WS#U##=D<Y&:W+3X4Z7I6J)?6ND?'>UNX8U@CEAO_+945=BJ,=E7Y1Z ^]
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M)+KS0[7$DAW+ D9/ED%MJ_/73Q>"8HFMG2R^/\,EK%Y,!CU';]G3&-JX^Z,
M<#CBL0_L^^&CXUD\2GPU\<#XA?A]1-\?M$OR[?F;^+Y?EY[<4#1TO[(7[5UW
MXE\2ZUX.\3>)H_B+>6FL)9Z5XI\/:!*=+U!&L;>[?S9;<RVT/EM,T8WR#.SU
MS6)^SI^UGXK\;?M/3:/K?B;PYJ&D:Q>>(;8Z!;VB07GA--,O_LUL\\GF%V%T
M@+#>B D';D5;\,_#>R\#Z0NGZ)I7Q[TJPC+.MM9W_DQ;F.6( [DGK4%O\(])
MM-:O]0AT7X[07^KLC7UU'?;);DI]S>PY;'4>Y)[T <U\<_VH/B]X.\"_$6"#
M4_".GZOI/Q$M] TV:VEM8%L=)EL%N0 U]/!%+<]2=SJ/F8 $+FNT\4?MYWO@
M_P" G@+Q'I'AR]\77?B+1KG5+G[5-%I\B162*US)@,T98_/LV,RL=I#;3NJA
MX@^$NE>+M,O+#5M$^.^I6.I.);N"YO1+'<. H#,#U8!5 /H .E6I_A]:W5O!
M!)I_Q\,%M$8(D.H82&(@*8U'92H (':@#D=<_P""KVI:';PV]QX&TS3-7@U
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M?_A<958Y0?\ A(-2,VGGY3]]3U;^[Z'%$M01[JGW12TB?=I: "BBB@ HHHH
M**** "BBB@ HHHH *;(<+GTIU!&10!X'K?Q&B^$_C'XY>()9].M!IB:9*9M0
MD*6J'[",%]OS%<]0OS'MS7"1?\%$-9B>))O#>DI,=.CU"2..XD<H58*]H"!@
MW%Q]^V'1T(W5[)\-(4N/V@/BNCHC*9M*!#*&'_'D.N:]'-I"HQY4>,C&$7@C
M[N..W;TH ^6?VD_%UG\6/B=#HT&A:O+J>GZ-(\UMK&@W4D5E!-(\2WMKL&//
MWJ5RW&T"O,;3P[JG@JZO;6V\<>.K1=-\,IHMK93P7H6QOH(HG>>3C.U6F+[1
MR%G3MBO5?B'\!/#/QX_X*%ZG)K5^NISZ!X,TR2*P:&)QI[B_NG!.1N._=GGT
M%;>D?\$\-&\-I;+IWB[Q?%N@:WO3<3K=B]$AB\YL2 ^47$$2_N\;0@QR33BT
MGJ,\BNO@EXE\1>![&WU2Z\<7>LQW=Q>W%]'H%YMG\ZRM;;8,KD ?9R<^CYZY
MK*TW]FOQA-XI\+ZAJ^M_$C4!X3GO#9F/2K^*5$DMXXX%&T;=T;QC)Z%5'4YK
M[]MX%B1552$48 QTQ4FP4)V!NY\2Z;\/_'3:KX>FU?4OB%K%OI.HPWEW;R:9
MJ'EWGER)()]NW'G':8RA_=!3D?-FD@^!2WMK>#4] \5W$A:\FL7C\.W>Z.66
M&XB260D?ZPF<,^W@F&,CH<_;84"@J#4[ZA=GPKJGP O)O 5S:0>%;V\\0W&F
MV^C^;?\ AV_^QP6PF6695VC?N!0")C]S<3]9] ^#FM:3X^M=0FT#5[[21K\6
MKW*3:'J/V_RXH]J^5(%P)6;!<G <<'BON/8,YI&  )[TQ'P[X^_9ZNO&GA_P
M#I5K-\2]#T_P)=7%VD=EX?GW7+22%E4LPR,*=N>2.M:W[/GPPOO@W\2=%UR[
MTOQA/:Z/87,'D6NA7K27,DQP$=I!S#$@4*#\Q8LYY-?9:<MUS^-."@4 ><K^
MT4@&/^$,^(!_[@4Q_I2_\-%I_P!"9\0?_!#-_A7HU% 'G/\ PT6G_0F?$'_P
M0S?X4?\ #1:?]"9\0?\ P0S?X5Z-10!YS_PT6G_0F?$'_P $,W^%'_#1:?\
M0F?$'_P0S?X5Z-10!YS_ ,-%I_T)GQ!_\$,W^%'_  T6G_0F?$'_ ,$,W^%>
MC4@8'H: /.O^&BT_Z$SX@_\ @AF_PH_X:+3_ *$SX@_^"&;_  KT:C(]: /.
M?^&BT_Z$SX@_^"&;_"C_ (:+3_H3/B#_ ."&;_"O1J* /.?^&BT_Z$SX@_\
M@AF_PI#^T8@/_(F?$#_P13?X5Z/37!(/Z4 >4^)/VN-%\(Z>UUJ^@>,=+M!'
M)(9KK2)8D"1H9'8DCHJ*S'T"DUX[^T5\8=*^-8M[;19M<L);Y;OPI?1W-A<
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MKT39'G&U,_2C;'Z)^5 'G7_#5'@\_P#+WJ7_ ( 3?_$T?\-4>#S_ ,O6H_\
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M&@_K1< HHS1UI@&,44A[4A..] #J*3<*7/&: "BBB@ HHHH *9''P">M/HH
M*Y'XS?&/PY\!_ 6H^*/%NIP:/H6F!3/<S$ #)  'J3GI]:ZF1B&[]>*^-?CE
M?V'[?7[3$7PO;2?%,W@OP1>+-XG>>QMIM(DO(OWD4,J/EMQ5@RL<KP?ER :
M/K_PYK-KXGT2TU&RN%NK'4(4NK:9/NS1.H96'L5((^M: &T8JIH]A#I5A!;6
M\:PVUM&L,2*<A$4 *!] *MT %!Y%%% ";1Z"C'-+10 8Q1BBB@#S']I;_CY^
M'7_8Z6'_ *+GKJ/C3_R1_P 5_P#8%O/_ $0]<O\ M+?\?/PZ_P"QTL/_ $7/
M74?&G_DC_BO_ + MY_Z(>@"'X"_\D,\%_P#8"L?_ $G2NLKD_@+_ ,D,\%_]
M@*Q_])TKK* /-?VL 3\)H, G_BH-$_\ 3I:U:\6?M%^$O"GB*^TNXU&2XO\
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MWETNB>BW/1=%_P""D6D6/AKQ?-XH\.3Z!X@\(I9/)I5IJ4.IB^-[(8K40SQ
M*S/(-I&/ER">#6'^TO\ MC_%CX>?LYS^(H/A;/X8UZ'Q#I&GF&ZUFWNHF@NK
MR*,[7";69]WE$8S&90V2!S<?]A/4O&7P<\2>'M7M_AEX4U#4+FRU#2[SP;X<
M.GBUN[6=9XY)U:1O.7S40XR,+N&<G-;OC_\ 9S^*'QZ_9[U[PSXX\6>%#K]S
M>Z?J&E3:5I4L%G:RV=S'<+YJ/*SR"22)=P#* ,@8K:;Q+@WL[.WKJ>?1ED-/
M$4ZJIP<>=<\93DURZ7Y;;Q>M[MM>>C&2?M/0^#_C#J5[XRM=:\+OH7P\F\3Z
MIIQOH[NPLHHYT\S&Q1OF . PXQD8YJQ\./VV]1U[X@>&]%\4?#[5?!=MXVM[
MBZ\.7D^HQ70U'RH6G:*1%4&"3REW!6)XXSFJOB?]BS6/C!KVN7_CC7M,GF\3
M_#V?P7JBZ19O;Q^;+*KFXA\QW*J I 5BW)!S4?P\_90\?ZAX[\&ZE\1/%_AO
M6M/^&]K/%H,6DZ7+:2W$\MN;8SW322N'(B/ 0*-W-7?$J:B]K_KU^1C..22I
MMMKFY4K7GH^27P65I>_9/FZ.Y0^%G_!1R7XB:GX*NKOX<:_H/A/QWJ T;3]:
MNKV-@+PMM2,P!=WEL>%ES@^E?34^Z)';()09 '!X_G7SMH7[$E_H/P3^%'A5
M]>MI9_AMXDL==GNA;-MOUMY"YC5=V59AP"2<'M7H7P'U7QUXQTCQ=<>,[1M'
M2ZUJ\AT*!8PES;Z>&,<+R$$@NV/,'H&&>0:O"2KQBHUM96W^1PY[A\KK-U<K
MY8PBVG%R;;3G:+2E=WY;N5ME]QP]E^W+=:)\<+'PGXH\%_\ ".6&LW-Q;:;J
M2Z[!>M*T7/[ZW0![?<F6&XGH17E7QC_;6\1_%NZ^&MQHOA/Q+X;\'ZI\1K6Q
MM/$"7R^7K4,?VI'22%0&CBD*AEWE@X .*O\ @#_@F=K>B?%'PKJFLZSX,N[7
MPUJMY?/?6^BNFN:Y%.7REW=/(Q=E5P.,#()QC &GHO[!'Q"M],\'^&;KQSH$
M_@3P'XI7Q!I-M%I#IJ4\*-,8X)Y3(4.Q9MH*(N=HSFN*7UV<9)Z*^FU^GX73
M/J*,.&L/6IU*4HR:3YFW.W_+Q)Q5FW*SAI+1>J/1-3_;CTK3?A1\1O%?]A7K
M0?#GQ&/#EQ;BX4/=.7MD\U3T5?\ 25.#_=->+_&O]I;QM\*/'WQ\UGPS'<ZQ
M-HVBZ%<V5G<WRI;:;Y@N3)*JR IDX&5 !. :Z/XG_L"^._$MQ\0-!T'QMH6F
M^!?B#X@A\1W5O+I3RZC#,K6Q>%9?,">4WV<'[F[GK78^./V(;KQH_P 6'.OP
MVK?$70[#2K,QVQ+:=):I,!(^20X9I%.T8X4C/.:UJ+%S7+'1J_ZGG8.60X5*
M<FIJ35XOFTC^[=I:*SO[39O0]/\ A/\ %#4M9^"%GXI\7:6OAB<6'VZ\@:[2
MY$<8B#F3>@ &1DXQQ7S%XE_;#\4?&#XJ_ R[M_"7B7P5X4\0>*)WM+^74%:+
M6K465QA9XEQY9)PX1]W"YR"*^E/A_P##?7;WX$+X2\>76DZG=SZ:^F7<^E6S
MVL$D!C$7"2.[!BN2><9->(>!_P!B#XCVNH?#/3_$OCCPYJ'A;X5:C)<Z;#9Z
M/)#=7\302PI]HD:5AO5).J*JG!R*VQ'UCE2ATMVWNK_A<YLCK971KUJN)4=Y
M<MW*RBX5$N5+23YG'27J;&J?\%&4L+FZUU/ VIR_#*TU<Z+-XM_M&)%$HE\D
MS+:E=[P!^L@;IDXXKKO"7[7DWCK]H'6O!VE^%A-I?AJX6VU35YM6BAE@<Q^9
MN6S*^8\?.-X.T]:^-KS]F*?]I[]H9/@EI7Q!TC5?A1\/=>?Q5=P65I(;]FDE
M)-A+<;O*:*-C@,H+9PIS7U)XL_8]\3?$3]I;1/%NJZGX/L=,\/W1D@N](TJ6
MVUR^MMA5;.XN?-*R1#C(*8(' !YK&G+&63?=?\$Z,3A<@C!14DFXR=U*3MMR
M-K=S=I*4=%%M;I%72?\ @I/I6K^/=-@'AJ:/P=K>M_\ "/:?KZZM \D]UYC1
MJ6LP/,2%G0@2$XQ@XYKZBM@3 A/4C.,YQ[5\D_!7_@G[J7P/\?68L+'X1ZEX
M;LM7EU"&\OO"F[Q#'#)(SF);I9 N]2V%D*_= R#UKZW@.8E]<5UX655I^U/
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M^[&3OK[NDEZNZZ'??&GXN:;\"_A/XA\9ZRMTVD>&["34;P0(7E\F-2S;5[G
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M+#_T7/74?&@_\6>\6#_J#7G_ *(>N7_:6_X^?AU_V.EA_P"BYZZCXT_\D?\
M%?\ V!;S_P!$/0!#\!?^2&>"_P#L!6/_ *3I765R?P%_Y(9X+_[ 5C_Z3I76
M4 >:_M8#/PFM_P#L8-$_].EK7H[H,$^U><?M8''PF@_[&#1.V?\ F*6M<Y\6
MOVP3\+OB)<:#)X;GFBM;ZTMY;Z:]CBB,,T3RO*JC<[; FT*%RS$#@<T 3_MB
M6L-QH/@EY;'4KMXO&NC/%+;2LB6K?;(ANE 8;E(.T AADC@=:]F'(KY4\=?M
M+:/\>?AWX"NA<:EH][/XYT^..ULXWN;6]\C48XR'N%B,87C< 60Y&.>E?58X
M% "$9--: $'IDT^B@5B$6@'<=.]+]D4LI/)7I[5)N&:6E9#(C; D].?:D%K@
MYSD_RJ:@G%._05B%[,/UZ^HXI3:@CMQ[5)N%+UHM8+(A:T#]<9H6UV@\CGGI
M4U% 6(3:#)QCG]*0V0+;L\XQ4]%'6X6(?L@+[CR:<T (&,?E4E% R$VH4'IT
MQ7EG[7G[36G?LG? O7O&%U:?VQ=:3"C0Z7%*$GOY'<1HB !CEF.!\ISTKU:9
MMH&3CFOAWX=_&'6/V[?VVK1(_!OV/PS\(]3N[?7(-9MYK.XBD9&%G.JN@\XM
M@LF"44 MPZJ*2;N+E6QZ[_P3U^$WB7X;?"*]O/&-GI-GK7B6_?5<6<*6^R*;
M#*C11HJ0D9 V*#@CEF.37T&MJH7& !G(]J5(L#N/ZU(.!3N/K<C%N-Q/KZ4]
M$"* .@I:*25M@"BBBF 4444 %>;?##_DO_Q1_P"NVE_^D@KTFO-OAA_R7_XH
M_P#7;2__ $D% $WQ%/\ Q?/X=?74_P#TF%>AUYY\1O\ DN7PZ^NI_P#I.*]#
MH **** &2,0>.]>;6R!_VL;U3R&\-)_Z45Z9BO,[=MO[6%Z1C(\,I_Z44 >D
M/'L4GTKQ>UMH$_X*#>8EAJ45PW@*57NY)2UK.HOX-JQKO(#+SNPHSD9)KV9G
M<KR.3VP>/\:\8M[J&3_@H*D2ZCJ4L\?@&5FLI(2MK;*;^WP\;;!EFP=PW,1M
M'"]P#VVLO5O"=AX@^R_;[*TO393I=6YGA63R)EY61<@X8'D$<BM2D<G8<4#3
M:=T[,YZ]^'^A7EAJ5I+HVE26VL2&2^A>T1H[YB "95(PYP!][/0>E>??"S]F
MG_A"_C'XV\8ZIK!UN_\ %\,5@+=K=(K>SL86=HK<(,[N9'W,3SGI7KOE#<3D
MY(^M1O!N.1QGK4.E&70Z:./Q%.,Z5.5E-6EYJZ?YI?<NR.4\"? KP7\-FO/^
M$<\)>&]!;4!MNS8:;#;?:1SP^Q1N')Z^M2^%?@%X,\"6&I6FB>%?#FD6NLDF
M_AL]-A@CO<YSYJJH#]3USUKJ,^4Y/.T=O6ID?/7.,4W3CV,WBJTKMSEKYO6W
M?74YKPM\'/#'@9+--$\/Z%I":=')#:)9V$4*VJ2$%UC"@; Q )"X!(&>E0^&
M_@9X/\$>*+S7='\+^'=+UK4,_:K^TTZ&"YN,G)WR*H9LD=S76;@>]))\RD#D
MT<D>POK%77WGKOJ]?Q,!OAMH#:0^GOHNCFP-R+TVQLX_),X<2"4IC&\. V[&
M=P!S6'\+?@CH_P *M9\3:EIPN)]2\7ZDVI:G=7+!I)F *QQY  V1I\JCKM')
M-=V5&2.Y%1^0J>JY.>*=E>]@CB*JA*GS.TMU?>SNK_/4\:^#7[&/A+X8ZSJ.
MJ7>FZ5KFNW&OWVN6VHW.GQM=V#7<[3&.*0C<JJ6QP>U=MXX^ O@OXF:S:7WB
M/PIX;UZ_L.+:XO\ 3(;B2 9S\K.I(YYX/I77QQA23C '3VH( 4G/-1&E!*UD
M;ULPQ56I[6=27-:U[O;33?1:'-^*?@IX3\<:O8ZAK'AK0-4O],4I:7%WI\4T
MUJI&"L;L"R CL"/U-7H?AUHMJ]N\.E:7"]I:FQ@*6B+Y%N1@Q)@?*AP/E''%
M;46-O'-.JN2-[V,/;U7%1<G9;:O_ #.0\&_ 3P9\.KPW/A_PKX;T2X;S,R6.
MFPV['S"IDY11]XJN?7:,]*=H?P)\'>&#_P 2WPOX=T__ $TZE_HVG0Q?Z40R
MF?Y5'[S#,-_WL,>>:ZVBA0BMD-XBJVVYN[\W_F8T_@/2KB_OKE].T]Y]2B6"
MZD:V0O=1J"%21L9=0&. >!D^IJEX ^#GA?X4VD]OX9\/Z)X?M[IS+/%IUC%:
MI*W]Y@@ )]S734DAVKD]!UI\JO>Q'M9\O)=V?2[L<GXB^!'@WQ?XD.LZKX5\
M.:EJQMS:F\NM.BFG,)ZQ[V4ML/=<X/I1XY^!?A#XFR6+^(O#'A[76TLAK,W^
MG17!M2#D%"ZG9_P'%=-]JY(YR.OM_P#6J>ER1[&BQ5=--3>FVKT]-=/D<EXN
M^!/@_P ?ZEI]WKGA?P]K%UI(464U[IT,\EH%.0(V925 /0#%-\>_ ;P?\4YK
M23Q-X8\.^(9+#_CV?4M-ANF@_P!TNIQ^%=?11R1WL*.)K1MRS:MMJ]+[VU(-
M/TZ'3+**W@CCAA@01QQHH5(U P% '  ' %3*@4Y'IBEHJC)N^K"BBB@12\0_
M\@.^_P"O=_\ T$UR?[-/_)!/"'_8*A_]!%=9XA_Y =]_U[O_ .@FN3_9I_Y(
M)X0_[!4/_H(H [FBBB@ HHHH **** "BBB@ HHHH **** "D9=RD'H:6B@#Q
MG1= F\4_%3XTZ9;WEYIUQ?1Z=!'=6LHCFA9K# =&((5AGK@UY;_PR=\5(KB6
M6'7K9KN:WMU>[GU29V6[C0+%=)A<;("H;RB,2-G)(KVGX6Y/[0WQ7'/^NTO'
M_@$*]*$&"QX;/08H \*^'/\ :<'[</B6UU;Q%IFNW4'@NS.RTLQ:O9H;ZY*K
M(HE<EB,'/RY!' KW6--\8.< CI7CFA6UVO[=WB)Y[:PBMF\#V(MYH78S3#[;
M<[C(-H P1QAFX]*]EAP8@1@@\Y'>@"/R,$'-5TTF*WEE=$13,<R$* 7/OZ^G
MTJ]M%&P'M0[,-=D_ZZ&;/X?L[NV$$MI;/$KAU1H5958=& /&??K277ABPO5C
M6>TM)_(821B2%6\MQ_$,]#[]:T]HH" =JGE78OVD^[^\I7>CV^I&,SPQ2M"W
MF(70,8VQU7T/N*AG\+V%VD(>TM)!:G="&A5A"1TVY^[^%:>P>E&P9Z4<BVL)
M3FM$WIYE22R6XC:-U#*XPP90P(]#GK4=GHD&F0F.VBAMU)R5CC"*3]!BK_EC
M.<<]* @':FXQTTV%S2MRWT,W_A&;)M4%ZUM;M>JNU;@PKYBC'0-C/ZU,^F1M
M*9=B&; 4R;!N*@YQGKZU<VBC:/2BR$W)[OI;KMVW*%UHUM=VLEN\,30S9\R,
MQ@I)GJ"#P??-,E\.V<VE_8GMK=[+;L^SF(&/;Z;>F*T@@';K04![4674I3DM
MGY_/N5=/TN'3(4BMXXX8HQA410JJ/0 <8JTOW:-HSTI0,"FE83;;NPKB_CIK
MFF>%?A-XAU#5_$,_A+3K2U:2;6H<!].'_/4<'H?4>M=I7AO[?7A^X\8? --"
MM2CGQ!KNGV$L;\)-&]PN]&]B ?RH$>A_"WP#J7A:PFGU_6H_$>O7VS[7?Q67
MV*&4(N$"0;W" #DC<<L2>,XKK8P%0 9Q6%\+?$<'C'X;>']6MF9X-2TZWNHV
M;[Q5XU89_.M^@ HHHH **** "BBB@ HHHH \Q_:6_P"/GX=?]CI8?^BYZZCX
MT_\ )'_%?_8%O/\ T0]<O^TM_P ?/PZ_['2P_P#1<]=1\:?^2/\ BO\ [ MY
M_P"B'H A^ O_ "0SP7_V K'_ -)TKK*Y/X"_\D,\%_\ 8"L?_2=*ZR@#S7]K
M$9^$L'3_ )&#1.O_ &%+6N[U#PSI^IW FN;&SN)4975Y8%=E9?NG)'4=O2N#
M_:Q_Y)-;X_Z&'1/_ $Z6M>C22A21DG/H* /'/VI[.U\,>"_!EG87.EZ):R>-
M=&_T06Z@7F;Z)BD8#+M;/SD@'[IXYS7LZC KR;]K2"ZN/#/A/[/;6-Q%'XPT
M9IVG8^9 GVV+#1@*06)P.2!@GFO6@<B@ J*:X\LD;2>*=+TZD<>M?-?[:/QT
MUGP3\9/AIX)L_%-EX T;QJ=0EU#Q'=I&_E-;1Q-':Q^80JR2^8V&SD!#@'-9
MUJL:<.>1W9=@)XVNL/3=G9O6^T4V]$FV[+1)-MZ'T@;D*P!QEN!S1]K*DC8<
M =<BO@.X_;N\8G]G";4Y/&&G/I'A;QXWACQ+XWTZT2=(]/"%TNEB4D GS(8V
M9=V"&/<X]Y_X)_?&/Q-\:OAWK>IZMK$?B30(=:F@\-:Y]G%M+K&GJJ 3/&"<
M,)1,F3@L$#8Y!KDHX^G4J^SCU5_Z_JWF>WFG".-P&%EBJ[5HRY>N_N^25_>3
MY?B2U:L?0BW/!W#!'4>E(]X%3)&,]N]?-OQO^)_Q'\ _M@_"[3EUK1[7P/XK
MU:XTYM,AM?-N;P+9RR^9),V"A5T'RJ"".I%<5XY_:U\;_"W]IN];7)KZV\):
M1KEQ9W6GC2V> Z0ME))#=+, =TTER$C4#+$D+CYA53QT([KK8SPG"^)Q*C[&
M49<T.=)-M[N/+M\5_EMJS[&CNQD@X![#UJ3S#UZBO(/V3_'NH_$/PMJ6JZ]K
M=A>:W?7;32:3:SQR#PW"PS%9OL)_>*O+$X))Z#%>M(S,HXQP.M=5.I&I'G@]
M#PL5AI8>M*A/=?UU2_K;34LT4U/<TZK.<**** "BBB@#"^([ZQ%X.O9- GTV
MWU>)!);&_!^S2,I!\MR.4#XV[P"5SG#8P<SX7:/K)6YU?Q$EM:ZSJ8C\RSMI
M!-!9*@("1R;59\YR68#/H.E<)_P4%UF]T#]EG7;ZPN9;6XL;JPN,QXS,B7D+
M/%D] Z*RD]0&->O:-+]LTJTGQL$L*.%'.W*@XH NT444 %%%% !1110 4444
M %>;?##_ )+_ /%'_KMI?_I(*])KS;X8?\E_^*/_ %VTO_TD% $WQ%_Y+G\.
M_KJ?_I,*]#KSSXC?\ER^'7UU/_TG%>AT %%%% !7EL]H+[]J/4X3)-#YOA98
M_,B.)(\SXW*>S#/!]:]2KS.U7=^UG>C_ *EI/_1] 'B%W^Q9\15LB(?$5M=W
MK:+%IKW%WK5R?/=)96BF"K& C1%XY<_-YKQ!6PI.>]\"P:UI'[;L%AK?B?2]
M>GA\"SR1Q6^G?9)K9#?6XRY\U]^XJ><+T]Z]X>(@$\C]:\C,=PO[>-HTB60M
MCX#N!$R ^>6_M"WW!SC[O3'/K0![$3@9J)9BQ/\ =/0BI'^Z?I7*?$[XN>'/
M@UX9_M?Q+JEOI-CYJP1O*26FD;A8T4<LY/10"34S:2NRZ5*=6:ITTVWLEJWZ
M'4!R>](2%P3^M<%X;_:5\#>*_A?=>,[+Q/I;^&+$R"[OY)/*CLVC.'24-@HR
MG@A@"#5GX2?'WPK\<].N;KPSJ+:A!9N(Y&:WDAP2,@@.HW*1R&'!]:E3@W9.
MYO/ XJ$9.I3DE%V=TU9]GIOY':!Q* 1C%*K[5.?K7EGQ+_;&^&WP>\9Q^'O$
M?BW3=*U5C'OAD+;;?S&VQ^:P!6/<W WD9-;.M?M%>#-!^(]GX2NM>LXM?U%$
M:&U8MR'#F,%L;59Q&^T$Y;8<#BDZT%+E;V'_ &=B^53]E*TDVG9V:6[3MLNI
MW/F^F/7K3D?<V*YKPY\2-&\4^,-:T/3[T7>H^'5A&H(B,5MFE#%$+8VE\*25
M!R,C(&171(I1QZ9ZUJFFKHY7&47:2LR7;\^?;%#+N(YQ2T4"&A,*1GK2>7[_
M *4^B@!%7:*6BB@ HHH) Z\4 -=]@KF_B7\2],^%O@K4-;UK4-,TJSL+=YO/
MU"Z%M 652VTN?H>@)]C70R2!SA3STR,5\;_M[>-/%GQY^+>D?!CP)X5\,>)(
M8(H_$6N:CJ\XV6#QL7@BA0@*\S%0XRV!M^8!<FDV!O\ [$GA#4OC3\9_$7[0
MEWK5^=$\<:?%8^'M&^VK-;VMG&?EE9(V:-7(&.&8N"&(0_*/JZLKP_I,&B:+
M9VMO;V]E#"BJ(8(ECCC('("K\HYSTXK5I@%%%% !1110 4444 4O$/\ R [[
M_KW?_P!!-<G^S3_R03PA_P!@J'_T$5UGB'_D!WW_ %[O_P"@FN3_ &:?^2">
M$/\ L%0_^@B@#N:*** "BBB@ HHHH **** "BBB@ HHHH *1FV@FEID@+(P'
MX4 >9?#"98?V@OBN[%51)=+8L3@ ?8NIKKK_ .+?AC2YI8[GQ!HUN\,D,,BR
M7B*5>7_5*1GJ^?E'?M7GN@>$++Q_\5OC1H>IV\-SIVK)IUI<12KO5T>PVL"#
MP>#7'VG[ 4L%W;._BG?_ &9#!9Z5-%IT<$NG6Z8+!=IP7W9<.?F))SQ1'?4#
MI/#.FQ6_[?GBR9-(%C+<^"=/+WF]#_:.+RX&[ 8D!?N_, >.XKVV.0;!T&..
M*\(^'.@VOAG]N/Q-9P7FOWL@\&64LKZE<RW"@M?7) B:3C;[+P#7NB+M&,<"
M@!XN 2>V*0SX[5$Y!/.0#WSUKS#6_P!KSP/I'Q]TSX9MJK3^+M4#E;6"%Y$M
MRJ[BLL@&V,E>0&(SVI3G&*4I,VP^&K5Y.-&#E9-NVMDMV_)'J?VD8Z?7FE-R
M!CCJ,UXA\5/V[/ 'P5\=7NA:I+KL[Z1'%-J]WI^CW%Y9:(DA(5KN:-2D(X).
MXC Y/%-^+?[>G@'X/ZX;&ZFUS6I+>P35+YM%TR;48M*M) 2EQ<O$I$,; $@M
M@$ GM6+Q%)?:1U0R?&SY>2G+WM5INOOTW6_==U?W 76YBNWGZTHN 3C'->.Z
MK^VQ\/\ 3?B%IGAPZE=7-WJHL_+N[:REELH#>#_15EG \N-I>B!CDUV?@WXL
M:3XX\;>(='TQI;F3PM.EK?3+&1;K.R[C$KXP[KC# 'Y3P>:I5H/1.[,JN7XJ
MFN>I!Q5KZJVE[?GWMZ'9*V[M2TU&!( ]*=6IR!1110 4444 %%%% !7F/[2\
M22^&_#0==P_X2?3B/J)"0?SKTUONG'6O,_VD/])TOPO:1?/=2^(K.98EY=HX
MCOD8#T51DGL* -/]F!=O[.'@(=2/#]B/3_E@E=U7"_LQ./\ AG+P&,\G0++_
M -$)7=4 %%%% !1110 4444 %%%% 'F/[2W_ !\_#K_L=+#_ -%SUU'QH'_%
MGO%A_P"H->?^B'KE_P!I;_CY^'7_ &.EA_Z+GKJ/C1_R1_Q9Z?V->?\ HAZ
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MF%>AT %%%% !7F#7L.F_M3ZE<SR)#!;^%EEDD<[511/DL3V '->GUYA&F_\
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MO0!<\H]>">YQUJ:@# HH **** "BBB@ HHHH I>(?^0'??\ 7N__ *":Y/\
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M.3U'K7R+^U5\8_!GA#]MWX-P3ZYI-C>Z=?WIU)&<(\7F0A4W\=\ #UXKZZE
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M>HI,D$<Z@1>8,$;1@9! R:W_ (B?\%$?!VJ>$/'\/A^]\4:9=^"A>0:EKO\
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M@J'_ -!%=9XA_P"0'??]>[_^@FN3_9I_Y()X0_[!4/\ Z"* .YHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH \J^'%DFH?'SXN02!C'-)I:,%.#@V(!YK.
ME_8;^'<DA<:=> BV%BJB]D(%L2&E@ S]R4\OGDYK9^%(_P",A_BM_P!=M*_]
M(A7I9C'/:A:; >&>!/"NG^%?VY/$D&G:#9Z/!)X*LI#+;*J"[8W]T68JHZ@\
M9.37MXR5R3ZUXSX;EA;]OGQ3Y<UZUPG@FP$L<P;RHS]LN<>7D8((ZX)YS7L_
M_+-OH.O6@!K-@=<>]?.WP(^)%QXU_:D^-6MZEJ\EGX?\(75KX7M[:XN/+LX'
MBB%Q+<#)V;G^TQH2?^>5?0\O ^G:OF?X,?"B"P_:5^.W@WQ)HK:CH'C.\M/%
M4!NK7?97:S1+!)"&(*ET:T5BO_31:Y,0YJI34=M?R=CW,H]B\/BO:VORQMW_
M (D;\M^MOPN:?[0?Q*E^'W[0/P<\5Z9K3WV@^*=5G\'7MM;W/FV3B>"2YCN,
M*2I='M @/82MZUA?\%,/CCJOP4T3X;)9>,]3\!:7XA\5+IVKZOI]E%>74=M]
MDN)=J))%*.9(TY"'H:G^.?PEM=3^.'P1^'_AG0O[+T'PUK%QXQO&M+?RK2&&
MWMI;=8R0-H=I;N-@O4A&/:NM_;'^ WBOXRR?#W5_!U]I-CK?@/Q -;C744<P
MW"_9IH3'E2"#^]Z^U8555Y*J3[6_"Y[.">70Q."E6M:U3F;LM+S]GS64DGM>
MZ?1G*>'OVI=$^!7[/WA[7T\6^-OC#;>*-:_LS3[Z?3H8=0GF?A8EA2&W7:".
MI4'D\FH/'7[:<'B;X8^-[74[/Q=\/O%/@JZLHM2M;80RWD<=P5:&6%G5HW1U
MZY7CD=>:P/VNM!^*OB'X<?#:+5)M$@\81^.;66"YTZRFNK.VC7)4RID';QAC
MD<'K6AJO[#/C+XD>&_B)J'BCQ#I!\6^/+G3U"V,+K8Z;;694*B[B6=FQN)..
M>!6$ZN(3G&">RM=>3\^]CU</@,EA1H8G&SBG.4N9J3;LJBCHE'EMR.3;:6J3
M2Z'0?%7_ (*!0_#?QUXVT*Q\$>*?$3?#JWL[O7+VT5%@B@N($F#H2<NZJW^K
MQS@\BM?XC?MW:/X8URQTK0M+N?%&I7.BIXBFBCNHK5+>P8L%?=(<,[%6"H.N
M!R*9??LFZI=:_P#'&[BU*U5?BG:V,-DIC/\ H9@L([9BY[Y9,X':N"\9?L :
MO9^*?#WB+1XO">NWEMX7M/#>I6&N6S- [6^=EQ"ZG*DYP5(((4=#5SGC$[1_
M+;WG^ECCPE+ARHH>V;BTM;-^\^2,M;K3WW):::)>9U]]_P %#M*UJ;PA;>#_
M  OX@\87OCG1SK.F06JI%LC4X<3,Q(C*G@]>3CUKSOXK?MP2^,]:^"_B?PM8
M^*6@U/7-1TN_\/0Q8O);F &%H)5W!<)(C,6R1MY]J;XX^%WQ"\'_ +67P\MO
M \7AG3M0T/PA<I<HVERKH]PQDYB4JW[G!^9>23D\=*[+X7_L+:SX#G^&]S>>
M(;74M2\,Z]J6OZU.+8Q+>S7I=BD*Y.U4+;1DG(4'K6,:F,E>VCUZ:*UK-;WO
MJ=:IY!A8PK64KIM+GDY._M%::2LM%!IK5MOY7KO_ (*1:%H'PBU3Q)J?AGQ%
M;:GX<\0+X9U?1(XQ+>6UXZHT:KC D5Q+$01CB3V-"?M4-I'CK6]7\06/BK0K
MK0?!-SXBO?#4I@DMX8X6+;MX7>9RJ_WMHW=#UK/\2?L+:UK_ (A\<W::O:(O
MBGX@6?B^$,A/E00VEO"T1_VBT+$=N172_'?]D[5/BMX\\=ZK9ZE:VD/BOP+=
M^$X(Y(R3#-,K 2-CJHSVKIE'$KKVZ?XO^ >?3_L'X-N:+=[R=G>E:*5NEZFN
MKT3]8?@W^WG9_$_QUX?TF^\)>(_#%KXPTI]7T*^U-46.\CC56D5U!/ELH8,
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M?'RG[1#'<)CW"R@'W%>GJ<B@8M%%% !1110 4444 %%%% 'F/[2W_'S\.O\
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M&'_)?_BC_P!=M+_])!7HL;[VR"2*\Y^&/_)P/Q1_ZZZ5_P"DE971T$_Q%/\
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M>6=M[<@&% 3M4XYZ9/;O7O4(*Q@'KWH =2$=:6B@! ,&EHHH **** "BBB@
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M' E< (QP<[-V<>F17'^%?V3O%VE_LY_"OPW<P6)U7PEXX?7[X+<!E2V-U>R
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MCSOWK7^7_#F7U.@Y*7(O=O;YG5R^ -&D:9GTJP<W%XE_)FW0E[E""DQX^^"
M0W48JPWA:PCU"[O/L-J;N^C$=S)Y2[[A0,!7/\0QV-:NW=R%SGVI 0.P(K)S
MGW_K3_)&JHTTK.*_J_\ FSS7Q5^S1X9U;X8>)?#>D:5IOAC_ (2>RDM;BYT^
MSCBD ;OP.<9)P>YKQ+]I33M)\ ^$[;X,?#E_"VF?$/XB:.VEF_B:WAU*""*,
M))=O&!^].#PI!!9CD$<5]/>/?&VF_#7P=J6O:O.EMI^E6SW4[GCY5!) '<G
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M7II0'L,_2@#P/X:/J5U^V]XGN]6\+Z?X=NIO!]D!-;WB73WZK?7*J\C*BX.
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MZS$,*/UI@*HVC%+110 4 8%%%*P%+Q#_ ,@.^_Z]W_\ 037)_LT_\D$\(?\
M8*A_]!%=9X@/_$COO^O=_P#T$UR7[-)S\!?"'_8*A_\ 013 [JBBB@ HHHH
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MS*J@ G=Q0!P_[;NJZ]IWAGP[=6'A*P\2V6G^)-)N%87BI?K-]NB"I!&T>W+
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MI_\ 0E>$?_"FE_\ D2HI/VAK^!K+S/AOX_7^T7$<&(+1LDH7&_%P?+&%/+X
M/!YXI\7Q\U*?4KFT3X;^/S-:*C2$Q6:H=X)7:QN-K=#G:3COU% #O^$O^*?_
M $)7A'_PII?_ )$H_P"$O^*?_0E>$?\ PII?_D2L[4_VH9=&\/7NKWGP^\?6
MNG:8)#=2R06B^4$^\=IN,L/0@'/:K<_[0NHPS6,1^''CXOJ61!MBLF7A-YW$
M7&%^7^]C)XZT 3?\)?\ %/\ Z$KPC_X4TO\ \B4?\)?\4_\ H2O"/_A32_\
MR)3+/X_:G>7]Y GPX\?;[)E67=%9J,LNX;2;C#\=2.A.#S4"_M'WW]CRW_\
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MN"$<J4!X3'>N0^&/[/WQ!TKXHZ7KVI2"RA@OY7FLY-0^V6T$98[I4R0QEE3
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M>);SQO81VUU'>)#83%4#O%L5I54J23")MVS..,=:]2:)\@CL?7&:&@).>_\
M.@!4@R0=V!V I?( .=QJ2B@+'#_&32M>U%/#ZZ#>7UDPU6)KZ6V=1LM0KLY9
M2#OR55<=?GSVKQ_1]4^+ME\7K=;?3+A/#U]K,UQ=3,(E@52%\N,J2&""/<2P
MW%GQTQBOI62,LW'%-:$L1R<#KGO0 U8]Q)7(!Z>GU_&EDCVH3][''TIZQE7!
MSQCFE==R$=Z /G_Q9=_$S7?B-\1=(?3;X^&9=#=="DC=$%Q>#F- WS; R@@D
M@@YYVG /3?L]P^-M)\2>)K#Q7/>:E9V\R+I]],5C5HP %58P.N,EFSR1C KU
M06A##G/.?3'TIYA+<=AZT *(/FR3P.E<W\7(]??X<:P/"]W':>(1 6L99+<7
M"K(".-C,H.>1R1UKJ!P*C$6203QDGIZT ?+]_J_QG?PSJ-S+H=PVOV^O)%:2
M"* O!9L["7RCOP(S$("QSNW&3 )KU;]F._\ '.J>&M<;Q[:M:W\>MSQV2E4
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MX1?#?5/#OVWP5J%[=ZE/-#9)9W5R5WB%B0Y,H7D# SW->>76E?"'P*6U_4?
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M5!(&?6K_ ,-?A'>Z!\08]3NO _@O1RT\UV]]I]W*]R)I$*%L% #D<')X'04
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M@?Y-'D#_ ":DHH C$)SUX]*<$V].!3J* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
J**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>formdrs_027.jpg
<TEXT>
begin 644 formdrs_027.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "( /$# 2(  A$! Q$!_\0
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M(4!UR1R,$DXX/:@JSM<ZJBJT%UYS*"/)?:6,+D;\9P#P?:K-!(4444 %%%%
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M7CW_ (*F?"+X7_%3Q+X$\3Z=XFL-0T*\>SFO8;**:VD9<<J5EW\Y[I7M_P
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M0"."3U7%>D*P900<@\@UV0FIJZ.6<6GKKYBT4459F?RZ>/?^1Z\1?]A*Y_\
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M]C2-8U"HH50,!5& *].G&RNSS)UG)60ZBBBMSG"BBB@ HHHH **** "BBB@
MHHHH *X;XP^/])^'_@?4M2U5_,@1 IMXW422[CM"KD]2375ZMJT.EV[O)EG$
M;.L2E0S[1D@;B!GZD"OGSX@_#6\^)4.I>'KS5476K74)-5T]?-6[NH8&&(RC
M,JF##98+R/EQNQTXL56G3@U35Y,]?+</0JUXRQ,K4TU?O;^ON/-4\0Q^)M,U
MS5[:&Y\.SV<(NYM+LYFG2ZMW *A$"J-Y^=B0Q8$L&]!L?"?X.>(?$'FM(T=E
MHU_9I<&.YL768SAU.6E^1T?(&1AD8'D,.*]?\-_LR^&=)\.Z5IMU%+J,5I))
M-Y>H3R7'EM+%Y<HB8L"@8DMU(RS'&2"/7;.SBL;=(85VJJA?4G  &3WX%<-+
M!U)M3Q$MCZ+%YWAZ,)4LOCHWNTM%TM>[\[]-O,Y;P'\,]+\%:1;0F"WO-24,
MUQJ#6Z)+<2NP>1W*J 69QNS@=!Z5V%%%>TE;1'P[=W<****8@HHHH **** "
MBBJM[J-O8F)9I5C>8E8U9@"[ $X'X G\* .;^*'CC3/ /@O5M7U.;9!:P&5H
MU90\@! V+GC))"_5AR,U\H6?B:'QG+JMW;Z>_A.9K?\ M&!;.<3"\@3$3AD"
M@-(1&JA6?>I4#C!)]6\>>!IOBDNL>'M2O8[>XOYDU72K>YE2ZN(85C4,5!'[
M@B0CE68?*0" :VO O[,NA:!X9M;2^-QJ<[S07URFISO<1_:DR7F121L=RS$D
M'JW(( %>+5]OB9M0TC8^VP4LMR_#<V(O*JWTZ+\N_?L>0_"'X6^(/$UZET&^
MQ:+J5I.)EOM/D,LK%2%#3 QO$=LG#(W(&,DYKZ2^'OPML?!NEA;M8=3U5Y7E
MEOYH8_-?)^4%E1=P5511D=% [5U>BZ+9^']-MK"QB\FUMXEABCR3M15"J,GD
MX  Y]*O5VX?#*A'5W9X>99E/,)OW4HK967]7[A1117:>*%%%% 'CO[7WQ>U?
MX"_LW^-_'>@P6UQK&DVT1M4O%+1!Y)XX@S $$[?,W8SSBO(/A+X'^+/QF_9W
M\-_$"T^._BK2_&NO:/'J<$'V#3'TN&=UW",P?9=QC[??SWYZ'I?^"EO_ "8_
M\4?^O:S_ /2ZWKRS]F3XP_&NU_9;^'VA^#O@1=:EL\/V]OI_B*_\26,%E(-@
M"SM'O,H7'S;=NXXQQ0!ZC_P3W_:<UW]J#X)W>L>*[>W@\3Z+JDNDWTEJGEQW
M!5$=90G\)(DVD#C*$C&<#Z>KYQ_83_98O?V3_@_=>']9U6WUCQ#JVHOJNH36
M8;R(Y&1$$498 LJA,[B!DL>!7T=0 5Y/^U=XTUGX=_LW?$;Q-X=O6TW7-*T:
M>[L[M41S%*JY5MK@J<>A!%>L5X;^W'_R:%\6_P#L7KK_ -!H ;^QK\3?$?Q:
M_93\%>,O%-^-1\1:C93R75XL,<7F,D\J [$4*.$7H!7FG_!,GX]>.?V@O@MX
MEUKQ[K7]NZII_B*;3H+G[-# 1 MO X4B)%!(:1N2,\]:X7]AS]F'P=XZ_9!\
M!>(=2O\ Q;#?W5E</(FG^+=3M+?*W,P&V&*=408 X50#R>I-0?\ !&!=G[.W
MC4#_ *&^X_\ 26UH _0"BBDH \2_:"U[5-#^&?Q2\075MI>L^%])\-75Q;Z5
M=(29[J*-W.]U;/EDA1@8;(.,<$^ _LCZ/\1/VH/@3:_$^?XLZQX.\3ZDUS:6
MMOH>D:8+&T2"5XXDVR6S2R1@C)4R]S@CK7NW[7%D]C^R-\8%RV^3PYJ$A.[(
MW-$Q.,Y.,D\=NE?,/_!-WP)\5M>_9+\,WGA3XJZ?X4T9[N^$>FW'A6._=&%S
M(&8S-<(3D@G&WC.*S45N]S:=64ERIV7;]?5GM/[!7[2'B_XVZ5X_\,_$!K.Y
M\9>!=9;2;O4+"'R8[Q,NBR%!P&WPRYP ,;>!S7U77YW_ /!+&&[MOBY^U!%?
MW:W]\GB>-;BZ2'R5FD$]Z&<)DA03D[<G&<9-?HA6AB%0WEQ]EM)YMN[RT9]N
M<9P,XJ:JFK_\@F]_ZX/_ .@F@#X9_8W\=_$S]MSP/XJ\<:W\4M?\#_9=;FTR
MRT?PI:V$=M!&L,4BL6GMY9';,I!RW.T=*Z']C[]I7X@:U^T-\2O@3\2]2LO$
MVL^$XVN+'Q':VBVKWD*2(A\V-/D#$31,-H&#O!+<&O /^"=_QDO?@#^PK\3/
M'5IX6N/%T6D^+YI+JQM;CR72$VEJ&ESL;Y5)!;CA=S=J]H_X)]_"6Z\:>./%
M?[46M:QIEQJ7Q"@D2TT?2&:2/383*I>.61@"95,,:%0,#:QR=P 0S[GHHHIB
M"O@CX)_MM>*KK]LWXK>!/&5S]K^'UGKIT32M1^SQ1QZ3=>;(D$4KJH)28QN@
M9RWSB-<_/7WO7YI_L)^!-'^+_P 9/VS-+\16HO\ 2-9U[[), =IPUW?G<I'*
MNI",K#E6 (Y% 'OW_!03]J+6O@#\*=1MO K%_'4ELMZ9T@69=*L?/CA:[D5@
M5YDD2- P.68G!"-CO/@'XB\3?&#X6?#_ %W7K^PU+3=5\)6<FKPF!/-N;V:%
M&D?Y0%1?F8%0!UXXKQ#]HK]GV7X5_L/_ !IDU[Q+>>._%VI6,4EYXCU*-1<3
M6]K-']D@P,X6-$!/]YWE<\N:]>_8(Q)^R3\,ID\S9)HT /F,#\R*$./090\'
M_"IE'FT9K"7)=K^O^">TZ+X-T;P^MI]ATVW@>SMA9V\BQC?% ,8C#'G;P./4
M9K:HHII**LD1*4I.\G<^</V_/VAO$?[,_P"S[<>+?"D-E+K4NHV^GQ/?QF2.
M(2!RS[01N("8 )QSGG&*X/Q)X3^,5A^S:GQ4\/\ QS\1S>*X?#L?B273=3TW
M39-,N,6PGE@6)+960$;E4[R1Q]:R/^"P_P#R:&G_ &,5E_Z!-5P?#OXR']D0
MWO\ PN+2_P"PSX&\X:3_ ,(;'N%O]@SY'G?:<YV?+OVY[X[4Q'MG[''QWO/V
MDOV=_"OCO4K2&QU:]26"^AML^5Y\,K1.R DD*VS< 2<;L9.,U[57QQ_P28_Y
M,M\.?]A'4/\ T>U?8] @HHHH XOXR_"70OCI\--;\"^)3=#0]82-+DV4HCEP
MDJ2KM8@X^9%[=,U?^&OP_P!+^%/@#0/!^B&<Z1HEG'8VING#R^6@PNY@!DX[
MXHHH Z6BBB@ KF/B9\/=*^+'P_U_P=KAG&D:U:/971M7"2^6PP=K$'!_ T44
M 4?A'\(]"^"OPQT?P'X=-T=#TJ&2&W-Y*))MKNSG<P R<N>U<]^SI^S7X0_9
M?\(ZEX;\&'4#IU_J#ZE-_:,XF?S6C1#@A5PNV->,>M%% 'JU)_%110!SGQ \
M":?\3? >O>$M::8:7K5E+871M6\N3RI%*MM)S@X/7%8?P+^"/AS]GCX;V'@C
MPH;PZ+92S2Q?;YA++NDD,C98 9Y8XXHHH R/@O\ LT^#_@/XD\<ZYX8.H?;?
M&-__ &CJ8O+@2)YN^1_W8"C:,S/QSVKU>BB@ J.XA6YMY(7SMD4H<=<$8HHH
M \F^ ?[+O@?]G+P#K'@WPO#>76A:M=RWEW#JTRW!D:2)(G7A5&TK&HQCUJ+]
MGC]EGPA^S#:ZU8^"KS6DTG5)Q<OI>H7HGMX)!QNB7:"I(P#R<A5SG%%% 'L5
M%%% !7DWP-_9F\'_ +/NK>,]2\+OJ4EWXLO_ .T=2;4+@2_O=TC?)A1M&96X
MY[444 =C\3OAWI/Q:\ :[X.UTW T?6K5[.Z^RR!)?+;&=K$'!_"JWPA^%^D?
M!?X<:'X*T![E]&T>%H+8W;[Y=A=F^9L#/+'MZ444 =C1110!YI^T#^S]X6_:
M5\ CP?XP-\-(%W'>_P#$OG$,GF(&"_,5/'SGM72?\*\TG_A6?_""_OSH?]D?
MV)_K!YOV?R?)^]C[VSOCKVHHH Q?@3\#_#?[._PYL_!/A,WAT6TEEFC^W2B6
57=(Y=LL%7/)/:O0:** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
